NCT Number,Status,Conditions,Interventions,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Start Date,Completion Date
NCT04461977,UNKNOWN,Peripheral Neuropathy Due to Chemotherapy,OTHER: True acupuncture|OTHER: Sham acupuncture,Instituto Brasileiro de Controle do Cancer,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/30/2020,2/28/2022
NCT05422794,RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Triple-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,DRUG: BET Bromodomain Inhibitor ZEN-3694|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,57,NIH,INTERVENTIONAL,5/18/2023,12/31/2025
NCT05122494,RECRUITING,Breast Cancer,DRUG: Hemay022+AI|DRUG: Lapatinib+Capecitabine,"Tianjin Hemay Oncology Pharmaceutical Co., Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,339,INDUSTRY,INTERVENTIONAL,1/19/2022,2024-06
NCT05000294,SUSPENDED,Bile Duct Cancer|Gall Bladder Cancer|Breast Cancer|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Adenocarcinoma|Soft Tissue Sarcoma|Vulvar Cancer|Prostate Cancer,DRUG: Atezolizumab|DRUG: Tivozanib,University of Florida,"Genentech, Inc.|Aveo Oncology Pharmaceuticals",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,29,OTHER,INTERVENTIONAL,11/3/2021,2024-06
NCT05134194,UNKNOWN,Triple Negative Breast Cancer,DRUG: Camrelizumabã€Capecitabine/eribulin/gemcitabine/vinorelbine|DRUG: Capecitabine/eribulin/gemcitabine/vinorelbine,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,104,INDUSTRY,INTERVENTIONAL,11/30/2021,4/30/2023
NCT05968677,RECRUITING,Breast Cancer,DIETARY_SUPPLEMENT: FSMP|OTHER: Nutritional counseling,Flavolife Srl,,FEMALE,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,INTERVENTIONAL,8/4/2023,2025-08
NCT05291494,COMPLETED,Breast Cancer Female,BEHAVIORAL: follow the WeChat public platform to watch the education videos|BEHAVIORAL: regular preoperative visits and education by ward nurses.,West China Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,392,OTHER,INTERVENTIONAL,2/1/2021,3/31/2022
NCT04532177,ACTIVE_NOT_RECRUITING,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT),Stony Brook University,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,OTHER,INTERVENTIONAL,8/19/2020,8/31/2027
NCT05288777,RECRUITING,Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,DRUG: T-DM1|DRUG: Capecitabine|RADIATION: External Beam Radiation Therapy 0|RADIATION: External Beam Radiation Therapy 1,University of Virginia,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,45,OTHER,INTERVENTIONAL,7/11/2022,2026-10
NCT04953377,RECRUITING,Advanced Breast Cancer,BEHAVIORAL: PFMT educational intervention,Onkologikoa,,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,9/2/2021,4/10/2023
NCT05928429,RECRUITING,CIPN - Chemotherapy-Induced Peripheral Neuropathy|Breast Cancer,"DEVICE: Elasto-Gelâ„¢ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA",Maria Lendorf,"Danish Cancer Society|Aarhus University Hospital|NordsjÃ¦llands Hospital, Denmark|Hospital of Southern Jutland",ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,1/15/2021,11/30/2026
NCT05275777,RECRUITING,HER2-negative Breast Cancer|Advanced Solid Tumor,DRUG: ADG106|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel,"National University Hospital, Singapore",Adagene Inc,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,66,OTHER,INTERVENTIONAL,5/19/2022,2030-02
NCT04881929,RECRUITING,Breast Cancer,DRUG: KN026,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,INTERVENTIONAL,8/9/2021,2/15/2023
NCT04341129,COMPLETED,Breast Neoplasms|Breast Diseases|Breast Fibroadenoma|Breast Cancer,DRUG: Abbreviated MRI protocol: initial experience with DotaremÂ® (Gadoterate Meglumine),University of Chicago,Guerbet,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,INTERVENTIONAL,7/13/2020,6/30/2023
NCT05564377,RECRUITING,Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Unresectable HER2-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm,DRUG: Alpelisib|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fluorouracil|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Leucovorin|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Mutation Carrier Screening|DRUG: Neratinib Maleate|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Panitumumab|PROCEDURE: Positron Emission Tomography|DRUG: Selumetinib Sulfate|DRUG: Sotorasib,National Cancer Institute (NCI),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,2900,NIH,INTERVENTIONAL,4/7/2023,7/1/2030
NCT05894239,RECRUITING,Metastatic Breast Cancer,DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,INTERVENTIONAL,7/28/2023,10/31/2028
NCT05986071,NOT_YET_RECRUITING,Breast Cancer,DRUG: M1774|DRUG: Fulvestrant injection,Institut Paoli-Calmettes,"Merck Sharp & Dohme LLC|National Cancer Institute, France",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,57,OTHER,INTERVENTIONAL,4/1/2024,9/15/2027
NCT04496739,RECRUITING,Atypical Hyperplasia of the Breast|Lobular Breast Carcinoma In Situ|Pleomorphic Lobular Breast Carcinoma In Situ,BEHAVIORAL: Cancer Educational Materials|OTHER: Decision Aid|OTHER: Decision Aid|OTHER: Interview|OTHER: Questionnaire Administration,SWOG Cancer Research Network,National Cancer Institute (NCI),ALL,"CHILD, ADULT, OLDER_ADULT",NA,415,NETWORK,INTERVENTIONAL,9/1/2022,6/1/2028
NCT05720039,RECRUITING,"Breast Cancer Female|Breast Cancer|Breast Cancer, Early-Onset|Breast Disease|Breast",DEVICE: Robotic NSM|PROCEDURE: Open NSM,Intuitive Surgical,,FEMALE,"ADULT, OLDER_ADULT",NA,204,INDUSTRY,INTERVENTIONAL,5/8/2023,2026-12
NCT04657679,TERMINATED,Breast Cancer,DRUG: Ribociclib,Georgetown University,Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS),FEMALE,"ADULT, OLDER_ADULT",PHASE4,21,OTHER,INTERVENTIONAL,5/20/2021,10/30/2023
NCT05633979,RECRUITING,Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Valemetostat,M.D. Anderson Cancer Center,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE1,37,OTHER,INTERVENTIONAL,2/9/2023,12/31/2032
NCT05365191,RECRUITING,Breast Cancer|Sentinel Lymph Node,PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping,National Taiwan University Hospital Hsin-Chu Branch,National Yang Ming Chiao Tung University,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,4/8/2022,4/7/2023
NCT05891171,RECRUITING,Advanced Cancer|Advanced Malignancies|Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Gastroesophageal-junction Cancer (GEJ)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Non-Small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Triple Negative Breast Cancer (TNBC),DRUG: AB598|DRUG: Zimberelimab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin,"Arcus Biosciences, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,81,INDUSTRY,INTERVENTIONAL,10/13/2023,2025-08
NCT04175639,RECRUITING,Breast Cancer,BEHAVIORAL: Mobile Health Pain Coping Skills Training (mPCST),Duke University,,FEMALE,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,10/20/2021,1/31/2025
NCT05011279,COMPLETED,Breast Cancer Survivor|Breast Cancer|Fitness Trackers,OTHER: Move Together app/Garmin Activity Tracker,Dana-Farber Cancer Institute,"University of Massachusetts, Boston|University of Rochester|National Cancer Institute (NCI)",ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,9/10/2021,1/21/2022
NCT04683679,RECRUITING,Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer,DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,INTERVENTIONAL,4/21/2021,2025-01
NCT04583891,ACTIVE_NOT_RECRUITING,"Depression, Anxiety|Engagement, Patient",BEHAVIORAL: IntelliCare|BEHAVIORAL: Psychoeducation|BEHAVIORAL: Coaching,University of Virginia,Northwestern University,FEMALE,"ADULT, OLDER_ADULT",NA,314,OTHER,INTERVENTIONAL,9/27/2021,11/30/2024
NCT05731791,RECRUITING,Breast Cancer,RADIATION: Radiation Therapy to partial breast,Weill Medical College of Cornell University,,FEMALE,"ADULT, OLDER_ADULT",NA,380,OTHER,INTERVENTIONAL,4/3/2023,2028-12
NCT05297591,RECRUITING,Breast Cancer,OTHER: assessment of UL function and prognostic factors,KU Leuven,Universitaire Ziekenhuizen KU Leuven|Vrije Universiteit Brussel,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,4/26/2022,2025-02
NCT05042791,RECRUITING,HER2-positive Metastatic Breast Cancer,COMBINATION_PRODUCT: radiation combined with pyrotinib and capecitabine,Jiangxi Provincial Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,362,OTHER,INTERVENTIONAL,3/1/2022,9/30/2025
NCT04534309,COMPLETED,Breast Cancer|Prostate Cancer|Melanoma (Skin)|Endometrial Cancer|Gallbladder Cancer|Rectal Cancer|Kidney Cancer|Bladder Cancer,BEHAVIORAL: Written Weight Loss Material|BEHAVIORAL: Weight Loss App|BEHAVIORAL: Behavioral Lifestyle Weight Loss Intervention (Coaching),Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Maryland Cigarette Restitution Fund,ALL,"ADULT, OLDER_ADULT",NA,340,OTHER,INTERVENTIONAL,9/22/2020,6/30/2023
NCT04965909,RECRUITING,"Breast Neoplasms|Pain, Chronic|Quality of Life",OTHER: Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.,University of Seville,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,4/1/2021,12/1/2024
NCT06195709,NOT_YET_RECRUITING,Breast Carcinoma,COMBINATION_PRODUCT: Endocrine therapy|COMBINATION_PRODUCT: Endocrine therapy combined with the local treatment of FES-negative lesions|COMBINATION_PRODUCT: Chemotherapy,Institut Curie,Zionexa,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,INTERVENTIONAL,2/15/2024,8/15/2029
NCT05508906,RECRUITING,Metastatic Breast Cancer|Advanced Breast Cancer|HR-positive Breast Cancer|HER2-negative Breast Cancer,DRUG: OP-1250|DRUG: Ribociclib|DRUG: Alpelisib,"Olema Pharmaceuticals, Inc.",Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,INTERVENTIONAL,8/31/2022,8/31/2024
NCT05130606,ENROLLING_BY_INVITATION,Hereditary Breast and Ovarian Cancer,"BEHAVIORAL: Culturally Targeted Narrative Video: ""Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.""|BEHAVIORAL: FORCE Fact Sheet",Georgetown University,National Cancer Institute (NCI)|Virginia Commonwealth University,FEMALE,"ADULT, OLDER_ADULT",NA,332,OTHER,INTERVENTIONAL,6/1/2021,12/31/2025
NCT05277909,COMPLETED,Shoulder Pain|Late Effect|Breast Cancer|Rehabilitation,OTHER: The expert assessment of shoulder impairments and individualised treatment plan|OTHER: A minimal physiotherapeutic rehabilitation program delivered in a pamphlet,Vejle Hospital,Open Patient data Explorative Network,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,4/4/2022,10/10/2022
NCT05368506,WITHDRAWN,Advanced Fallopian Tube Carcinoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8,DRUG: Wee1 Inhibitor ZN-c3,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,7/30/2023,7/31/2025
NCT06172127,NOT_YET_RECRUITING,HER2-positive Breast Cancer,"DRUG: Trastuzumab deruxtecan|DRUG: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|DRUG: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection",MedSIR,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,165,OTHER,INTERVENTIONAL,2024-05,2029-05
NCT04356209,RECRUITING,Breast Cancer,OTHER: e-PRO Intervention|DRUG: Pravastatin,Institut du Cancer de Montpellier - Val d'Aurelle,,ALL,"ADULT, OLDER_ADULT",PHASE2,105,OTHER,INTERVENTIONAL,9/28/2020,6/30/2025
NCT04240106,COMPLETED,Breast Cancer|Breast Cancer Metastatic,DRUG: Niraparib|DRUG: Aromatase Inhibitors,MedSIR,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,INTERVENTIONAL,6/15/2020,11/17/2023
NCT04578106,RECRUITING,HER2-positive Breast Cancer|Stage I Breast Cancer,BIOLOGICAL: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination,Fundacio Clinic Barcelona,SOLTI Breast Cancer Research Group|Roche Pharma AG,FEMALE,"ADULT, OLDER_ADULT",PHASE2,17,OTHER,INTERVENTIONAL,9/23/2020,2026-12
NCT04574609,ACTIVE_NOT_RECRUITING,Breast Cancer,DEVICE: OncomfortÂ® clinical virtual reality,Fondation HÃ´pital Saint-Joseph,,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,9/24/2020,1/30/2024
NCT04477109,COMPLETED,Insulin Resistance|Inflammatory Markers,DEVICE: low level laser in addition to diet recommendations|OTHER: sham laser application in addition to diet recommendations,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,7/1/2020,4/1/2023
NCT04449809,WITHDRAWN,Breast Cancer,BEHAVIORAL: Exercise program,Duke University,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2021-09,2022-09
NCT05323409,RECRUITING,Breast Cancer|Gastrointestinal Cancer|Hematologic Cancer,BEHAVIORAL: OPTIMISE,Baylor College of Medicine,,ALL,"ADULT, OLDER_ADULT",NA,340,OTHER,INTERVENTIONAL,4/1/2022,2025-06
NCT04895709,RECRUITING,"Cervical Cancer|Gastric/Gastroesophageal Junction Adenocarcinoma|Microsatellite Stable Colorectal Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Carcinoma, Renal Cell|Urothelial Carcinoma|Pancreatic Adenocarcinoma|Melanoma|Ovarian Neoplasms|Triple Negative Breast Neoplasms",DRUG: BMS-986340|DRUG: BMS-936558-01|DRUG: Docetaxel,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,665,INDUSTRY,INTERVENTIONAL,5/27/2021,9/15/2026
NCT05900206,RECRUITING,Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Ribociclib|DRUG: Letrozole|DRUG: Epirubicin|DRUG: Cyclophosphamide,Karolinska University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,370,OTHER,INTERVENTIONAL,10/9/2023,12/31/2031
NCT04444427,COMPLETED,Non-small Cell Lung Cancer|Glioblastoma Multiforme,DRUG: GLR2007,"Gan and Lee Pharmaceuticals, USA",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,19,INDUSTRY,INTERVENTIONAL,7/15/2020,7/29/2022
NCT05757427,RECRUITING,Breast Cancer,DEVICE: Wavelia #2,MVG Industries SAS,,FEMALE,"ADULT, OLDER_ADULT",NA,103,INDUSTRY,INTERVENTIONAL,3/9/2023,11/30/2024
NCT03980509,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Curcumin,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",PHASE1,22,OTHER,INTERVENTIONAL,1/29/2020,3/31/2024
NCT04720209,RECRUITING,Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,OTHER: CARE|OTHER: TARE|OTHER: Home-Based Stretching,Dana-Farber Cancer Institute,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,8/13/2021,6/15/2026
NCT05555706,RECRUITING,Triple Negative Breast Cancer (TNBC),DRUG: B013+Nab-Paclitaxel,"Shanghai Jiaolian Drug Research and Development Co., Ltd","Shanghai Pharmaceuticals Holding Co., Ltd",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,450,INDUSTRY,INTERVENTIONAL,12/6/2022,12/31/2026
NCT05215106,RECRUITING,Early Small (cT1N0) Triple Negative Breast Cancer,DRUG: Durvalumab,"Gustave Roussy, Cancer Campus, Grand Paris",AstraZeneca,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,12/6/2021,2026-06
NCT05007106,RECRUITING,Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms,BIOLOGICAL: Pembrolizumab/Vibostolimab Co-Formulation|BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: 5-Fluorouracil|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Oxaliplatin,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE2,610,INDUSTRY,INTERVENTIONAL,9/16/2021,2/22/2027
NCT05457309,RECRUITING,Malignant Fungating Wound,PROCEDURE: malignant fungating wounds care regimen,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,6/24/2022,7/30/2024
NCT05596409,RECRUITING,Metastatic Breast Cancer,DRUG: Elacestrant,"Stemline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,5/19/2023,2025-08
NCT05428709,TERMINATED,Breast Cancer,BEHAVIORAL: Acute Exercise,Milton S. Hershey Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,2/1/2023,6/29/2023
NCT04402606,RECRUITING,"Solid Tumor, Adult|Breast Cancer|Lung Cancer",OTHER: Evaluation on skin toxicities,Institut Curie,,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,11/25/2020,7/25/2024
NCT04711109,RECRUITING,BRCA1 Mutation|Breast Cancer|Breast Diseases|Breast Neoplasms|Breast Carcinoma|Neoplasms,DRUG: Denosumab|DRUG: Placebo|OTHER: Quality-of-Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI)|Austrian Breast & Colorectal Cancer Study Group (ABCSG),FEMALE,ADULT,PHASE3,300,OTHER,INTERVENTIONAL,2/23/2022,2033-12
NCT06154109,NOT_YET_RECRUITING,Triple Negative Breast Neoplasms,DRUG: Xiaopi granules|DRUG: Xiaopi decoction|DRUG: Placebo,Zhiyu Wang,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,11/25/2023,3/30/2026
NCT04197206,COMPLETED,Postoperative Pain,OTHER: costotransverse block,Cigli Regional Training Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,1/6/2020,4/29/2020
NCT06081127,RECRUITING,Breast Cancer,OTHER: MOve-ABC|OTHER: Enhanced Usual Care,Northwestern University,Northwestern Medicine,FEMALE,"ADULT, OLDER_ADULT",PHASE1,75,OTHER,INTERVENTIONAL,2023-11,2024-06
NCT04554927,RECRUITING,Web-application|Breast Cancer|Hormono Therapy,OTHER: WEB-Application|OTHER: Standard accompaniment,Centre Francois Baclesse,,FEMALE,"ADULT, OLDER_ADULT",NA,438,OTHER,INTERVENTIONAL,9/3/2020,3/3/2025
NCT05207709,RECRUITING,Metastatic Breast Cancer,DRUG: Ribociclib + Letrozole OR Fulvestrant|DRUG: Palbociclib + Letrozole OR Fulvestrant|DRUG: Paclitaxel +/- Tislelizumab,SOLTI Breast Cancer Research Group,"Novartis|Alliance Foundation Trials, LLC.",ALL,"ADULT, OLDER_ADULT",PHASE3,456,OTHER,INTERVENTIONAL,3/28/2022,3/1/2027
NCT04230109,RECRUITING,Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,Aditya Bardia,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,260,OTHER,INTERVENTIONAL,7/14/2020,2026-10
NCT04882306,RECRUITING,Breast Cancer,DEVICE: Bilateral MARIA scan,"Micrima, Ltd.",,FEMALE,"ADULT, OLDER_ADULT",NA,800,INDUSTRY,INTERVENTIONAL,2/16/2022,10/31/2022
NCT04482309,ACTIVE_NOT_RECRUITING,"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer|Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",DRUG: Trastuzumab deruxtecan,AstraZeneca,"Daiichi Sankyo Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,468,INDUSTRY,INTERVENTIONAL,8/18/2020,7/30/2027
NCT04217109,COMPLETED,Breast Cancer,DIAGNOSTIC_TEST: Odour sampling,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,2/3/2020,4/25/2023
NCT05595109,ENROLLING_BY_INVITATION,Breast Cancer|Peripheral Neuropathy|Cardiac Toxicities|Hepatic Toxicity|Cognitive Impairment,DRUG: Silymarin|DRUG: Placebo,Tanta University,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,56,OTHER,INTERVENTIONAL,10/28/2022,10/28/2024
NCT04495309,RECRUITING,Metastatic Breast Cancer,RADIATION: Metastases-directed Radiotherapy,University Hospital Schleswig-Holstein,,FEMALE,"ADULT, OLDER_ADULT",NA,564,OTHER,INTERVENTIONAL,3/5/2021,6/30/2025
NCT06195306,NOT_YET_RECRUITING,Breast Atypical Hyperplasia|Breast Carcinoma|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ,PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|DRUG: Omega-3-Acid Ethyl Esters|OTHER: Questionnaire Administration|PROCEDURE: Random Periareolar Fine-Needle Aspiration|DRUG: Tamoxifen,National Cancer Institute (NCI),,FEMALE,"ADULT, OLDER_ADULT",PHASE2,66,NIH,INTERVENTIONAL,6/16/2024,1/1/2027
NCT05156606,RECRUITING,Male Breast Cancer,DRUG: AndroGel,University Medical Center Groningen,,MALE,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,11/10/2022,1/3/2024
NCT05878106,NOT_YET_RECRUITING,Breast Cancer|Supplementation|Resistance Training|Physical Performance|Quality of Life,DIETARY_SUPPLEMENT: Creatine supplementation|OTHER: Resistance training,University of Deusto,Hospital de Cruces|Hospital de Basurto|Poznan University of Medical Sciences|Hospital Universitario de Burgos|Dynamical Business & Science Society - DBSS|University of Calabria,ALL,ADULT,NA,120,OTHER,INTERVENTIONAL,1/8/2024,12/8/2025
NCT05138627,COMPLETED,Breast Cancer,OTHER: oral cryotherapy,Berna KURT,,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,7/21/2020,5/17/2021
NCT05682209,COMPLETED,Seroma Following Procedure,DRUG: Octreotide Injection|OTHER: Sterile water,Ikechukwu Bartholomew Ulasi,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,41,OTHER,INTERVENTIONAL,12/18/2020,12/2/2021
NCT04705909,UNKNOWN,Breast Cancer,DRUG: Pitavastatin|DRUG: placebo,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,1/15/2021,12/15/2021
NCT05234606,WITHDRAWN,Urothelial Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Hormone Receptor-positive/HER2-negative Breast Cancer,DRUG: SBT6290|DRUG: SBT6290|DRUG: pembrolizumab,Silverback Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,2022-03,3/31/2022
NCT04333706,RECRUITING,Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell,DRUG: Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg or 200 mg plus Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg plus Capecitabine,University of Southern California,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER,INTERVENTIONAL,9/26/2020,11/3/2026
NCT04816006,NOT_YET_RECRUITING,Breast Cancer|Breast Neoplasms|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Cancer-related Cognitive Dysfunction,BEHAVIORAL: Aerobic Exercise Training|OTHER: Health Education (Active comparator)|PROCEDURE: Magnetic Resonance Imaging|OTHER: Medical Device Usage and Evaluation,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,3/1/2024,7/31/2027
NCT05797727,RECRUITING,Breast Cancer|Prostate Cancer,DEVICE: LifeChamps Platform HCP|DEVICE: LifeChamps Platform,Aristotle University Of Thessaloniki,University of Glasgow|Region Stockholm|Hospital Universitario La Fe,ALL,OLDER_ADULT,NA,200,OTHER,INTERVENTIONAL,1/15/2023,10/15/2023
NCT04875806,ACTIVE_NOT_RECRUITING,Advanced or Metastatic Solid Tumors|Ovarian Cancer|Non-small Cell Lung Cancer|Breast Cancer,DRUG: NC762,"NextCure, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,INTERVENTIONAL,6/30/2021,2024-10
NCT04450706,RECRUITING,HER2-negative Breast Cancer,OTHER: Precision Medicine|OTHER: Physican Decision Making,University of Utah,,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,2/16/2021,2026-08
NCT06126406,RECRUITING,Gastric Cancer|Colon Cancer|Rectal Cancer|Breast Cancer|Lung Cancer|Esophagus Cancer|Cholangiocarcinoma|Pancreas Cancer,BIOLOGICAL: CEA-targeted CAR-T cells|BIOLOGICAL: CEA-targeted CAR-T cells,"Chongqing Precision Biotech Co., Ltd",First Affiliated Hospital of Wannan Medical College,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,11/6/2023,12/31/2026
NCT05186727,COMPLETED,Genetic Predisposition to Disease,OTHER: Family History education|OTHER: Patient Ambassador,State University of New York at Buffalo,,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,4/1/2021,9/30/2022
NCT04837209,RECRUITING,Breast Cancer|Triple Negative Breast Cancer,DRUG: Niraparib|DRUG: Dostarlimab|RADIATION: Radiation therapy,Massachusetts General Hospital,Sibley Memorial Hospital|Duke University|University of Pennsylvania,ALL,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,INTERVENTIONAL,7/21/2021,12/1/2029
NCT04639609,COMPLETED,Breast Cancer,OTHER: Characterization of Neuromuscular Function and Fatigue,Institut de cancÃ©rologie Strasbourg Europe,"UR 3072 - Mitochondrie, Stress oxydant et Protection musculaire",FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/29/2020,9/6/2021
NCT04674306,RECRUITING,Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Residual Disease,BIOLOGICAL: Î±-lactalbumin vaccine|BIOLOGICAL: Zymosan,George T. Budd,"United States Department of Defense|Anixa Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,45,OTHER,INTERVENTIONAL,10/1/2021,9/1/2024
NCT05889871,NOT_YET_RECRUITING,HR+/HER2-breast Cancer,DRUG: Standard endocrine therapy plus Apatinib,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,916,OTHER,INTERVENTIONAL,6/1/2023,6/1/2026
NCT06152471,RECRUITING,Early-stage Breast Cancer|Diarrhea|Adverse Drug Event,DRUG: SPC-flakes|DRUG: Salovum|DRUG: Placebo,Henrik Lindman,,ALL,"ADULT, OLDER_ADULT",PHASE3,100,OTHER,INTERVENTIONAL,6/7/2023,3/31/2025
NCT05848739,RECRUITING,"Breast Cancer Metastatic|Pancreatic Cancer|NSCLC, Metastatic|Synovial Sarcoma|Colon Cancer|Metastatic Colon Cancer|Melanoma Recurrent|Metastatic Skin Cancer|Melanoma Stage IV|Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Cholangiocarcinoma|Ovarian Cancer|Metastatic Melanoma|Hepatocellular Carcinoma",DRUG: ST316,Sapience Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,156,INDUSTRY,INTERVENTIONAL,6/5/2023,5/31/2027
NCT02850939,ACTIVE_NOT_RECRUITING,Breast Cancer,BEHAVIORAL: Mobile phone app + patient navigation,The University of Texas Health Science Center at San Antonio,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,5/3/2021,2025-06
NCT04778839,RECRUITING,Advanced Solid Tumors,DRUG: Paclitaxel Micelles for Injection|DRUG: Paclitaxel injection,First Affiliated Hospital of Zhejiang University,"Hangzhou Dihua Biotechnology Co., LTD.",ALL,"ADULT, OLDER_ADULT",PHASE1,98,OTHER,INTERVENTIONAL,3/4/2021,3/1/2023
NCT05610579,COMPLETED,"Lymphedema, Breast Cancer",OTHER: Remedial exercise|OTHER: Compression bandage,Hacettepe University,,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,11/14/2022,2/28/2023
NCT04612439,UNKNOWN,Breast Cancer,DEVICE: VABB Elite 10G|DEVICE: BARD 14G CNB,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE3,1470,OTHER,INTERVENTIONAL,11/1/2020,6/30/2022
NCT06038539,NOT_YET_RECRUITING,HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients,"BIOLOGICAL: PERT-IJS plus trastuzumab, carboplatin and docetaxel|BIOLOGICAL: Perjeta plus trastuzumab, carboplatin and docetaxel",Biocon Biologics UK Ltd,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,382,INDUSTRY,INTERVENTIONAL,3/15/2024,11/15/2026
NCT04478279,RECRUITING,Glioblastoma|Melanoma Stage IV|Breast Cancer|Prostate Cancer|Glioblastoma Multiforme|GBM|Brain Cancer|Metastatic Breast Cancer|Metastatic Melanoma|Metastatic Prostate Cancer|Melanoma Recurrent|Prostate Cancer Metastatic|Recurrent Glioblastoma|Newly Diagnosed Glioblastoma,DRUG: ST101|DRUG: Temozolomide|RADIATION: Radiation,Sapience Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,162,INDUSTRY,INTERVENTIONAL,7/1/2020,2025-12
NCT04320979,RECRUITING,Breast Cancer,RADIATION: internal mammary nodal irradiation|RADIATION: no internal mammary nodal irradiation,Chinese Academy of Medical Sciences,"Hebei Medical University Fourth Hospital|Shanghai Zhongshan Hospital|Zhejiang Cancer Hospital|Beijing Hospital|Liaoning Tumor Hospital & Institute|Jilin Provincial Tumor Hospital|Shanxi Province Cancer Hospital|Tangshan People's Hospital|China-Japan Union Hospital, Jilin University|The First Hospital of Jilin University|West China Hospital|Peking Union Medical College Hospital|Anyang Tumor Hospital|Guizhou people's Hospital|Henan Cancer Hospital|Wuhan University|Peking University Cancer Hospital & Institute|Fudan University|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University|Air Force Military Medical University, China|Shanxi Dayi Hospital|First Affiliated Hospital Xi'an Jiaotong University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Chinese Academy of Medical Sciences, Fuwai Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE3,2000,OTHER,INTERVENTIONAL,5/8/2020,2024-05
NCT04109079,RECRUITING,"Breast Cancer|Sentinel Lymph Node|Neoplasm, Breast",PROCEDURE: Axillary lymph node dissection|RADIATION: Axillary radiotherapy|RADIATION: Breast or chest wall radiotherapy,University Hospitals of Derby and Burton NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",NA,1900,OTHER,INTERVENTIONAL,2/26/2021,2/28/2030
NCT04086771,ACTIVE_NOT_RECRUITING,Breast Cancer|Cervical Cancer,BEHAVIORAL: Navigation|OTHER: Information only,Ohio State University,"University of South Florida|American Cancer Society, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,540,OTHER,INTERVENTIONAL,10/16/2020,2024-12
NCT04690439,RECRUITING,Breast Cancer|Breast Cancer Related Lymphedema|Lymphedema of Upper Arm,DEVICE: Photobiomodulation therapy (PBMT)|PROCEDURE: Manual Lymphatic drainage,Jessa Hospital,Hasselt University,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,INTERVENTIONAL,2/22/2021,2028-02
NCT06222879,NOT_YET_RECRUITING,Breast Cancer,DRUG: HRS-8080; SHR-A1811|DRUG: HRS-8080; SHR-A2009|DRUG: SHR-A2009; SHR-1316,"Shandong Suncadia Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,350,INDUSTRY,INTERVENTIONAL,2024-01,10/31/2026
NCT05489679,TERMINATED,Breast Cancer,DRUG: AC682,Accutar Biotechnology Inc,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,10/1/2022,9/28/2023
NCT05768139,RECRUITING,"Breast Cancer|Gynecologic Cancer|HNSCC|Solid Tumors, Adult",DRUG: STX-478|DRUG: Fulvestrant,"Scorpion Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,220,INDUSTRY,INTERVENTIONAL,4/17/2023,6/1/2026
NCT03979339,UNKNOWN,HER2-positive Metastatic Breast Cancer|Ovarian Cancer|Hormone-resistant Prostate Cancer|Circulating Tumor Cell,PROCEDURE: Blood sample collection,Centre Oscar Lambret,,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,3/11/2020,2023-12
NCT04809779,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Sintilimab,"First Affiliated Hospital, Sun Yat-Sen University",,FEMALE,ADULT,PHASE2,49,OTHER,INTERVENTIONAL,2021-03,2024-03
NCT05449691,RECRUITING,Breast Cancer,PROCEDURE: One-stage immediate breast reconstruction,University Hospitals of Derby and Burton NHS Foundation Trust,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,11/2/2023,4/30/2026
NCT04301739,NOT_YET_RECRUITING,Triple Negative Breast Cancer,"DRUG: HLX10|DRUG: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|DRUG: Placebo",Shanghai Henlius Biotech,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,522,INDUSTRY,INTERVENTIONAL,4/17/2020,4/9/2027
NCT06112379,RECRUITING,Breast Cancer,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Olaparib,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,1728,INDUSTRY,INTERVENTIONAL,11/14/2023,8/28/2030
NCT06127979,RECRUITING,Breast Cancer,PROCEDURE: core needle biopsy|OTHER: blood draw,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,11/6/2023,2028-11
NCT05522491,NOT_YET_RECRUITING,Solid Tumor,DRUG: Olaparib,Hebei Medical University Fourth Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,9/1/2022,9/1/2024
NCT04081779,ENROLLING_BY_INVITATION,Breast Carcinoma|Colorectal Carcinoma|Lung Carcinoma|Lymphoma|Prostate Carcinoma,OTHER: Survivorship Care Plan|OTHER: Educational Intervention|OTHER: Questionnaire Administration,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,2/19/2020,12/31/2025
NCT03975179,RECRUITING,Breast Cancer,PROCEDURE: Omission of intraoperative frozen section biopsy for margin status|PROCEDURE: Frozen section biopsy for margin status,Samsung Medical Center,Korean Breast Cancer Study Group,FEMALE,"ADULT, OLDER_ADULT",NA,1292,OTHER,INTERVENTIONAL,9/24/2020,2026-06
NCT05560308,NOT_YET_RECRUITING,HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy,DRUG: Trastuzumab Emtansine for Injection|DRUG: Pyrotinib Maleate Tablets,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,9/30/2022,8/23/2025
NCT05115279,RECRUITING,Safety of Excision the New Tumor Size,PROCEDURE: breast conservative surgery for post chemotherapy tumour size,Assiut University,,FEMALE,ADULT,NA,1,OTHER,INTERVENTIONAL,6/1/2021,12/1/2024
NCT05150691,RECRUITING,HER2-positive Advanced Solid Tumor,BIOLOGICAL: DB-1303|DRUG: Pertuzumab Injection|DRUG: Ritonavir|DRUG: Itraconazole,DualityBio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,631,INDUSTRY,INTERVENTIONAL,1/31/2022,2025-10
NCT05076591,RECRUITING,Advanced Solid Tumor|Advanced Breast Cancer|Advanced Gastric Cancer,DRUG: IMM2902,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,135,OTHER,INTERVENTIONAL,6/20/2022,2024-12
NCT05859971,RECRUITING,Breast Cancer,DRUG: SLN mapping using technetium-99m +/- isosulfan blue dye|DEVICE: SLN mapping with ICG fluorescence using the Asimov Platform,"University of Wisconsin, Madison",OnLume Inc.|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,4/13/2023,2024-03
NCT06247449,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Brain imaging|DIAGNOSTIC_TEST: Analysis of circulating tumor DNA|BEHAVIORAL: Testing Morbidities Index,Sunnybrook Health Sciences Centre,"Princess Margaret Hospital, Canada|MOUNT SINAI HOSPITAL|Trillium Health Partners",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/29/2023,6/1/2028
NCT04795349,UNKNOWN,Breast Cancer,PROCEDURE: Vacuum-assisted breast biopsy,"Clinica Universidad de Navarra, Universidad de Navarra",,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,12/1/2020,2022-12
NCT05629949,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: QL1701|DRUG: HerceptinÂ®|DRUG: Docetaxel,"Qilu Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,474,INDUSTRY,INTERVENTIONAL,4/29/2020,2023-10
NCT05226663,RECRUITING,Breast Carcinoma,PROCEDURE: Computed Tomography|RADIATION: Fluorine F 18 Fluorthanatrace|PROCEDURE: Positron Emission Tomography,M.D. Anderson Cancer Center,"National Cancer Institute (NCI)|Trevarx Biomedical, Inc",ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,2/27/2023,8/20/2026
NCT05307705,RECRUITING,Breast Cancer,"DRUG: LOXO-783|DRUG: Fulvestrant|DRUG: Imlunestrant|DRUG: Abemaciclib|DRUG: Anastrozole, Exemestane, or Letrozole|DRUG: Paclitaxel",Eli Lilly and Company,"Loxo Oncology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,400,INDUSTRY,INTERVENTIONAL,5/11/2022,2025-05
NCT05193149,RECRUITING,Cancer Survivors|Obesity|Breast Cancer,BEHAVIORAL: Inspiratory muscle training|BEHAVIORAL: Exercise training,Ohio State University Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,11/13/2023,6/30/2029
NCT05451849,ACTIVE_NOT_RECRUITING,"Mesothelioma|Mesotheliomas Pleural|Mesothelioma, Malignant|Mesothelioma Peritoneum|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Pancreatic Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer|Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Ovarian Adenocarcinoma|Pancreatic Neoplasms|Colorectal Neoplasms|Ovarian Neoplasms|Cholangiocarcinoma|Non Small Cell Lung Cancer",BIOLOGICAL: TC-510|DRUG: Fludarabine|DRUG: Cyclophosphamide,TCR2 Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,INTERVENTIONAL,6/21/2022,2027-12
NCT05447949,COMPLETED,Breast Cancer|Post Operative Pain,PROCEDURE: Adjuncts to levobupivacaine in Erector Spinae Plane Block,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,12/15/2020,3/15/2022
NCT05298605,RECRUITING,"Breast Cancer Female|Health Knowledge, Attitudes, Practice|Cancer Screening|Health Disparities",BEHAVIORAL: Faith in Action! Church-based Navigation Model|OTHER: Control,Cedars-Sinai Medical Center,California Breast Cancer Research Program,FEMALE,"ADULT, OLDER_ADULT",NA,320,OTHER,INTERVENTIONAL,7/16/2022,12/1/2024
NCT04577963,ACTIVE_NOT_RECRUITING,"Triple Negative Breast Cancer|Endometrial Cancer|Solid Tumor, Unspecified, Adult|Colorectal Cancer",DRUG: Fruquintinib|DRUG: Tislelizumab,Hutchison Medipharma Limited,BeiGene,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,112,INDUSTRY,INTERVENTIONAL,8/9/2021,2024-11
NCT04481763,RECRUITING,Triple-Negative Breast Cancer,DRUG: Camrelizumab|RADIATION: radiotherapy,Jiangxi Provincial Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,7/14/2020,10/1/2026
NCT05754749,RECRUITING,Breast Cancer,DRUG: Iohexol 350 Mg/mL Injectable Solution,UNC Lineberger Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,3/13/2023,2024-10
NCT05607849,NOT_YET_RECRUITING,Breast Cancer,"OTHER: Leaflet ""decidons ensemble"" (making a decision together)",Nantes University Hospital,"National Cancer Institute, France",FEMALE,"ADULT, OLDER_ADULT",NA,66000,OTHER,INTERVENTIONAL,1/1/2023,1/1/2025
NCT05276505,COMPLETED,"Patient Relations, Nurse|Patient Satisfaction|Anxiety State|Breast Cancer",OTHER: Lavender Aromatherapy Tablet,Acibadem University,,FEMALE,"ADULT, OLDER_ADULT",NA,135,OTHER,INTERVENTIONAL,7/1/2021,3/1/2023
NCT03934905,RECRUITING,Anthracycline Related Cardiotoxicity in Breast Cancer,DRUG: sulforaphane|DRUG: Placebo Oral Tablet,Texas Tech University Health Sciences Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,70,OTHER,INTERVENTIONAL,6/1/2022,6/1/2026
NCT05071105,RECRUITING,Breast Neoplasm Female,RADIATION: Stereotactic Body Radiation Therapy,University of Rome Tor Vergata,,FEMALE,OLDER_ADULT,NA,30,OTHER,INTERVENTIONAL,1/1/2021,2023-11
NCT04270149,RECRUITING,Breast Cancer,BIOLOGICAL: ESR1 peptide vaccine,Herbert Lyerly,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,9/1/2020,2/1/2026
NCT05584163,RECRUITING,Breast Cancer,DEVICE: Extracorporeal shock waves,Ewha Womans University Mokdong Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,10/1/2020,2023-06
NCT05759949,RECRUITING,"PIK3CA Mutation|Solid Tumor, Adult|HER2-negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Unresectable Solid Tumor|Hormone Receptor Positive Tumor",DRUG: RLY-5836|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib,"Relay Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,265,INDUSTRY,INTERVENTIONAL,3/29/2023,1/13/2026
NCT04266249,RECRUITING,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,DRUG: Docetaxel|PROCEDURE: Lumpectomy|PROCEDURE: Mastectomy|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|BIOLOGICAL: Pertuzumab|RADIATION: Radiation Therapy|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,2156,NETWORK,INTERVENTIONAL,3/13/2020,12/31/2038
NCT00455039,WITHDRAWN,Breast Cancer,DRUG: GW572016,University of New Mexico,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,7/31/2023,7/31/2023
NCT05806671,NOT_YET_RECRUITING,Breast Cancer,DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: Fulvestrant,Tianjin Medical University Cancer Institute and Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,2023-05,2025-12
NCT06238479,NOT_YET_RECRUITING,Metastatic Solid Tumor|Recurrent Solid Tumor|Advanced Solid Tumor|Urinary Bladder Neoplasm|Triple Negative Breast Cancer|Non-small Cell Lung Cancer|Esophageal Cancer|Pancreatic Cancer|Ovarian Cancer|Cervical Cancer|Head and Neck Squamous Cell Carcinoma|Prostate Cancer|Renal Pelvis Cancer|Bladder Cancer,DRUG: LY4101174,Eli Lilly and Company,"Loxo Oncology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,280,INDUSTRY,INTERVENTIONAL,2/29/2024,3/4/2027
NCT04540471,UNKNOWN,"Music Therapy, Breast Cancer, Anxiety, Fatigue",OTHER: music|OTHER: comprehensive in-patient education program,Chang Gung Memorial Hospital,,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,9/1/2020,12/31/2020
NCT05483439,RECRUITING,Stage II-III Breast Cancer,"DRUG: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|DRUG: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|DRUG: traditional herbal medicine",Shengjing Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,10/20/2021,7/1/2023
NCT04435639,UNKNOWN,Lymphedema of Upper Arm,OTHER: Manual lymph drainage.|PROCEDURE: Coban compression bandage..|DEVICE: Adjustable Compression Sleeve,"Institute of Technology, Sligo",Sligo General Hospital,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,10/30/2020,1/31/2022
NCT04330339,COMPLETED,Fasting|Breast Cancer|Survivorship|Breast Cancer Recurrent,BEHAVIORAL: Fasting,Massachusetts General Hospital,Kully Family Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,7/24/2020,7/5/2022
NCT04803539,RECRUITING,Breast Cancer,DRUG: capecitabine|DRUG: capecitabine + camrelizumab + apatinib,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,260,OTHER,INTERVENTIONAL,4/1/2021,9/1/2033
NCT05675579,RECRUITING,Breast Cancer,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,M.D. Anderson Cancer Center,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,5/23/2023,3/29/2024
NCT04960839,RECRUITING,Breast Cancer,RADIATION: Prophylactic contralateral breast irradiation,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",NA,323,OTHER,INTERVENTIONAL,1/1/2023,12/1/2029
NCT05314179,RECRUITING,Metastatic Breast Cancer,BEHAVIORAL: DOULA-AC 1,University of Pittsburgh,,FEMALE,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,3/13/2022,2024-06
NCT05427071,RECRUITING,Breast Neoplasm|Chemotherapy Effect,DEVICE: Magnetic seed localization,The University of Hong Kong,Endomagnetics Ltd.,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,10/15/2020,12/31/2028
NCT05957939,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: Alkaline Glucosodiene Molecules,"Ministry of Health, Saudi Arabia",Maher M.akl,FEMALE,ADULT,PHASE1,2,OTHER_GOV,INTERVENTIONAL,1/1/2024,12/31/2024
NCT04762979,RECRUITING,Hormone Receptor Positive Breast Carcinoma|HER2-negative Breast Cancer|PIK3CA Mutant Metastatic Breast Cancer,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Aromatase inhibitor,Marina N Sharifi,"Novartis|University of Wisconsin, Madison",ALL,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,INTERVENTIONAL,2/12/2021,2025-01
NCT05927779,RECRUITING,"ER+, HER2- Advanced Breast Cancer|Metastatic Breast Cancer",DRUG: TFX06 tablet,"Shenzhen Yangli Pharmaceutical Technology Co., Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,INDUSTRY,INTERVENTIONAL,4/17/2023,4/30/2025
NCT04986579,RECRUITING,Metastatic Breast Cancer|Chemotherapy-induced Alopecia,DEVICE: Paxman Scalp Cooling System|DRUG: Eribulin|DRUG: Sacituzumab govitecan|DRUG: Trastuzumab deruxtecan,Dana-Farber Cancer Institute,Paxman Coolers Limited|AstraZeneca|Eisai Inc.|Daiichi Sankyo|Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,10/7/2021,6/1/2026
NCT04261179,UNKNOWN,Head Cancer|Neck Cancer|Melanoma|Breast Cancer,DRUG: Lymphoseek|DRUG: Nanocoll,Anna Cruceta,,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,2020-03,2021-08
NCT04771871,UNKNOWN,Triple Negative Breast Cancer,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin,"University College Hospital, Ibadan","Lagos State University|Obafemi Awolowo University Teaching Hospital|University of Chicago|University of Lagos, Nigeria|University of Ibadan",FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,INTERVENTIONAL,11/29/2021,2023-08
NCT05861271,NOT_YET_RECRUITING,Breast Cancer Stage I,DRUG: Capecitabineï¼ŒPyrotinib,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,1008,OTHER,INTERVENTIONAL,7/1/2023,7/1/2028
NCT05395871,COMPLETED,Breast Cancer,BEHAVIORAL: Behavioural Message|BEHAVIORAL: Behavioural Message + Video|OTHER: Usual Care Message,Imperial College London,NHS England (NHSE/I) London,FEMALE,"ADULT, OLDER_ADULT",NA,34047,OTHER,INTERVENTIONAL,7/15/2022,1/15/2023
NCT04913571,UNKNOWN,Triple Negative Breast Cancer,DRUG: Eribulin|DRUG: Tislelizumab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,265,OTHER,INTERVENTIONAL,5/27/2021,6/1/2023
NCT04549571,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Decision Aid iCanDecide - ESE website|OTHER: Decision Aid iCanDecide - S website|PROCEDURE: Therapeutic Conventional Surgery|OTHER: Interview|OTHER: Training|OTHER: Media Intervention|OTHER: Best Practice|OTHER: Survey Administration|OTHER: Quality-of-Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,700,OTHER,INTERVENTIONAL,1/15/2021,2027-01
NCT06169371,RECRUITING,Breast Cancer,DRUG: Abemaciclib|DRUG: Abemaciclib|DRUG: Abemaciclib|DRUG: Abemaciclib,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,12/28/2023,2030-11
NCT05650879,RECRUITING,HER2 Mutant Non-small Cell Lung Cancer|HER2-positive Metastatic Breast Cancer|HER2 Gene Mutation|HER2 Amplification,DRUG: ELVN-002|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Trastuzumab emtansine,Enliven Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,178,INDUSTRY,INTERVENTIONAL,3/20/2023,2026-07
NCT04639271,UNKNOWN,Breast Cancer|HER2-positive Breast Cancer,DRUG: Pyrotinib Plus And|DRUG: Trastuzumab|DRUG: Abraxane,Shandong Cancer Hospital and Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,1/1/2021,3/1/2022
NCT04205071,WITHDRAWN,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Digestive System Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Lorcaserin|DRUG: Lorcaserin Hydrochloride|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,11/1/2020,12/31/2021
NCT05358639,RECRUITING,High Grade Serous Carcinoma|Triple Negative Breast Cancer|Ovarian Cancer,DRUG: Olaparib tablet|DRUG: Navitoclax,Sunnybrook Health Sciences Centre,"Exactis Innovation|Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)|Princess Margaret Hospital, Canada",FEMALE,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,INTERVENTIONAL,11/9/2022,4/28/2025
NCT05453591,RECRUITING,Breast Cancer|Urine|Liquid Biopsy,DEVICE: Colli-Pee UAS devices,Novosanis NV,Universiteit Antwerpen,ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,INTERVENTIONAL,12/21/2022,2024-04
NCT05852691,RECRUITING,Breast Cancer,DRUG: Tobemstomig|DRUG: Pembrolizumab|DRUG: Nab-Paclitaxel,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE2,160,INDUSTRY,INTERVENTIONAL,7/18/2023,2/27/2026
NCT05287308,NOT_YET_RECRUITING,Breast Cancer,DRUG: doxorubicin|DRUG: epirubicin|DRUG: pirarubicin|DRUG: cyclophosphamide|DRUG: albumin-bound paclitaxel|DRUG: paclitaxel|DRUG: docetaxel,Chinese Academy of Medical Sciences,"CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,2022-03,2027-09
NCT04546009,ACTIVE_NOT_RECRUITING,"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",DRUG: Giredestrant|DRUG: Giredestrant-matched Placebo|DRUG: Letrozole|DRUG: Letrozole-matched Placebo|DRUG: Palbociclib|DRUG: LHRH Agonist,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,992,INDUSTRY,INTERVENTIONAL,10/9/2020,3/18/2027
NCT05420779,NOT_YET_RECRUITING,Breast Cancer Metastatic,DRUG: TSL-1502 capsules(low dose)|DRUG: TSL-1502 capsules(high dose)|DRUG: Investigator's choice of chemotherapy,"Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,125,INDUSTRY,INTERVENTIONAL,8/1/2022,6/30/2026
NCT05417308,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Endocrine Therapy-Induced Alopecia|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Minoxidil|DRUG: Minoxidil|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,INTERVENTIONAL,3/1/2023,12/31/2024
NCT05870579,RECRUITING,Breast Cancer,DRUG: [68Ga]Ga-NeoB|DRUG: [177Lu]Lu-NeoB|DRUG: Ribociclib|DRUG: fulvestrant|OTHER: Goserelin,Novartis Pharmaceuticals,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,INTERVENTIONAL,11/13/2023,10/26/2029
NCT06035679,NOT_YET_RECRUITING,Breast Cancer Female,DRUG: Pyrotinib and Trastuzumab,Youzhi Zhu,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/20/2023,11/30/2026
NCT05483491,RECRUITING,Gastric Cancer|Breast Cancer|Cervical Cancer|Lung Cancer,"DRUG: KK-LC-1 TCR-T cells|DRUG: Aldesleukin 720,000 IU/kg IV every eight hours",Christian Hinrichs,Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,42,OTHER,INTERVENTIONAL,9/26/2022,12/31/2028
NCT04975308,RECRUITING,Breast Neoplasms|Neoplasm Metastasis,DRUG: Imlunestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Abemaciclib,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,860,INDUSTRY,INTERVENTIONAL,10/4/2021,8/31/2027
NCT05037708,COMPLETED,Lymphedema of Upper Limb,PROCEDURE: Manual lymphatic drainage|PROCEDURE: Manual lymphatic drainage,University of Vigo,AsociaciÃ³n Gallega de Linfedema,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,3/1/2022,10/27/2022
NCT04398108,COMPLETED,HER2 Positive Metastatic Breast Cancer,DRUG: Margetuximab Margetuximab-IV,"Zai Lab (Shanghai) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,INTERVENTIONAL,8/25/2020,4/27/2021
NCT05059379,RECRUITING,Breast Cancer|Radiotherapy; Complications|Effect of Radiation Therapy,RADIATION: Entire supraclavicular lymph node radiotherapy|RADIATION: Medial supraclavicular lymph node radiotherapy,Fudan University,The First Affiliated Hospital of University of Science and Technology of China|Quanzhou First Hospital|Jiangyin People's Hospital|Affiliated Hospital of Jiangnan University|Guizhou Provincial People's Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1650,OTHER,INTERVENTIONAL,9/20/2021,2027-08
NCT05959291,RECRUITING,HER2-positive Metastatic Breast Cancer|Stage IV Breast Cancer,OTHER: Discontinuation of Anti-HER-2 Maintenance Treatment,University of Miami,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,7/17/2023,7/31/2029
NCT05032079,WITHDRAWN,Ductal Carcinoma in Situ,PROCEDURE: cryoablation,Larkin Community Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,11/16/2020,9/1/2023
NCT05313191,RECRUITING,CNS Cancer|Head and Neck Cancer|GI Cancer|Gynecologic Cancer|Prostate Cancer|Thoracic Cancer|Breast Cancer,RADIATION: Pencil Beam Scanning Proton Therapy,The New York Proton Center,,ALL,"ADULT, OLDER_ADULT",NA,1800,OTHER,INTERVENTIONAL,1/24/2022,2027-01
NCT04922008,NOT_YET_RECRUITING,Breast Cancer,DRUG: capecitabine and trastuzumab|DRUG: vinorelbine and trastuzumab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,356,OTHER,INTERVENTIONAL,7/1/2021,6/30/2026
NCT04815291,RECRUITING,Breast Cancer,DEVICE: Receives SCOUT at biopsy,"Merit Medical Systems, Inc.",,FEMALE,"ADULT, OLDER_ADULT",NA,500,INDUSTRY,INTERVENTIONAL,4/1/2022,2025-03
NCT04929808,COMPLETED,Radiodermatitis; Acute|Radiation Dermatitis,OTHER: Hydrating emollient for acute radiodermatitis|OTHER: Standard institutional skin care,Jessa Hospital,Hasselt University,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,2/1/2022,6/13/2023
NCT05386108,RECRUITING,Breast Neoplasms|Brain Neoplasms|Neoplasms by Site|Neoplasms|Breast Diseases|Central Nervous System Neoplasms|Brain Diseases|Central Nervous System Diseases,DRUG: Elacestrant|DRUG: Abemaciclib,"Stemline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,OTHER,INTERVENTIONAL,8/31/2022,2025-12
NCT04899908,RECRUITING,Brain Cancer|Brain Metastases|Melanoma|Lung Cancer|Breast Cancer|HER2-positive Breast Cancer|Colorectal Cancer|Gastrointestinal Cancer|SRS|SRT|Whole Brain Radiation|Stereotactic Radiation|AGuIX|Nanoparticle|Cystic|Brain Tumor,RADIATION: Stereotactic Radiation|DRUG: AGuIX gadolinium-based nanoparticles|OTHER: Placebo,Dana-Farber Cancer Institute,NH TherAguix SAS,ALL,"ADULT, OLDER_ADULT",PHASE2,134,OTHER,INTERVENTIONAL,9/15/2021,2026-02
NCT06225505,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DIAGNOSTIC_TEST: ctDNA monitoring|DIAGNOSTIC_TEST: 68Ga-FAPI-46-PET-CT,Institut Curie,"National Research Agency, France|Roche Pharma AG",FEMALE,"ADULT, OLDER_ADULT",PHASE2,450,OTHER,INTERVENTIONAL,3/1/2024,9/15/2028
NCT05999149,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: Camrelizumab Plus Chemotherapy and Famitinib|DRUG: Camrelizumab Plus Chemotherapy,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,424,OTHER,INTERVENTIONAL,9/1/2023,8/30/2027
NCT04509063,COMPLETED,Breast Neoplasm Female|Mammography Screening|Decision Making|Information Seeking Behavior,BEHAVIORAL: Information about hypothetical mammography screening without benefits,University of Aarhus,,FEMALE,ADULT,NA,768,OTHER,INTERVENTIONAL,11/6/2020,1/4/2021
NCT04421963,ENROLLING_BY_INVITATION,Ovarian Cancer|Breast Cancer,DRUG: Olaparib,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,292,INDUSTRY,INTERVENTIONAL,8/4/2020,4/30/2025
NCT04899349,TERMINATED,Breast Cancer,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Metformin XR|DRUG: Dapagliflozin + metformin XR|DRUG: Dapagliflozin,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,INTERVENTIONAL,4/6/2022,5/10/2023
NCT06162663,NOT_YET_RECRUITING,Breast Cancer|Insomnia,DRUG: Suvorexant Tablets|OTHER: Placebo Control,Medical University of South Carolina,Merck Sharp & Dohme LLC,FEMALE,"ADULT, OLDER_ADULT",PHASE4,44,OTHER,INTERVENTIONAL,2024-01,2026-03
NCT05448963,ACTIVE_NOT_RECRUITING,Nipple-sparing Mastectomy|Prophylactic Mastectomy|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation,DEVICE: da Vinci SPâ“‡ Single-port System,Chang Gung Memorial Hospital,Intuitive Surgical,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/30/2022,8/1/2023
NCT05955105,NOT_YET_RECRUITING,Head and Neck Cancer|Cervical Cancer|Endometrial Cancer|Triple Negative Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Melanoma|Nasopharyngeal Carcinoma|Non Small Cell Lung Cancer|Classic Hodgkin Lymphoma,DRUG: ILB-2109|DRUG: Toripalimab,Innolake Biopharm,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,200,INDUSTRY,INTERVENTIONAL,7/25/2023,7/24/2026
NCT04799249,ACTIVE_NOT_RECRUITING,TNBC - Triple-Negative Breast Cancer|Breast Cancer,DRUG: Trilaciclib|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Carboplatin,"G1 Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,194,INDUSTRY,INTERVENTIONAL,4/15/2021,10/25/2024
NCT04796363,COMPLETED,Analgesia|Breast Cancer,PROCEDURE: Erector Spinae Plane Block with Bubivacaine|PROCEDURE: Standard General Anaesthesia,Alexandria University,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,11/25/2020,1/21/2022
NCT05176405,COMPLETED,Breast Cancer|Behavior,BEHAVIORAL: You-Tube Video: Elissa's EE song|BEHAVIORAL: Active Comparator: Standard of Care,Virginia Commonwealth University,,FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,2/10/2022,3/14/2022
NCT05201963,UNKNOWN,Breast Cancer|Post-mastectomy Pain Syndrome|Acute Pain,PROCEDURE: Serratus Anterior Plane Block|PROCEDURE: Erector Spinae Plane Block,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,11/1/2021,12/30/2022
NCT05241405,RECRUITING,Breast Cancer|Fatigue,DIETARY_SUPPLEMENT: QISENG|DIETARY_SUPPLEMENT: PLACEBO,Centre Francois Baclesse,NATSUCA laboratory|Groupement InterrÃ©gional de Recherche Clinique et d'Innovation,FEMALE,"ADULT, OLDER_ADULT",NA,354,OTHER,INTERVENTIONAL,9/27/2022,2025-09
NCT04551105,COMPLETED,Breast Cancer|Breast Diseases,DIAGNOSTIC_TEST: Reader Group X - Session 1|DIAGNOSTIC_TEST: Reader Group Y - Session 1|DIAGNOSTIC_TEST: Reader Group X - Session 2|DIAGNOSTIC_TEST: Reader Group Y - Session 2,TaiHao Medical Inc.,"Columbia University|Taipei Veterans General Hospital, Taiwan|Virginia Polytechnic Institute and State University",FEMALE,"ADULT, OLDER_ADULT",NA,16,INDUSTRY,INTERVENTIONAL,8/15/2020,11/1/2020
NCT06185205,RECRUITING,Breast Cancer,DRUG: Accelerated partial breast irradiation,Virginia Commonwealth University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,12/12/2023,1/31/2033
NCT05388149,RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: Neratinib,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,12/6/2022,2025-07
NCT05363605,TERMINATED,Advanced Solid Tumor|Head and Neck Squamous Cell Carcinoma|Bladder Carcinoma|Susceptible FGFR3 Genetic Alterations|FGFR3|FGFR3 Overexpression|FGFR3 Receptor|FGFR3 Protein Overexpression|Ovarian Cancer|Colorectal Cancer|Breast Cancer|Liver Cancer|Lung Cancer|Gastric Cancer,DRUG: [225Ac]-FPI-1966|DRUG: [111In]-FPI-1967|BIOLOGICAL: vofatamab,Fusion Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,INTERVENTIONAL,4/20/2022,9/8/2023
NCT03872505,WITHDRAWN,Breast Cancer|Triple Negative Breast Cancer,DRUG: Durvalumab|RADIATION: Radiation Therapy|DRUG: Carboplatin|DRUG: Paclitaxel,Cedars-Sinai Medical Center,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2022-07,2027-07
NCT06151249,NOT_YET_RECRUITING,Metastatic Breast Cancer,COMBINATION_PRODUCT: Meritup oral solution,Chung Shan Medical University,"Phytofound Biotech Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,INTERVENTIONAL,12/1/2023,11/30/2025
NCT05841849,NOT_YET_RECRUITING,Breast Cancer|Chemotherapy-induced Nausea and Vomiting,DRUG: Aprepitant|DRUG: Palonosetron|DRUG: Fosaprepitant,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1028,OTHER,INTERVENTIONAL,2023-07,2029-07
NCT05077449,RECRUITING,Advanced Breast Cancer,DRUG: XZP-3287+Fulvestrant|DRUG: Placebo + Fulvestrant,"Xuanzhu Biopharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,11/16/2021,2029-11
NCT04072393,RECRUITING,Lung Cancer|Esophageal Cancer|Thoracic Cancer|Hodgkin Lymphoma|Hodgkin Disease|Non-hodgkin Lymphoma|Sarcoma|Thymoma|Breast Cancer,PROCEDURE: Home-based cardiac rehabilitation,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,1/15/2021,3/31/2025
NCT05114005,ACTIVE_NOT_RECRUITING,"Cancer, Breast|Neuropathy",BEHAVIORAL: Rhythmic Auditory Stimulation|BEHAVIORAL: Evidence-Based Exercise,Ohio State University Comprehensive Cancer Center,National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,8/15/2021,8/14/2024
NCT04141449,RECRUITING,Neoplasms|Hiv|Cervical Cancer|Breast Cancer|HNSCC|Vulvar Cancer|Anal Cancer|Cancer Suspect,OTHER: Potlako intervention|OTHER: Enhanced care,Brigham and Women's Hospital,Botswana Harvard AIDS Institute Partnership|Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|University of Oxford,ALL,"ADULT, OLDER_ADULT",PHASE2,1500,OTHER,INTERVENTIONAL,11/18/2020,9/30/2025
NCT05264649,RECRUITING,Arthralgia,DEVICE: acupuncture|DRUG: Guizhi-Shaoyao-Zhimu decoction,Show Chwan Memorial Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,5/5/2022,3/3/2023
NCT04903249,COMPLETED,Breast Cancer,BEHAVIORAL: Core Exercise Promotion Intervention,Dartmouth-Hitchcock Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,INTERVENTIONAL,8/10/2021,6/13/2022
NCT05883852,RECRUITING,HER2 Positive Early Breast Cancer,DRUG: Docetaxel|DRUG: carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Epirubicin|DRUG: cyclophosphamide,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1406,OTHER,INTERVENTIONAL,6/7/2023,7/1/2031
NCT04174352,RECRUITING,ERÎ±+ Breast Cancer|ESR1 Gene Mutation,DRUG: Tamoxifen|DIAGNOSTIC_TEST: FES PET/CT,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,INTERVENTIONAL,10/20/2020,2025-12
NCT04557449,RECRUITING,Liposarcoma|CRC|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung|Solid Tumors,DRUG: PF-07220060|COMBINATION_PRODUCT: Letrozole|COMBINATION_PRODUCT: Fulvestrant|DRUG: Midazolam|COMBINATION_PRODUCT: Enzalutamide,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,337,INDUSTRY,INTERVENTIONAL,9/23/2020,10/19/2027
NCT05016349,UNKNOWN,Breast Cancer Female,DRUG: All trans-retinoic acid|DRUG: 13-Cis Retinoic Acid plus Tocopherol|DRUG: Mifepristone|DRUG: Cannabidiol|DRUG: 9 cis retinoic acid|DRUG: Tamoxifen|DRUG: Standard therapy,Mahmoud Ramadan mohamed Elkazzaz,"Ministry of Health, Saudi Arabia",FEMALE,"ADULT, OLDER_ADULT",PHASE3,160,OTHER,INTERVENTIONAL,2021-08,2021-12
NCT04332549,WITHDRAWN,Metastatic Breast Cancer|Locally Recurrent Cancer,DRUG: PICS (Reconstitution Method 1 or 2),Sun Pharma Advanced Research Company Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,4/27/2020,1/28/2021
NCT05266105,UNKNOWN,Breast Cancer,DRUG: OP-1250|DRUG: Palbociclib,"Olema Pharmaceuticals, Inc.",Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,12/10/2021,2023-12
NCT05440149,RECRUITING,Radiotherapy|Breast Cancer,RADIATION: No PMRT for mastectomy / No regional RT for BCS|RADIATION: PMRT for mastectomy / WBI + Regional RT for BCS,Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1106,OTHER,INTERVENTIONAL,8/1/2022,12/31/2033
NCT05036005,RECRUITING,Breast Cancer|Breast Neoplasms|Breast Cancer Female|HER2-positive Breast Cancer,DRUG: Ontruzant|DRUG: Chemotherapy|DRUG: Pertuzumab,Institut fuer Frauengesundheit,"Samsung Bioepis Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE4,108,OTHER,INTERVENTIONAL,7/11/2021,2023-07
NCT04469205,RECRUITING,Breast Cancer|Surgery,OTHER: Coaching sessions,Institut Curie,,FEMALE,ADULT,NA,200,OTHER,INTERVENTIONAL,10/5/2020,4/5/2024
NCT05453604,ACTIVE_NOT_RECRUITING,Breast Cancer|Prostate Cancer|Urine|Liquid Biopsy,DEVICE: Colli-Pee UAS devices,Novosanis NV,Universiteit Antwerpen,ALL,"ADULT, OLDER_ADULT",NA,105,INDUSTRY,INTERVENTIONAL,6/18/2020,2023-12
NCT05726604,RECRUITING,Breast Cancer|Radiation-Induced Vascular Disease|Left Anterior Descending Coronary Artery Stenosis|Radiotherapy Side Effect|Cardiac Ischemia|Left Sided Breast Cancer|LAD (Left Anterior Descending) Coronary Artery Stenosis,OTHER: Respiratory gating,Central Hospital Saint Quentin,,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER_GOV,INTERVENTIONAL,3/2/2023,6/15/2023
NCT04675827,SUSPENDED,HER2-positive Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|Node-negative Breast Cancer,DRUG: Pertuzumab and tratuzumab fixed dose combination|DRUG: Trastuzumab emtansine,Jules Bordet Institute,Breast International Group|Hoffmann-La Roche|International Drug Development Institute|Institut Curie,ALL,"ADULT, OLDER_ADULT",PHASE2,1065,OTHER,INTERVENTIONAL,1/17/2022,2029-03
NCT04648904,RECRUITING,Invasive Breast Cancer|Post-mastectomy,RADIATION: Radiotherapy,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,72,OTHER,INTERVENTIONAL,11/24/2020,2024-11
NCT05376527,RECRUITING,Oncolytic Virotherapy,BIOLOGICAL: Double Recombinant Vaccinia Virus VV-GMCSF-Lact,"""Oncostar"" LLC",N.N. Petrov National Medical Research Center of Oncology,FEMALE,"ADULT, OLDER_ADULT",PHASE1,73,INDUSTRY,INTERVENTIONAL,5/11/2022,5/5/2024
NCT06013527,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: Supervised Training|OTHER: Individually tailored home program,Gulf Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,7/1/2023,2024-07
NCT03982004,TERMINATED,Metastatic Breast Cancer,DEVICE: Epicutaneous cryoimmunotherapy|DRUG: Topical imiquimod|DRUG: Pembrolizumab|OTHER: Dermatologic Quality of Life Index|OTHER: Functional Assessment of Cancer Therapy|DRUG: Intra-lesional GM-CSF|DEVICE: Cry-AC|PROCEDURE: Cutaneous tumor biopsy|PROCEDURE: Peripheral blood draw for research,Washington University School of Medicine,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,1,OTHER,INTERVENTIONAL,9/14/2020,3/3/2021
NCT05613504,NOT_YET_RECRUITING,Hot Flashes|Breast Cancer|Acupuncture,OTHER: Acupuncture treatment|OTHER: Sham acupuncture treatment,Nanjing University of Traditional Chinese Medicine,Health Science Center of Xi'an Jiaotong University|Hanzhong Hospital of Traditional Chinese Medicine|Xiang'an Hospital of Xiamen University|Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,12/1/2022,12/1/2027
NCT04262804,ACTIVE_NOT_RECRUITING,Breast Cancer Metastatic,DRUG: Margetuximab|DRUG: Trastuzumab|DRUG: Chosen Chemotherapy (Capecitabine)|DRUG: Chosen Chemotherapy (Vinorelbine )|DRUG: Chosen Chemotherapy (Gemcitabine ),"Zai Lab (Shanghai) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,123,INDUSTRY,INTERVENTIONAL,1/13/2020,2023-12
NCT05191004,WITHDRAWN,Advanced Breast Cancer|Metastatic Breast Cancer|Breast Cancer|Breast Carcinoma|Cancer of the Breast|Cancer of Breast|Malignant Tumor of Breast|Breast Tumor,DRUG: NUV-422|DRUG: Fulvestrant,Nuvation Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,2022-09,2026-09
NCT05982093,RECRUITING,Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Premenopausal Breast Cancer,DRUG: Elacestrant|DRUG: Triptorelin,SOLTI Breast Cancer Research Group,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,10/3/2023,2025-01
NCT06110793,RECRUITING,Metastatic Breast Cancer,DRUG: Lenvatinib|DRUG: Pembrolizuma|DRUG: Fulvestrant,Memorial Sloan Kettering Cancer Center,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,43,OTHER,INTERVENTIONAL,12/29/2023,2026-11
NCT05159193,RECRUITING,Breast Cancer,DRUG: pegylated liposomal doxorubicin (PLD)|DRUG: cyclophosphamide (C)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P)|DRUG: docetaxel (T)|DRUG: docetaxel (T)|DRUG: carboplatin (Cb)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P),Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE3,372,OTHER,INTERVENTIONAL,12/20/2021,1/31/2028
NCT05664893,RECRUITING,HER2 Negative Breast Cancer Not Immediately Operated,DRUG: Ribociclib Oral Tablet,Centre Antoine Lacassagne,,FEMALE,OLDER_ADULT,PHASE1|PHASE2,85,OTHER,INTERVENTIONAL,6/26/2023,2032-03
NCT05716893,RECRUITING,Breast Cancer|Breast Carcinoma,BEHAVIORAL: Adaptive Aerobic Training/AT Dosing|BEHAVIORAL: Standard (fixed) Aerobic Training/AT dosing,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,INTERVENTIONAL,1/30/2023,1/30/2028
NCT05891093,RECRUITING,Breast Cancer,DRUG: Fluzoparib|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Tamoxifen|DRUG: Toremifene|DRUG: Abemaciclib|DRUG: LHRH agonist,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,766,OTHER,INTERVENTIONAL,6/1/2023,5/31/2031
NCT05103293,COMPLETED,"Pathological Conditions, Signs and Symptoms",DIAGNOSTIC_TEST: patient-derived tumor-like cell clusters drug sensitivity test,Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,INTERVENTIONAL,11/1/2021,12/10/2023
NCT04276493,ACTIVE_NOT_RECRUITING,Breast Cancer|Gastric Cancer|Gastroesophageal Junction Cancer,BIOLOGICAL: ZW25|DRUG: Docetaxel|BIOLOGICAL: Tislelizumab|DRUG: Capecitabine|DRUG: Oxaliplatin,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,71,INDUSTRY,INTERVENTIONAL,3/26/2020,12/31/2026
NCT05750693,ACTIVE_NOT_RECRUITING,HER2-positive Breast Cancer,GENETIC: PIK3CA analysis,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,5/2/2022,9/1/2023
NCT05267171,COMPLETED,Breast Neoplasm|Primary Prevention|Risk Factors|Telemedicine,OTHER: Web access,University of Oviedo,,FEMALE,ADULT,NA,424,OTHER,INTERVENTIONAL,1/15/2022,6/26/2022
NCT05656079,RECRUITING,Breast Cancer,DRUG: Pegylated liposomal doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel,Shanghai Pudong Hospital,"CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,INTERVENTIONAL,7/1/2021,2025-09
NCT05935891,RECRUITING,Musculoskeletal Syndrome,DRUG: CBD-dominant|DRUG: THC dominant,University of Minnesota,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,4/1/2023,4/1/2025
NCT05467891,RECRUITING,Locoregional Recurrence|Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer,DRUG: Ribociclib|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,Oana Danciu,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,9/13/2022,2027-12
NCT04174391,RECRUITING,Malignant Tumor of Breast,BEHAVIORAL: Mediterranean diet supplemented with extra-virgin olive oil|BEHAVIORAL: Low-fat diet,University of Navarra,Instituto de Salud Carlos III,FEMALE,"ADULT, OLDER_ADULT",NA,766,OTHER,INTERVENTIONAL,5/29/2020,2024-12
NCT05465408,RECRUITING,Breast Cancer|Survivorship|Treatment Compliance|Treatment Adherence|Treatment Refusal,BEHAVIORAL: Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention,Massachusetts General Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/21/2022,6/30/2024
NCT04088708,RECRUITING,Breast Cancer|Gut Microbiome|Exercise|Fatigue,OTHER: Aerobic Exercise Training|OTHER: Attention Control,University of Alabama at Birmingham,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,1/17/2020,8/31/2025
NCT05871008,RECRUITING,Breast Cancer|Hodgkin Lymphoma|Kidney Cancer|Leukemia|Lymphoid Leukemia|Multiple Myeloma|Myeloid Leukemia|Monocytic Leukemia|Prostate Cancer|Bladder Cancer,OTHER: Assessment tool IA3-CP with SDoH|OTHER: Assessment tool IA3-CP without SDoH,"University of Colorado, Denver",National Cancer Institute (NCI),ALL,OLDER_ADULT,NA,35,OTHER,INTERVENTIONAL,2024-12,2026-12
NCT04937309,RECRUITING,Breast Cancer,DEVICE: non invasive auricular vagal stimulation|DRUG: usual medical treatment|DEVICE: sham stimulation,"University Hospital, Tours",,ALL,"ADULT, OLDER_ADULT",NA,338,OTHER,INTERVENTIONAL,6/24/2022,5/1/2024
NCT05919108,NOT_YET_RECRUITING,Anatomic Stage I Breast Cancer|Anatomic Stage II Breast Cancer|Anatomic Stage III Breast Cancer|Invasive Breast Lobular Carcinoma,PROCEDURE: Endocrine Therapy|PROCEDURE: Biopsy of breast|DRUG: Neratinib|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammogram|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Breast Surgery|PROCEDURE: Ultrasound,Vanderbilt-Ingram Cancer Center,"National Cancer Institute (NCI)|Puma Biotechnology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,4/30/2024,1/30/2030
NCT04872608,WITHDRAWN,Metastatic Breast Cancer|Unresectable Breast Cancer,DRUG: Letrozole|DRUG: Palbociclib|DRUG: Onapristone ER,Memorial Sloan Kettering Cancer Center,Context Therapeutics Inc.,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,9/9/2021,4/25/2023
NCT05392608,RECRUITING,"Neoplasm, Breast|Congenital, Familial and Genetic Disorders",DRUG: Alpelisib 150 MG Oral Tablet [Piqray]|DRUG: Fulvestrant,Borstkanker Onderzoek Groep,Novartis Pharma B.V.|BOOG Study Center,ALL,"ADULT, OLDER_ADULT",PHASE2,130,NETWORK,INTERVENTIONAL,6/2/2022,2028-03
NCT05605808,RECRUITING,"Immune Deficiency|Diet, Healthy|Breast Cancer",OTHER: Aerobic exercises|OTHER: Diet protocol,Cairo University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,5/20/2022,3/28/2023
NCT04541108,RECRUITING,Solid Tumor,BIOLOGICAL: Pembrolizumab|COMBINATION_PRODUCT: MK-0482 + Pembrolizumab|COMBINATION_PRODUCT: MK-4830 + Pembrolizumab,Presage Biosciences,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,INDUSTRY,INTERVENTIONAL,7/26/2021,2031-12
NCT04893109,RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: trastuzumab-emtansine|DRUG: Trastuzumab SC|DRUG: Paclitaxel,Dana-Farber Cancer Institute,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,INTERVENTIONAL,6/16/2021,5/1/2028
NCT04491591,ACTIVE_NOT_RECRUITING,Breast Reconstruction|Breast Cancer,OTHER: Breast Reconstruction Education and Support Tool (BREASTChoice)|OTHER: Attention Control Website|OTHER: Clinician Survey,Washington University School of Medicine,Agency for Healthcare Research and Quality (AHRQ),FEMALE,"ADULT, OLDER_ADULT",NA,412,OTHER,INTERVENTIONAL,11/4/2020,6/30/2023
NCT05766891,RECRUITING,Breast Cancer,BEHAVIORAL: Group 1|BEHAVIORAL: Group 2|BEHAVIORAL: Group 3,M.D. Anderson Cancer Center,National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,225,OTHER,INTERVENTIONAL,10/12/2023,12/31/2028
NCT04176809,RECRUITING,Breast Cancer,OTHER: Routine Assessment of HRQoL coupled with Therapeutic Information,Centre Georges Francois Leclerc,,FEMALE,"ADULT, OLDER_ADULT",NA,342,OTHER,INTERVENTIONAL,5/14/2021,2025-10
NCT04228991,RECRUITING,Breast Neoplasms|Radiotherapy|Lymphedema,RADIATION: Locoregional radiation treatment - Conventional fractionation|RADIATION: Locoregional radiation treatment - Hypofractionation,Ontario Clinical Oncology Group (OCOG),,ALL,"ADULT, OLDER_ADULT",PHASE3,588,OTHER,INTERVENTIONAL,2/10/2021,12/31/2030
NCT05327608,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Breast Ductal Carcinoma in Situ|HER2 Negative Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Carcinoma,OTHER: Short-Term Fasting,Thomas Jefferson University,,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,7/28/2022,5/1/2024
NCT05500508,RECRUITING,"Cancer|Solid Tumor|Solid Carcinoma|Advanced Cancer|DIPG Brain Tumor|Ovary Cancer|Breast Cancer|Papillary Thyroid Cancer|Head and Neck Cancer|Gastric Cancer|Nsclc|Mesotheliomas Pleural|Mesothelioma Peritoneum|Esophageal Cancer|Diffuse Midline Glioma, H3 K27M-Mutant|Endometrial Cancer|Cervical Cancer|Melanoma|Colorectal Cancer|Glioma, Malignant",DRUG: AMXT1501|DRUG: DFMO,"Aminex Therapeutics, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,56,INDUSTRY,INTERVENTIONAL,11/29/2022,9/30/2024
NCT04248608,COMPLETED,Analgesia,PROCEDURE: serratus plane block|PROCEDURE: erector spinae block|DRUG: Morphine Sulfate,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,1/28/2020,7/1/2020
NCT04871139,RECRUITING,Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Contrast-Enhanced Mammography|OTHER: Questionnaire Administration|OTHER: Radioactive Iodine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,4/8/2021,3/1/2026
NCT04511871,RECRUITING,Solid Tumor|Gastric Cancer|Breast Cancer|Ovarian Cancer|Sarcoma,BIOLOGICAL: CCT303-406,"Shanghai PerHum Therapeutics Co., Ltd.",Shanghai Zhongshan Hospital,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,INTERVENTIONAL,7/9/2020,3/29/2025
NCT06120439,RECRUITING,Breast Cancer|Pectoral Nerves Block|Breast-Conserving Surgery|Sentinel Lymph Node Biopsy,COMBINATION_PRODUCT: PECS II combined with intercostal nerve blockade;|COMBINATION_PRODUCT: General anesthesia with laryngeal mask,Jun Zhang,,FEMALE,"ADULT, OLDER_ADULT",NA,96,OTHER,INTERVENTIONAL,10/15/2023,2/28/2024
NCT04824339,UNKNOWN,Breast Neoplasms,BEHAVIORAL: Immediate Intervention Group|BEHAVIORAL: Delayed Intervention Group,University of British Columbia,British Columbia Cancer Agency,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,INTERVENTIONAL,3/15/2021,12/31/2023
NCT06176339,NOT_YET_RECRUITING,Breast Cancer Female,DRUG: Pentoxifylline Oral Tablet|DRUG: Placebo,Mansoura University,,ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,12/15/2023,9/30/2024
NCT05258539,RECRUITING,Breast Cancer,OTHER: Questionnaire,Assistance Publique - HÃ´pitaux de Paris,,FEMALE,"ADULT, OLDER_ADULT",NA,189,OTHER,INTERVENTIONAL,5/31/2022,4/1/2032
NCT04395339,RECRUITING,"Brain Metastases|Radiotherapy Side Effect|Cognitive Impairment|Gangliosidosis, GM1|Breast Cancer",DRUG: Monosialotetrahexosyl ganglioside (GM1)|DRUG: Control,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,204,OTHER,INTERVENTIONAL,5/15/2020,12/31/2024
NCT05641571,NOT_YET_RECRUITING,CIPN - Chemotherapy-Induced Peripheral Neuropathy,BEHAVIORAL: The home-based extremity exercise program,Taichung Veterans General Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,12/1/2022,12/31/2023
NCT04246671,ACTIVE_NOT_RECRUITING,Chordoma|HER2-positive Breast Cancer|HER2-positive Gastric/Gastroesophageal Junction Cancer,BIOLOGICAL: TAEK-VAC-HerBy,Bavarian Nordic,,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INDUSTRY,INTERVENTIONAL,8/10/2020,2026-06
NCT05226871,RECRUITING,Breast Cancer|Head and Neck Cancer,DRUG: Palbociclib|DRUG: Cetuximab|DRUG: Fulvestrant|DRUG: Letrozole,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INDUSTRY,INTERVENTIONAL,7/7/2022,4/19/2026
NCT05278871,COMPLETED,Lymphedema of Upper Arm|Breast Cancer,DEVICE: Constructive Shearwave Interference (CSI),Microelastic Ultrasound Systems Inc,Duke Health,ALL,"ADULT, OLDER_ADULT",NA,21,INDUSTRY,INTERVENTIONAL,5/26/2022,8/31/2023
NCT04849871,RECRUITING,Breast Carcinoma|Breast Cancer|Stage 0 Breast Cancer|Stage I Breast Cancer,RADIATION: External Beam Accelerated Partial Breast Irradiation,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,8/12/2021,6/30/2029
NCT04560439,WITHDRAWN,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,DIETARY_SUPPLEMENT: Dietary Intervention,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,6/15/2022,6/15/2023
NCT06189209,NOT_YET_RECRUITING,Triple Negative Breast Cancer (TNBC),DRUG: Tenalisib,Rhizen Pharmaceuticals SA,Incozen Therapeutics Pvt Ltd,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,INTERVENTIONAL,12/26/2023,2025-03
NCT04744506,RECRUITING,Breast Cancer|Surgery|Lymph Node Metastases,DEVICE: Tissue Marker Clip,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",NA,332,OTHER,INTERVENTIONAL,11/15/2020,7/15/2025
NCT05558917,ENROLLING_BY_INVITATION,Breast Cancer|Breast Neoplasms|Breast Carcinoma,PROCEDURE: PECS BLOCK 2|PROCEDURE: ESP BLOCK,Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria,,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,9/7/2022,11/7/2023
NCT04442126,ACTIVE_NOT_RECRUITING,Advanced Solid Tumor|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma|Ovarian Carcinoma|Peritoneal Carcinoma|Fallopian Tube Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer,BIOLOGICAL: NM21-1480,Numab Therapeutics AG,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,406,INDUSTRY,INTERVENTIONAL,8/19/2020,2024-01
NCT04472104,COMPLETED,Sexual Dysfunction,BEHAVIORAL: MBCT-S|BEHAVIORAL: SexEd,University of British Columbia,University of Calgary,FEMALE,"ADULT, OLDER_ADULT",NA,118,OTHER,INTERVENTIONAL,1/6/2020,4/1/2023
NCT05189717,ENROLLING_BY_INVITATION,Metastatic or Local Advanced Breast Cancer of Patients,DRUG: HRS-8080 tabletsã€SHR 6390 tabletsã€Abemaciclibã€Everolimus,"Shandong Suncadia Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,156,INDUSTRY,INTERVENTIONAL,2/17/2022,7/31/2025
NCT05438706,NOT_YET_RECRUITING,Triple-negative Breast Cancer,DRUG: chidamide|DRUG: camrelizumab|DRUG: carboplatin|DRUG: capecitabine,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,7/10/2022,7/10/2024
NCT05278806,COMPLETED,Hypertension|Diabetes|Breast Cancer,"OTHER: Equity Dashboard, Population Health Coordinator and Community Health Worker Support|OTHER: Equity Dashboard and Population Health Coordinator Support",Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",NA,10766,OTHER,INTERVENTIONAL,3/24/2022,4/30/2023
NCT04946227,UNKNOWN,Breast Cancer,DRUG: Pembrolizumab 200mg +Paclitaxel 80mg/m2,Yonsei University,,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,INTERVENTIONAL,2021-07,2022-12
NCT04925817,ACTIVE_NOT_RECRUITING,Breast Carcinoma,OTHER: Electronic Health Record Review|PROCEDURE: Ultrasound Microvessel Imaging,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,INTERVENTIONAL,8/19/2021,2024-04
NCT04625517,TERMINATED,Breast Cancer,"PROCEDURE: Digital Mammography|DRUG: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml",University of Texas Southwestern Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE4,6,OTHER,INTERVENTIONAL,1/22/2020,6/15/2022
NCT04531917,ACTIVE_NOT_RECRUITING,Breast Neoplasms|Survivors|Chronic Pain,OTHER: Pain Neuroscience Education|OTHER: Behavioural Graded Activity|OTHER: Usual care,Universitair Ziekenhuis Brussel,"Fund for Scientific Research, Flanders, Belgium|Vrije Universiteit Brussel",FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,INTERVENTIONAL,10/12/2020,2024-04
NCT04602117,WITHDRAWN,HER2-positive Breast Cancer|HER2 Low|SYD-985|SYD985|Vic-trastuzumab Duocarmazine|Metastatic Cancer|Metastatic Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic|HER2 Low Breast Cancer|GastroEsophageal Cancer|Gastroesophageal Adenocarcinoma|Endometrium Tumor|Ovarian Cancer|Ovarian Carcinoma|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2 Low HR Positive|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Bladder Cancer,DRUG: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,QuantumLeap Healthcare Collaborative,Byondis B.V.,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,7/28/2021,11/17/2021
NCT06073717,RECRUITING,Breast Cancer Survivors|Cognitive Impairment|Executive Dysfunction,BEHAVIORAL: Exercise|BEHAVIORAL: Motor-cognitive Training|BEHAVIORAL: Health and Wellness,University of Seville,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,2024-03,2025-02
NCT04568226,RECRUITING,Fear of Cancer Recurrence,OTHER: ConquerFear Intervention|OTHER: Active control: Basic Cancer Care,The University of Hong Kong,"Research Grants Council, Hong Kong",ALL,"ADULT, OLDER_ADULT",NA,174,OTHER,INTERVENTIONAL,7/21/2021,12/31/2024
NCT05103826,TERMINATED,ER+ / HER2- Advanced Breast Cancer,DRUG: SHR6390ã€Famitinib,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,3,INDUSTRY,INTERVENTIONAL,10/25/2021,6/15/2023
NCT05272904,NOT_YET_RECRUITING,Seroma,PROCEDURE: Quilting|PROCEDURE: Conventional wound closure,Canisius-Wilhelmina Hospital,"Rijnstate Hospital|OLVG|Martini Hospital Groningen|Catharina Ziekenhuis Eindhoven|St Jansdal Hospital|Bravis Hospital|Diakonessenhuis, Utrecht|St. Antonius Hospital|Gelderse Vallei Hospital",ALL,"ADULT, OLDER_ADULT",NA,113,OTHER,INTERVENTIONAL,8/1/2022,7/1/2023
NCT05720026,RECRUITING,HER2-positive Breast Cancer,DRUG: SYSA1901|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,INTERVENTIONAL,1/9/2023,2/21/2026
NCT06130826,NOT_YET_RECRUITING,Breast Carcinoma|Colorectal Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Immunotherapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Stereotactic Body Radiation Therapy,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,6/12/2024,10/22/2026
NCT05782504,RECRUITING,Breast Cancer|Breast Neoplasms|Surgery,BEHAVIORAL: Patient-centered teleprehabilitation,Universitair Ziekenhuis Brussel,Vrije Universiteit Brussel|Ziekenhuis Oost-Limburg|Hasselt University|Kom Op Tegen Kanker,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,1/30/2023,8/31/2024
NCT06000917,RECRUITING,Breast Cancer|Neoadjuvant,"DRUG: pyrotinib,Trastuzumabï¼Œcarboplatinï¼ŒAlbumin paclitaxel","Wuhan Union Hospital, China",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,62,OTHER,INTERVENTIONAL,5/11/2023,5/11/2028
NCT05607017,RECRUITING,Breast Cancer|Myocardial Fibrosis|Radiation-Induced Fibrosis,DRUG: Losartan|RADIATION: Radiation Therapy,Massachusetts General Hospital,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,1/1/2024,12/1/2024
NCT05357417,RECRUITING,Breast Cancer,DRUG: utidelone|DRUG: Bevacizumab,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,INTERVENTIONAL,4/29/2022,2024-05
NCT04881604,COMPLETED,"Breast Cancer Related Lymphedema|Lymphedema, Secondary|Lymphedema of Upper Arm|Breast Neoplasms",DEVICE: Adjustable Compression Wrap|DEVICE: Compression Sleeve,"Instituto Nacional de Cancer, Brazil",,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,INTERVENTIONAL,6/1/2021,3/31/2023
NCT04768426,RECRUITING,Triple Negative Breast Cancer|Breast Cancer,DRUG: Capecitabine,Stanford University,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,2/3/2021,2026-02
NCT04733417,ACTIVE_NOT_RECRUITING,Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: SHR6390|DRUG: famitinib,Tianjin Medical University Cancer Institute and Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,5/26/2021,9/30/2023
NCT05331326,RECRUITING,Metastatic Breast Cancer,DRUG: RC48-ADC,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,INTERVENTIONAL,2022-04,2024-08
NCT05868226,RECRUITING,"HER2-positive Breast Cancer|Metastatic Cancer|Metastatic Breast Cancer|Metastatic|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2-negative Breast Cancer|Triple Negative Breast Cancer|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Solid Tumor|Solid Tumor, Adult|Solid Carcinoma|HER2 Low Breast Cancer|HER2 Low Breast Carcinoma|ER Positive Breast Cancer|PR-positive Breast Cancer",DRUG: ALX148|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Zanidatamab|DRUG: Tucatinib,QuantumLeap Healthcare Collaborative,,ALL,"ADULT, OLDER_ADULT",PHASE1,54,OTHER,INTERVENTIONAL,12/22/2022,12/30/2027
NCT05807126,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Stage IVB Prostate Cancer AJCC v8,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Magrolimab|DRUG: Olaparib,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,33,NIH,INTERVENTIONAL,3/5/2024,12/6/2026
NCT05491226,RECRUITING,TNBC - Triple-Negative Breast Cancer|Breast Cancer,DRUG: Pembrolizumab|RADIATION: Radiation Therapy|DRUG: Axatilimab,Stephen Shiao,Merck Sharp & Dohme LLC|Incyte Corporation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,12/1/2023,12/1/2025
NCT05258526,RECRUITING,Breast Cancer|Prostate Cancer,OTHER: Home based exercise training,Hospital de Clinicas de Porto Alegre,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,4/7/2022,12/30/2023
NCT05565417,RECRUITING,Non Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Cutaneous Squamous Cell Carcinoma|Hormone Receptor Positive Breast Carcinoma|Small Bowel Cancer|Esophageal Cancer|Colorectal Cancer|Diffuse Large B Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|T-cell Lymphoma,DRUG: IMT-009,Immunitas Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,119,INDUSTRY,INTERVENTIONAL,11/28/2022,2025-04
NCT05365204,RECRUITING,Breast Cancer|Sentinel Lymph Node,PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping,National Taiwan University Hospital Hsin-Chu Branch,National Yang Ming Chiao Tung University,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,4/8/2022,4/7/2023
NCT05103917,UNKNOWN,Triple Negative Breast Cancer,DRUG: X4P-001,"Abbisko Therapeutics Co, Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,INDUSTRY,INTERVENTIONAL,7/21/2021,5/21/2023
NCT06015126,RECRUITING,Breast Cancer,DRUG: metronomic oral vinorelbine plus anlotinib,Yan Xue,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,10/5/2022,2026-01
NCT04316117,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,138,NETWORK,INTERVENTIONAL,9/15/2020,8/31/2027
NCT05721326,ENROLLING_BY_INVITATION,Genetic Predisposition to Disease|Breast Cancer Female|Ovarian Cancer|Hereditary Breast and Ovarian Cancer|Hereditary Cancer Syndrome|Hereditary Diseases|Gene Mutation-Related Cancer,OTHER: Sequential EHR Communications,Abramson Cancer Center at Penn Medicine,,FEMALE,"ADULT, OLDER_ADULT",NA,450,OTHER,INTERVENTIONAL,5/1/2023,6/1/2024
NCT05473026,COMPLETED,"Cancer Survivors|African Americans|Women|Psychology, Positive|Cardiometabolic Syndrome|Exercise|Feasibility Studies|Breast Neoplasm Female",BEHAVIORAL: Gratitude Intervention,University of Florida,National Institute on Aging (NIA),FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,11/8/2022,7/25/2023
NCT05523609,RECRUITING,Breast Cancer,DRUG: Letrozole 2.5mg|DRUG: Letrozole + vitamin D3 and calcium,Tanta University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,40,OTHER,INTERVENTIONAL,11/1/2022,2024-10
NCT05063604,TERMINATED,Breast Cancer|Major Depressive Episode,DRUG: Citalopram|BEHAVIORAL: Psychotherapy,Hospital Universitari de Bellvitge,Institut CatalÃ  d'Oncologia,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,5/10/2022,6/29/2022
NCT04505826,ACTIVE_NOT_RECRUITING,Hormone Receptor Positive Breast Carcinoma|HER2-negative Breast Cancer,DRUG: OP-1250,"Olema Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,153,INDUSTRY,INTERVENTIONAL,8/13/2020,2024-07
NCT05673304,RECRUITING,Breast Cancer|Radiotherapy,RADIATION: SBRT anticipated boost,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,6/1/2023,12/31/2026
NCT05296317,RECRUITING,Localized Breast Cancer,"DRUG: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|DRUG: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)",Centre Georges Francois Leclerc,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,9/2/2022,4/2/2024
NCT06227117,NOT_YET_RECRUITING,Breast Cancer,DRUG: Disitamab Vedotin Injection ï¼ˆ18 weeksï¼‰|DRUG: Toripalimab ï¼ˆ18weeksï¼‰|DRUG: Carboplatin|DRUG: Disitamab Vedotin Injection ï¼ˆ12 weeksï¼‰|DRUG: Sequential Epirubicin|DRUG: Sequential CTX|DRUG: Toripalimab ï¼ˆ12weeksï¼‰,"RemeGen Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,160,INDUSTRY,INTERVENTIONAL,2024-01,2026-12
NCT05378204,RECRUITING,Breast Cancer,OTHER: Main study:|OTHER: Sub-study:,Institut Claudius Regaud,Artios Pharma Ltd,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,6/23/2022,2025-06
NCT05607004,RECRUITING,Breast Neoplasms|Invasive Breast Cancer|Estrogen-receptor-positive Breast Cancer|HER2-negative Breast Cancer,DRUG: (Z)-endoxifen|DRUG: exemestane|DRUG: goserelin,"Atossa Therapeutics, Inc.",InClin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,INDUSTRY,INTERVENTIONAL,2/14/2023,2026-09
NCT04362826,NOT_YET_RECRUITING,Breast Cancer,BIOLOGICAL: Novel probiotic|OTHER: Placebo,Case Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,6/1/2024,1/1/2026
NCT05085626,RECRUITING,Advanced HER2 Negative Breast Carcinoma|HRD+Breast Cancer,DRUG: fluzoparib+chidamide|DRUG: fluzoparib+camrelizumab,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,2/8/2021,12/31/2024
NCT04999917,RECRUITING,Breast Cancer|Breast Cancer Invasive|Breast Cancer in Situ,DIAGNOSTIC_TEST: high-resolution PET-CT specimen imaging.,XEOS Medical,,FEMALE,"ADULT, OLDER_ADULT",NA,160,INDUSTRY,INTERVENTIONAL,6/17/2022,4/30/2024
NCT04982926,RECRUITING,Solid Tumor|Glioblastoma|Non-small Cell Lung Cancer|Breast Cancer,DRUG: TAS2940|DRUG: TAS2940,"Taiho Oncology, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,INTERVENTIONAL,9/16/2021,2025-06
NCT05514717,SUSPENDED,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Non-Small Cell Lung Cancer|HER2-positive Colorectal Cancer|HER2-positive Tumors|HER2 Low Breast Cancer,DRUG: XMT-2056,Mersana Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,171,INDUSTRY,INTERVENTIONAL,1/24/2023,2025-11
NCT04713917,RECRUITING,Breast Cancer,DEVICE: Hyaluronique Acid Gel|DEVICE: Laser CO2|DEVICE: Hyaluronique Acid Injection,Assistance Publique - HÃ´pitaux de Paris,INTERmedic|Laboratoires Vivacy|Laboratoires IPRAD PHARMA,FEMALE,"ADULT, OLDER_ADULT",NA,330,OTHER,INTERVENTIONAL,2/21/2021,2/1/2024
NCT05879926,RECRUITING,Breast Cancer,DRUG: Ovarian Function Suppression + Aromatase Inhibitor|DRUG: Adjuvant Chemotherapy + Ovarian Function Suppression,NRG Oncology,National Cancer Institute (NCI),FEMALE,ADULT,PHASE3,3960,OTHER,INTERVENTIONAL,8/31/2023,2034-07
NCT04247126,COMPLETED,Advanced Solid Tumor|Breast Cancer|Small-cell Lung Cancer|Pancreatic Cancer,DRUG: SY-5609|DRUG: Fulvestrant|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,Syros Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,105,INDUSTRY,INTERVENTIONAL,1/23/2020,3/30/2023
NCT04339517,SUSPENDED,Breast Cancer,PROCEDURE: Aspiration of seroma fluid,Lawson Health Research Institute,,FEMALE,"CHILD, ADULT",NA,20,OTHER,INTERVENTIONAL,8/17/2021,8/30/2026
NCT04842617,ENROLLING_BY_INVITATION,"Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stageï¼ŒFemale Breast Cancer",DRUG: SHR6390|DRUG: placebo,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,4350,INDUSTRY,INTERVENTIONAL,4/30/2021,10/31/2031
NCT04140526,RECRUITING,Non Small Cell Lung Cancer|Advanced Solid Tumor|Metastatic Melanoma|Metastatic Head and Neck Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Colorectal Cancer|Sarcomas|Metastatic Prostate Cancer|Ovarian Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Pancreas Cancer|Gastric Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma|Cervical Cancer|Adenoid Cystic Carcinoma|Salivary Gland Cancer|Urothelial Carcinoma,DRUG: ONC-392|DRUG: Pembrolizumab,"OncoC4, Inc.",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,914,INDUSTRY,INTERVENTIONAL,9/16/2020,12/31/2024
NCT05206526,COMPLETED,Breast Cancer,BEHAVIORAL: Dragon Boat|BEHAVIORAL: Home-based Exercise,University of Padova,,FEMALE,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,5/15/2021,9/30/2021
NCT04459104,COMPLETED,Chronic Pain,OTHER: Low glycemic load|OTHER: High glycemic load,Vrije Universiteit Brussel,KU Leuven,FEMALE,"ADULT, OLDER_ADULT",NA,121,OTHER,INTERVENTIONAL,9/21/2020,12/19/2022
NCT04225117,RECRUITING,Locally Advanced or Metastatic Malignant Solid Tumors,DRUG: enfortumab vedotin|DRUG: pembrolizumab,"Astellas Pharma Global Development, Inc.",Seagen Inc.|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,320,INDUSTRY,INTERVENTIONAL,3/9/2020,9/30/2026
NCT06086704,RECRUITING,Breast Cancer,DRUG: 18F-fluorofuranylnorprogesterone|DEVICE: Positron Emissions Tomography / Magnetic Resonance Imaging|DRUG: Anastrozole|OTHER: Blood Sampling|DRUG: Gadobenate dimeglumine,"University of Wisconsin, Madison",National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,INTERVENTIONAL,2024-02,2030-01
NCT05696626,RECRUITING,Metastatic Breast Cancer,DRUG: Lasofoxifene in combination with abemaciclib|DRUG: Fulvestrant in combination with abemaciclib,Sermonix Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,10/31/2023,2026-06
NCT05981326,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: Biopsy|PROCEDURE: Blood samples|BEHAVIORAL: Questionnaires,Institut Cancerologie de l'Ouest,,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,2023-10,2033-04
NCT05573126,RECRUITING,Hormone Receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Metastatic Breast Cancer,DRUG: EP0062,Ellipses Pharma,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,128,INDUSTRY,INTERVENTIONAL,1/11/2023,2025-03
NCT05982626,RECRUITING,HER2-positive Breast Cancer,RADIATION: 68Ga/131I-SGMIB-5F7,Huashan Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,5/15/2023,5/14/2024
NCT05747326,RECRUITING,Breast Cancer,DRUG: oral vinorelbine and capecitabine,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,1/1/2022,2023-06
NCT04940026,COMPLETED,Breast Cancer|Healthy Volunteers,DRUG: amcenestrant|DRUG: [14C]-SAR439859 microtracer|DRUG: [14C]-SAR439859,Sanofi,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,6/15/2021,8/19/2021
NCT04986852,RECRUITING,Metastatic Triple-Negative Breast Cancer,DRUG: Olinvacimab,PharmAbcine,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,INTERVENTIONAL,9/30/2021,8/30/2026
NCT04054752,WITHDRAWN,Breast Carcinoma|Colorectal Adenocarcinoma|Bladder Carcinoma,BIOLOGICAL: Recombinant human IL-7-hyFc (NT-I7)|BIOLOGICAL: Vaccine sequence 1|BIOLOGICAL: Vaccine sequence 2,National Cancer Institute (NCI),NeoImmuneTech,ALL,"ADULT, OLDER_ADULT",PHASE1,0,NIH,INTERVENTIONAL,5/30/2023,11/1/2023
NCT04864405,COMPLETED,Breast Cancer,OTHER: Morning administration of endocrine therapy|OTHER: Evening administration of endocrine therapy,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,247,OTHER,INTERVENTIONAL,6/30/2021,7/29/2023
NCT05164952,UNKNOWN,Use of Zoledronic Acid in Breast Cancer,DRUG: Zoledronic Acid 4 MG,Assiut University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,INTERVENTIONAL,9/30/2021,9/30/2023
NCT06052852,RECRUITING,Triple Negative Breast Cancer|Clear Cell Renal Cell Carcinoma|Ovarian Cancer|Head and Neck Cancer|Colorectal Cancer|Non-small Cell Lung Cancer,DRUG: BDC-3042|DRUG: Pembrolizumab,"Bolt Biotherapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,167,INDUSTRY,INTERVENTIONAL,10/11/2023,2028-03
NCT05395117,COMPLETED,Healthy Participants,DRUG: AZD5462|DRUG: Midazolam|DRUG: Rosuvastatin|DRUG: Digoxin,AstraZeneca,Parexel,ALL,ADULT,PHASE1,32,INDUSTRY,INTERVENTIONAL,6/30/2022,9/12/2022
NCT05179304,UNKNOWN,Oncoplastic Breast Surgery|Breast Cancer|Aesthetic Outcomes,PROCEDURE: Oncoplastic technique with a droplet-shaped glandular flap,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,109,OTHER,INTERVENTIONAL,1/18/2022,2022-11
NCT05297617,RECRUITING,Breast Cancer,DRUG: Anti-aromatase inhibitor,UNICANCER,Agendia,FEMALE,"ADULT, OLDER_ADULT",PHASE2,696,OTHER,INTERVENTIONAL,10/12/2022,2034-11
NCT04336917,COMPLETED,Breast Cancer Surgery|Postoperative Analgesia,DRUG: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic,Konya Meram State Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,8/31/2020,3/1/2021
NCT04947917,TERMINATED,Breast Cancer|Lymph Node Metastases,PROCEDURE: SpotTM Tattoo Ink,Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,12/29/2021,4/13/2023
NCT04132817,COMPLETED,Breast Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Nab-paclitaxel,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,9/22/2020,8/15/2022
NCT04829604,RECRUITING,HER2 Positive Metastatic Breast Cancer,DRUG: ARX788,"Ambrx, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,71,INDUSTRY,INTERVENTIONAL,10/26/2021,2026-12
NCT06009627,RECRUITING,Breast Cancer,DRUG: Dalcelliã€Exemestaneã€Gosserine|DRUG: Docetaxel for injectionã€Epirubicin hydrochloride for injectionã€Cyclophosphamide for injection,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,119,OTHER,INTERVENTIONAL,4/11/2023,9/11/2026
NCT06113627,NOT_YET_RECRUITING,Breast Cancer Lymphedema|Survivorship|Lymphedema of Upper Limb,OTHER: Resistance Therapeutic Exercise,University of Malaga,,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,INTERVENTIONAL,2024-08,1/15/2027
NCT05622227,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Drug: 68Ga-P16-093,Peking Union Medical College Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,INTERVENTIONAL,11/15/2022,12/31/2024
NCT05575804,ACTIVE_NOT_RECRUITING,Advanced/ Metastatic Her-2 Positive Breast Cancer,DRUG: GQ1001+pyrotinib|DRUG: pyrotinib+capecitabine,Fudan University,"GeneQuantum Healthcare (Suzhou) Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,75,OTHER,INTERVENTIONAL,10/1/2022,1/1/2024
NCT04989504,RECRUITING,Breast Carcinoma|Mastectomy Patient,OTHER: Best Practice|DEVICE: Wound Dressing Material|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,INTERVENTIONAL,6/15/2022,12/31/2025
NCT05637671,RECRUITING,Vasomotor Symptoms,DRUG: oxybutynin ER|DRUG: Paroxetine CR,Cairo University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,146,OTHER,INTERVENTIONAL,2/10/2022,2023-12
NCT04856371,UNKNOWN,Advanced Breast Cancer,DRUG: CYH33|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib,"Haihe Biopharma Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,228,INDUSTRY,INTERVENTIONAL,2021-04,2022-12
NCT05645471,RECRUITING,Breast Cancer|Quality of Life|Communication,BEHAVIORAL: Together After Cancer,University of South Florida,H. Lee Moffitt Cancer Center and Research Institute|University of Miami Sylvester Comprehensive Cancer Center|AdventHealth|University of Central Florida,ALL,"ADULT, OLDER_ADULT",NA,480,OTHER,INTERVENTIONAL,1/1/2023,3/1/2026
NCT04920708,RECRUITING,Metastatic Breast Cancer|ER+ Breast Cancer|Advanced Breast Cancer,DRUG: Ipatasertib 300mg|DRUG: Fulvestrant 500g|DRUG: Palbociclib 75mg-125mg|DRUG: CDK4/6 Inhibitor,Royal Marsden NHS Foundation Trust,Pfizer|Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,324,OTHER,INTERVENTIONAL,12/28/2022,2026-09
NCT05773391,RECRUITING,Breast Cancer,DRUG: Take probiotics,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,4/12/2023,2024-08
NCT06105008,NOT_YET_RECRUITING,Breast Neoplasms,DRUG: Disitamab Vedotin|DRUG: Toripalimab,"RemeGen Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,INTERVENTIONAL,12/20/2023,4/10/2026
NCT03979508,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Ductal Carcinoma In Situ|Breast Fibrocystic Change|Breast Lobular Carcinoma In Situ|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,DRUG: Abemaciclib|PROCEDURE: Therapeutic Conventional Surgery,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,1/10/2020,7/31/2024
NCT05436808,WITHDRAWN,Breast Cancer|Breast Cancer Female|DCIS|Stage II Breast Cancer|Stage I Breast Cancer,RADIATION: Partial Chest Wall Radiation Therapy,Stony Brook University,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,7/15/2022,2029-08
NCT05503108,SUSPENDED,Fasting Mimicking Diet|HER2-negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Pathological Complete Response|Objective Response Rate|Neoadjuvant Chemotherapy,OTHER: Fasting Mimicking diet program,Leiden University Medical Center,The Netherlands Cancer Institute|Borstkanker Onderzoek Groep|Comprehensive Cancer Centre The Netherlands|Koningin Wilhelmina Fonds|World Cancer Research Fund International|L-Nutra Inc,ALL,"ADULT, OLDER_ADULT",PHASE3,10,OTHER,INTERVENTIONAL,3/17/2023,1/1/2024
NCT05448209,COMPLETED,Breast Cancer|Peripheral Neuropathies|Arthralgia|Myalgia,BEHAVIORAL: walking exercise,Necmettin Erbakan University,,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,INTERVENTIONAL,7/20/2022,10/6/2023
NCT05272709,RECRUITING,Advanced Solid Tumors,DRUG: TT-702,Cancer Research UK,"Teon Therapeutics, Inc.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,114,OTHER,INTERVENTIONAL,1/19/2022,2025-09
NCT06225908,ACTIVE_NOT_RECRUITING,"Pain, Postoperative|Pain, Acute|Opioid Consumption",PROCEDURE: Serratus posterior superior intercostal plane block,Zonguldak Bulent Ecevit University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/1/2024,5/1/2024
NCT04642508,ACTIVE_NOT_RECRUITING,Breast Cancer|Quality of Life|Surgery--Complications,PROCEDURE: Prepectoral reconstruction,University Hospital A CoruÃ±a,,FEMALE,"ADULT, OLDER_ADULT",NA,81,OTHER,INTERVENTIONAL,6/22/2020,2026-12
NCT05445908,RECRUITING,Triple-negative Breast Cancer and HR+/HER2- BC,DRUG: SKB264|DRUG: KL-A167,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,175,INDUSTRY,INTERVENTIONAL,8/17/2022,2025-07
NCT05898009,NOT_YET_RECRUITING,Breast Cancer|Genetic Disease|BRCA2 Mutation,GENETIC: blood sample for BRCA2 mutation detection,Centre Hospitalier Universitaire de la RÃ©union,,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,8/22/2023,3/22/2026
NCT05535452,NOT_YET_RECRUITING,Radiodermatitis,DEVICE: Photobiomodulation through LED board,"Instituto Nacional de Cancer, Brazil",,FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER_GOV,INTERVENTIONAL,2/6/2023,2/6/2025
NCT05395052,TERMINATED,Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer,DRUG: FT536|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|COMBINATION_PRODUCT: Avelumab|COMBINATION_PRODUCT: Pembrolizumab|COMBINATION_PRODUCT: Nivolumab|COMBINATION_PRODUCT: Atezolizumab|COMBINATION_PRODUCT: Trastuzumab|COMBINATION_PRODUCT: Cetuximab|COMBINATION_PRODUCT: Amivantamab|DRUG: IL-2,Fate Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,5,INDUSTRY,INTERVENTIONAL,5/31/2022,8/11/2023
NCT05809752,RECRUITING,Leptomeningeal Disease|Triple Negative Breast Cancer|HER2-positive Breast Cancer,BIOLOGICAL: Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,3/28/2023,2026-03
NCT05653752,RECRUITING,Non Small Cell Lung Cancer|Breast Cancer,DRUG: YL202,"MediLink Therapeutics (Suzhou) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,INTERVENTIONAL,12/20/2022,2025-12
NCT04244552,TERMINATED,Breast Cancer|Colorectal Cancer|Ovarian Cancer|Non-Small Cell Lung Cancer|Acral Lentiginous Melanoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|Esophageal Squamous Cell Carcinoma|Urothelial Carcinoma|DMMR Colorectal Cancer|MSI-H Colorectal Cancer|Melanoma|Platinum-Resistant Primary Peritoneal Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Epithelial Ovarian Cancer|Triple Negative Breast Cancer,BIOLOGICAL: ATRC-101|BIOLOGICAL: Pembrolizumab|DRUG: Pegylated liposomal doxorubicin (PLD),"Atreca, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,87,INDUSTRY,INTERVENTIONAL,2/11/2020,11/1/2023
NCT04812652,RECRUITING,Breast Neoplasm Female,BEHAVIORAL: Digitally distributed yoga,Region Ã–rebro County,,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,10/1/2021,10/1/2028
NCT04756505,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic HER2 Negative Breast Adenocarcinoma|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Bintrafusp Alfa|BIOLOGICAL: Immunocytokine NHS-IL12|RADIATION: Radiation Therapy,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,3/7/2021,2/16/2022
NCT04674852,COMPLETED,Breast Neoplasm Female|Ultrasound Therapy; Complications,DEVICE: Research Marker,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",NA,8,OTHER,INTERVENTIONAL,11/2/2020,4/7/2022
NCT05140252,COMPLETED,Breast Cancer,BEHAVIORAL: Breast cancer decision aid,University of Michigan Rogel Cancer Center,,FEMALE,OLDER_ADULT,NA,22,OTHER,INTERVENTIONAL,5/12/2022,9/14/2023
NCT04790305,RECRUITING,"Carcinoma Breast|Triple-negative Breast Cancer|Invasive Ductal Carcinoma, Breast",DRUG: Huaier Granule,Fudan University,LinkDoc Technology (Beijing) Co. Ltd.|Huazhong University of Science and Technology,ALL,"ADULT, OLDER_ADULT",PHASE4,1072,OTHER,INTERVENTIONAL,6/18/2021,7/28/2028
NCT05549505,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: ARV-471|DRUG: Anastrozole|PROCEDURE: Surgical resection of breast tumor,Arvinas Inc.,Pfizer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,152,INDUSTRY,INTERVENTIONAL,2/15/2023,8/15/2024
NCT05327452,RECRUITING,Breast Cancer|Colorectal Cancer|Prostate Cancer,BEHAVIORAL: Supervised Home-Based Exercise|BEHAVIORAL: Unsupervised Home-Based Exercise|BEHAVIORAL: Attention Control,Dana-Farber Cancer Institute,"National Cancer Institute (NCI)|University of Massachusetts, Boston",ALL,"ADULT, OLDER_ADULT",NA,135,OTHER,INTERVENTIONAL,10/31/2022,1/31/2025
NCT04405505,UNKNOWN,Triple Negative Breast Cancer,DRUG: TQB2450|DRUG: Anlotinib|DRUG: Paclitaxel for Injection (albumin bound),"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,332,INDUSTRY,INTERVENTIONAL,6/1/2020,7/1/2022
NCT05463952,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DRUG: ARV-471,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,8/16/2022,3/31/2024
NCT05409352,RECRUITING,"Cancer, Breast|Fatigue|Acupressure|Exercise",BEHAVIORAL: Self-administered acupressure|BEHAVIORAL: Aerobic exercise,The University of Hong Kong,,ALL,"ADULT, OLDER_ADULT",NA,138,OTHER,INTERVENTIONAL,6/1/2022,2025-05
NCT04698252,RECRUITING,Breast Cancer,RADIATION: Radiotherapy|PROCEDURE: Surgery|OTHER: Radiofrequency ablation,Instituto do Cancer do Estado de SÃ£o Paulo,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,74,OTHER,INTERVENTIONAL,4/1/2021,4/1/2031
NCT04855552,ACTIVE_NOT_RECRUITING,Cancer Survivors|Cancer of Breast|Body Weight|Overweight and Obesity,BEHAVIORAL: Behavioral Weight-loss Program Via Telehealth|BEHAVIORAL: Behavioral Weight-Loss Program Via Telehealth - Weight Measures|BEHAVIORAL: Validated Surveys of Patient-Reported Outcomes,Abramson Cancer Center at Penn Medicine,,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,7/19/2021,2025-12
NCT04903652,COMPLETED,HER2-positive Advanced Breast Cancer,DRUG: Pyrotinib Maleate|DRUG: Vinorelbine,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,1/1/2021,2/6/2022
NCT05150652,RECRUITING,Breast Cancer|HER2-negative Breast Cancer|Node-negative Breast Cancer|Breast Carcinoma,DRUG: Anastrozole 1mg|DRUG: Letrozole 2.5mg|DRUG: Exemestane 25 mg|DRUG: Tamoxifen,Veronica Morgan Jones,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,2/18/2022,2036-10
NCT05924152,RECRUITING,Healthy Adults,DRUG: Adagrasib|DRUG: Eltrombopag + adagrasib,Mirati Therapeutics Inc.,,ALL,ADULT,PHASE1,16,INDUSTRY,INTERVENTIONAL,6/29/2023,8/17/2024
NCT05665920,RECRUITING,Malignant Breast Neoplasm,RADIATION: Ultra-hypofractionated whole breast radiotherapy|RADIATION: Standard Radiation,Instituto Brasileiro de Controle do Cancer,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,10/18/2022,12/31/2030
NCT05123482,RECRUITING,Breast Cancer|Biliary Tract Carcinoma|Ovarian Cancer|Endometrial Cancer,DRUG: AZD8205,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,248,INDUSTRY,INTERVENTIONAL,10/18/2021,6/30/2025
NCT05533320,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma,DEVICE: Cold Cap Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,12/14/2022,11/14/2023
NCT04170920,COMPLETED,Breast Cancer|DCIS,DEVICE: LifeExtend-AI,Indiana University,,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,2/17/2020,8/9/2022
NCT04836520,COMPLETED,Breast Cancer,DRUG: SHR6390+anatrozole,Tianjin Medical University Cancer Institute and Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,8/2/2021,3/31/2023
NCT05431582,WITHDRAWN,Tumors|Ovarian Cancer|Breast Cancer|Lung Cancer|Pancreatic Cancer,DRUG: ZN-c3|DRUG: Bevacizumab|DRUG: Pembrolizumab,M.D. Anderson Cancer Center,Zentalis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,12/14/2022,12/14/2022
NCT04771520,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Primary Malignant Central Nervous System Neoplasm|Locally Advanced Sarcoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Primary Malignant Central Nervous System Neoplasm|Metastatic Sarcoma|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,DRUG: Avapritinib,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,1/20/2021,2/3/2025
NCT05324020,COMPLETED,Breast Cancer,BEHAVIORAL: Medication adherence eHealth intervention,Luxembourg Institute of Health,Centre Hospitalier du Luxembourg|Centre Hospitalier Emile Mayrisch,FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER_GOV,INTERVENTIONAL,10/4/2021,11/30/2022
NCT05825482,RECRUITING,Breast Cancer,PROCEDURE: Arm 1 Partial mastectomy with Savi ScoutÂ® localization and shave margins.|PROCEDURE: Arm 2 Partial mastectomy with Savi ScoutÂ® localization and selective shave margins.,Cleveland Clinic Akron General,,FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,INTERVENTIONAL,7/17/2023,2026-11
NCT04199520,WITHDRAWN,Stage IV Breast Cancer,COMBINATION_PRODUCT: surgery combined with systemic therapy|OTHER: systemic therapy,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,INTERVENTIONAL,4/15/2020,5/1/2022
NCT04716920,COMPLETED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Tai Chi|DEVICE: FitBit|OTHER: Support Group Therapy|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,Thomas Jefferson University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,39,OTHER,INTERVENTIONAL,3/11/2020,12/23/2021
NCT06082882,RECRUITING,Breast Cancer|Cervical Cancer,BEHAVIORAL: Education|BEHAVIORAL: Navigation to clinic,"The University of Texas Health Science Center, Houston",Cancer Prevention Research Institute of Texas,FEMALE,"ADULT, OLDER_ADULT",NA,8000,OTHER,INTERVENTIONAL,2/20/2020,7/30/2024
NCT05974449,RECRUITING,Breast Cancer Female,DRUG: Vaginal Lactobacillus capsules,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,ADULT,PHASE2,60,OTHER,INTERVENTIONAL,8/24/2023,12/30/2024
NCT05787249,ENROLLING_BY_INVITATION,Breast Cancer,BEHAVIORAL: Patient nudge|BEHAVIORAL: Provider nudge,University of Pennsylvania,,FEMALE,"ADULT, OLDER_ADULT",NA,1600,OTHER,INTERVENTIONAL,10/4/2023,2024-09
NCT05076682,RECRUITING,Triple-negative Breast Cancer,DRUG: Choline|DRUG: anti-PD-1 antibody and chemotherapy|DRUG: Sodium Cromoglicate|DRUG: Efavirenz,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,6/30/2022,2023-03
NCT04355520,UNKNOWN,"HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",DRUG: TQ-B3525|DRUG: Fulvestrant injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,42,INDUSTRY,INTERVENTIONAL,2020-07,2021-09
NCT04440982,RECRUITING,Breast Cancer|Neoadjuvant Therapy,COMBINATION_PRODUCT: Study Device Arm,"Lumicell, Inc.",National Cancer Institute (NCI)|Massachusetts General Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE2,323,INDUSTRY,INTERVENTIONAL,9/1/2020,2025-12
NCT05492682,RECRUITING,Melanoma (Skin)|Triple-Negative Breast Cancer|Non-Small Cell Lung Cancer|Synovial Sarcoma|Myxoid Liposarcoma|Colorectal Cancer,DRUG: PeptiCRAd-1|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,Valo Therapeutics Oy,,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,INTERVENTIONAL,2/2/2023,2025-09
NCT04671693,RECRUITING,"Late Effects|Testicular Germ Cell Tumor Mixed|Non-Metastatic Breast Carcinoma|Soft Tissue Sarcoma, Adult, Stage IIC|Osteosarcoma|Ewing's Sarcoma|Acute Myeloid Leukemia|Hodgkin Disease|Non Hodgkin Lymphoma",OTHER: PASCA intervention,Centre Leon Berard,Malakoff-Humanis|Fondation Apicil|FÃ©dÃ©ration LeucÃ©mie Espoir|Biogaran|Le dÃ©fi Anthony|Novartis|Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",NA,858,OTHER,INTERVENTIONAL,12/24/2020,4/24/2028
NCT04837820,RECRUITING,Breast Cancer,PROCEDURE: Acupuncture|PROCEDURE: Sham Acupuncture|OTHER: Wait-List Control (WLC)|OTHER: Questionnaires,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,260,OTHER,INTERVENTIONAL,4/6/2021,2025-04
NCT04200482,COMPLETED,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,BEHAVIORAL: One Diet and Physical Activity Session|OTHER: Electronic (e) Health (eHealth) Communication Intervention|BEHAVIORAL: Twelve Diet and Physical Activity Group Sessions|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,Fred Hutchinson Cancer Center,Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,2/21/2020,10/28/2021
NCT05941520,NOT_YET_RECRUITING,Breast Atypical Hyperplasia|Breast Carcinoma|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ,DRUG: Acolbifene Hydrochloride|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|PROCEDURE: Random Periareolar Fine-Needle Aspiration|DRUG: Tamoxifen,National Cancer Institute (NCI),,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,NIH,INTERVENTIONAL,3/1/2024,9/1/2028
NCT04139993,TERMINATED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Adenocarcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,DRUG: Microbiota-based Formulation RBX7455,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,3,OTHER,INTERVENTIONAL,8/31/2020,1/11/2023
NCT04676516,COMPLETED,Breast Cancer,DRUG: GSK3326595,Ottawa Hospital Research Institute,"Ontario Institute for Cancer Research|GlaxoSmithKline|London Regional Cancer Program, Canada|Hamilton Health Sciences Corporation",FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,6/8/2021,8/15/2022
NCT04567420,RECRUITING,Breast Cancer,DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Adjuvant Therapy,"Criterium, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,INTERVENTIONAL,2/9/2021,12/15/2026
NCT05860582,COMPLETED,Breast Cancer|Nonsmall Cell Lung Cancer,DRUG: [14C]GB491,"Genor Biopharma Co., Ltd.",,MALE,ADULT,PHASE1,6,INDUSTRY,INTERVENTIONAL,9/14/2022,11/14/2022
NCT04239716,COMPLETED,Breast Cancer,OTHER: regional anesthesia,Tanta University,Dr. Mohamed Elsayed Afandy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,13,OTHER,INTERVENTIONAL,1/1/2022,10/31/2022
NCT04683120,SUSPENDED,"Oncology|Breast Cancer|Cancer Diagnosis|Margins of Excision|Margins, Tumor-Free",DIAGNOSTIC_TEST: Zenith FLIM Diagnostics,Laser LabCorp,,FEMALE,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,INTERVENTIONAL,12/15/2021,11/2/2022
NCT04703920,RECRUITING,Metastatic Breast Cancer|Metastatic Castration-resistant Prostate Cancer|Metastatic Ovarian Carcinoma,DRUG: Talazoparib|DRUG: Belinostat,University of Michigan Rogel Cancer Center,Pfizer|Acrotech Biopharma Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,INTERVENTIONAL,3/4/2021,2024-07
NCT05417516,RECRUITING,Breast Neoplasm Female|Radiotherapy|Cosmetic Outcome,RADIATION: Whole Breast Irradiation (WBI)|RADIATION: Partial Breast Irradiation (PBI),Ontario Clinical Oncology Group (OCOG),,FEMALE,"ADULT, OLDER_ADULT",PHASE3,910,OTHER,INTERVENTIONAL,11/20/2023,2031-11
NCT05322720,NOT_YET_RECRUITING,"Solid Tumor, Adult",BIOLOGICAL: EOC202|DRUG: albumin-bound paclitaxel,"Taizhou EOC Pharma Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,INTERVENTIONAL,2022-04,2025-05
NCT04784182,TERMINATED,Anxiety Generalized|Breast Cancer Female,DIETARY_SUPPLEMENT: probiotic plus prebiotic supplement|DIETARY_SUPPLEMENT: placebo,Auburn University,National Center for Advancing Translational Sciences (NCATS),FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,7/20/2021,5/1/2022
NCT04348916,TERMINATED,Cancer|Melanoma|Solid Tumor|Squamous Cell Carcinoma of Head and Neck|Breast Cancer|Advanced Solid Tumor|Triple Negative Breast Cancer|Colorectal Carcinoma|Non-melanoma Skin Cancer|Liver Metastases,BIOLOGICAL: ONCR-177|BIOLOGICAL: pembrolizumab,"Oncorus, Inc.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,INTERVENTIONAL,5/20/2020,5/31/2023
NCT05563220,RECRUITING,Breast Cancer|Metastatic Breast Cancer,DRUG: Elacestrant|DRUG: Alpelisib|DRUG: Everolimus|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Capivasertib|DRUG: Abemaciclib,"Stemline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,400,OTHER,INTERVENTIONAL,1/24/2023,8/31/2026
NCT04456920,ACTIVE_NOT_RECRUITING,Breast Cancer|Biopsy Wound,OTHER: phone consultation|OTHER: e-PRO self-completed via connected objects (tablet/phone)|OTHER: phone consultation|OTHER: visit,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,197,OTHER,INTERVENTIONAL,2/9/2021,2024-03
NCT05184582,RECRUITING,Breast Cancer,BEHAVIORAL: Physical training,Karolinska Institutet,,ALL,"ADULT, OLDER_ADULT",NA,712,OTHER,INTERVENTIONAL,11/9/2022,2027-12
NCT05834582,RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: Fluzoparib+Paclitaxel|DRUG: Epirubicin+Cyclophosphamide,The First Affiliated Hospital with Nanjing Medical University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,4/8/2023,6/1/2026
NCT06080620,RECRUITING,Locally Advanced Breast Cancer,PROCEDURE: Modified radical mastectomy for breast cancer|PROCEDURE: neoadjuvant therapy|PROCEDURE: Systematic treatment,Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/8/2023,8/1/2026
NCT04498520,WITHDRAWN,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Endometrioid Adenocarcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Breast Carcinoma|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8,DRUG: Abexinostat Tosylate|DRUG: Fulvestrant|DRUG: Palbociclib,Pamela Munster,"Pfizer|Xynomic Pharmaceuticals, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,3/31/2021,6/30/2025
NCT05263882,NOT_YET_RECRUITING,HER2-negative Breast Cancer,DRUG: Gemcitabine combined with eribulin,"Fifth Affiliated Hospital, Sun Yat-Sen University",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,INTERVENTIONAL,2022-03,2024-09
NCT04665882,RECRUITING,Breast Cancer|Axillary Lymph Node Dissection|Breast Cancer Related Lymphedema|Axillary Reverse Mapping,PROCEDURE: Axillary surgery based on lymphedema prediction nomogram,Wuhan University,,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,12/11/2020,12/31/2027
NCT05578820,RECRUITING,Sarcoma|Melanoma|Squamous Cell Carcinoma of Head and Neck|Breast Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Penile Neoplasms|Anus Neoplasms,BIOLOGICAL: Intratumoral administration of Stimotimagene copolymerplasmid|DRUG: Intravenous administration of Ganciclovir (CymevenÂ®),Gene Surgery LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,1/1/2022,2023-12
NCT04796220,RECRUITING,Breast Cancer|Breast Neoplasms,DRUG: Gemcitabine|DEVICE: Focused Ultrasound|OTHER: Gemcitabine and Focused Ultrasound,"Patrick Dillon, MD",,ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,INTERVENTIONAL,1/27/2022,2025-01
NCT06253520,NOT_YET_RECRUITING,Metastatic Solid Cancers|Colorectal Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Gastrointestinal Cancer|Ovarian Cancer|Genitourinary Cancer,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: KRAS TCR-Transduced PBL|BIOLOGICAL: GRT-C903/GRT-R904,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,210,NIH,INTERVENTIONAL,3/15/2024,6/15/2033
NCT06230068,NOT_YET_RECRUITING,Breast Cancer|Quality of Life,OTHER: Expressive writing,Region Skane,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,2/12/2024,12/1/2025
NCT04644068,RECRUITING,Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Additional Indications Below for Module 4 and 5|Non-small Cell Lung Cancer|Colorectal Cancer|Bladder Cancer|Gastric Cancer|Biliary Cancer|Cervical Cancer|Endometrial Cancer|Small Cell Lung Cancer Only in Module 5,DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,804,INDUSTRY,INTERVENTIONAL,11/12/2020,12/15/2026
NCT06027268,RECRUITING,Metastatic Triple-Negative Breast Cancer,DRUG: Trilaciclib|DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Carboplatin,Wake Forest University Health Sciences,"Merck Sharp & Dohme LLC|G1 Therapeutics, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,1/10/2024,2027-03
NCT05265715,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: Low AGE diet|PROCEDURE: Research blood draw,Washington University School of Medicine,"American Cancer Society, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,14,OTHER,INTERVENTIONAL,10/14/2022,12/10/2023
NCT05797545,RECRUITING,Breast Neoplasms|Breast Cancer,DIAGNOSTIC_TEST: Breast MRI for Breast Cancer Detection,Samsung Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,1464,OTHER,INTERVENTIONAL,4/23/2023,5/28/2028
NCT06125145,NOT_YET_RECRUITING,Breast Cancer|Colorectal Cancer|Prostate Cancer,BEHAVIORAL: Geriatric Assessment and Promotora Coaching,"University of California, Davis",,ALL,OLDER_ADULT,NA,49,OTHER,INTERVENTIONAL,2/7/2024,8/6/2025
NCT04639245,TERMINATED,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Stage IV Lung Cancer AJCC v8,DRUG: Atezolizumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|BIOLOGICAL: PD1 Inhibitor,Fred Hutchinson Cancer Center,"SignalOne Bio, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,OTHER,INTERVENTIONAL,7/19/2021,8/16/2022
NCT05488145,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,OTHER: Best Practice|OTHER: Internet-Based Intervention|OTHER: Questionnaire Administration|OTHER: Survey Administration,Emory University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,3/21/2023,3/30/2025
NCT05505045,RECRUITING,Breast Cancer Female,BEHAVIORAL: CO-OP Procedures|BEHAVIORAL: Attention Control Procedures,University of Missouri-Columbia,,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,10/11/2022,2/15/2024
NCT04200768,RECRUITING,Breast Neoplasms,OTHER: Prospective data and sample collection,Universitaire Ziekenhuizen KU Leuven,KU Leuven,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,9/1/2020,10/31/2024
NCT05256745,RECRUITING,Cancer Related Cognitive Decline|Non-metastatic Breast Cancer,DRUG: TTP488|DRUG: ddAC/ddT|DRUG: TC|DRUG: TCHP|DRUG: Chemotherapy regimen that includes ddAC,Georgetown University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,OTHER,INTERVENTIONAL,6/6/2023,2024-11
NCT05751668,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Metastatic Breast Carcinoma,DRUG: Paclitaxel|DRUG: Monosialotetrahexosylganglioside|OTHER: Questionnaire Administration|OTHER: Quality-of-life assessment|DRUG: Placebo Administration,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,INTERVENTIONAL,5/31/2023,5/31/2030
NCT05929768,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure,SWOG Cancer Research Network,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,2400,NETWORK,INTERVENTIONAL,9/15/2023,2033-04
NCT05186545,RECRUITING,Breast Cancer|Breast Cancer Female,DRUG: surufatinib + fulvestrant + chidamide,The First Affiliated Hospital of Zhengzhou University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,7/1/2022,2025-07
NCT06096545,NOT_YET_RECRUITING,Breast Cancer|Breast Neoplasms|Breast Cancer Female,PROCEDURE: Axillary sentinal lymph node biopsy,Medipol University,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/20/2023,1/15/2024
NCT05160545,RECRUITING,Breast Cancer,DRUG: GNC-035,"Sichuan Baili Pharmaceutical Co., Ltd.","Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1,29,INDUSTRY,INTERVENTIONAL,11/26/2021,2024-06
NCT03110445,WITHDRAWN,Breast Carcinoma,BIOLOGICAL: rVV-740CTA,"University Hospital, Basel, Switzerland",,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,2020-03,2021-09
NCT04427215,UNKNOWN,Breast Cancer,OTHER: Complementary and alternative medicines,KlaipÄ—da University,Ministry of Health of The Republic of Lithuania,ALL,"ADULT, OLDER_ADULT",PHASE1,250,OTHER,INTERVENTIONAL,7/1/2020,10/30/2021
NCT04568616,RECRUITING,Breast Cancer|ER Positive Breast Cancer,DRUG: Letrozole 2.5mg,Dartmouth-Hitchcock Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,INTERVENTIONAL,8/13/2021,2024-09
NCT05486520,ENROLLING_BY_INVITATION,Breast Benign|Malignant Neoplasm of Breast|Breast Malignant Tumor,DEVICE: Magnetic Resonance Imaging (MRI),Massachusetts General Hospital,National Institutes of Health (NIH),FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,9/1/2022,9/1/2024
NCT05464082,RECRUITING,Breast Cancer Recurrent,OTHER: Functional Precision Oncology,University of Utah,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,1/6/2023,9/30/2027
NCT05716516,RECRUITING,Metastatic Breast Cancer,DRUG: Estradiol,Dartmouth-Hitchcock Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,5/4/2023,2027-05
NCT05274893,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: SYHX2011 and AbraxaneÂ®,"CSPC Ouyi Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,28,INDUSTRY,INTERVENTIONAL,3/31/2022,10/30/2022
NCT06253182,RECRUITING,Breast Cancer|Gynecologic Cancer|Sexual Dysfunction|Partner Communication,BEHAVIORAL: Self-Guided PEPP Intervention Workbook|BEHAVIORAL: Self-Guided PEPP Education Workbook,"The University of Tennessee, Knoxville",,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/1/2024,9/30/2024
NCT04715516,COMPLETED,"Health Knowledge, Attitudes, Practice|Alcohol Consumption",BEHAVIORAL: alcohol brief intervention|BEHAVIORAL: lifestyle health promotion,Turning Point,Eastern Health|Monash University,FEMALE,"ADULT, OLDER_ADULT",NA,558,OTHER,INTERVENTIONAL,2/5/2021,12/2/2021
NCT04753268,COMPLETED,"Weight Loss|Behavior, Health",BEHAVIORAL: Noom Healthy Weight Program,Noom Inc.,,FEMALE,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,INTERVENTIONAL,3/24/2021,10/1/2021
NCT05354882,RECRUITING,Breast Cancer|Colo-rectal Cancer|Lung Cancer|Prostate Cancer,BEHAVIORAL: Physical activity program,UniversitÃ© Sorbonne Paris Nord,"Ligue contre le cancer, France|Garmin International|Stimulab",ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,3/29/2022,2023-12
NCT05002868,ACTIVE_NOT_RECRUITING,Solid Tumor|Extensive-stage Small-cell Lung Cancer|Locally Advanced Breast Cancer|Metastatic Breast Cancer|Platinum-sensitive Ovarian Cancer|Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Peritoneal Cancer,DRUG: RP12146,Rhizen Pharmaceuticals SA,,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INDUSTRY,INTERVENTIONAL,10/5/2021,2024-02
NCT05923268,ENROLLING_BY_INVITATION,Breast Cancer Female,DRUG: [99mTc]Tc-G3-(G3S)3C,Tomsk National Research Medical Center of the Russian Academy of Sciences,,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,6/4/2023,6/15/2024
NCT06246968,RECRUITING,Metastatic Breast Cancer|Breast Cancer|Breast Cancer Stage IV|Triple Negative Breast Cancer|Triple Negative Breast Neoplasms|Metastatic Triple-Negative Breast Carcinoma|Locally Advanced Breast Cancer|Locally Advanced Triple-Negative Breast Carcinoma,DRUG: Pembrolizumab|DEVICE: Cryoablation,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,1/29/2024,1/29/2027
NCT05025020,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: interactive 3D tool|OTHER: BREAST-Q Reconstruction Module|OTHER: DQI|OTHER: Ottawa Decision Regret Scale,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,8/23/2021,2024-08
NCT04191382,TERMINATED,Breast Cancer,DRUG: Amcenestrant (SAR439859)|DRUG: Letrozole,Sanofi,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,105,INDUSTRY,INTERVENTIONAL,2/4/2020,5/28/2021
NCT05686720,NOT_YET_RECRUITING,Advanced Triple Negative Breast Cancer,DRUG: SZ011 CAR-NK,First Affiliated Hospital of Shantou University Medical College,"Guangdong ProCapZoom Biosciences Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,INTERVENTIONAL,2/1/2023,6/1/2024
NCT04861220,UNKNOWN,Breast Neoplasm,BEHAVIORAL: Physical exercise,"Instituto Nacional de Cancer, Brazil",,FEMALE,"ADULT, OLDER_ADULT",NA,248,OTHER_GOV,INTERVENTIONAL,1/1/2022,12/30/2023
NCT06188520,RECRUITING,ER+ HER2- Advanced Breast Cancer|High-grade Serous Ovarian Cancer (HGSOC),DRUG: AZD8421|DRUG: Camizestrant|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Abemaciclib,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,INDUSTRY,INTERVENTIONAL,12/5/2023,6/18/2025
NCT05574920,ACTIVE_NOT_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Al18F-NOTA-FAPI-04 PET/CT scan,Peking Union Medical College Hospital,,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,5/10/2022,2/1/2024
NCT04136782,RECRUITING,Breast Cancer,DRUG: Albumin-bound paclitaxel combined with carboplatin|DRUG: Epirubicin combined with docetaxel,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,110,OTHER,INTERVENTIONAL,7/19/2021,11/30/2026
NCT04477616,COMPLETED,Breast Cancer,DRUG: Day 7 regimen|DRUG: Day 3 regimen,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,INTERVENTIONAL,7/13/2021,11/6/2022
NCT04871516,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Invasive Breast Carcinoma|Non-Metastatic Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Boost|PROCEDURE: Therapeutic Surgical Procedure|RADIATION: Whole Breast Irradiation|OTHER: Breast MRI,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,5/18/2021,1/31/2024
NCT04640220,COMPLETED,Breast Neoplasm|Shoulder Capsulitis|Range of Motion,PROCEDURE: Intra-articular steroid injection,Yeungnam University Hospital,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,10/26/2020,12/31/2021
NCT03935282,ACTIVE_NOT_RECRUITING,Breast Neoplasm|Prostatic Neoplasm|Colorectal Neoplasms|Endometrial Neoplasms|Hodgkin Disease|Non Hodgkin Lymphoma,OTHER: AH-HA Tool in the EPIC EHR,Wake Forest University Health Sciences,National Cancer Institute (NCI)|Washington University School of Medicine|University of Texas Southwestern Medical Center,ALL,"ADULT, OLDER_ADULT",NA,645,OTHER,INTERVENTIONAL,10/1/2020,3/7/2024
NCT05244382,RECRUITING,Breast Neoplasm Female|Neoplasm Metastasis|Spinal Neoplasms,OTHER: Overcome,Universidad de Granada,,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,2/7/2022,2025-06
NCT04160182,WITHDRAWN,Breast Cancer|Fatigue,BEHAVIORAL: Energy Conservation Work Simplification Education,Danielle Mockensturm,University of Toledo,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,1/27/2020,9/1/2020
NCT05600582,WITHDRAWN,Breast Neoplasms|Neoplasm Metastasis,BIOLOGICAL: CodaLytic,"Codagenix, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,1/15/2023,1/30/2025
NCT04677816,RECRUITING,Triple Negative Breast Cancer|Vitamin D Deficiency|Invasive Breast Cancer,DRUG: Standard of Care Neoadjuvant Chemotherapy|DIETARY_SUPPLEMENT: Vitamin D3|OTHER: Drug Diary,Wake Forest University Health Sciences,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,10/22/2021,2024-10
NCT05979220,NOT_YET_RECRUITING,Breast Cancer,DRUG: Dalpiciclib combined with Letrozole,Shuangyue Liu,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,178,OTHER,INTERVENTIONAL,12/1/2023,6/30/2028
NCT04896320,WITHDRAWN,Breast Cancer Stage IV,DRUG: Tucatinib,Providence Health & Services,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,12/15/2021,6/19/2023
NCT06143020,COMPLETED,Mammary Cancer|Erector Spinae Plane Block|Postoperative Pain,PROCEDURE: Erector spinae plane block,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/1/2021,1/2/2024
NCT05114720,RECRUITING,Breast Cancer,DRUG: standard adjuvant chemotherapy plus moxifloxacin|DRUG: standard adjuvant chemotherapy plus placebo,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,520,OTHER,INTERVENTIONAL,11/11/2021,2028-12
NCT03972020,UNKNOWN,Breast Cancer|Depressive Symptoms,BEHAVIORAL: Mindfulness Based Intervention|BEHAVIORAL: Cognitive Behavioral Therapy,"University of Turin, Italy",,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,1/1/2022,12/31/2022
NCT04800393,RECRUITING,Anesthesia|Breast Cancer,DRUG: Sevoflurane|DRUG: Propofol,Moscow Clinical Scientific Center,Negovsky Reanimatology Research Institute,FEMALE,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,3/29/2022,4/1/2028
NCT04290793,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pyrotinib|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Taxanes|BIOLOGICAL: Trastuzumab,Hebei Medical University Fourth Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,280,OTHER,INTERVENTIONAL,3/1/2020,3/1/2024
NCT05808582,NOT_YET_RECRUITING,Hormone Receptor-positive Advanced Breast Cancer,DRUG: chidamideï¼Œfulvestrant,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,5/1/2023,9/1/2024
NCT05486182,RECRUITING,Metastatic Breast Cancer,DRUG: 18F Fluoroestradiol Radiopharmaceutical with PET/CT,Zionexa,GE Healthcare|Simbec-Orion Group|Keosys,FEMALE,"ADULT, OLDER_ADULT",PHASE4,152,INDUSTRY,INTERVENTIONAL,2/8/2022,2025-06
NCT03749850,UNKNOWN,Metastatic Breast Cancer|Breast Cancer|Breast Neoplasms|Stage IV Breast Cancer|Metastatic Cancer|Invasive Ductal Carcinoma of Female Breast|Invasive Ductal Breast Cancer|Adenocarcinoma Breast,DRUG: LTLD|PROCEDURE: MR-HIFU induced hyperthermia|DRUG: Cyclophosphamide,UMC Utrecht,Dutch Cancer Society|Center for Translational Molecular Medicine|Vrienden UMC Utrecht,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,2021-03,2022-11
NCT05792475,ACTIVE_NOT_RECRUITING,Breast Cancer|Breast Diseases,DIAGNOSTIC_TEST: Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software,TaiHao Medical Inc.,,FEMALE,"ADULT, OLDER_ADULT",NA,3,INDUSTRY,INTERVENTIONAL,1/30/2023,11/30/2023
NCT04020575,RECRUITING,Metastatic Breast Cancer,BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D,Minerva Biotechnologies Corporation,City of Hope Medical Center,ALL,"ADULT, OLDER_ADULT",PHASE1,69,INDUSTRY,INTERVENTIONAL,1/15/2020,1/15/2035
NCT06008275,NOT_YET_RECRUITING,Metastatic Triple-Negative Breast Carcinoma|Breast Cancer,DRUG: Neratinib Oral Tablet|DRUG: Ruxolitinib Oral Tablet,Baylor Research Institute,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,2023-11,2025-12
NCT05229575,UNKNOWN,Stage IV Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT),Campus Bio-Medico University,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/10/2020,4/10/2023
NCT04459650,ACTIVE_NOT_RECRUITING,Alopecia,PROCEDURE: Platelet Rich Plasma system,Memorial Sloan Kettering Cancer Center,,ALL,ADULT,EARLY_PHASE1,30,OTHER,INTERVENTIONAL,6/23/2020,2024-06
NCT05708950,RECRUITING,Cancer|Solid Tumor|Melanoma|Carcinoma|Sarcoma|Lung Cancer|Prostate Cancer|Breast Cancer|Colo-rectal Cancer|Uterine Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Thyroid Cancer|Ovarian Cancer|Kidney Cancer|Head and Neck Cancer,DRUG: KVA12123 - Dose Escalation|DRUG: KVA12123 Plus Pembrolizumab - Dose Escalation|DRUG: KVA12123 - Dose Expansion|DRUG: KVA12123 Plus Pembrolizumab - Dose Expansion,Kineta Inc.,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,314,INDUSTRY,INTERVENTIONAL,3/3/2023,12/31/2024
NCT04514159,COMPLETED,Breast Cancer,DRUG: ZN-c5|DRUG: Abemaciclib,Zeno Alpha Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,INTERVENTIONAL,11/12/2020,10/24/2022
NCT04781959,ACTIVE_NOT_RECRUITING,Early-stage Breast Cancer,DRUG: Filgrastim|DRUG: Pegfilgrastim,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,233,OTHER,INTERVENTIONAL,6/9/2021,2023-12
NCT05689359,NOT_YET_RECRUITING,Breast Cancer|Gynecologic Cancer|Early-stage Breast Cancer|Peripheral Neuropathy|Chemotherapy-induced Peripheral Neuropathy,DRUG: Hydroxychloroquine,University of Arizona,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,INTERVENTIONAL,2024-06,12/1/2025
NCT04675450,WITHDRAWN,Breast Cancer|Peripheral Neuropathy,DRUG: Placebo|DRUG: NBP Softgel Capsules,"Conjupro Biotherapeutics, Inc.","CSPC-NBP Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,6/30/2023,1/30/2025
NCT05142475,RECRUITING,Breast Cancer|Treatment Side Effects|Advanced Breast Cancer|Effects of Immunotherapy,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL),Shanghai Juncell Therapeutics,Shanghai 10th People's Hospital,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,INDUSTRY,INTERVENTIONAL,11/19/2021,12/20/2024
NCT04745975,RECRUITING,Triple Negative Breast Cancer,DRUG: Personalized treatment guided by mini-PDX and RNA sequencing|DRUG: Nab paclitaxel|DRUG: Eribulin|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Capecitabine,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,2/1/2021,2023-01
NCT05625659,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM),American College of Radiology,GE Healthcare|Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,2032,OTHER,INTERVENTIONAL,3/24/2023,1/1/2027
NCT06199050,RECRUITING,Fear|Anxiety|Breast Cancer|Lung Cancer|Prostate Cancer|Head and Neck Cancer|Brain Tumor,OTHER: Questionnaire: SPIRIT|OTHER: Questionnaire: HADS|OTHER: Questionnaire: QSC-R23|OTHER: General questions|OTHER: Clinical data collected,Maastricht Radiation Oncology,,ALL,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,6/16/2023,6/30/2025
NCT05396950,NOT_YET_RECRUITING,Cancer,DEVICE: CPAP,Waikato Hospital,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,2022-07,2023-07
NCT05469750,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: Dalpiciclib+ letrozole +capecitabine,Fujian Medical University Union Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,8/10/2022,2024-08
NCT06053775,RECRUITING,Depressive Symptoms|Cognitive Impairment,DEVICE: Transcranial Direct Current Stimulation|DEVICE: Transcranial Alternating Current Stimulation|DEVICE: tES sham|DEVICE: Online Cognitive Training,University of Santiago de Compostela,Fundacin Biomedica Galicia Sur,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,9/27/2023,2025-09
NCT05545150,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Bilateral Breast Carcinoma|Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma|Multicentric Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8,PROCEDURE: Intraoperative Imaging|DEVICE: Lumpectomy,Northwestern University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,11/28/2022,7/1/2024
NCT04691375,ACTIVE_NOT_RECRUITING,Advanced Solid Tumor|Gynecologic Cancer|Breast Cancer|Colorectal Cancer|Lung Adenocarcinoma|Renal Cell Carcinoma|Triple Negative Breast Cancer|Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer|Ovarian Cancer,DRUG: PY314|DRUG: Combination Therapy: PY314 + Pembrolizumab,Pionyr Immunotherapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,288,INDUSTRY,INTERVENTIONAL,10/29/2020,10/28/2023
NCT04296175,RECRUITING,Triple-negative Breast Cancer,DRUG: Epirubicin|DRUG: CTX|DRUG: Paclitaxel|DRUG: ddEpirubicin|DRUG: ddCTX|DRUG: Paclitaxel(with carbo)|DRUG: Carboplatin,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,808,OTHER,INTERVENTIONAL,3/5/2020,2025-06
NCT06230575,NOT_YET_RECRUITING,Analgesia,PROCEDURE: erector spinae block|PROCEDURE: retrolaminar block|PROCEDURE: serratus anterior block|PROCEDURE: pectoral nerve block,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,2/1/2024,7/25/2025
NCT04301375,NOT_YET_RECRUITING,Mammary Cancer,DRUG: Pertuzumab and trastuzumab FDC subcutaneous|DRUG: Paclitaxel|DRUG: TDM1|DRUG: Endocrine therapy|PROCEDURE: Omission surgery,David Garcia Cinca,Fundacion Clinic per a la Recerca BiomÃ©dica,FEMALE,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,INTERVENTIONAL,6/15/2020,7/15/2027
NCT05825768,RECRUITING,Breast Cancer,DEVICE: Breast MRI|DIAGNOSTIC_TEST: standard breast imaging,Aarhus University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,INTERVENTIONAL,2/1/2021,8/31/2026
NCT04252768,WITHDRAWN,Metastatic Breast Cancer,DRUG: Eftilagimod Alpha|DRUG: Paclitaxel,Immutep S.A.S.,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,2023-06,2026-02
NCT06228768,NOT_YET_RECRUITING,Postmenopausal|Breast Cancer,OTHER: Acupressure|OTHER: Acupressure,University of Michigan Rogel Cancer Center,Breast Cancer Research Foundation,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,2024-03,2026-05
NCT05953168,NOT_YET_RECRUITING,Triple-Negative Breast Cancer,DRUG: Trastuzumab Deruxtecan,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,69,OTHER,INTERVENTIONAL,2023-08,2026-08
NCT03971045,NOT_YET_RECRUITING,Breast Cancer|Chest Wall Tumor,DRUG: Pembrolizumab,European Institute of Oncology,,ALL,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,7/1/2023,12/1/2023
NCT05950945,RECRUITING,Breast Cancer,DRUG: Trastuzumab Deruxtecan,Daiichi Sankyo,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE3,250,INDUSTRY,INTERVENTIONAL,12/30/2023,10/1/2027
NCT05461768,RECRUITING,Breast Cancer|Locally Advanced or Metastatic Solid Tumor,DRUG: BL-M07D1,"Sichuan Baili Pharmaceutical Co., Ltd.","SystImmune Inc.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,INTERVENTIONAL,8/9/2022,2024-08
NCT04755868,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: Talazoparib|DRUG: Placebo,Yonsei University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,206,OTHER,INTERVENTIONAL,2021-03,3/1/2024
NCT05976815,RECRUITING,Breast Cancer,BEHAVIORAL: Combined Aerobic and Resistance Exercise,University Institute of Maia,Aveiro University|Centro Hospitalar de Vila Nova de Gaia/Espinho|Associacao de Investigacao de Cuidados de Suporte em Oncologia|University of Maia,FEMALE,"ADULT, OLDER_ADULT",NA,86,OTHER,INTERVENTIONAL,7/31/2023,8/1/2026
NCT04891068,RECRUITING,Breast Cancer Female|Breast Cancer Invasive,DRUG: Azacitidine,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,1/10/2022,2024-05
NCT03824145,RECRUITING,Metastatic Breast Cancer,BEHAVIORAL: Lifestyle Intervention|BEHAVIORAL: Attention Control,Medical College of Wisconsin,Loyola University Chicago,FEMALE,"ADULT, OLDER_ADULT",NA,176,OTHER,INTERVENTIONAL,11/1/2022,2/1/2027
NCT05813145,RECRUITING,Breast Cancer,DRUG: Placebo|DRUG: Fenofibrate 160mg,Damanhour University,,FEMALE,ADULT,NA,50,OTHER,INTERVENTIONAL,1/1/2023,2/1/2024
NCT05424068,RECRUITING,Advanced Breast Cancer|Advanced Colorectal Cancer|Cancer Rehabilitation,BEHAVIORAL: In-person rehabilitaiton group|BEHAVIORAL: Virtual rehabilitation group,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",NA,117,OTHER,INTERVENTIONAL,12/2/2022,4/30/2024
NCT05203445,RECRUITING,Breast Cancer,DRUG: Olaparib|DRUG: Pembrolizumab,Memorial Sloan Kettering Cancer Center,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,INTERVENTIONAL,1/31/2022,2026-01
NCT04588545,RECRUITING,HER2-positive Breast Cancer|Leptomeningeal Metastasis|Leptomeningeal Disease,RADIATION: Radiation Therapy|DRUG: Pertuzumab|DRUG: Trastuzumab,H. Lee Moffitt Cancer Center and Research Institute,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,39,OTHER,INTERVENTIONAL,12/10/2020,11/1/2024
NCT05931445,ENROLLING_BY_INVITATION,Breast Cancer|Lung Cancer|Colorectal Cancer|Liver Cancer|Stomach Cancer|Endometrial Cancer|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck,OTHER: e-PRO monitoring,Comprehensive Support Project for Oncology Research,,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,1/26/2021,3/31/2027
NCT04582968,ACTIVE_NOT_RECRUITING,Breast Cancer|Brain Metastases|HER2-positive Breast Cancer,OTHER: Pyrotinib Plus Capecitabine combined with brain radiotherapy,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,39,OTHER,INTERVENTIONAL,1/2/2020,8/12/2023
NCT04507568,ACTIVE_NOT_RECRUITING,Breast Cancer|Quality of Life,OTHER: Quality of Life Questionnaires,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",NA,109,OTHER,INTERVENTIONAL,8/13/2020,2024-08
NCT04752150,COMPLETED,Breast Cancer|Breast Neoplasms|Breast Cancer Female,OTHER: Analgesia management; group ESPB and RIB,Medipol University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/16/2021,12/20/2021
NCT05460650,COMPLETED,"Breast Cancer|Overweight and Obesity|Diet, Healthy|Weight Gain|Alcohol Drinking|Smoking Behaviors|Healthy Nutrition|Healthy Lifestyle|Healthy Eating Index",BEHAVIORAL: App Promoting Healthy Behaviours,University of Manchester,Manchester University NHS Foundation Trust,FEMALE,ADULT,NA,35,OTHER,INTERVENTIONAL,11/3/2022,3/10/2023
NCT05056350,RECRUITING,Breast Cancer,OTHER: Questionnaires|OTHER: back to work coaching,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,9/13/2021,8/22/2023
NCT05726175,NOT_YET_RECRUITING,Breast Cancer,DRUG: Disitamab Vedotin|DRUG: Penpulimab,West China Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,3/1/2023,8/31/2024
NCT05749575,RECRUITING,Breast Cancer,DRUG: Chidamide Plus Toripalimab Plus Paclitaxel,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,INTERVENTIONAL,2023-02,2024-08
NCT04584775,UNKNOWN,Advanced Cancer|Lung Cancer|Breast Cancer|Colo-rectal Cancer|Pancreas Cancer|Cholangiocarcinoma|Quality of Life|Symptoms and Signs,"OTHER: Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|OTHER: Standard care",Medical University of Graz,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,2021-02,2022-07
NCT04784715,ACTIVE_NOT_RECRUITING,Breast Cancer; HER2-positive; Metastatic,DRUG: Trastuzumab deruxtecan|DRUG: Placebo|DRUG: Taxane|DRUG: Pertuzumab|DRUG: Trastuzumab,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,1157,INDUSTRY,INTERVENTIONAL,4/26/2021,12/30/2029
NCT04763915,RECRUITING,Inherited Cancer Syndrome|Prostate Cancer|Colorectal Cancer|Endometrial Cancer|Breast Cancer,OTHER: Correlative Studies (Survey)|OTHER: Correlative Studies (Interview)|BEHAVIORAL: GeneSHARE|BEHAVIORAL: LivingLabReport|BEHAVIORAL: Standard-of-care & Adaptive Intervention|OTHER: Access to Education Materials,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|University of South Florida,ALL,"ADULT, OLDER_ADULT",NA,720,OTHER,INTERVENTIONAL,8/5/2022,2028-12
NCT05173415,RECRUITING,Breast Cancer,DEVICE: Sirius Pintution|DEVICE: HydroMARK (C) Clip,Constanze Elfgen,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,8/1/2023,2025-01
NCT05425550,RECRUITING,Breast Cancer,DEVICE: mediduxâ„¢ app,Palleos Healthcare GmbH,mobile Health AG,ALL,"ADULT, OLDER_ADULT",NA,585,INDUSTRY,INTERVENTIONAL,8/29/2022,5/31/2024
NCT04779450,UNKNOWN,Breast Cancer,OTHER: Kinesiotherapy protocol|OTHER: Usual orientations,University of the State of Santa Catarina,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,8/1/2021,2021-12
NCT05935150,RECRUITING,Breast Cancer|Clinically Assessed Negative Axillary Lymph Nodes|Sentinel Lymph Node,PROCEDURE: Omit SLNB,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,311,OTHER,INTERVENTIONAL,6/21/2023,10/1/2027
NCT05415215,ACTIVE_NOT_RECRUITING,Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer,DRUG: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Trastuzumab Emtansine|DRUG: Investigator's Choice of Chemotherapy|PROCEDURE: Surgery|RADIATION: Radiotherapy,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,346,INDUSTRY,INTERVENTIONAL,7/5/2022,9/25/2025
NCT05374915,RECRUITING,Cutaneous Breast Cancer,COMBINATION_PRODUCT: REM-001 photodynamic therapy,"Kintara Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,INTERVENTIONAL,2/12/2024,12/31/2024
NCT04267315,ACTIVE_NOT_RECRUITING,"Post-mastectomy Pain Syndrome|Myofascial Pain Syndrome|Trigger Point Pain, Myofascial|Breast Cancer",PROCEDURE: Trigger point injection|PROCEDURE: Subcutaneous saline injection|OTHER: Comprehensive Rehabilitation program,Instituto do Cancer do Estado de SÃ£o Paulo,Hospital de CÃ¢ncer de Barretos,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,72,OTHER,INTERVENTIONAL,1/3/2020,2/15/2024
NCT04589468,RECRUITING,Breast Cancer|Prostate Cancer|Colorectal Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Stage I Prostate Cancer|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage I Colorectal Cancer|Stage II Colorectal Cancer|Stage III Colorectal Cancer,OTHER: Exercise,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,10/2/2020,10/2/2024
NCT05742945,ACTIVE_NOT_RECRUITING,Breast Cancer Lymphedema,PROCEDURE: Immediate lymphatic reconstruction,National Taiwan University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,2/14/2023,2028-08
NCT04418115,RECRUITING,"Fatigue|Depression, Anxiety|Insomnia|Hot Flashes|Quality of Life",OTHER: Acupuncture; based on Tradidtional Chinese Medicine,Kristiania University College,"Norwegian Cancer Society|University of Bergen|Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|University Hospital, Akershus|University of York|University of Tromso",FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,9/1/2021,12/1/2024
NCT04609215,RECRUITING,Triple Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer,OTHER: ALECSAT,Henrik Ditzel,"CytoVac A/S|National Board of Health, Denmark",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,4/21/2020,5/21/2023
NCT05914415,NOT_YET_RECRUITING,Mastectomy; Lymphedema|Breast Cancer,OTHER: Supportive care and education before surgery,Saglik Bilimleri Universitesi,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,7/1/2023,12/30/2023
NCT04680715,RECRUITING,Localized Breast Cancer,RADIATION: Per-Operative Radiotherapy technique by Papillon +TM,Centre Antoine Lacassagne,,FEMALE,OLDER_ADULT,NA,40,OTHER,INTERVENTIONAL,7/16/2021,2028-06
NCT05520515,NOT_YET_RECRUITING,Breast Cancer,OTHER: Aquatic Training Plus Health Education|OTHER: Land Training Plus Health Education|OTHER: Health Education,Federal University of Pelotas,,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,9/1/2022,8/30/2025
NCT06131515,RECRUITING,Carpal Tunnel Syndrome,DEVICE: extra corporeal shock wave therapy device,Cairo University,,FEMALE,ADULT,NA,68,OTHER,INTERVENTIONAL,2023-11,2023-12
NCT04499950,ACTIVE_NOT_RECRUITING,Breast Cancer|Overweight or Obesity,DRUG: Contrave|BEHAVIORAL: Behavioral Weight Loss,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,American Institute for Cancer Research|Breast Cancer Research Foundation|Hopkins-WellSpan Cancer Research Fund,FEMALE,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,2/8/2021,12/31/2023
NCT04979715,COMPLETED,Breast Cancer Surgery,PROCEDURE: physitherapy follow-up|OTHER: control,Pamukkale University,,FEMALE,"ADULT, OLDER_ADULT",NA,63,OTHER,INTERVENTIONAL,7/1/2020,1/19/2022
NCT04860115,UNKNOWN,Inflammatory Markers,PROCEDURE: Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB),"St. Elizabeth Cancer Institute, Slovakia",F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica|Louis Pasteur University Hospital Kosice,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,11/1/2021,12/1/2023
NCT04644315,TERMINATED,"Neoplasms|Colorectal Neoplasms|Melanoma|Pancreatic Neoplasms|Sarcoma|Ovarian Neoplasms|Brain Neoplasms|Thyroid Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Salivary Gland Neoplasms|Head and Neck Neoplasms|Thyroid Cancer, Papillary|Lymphoma, Large-Cell, Anaplastic|Neoplasms by Site|Respiratory Tract Neoplasms|Thoracic Neoplasms|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Central Nervous System",DRUG: Alectinib,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,INTERVENTIONAL,5/24/2021,5/16/2022
NCT04530890,RECRUITING,Breast Cancer|Digestive Cancer|Gynecologic Cancer|Circulating Tumor DNA|Exosomes,DIAGNOSTIC_TEST: Blood samples,Poitiers University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,1/20/2021,2030-09
NCT05746897,RECRUITING,Ovarian Cancer|Melanoma|Triple Negative Breast Cancer|Colorectal Cancer,DRUG: NM1F Injection|DRUG: Pembrolizumab injection,"Hefei TG ImmunoPharma Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,38,OTHER,INTERVENTIONAL,4/13/2023,9/30/2027
NCT04300556,RECRUITING,Solid Tumor,DRUG: Farletuzumab ecteribulin|DRUG: Prednisone|DRUG: Prednisolone|DRUG: Dexamethasone,Eisai Inc.,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,142,INDUSTRY,INTERVENTIONAL,8/6/2020,3/31/2025
NCT04222790,COMPLETED,Early Breast Cancer,DRUG: monosialic gangliosides|OTHER: Placebo,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,159,OTHER_GOV,INTERVENTIONAL,8/28/2020,4/21/2022
NCT05461690,NOT_YET_RECRUITING,Homologous Recombination Deficiency|Triple Negative Breast Cancer,DRUG: Niraparib,Zhejiang Cancer Hospital,Sun Yat-sen University|Hunan Cancer Hospital|Fujian Cancer Hospital|Zhejiang University|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,9/1/2022,6/30/2025
NCT05551897,COMPLETED,Healthy Subjects,DRUG: Camizestrant|DRUG: Itraconazole,AstraZeneca,Parexel,FEMALE,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,INTERVENTIONAL,10/4/2022,12/28/2022
NCT05874297,NOT_YET_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,OTHER: Best Practice|BEHAVIORAL: Internet-Based Intervention|OTHER: Questionnaire Administration,Fred Hutchinson Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,2/11/2024,12/31/2024
NCT05867667,RECRUITING,Breast Cancer|Cardiovascular Diseases,OTHER: Cardiac Rehab,University of Michigan Rogel Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2024-03,2025-08
NCT05074290,RECRUITING,Breast Cancer,DRUG: Epidiferphane|DRUG: Taxane Chemotherapy,University of Florida,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,OTHER,INTERVENTIONAL,3/22/2023,2026-01
NCT06175390,NOT_YET_RECRUITING,Triple Negative Breast Cancer,RADIATION: 68Ga-FAPI-46 PET/CT|BIOLOGICAL: Tumor samples analysis|BIOLOGICAL: Blood samples analysis: Circulating Tumor DNA,Institut Curie,Hoffmann-La Roche,FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,INTERVENTIONAL,2/15/2024,2/15/2029
NCT05169567,ACTIVE_NOT_RECRUITING,Breast Neoplasm|Neoplasm Metastasis,DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Placebo,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,368,INDUSTRY,INTERVENTIONAL,3/11/2022,2/16/2026
NCT05189067,RECRUITING,HER2-positive Breast Cancer|Adjuvant Therapy,DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Docetaxel,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,190,OTHER,INTERVENTIONAL,1/31/2022,6/30/2025
NCT05889390,RECRUITING,HER2-negative Breast Cancer,DEVICE: Oncotherm EHY-2030|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cyclophosphamide/Doxorubicin|PROCEDURE: Breast cancer removal surgery,Semmelweis University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,120,OTHER,INTERVENTIONAL,2/20/2023,4/30/2025
NCT04367090,COMPLETED,Metastatic Breast Cancer,"DRUG: Docetaxel, trastuzumab|DRUG: Pyrotinib","Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,97,INDUSTRY,INTERVENTIONAL,5/28/2020,5/24/2023
NCT05012397,TERMINATED,Solid Tumors|Head and Neck Carcinoma|Cholangiocarcinoma|Sarcoma|Lung Adenocarcinoma|Bladder Urothelial Carcinoma|Stomach Adenocarcinoma|Breast Cancer Invasive|Ovarian Carcinoma|Cervical Cancer|Non Small Cell Lung Cancer|Gastric Cancer|Biliary Tract Cancer|Melanoma|Pancreas Cancer|MDM2 Gene Amplification|Testicular Germ Cell Tumor|Adrenocortical Carcinoma,DRUG: RAIN-32,Rain Oncology Inc,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,INTERVENTIONAL,11/1/2021,10/15/2023
NCT05684367,RECRUITING,"Fatigue|Breast Cancer|Cancer, Therapy-Related",BEHAVIORAL: Center-Based Walking Exercise|BEHAVIORAL: Home-Based Walking Exercise,University of Florida,,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,11/29/2023,2025-08
NCT05464667,RECRUITING,Breast Cancer,RADIATION: Radiation Therapy (RT),Parul Barry,,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,2/8/2023,2027-09
NCT04237090,COMPLETED,Breast Cancer|Lung Cancer|Ovarian Cancer|Oesophageal Cancer|Head Cancer Neck|Cervical Cancer|Endometrial Cancer,DRUG: Diphenhydramine|DRUG: Cetirizine|DRUG: Lactose pill|DRUG: Sodium chloride 0.9%,Ciusss de L'Est de l'ÃŽle de MontrÃ©al,,ALL,"ADULT, OLDER_ADULT",PHASE3,27,OTHER,INTERVENTIONAL,2/14/2020,9/4/2020
NCT05909397,RECRUITING,Breast Cancer,DRUG: ARV-471 (PF-07850327)|COMBINATION_PRODUCT: Palbociclib|DRUG: Letrozole|COMBINATION_PRODUCT: Palbociclib,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,1180,INDUSTRY,INTERVENTIONAL,8/9/2023,7/26/2030
NCT05659797,RECRUITING,Breast Cancer,DEVICE: BPET/DBT imaging|DRUG: 18F-FES,Abramson Cancer Center at Penn Medicine,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,10/2/2023,2026-01
NCT05784597,RECRUITING,Breast Cancer|Colorectal Cancer|Oesophageal Cancer|Pancreas Adenocarcinoma,DRUG: [68Ga]Ga-OncoFAP administration,Philogen S.p.A.,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,4/27/2023,2024-01
NCT04465097,COMPLETED,Breast Cancer,DRUG: Tucidinostat|DRUG: Exemestane|DRUG: Ovarian function suppression,"First Affiliated Hospital, Sun Yat-Sen University",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,7/8/2020,10/1/2023
NCT04090567,RECRUITING,Advanced Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|HER2/Neu Negative|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Cediranib|DRUG: Ceralasertib|DRUG: Olaparib,M.D. Anderson Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,7/28/2020,3/31/2025
NCT05033756,RECRUITING,Malignant Neoplasm of Breast|Breast Cancer,DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Olaparib Oral Tablet [Lynparza],Institut fuer Frauengesundheit,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,89,OTHER,INTERVENTIONAL,7/30/2022,2026-02
NCT04890197,UNKNOWN,Breast Cancer,DIETARY_SUPPLEMENT: tahini|OTHER: control,National Nutrition and Food Technology Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,5/8/2021,7/15/2021
NCT06254690,RECRUITING,Breast Cancer,DRUG: Pyrotinib dose escalation|DRUG: Pyrotinib dose normal,The First Affiliated Hospital with Nanjing Medical University,Zhongda Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Jingjiang People's Hospital|Yancheng First People's Hospital|Affiliated Hospital of Jiangnan University|Affiliated Hospital of Nantong University|Anhui Provincial Cancer Hospital|Huai'an First People's Hospital|The Affiliated Hospital of Xuzhou Medical University|Suzhou Municipal Hospital|Affiliated Hospital of Jiangsu University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,INTERVENTIONAL,1/1/2024,12/1/2026
NCT04632797,UNKNOWN,Chemotherapy-induced Peripheral Neuropathy|Chemotherapeutic Toxicity|Chemotherapeutic Agent Toxicity,DEVICE: Hilotherm Chemo Care,Medical University Innsbruck,,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,2/3/2020,2/3/2024
NCT04676997,RECRUITING,Triple Negative Breast Cancer,BIOLOGICAL: Camrelizumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,Shandong Cancer Hospital and Institute,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,5/20/2020,2/28/2024
NCT05800756,RECRUITING,Breast Cancer,"DRUG: pyrotinib combined with trastuzumab, dalpiciclib and letrozole",Yantai Yuhuangding Hospital,"Jiangsu Hengrui Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,8/4/2022,7/30/2025
NCT05642897,RECRUITING,Breast Cancer Female,BEHAVIORAL: Mind|BEHAVIORAL: Support Group,University of Coimbra,IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,1/2/2023,8/31/2025
NCT05660083,RECRUITING,HER2-negative Breast Cancer|Metastatic Breast Cancer|Metaplastic Breast Carcinoma|TNBC - Triple-Negative Breast Cancer,DRUG: L-NMMA,The Methodist Hospital Research Institute,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,1/12/2023,12/2/2028
NCT06085833,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Nanomechanical Phenotype Test,ARTIDIS AG,,ALL,"ADULT, OLDER_ADULT",NA,2706,INDUSTRY,INTERVENTIONAL,11/2/2023,2035-11
NCT04705883,COMPLETED,Vulvar Atrophy|Breast Cancer|Genitourinary Syndrome of Menopause,"DRUG: Prasterone (DHEA), Micronized",Hospital Clinic of Barcelona,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,10,OTHER,INTERVENTIONAL,9/1/2020,12/1/2021
NCT05995483,ACTIVE_NOT_RECRUITING,Breast Self-Examination|Breast Cancer|Nursing Caries|Cancer|Awakening Early,OTHER: Early Diagnosis on BSE,Eastern Mediterranean University,,FEMALE,ADULT,NA,76,OTHER,INTERVENTIONAL,4/4/2023,9/4/2023
NCT04913337,RECRUITING,Mesothelioma|Glioblastoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Melanoma|Pancreatic Ductal Adenocarcinoma|Gastric Cancer|Squamous Cell Carcinoma of Head and Neck|Cholangiocarcinoma|Breast Cancer|Ovarian Cancer|Cervical Cancer|Endocervical Cancer|Colorectal Cancer|Esophageal Cancer,DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707 plus pembrolizumab,"NGM Biopharmaceuticals, Inc",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,179,INDUSTRY,INTERVENTIONAL,6/9/2021,2025-07
NCT05677737,COMPLETED,Breast Cancer Female,OTHER: Education,Ataturk University,,FEMALE,"ADULT, OLDER_ADULT",NA,165,OTHER,INTERVENTIONAL,8/15/2022,7/15/2023
NCT06067061,NOT_YET_RECRUITING,Triple Negative Breast Neoplasms,COMBINATION_PRODUCT: Atezolizumab + RP1,Institut Curie,Replimune Inc.|Roche Pharma AG,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,51,OTHER,INTERVENTIONAL,12/30/2023,4/30/2031
NCT06156761,NOT_YET_RECRUITING,Breast Cancer,DRUG: Mitoxantrone hydrochloride liposome|DRUG: Capecitabine|DRUG: Mitoxantrone hydrochloride liposome|DRUG: Capecitabine,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,11/28/2023,2025-04
NCT06202261,RECRUITING,Metastatic Breast Cancer|Recurrent Breast Cancer,DRUG: TQB2930 for injection|DRUG: Docetaxel injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,89,INDUSTRY,INTERVENTIONAL,4/13/2023,2025-10
NCT05398861,NOT_YET_RECRUITING,HER-2 Negative Breast Cancer,DRUG: Utidelone Combined with Bevacizumab,Henan Cancer Hospital,"Qilu Pharmaceutical Co., Ltd.|Beijing Biostar Pharmaceuticals Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,71,OTHER_GOV,INTERVENTIONAL,6/1/2022,12/30/2024
NCT05639829,COMPLETED,"Cancer, Breast",BEHAVIORAL: Time-restricted eating,University of Alberta,,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,8/5/2020,7/28/2021
NCT04862429,UNKNOWN,Breast Cancer|Calcification,OTHER: Contrast enhanced mammography guided biopsy (diagnostic procedure)|OTHER: Mammography guided biopsy (diagnostic procedure),Azienda UnitÃ  Sanitaria Locale Reggio Emilia,General Electric,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER_GOV,INTERVENTIONAL,7/24/2021,2022-12
NCT05346861,RECRUITING,HER2-positive Breast Cancer|Metastatic Breast Cancer,DRUG: Trastuzumab plus chemotherapy|DRUG: Trastuzumab in combination with pyrotinib plus chemotherapy,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,INTERVENTIONAL,9/15/2021,10/31/2024
NCT04512261,WITHDRAWN,Breast Cancer|Brain Metastases|HER2-positive Breast Cancer|CNS Disease,DRUG: Tucatinib|DRUG: Pembrolizumab|DRUG: Trastuzumab,Reva Basho,Merck Sharp & Dohme LLC|Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,6/1/2022,6/1/2024
NCT05891561,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pertuzumab,Shanghai Jiao Tong University School of Medicine,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,125,OTHER,INTERVENTIONAL,2023-07,2026-12
NCT04487561,COMPLETED,Breast Cancer|Breast-conserving Surgery|Axillary Lymph Node Dissection,DEVICE: hemopatch|PROCEDURE: Aspirative drainage,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,FEMALE,"ADULT, OLDER_ADULT",NA,228,OTHER,INTERVENTIONAL,3/1/2020,2/14/2023
NCT02883361,UNKNOWN,Breast Cancer|Medication Adherence,BEHAVIORAL: Motivational enhancement therapy|BEHAVIORAL: Attention Control,University of Calgary,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,128,OTHER,INTERVENTIONAL,2020-10,2023-01
NCT05374161,RECRUITING,Female Breast Cancer|Depression|Pain,BEHAVIORAL: Acceptance and Commitment Therapy|OTHER: Waitlist Control Group,University of Cyprus,,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,1/20/2022,6/30/2025
NCT05332561,RECRUITING,Early-stage Breast Cancer,DRUG: Atezolizumab 1200 mg in 20 ML Injection|DRUG: Inavolisib|DRUG: Ipatasertib|DRUG: Olaparib|DRUG: Sacituzumab govitecan|DRUG: Trastuzumab/pertuzumab,German Cancer Research Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,240,OTHER,INTERVENTIONAL,6/29/2023,2030-12
NCT04273061,RECRUITING,Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Gynecologic Cancer|Sarcoma|Unknown Primary Tumors|Head and Neck Cancer|Skin Cancer,DRUG: Atezolizumab,British Columbia Cancer Agency,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,6/17/2020,2026-10
NCT04468061,RECRUITING,Breast Cancer|Triple Negative Breast Cancer|PD-L1 Negative,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,Dana-Farber Cancer Institute,Gilead Sciences|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,INTERVENTIONAL,7/20/2020,4/1/2027
NCT06167694,RECRUITING,Unresectable or Metastatic Breast Cancer,DRUG: HRS-8080; Dalpiciclib Isethionate Tablets,"Shandong Suncadia Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,146,INDUSTRY,INTERVENTIONAL,12/20/2023,12/31/2025
NCT06107894,NOT_YET_RECRUITING,Advanced Breast Cancer|Advanced Lung Cancer,BIOLOGICAL: Tumor-infiltrating lymphocytes|DRUG: IL-2,NeogenTC,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,2024-01,2026-05
NCT04036994,RECRUITING,Breast Cancer|Chemotherapy-induced Alopecia|Alopecia,DEVICE: Photobiomodulation therapy,Hasselt University,Jessa Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,6/17/2020,12/31/2022
NCT04481932,RECRUITING,HER2-positive Breast Cancer,DRUG: Trastuzumab combined with Pyrotinib and chemotherapy,Peking University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,104,OTHER,INTERVENTIONAL,2020-07,2026-12
NCT05216432,RECRUITING,"PIK3CA Mutation|Solid Tumor, Adult|HER2-negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Unresectable Solid Tumor",DRUG: RLY-2608|DRUG: Fulvestrant|DRUG: Palbociclib 125mg|DRUG: Ribociclib 400mg|DRUG: Ribociclib 600mg,"Relay Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,400,INDUSTRY,INTERVENTIONAL,12/8/2021,8/31/2025
NCT05562518,RECRUITING,Vulvovaginal Atrophy|Breast Cancer,DRUG: Estrogen|DRUG: dehydroepiandrosterone|DRUG: Estrogen + probiotics|DRUG: Moisturizer,"University Hospital, Ghent",University Ghent,FEMALE,"ADULT, OLDER_ADULT",PHASE4,160,OTHER,INTERVENTIONAL,3/21/2022,3/1/2027
NCT05890677,RECRUITING,"Lymphedema, Breast Cancer",PROCEDURE: Surgical Intervention|PROCEDURE: Conservative Complex Physical Decongestion Therapy,"University Hospital, Basel, Switzerland","Swiss National Science Foundation|Rising Tide Foundation|Krebsforschung Schweiz, Bern, Switzerland",ALL,"ADULT, OLDER_ADULT",NA,280,OTHER,INTERVENTIONAL,7/14/2023,2035-12
NCT05880394,ACTIVE_NOT_RECRUITING,Breast Cancer Stage IV,DRUG: Gallium-68 DOTATATE|DRUG: Copper-64 DOTATATE,Hoag Memorial Hospital Presbyterian,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,1/10/2023,7/31/2024
NCT04293094,COMPLETED,Advanced Solid Tumors,DRUG: AMG 650,"Volastra Therapeutics, Inc.",Amgen,ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,INTERVENTIONAL,3/11/2020,2/15/2023
NCT05983094,NOT_YET_RECRUITING,Breast Cancer|Neoadjuvant Therapy,DRUG: Utidelone|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Trastuzumab|DRUG: Pertuzumab,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Chinese Academy of Medical Sciences Cancer Hospitalï¼ŒShanxi Center|Chinese Academy of Medical Sciences Cancer Hospitalï¼ŒShenzhen Center|First Affiliated Hospital of China Medical University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,181,OTHER,INTERVENTIONAL,9/1/2023,9/1/2027
NCT04228432,COMPLETED,Breast Cancer,OTHER: Dedicated and coordinated monitoring,Institut Claudius Regaud,,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,2/28/2020,7/21/2021
NCT04726332,ACTIVE_NOT_RECRUITING,Neoplasm Malignant|Epithelial Ovarian Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Metastatic Castration-resistant Prostate Cancer,DRUG: XL102|DRUG: Fulvestrant|DRUG: Abiraterone|DRUG: Prednisone,Exelixis,,ALL,"ADULT, OLDER_ADULT",PHASE1,373,INDUSTRY,INTERVENTIONAL,2/10/2021,2024-10
NCT05699902,NOT_YET_RECRUITING,"Breast Cancer Female|Pain, Postoperative",PROCEDURE: PECs block during mastectomy|PROCEDURE: Sham block,Assiut University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,4/1/2023,12/30/2024
NCT04783402,ENROLLING_BY_INVITATION,Breast Neoplasms,OTHER: e-OTCAT program|OTHER: Educational handbook and standard care,Universidad de Granada,,FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,INTERVENTIONAL,10/31/2020,12/30/2024
NCT05094102,COMPLETED,Lymphedema|Surgery|Breast Cancer,DEVICE: OnLume Imaging System|DRUG: Indocyanine green,"University of Wisconsin, Madison",National Institutes of Health (NIH)|OnLume Inc.|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,9,OTHER,INTERVENTIONAL,5/5/2022,4/27/2023
NCT05914402,RECRUITING,Breast Cancer,PROCEDURE: axillary surgery de-escalation after NAT,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,6/18/2023,12/1/2025
NCT05613270,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: 18F-FES PET/CT scan,Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,5/1/2021,12/31/2024
NCT04379570,SUSPENDED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2 Negative Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8,OTHER: Educational Intervention|OTHER: Text Message-based Navigation Intervention|BEHAVIORAL: Motivational Interviewing|OTHER: Best Practice|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE3,1180,OTHER,INTERVENTIONAL,2/15/2021,2025-10
NCT04486911,ACTIVE_NOT_RECRUITING,Breast Cancer,"DRUG: Pyrotinib maleate, SHR6390, letrozole",Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,89,OTHER,INTERVENTIONAL,7/27/2020,12/30/2026
NCT03847311,RECRUITING,Breast Cancer|Chronic Pain Due to Malignancy (Finding),DRUG: Sulfasalazine|DRUG: Placebos,University of Arizona,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,5/3/2021,5/1/2025
NCT04624711,UNKNOWN,HER2-negative Breast Cancer,DRUG: Eribulin Mesylate|DRUG: Anlotinib hydrochloride,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,3/1/2021,2022-12
NCT05961111,RECRUITING,Sarcoma|Carcinoma|Digestive Cancer|Breast Cancer|Lung Cancer|Brain Cancer|Melanoma|Gynecologic Cancer|Head and Neck Cancer|Kidney Cancer,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),Shanghai Yunying Medical Technology,Linyi Central Hospital,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,INDUSTRY,INTERVENTIONAL,6/24/2023,2026-06
NCT04993313,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Breast Carcinoma,OTHER: Counseling|OTHER: Educational Intervention|BEHAVIORAL: Questionnaire,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,3/18/2022,9/30/2024
NCT05057013,RECRUITING,Bladder Cancer|Triple Negative Breast Cancer|Castration-resistant Prostate Cancer|Cervical Cancer|RAS Wild Type Colorectal Cancer|Endometrial Cancer|Gastric Cancer|Hepatocellular Carcinoma (HCC)|Melanoma|Non-small Cell Lung Cancer (NSCLC)|Oesophageal Cancer|Ovarian Cancer|Pancreatic Cancer|Squamous Cell Cancer of the Head and Neck,DRUG: HMBD-001,Cancer Research UK,Hummingbird Bioscience,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,135,OTHER,INTERVENTIONAL,11/10/2021,2026-09
NCT04498611,COMPLETED,"Carcinoma, Ductal, Breast|Invasive Breast Cancer|IMAGE",DIAGNOSTIC_TEST: contrast-enhanced breast MRI,Seoul National University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,113,OTHER,INTERVENTIONAL,7/13/2020,8/15/2021
NCT05727813,COMPLETED,"Cancer, Treatment-Related|Tumor of Breast|Systemic Inflammatory Response|Stage I Breast Cancer",DEVICE: cryoablation,University of Roma La Sapienza,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,9/1/2022,1/27/2023
NCT04778670,ACTIVE_NOT_RECRUITING,Breast Neoplasm Female,DIAGNOSTIC_TEST: AI CAD|DIAGNOSTIC_TEST: Radiologist reading,Karolinska University Hospital,Capio Sankt GÃ¶rans Hospital|Lunit Inc.|Karolinska Institutet,FEMALE,"ADULT, OLDER_ADULT",NA,55579,OTHER,INTERVENTIONAL,4/1/2021,2024-12
NCT04407611,RECRUITING,Hereditary Breast and Ovarian Cancer|Lynch Syndrome,BEHAVIORAL: Online modality|BEHAVIORAL: Genetic counselor follow-up,Boston University,University of Washington|MGH Institute of Health Professions|National Institute on Minority Health and Health Disparities (NIMHD),FEMALE,"ADULT, OLDER_ADULT",NA,2275,OTHER,INTERVENTIONAL,3/6/2023,2024-06
NCT04498013,UNKNOWN,Mammographic Breast Density,DRUG: Cyclodynon|BEHAVIORAL: Lifestyl modification,Dr. Struk Tetiana,Bionorica SE,FEMALE,ADULT,PHASE4,150,OTHER,INTERVENTIONAL,7/22/2020,5/1/2022
NCT04563013,COMPLETED,"Breast Cancer|Cancer, Therapy-Related|Cancer-related Fatigue|Quality of Life",DEVICE: Transcutaneous vagus nerve stimulation,Xidian University,The First Affiliated Hospital of the Fourth Military Medical University,ALL,"ADULT, OLDER_ADULT",NA,288,OTHER,INTERVENTIONAL,4/3/2020,5/30/2022
NCT04553770,RECRUITING,Early-stage Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer,DRUG: Anastrozole|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab Deruxtecan,Jonsson Comprehensive Cancer Center,"Translational Research in Oncology-U.S|Daiichi Sankyo Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,88,OTHER,INTERVENTIONAL,10/9/2020,9/30/2025
NCT02627313,UNKNOWN,Breast Neoplasms,DEVICE: GammaPod Tumour Bed Boost,Ottawa Hospital Research Institute,,FEMALE,ADULT,NA,20,OTHER,INTERVENTIONAL,2021-01,2022-01
NCT03658213,WITHDRAWN,Breast Cancer,DRUG: ZOLADEX 10.8 mg|DRUG: ZOLADEX 3.6mg,AstraZeneca,,FEMALE,ADULT,PHASE3,0,INDUSTRY,INTERVENTIONAL,3/31/2020,11/4/2021
NCT05110170,COMPLETED,Breast Cancer,DRUG: LY01005|DRUG: ZOLADEXÂ® 3.6 mg,Luye Pharma Group Ltd.,,FEMALE,ADULT,PHASE3,188,INDUSTRY,INTERVENTIONAL,10/15/2020,6/24/2022
NCT05992870,RECRUITING,Breast Cancer|Implant Breast Reconstruction|Neoadjuvant Radiotherapy,RADIATION: Neoadjuvant radiotherapy,Hubei Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,7/8/2023,10/31/2025
NCT05467111,RECRUITING,Early-stage Breast Cancer,OTHER: Acute Exercise,Technical University of Madrid,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/23/2023,2024-10
NCT05504213,RECRUITING,Breast Cancer,DRUG: HS-10352 combined with fulvestrant (Stage 1)|DRUG: HS-10352 combined with fulvestrant (Stage 2),"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,224,INDUSTRY,INTERVENTIONAL,1/12/2022,12/31/2025
NCT06078670,NOT_YET_RECRUITING,Advanced Solid Tumor,DRUG: CVL218,Fujian Cancer Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,96,OTHER_GOV,INTERVENTIONAL,10/10/2023,2026-06
NCT06193070,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,OTHER: Educational Intervention|OTHER: Interview|OTHER: Survey Administration|OTHER: Telemedicine,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2/11/2024,4/30/2024
NCT05519670,NOT_YET_RECRUITING,Breast Cancer,DRUG: Niraparib Oral Product,Institut Paoli-Calmettes,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,OTHER,INTERVENTIONAL,2023-03,2027-12
NCT06202313,NOT_YET_RECRUITING,Triple Negative Breast Cancer,BIOLOGICAL: Cadonilimab|DRUG: Eribulin,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,128,OTHER,INTERVENTIONAL,2/10/2024,12/30/2028
NCT05064670,RECRUITING,Prostate Cancer|Breast Cancer|Colorectal Cancer,BEHAVIORAL: Exercise,Karolinska Institutet,Swedish Cancer Society|SATS,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,1/11/2022,2024-11
NCT05959811,NOT_YET_RECRUITING,CIPN - Chemotherapy-Induced Peripheral Neuropathy|Breast Cancer,OTHER: yoga,China Medical University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,7/24/2023,6/6/2024
NCT04671511,RECRUITING,Breast Cancer Female|Early-stage Breast Cancer|Lymph Node Metastases|Axillary Metastases|Sentinel Lymph Node,PROCEDURE: Targeted Axillary Dissection|DIAGNOSTIC_TEST: Ultrasound of the axilla,Jewish General Hospital,Quebec Breast Cancer Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,INTERVENTIONAL,3/30/2021,2025-05
NCT05397457,RECRUITING,Breast Cancer|Chemotherapy-induced Alopecia,DEVICE: low-level light therapy,Chang Gung Memorial Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,8/17/2022,12/31/2025
NCT04947280,RECRUITING,Bone Metastases|Breast Cancer,RADIATION: Fractionated Stereotatic Radiation Therapy,Fudan University,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,120,OTHER,INTERVENTIONAL,1/1/2021,12/31/2026
NCT05351424,RECRUITING,Breast Cancer Invasive|Prostate Cancer,OTHER: Audiovisual Intervention- Radiation Therapy Education|OTHER: ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|OTHER: Audiovisual Intervention- Cancer Clinical Trials Education|OTHER: NCI Taking Part in Cancer Research Studies Brochure,Columbia University,Varian Medical Systems,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,5/3/2022,12/31/2026
NCT04208724,COMPLETED,Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma|Malignant Solid Neoplasm,OTHER: Training|OTHER: Cancer Screening intervention|OTHER: Survey Administration,Fred Hutchinson Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,11/18/2020,6/30/2022
NCT06245824,NOT_YET_RECRUITING,Breast Cancer,DRUG: Trastuzumab deruxtecan (T-DXd) with pyrotinib,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,ALL,"ADULT, OLDER_ADULT",PHASE4,51,OTHER,INTERVENTIONAL,1/30/2024,12/1/2026
NCT04258280,RECRUITING,Breast Cancer,BEHAVIORAL: Education and counseling|BEHAVIORAL: Education,Georgetown University,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,7/1/2020,12/31/2025
NCT04896580,ACTIVE_NOT_RECRUITING,Breast Cancer|Cancer|Lymphoma|Leukemia|Prostate Cancer|Thyroid Cancer|Hematologic Malignancy|Non-hodgkin Lymphoma,BEHAVIORAL: Nature based exercise,Cedars-Sinai Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,6/21/2021,2024-05
NCT05328440,RECRUITING,Breast Neoplasms,DRUG: Pyrotinib Maleate|DRUG: Dalpiciclib Isethionate Tablets|DRUG: Inetetamab|DRUG: Fulvestrant,Henan Cancer Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER_GOV,INTERVENTIONAL,5/20/2022,1/1/2026
NCT04330040,COMPLETED,Ovarian Cancer|Breast Cancer,DRUG: Olaparib,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,162,INDUSTRY,INTERVENTIONAL,5/30/2020,9/30/2022
NCT05502224,RECRUITING,Breast Cancer|Germ Cell Tumor,OTHER: Ergospirometry,Jules Bordet Institute,,ALL,ADULT,NA,50,OTHER,INTERVENTIONAL,8/19/2022,2027-09
NCT06126640,NOT_YET_RECRUITING,HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy,DRUG: SHR-A1811|DRUG: Trastuzumab Emtansine,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,INTERVENTIONAL,2023-11,2032-04
NCT04456140,COMPLETED,Breast Carcinoma|Digestive System Neoplasm|Malignant Brain Neoplasm|Malignant Central Nervous System Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Genitourinary System Neoplasm|Malignant Head and Neck Neoplasm|Malignant Musculoskeletal Neoplasm|Malignant Solid Neoplasm|Metastatic Malignant Neoplasm of Unknown Primary|Skin Carcinoma,PROCEDURE: Biospecimen Collection|OTHER: Genetic Counseling|OTHER: Genetic Testing|OTHER: Survey Administration,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",PHASE1,230,OTHER,INTERVENTIONAL,6/29/2020,9/21/2021
NCT04555057,UNKNOWN,Breast Cancer,PROCEDURE: Music therapy,Asan Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,304,OTHER,INTERVENTIONAL,9/21/2020,12/31/2021
NCT05925257,NOT_YET_RECRUITING,Breast Cancer,OTHER: ePRO application and proactive clinical care with nurses.,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,410,OTHER_GOV,INTERVENTIONAL,1/15/2024,3/31/2025
NCT05305924,RECRUITING,ER-Positive Breast Cancer|HER2-negative Breast Cancer,OTHER: Fulvestrant Run-In|OTHER: No Fulvestrant Run-In,The Methodist Hospital Research Institute,Eli Lilly and Company,FEMALE,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,INTERVENTIONAL,2/25/2021,12/1/2026
NCT05989724,RECRUITING,Solid Tumor|Breast Cancer|Pancreatic Cancer|Ovarian Cancer|Colorectal Cancer,DRUG: SON-DP,Qurgen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,INTERVENTIONAL,9/19/2023,2026-03
NCT04544501,COMPLETED,Hereditary Breast and Ovarian Cancer Syndrome,BEHAVIORAL: Culturally-Targeted Video|OTHER: FORCE Fact Sheet,Georgetown University,"Basser Center for BRCA|Nueva Vida, Inc.|Capital Breast Care Center|Virginia Commonwealth University|Arlington Free Clinic",ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,2/24/2020,1/31/2022
NCT05176080,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Famitinib|DRUG: SHR6390|DRUG: Fulvestrant,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER_GOV,INTERVENTIONAL,12/8/2021,1/30/2026
NCT05645380,RECRUITING,Triple Negative Breast Cancer|Breast Cancer,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,University of Kansas Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,139,OTHER,INTERVENTIONAL,12/5/2022,2025-12
NCT04379024,TERMINATED,Focus of Study is Healthy Women at Risk for Breast Cancer,DRUG: DUAVEE 0.45Mg-20Mg Tablet,"Carol Fabian, MD",Breast Cancer Research Foundation,FEMALE,ADULT,EARLY_PHASE1,11,OTHER,INTERVENTIONAL,6/1/2020,7/31/2021
NCT06070324,NOT_YET_RECRUITING,Breast Cancer|Gynecomastia|Transgenderism|Breast Asymmetry,PROCEDURE: Breast surgery|DEVICE: Suturing of surgical incision,Lawson Health Research Institute,,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,INTERVENTIONAL,2023-12,2024-11
NCT04583124,RECRUITING,Breast Neoplasm,OTHER: ATENTO-B|OTHER: ATENTO-T,Universidad de Granada,AsociaciÃ³n EspaÃ±ola contra el CÃ¡ncer,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,9/30/2021,9/30/2025
NCT05433480,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: BPI-16350|DRUG: placebo|DRUG: Fulvestrant,"Betta Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,274,INDUSTRY,INTERVENTIONAL,5/25/2022,7/31/2025
NCT05809024,RECRUITING,Locally Advanced Breast Cancer|Hormone Receptor Positiveï¼ŒHER2-negative Breast Cancer,DRUG: letrozole,Yongsheng Wang,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,3/1/2023,3/25/2026
NCT03878524,ACTIVE_NOT_RECRUITING,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",DRUG: Abemaciclib|DRUG: Abiraterone|DRUG: Afatinib|BIOLOGICAL: Bevacizumab|DRUG: Bicalutamide|PROCEDURE: Biospecimen Collection|DRUG: Bortezomib|DRUG: Cabazitaxel|DRUG: Cabozantinib|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Celecoxib|DRUG: Cobimetinib|DRUG: Copanlisib|DRUG: Dabrafenib|DRUG: Dacomitinib|DRUG: Darolutamide|DRUG: Dasatinib|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|DRUG: Enasidenib|DRUG: Entrectinib|DRUG: Enzalutamide|DRUG: Erlotinib|DRUG: Everolimus|DRUG: Fluorouracil|DRUG: Idelalisib|DRUG: Imatinib|BIOLOGICAL: Ipilimumab|DRUG: Lenvatinib|DRUG: Leucovorin|DRUG: Lorlatinib|DRUG: Losartan|DRUG: Nab-paclitaxel|DRUG: Neratinib|BIOLOGICAL: Nivolumab|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Palbociclib|DRUG: Panobinostat|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Pertuzumab|DRUG: Ponatinib|OTHER: Quality-of-Life Assessment|DRUG: Regorafenib|DRUG: Ruxolitinib|DRUG: Sirolimus|DRUG: Sorafenib|DRUG: Sunitinib|DRUG: Trametinib|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Tretinoin|DRUG: Vemurafenib|DRUG: Venetoclax|DRUG: Vismodegib|DRUG: Vorinostat,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE1,2,OTHER,INTERVENTIONAL,4/1/2020,6/30/2027
NCT04948840,RECRUITING,Radiation Toxicity|Fibrosis|Breast Cancer,BIOLOGICAL: Blood sampling,"Centre Francois Baclesse, Luxembourg",Inotrem,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,4/1/2022,12/31/2024
NCT04763824,ACTIVE_NOT_RECRUITING,Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer,BEHAVIORAL: Telementoring with Practice Facilitation,University of Kansas Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,11/18/2020,2024-07
NCT05315011,RECRUITING,Breast Cancer|Aromatase Inhibitors,OTHER: Whole-body cryotherapy|OTHER: Placebo cryotherapy,"University Hospital, Montpellier",CryoMed Millenaire,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,5/5/2023,2/4/2026
NCT04485013,ACTIVE_NOT_RECRUITING,Cancer,DRUG: TTX-080|DRUG: TTX-080|DRUG: pembrolizumab|DRUG: cetuximab,"Tizona Therapeutics, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1,240,INDUSTRY,INTERVENTIONAL,7/14/2020,6/1/2024
NCT05318469,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma,DRUG: Ivermectin|DRUG: Balstilmab,Yuan Yuan,Agenus Inc.|Gateway for Cancer Research,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,INTERVENTIONAL,10/13/2023,2026-10
NCT05263869,RECRUITING,Breast Cancer With Liver Metastases,DRUG: MRG002,Shanghai Miracogen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,99,INDUSTRY,INTERVENTIONAL,3/23/2022,2023-10
NCT05143970,RECRUITING,Metastatic Cancer|Metastatic Breast Cancer|Metastatic Pancreatic Cancer|Metastatic Gastric Cancer|Metastatic Lung Cancer|Metastatic Ovary Cancer|Oesophageal Cancer|Endometrial Cancer|Advanced Solid Tumor,DRUG: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB,Institut Paoli-Calmettes,Innate Pharma,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,INTERVENTIONAL,1/21/2022,2025-02
NCT06186011,RECRUITING,Breast Cancer,PROCEDURE: Wire-guided surgery|PROCEDURE: Radioactive seed localization|PROCEDURE: Intraoperative ultrasound localization,Hospital Clinic of Barcelona,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,10/4/2023,2025-10
NCT04603911,ACTIVE_NOT_RECRUITING,Breast Cancer,"DRUG: Liposomal bupivacaine|DRUG: Bupivacaine, epinephrine, dexamethasone, and clonidine",Tufts Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,INTERVENTIONAL,12/4/2020,2023-12
NCT05215769,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Lung Carcinoma|Metastatic Malignant Solid Neoplasm|Prognostic Stage IV Breast Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,BEHAVIORAL: Health Education|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,225,OTHER,INTERVENTIONAL,3/30/2022,12/31/2025
NCT05628870,ENROLLING_BY_INVITATION,Breast Cancer,DRUG: HRS-1358,"Shandong Suncadia Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,102,INDUSTRY,INTERVENTIONAL,2/7/2023,6/30/2025
NCT04739670,RECRUITING,Metastatic Triple Negative Breast Cancer,DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Gemcitabine|DRUG: Carboplatin,"Peter MacCallum Cancer Centre, Australia",,ALL,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,INTERVENTIONAL,3/1/2021,9/30/2025
NCT04880369,WITHDRAWN,Breast Cancer|Breast Neoplasms|Breast Cancer Female,DIETARY_SUPPLEMENT: Soy isoflavones|DIETARY_SUPPLEMENT: Lignans|DIETARY_SUPPLEMENT: Placebo,Danish Cancer Society,"Rigshospitalet, Denmark",FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2021-03,2022-12
NCT05703269,RECRUITING,"NSCLC|Renal Cell Carcinoma|Breast Carcinoma|Melanoma|Brain Metastases, Adult|Non-small Cell Lung Cancer",RADIATION: single fraction stereotactic radiosurgery (SSRS)|RADIATION: fractionated stereotactic radiosurgery (FSRS),Wake Forest University Health Sciences,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,244,OTHER,INTERVENTIONAL,7/11/2023,3/31/2028
NCT04681911,RECRUITING,Breast Cancer,DRUG: Inetetamab|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine|DRUG: Carboplatin|DRUG: Albumin paclitaxel|DRUG: Eribulin,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,71,OTHER,INTERVENTIONAL,9/9/2020,9/9/2024
NCT05435911,COMPLETED,Recovery,"DRUG: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|DRUG: Flumazenil|DRUG: Propofol",Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,8/2/2022,12/21/2022
NCT04349111,WITHDRAWN,Invasive Ductal Carcinoma|Ductal Carcinoma In Situ,RADIATION: Intra-operative Radiation Therapy - IORT,"Xoft, Inc.","Icad, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,INTERVENTIONAL,6/30/2022,6/30/2034
NCT06259513,RECRUITING,Breast Cancer|Sentinel Lymph Node|Breast Neoplasms,PROCEDURE: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO,KK Women's and Children's Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER_GOV,INTERVENTIONAL,2/6/2024,12/31/2033
NCT05535413,RECRUITING,Metastatic HER2 Negative Breast Carcinoma|Brain Metastases|Capecitabine|UDT1,DRUG: UTD1 combined with capecitabine,Hunan Cancer Hospital,,MALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,8/1/2022,2025-07
NCT05695313,NOT_YET_RECRUITING,Breast Cancer,DRUG: OnLifeÂ®|OTHER: Placebo,Centre Georges Francois Leclerc,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,3/31/2024,6/30/2026
NCT04890613,RECRUITING,Advanced Solid Tumor,DRUG: CX-5461,"Senhwa Biosciences, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,52,INDUSTRY,INTERVENTIONAL,9/8/2021,2025-06
NCT05452213,RECRUITING,Breast Cancer|Breast Neoplasms|Breast Neoplasm Female|Breast Cancer Female|HER2-negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Advanced Breast Cancer,DRUG: Ribociclib,Institut fuer Frauengesundheit,AGO Breast Study Group e.V.|Novartis Pharmaceuticals,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1000,OTHER,INTERVENTIONAL,10/12/2022,2026-10
NCT04251169,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel,SOLTI Breast Cancer Research Group,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,7/21/2020,11/1/2024
NCT04481113,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|HER2 Negative Breast Adenocarcinoma|Hormone Receptor Positive Breast Adenocarcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Unilateral Breast Carcinoma,DRUG: Abemaciclib|DRUG: Niraparib Tosylate Monohydrate,OHSU Knight Cancer Institute,Eli Lilly and Company|GlaxoSmithKline|Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE1,8,OTHER,INTERVENTIONAL,6/7/2021,6/30/2025
NCT05677802,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Negative Breast Carcinoma|Triple-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|OTHER: Medical Chart Review|PROCEDURE: Stress Management Therapy|OTHER: Survey Administration,Ohio State University Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,12/14/2022,12/31/2024
NCT05475678,RECRUITING,Breast Cancer|Triple Negative Breast Cancer|Camrelizumab,DRUG: ï¼ˆCarrelizumab + TCbï¼‰ regimen|DRUG: TCb regimen,Zhenzhen Liu,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,369,OTHER_GOV,INTERVENTIONAL,12/20/2022,12/31/2029
NCT05365178,ACTIVE_NOT_RECRUITING,"HR-positive, HER2-negative Breast Neoplasms",DRUG: TQB3616 capsule|DRUG: Placebo|DRUG: Fulvestrant injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,432,INDUSTRY,INTERVENTIONAL,7/1/2022,2026-06
NCT06121258,ENROLLING_BY_INVITATION,Breast Cancer Female|Sexual Dysfunction,OTHER: Educational video series,"University of Colorado, Denver",,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,12/5/2023,8/1/2025
NCT05720858,RECRUITING,Breast Cancer|Telerehabilitation|Exercise|Survival,OTHER: Aerobic exercise,Hasan Kalyoncu University,,FEMALE,"ADULT, OLDER_ADULT",NA,69,OTHER,INTERVENTIONAL,10/20/2022,12/30/2023
NCT04355858,RECRUITING,Breast Cancer|Metastatic Cancer,DRUG: SHR7390|DRUG: Famitinib|DRUG: SHR3162|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: SHR1210|DRUG: Everolimus|DRUG: Nab paclitaxel|DRUG: SHR2554|DRUG: SHR3680|DRUG: SHR6390|DRUG: SHR1701|DRUG: SERD|DRUG: AI|DRUG: VEGFi,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,319,OTHER,INTERVENTIONAL,5/1/2020,4/1/2025
NCT04337658,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Fulvestrant|DRUG: Capecitabine,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,493,OTHER,INTERVENTIONAL,7/1/2020,4/30/2026
NCT04715958,RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,PROCEDURE: Contrast-Enhanced Ultrasound|DRUG: Perflutren Lipid Microspheres,Kibo Nam,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER,INTERVENTIONAL,12/7/2020,4/1/2024
NCT05289258,RECRUITING,"Cancer, Breast",BEHAVIORAL: Neuropsychological treatment|BEHAVIORAL: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|BEHAVIORAL: Waitlist group,Universidad de CÃ³rdoba,,ALL,"ADULT, OLDER_ADULT",NA,123,OTHER,INTERVENTIONAL,1/25/2021,12/31/2025
NCT04246502,NOT_YET_RECRUITING,Metastatic Breast Cancer,"DRUG: Capecitabine and Pyrotinib|DRUG: Capecitabine,Trastuzumab, and Pertuzumab",Shandong Cancer Hospital and Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,2020-01,2024-12
NCT05142358,RECRUITING,Lung Cancer|Left Sided Breast Cancer,DEVICE: Continuous Positive Airway Pressure|OTHER: Deep inspiratory breath hold|OTHER: Free Breath,Case Comprehensive Cancer Center,Varian Medical Systems,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,10/19/2022,6/30/2025
NCT03915678,RECRUITING,"Solid Tumor, Adult|Pancreatic Cancer|Virus-associated Tumors|Non Small Cell Lung Cancer|Melanoma|Bladder Cancer|Triple Negative Breast Cancer",DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT,Institut BergoniÃ©,"Roche Pharma AG|National Cancer Institute, France|Seven and Eight Biopharmaceuticals Inc",ALL,"ADULT, OLDER_ADULT",PHASE2,247,OTHER,INTERVENTIONAL,3/31/2021,2026-03
NCT05226078,RECRUITING,Chronic Insomnia|Cancer-related Problem/Condition|Cancer-Related Syndrome,BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia,Abramson Cancer Center at Penn Medicine,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,3/1/2023,9/30/2025
NCT05300958,RECRUITING,Triple Negative Breast Cancer,DRUG: Deferoxamine Plus Chemotherapy,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,3/21/2022,10/1/2024
NCT05881902,RECRUITING,Cancer,BEHAVIORAL: HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|BEHAVIORAL: STANDART CANCER EDUCATÄ°ON,YeÅŸim KAYAPA,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/1/2023,7/1/2023
NCT04862078,ENROLLING_BY_INVITATION,Breast Cancer|Survivorship|Quality of Life,DIAGNOSTIC_TEST: Shared decision making|DIAGNOSTIC_TEST: Usual care,Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,368,OTHER,INTERVENTIONAL,7/6/2021,1/31/2024
NCT05190978,RECRUITING,"Breast Cancer|Breast Implant; Complications, Infection or Inflammation",DEVICE: Acellular Dermal Matrix|PROCEDURE: Reconstruction without ADM,"University of California, Los Angeles",University of Michigan|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Weill Medical College of Cornell University,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,10/20/2022,3/31/2025
NCT05085002,TERMINATED,Advanced Breast Cancer,DRUG: Lerociclib + Letrozole or Fulvestrant,"EQRx, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,INTERVENTIONAL,12/21/2021,11/29/2023
NCT05703178,RECRUITING,"Breast Cancer|Arthralgia|Pain, Chronic",BEHAVIORAL: Online Pain Coping Skills Training|OTHER: Education,Northwestern University,Duke University|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE3,452,OTHER,INTERVENTIONAL,1/19/2023,11/30/2026
NCT05774678,RECRUITING,Breast Cancer,RADIATION: Group 1 (preoperative radiation hypofractionated)|OTHER: Group 2 (preoperative radiation conventionally fractionated),M.D. Anderson Cancer Center,Artidis,ALL,"ADULT, OLDER_ADULT",PHASE3,126,OTHER,INTERVENTIONAL,4/5/2023,11/1/2028
NCT05932758,RECRUITING,Atypical Ductal Hyperplasia|Ductal Carcinoma in Situ,PROCEDURE: Vacuum-assisted excisional biopsy|PROCEDURE: Not excisional biopsy,European Institute of Oncology,"Ministero della Salute, Italy",FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,1/17/2023,7/31/2025
NCT04568902,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DRUG: H3B-6545|DRUG: Antihistamine,"Eisai Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,33,INDUSTRY,INTERVENTIONAL,9/30/2020,8/31/2024
NCT06025058,COMPLETED,Skin Lesion,DEVICE: Easy Dew MD Regen Cream,Eun-ji Kim,,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,INTERVENTIONAL,11/11/2022,7/28/2023
NCT04834778,RECRUITING,Renal Cell Carcinoma|Gastric Cancer|Metastatic Breast Cancer|Small-cell Lung Cancer|Other Solid Tumors,DRUG: HC-5404-FU,"HiberCell, Inc.",Covance,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,6/8/2021,3/8/2024
NCT04291378,RECRUITING,Early Breast Cancer|Radiation Associated Cardiac Failure,RADIATION: Proton versus photon radiation therapy,Danish Breast Cancer Cooperative Group,,ALL,"ADULT, OLDER_ADULT",NA,1502,OTHER,INTERVENTIONAL,6/1/2020,6/1/2037
NCT05622058,TERMINATED,Prevention of Chemotherapy-induced Myelosuppression,DRUG: ALRN-6924|DRUG: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2),"Aileron Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,1/9/2023,2/22/2023
NCT06095323,RECRUITING,Breast Cancer-related Arm Lymphedema,DEVICE: compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg),Zhenzhen Liu,,FEMALE,"ADULT, OLDER_ADULT",NA,480,OTHER_GOV,INTERVENTIONAL,10/16/2023,10/16/2025
NCT05183828,SUSPENDED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Breast Adenocarcinoma|Invasive Breast Carcinoma of No Special Type,PROCEDURE: Biospecimen Collection|DRUG: Letrozole|OTHER: Questionnaire Administration,University of Washington,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,INTERVENTIONAL,1/23/2022,12/31/2024
NCT05346328,NOT_YET_RECRUITING,Breast Cancer,DRUG: Injection of A166,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,6/1/2022,12/31/2024
NCT05732428,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: ARV-471,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,INTERVENTIONAL,2/20/2023,11/7/2024
NCT05035836,ACTIVE_NOT_RECRUITING,Breast Cancer|HER2-positive,DRUG: Zanidatamab|DRUG: Letrozole|DRUG: Tamoxifen,M.D. Anderson Cancer Center,Zymeworks BC Inc.,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,11/16/2021,12/29/2024
NCT05907941,NOT_YET_RECRUITING,"Breast Cancer|Wound Dehiscence, Surgical",DEVICE: ciNPT|OTHER: Conventional Tape Dressings|PROCEDURE: DIEP Breast Reconstruction,McMaster University,Western University,FEMALE,"ADULT, OLDER_ADULT",NA,114,OTHER,INTERVENTIONAL,2023-07,2026-03
NCT03946423,NOT_YET_RECRUITING,Early-stage Breast Cancer|Obesity,PROCEDURE: Bariatric Surgery with Sleeve Gastrectomy|BEHAVIORAL: Lifestyle Intervention,"Masonic Cancer Center, University of Minnesota",,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2024-01,2025-02
NCT04303741,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Eribulin,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,3/25/2020,8/31/2023
NCT04931823,RECRUITING,Solid Tumor,DRUG: CPO-100,"Conjupro Biotherapeutics, Inc.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1,126,INDUSTRY,INTERVENTIONAL,3/24/2021,3/1/2025
NCT06246084,NOT_YET_RECRUITING,Breast Cancer|Breast Cancer Female|Breast Carcinoma,BEHAVIORAL: Endocrine Therapy Education Program,Dana-Farber Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,2024-07,12/31/2024
NCT05386628,NOT_YET_RECRUITING,Breast Cancer Survivors,OTHER: conventional physiotherapy|OTHER: Manual lymphatic drainage|OTHER: Myofascial relasing,Istanbul Medeniyet University,,FEMALE,ADULT,NA,48,OTHER,INTERVENTIONAL,8/15/2022,2/15/2024
NCT05341141,RECRUITING,Breast Cancer,DEVICE: Frozen glove and sock|DRUG: ddEC-ddT,Peking University,"CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,6/10/2022,2026-11
NCT04965428,RECRUITING,Fear of Cancer Recurrence,BEHAVIORAL: Fear-focused Self-Compassion Therapy,Shaanxi Normal University,Shanxi Provincial Cancer Hospital,FEMALE,ADULT,NA,160,OTHER,INTERVENTIONAL,9/15/2021,2023-12
NCT04821141,RECRUITING,Risk Reduction|Breast Cancer,DRUG: Bazedoxifene and Conjugated Estrogens,University of Kansas Medical Center,National Cancer Institute (NCI),FEMALE,ADULT,PHASE2,120,OTHER,INTERVENTIONAL,12/14/2021,7/31/2027
NCT04996836,UNKNOWN,Breast Cancer,BIOLOGICAL: Next Generation Sequencing and Network Analysis,"University of Campania ""Luigi Vanvitelli""",,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,2022-01,2023-12
NCT05373628,NOT_YET_RECRUITING,Breast Carcinoma; Magnetic Resonance Imagingï¼›OGSE,DIAGNOSTIC_TEST: Gradient and pulse imaging,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,5/11/2022,7/1/2023
NCT05139641,NOT_YET_RECRUITING,Young Womenwith Breast Cancer,BEHAVIORAL: Counseling to preserve fertility,MedicalExcellence,Asan Medical Center,FEMALE,ADULT,NA,4100,OTHER,INTERVENTIONAL,2021-12,2028-12
NCT05120180,RECRUITING,Breast Cancer Lymphedema,PROCEDURE: axillary lymph node dissection with vein branches reservation|PROCEDURE: axillary lymph node dissection without vein branches reservation,Xiangyun Zong,,ALL,"ADULT, OLDER_ADULT",NA,261,OTHER,INTERVENTIONAL,1/3/2022,2025-03
NCT04000880,ACTIVE_NOT_RECRUITING,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Ovary Cancer|Prostate Cancer|Thyroid Cancer|Non-Hodgkin Lymphoma,BEHAVIORAL: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|OTHER: Diet-Exercise|OTHER: Exercise-Diet|OTHER: Combined Diet and Exercise,University of Alabama at Birmingham,University of Tennessee|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,603,OTHER,INTERVENTIONAL,3/4/2020,8/31/2024
NCT05949424,NOT_YET_RECRUITING,Renal Cell Carcinoma|Ovarian Carcinoma|Thyroid Carcinoma|Breast Carcinoma|Endometrium Carcinoma,DRUG: Olaparib|DRUG: Lenvatinib|DRUG: Sunitinib|DRUG: Palbociclib|DRUG: Pazopanib|DRUG: Olaparib|DRUG: Lenvatinib|DRUG: Sunitinib|DRUG: Palbociclib|DRUG: Pazopanib,University Medical Center Groningen,,ALL,OLDER_ADULT,PHASE4,30,OTHER,INTERVENTIONAL,2024-05,2025-03
NCT05838001,RECRUITING,Breast Cancer|Breast-conserving Surgery,PROCEDURE: Wire-guided localization and marker clip localization|PROCEDURE: marker clip localization,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,INTERVENTIONAL,2/16/2023,12/1/2025
NCT04213001,COMPLETED,Lymphedema of Upper Arm,DIAGNOSTIC_TEST: ultrasonographic measurement,Dokuz Eylul University,,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,1/2/2020,1/31/2020
NCT05346224,RECRUITING,Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer,DRUG: HLX11|DRUG: EU-PerjetaÂ®,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,INTERVENTIONAL,4/25/2022,12/30/2025
NCT04304924,UNKNOWN,Overweight or Obese Breast Cancer Patients,OTHER: The personalized telephone based intervention,"Gustave Roussy, Cancer Campus, Grand Paris",,FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,6/17/2020,2023-03
NCT05041101,ACTIVE_NOT_RECRUITING,Breast Inflammatory Carcinoma|Recurrent Breast Inflammatory Carcinoma|Stage IV Breast Inflammatory Carcinoma,DRUG: Eribulin Mesylate|DRUG: Grapiprant,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,OTHER,INTERVENTIONAL,11/4/2021,12/31/2025
NCT04669301,RECRUITING,Cancer-related Problem/Condition|Cognitive Impairment,BEHAVIORAL: MAAT-G|BEHAVIORAL: Supportive therapy (time and attention control),University of Rochester,National Institute on Aging (NIA),ALL,OLDER_ADULT,NA,85,OTHER,INTERVENTIONAL,4/2/2021,9/1/2024
NCT04640480,NOT_YET_RECRUITING,Colorectal Cancer|Breast Cancer|Pancreas Cancer|Ovarian Cancer|Small-cell Lung Cancer|Gastric Cancer|Head and Neck Cancer,DRUG: SNB-101,SN BioScience,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,6/21/2024,6/30/2025
NCT05411380,RECRUITING,Breast Cancer,DRUG: Tucidinostat|DRUG: Capecitabine|DRUG: Endocrine Therapy,wang shusen,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,INTERVENTIONAL,10/3/2022,4/1/2025
NCT04073680,UNKNOWN,Breast Cancer|Endometrial Cancer|Lung Cancer|Colo-rectal Cancer|Head and Neck Cancer,DRUG: Serabelisib|DRUG: Canagliflozin 300mg,Petra Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,INTERVENTIONAL,9/1/2020,12/30/2021
NCT03978780,NOT_YET_RECRUITING,Breast Cancer|Nerve Block|Regional Anesthesia|Neuromuscular Blockade,PROCEDURE: Erector spinae plane block|PROCEDURE: Placebo Block,Women's College Hospital,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2023-09,2024-12
NCT05512780,NOT_YET_RECRUITING,Solid Tumor,DRUG: Dalpiciclib,Hebei Medical University Fourth Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,9/10/2022,8/10/2024
NCT04262180,ACTIVE_NOT_RECRUITING,Physical Activity|Breast Cancer Survivors|Endometrial Cancer Survivors,OTHER: Base intervention-Fitbit with EHR integration|OTHER: Coaching Calls|OTHER: Online Gym,"University of Wisconsin, Madison",Northwestern University|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,323,OTHER,INTERVENTIONAL,11/9/2020,1/31/2026
NCT05160480,ENROLLING_BY_INVITATION,Prostate Cancer|Breast Cancer|Neuroendocrine Tumors,DIAGNOSTIC_TEST: Total-body PET imaging,"University of California, Davis",Lantheus Medical Imaging,ALL,"ADULT, OLDER_ADULT",NA,9,OTHER,INTERVENTIONAL,2024-03,3/1/2025
NCT05484180,COMPLETED,Breast Cancer Female,OTHER: training and counseling supported guided imagery application,Ataturk University,,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,2/1/2022,11/15/2022
NCT05981001,RECRUITING,Breast Neoplasms,PROCEDURE: Surgery for harvesting tumor-draining lymph nodes|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Camrelizumab|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,170,OTHER,INTERVENTIONAL,8/1/2023,4/30/2035
NCT05705401,RECRUITING,HER2-positive Breast Cancer,RADIATION: Standard of Care Adjuvant Breast Radiation|DRUG: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation,NRG Oncology,National Cancer Institute (NCI)|Alliance for Clinical Trials in Oncology|Eastern Cooperative Oncology Group|SWOG Cancer Research Network,ALL,"ADULT, OLDER_ADULT",PHASE3,1300,OTHER,INTERVENTIONAL,3/13/2023,2/1/2037
NCT04272801,ACTIVE_NOT_RECRUITING,Breast Cancer Female,"DRUG: tamoxifen, letrozole, anastrozole, or exemestane|BEHAVIORAL: Patient reported outcomes","Shayna Showalter, MD",,FEMALE,OLDER_ADULT,PHASE2,83,OTHER,INTERVENTIONAL,4/7/2020,6/7/2025
NCT04914780,COMPLETED,Breast Cancer,BEHAVIORAL: Education,KTO Karatay University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,81,OTHER,INTERVENTIONAL,6/1/2022,12/1/2022
NCT04489940,TERMINATED,Triple Negative Breast Neoplasms,DRUG: Bintrafusp alfa,"EMD Serono Research & Development Institute, Inc.","Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",PHASE2,11,INDUSTRY,INTERVENTIONAL,10/12/2020,7/8/2022
NCT05744557,RECRUITING,Breast Cancer,OTHER: num Vapocoolant,M.D. Anderson Cancer Center,"Gilero, LLC",ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,3/1/2023,4/30/2025
NCT06121557,RECRUITING,Breast Neoplasms,"PROCEDURE: Surgery for harvesting tumor-draining lymph nodes|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Camrelizumab|DRUG: Chemotherapeutic drug, ADC or PARP inhibitor",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,11/1/2023,12/31/2031
NCT05130840,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: Lumbar puncture,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,7/13/2022,2026-07
NCT05793957,COMPLETED,Hematopoietic and Lymphoid System Neoplasm|Malignant Breast Neoplasm|Malignant Head and Neck Neoplasm|Malignant Solid Neoplasm|Malignant Thoracic Neoplasm,OTHER: Questionnaire Administration|BEHAVIORAL: Telephone-Based Intervention|OTHER: Virtual Technology Intervention,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,4/20/2023,9/28/2023
NCT04202640,TERMINATED,Breast Cancer,PROCEDURE: Mechanical Stimulation|PROCEDURE: Massages,Centre Oscar Lambret,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,5/27/2020,12/7/2023
NCT05939440,RECRUITING,"Cancer, Breast|Cancer Colorectal|Cancer, Ovarian|Cervical Cancer|Uterine Cancer|Vulvar Cancer",OTHER: Proactive Cost of Care (P-COC) intervention|OTHER: Usual Care,University of Alabama at Birmingham,O'Neal Comprehensive Cancer Center at UAB,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,6/1/2022,5/31/2024
NCT04350957,WITHDRAWN,Breast Cancer,DIAGNOSTIC_TEST: Low-dose Imaging,University of Chicago,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,8/24/2020,8/24/2020
NCT05952557,RECRUITING,"Breast Cancer, Early Breast Cancer",DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Abemaciclib,AstraZeneca,Austrian Breast and Colorectal Cancer Study Group (ABCSG),ALL,"ADULT, OLDER_ADULT",PHASE3,5500,INDUSTRY,INTERVENTIONAL,10/5/2023,5/6/2037
NCT04248257,RECRUITING,Breast Cancer Risk,BEHAVIORAL: PeACE|BEHAVIORAL: Community peer coaching,Georgetown University,,ALL,"ADULT, OLDER_ADULT",NA,560,OTHER,INTERVENTIONAL,7/15/2020,2025-12
NCT05530057,RECRUITING,Advanced Breast Cancer,DRUG: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|DRUG: Eribulin Mesylate,Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,INTERVENTIONAL,2/18/2020,12/31/2025
NCT04585724,WITHDRAWN,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Abemaciclib|DRUG: Palbociclib|OTHER: Quality-of-Life Assessment|DRUG: Ribociclib,Emory University,National Cancer Institute (NCI),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,6/12/2020,9/13/2021
NCT05566457,RECRUITING,Breast Cancer,DRUG: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,INTERVENTIONAL,1/1/2020,1/1/2023
NCT05549024,RECRUITING,Breast Cancer|Prostate Cancer|Brain Tumor|PET/CT Imaging,DRUG: 68Ga-RM26-RGD|DRUG: 18F-FDG|DRUG: 68Ga-RM26|DRUG: 68Ga-RGD,Peking Union Medical College Hospital,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,90,OTHER,INTERVENTIONAL,8/16/2022,12/31/2023
NCT05812040,RECRUITING,Breast Neoplasms|Nipple Discharge,DIAGNOSTIC_TEST: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD),Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,3/2/2023,5/30/2024
NCT04319757,RECRUITING,Locally Advanced Solid Tumor|Metastatic Cancer|Solid Tumor|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer,DRUG: ACE1702|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Acepodia Biotech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,5/19/2020,2024-06
NCT04176757,COMPLETED,Breast Cancer,DRUG: ZN-c5,Zeno Alpha Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,35,INDUSTRY,INTERVENTIONAL,1/3/2020,5/25/2021
NCT04653740,UNKNOWN,Advanced Breast Cancer,PROCEDURE: specimen sample collection,Centre Oscar Lambret,Laboratoire PRISM - Michel SALZET,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,9/8/2020,2023-09
NCT04118140,COMPLETED,Cancer,OTHER: Somatic Acupressure|OTHER: Sham acupressure|OTHER: Usual care,Charles Darwin University,The Affiliated Hospital Of Southwest Medical University,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,3/15/2021,7/20/2022
NCT05952011,RECRUITING,Anesthesia,PROCEDURE: Left stellate ganglion block,Ain Shams University,,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,8/8/2023,3/1/2024
NCT05022511,COMPLETED,Uterine Cervical Cancer|Uterine Cervix Cancer|Uterine Cervical Neoplasm|Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Mass Screening|Early Detection of Cancer,BEHAVIORAL: Screening status,University of Aarhus,,FEMALE,"ADULT, OLDER_ADULT",NA,27099,OTHER,INTERVENTIONAL,9/1/2021,9/1/2023
NCT03924011,COMPLETED,Radiodermatitis|Breast Cancer,DEVICE: Photobiomodulation therapy (PBMT)|DEVICE: Sham laser,Hasselt University,Jessa Hospital|Ziekenhuis Oost-Limburg,FEMALE,"ADULT, OLDER_ADULT",NA,71,OTHER,INTERVENTIONAL,7/1/2020,6/1/2021
NCT05554211,RECRUITING,Breast Cancer|BRCA Mutation,DRUG: Tranexamic acid|DRUG: Normal saline,Northwestern University,"Saint Joseph Hospital, Chicago, Illinois|Northwestern Memorial Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,7/12/2022,2024-12
NCT04900311,NOT_YET_RECRUITING,HER2+ Early or Locally Advanced Breast Cancer,DRUG: pyrotinib + trastuzumab + nab-paclitaxel|DRUG: pertuzumab + trastuzumab + nab-paclitaxel,Tianjin Medical University Cancer Institute and Hospital,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,490,OTHER,INTERVENTIONAL,2021-05,2025-12
NCT03721211,WITHDRAWN,Breast Cancer,DRUG: [11C]Martinostat|DEVICE: MR-PET scanner,Christine Elizabeth Edmonds,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,2/1/2020,10/31/2024
NCT05582499,RECRUITING,Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: SHR-A1811|DRUG: SHR-1316|DRUG: Camrelizumab|DRUG: Trophoblast cell-surface antigen 2 (TROP2) ADC|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Goserelin|DRUG: Letrozole|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Fluzoparib|DRUG: HER2 ADC,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,716,OTHER,INTERVENTIONAL,11/1/2022,2025-09
NCT04724499,RECRUITING,Breast Cancer|Chemotherapy Effect|Exercise Therapy|Cognitive Change,BEHAVIORAL: High-Intensity Intervals Training|OTHER: Attention Control,Dana-Farber Cancer Institute,American Institute for Cancer Research,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/14/2021,6/15/2025
NCT04942899,NOT_YET_RECRUITING,Metastasis Breast,DRUG: letrozole,Assiut University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,8/30/2023,5/31/2025
NCT04452370,UNKNOWN,Triple Negative Breast Cancer,DRUG: oral etoposide + anlotinib,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,9/23/2020,7/11/2023
NCT05190770,RECRUITING,Breast Cancer|Breast Cancer Stage|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Stage IV,DRUG: Triamcinolone Acetonide|DRUG: Oleogel-S10,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,12/15/2021,12/15/2026
NCT04296370,RECRUITING,Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation,DRUG: Fluzoparib; Apatinib|DRUG: Fluzoparib|DRUG: Physician's choice chemotherapy,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,474,INDUSTRY,INTERVENTIONAL,7/13/2020,6/30/2025
NCT05340413,RECRUITING,HER2-negative Breast Cancer|Metastatic Breast Cancer|Triple Negative Breast Cancer,DRUG: Olaparib,SOLTI Breast Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,3/25/2022,2024-06
NCT06015113,NOT_YET_RECRUITING,Breast Cancer,DRUG: Disitamab Vedotin plus pyrotinib or naratinib,Xi'an International Medical Center Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,2023-09,2027-04
NCT05339113,RECRUITING,Breast Neoplasms|Positron Emission Tomography|Fibroblast Activation Protein Inhibitor|Fluorodeoxyglucose F18,DIAGNOSTIC_TEST: 68Ga-FAPI-46 PET/CT,"The National Center of Oncology, Azerbaijan",SOFIE INC,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER_GOV,INTERVENTIONAL,2/4/2021,2022-12
NCT05603013,NOT_YET_RECRUITING,"Carcinoma, Non-Small-Cell Lung|Carcinoma Breast",DRUG: Vinorelbine|RADIATION: Radiotherapy|DRUG: PD-1/PD-L1 inhibitor|DRUG: GM-CSF|DRUG: IL-2,Second Affiliated Hospital of Soochow University,,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,INTERVENTIONAL,10/30/2022,10/17/2024
NCT05012813,ENROLLING_BY_INVITATION,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Malignant Solid Neoplasm|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage IIA Prostate Cancer AJCC v8|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8,OTHER: Aromatherapy with Essential Oils,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,7/19/2022,12/31/2024
NCT06112613,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,OTHER: Electronic Health Record Review|OTHER: Health Promotion and Education|PROCEDURE: Health Telemonitoring|OTHER: Interview|BEHAVIORAL: Patient Navigation|OTHER: Survey Administration|OTHER: Text Message-Based Navigation Intervention,ECOG-ACRIN Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",NA,410,NETWORK,INTERVENTIONAL,10/31/2023,1/31/2027
NCT06085313,NOT_YET_RECRUITING,Cancer of Breast|Depressive Symptoms|Cancer Pain,BEHAVIORAL: CAI|BEHAVIORAL: CAPA,University of Texas at Austin,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,4/15/2024,8/31/2028
NCT05196269,RECRUITING,Breast Cancer,DEVICE: Artificial Intelligence and Digital Health Arm,Fundacao Champalimaud,"European Commission|INESC TEC - Institute for Systems and Computer Engineering, Technology and Science (Porto, Portugal)|Cankado GmbH|FCiÃªncias.ID - AssociaÃ§Ã£o para a InvestigaÃ§Ã£o e Desenvolvimento de CiÃªncias (Lisbon, Portugal)|Bocconi University",ALL,"ADULT, OLDER_ADULT",NA,1030,OTHER,INTERVENTIONAL,8/8/2023,2025-12
NCT04366713,COMPLETED,HER2 Amplified Breast Cancer,DRUG: Neratinib|DRUG: Capecitabine|DRUG: Loperamide,"Puma Biotechnology, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INDUSTRY,INTERVENTIONAL,6/30/2020,12/28/2021
NCT05747313,RECRUITING,Breast Cancer|Chemotherapy Effect,DRUG: Chidamide,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,INTERVENTIONAL,11/1/2022,12/31/2023
NCT05033769,RECRUITING,"Breast Cancer Female|Neoplasm, Breast|Breast Cancer Metastatic",DRUG: Eribulin Injection [Halaven]|DRUG: Paclitaxel injection,Institut fuer Frauengesundheit,Eisai GmbH,FEMALE,"ADULT, OLDER_ADULT",PHASE4,82,OTHER,INTERVENTIONAL,3/11/2021,9/15/2023
NCT04345913,ACTIVE_NOT_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Copanlisib Hydrochloride|DRUG: Eribulin Mesylate|PROCEDURE: Magnetic Resonance Imaging,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,NIH,INTERVENTIONAL,3/1/2021,12/31/2024
NCT03775213,COMPLETED,Ductal Carcinoma in Situ,BEHAVIORAL: Decision Support Tool with Active Monitoring|BEHAVIORAL: Decision Support Tool without Active Monitoring,Duke University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,322,OTHER,INTERVENTIONAL,10/12/2021,1/31/2022
NCT04504669,ACTIVE_NOT_RECRUITING,Clear Cell Renal Cell Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Neoplasms|Squamous Cell Cancer of Head and Neck|Small Cell Lung Cancer|Gastroesophageal Cancer|Melanoma|Cervical Cancer|Advanced Solid Tumours,DRUG: AZD8701|BIOLOGICAL: Durvalumab,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,8/18/2020,12/15/2023
NCT05497869,COMPLETED,Postgastrectomy Syndrome,OTHER: active release group|OTHER: active control group,Riphah International University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,8/10/2022,1/15/2023
NCT06103669,RECRUITING,Breast Cancer|Oligoprogressive|Head and Neck Cancer|Sarcoma|Other Cancer,DEVICE: Ablative local therapy,"University of California, Davis",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,10/5/2023,1/5/2031
NCT05165069,RECRUITING,Hand-foot Syndrome,DRUG: Mecobalamin 5 MG Disintegrating Oral Tablet|DRUG: placebo,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,234,OTHER,INTERVENTIONAL,1/1/2022,12/31/2030
NCT05700669,RECRUITING,Metastatic Castration-resistant Prostate Cancer|Recurrent Epithelial Ovarian Cancer|Breast Cancer,DRUG: AsiDNA|DRUG: Olaparib,Valerio Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,INTERVENTIONAL,2/20/2023,2027-04
NCT05595213,RECRUITING,Hot Flashes,DEVICE: Wrist cooling device with cooling plate|DEVICE: Wrist fan activating device without cooling plate|OTHER: Hot Flash Diary,Boston University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,3/5/2023,2024-07
NCT04520269,UNKNOWN,Breast Cancer,DRUG: Pacritinib,"National University Hospital, Singapore",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,OTHER,INTERVENTIONAL,7/13/2020,2023-07
NCT05935059,RECRUITING,Post-mastectomy Pain Syndrome,DRUG: Pregabalin|DRUG: Tianeptine,"National Cancer Institute, Egypt",,FEMALE,ADULT,NA,90,OTHER,INTERVENTIONAL,6/21/2023,2024-01
NCT04252859,RECRUITING,Invasive Lobular Breast Carcinoma,DRUG: [18F]Fluoroestradiol (FES) PET/CT,University of Utah,,ALL,"ADULT, OLDER_ADULT",PHASE2,79,OTHER,INTERVENTIONAL,12/11/2020,6/30/2024
NCT04372459,UNKNOWN,Breast Cancer|Psychological Distress|Emotional Disorder,BEHAVIORAL: Online integrated and stepped psychosocial care|BEHAVIORAL: Usual psychosocial care,Institut CatalÃ  d'Oncologia,,FEMALE,"ADULT, OLDER_ADULT",NA,193,OTHER,INTERVENTIONAL,1/1/2021,6/30/2022
NCT04508803,RECRUITING,Treatment Efficacy,DRUG: HX008ï¼ŒNiraparib|DRUG: HX008ï¼ŒNiraparib|DRUG: HX008ï¼ŒNiraparibï¼ŒTrastuzumab|DRUG: HX008ï¼ŒNiraparibï¼ŒPyrrolitinib,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,INTERVENTIONAL,9/14/2020,12/28/2022
NCT04467515,ACTIVE_NOT_RECRUITING,"Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment",DRUG: CAM-H2,Precirix,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,13,INDUSTRY,INTERVENTIONAL,9/14/2021,1/31/2024
NCT05740956,RECRUITING,Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostatic Cancer|Colorectal Cancer,DRUG: HS-10502,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,318,INDUSTRY,INTERVENTIONAL,6/9/2023,10/1/2026
NCT04704856,COMPLETED,Breast Cancer,BEHAVIORAL: Supervised exercise,"Amsterdam UMC, location VUmc",,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/6/2021,7/25/2022
NCT04554056,COMPLETED,Breast Cancer Female,DRUG: MW05|DRUG: PEG-rhG-CSF,"Mabwell (Shanghai) Bioscience Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,586,INDUSTRY,INTERVENTIONAL,9/21/2020,11/5/2022
NCT05993559,NOT_YET_RECRUITING,Breast Cancer,RADIATION: Arm I (No PMRT)|RADIATION: Arm II (PMRT),Gangnam Severance Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,1314,OTHER,INTERVENTIONAL,11/11/2024,7/10/2031
NCT06162559,RECRUITING,Breast Cancer,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab,The Netherlands Cancer Institute,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,12/18/2023,2036-05
NCT06174259,RECRUITING,Locally Advanced Breast Cancer|Intermittent Fasting,OTHER: intermittent fasting,Menoufia University,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,6/1/2023,6/1/2025
NCT04646759,RECRUITING,Breast Cancer,DRUG: Fulvestrant combined with Pyrotinib|DRUG: Capecitabine combined with Pyrotinib,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,516,OTHER,INTERVENTIONAL,10/14/2020,12/14/2030
NCT05479409,RECRUITING,Breast Neoplasms,RADIATION: Neoadjuvant radiotherapy,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,3/1/2021,2025-12
NCT04652609,RECRUITING,Breast Neoplasm,OTHER: PRESIONA,Universidad de Granada,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,1/1/2021,1/1/2027
NCT05163106,RECRUITING,Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|Locally Advanced Breast Cancer|Luminal A Breast Cancer|Luminal B Breast Cancer,DRUG: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|DRUG: Goserelin,"University Hospital, Akershus",Novartis|Vestre Viken Hospital Trust,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,12/1/2022,12/1/2024
NCT06215027,NOT_YET_RECRUITING,Breast Cancer,OTHER: Dance,AC Camargo Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2/1/2024,11/30/2025
NCT05927727,COMPLETED,Diagnosis|Axilla; Breast,DIAGNOSTIC_TEST: Ultrasound and biyopsy,Ankara Education and Research Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER_GOV,INTERVENTIONAL,4/1/2021,5/30/2023
NCT05113927,RECRUITING,Breast Cancer,DEVICE: Selene,Perimeter Medical Imaging,"Cancer Prevention Research Institute of Texas|Proxima Clinical Research|Biostatistical Consulting, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,333,INDUSTRY,INTERVENTIONAL,12/1/2021,2024-12
NCT04227327,ACTIVE_NOT_RECRUITING,Advanced Breast Cancer,DRUG: Abemaciclib|DRUG: Aromatase Inhibitors,University of Milano Bicocca,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,INTERVENTIONAL,1/7/2020,2023-12
NCT06037954,RECRUITING,Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer,OTHER: Questionnaires|OTHER: Interviews|OTHER: 30-minute telephone or videoconference sessions,Memorial Sloan Kettering Cancer Center,Weill Medical College of Cornell University,ALL,OLDER_ADULT,NA,130,OTHER,INTERVENTIONAL,9/7/2023,2026-09
NCT06067503,RECRUITING,Metastatic Cancer|Breast Cancer|Lobular Breast Carcinoma,DRUG: 18F-fluorofuranylnorprogesterone|DEVICE: Liquid Biopsy|DEVICE: Positron Emission Tomography/Computed Tomography,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,INTERVENTIONAL,2024-02,2026-01
NCT04990856,UNKNOWN,Tumor,PROCEDURE: Exercise,Turku University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER_GOV,INTERVENTIONAL,8/10/2021,12/31/2022
NCT05694559,RECRUITING,Breast Cancer|Colorectal Cancer,BEHAVIORAL: Genetic Testing and Counseling|BEHAVIORAL: Screening Form,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,11/23/2022,2/2/2027
NCT04659603,ACTIVE_NOT_RECRUITING,Breast Cancer Metastatic|Pancreatic Carcinoma Metastatic,DRUG: tusamitamab ravtansine|DRUG: Gemcitabine,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,INTERVENTIONAL,3/29/2021,10/1/2024
NCT04205903,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,DRUG: Nilotinib|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Paclitaxel|OTHER: Placebo|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,12/11/2020,1/2/2024
NCT05212454,RECRUITING,Breast Cancer|Chemotherapy Effect,DRUG: Capecitabine,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,INTERVENTIONAL,3/15/2023,2029-12
NCT05420454,RECRUITING,Breast Cancer,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Nab paclitaxel,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1576,OTHER,INTERVENTIONAL,7/10/2022,12/20/2027
NCT05634954,NOT_YET_RECRUITING,Breast Cancer,DRUG: GEH121224 (18F) Injection|DIAGNOSTIC_TEST: Dynamic and Static - PET/CT Scan|DIAGNOSTIC_TEST: Static - PET/CT Scan,GE Healthcare,Laboratory Corporation of America,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,2023-12,2024-12
NCT04942054,TERMINATED,HER2-negative Breast Cancer|Advanced Breast Cancer|Hormone Receptor-positive Breast Cancer,DRUG: Part 1|DRUG: Part 2|DRUG: Part 3,Sun Pharma Advanced Research Company Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,INTERVENTIONAL,5/20/2022,2/28/2023
NCT06187103,NOT_YET_RECRUITING,Head and Neck Cancer|Breast Cancer|Upper Gastrointestinal Cancer|Lung Cancer|Pelvic Cancer,DEVICE: HyperSight Imaging,"Varian, a Siemens Healthineers Company",,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,INTERVENTIONAL,2024-02,2025-01
NCT06179303,NOT_YET_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Unresectable HER2-Negative Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma,DRUG: Abemaciclib|DRUG: Anastrozole|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Diagnostic Imaging|DRUG: Exemestane|OTHER: Fludeoxyglucose F-18|DRUG: Fluorine F 18 Fluoro Furanyl Norprogesterone|DRUG: Fulvestrant|BIOLOGICAL: Gonadotropin-releasing Hormone Analog|DRUG: Letrozole|PROCEDURE: Positron Emission Tomography|DRUG: Tamoxifen|DRUG: Therapeutic Estradiol,University of Washington,Breast Cancer Research Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/1/2024,3/1/2025
NCT05856656,NOT_YET_RECRUITING,Anxiety|Breast Cancer|Chemotherapy,BEHAVIORAL: Music therapy,Institut Cancerologie de l'Ouest,,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,2023-09,2025-09
NCT06178159,NOT_YET_RECRUITING,Breast Cancer,DRUG: Disitamab Vedotin Injection|DRUG: Pertuzumab Injection|DRUG: Toripalimab,"RemeGen Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,INTERVENTIONAL,2023-12,2025-06
NCT06133959,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: The-Optimal-Lymph-Flow (TOLF) Program,"University of Missouri, Kansas City",,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,12/1/2023,12/31/2025
NCT03463954,RECRUITING,Malignant Neoplasm of Breast,DEVICE: Novilase Laser ablation,Novian Health Inc.,,FEMALE,"ADULT, OLDER_ADULT",NA,122,INDUSTRY,INTERVENTIONAL,8/9/2023,9/30/2025
NCT04692103,ACTIVE_NOT_RECRUITING,Estrogen Receptor Positive|Primary or Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7,DRUG: F-18 16 Alpha-Fluoroestradiol|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|DRUG: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|OTHER: Laboratory Biomarker Analysis,University of Washington,,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,INTERVENTIONAL,7/10/2021,4/30/2041
NCT04215003,UNKNOWN,Breast Cancer,DRUG: A|DRUG: B|DRUG: CL1|DRUG: CL2|DRUG: CLH1|DRUG: CLH2|DRUG: CH1|DRUG: CH2|DRUG: CT1,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,1/20/2020,12/31/2021
NCT04255056,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pyrotinib,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,INTERVENTIONAL,2/1/2020,2/1/2025
NCT05176756,RECRUITING,Cardiovascular Diseases|Breast Cancer|Prostate Cancer|Physical Inactivity,BEHAVIORAL: Gamification and Social Support|BEHAVIORAL: Attention control,Abramson Cancer Center at Penn Medicine,American Heart Association|City of Hope National Medical Center,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,4/14/2022,2/1/2024
NCT04316156,COMPLETED,Breast Cancer,DEVICE: Uincare Homeplus|OTHER: Brochure,Samsung Medical Center,"Ministry of Health, Republic of Korea",FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,4/1/2020,11/17/2021
NCT05445050,RECRUITING,Primary Breast Cancer,DIAGNOSTIC_TEST: Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS),RWTH Aachen University,,FEMALE,"ADULT, OLDER_ADULT",NA,74,OTHER,INTERVENTIONAL,4/26/2021,10/1/2024
NCT05886075,RECRUITING,Lung Cancer|Bronchial Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Sarcoma|Colorectal Cancer|Gastric Cancer|Liver Cancer|Breast Cancer|Pancreatic Cancer|Head and Neck Cancer|Ovarian Cancer,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),Shanghai Yunying Medical Technology,The PLA Navy Anqing Hospital,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,INDUSTRY,INTERVENTIONAL,3/30/2023,2025-03
NCT04856475,WITHDRAWN,Breast Cancer|Brain Metastases,DRUG: Neratinib,Jules Bordet Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,11/24/2021,11/24/2021
NCT05489354,COMPLETED,Breast Cancer,OTHER: mHealth psychoeducational intervention,Chinese University of Hong Kong,,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,9/1/2022,6/30/2023
NCT04418154,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer,DRUG: epirubicin hydrochloride|DRUG: Cyclophosphamide|DRUG: Albumin bound paclitaxel|DRUG: Toripalimab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,6/9/2020,12/31/2023
NCT05661656,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: Intra-arterial chemoinfusion of breast cancer,Assiut University,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,2023-04,2025-05
NCT04565054,RECRUITING,Breast Cancer Female,DRUG: Abemaciclib 50 MG; 150mg 1-0-1 per os,West German Study Group,"Eli Lilly and Company|Genomic HealthÂ®, Inc.",FEMALE,"ADULT, OLDER_ADULT",PHASE3,1250,OTHER,INTERVENTIONAL,9/2/2020,2027-12
NCT05916703,RECRUITING,Breast Disease,DIAGNOSTIC_TEST: SOLUS examination,IRCCS San Raffaele,"Politecnico di Milano|Commissariat A L'energie Atomique|SuperSonic Imagine|VERMON|University College, London|MICRO PHOTON DEVICES (MPD)|EIBIR - European Institute for biomedical imaging research|IC-HAUS",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,11/11/2021,2023-12
NCT04838756,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: AI screening modality|OTHER: Conventional screening modality,Region Skane,Unilabs|Cancer Registry of Norway,FEMALE,"ADULT, OLDER_ADULT",NA,100000,OTHER,INTERVENTIONAL,4/12/2021,4/12/2025
NCT05911854,COMPLETED,Lymphedema,DEVICE: Multi-waved Locked System Laser|DEVICE: Cold Compression therapy|OTHER: complete decongestive therapy,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,1/21/2023,6/5/2023
NCT05814354,RECRUITING,Breast Cancer,DRUG: SHR-A1811|DRUG: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,530,INDUSTRY,INTERVENTIONAL,6/30/2023,6/30/2026
NCT04871854,COMPLETED,Breast Cancer,DRUG: Tocilizumab|DRUG: traditional Covid -19 therapy,Beni-Suef University,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,4/26/2021,8/26/2022
NCT04097756,COMPLETED,Advanced Breast Cancer,DRUG: LX-039 tablets,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,44,INDUSTRY,INTERVENTIONAL,1/7/2020,2/7/2023
NCT05082259,RECRUITING,Advanced Cancer|Cervical Cancer|Triple Negative Breast Cancer,DRUG: ASTX660|DRUG: Pembrolizumab,"Institute of Cancer Research, United Kingdom","Astex Pharmaceuticals, Inc.|Merck Sharp & Dohme LLC|Cancer Research UK",ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,INTERVENTIONAL,3/2/2022,3/16/2026
NCT04432454,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Lasofoxifene and abemaciclib (VERZENIO (R)).,Sermonix Pharmaceuticals Inc.,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,29,INDUSTRY,INTERVENTIONAL,9/29/2020,5/31/2024
NCT05459454,RECRUITING,Breast Cancer,DEVICE: A digital health program for patients with Breast Cancer,Sidekick Health,Landspitali University Hospital|LjÃ³siÃ° Cancer Rehabilitation Center,FEMALE,"ADULT, OLDER_ADULT",NA,66,INDUSTRY,INTERVENTIONAL,7/15/2022,2/1/2024
NCT04848454,RECRUITING,HER2-negative Breast Cancer|Neoadjuvant Therapy|Pathological Complete Response|Immunotherapy|Vinorelbine|Cisplatin,DRUG: Camrelizumab with vinorelbine and cisplatin,Peking University First Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/20/2021,12/31/2024
NCT04679454,RECRUITING,Breast Cancer,RADIATION: Phase I|RADIATION: Phase II,European Institute of Oncology,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,79,OTHER,INTERVENTIONAL,7/31/2021,2029-03
NCT04741503,COMPLETED,Breast Cancer Screening|Oncology|Preventative Medicine|Mammography,OTHER: Breast Cancer Screening Decision Support Tool|OTHER: National Cancer Institute Breast Cancer Screening PDQ,Washington University School of Medicine,National Institute on Minority Health and Health Disparities (NIMHD),FEMALE,ADULT,NA,1277,OTHER,INTERVENTIONAL,4/19/2021,8/30/2021
NCT04207359,COMPLETED,Breast Cancer|Chemotherapy Effect|Muscle Weakness|Muscle Loss|Exercise,DIETARY_SUPPLEMENT: Creatine,The University of Texas Health Science Center at San Antonio,ThriveWell Cancer Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,9/30/2020,3/7/2023
NCT04476654,COMPLETED,Breast Cancer,BEHAVIORAL: YouTube Video Arm,Virginia Commonwealth University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,11/1/2021,6/1/2023
NCT04650256,RECRUITING,Skin Toxicity,OTHER: Complementary and alternative medicine (CAM),University of Miami,"VAUGHN-JORDAN FOUNDATION, INC.|Florida Breast Cancer Foundation",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,7/1/2021,12/31/2024
NCT04836156,RECRUITING,HER2-negative Early Breast Cancer,DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,Peking University People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,46,OTHER,INTERVENTIONAL,4/2/2021,12/31/2026
NCT05946759,ENROLLING_BY_INVITATION,Breast Cancer - Ductal Carcinoma in Situ (DCIS)|Breast-Conserving Surgery,DEVICE: Histolog Scanner,SamanTree Medical SA,"St. Vincenz Krankenhaus GmbH, Paderborn",FEMALE,"ADULT, OLDER_ADULT",NA,90,INDUSTRY,INTERVENTIONAL,10/10/2023,2024-05
NCT04834154,ACTIVE_NOT_RECRUITING,"Breast Cancer|Depression, Anxiety|Mindfulness|Sleep Disturbance",BEHAVIORAL: Mindfulness|BEHAVIORAL: Control group,Stanford University,,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,3/15/2021,10/31/2026
NCT04623554,ACTIVE_NOT_RECRUITING,Breast Cancer,BEHAVIORAL: Prehabilitation program,Zealand University Hospital,"Danish Cancer Society|University Hospital Southampton NHS Foundation Trust|Region Zealand|Naestved, Slagelse and Ringsted Hospitals",FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,6/23/2021,3/15/2034
NCT04752059,COMPLETED,Breast Cancer Stage IV,DRUG: Trastuzumab deruxtecan,Medical University of Vienna,Daiichi Sankyo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,7/28/2020,5/1/2023
NCT04908254,UNKNOWN,"Lymphedema|Lymphedema of Upper Arm|Lymphedema, Breast Cancer",DEVICE: Crossover Device (PCD or Dayspring - alternate to first group),"Koya Medical, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,50,INDUSTRY,INTERVENTIONAL,6/1/2021,12/31/2021
NCT05013554,TERMINATED,Neoplasm Malignant|Breast Cancer|Lung Neoplasm Malignant|Gastric Cancer|Neoplasm,DRUG: SAR443216 IV|DRUG: SAR443216 SC,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE1,44,INDUSTRY,INTERVENTIONAL,8/16/2021,1/15/2024
NCT04142554,WITHDRAWN,Breast Cancer|Breast Neoplasms|Triple Negative Breast Cancer|HER2-positive Breast Cancer,DRUG: Parsaclisib,UNC Lineberger Comprehensive Cancer Center,Incyte Corporation,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,6/1/2020,9/7/2020
NCT05458154,COMPLETED,Post-mastectomy Pain Syndrome,OTHER: questionnaires,"General Committee of Teaching Hospitals and Institutes, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER_GOV,INTERVENTIONAL,3/3/2021,4/4/2022
NCT06081959,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: SKB264|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine,"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,376,INDUSTRY,INTERVENTIONAL,11/30/2023,12/31/2027
NCT04480203,RECRUITING,"Breast Cancer Patients|Health, Subjective",OTHER: Stressproffen cognitive based stress management|OTHER: Stressproffen mindfulness based intervention|OTHER: Control,Cancer Registry of Norway,,FEMALE,"ADULT, OLDER_ADULT",NA,390,OTHER_GOV,INTERVENTIONAL,1/15/2021,12/31/2035
NCT06055803,RECRUITING,Breast Cancer,BEHAVIORAL: Intake Session|BEHAVIORAL: Individual Sessions|BEHAVIORAL: Group Sessions|BEHAVIORAL: Graduation|BEHAVIORAL: Exercise,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,11/7/2023,12/31/2025
NCT05554354,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma,DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Fulvestrant|PROCEDURE: Magnetic Resonance Imaging,National Cancer Institute (NCI),NRG Oncology,ALL,"ADULT, OLDER_ADULT",PHASE2,95,NIH,INTERVENTIONAL,2/29/2024,11/1/2026
NCT06218303,NOT_YET_RECRUITING,Ductal Carcinoma in Situ,BIOLOGICAL: MUC1 Peptide Vaccine|DRUG: HiltonolÂ®|DRUG: Aromatase Inhibitor,"Finn, Olivera, PhD",A Glimmer of Hope Foundation|Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE1,50,OTHER,INTERVENTIONAL,1/31/2024,7/31/2027
NCT05530603,ACTIVE_NOT_RECRUITING,Breast Cancer,BEHAVIORAL: Educational mobile app,University of South Dakota,University of North Dakota,FEMALE,"ADULT, OLDER_ADULT",NA,142,OTHER,INTERVENTIONAL,10/3/2020,12/31/2024
NCT05524454,COMPLETED,Head and Neck Cancer|Lung Cancer|Breast Cancer|Abdominal Cancer|Pelvic Cancer,DEVICE: Novel CBCT Imaging,"Varian, a Siemens Healthineers Company",,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,INTERVENTIONAL,3/20/2023,8/18/2023
NCT03937154,RECRUITING,Chemotherapy-induced Thrombocytopenia,DRUG: Romiplostim|DRUG: Placebo,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,162,INDUSTRY,INTERVENTIONAL,2/26/2020,2/13/2027
NCT06065059,RECRUITING,Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer|BRCA1 Mutation|BRCA-Mutated Ovarian Carcinoma|BRCA-Associated Breast Carcinoma|HRD Positive Advanced Ovarian Cancer,DRUG: TNG348|DRUG: Olaparib,"Tango Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,140,INDUSTRY,INTERVENTIONAL,12/8/2023,2026-06
NCT03426254,WITHDRAWN,Advanced or Recurrent Solid Tumors|Breast Neoplasm,BIOLOGICAL: Injections Subcutaneously Talazoparib|DRUG: Oral capsules Talazoparib,Center Trials & Treatment,BioGene Pharmaceutical,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,11/10/2022,1/10/2024
NCT05089903,COMPLETED,Breast Cancer,BEHAVIORAL: Bulk Order|BEHAVIORAL: Texting|BEHAVIORAL: Clinician Endorsement|BEHAVIORAL: No Bulk Order|BEHAVIORAL: Standard Endorsement,Abramson Cancer Center at Penn Medicine,,FEMALE,"ADULT, OLDER_ADULT",NA,24680,OTHER,INTERVENTIONAL,10/25/2021,4/25/2022
NCT04745754,ACTIVE_NOT_RECRUITING,Breast Cancer|Colorectal Cancer,OTHER: Embedded primary care in cancer survivorship model,Kaiser Permanente,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,2450,OTHER,INTERVENTIONAL,9/21/2021,5/31/2025
NCT04730154,RECRUITING,"Breast Neoplasms|Survivorship|Pain, Chronic",BEHAVIORAL: Pain Neuroscience Education (PNE)|BEHAVIORAL: Motivational Interviewing (MI)|BEHAVIORAL: Biomedically-focused education,Universitair Ziekenhuis Brussel,Vrije Universiteit Brussel|Kom Op Tegen Kanker|Hasselt University,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,4/1/2021,2025-12
NCT05438303,COMPLETED,Healthy Volunteers,DRUG: AZD9833|DRUG: Midazolam|DRUG: Omeprazole|DRUG: Dabigatran Etexilate|DRUG: Celecoxib,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,59,INDUSTRY,INTERVENTIONAL,6/13/2022,12/13/2022
NCT04482803,COMPLETED,Location and Biopsy of Axillary Lymph Nodes,DRUG: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,159,OTHER,INTERVENTIONAL,9/24/2020,5/24/2023
NCT05590559,RECRUITING,Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction,DRUG: Morphine|OTHER: Ultrasound-guided erector spinae plane block,The Netherlands Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,6/1/2021,12/31/2022
NCT05633654,RECRUITING,Triple Negative Breast Cancer,DRUG: Sacituzumab govitecan-hziy (SG)|DRUG: Pembrolizumab|DRUG: Capecitabine,Gilead Sciences,"Alliance Foundation Trials, LLC.",ALL,"ADULT, OLDER_ADULT",PHASE3,1514,INDUSTRY,INTERVENTIONAL,12/12/2022,2031-08
NCT05385705,RECRUITING,Breast Neoplasms,DRUG: Cyclophosphamide|DRUG: Trastuzumab|DRUG: Pertuzumab|BIOLOGICAL: NK cells|DRUG: Interleukin-2,Vall d'Hebron Institute of Oncology,"Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits",FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,5/11/2022,4/11/2025
NCT06100263,NOT_YET_RECRUITING,Breast Cancer Female,OTHER: Individualized exercise program|OTHER: Control Arm,University of Michigan Rogel Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2024-04,2026-10
NCT05659563,RECRUITING,"Breast Cancer|Breast Cancer, Early-Onset",DRUG: Giredestrant|DRUG: Tamoxifen,MedSIR,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,INTERVENTIONAL,7/20/2023,2024-12
NCT05678205,NOT_YET_RECRUITING,Breast Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,DRUG: AB-201|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Artiva Biotherapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,133,INDUSTRY,INTERVENTIONAL,8/1/2023,2027-04
NCT05086705,ACTIVE_NOT_RECRUITING,Breast Carcinoma|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ|Hot Flashes,DEVICE: EMBr Wave|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,"Embr Labs, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/7/2020,12/31/2024
NCT04427449,UNKNOWN,Cancers Which Are CD44v6 Positive,BIOLOGICAL: CD44v6-specific CAR gene-engineered T cells,Shenzhen Geno-Immune Medical Institute,Shenzhen Hospital of Southern Medical University|The Seventh Affiliated Hospital of Sun Yat-sen University|Shenzhen Children's Hospital,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,INTERVENTIONAL,6/1/2020,12/31/2023
NCT06101849,NOT_YET_RECRUITING,"Breast Cancer|Cancer, Treatment-Related|Pain Cancer",BEHAVIORAL: I-Can-Manage-Pain after cancer (Pain Management Program),Hamilton Health Sciences Corporation,McMaster University,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,11/1/2023,7/30/2024
NCT04879849,ACTIVE_NOT_RECRUITING,"Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Neoplasms|Squamous Cell Carcinoma of Head and Neck",DRUG: Pembrolizumab|DRUG: TAK-676|RADIATION: Image-guided radiation therapy,Takeda,,ALL,"ADULT, OLDER_ADULT",PHASE1,65,INDUSTRY,INTERVENTIONAL,9/9/2021,2/18/2024
NCT05079763,UNKNOWN,Acute Radiation Dermatitis,OTHER: Bacterial cellulose-monolaurin hydrogel|OTHER: Placebo cream,University of the Philippines,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,9/1/2021,2022-12
NCT03978663,RECRUITING,High-Risk Cancer|Locally Advanced Breast Cancer,RADIATION: Neoadjuvant radiotherapy,Lawson Health Research Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,9/2/2020,2025-08
NCT04483505,COMPLETED,Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast,"DRUG: Combination, Rogaratinib + palbociclib + fulvestrant",Fundacion CRIS de InvestigaciÃ³n para Vencer el CÃ¡ncer,Bayer|Pfizer|Apices Soluciones S.L.,FEMALE,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,INTERVENTIONAL,11/25/2020,4/4/2023
NCT06105749,RECRUITING,Breast Cancer|Breast Neoplasms|Breast Cancer Female|Neoplasms,DEVICE: contrast-enhanced mammography,Wendie Berg,Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,1500,OTHER,INTERVENTIONAL,11/8/2023,2031-04
NCT04079049,RECRUITING,Breast Cancer|Liver Metastases,PROCEDURE: Surgical intervention|DRUG: Control,UmeÃ¥ University,Uppsala University|Karolinska Institutet|Linkoeping University|Lund University|GÃ¶teborg University,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,INTERVENTIONAL,1/1/2020,12/31/2029
NCT05132582,RECRUITING,HER2 Positive Breast Cancer,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Combination product: Trastuzumab + Pertuzumab|DRUG: Placebo,Seagen Inc.,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,650,INDUSTRY,INTERVENTIONAL,3/7/2022,6/30/2027
NCT04542382,ACTIVE_NOT_RECRUITING,Healthy Volunteers,DRUG: Rosuvastatin|DRUG: Rosuvastatin (Inhibitor arm)|DRUG: Eltrombopag,"University of California, San Francisco",Food and Drug Administration (FDA),ALL,ADULT,PHASE1,20,OTHER,INTERVENTIONAL,2/1/2022,2024-12
NCT05804916,RECRUITING,Breast Cancer|Optical Surface Monitoring Technology|Large-segment Radiotherapy,DEVICE: Surface Guided Radiation Therapy (SGRT),Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,556,OTHER,INTERVENTIONAL,4/1/2022,4/1/2027
NCT05840068,COMPLETED,Breast Cancer Female,DRUG: MetFORMIN 500 Mg Oral Tablet|DRUG: Chemotherapy,Beni-Suef University,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,107,OTHER,INTERVENTIONAL,6/1/2020,7/31/2021
NCT04670445,ACTIVE_NOT_RECRUITING,Stage IV Melanoma|Advanced Lung Cancer|Stage IV Non-Small Cell Lung Cancer|Unresectable Non-Small Cell Lung Carcinoma|Unresectable Stage III Non-Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage|Stage IV Merkel Cell Carcinoma|Stage IV Cutaneous Squamous Cell Carcinoma|Stage IV Basal Cell Carcinoma|Stage IV Breast Cancer|Stage IV Colorectal Cancer|Stage IV Gastric Cancer|Stage IV Esophageal Cancer|Stage IV Hepatocellular Cancer|Stage IV Renal Cell Carcinoma|Stage IV Bladder Cancer|Stage IV Head and Neck Squamous Cell Carcinoma|Stage IV Cervical Cancer|Stage IV Endometrial Cancer|Stage IV Mesothelioma|Immunotherapy|Immune Checkpoint Inhibitors,OTHER: Educational Video and QPL List|OTHER: Usual Care,Massachusetts General Hospital,Conquer Cancer Foundation,ALL,"ADULT, OLDER_ADULT",NA,210,OTHER,INTERVENTIONAL,1/23/2021,2024-04
NCT05957068,RECRUITING,Early-stage Breast Cancer|Locally Advanced Breast Cancer,BEHAVIORAL: Exercise Programme|BEHAVIORAL: Control,"National Cancer Centre, Singapore",Singapore Cancer Society|Genome Institute of Singapore|National University of Singapore|Singapore General Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,2156,OTHER,INTERVENTIONAL,7/1/2023,5/31/2033
NCT04789668,COMPLETED,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Hematopoietic and Lymphoid Cell Neoplasm|Hormone Receptor Positive Breast Adenocarcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Triple-Negative Breast Carcinoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Bintrafusp Alfa|DRUG: Pimasertib|OTHER: Quality-of-Life Assessment,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,OTHER,INTERVENTIONAL,1/15/2021,12/8/2023
NCT04472845,RECRUITING,Breast Cancer|Hypofractionation|Radiotherapy Side Effect,RADIATION: 1 week RT|RADIATION: 2 week RT,Postgraduate Institute of Medical Education and Research,,FEMALE,"ADULT, OLDER_ADULT",NA,1018,OTHER_GOV,INTERVENTIONAL,3/30/2021,8/20/2028
NCT05914168,RECRUITING,Breast Cancer,DEVICE: Breast Tomosynthesis,GE Healthcare,,FEMALE,"ADULT, OLDER_ADULT",NA,150,INDUSTRY,INTERVENTIONAL,2/15/2023,2024-02
NCT05035745,RECRUITING,Advanced Refractory Solid Tumors|Advanced Triple Negative Breast Cancers|Metastatic Triple Negative Breast Cancers,DRUG: Talazoparib|DRUG: Selinexor,"National University Hospital, Singapore",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,63,OTHER,INTERVENTIONAL,3/1/2021,2025-11
NCT06200168,RECRUITING,Electroacupuncture|Olanzapine-contained Four-drug Antiemetic|Nausea and Vomiting,DEVICE: Electroacupuncture|DRUG: Standard antiemetic treatment|DEVICE: Sham electroacupuncture|DRUG: Standard antiemetic treatment,Jiuda Zhao,,ALL,"ADULT, OLDER_ADULT",PHASE3,370,OTHER,INTERVENTIONAL,12/20/2023,12/31/2026
NCT05892068,RECRUITING,Metastatic Breast Cancer,DRUG: Tucatinib,Memorial Sloan Kettering Cancer Center,Seagen Inc.,FEMALE,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,INTERVENTIONAL,5/9/2023,5/9/2028
NCT04974268,ACTIVE_NOT_RECRUITING,Lymphedema,OTHER: Specific supervised exercise and weight loss program,FundaciÃ³n PÃºblica Andaluza para la InvestigaciÃ³n de MÃ¡laga en Biomedicina y Salud,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,5/17/2021,5/17/2024
NCT05512468,RECRUITING,Breast Cancer|Neoadjuvant Therapy|Sentinel Lymph Node Biopsy,DRUG: carbon dye,Fujian Medical University Union Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,3/1/2020,3/31/2023
NCT04494945,RECRUITING,BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome|Breast Ductal Carcinoma In Situ|Hematopoietic and Lymphoid System Neoplasm|Hereditary Neoplastic Syndrome|Lynch Syndrome|Malignant Solid Neoplasm,PROCEDURE: Biospecimen Collection|OTHER: Genetic Counseling|OTHER: Genetic Testing|OTHER: Survey Administration,OHSU Knight Cancer Institute,National Cancer Institute (NCI)|Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,27500,OTHER,INTERVENTIONAL,3/9/2020,6/10/2030
NCT05060068,RECRUITING,Breast Cancer Surgery,DRUG: S-ketamine (low dose)|DRUG: Placebo|DRUG: S-ketamine (high dose),The Second Hospital of Anhui Medical University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,352,OTHER,INTERVENTIONAL,10/7/2021,7/7/2024
NCT04794075,RECRUITING,Neoplasm of Breast,OTHER: Therapeutic Education and Nursing Support Program for Supportive Care,Centre Hospitalier Emile Roux,"University Hospital, Clermont-Ferrand|Walisco",FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,8/9/2021,2025-08
NCT05800275,RECRUITING,Leptomeningeal Metastasis|Leptomeningeal Disease|HER2-positive Metastatic Breast Cancer,DRUG: Tucatinib Oral Tablet|DRUG: Capecitabine tablets|DRUG: Trastuzumab Injection,UNICANCER,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,12/18/2023,2027-06
NCT04383275,NOT_YET_RECRUITING,Breast Cancer,DRUG: capecitabine and trastuzumab|DRUG: endocrine therapy and trastuzumab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,356,OTHER,INTERVENTIONAL,5/15/2020,5/15/2027
NCT04771975,COMPLETED,Breast Cancer|Breast Neoplasms,BEHAVIORAL: Exercise Counselling|BEHAVIORAL: Partner Matching|BEHAVIORAL: Resistance training sessions led by a QEP,Jenna Smith,Canadian Cancer Society (CCS),FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,5/10/2021,1/30/2022
NCT04354675,RECRUITING,Breast Cancer,GENETIC: Automated program (ChatBot)|GENETIC: Genetics counselor|OTHER: BCGCKQ Survey|OTHER: Satisfaction Survey|DEVICE: Genetic testing,Case Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,6/29/2021,6/1/2025
NCT04983875,RECRUITING,Mammography|Vascular Calcification,BEHAVIORAL: BAC-Enhanced Letter|BEHAVIORAL: Waitlist Control,Icahn School of Medicine at Mount Sinai,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,14875,OTHER,INTERVENTIONAL,9/29/2021,3/31/2026
NCT05303675,RECRUITING,Breast Cancer Female|Breast Cancer Lymphedema,OTHER: exercise and training,Gulseren MARAS,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,4/18/2022,5/30/2024
NCT04717050,RECRUITING,Breast Cancer|Coronary Artery Disease|Stroke|Type2 Diabetes,BEHAVIORAL: Progressive combine training (PCT)|BEHAVIORAL: Attention Control (AC),Dana-Farber Cancer Institute,"American Cancer Society, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,8/12/2021,6/15/2026
NCT04596150,COMPLETED,"Neoplasms|Breast Neoplasms|Breast Neoplasms, Triple-Negative|Breast Cancer|Breast Neoplasms, Hormone Receptor Positive/HER2 Negative",DRUG: CX-2009|DRUG: CX-072,CytomX Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE2,125,INDUSTRY,INTERVENTIONAL,12/29/2020,6/2/2023
NCT06134375,NOT_YET_RECRUITING,Triple Negative Breast Cancer|Residual Disease,DRUG: Tetrathiomolybdate|DRUG: Capecitabine|DRUG: Pembrolizumab,Dartmouth-Hitchcock Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,OTHER,INTERVENTIONAL,2024-03,2034-03
NCT05775575,RECRUITING,Advanced Breast Cancer,DRUG: TQB3909 tablets,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,INTERVENTIONAL,3/2/2023,2023-12
NCT05739175,RECRUITING,Breast Cancer|Nursing,DEVICE: Mobile Application with Interactive Nurse Support,Ankara University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,7/15/2022,2/15/2024
NCT06126575,NOT_YET_RECRUITING,Hepatic Impairment,DRUG: Elacestrant dihydrochloride,"Stemline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,16,OTHER,INTERVENTIONAL,1/24/2024,12/30/2024
NCT04608175,UNKNOWN,Acupuncture Therapy|Breast Neoplasms,OTHER: Acupuncture,University Ramon Llull,Hospital Quiron Sagrado Corazon,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2020-11,2023-03
NCT05970250,COMPLETED,Osteoporosis|Breast Cancer,OTHER: Whole body vibration group|OTHER: Weight bearing exercises|DRUG: vitamin D supplements and calcium,Cairo University,,ALL,ADULT,NA,45,OTHER,INTERVENTIONAL,1/20/2022,7/20/2022
NCT04343950,UNKNOWN,Mass Screening|Colorectal Cancer|Breast Cancer,BEHAVIORAL: SMS reminders to enhance colorectal cancer screening|BEHAVIORAL: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|BEHAVIORAL: Invitation by SMS to previous participants in breast cancer screening:,Institut CatalÃ  d'Oncologia,University of Dundee|University of Barcelona|University Rovira i Virgili,ALL,"ADULT, OLDER_ADULT",NA,20000,OTHER,INTERVENTIONAL,9/15/2020,12/31/2022
NCT05364450,ACTIVE_NOT_RECRUITING,"Breast Neoplasm|Breast Cancer|Breast Carcinoma|Malignant Neoplasm of Breast|Cancer of Breast|Mammary Neoplasms, Human|Human Mammary Carcinoma|Malignant Tumor of Breast|Mammary Cancer|Mammary Carcinoma, Human|Anxiety|Fear",BEHAVIORAL: Enhanced Usual Care|BEHAVIORAL: Acceptance Commitment Therapy|BEHAVIORAL: Cognitive Behavioral Therapy,Indiana University,National Cancer Institute (NCI)|Indiana University Health|Eskenazi Health,FEMALE,"ADULT, OLDER_ADULT",NA,390,OTHER,INTERVENTIONAL,7/17/2021,1/1/2025
NCT05728268,RECRUITING,Breast Cancer,DRUG: dose-dense nab-paclitaxel followed by EC,Shantou Central Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,INTERVENTIONAL,8/1/2021,12/30/2024
NCT05945368,RECRUITING,HER2-positive Breast Cancer,DRUG: Eribulin mesylate injectionã€Pertuzumabã€Trastuzumab,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,INTERVENTIONAL,2/25/2022,2/25/2025
NCT04454515,RECRUITING,Morphine Consumption,DRUG: Dexmedetomidine|DRUG: placebo,National Taiwan University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,4/20/2021,7/1/2025
NCT05131815,COMPLETED,"Cancer|Cancer Metastatic|Neoplasms|Breast Cancer|Lung Cancer|Thyroid Cancer|Lymphoma|Lymphoma, Non-Hodgkin|Hodgkin Lymphoma|Leukemia|Sarcoma|Skin Cancer|Bone Cancer|Gynecologic Cancer|Pancreas Cancer|Multiple Myeloma|Colorectal Cancer|Gastrointestinal Cancer|Prostate Cancer|Glioblastoma|Brain Cancer|Head and Neck Cancer",BEHAVIORAL: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board,Cedars-Sinai Medical Center,Walter Reed National Military Medical Center,ALL,ADULT,NA,8,OTHER,INTERVENTIONAL,1/10/2022,8/21/2023
NCT05047575,COMPLETED,Breast Cancer,OTHER: REASSURE,"University of Wisconsin, Madison",,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,8/24/2021,7/28/2022
NCT05025059,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,PROCEDURE: Discussion|OTHER: Exercise Intervention|OTHER: Exercise Intervention|OTHER: Informational Intervention|OTHER: Informational Intervention|OTHER: Medical Device Usage and Evaluation|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,,FEMALE,OLDER_ADULT,NA,30,OTHER,INTERVENTIONAL,12/3/2020,12/31/2023
NCT04888975,UNKNOWN,"Lymphedema|Lymphedema, Breast Cancer|Lymphedema Arm",DEVICE: Dayspring Active Wearable Compression System,"Koya Medical, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,20,INDUSTRY,INTERVENTIONAL,6/1/2021,12/31/2021
NCT05953350,RECRUITING,Inhibition of Autophagy Synergizes Anti-tumor Effect,DRUG: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|DRUG: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,29,OTHER,INTERVENTIONAL,6/12/2023,12/31/2024
NCT06058650,RECRUITING,Breast Neoplasm,PROCEDURE: Biopsy of Breast|OTHER: Medical Device Usage and Evaluation|RADIATION: Scintimammography|OTHER: Technetium Tc-99m Sestamibi,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,8/26/2021,8/26/2026
NCT04805775,COMPLETED,Desflurane|Propofol|Postoperative Sleep|PSQI|Breast Tumor,DRUG: Desflurane Inhalation,Zhongnan Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,118,OTHER,INTERVENTIONAL,10/21/2021,3/10/2023
NCT05744375,RECRUITING,Locally Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: Trastuzumab deruxtecan,Spanish Breast Cancer Research Group,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,INTERVENTIONAL,9/28/2023,3/1/2029
NCT04606550,WITHDRAWN,Breast Cancer Female|Genitourinary Syndrome of Menopause,DEVICE: Microablative Fractional CO2 Laser Therapy,"Mount Sinai Hospital, Canada",,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,9/1/2021,7/1/2022
NCT06100068,NOT_YET_RECRUITING,Breast Neoplasm|Radiotherapy|Breath Holding|Mental Test,BEHAVIORAL: Mental Exercises and Temporal Alteration,"University Hospital, Ghent",,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/30/2024,9/1/2024
NCT04605575,RECRUITING,Breast Cancer|Pyrotinib|Breast Diseases|Vinorelbine|HER2-positive Breast Cancer,DRUG: Pyrotinib 320mg + Vinorelbine|DRUG: Pyrotinib 400mg + Vinorelbine|DRUG: Pyrotinib plus Vinorelbine,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE2,208,OTHER,INTERVENTIONAL,5/22/2020,12/1/2023
NCT04818359,ACTIVE_NOT_RECRUITING,Breast Cancer Survivors,BEHAVIORAL: MoviS Training,"University of Urbino ""Carlo Bo""","Presidio Ospedaliero Unico ""Santa Maria della Misericordia"", Urbino|National Cancer Institute, Milan",ALL,"ADULT, OLDER_ADULT",NA,172,OTHER,INTERVENTIONAL,1/7/2020,12/31/2025
NCT03868475,NOT_YET_RECRUITING,Breast Fibroadenoma|Atypical Ductal Hyperplasia|Atypical Lobular Hyperplasia|Lobular Carcinoma in Situ|Flat Epithelial Atypia|Phyllodes; Fibroadenoma|Phyllodes Breast Tumor|Radial Scar|Breast Papilloma|Complex Sclerosing Papillary Lesion of the Breast,PROCEDURE: Vacuum-assisted percutaneous excision|PROCEDURE: Open surgical excision,Lawson Health Research Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,2025-01,1/1/2028
NCT04802759,RECRUITING,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",DRUG: Giredestrant|DRUG: Abemaciclib|DRUG: Ipatasertib|DRUG: Inavolisib|DRUG: Ribociclib|DRUG: Everolimus|DRUG: Samuraciclib|DRUG: PH FDC SC|DRUG: Palbociclib|DRUG: Atezolizumab,Hoffmann-La Roche,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,510,INDUSTRY,INTERVENTIONAL,6/20/2021,10/31/2026
NCT06234150,NOT_YET_RECRUITING,Breast Neoplasms|Exercise Therapy|Chemotherapy-Related Cognitive Impairment|Cognitive Dysfunction|Dance Therapy,OTHER: Aerobic dance|OTHER: Fast-walking,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,2/1/2024,1/1/2027
NCT04821375,ACTIVE_NOT_RECRUITING,Increased Risk for Development of Breast Cancer,DRUG: bazedoxifene plus conjugated estrogens,"Carol Fabian, MD",,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,16,OTHER,INTERVENTIONAL,12/2/2021,12/31/2024
NCT04024254,COMPLETED,Ovarian Cancer|Breast Cancer|Folic Acid Deficiency,DRUG: Folic Acid Tablet,Rush University Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,10,OTHER,INTERVENTIONAL,7/21/2020,6/1/2023
NCT04931615,RECRUITING,Breast Neoplasms|Mammaplasty,DRUG: ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|OTHER: no ARTISS,Mid and South Essex NHS Foundation Trust,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,138,OTHER,INTERVENTIONAL,2/1/2022,1/1/2024
NCT04303715,ACTIVE_NOT_RECRUITING,Breast Cancer|Sentinel Lymph Node,PROCEDURE: No SLNB|PROCEDURE: SLNB,Seoul National University Hospital,National Evidence-Based Healthcare Collaborating Agency,FEMALE,"ADULT, OLDER_ADULT",NA,1734,OTHER,INTERVENTIONAL,9/15/2020,12/31/2027
NCT05519059,COMPLETED,Advanced or Metastatic Breast Cancer,DRUG: Pelareorep,"Adlai Nortye Biopharma Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,INTERVENTIONAL,10/11/2021,5/30/2023
NCT05394259,RECRUITING,Pancreatic Cancer|Breast Cancer|Hepatocellular Carcinoma,DRUG: Piflufolastat F18,M.D. Anderson Cancer Center,Lantheus Medical Imaging,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,INTERVENTIONAL,10/28/2022,1/1/2025
NCT05574816,RECRUITING,Breast Neoplasm Female,DEVICE: Phi-Bra prototype measurements,Hospices Civils de Lyon,,FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,3/30/2023,8/30/2023
NCT06188559,NOT_YET_RECRUITING,Breast Cancer,DRUG: BB-1701,Eisai Inc.,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd",ALL,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,INTERVENTIONAL,12/27/2023,10/26/2026
NCT04827459,COMPLETED,Insomnia|Breast Cancer|Prostate Cancer|Colon Cancer,BEHAVIORAL: Sleep Coach App,University of Michigan Rogel Cancer Center,Breast Cancer Research Foundation,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,5/12/2021,8/8/2022
NCT06130254,RECRUITING,Advanced Solid Tumor|Non-small Cell Lung Cancers,DRUG: Adagrasib|DRUG: Olaparib,M.D. Anderson Cancer Center,Mirati Therapeutics Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,52,OTHER,INTERVENTIONAL,1/30/2024,8/25/2030
NCT05378854,COMPLETED,Breast Cancer|Prostate Cancer,OTHER: LifeChamps Platform,Aristotle University Of Thessaloniki,Region Stockholm,ALL,OLDER_ADULT,NA,27,OTHER,INTERVENTIONAL,7/31/2022,4/10/2023
NCT05670054,RECRUITING,Breast Cancer Stage IV,"DRUG: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival",Mansoura University,,ALL,"ADULT, OLDER_ADULT",PHASE3,116,OTHER,INTERVENTIONAL,3/1/2022,12/15/2023
NCT04742959,ACTIVE_NOT_RECRUITING,Advanced Solid Tumor|Cholangiocarcinoma|HER2-negative Breast Cancer|Triple Negative Breast Cancer|Bladder Cancer|Small-cell Lung Cancer|Prostate Cancer|Thyroid Cancer|Sarcoma|Gastric Cancer|Gallbladder Cancer,DRUG: TT-00420|COMBINATION_PRODUCT: Nab-Paclitaxel,"TransThera Sciences (Nanjing), Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,225,INDUSTRY,INTERVENTIONAL,3/14/2021,2/1/2024
NCT05403554,RECRUITING,Epithelial Ovarian Cancer|Triple Negative Breast Cancer|Non-squamous Non-small-cell Lung Cancer,BIOLOGICAL: NI-1801,Light Chain Bioscience - Novimmune SA,,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,INTERVENTIONAL,4/29/2022,9/30/2025
NCT05514054,RECRUITING,Breast Neoplasms,DRUG: Imlunestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,6000,INDUSTRY,INTERVENTIONAL,10/4/2022,3/15/2032
NCT05350059,NOT_YET_RECRUITING,Breast Cancer,DEVICE: High Intensity Focused Ultrasound (HIFU) to the Breast Cancer,University of Oxford,,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,5/1/2022,11/1/2022
NCT05887154,NOT_YET_RECRUITING,Breast Cancer Stage I,DEVICE: Microwave ablation,University Medical Center Groningen,,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,7/1/2023,6/1/2024
NCT05797454,RECRUITING,Breast Cancer|Breast-conserving Surgery,PROCEDURE: Wire-guided localization and marker clip localization|PROCEDURE: Wire-guided localization,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,INTERVENTIONAL,2/16/2023,12/1/2025
NCT04767659,UNKNOWN,Breast Cancer Female|Chemotherapy Effect,DEVICE: MAMMOT2,IRCCS San Raffaele,Politecnico di Milano,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/27/2020,1/27/2023
NCT05659056,RECRUITING,Breast Cancer,"DRUG: Pyrotinib, trastuzumab, paclitaxel-albumin",The First Affiliated Hospital with Nanjing Medical University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,INTERVENTIONAL,11/29/2022,2024-07
NCT04857697,COMPLETED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Breast Adenocarcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Probiotic|PROCEDURE: Therapeutic Conventional Surgery,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,INTERVENTIONAL,7/1/2021,3/8/2023
NCT05252390,RECRUITING,Advanced Solid Tumor|Ovarian Cancer|Ovary Cancer|Cancer of Ovary|Cancer of the Ovary|Ovary Neoplasm|Pancreatic Cancer|Pancreas Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Neoplasm|Prostate Cancer|Prostatic Cancer|Cancer of Prostate|Cancer of the Prostate|Prostate Neoplasm|Castrate Resistant Prostate Cancer|Castration Resistant Prostatic Cancer|Castration Resistant Prostatic Neoplasms|Triple-negative Breast Cancer|Triple Negative Breast Cancer|Triple Negative Breast Neoplasms|Breast Cancer|Breast Carcinoma|Cancer of Breast|Cancer of the Breast|Breast Tumor,DRUG: NUV-868|DRUG: Olaparib|DRUG: Enzalutamide,Nuvation Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,657,INDUSTRY,INTERVENTIONAL,3/29/2022,2026-11
NCT04035590,RECRUITING,Breast Cancer|Seroma|Wound Complication,PROCEDURE: No drain|PROCEDURE: With drain,Zuyderland Medisch Centrum,,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,6/26/2020,2023-12
NCT05975190,RECRUITING,Radiotherapy|Breast Cancer|Relaxation|Breathholding,OTHER: Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer,Technical University of Munich,German Cancer Aid,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,6/22/2022,12/31/2025
NCT05498597,RECRUITING,Advanced Solid Tumor|Advanced Cancer|Advanced Carcinoma|Ovarian Cancer|Ovarian Carcinoma|Ovarian Epithelial Cancer|Ovarian Endometrioid Adenocarcinoma|Endometrial Cancer|Endometrial Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Lung Adenocarcinoma|Triple Negative Breast Cancer|Pancreatic Ductal Adenocarcinoma|Malignant Pleural Mesothelioma|Ovarian Clear Cell Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Mucinous Adenocarcinoma,DRUG: AMT-151,Multitude Therapeutics Inc.,"Tigermed Consulting Co., Ltd",ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,1/25/2023,10/30/2024
NCT04300790,RECRUITING,Breast Cancer,DRUG: Alpelisib|DRUG: Metformin|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Exemestane|DRUG: Vildagliptin|DRUG: Tamoxifen,MedSIR,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE2,88,OTHER,INTERVENTIONAL,10/23/2020,6/30/2026
NCT05178797,COMPLETED,Post Mastectomy Lymphedema,OTHER: Kinesiology taping technique with exercise therapy|OTHER: Compression decongestive therapy,Dow University of Health Sciences,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,4/4/2021,1/17/2023
NCT03740256,RECRUITING,Bladder Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Salivary Gland|Lung Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer|Pancreatic Adenocarcinoma|Solid Tumor,BIOLOGICAL: CAdVEC,Baylor College of Medicine,The Methodist Hospital Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,INTERVENTIONAL,12/14/2020,12/30/2038
NCT05465590,WITHDRAWN,Advanced Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Ovary Cancer|Pancreatic Neoplasms,DRUG: MB1707,"Mainline Biosciences, Inc.",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,INDUSTRY,INTERVENTIONAL,2022-12,2024-12
NCT05019690,UNKNOWN,Advanced Triple Negative Breast Cancer,DRUG: Apatinib Mesylate|DRUG: Albumin-Bound Paclitaxel,Fujian Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER_GOV,INTERVENTIONAL,10/1/2021,12/31/2023
NCT06006390,RECRUITING,Gastric Cancer|Colon Cancer|Rectal Cancer|Esophageal Cancer|Pancreas Cancer|Lung Cancer|Breast Cancer,BIOLOGICAL: CEA-targeted CAR-T cells|BIOLOGICAL: CEA-targeted CAR-T cells,"Chongqing Precision Biotech Co., Ltd",Shanxi Bethune Hospital,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,INTERVENTIONAL,9/7/2023,8/31/2026
NCT03939897,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma|Recurrent Breast Carcinoma,DRUG: Abemaciclib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Copanlisib Hydrochloride|PROCEDURE: Diagnostic Imaging|PROCEDURE: Echocardiography|DRUG: Fulvestrant|PROCEDURE: Multigated Acquisition Scan,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,NIH,INTERVENTIONAL,6/17/2020,11/1/2024
NCT04766190,RECRUITING,Financial Toxicity|Cancer|Question Prompt List|Breast Cancer|Prostate Cancer,BEHAVIORAL: Group 2: The DISCO App|BEHAVIORAL: Group 1: Usual Care|BEHAVIORAL: Group 3: The DISCO App + Booster,Lauren Hamel,,ALL,"ADULT, OLDER_ADULT",NA,260,OTHER,INTERVENTIONAL,2/10/2021,8/31/2025
NCT04914390,RECRUITING,Triple-negative Breast Cancer,DRUG: AT regimen|DRUG: Tislelizumab|DRUG: Anlotinib,Sichuan Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,INTERVENTIONAL,9/15/2023,9/30/2025
NCT05360290,RECRUITING,Breast Cancer|Circulating Tumor Cell,DEVICE: GILUPI CellCollectorÂ®,RenJi Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,484,OTHER,INTERVENTIONAL,9/14/2022,2029-06
NCT04177056,UNKNOWN,Bone Metastases|Prostate Cancer|Breast Cancer|Renal Cell Carcinoma|Melanoma,RADIATION: SBRT,Hamilton Health Sciences Corporation,Juravinski Cancer Centre Foundation,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,12/4/2020,1/1/2023
NCT05887856,ENROLLING_BY_INVITATION,Patient Satisfaction|Preoperative Anxiety|Anxiety,OTHER: comprehensive educational program for reduction of Pre-Operative Anxiety,Shaukat Khanum Memorial Cancer Hospital & Research Centre,,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,6/1/2023,3/30/2024
NCT05206656,COMPLETED,Metastatic Breast Cancer,DRUG: Eribulin Mesylate|DRUG: Anlotinib,Hunan Cancer Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,10/9/2020,7/20/2022
NCT04123704,TERMINATED,Breast Cancer Stage IV|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer Metastatic,DRUG: Sitravatinib,"C. Kent Osborne, MD",Mirati Therapeutics Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,3,OTHER,INTERVENTIONAL,9/22/2021,1/3/2023
NCT03955627,RECRUITING,Breast Cancer Female,BEHAVIORAL: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN),Wake Forest University Health Sciences,"American Cancer Society, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,6/15/2021,2025-03
NCT06007027,NOT_YET_RECRUITING,Genitourinary Syndrome of Menopause,"DEVICE: SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy",University of Aarhus,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,3/1/2024,7/30/2025
NCT04741204,WITHDRAWN,Breast Cancer Stage|Insulin Resistance|Racial Bias,DRUG: Metformin Extended Release Oral Tablet,Woman's,"Our Lady of the Lake Hospital|American Cancer Society, Inc.|Pfizer",FEMALE,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,INTERVENTIONAL,2022-09,2022-09
NCT05232006,NOT_YET_RECRUITING,Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers,DRUG: Niraparib,Assistance Publique - HÃ´pitaux de Paris,,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,2022-05,2030-05
NCT05180006,RECRUITING,Breast Cancer,DRUG: Atezolizumab Injection|DRUG: Ipatasertib|DRUG: Bevacizumab|DRUG: Pertuzumab|DRUG: Trastuzumab,"Gustave Roussy, Cancer Campus, Grand Paris",Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,210,OTHER,INTERVENTIONAL,2/24/2022,2025-02
NCT04879927,COMPLETED,Breast Cancer|Lung Cancer|Gastrointestinal Cancer,OTHER: Resource Matching|OTHER: Usual Care,Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,125,OTHER,INTERVENTIONAL,5/17/2021,4/1/2023
NCT06039956,NOT_YET_RECRUITING,Breast Cancer|Axilla; Breast,PROCEDURE: Sentinel lymph Node Biopsy,Nova Scotia Health Authority,Obafemi Awolowo University,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/1/2023,5/31/2028
NCT05010356,RECRUITING,Insulin Sensitivity/Resistance|Breast Cancer|Survivorship|Metabolic Disturbance,DRUG: Insulin,University of Copenhagen,,FEMALE,ADULT,NA,24,OTHER,INTERVENTIONAL,2021-08,2026-09
NCT05726656,RECRUITING,Postmastectomy Lymphedema,OTHER: traditional physical therapy session|OTHER: wii console based exercise,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,11/1/2022,2023-12
NCT04925856,RECRUITING,Breast Cancer,OTHER: blood sample,Centre Georges Francois Leclerc,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,5/26/2020,5/26/2030
NCT05243056,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Best Practice|OTHER: Educational Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),FEMALE,ADULT,NA,40,OTHER,INTERVENTIONAL,6/1/2022,12/31/2024
NCT04197856,ENROLLING_BY_INVITATION,Familial Breast Cancer|Familial Colorectal Cancer|Hereditary Breast and Ovarian Cancer Syndrome|Hereditary Breast Cancer|Lynch Syndrome,OTHER: Standard care encouraging family-mediated disclosure of hereditary cancer risk|OTHER: Offer of health-care assisted disclosure by sending direct letters to at-risk relatives,UmeÃ¥ University,GÃ¶teborg University|Lund University|Karolinska Institutet,ALL,"ADULT, OLDER_ADULT",NA,490,OTHER,INTERVENTIONAL,2/6/2020,12/31/2025
NCT04460456,ACTIVE_NOT_RECRUITING,HER2 Positive Solid Tumors,DRUG: SBT6050|DRUG: pembrolizumab|DRUG: Cemiplimab,Silverback Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,58,INDUSTRY,INTERVENTIONAL,7/27/2020,2022-12
NCT03702556,COMPLETED,Breast Cancer,DEVICE: MRI scan,Maastricht University Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2/11/2020,8/15/2023
NCT05676255,RECRUITING,Breast Cancer Female|Psychological Distress,BEHAVIORAL: Cognitively-Based Compassion Training for Survivors|BEHAVIORAL: Cognitively-Based Compassion Training for Dyads|BEHAVIORAL: Health Education,University of Arizona,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,452,OTHER,INTERVENTIONAL,3/20/2023,2027-06
NCT05341492,RECRUITING,EGFR/ B7H3-positive Advanced Lung Cancer|EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer,BIOLOGICAL: EGFR/B7H3 CAR-T,Second Affiliated Hospital of Guangzhou Medical University,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,INTERVENTIONAL,5/1/2022,5/1/2025
NCT04142892,COMPLETED,Breast Cancer,DRUG: Onapristone,SOLTI Breast Cancer Research Group,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,11/6/2020,4/30/2021
NCT04493892,COMPLETED,Breast Cancer|Pregnancy Related|Exposure During Pregnancy,BEHAVIORAL: Educational Intervention,Columbia University,,FEMALE,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,3/31/2021,6/3/2022
NCT05904730,ENROLLING_BY_INVITATION,Breast Cancer|Ovarian Cancer|Breast Neoplasms|Ovarian Neoplasms|BRCA Mutation|HER2-positive Breast Cancer|HER2-negative Breast Cancer|HER-2 Protein Overexpression,DRUG: Axitinib,Lynkcell Europe,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,7/11/2023,11/9/2024
NCT05715255,RECRUITING,Breast Cancer|Colon Cancer|Lung Cancer|Skin Cancer|Rectum Cancer,BEHAVIORAL: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|BEHAVIORAL: Active control comparator,University of Arizona,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,5/8/2023,8/1/2027
NCT06070155,RECRUITING,Trace Elements Levels After Breast Cancer Radiotherapy,OTHER: Aerobic Exercise three time a week,Cairo University,,FEMALE,ADULT,NA,28,OTHER,INTERVENTIONAL,2023-10,2024-01
NCT05423730,COMPLETED,ER+ Breast Cancer|Breast Cancer|Aromatase Inhibitors,OTHER: White Wine|OTHER: Grape Juice,Beth Israel Deaconess Medical Center,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Dana-Farber Cancer Institute,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,9/1/2022,7/31/2023
NCT04827030,COMPLETED,Breast Surgery,DRUG: RopivacaÃ¯ne Hydrochloride by Erector Spinae block|DRUG: RopivacaÃ¯ne Hydrochloride by Paravertebral block,Institut Curie,"National Cancer Institute, France",FEMALE,"ADULT, OLDER_ADULT",PHASE4,292,OTHER,INTERVENTIONAL,6/28/2021,7/14/2023
NCT04281355,WITHDRAWN,Breast Cancer,PROCEDURE: Omission of axillary lymph node dissection|RADIATION: Omission of regional irradiation,Karolinska Institutet,,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,INTERVENTIONAL,1/1/2021,12/31/2029
NCT03324425,ACTIVE_NOT_RECRUITING,Breast Cancer Stage IV,DRUG: Simvastatin 80mg,Baylor Breast Care Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,5,OTHER,INTERVENTIONAL,3/4/2020,2030-12
NCT05602792,RECRUITING,Advanced Solid Tumor|Sarcoma|HNSCC|Breast Cancer|Esophagus Cancer|NSCLC|Non-melanoma Skin Cancer,BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011,ImmVira Pharma Co. Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,233,INDUSTRY,INTERVENTIONAL,4/21/2020,2024-01
NCT04807192,RECRUITING,Triple Negative Breast Cancer,RADIATION: stereotactic body radiotherapy|DRUG: CMP-001,Centre Hospitalier Universitaire Vaudois,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,4/8/2021,2025-12
NCT04576455,ACTIVE_NOT_RECRUITING,"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",DRUG: Giredestrant|DRUG: Fulvestrant or an Aromatase Inhibitor (Physician Choice)|DRUG: LHRH Agonist,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE2,303,INDUSTRY,INTERVENTIONAL,11/27/2020,6/27/2024
NCT04052555,ACTIVE_NOT_RECRUITING,Bilateral Breast Carcinoma|HER2-Negative Breast Carcinoma|Localized Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma,DRUG: Berzosertib|PROCEDURE: Biospecimen Collection|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,42,NIH,INTERVENTIONAL,9/24/2020,11/20/2024
NCT05084625,RECRUITING,Breast Cancer|Treatment Adherence|Quality of Life|Treatment Side Effects,OTHER: Digitized support,Region Stockholm,ScientificMed Tech AB|AstraZeneca|Novartis Sverige AB|BrÃ¶stcancerfÃ¶rbundet|Stockholm South General Hospital|Capio St Gorans hospital|Karolinska University Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER_GOV,INTERVENTIONAL,10/25/2021,2024-12
NCT05472792,RECRUITING,Breast Cancer|Quality of Life,"RADIATION: Accelerated Partial Breast Irradiation (APBI)|DRUG: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene",UNC Lineberger Comprehensive Cancer Center,,FEMALE,OLDER_ADULT,PHASE2,90,OTHER,INTERVENTIONAL,5/17/2022,5/17/2025
NCT05535192,RECRUITING,Breast Cancer|Stage III Breast Cancer|Breast Cancer Female|Stage I Breast Cancer|Stage II Breast Cancer,BEHAVIORAL: THRIVE|BEHAVIORAL: Health Education Support Program,Dana-Farber Cancer Institute,National Cancer Institute (NCI)|Case Western Reserve University|University of Pittsburgh,FEMALE,OLDER_ADULT,NA,270,OTHER,INTERVENTIONAL,3/20/2023,2/1/2027
NCT05887492,RECRUITING,"Non Small Cell Lung Cancer|Solid Tumors, Adult|Endometrial Cancer|Pancreatic Cancer|Cervical Cancer|Breast Cancer|Carcinoma of Unknown Primary",DRUG: TNG260|DRUG: Pembrolizumab,"Tango Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,126,INDUSTRY,INTERVENTIONAL,6/12/2023,2025-06
NCT04394325,ACTIVE_NOT_RECRUITING,Breast Cancer,BEHAVIORAL: Digital information tool,Jonkoping University,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,9/1/2020,12/31/2023
NCT05813392,NOT_YET_RECRUITING,Chronic Insomnia,BEHAVIORAL: Digital Cognitive Behavioral Therapy for Insomnia,Peking University First Hospital,"Shenzhen Zeen Health Technology Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,INTERVENTIONAL,8/16/2023,2025-08
NCT04993625,ACTIVE_NOT_RECRUITING,Breast Cancer,PROCEDURE: avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy,Jeong Eon Lee,Seoul National University Hospital|Severance Hospital|Gangnam Severance Hospital|Asan Medical Center,FEMALE,"ADULT, OLDER_ADULT",NA,178,OTHER,INTERVENTIONAL,9/27/2021,12/31/2028
NCT05756725,COMPLETED,Breast Cancer Screening|Colorectal Cancer Screening|Implementation,OTHER: Practice-Level Implementation Strategies,Harvard School of Public Health (HSPH),National Institutes of Health (NIH)|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,8,OTHER,INTERVENTIONAL,7/25/2023,1/4/2024
NCT05763992,RECRUITING,Breast Cancer|Triple Negative Breast Cancer|Dietary Exposure|Fasting,"DIETARY_SUPPLEMENT: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Istituto Oncologico Veneto IRCCS|Ospedale Policlinico San Martino|Federico II University|Azienda Policlinico Umberto I|European Institute of Oncology|Ospedale ""Carlo Poma"" - Mantova|Humanitas Clinical and Research Center",FEMALE,"ADULT, OLDER_ADULT",PHASE2,145,OTHER,INTERVENTIONAL,5/15/2023,5/15/2026
NCT04360330,RECRUITING,Breast Cancer|Early-stage Breast Cancer,RADIATION: Stereotactic Ablative Breast Radiotherapy,University of Miami,,FEMALE,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,8/5/2020,2026-05
NCT04990921,RECRUITING,Metastatic Breast Cancer,COMBINATION_PRODUCT: Palliative Radiation and Pembrolizumab,University of Louisville,James Graham Brown Cancer Center,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,9/2/2021,7/1/2031
NCT04893421,ACTIVE_NOT_RECRUITING,Breast Neoplasm,DEVICE: MOLLI Localization,Sunnybrook Health Sciences Centre,"Princess Margaret Hospital, Canada|North York General Hospital",FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,5/16/2021,6/30/2024
NCT04320030,COMPLETED,Triple Negative Breast Cancer,DRUG: [18F]-DPA-714 PET/CT scan,Institut Cancerologie de l'Ouest,SIRIC ILIAD,FEMALE,"ADULT, OLDER_ADULT",PHASE2,13,OTHER,INTERVENTIONAL,6/11/2020,7/21/2021
NCT04478630,TERMINATED,Nausea|Vomiting,"OTHER: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract",Milton S. Hershey Medical Center,Doctors Kienle Center for Humanistic Medicine/Penn State College of Medicine,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,8/30/2021,2/18/2023
NCT04373031,ACTIVE_NOT_RECRUITING,Breast Cancer|Breast Neoplasms,DRUG: Pembrolizumab|DRUG: IRX 2,Providence Health & Services,"Merck Sharp & Dohme LLC|Brooklyn ImmunoTherapeutics, LLC",ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,12/30/2020,2025-06
NCT06149130,RECRUITING,Breast Cancer,DRUG: Adebrelimab|DRUG: dalpiciclib,Tongji Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,INTERVENTIONAL,11/30/2023,11/30/2026
NCT04440930,COMPLETED,Oral Mucositis,OTHER: White tea|OTHER: Salt water with soda,Vejle Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,INTERVENTIONAL,9/2/2020,4/30/2023
NCT04682431,ACTIVE_NOT_RECRUITING,Advanced Solid Tumor|Gynecologic Cancer|Breast Cancer|Colorectal Cancer|Gastric Adenocarcinoma|Lung Adenocarcinoma|Pancreatic Cancer|Head and Neck Cancer,DRUG: PY159 Single agent dose level 1|DRUG: PY159 Single agent dose level 2|DRUG: PY159 Single agent dose level 3|DRUG: PY159 Single agent dose level 4|DRUG: PY159 Single agent dose level 5|DRUG: PY159 Single agent dose level 6|DRUG: PY159 Single agent dose level 7|DRUG: PY159/Pembrolizumab Combination dose level 1|DRUG: PY159/Pembrolizumab Combination dose level 2|DRUG: PY159/Pembrolizumab Combination dose level 3|DRUG: PY159/Pembrolizumab Combination dose level 4|DRUG: PY159 Single agent dose expansion cohort|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 1|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 2|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 3|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 4|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 5|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 6,Pionyr Immunotherapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,343,INDUSTRY,INTERVENTIONAL,11/10/2020,2025-12
NCT05227131,WITHDRAWN,Metastatic Breast Cancer|Advanced Breast Cancer|HER2-positive Breast Cancer,DRUG: Margetuximab|DRUG: Tucatinib|DRUG: Capecitabine,MedSIR,MacroGenics|Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,5/15/2022,2024-10
NCT06238921,NOT_YET_RECRUITING,Breast Cancer|Triple Negative Breast Cancer,RADIATION: Stereotactic Radiation|DRUG: Zimberelimab|DRUG: Sacituzumab govitecan,H. Lee Moffitt Cancer Center and Research Institute,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,31,OTHER,INTERVENTIONAL,2024-02,2027-02
NCT04725331,RECRUITING,Metastatic Cancer|Soft Tissue Sarcoma|Merkel Cell Carcinoma|Melanoma|Triple Negative Breast Cancer|Non Small Cell Lung Cancer,BIOLOGICAL: BT-001|DRUG: Pembrolizumab [Keytruda],Transgene,BioInvent International AB|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,INTERVENTIONAL,2/25/2021,4/30/2025
NCT05011721,RECRUITING,Breast Cancer,DEVICE: Activity tracker,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,9/20/2021,2025-09
NCT05949021,RECRUITING,Triple Negative Breast Cancer (TNBC),DRUG: Combination of liposomal doxorubicin,"Mridula George, MD",,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,10/7/2023,9/30/2027
NCT04142931,UNKNOWN,Stage IV Non-small Cell Lung Cancer|Stage IV Melanoma|Triple Negative Breast Cancer|Renal Cell Carcinoma Stage IV,COMBINATION_PRODUCT: ImmunicomAIAC,Dr. Ronnie Shapira,"Immunicom Inc. San Diego California, USA",ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER_GOV,INTERVENTIONAL,2/24/2020,12/30/2022
NCT05912231,RECRUITING,Breast Cancer|Breast Cancer Female|Breast Cancer Stage II|Breast Cancer Stage III|Myocardial Fibrosis,RADIATION: Accelerated Proton Beam Radiation Therapy (PBT)|RADIATION: Accelerated Photon Radiation Therapy (XRT),Massachusetts General Hospital,National Cancer Institute (NCI)|American Society of Clinical Oncology,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,8/15/2023,9/17/2025
NCT06051331,RECRUITING,"Breast Cancer|Health Knowledge, Attitudes, Practice",BEHAVIORAL: simulation-based breast health education,Hacettepe University,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,10/1/2023,9/1/2024
NCT04965688,RECRUITING,Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer,DRUG: Drug determined by treating oncologist based on recommendation from systems biology analysis.,Inova Health Care Services,City of Hope Medical Center,ALL,"ADULT, OLDER_ADULT",PHASE2,74,OTHER,INTERVENTIONAL,8/8/2021,2025-07
NCT05280288,NOT_YET_RECRUITING,Early-stage Breast Cancer,DEVICE: Bone@BC app,"Rigshospitalet, Denmark",,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,5/1/2022,10/1/2025
NCT04756765,RECRUITING,Breast Cancer|Advanced Breast Cancer,DRUG: Talazoparib Tosylate,Stanford University,Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,2/23/2023,2024-03
NCT05326165,NOT_YET_RECRUITING,Breast Cancer|Breast Cancer Treatment Related Lymphedema,DEVICE: Juzo Compression Sleeve and Glove|DEVICE: Compression Sleeve Sensor,Massachusetts General Hospital,Heinz Family Foundation|Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema|Olayan-Xefos Family Fund for Breast Cancer Research,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2024-05,6/30/2025
NCT04918589,NOT_YET_RECRUITING,Hematoma Postoperative|Breast Cancer|Tranexamic Acid,DRUG: Tranexamic acid|DRUG: Normal Saline,McMaster University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,106,OTHER,INTERVENTIONAL,2022-08,2024-08
NCT05322889,RECRUITING,Neuropathic Pain|Chemotherapy Effect,DRUG: Telmisartan tablets,Dr. Frank Behrens,Johann Wolfgang Goethe University Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,4/9/2020,2023-06
NCT03989089,UNKNOWN,HER2-Negative Breast Cancer,DRUG: Pembrolizumab,University of Malaya,"Merck Sharp & Dohme LLC|National University Hospital, Singapore|Cancer Research Malaysia",FEMALE,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,INTERVENTIONAL,7/3/2020,12/1/2023
NCT05898789,RECRUITING,"Breast Cancer, Stage 0|Colorectal Cancer Stage I|Head and Neck Cancer Stage I|Lymphoma|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Head and Neck Cancer Stage II|Head and Neck Cancer Stage III|Lymphoproliferative Disorders",BEHAVIORAL: CaRE@Home intervention,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",NA,388,OTHER,INTERVENTIONAL,7/7/2023,2025-02
NCT05725265,RECRUITING,Breast Cancer Lymphedema,DEVICE: Large-area low-level laser therapy(Venusure)|DEVICE: Conventional low-level laser therapy,National Taiwan University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,10/24/2023,10/31/2024
NCT05846789,RECRUITING,Metastatic Breast Cancer|Triple Negative Breast Cancer|Estrogen-receptor-low Breast Cancer,DRUG: Carboplatin|DRUG: Tocilizumab,Kathy Miller,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,168,OTHER,INTERVENTIONAL,2024-01,2027-12
NCT05902988,RECRUITING,Advanced Solid Tumor|High Grade Serous Adenocarcinoma of Ovary|Squamous Non-small-cell Lung Cancer|Triple Negative Breast Cancer|Gastric Adenocarcinoma|Colorectal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Transitional Cell Carcinoma of Bladder|Head and Neck Squamous Cell Carcinoma|Ovarian Carcinosarcoma|Uterine Carcinosarcoma|Uterine Serous Carcinoma|Endometrium Cancer|Chromosomal Instability,DRUG: VLS-1488,"Volastra Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,120,INDUSTRY,INTERVENTIONAL,10/18/2023,2026-06
NCT04983342,RECRUITING,Fatigue|Metastatic Breast Carcinoma,DEVICE: Apollo Armband,Margaret Quinn Rosenzweig,"Apollo Neuroscience, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2/1/2021,2026-03
NCT05539365,NOT_YET_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,BIOLOGICAL: Alpha-type-1 Polarized Dendritic Cells|PROCEDURE: Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Leukapheresis|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment,Roswell Park Cancer Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,19,OTHER,INTERVENTIONAL,3/7/2024,3/7/2026
NCT04288089,ACTIVE_NOT_RECRUITING,"Receptors, Estrogen|Genes, Erbb-2|Breast Neoplasms","DRUG: Palbociclib (75, 100, 125 milligram [mg])|DRUG: H3B-6545 (150, 300, 450 mg)",Eisai Inc.,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,4/1/2020,3/31/2024
NCT05577442,NOT_YET_RECRUITING,Breast Neoplasm Female,"DRUG: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy",Peking University Cancer Hospital & Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,INTERVENTIONAL,10/20/2022,10/20/2024
NCT04430842,COMPLETED,Astrocytoma|Brain Cancer|Brain Metastases|Bladder Cancer|Breast Cancer|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophagus Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Lung Cancer|Melanoma|Ovarian Cancer|Pancreatic Cancer|Pleural Mesothelioma|Prostate Cancer|Sarcoma|Tongue Cancer|Thymic Carcinoma|Urinary Tract Cancer,DRUG: QBS10072S,"Quadriga Biosciences, Inc.",Novotech (Australia) Pty Limited,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,INTERVENTIONAL,7/20/2020,12/22/2022
NCT06106165,NOT_YET_RECRUITING,Breast Cancer|Bowel Cancer|Cervical Cancer,"OTHER: In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|OTHER: Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women",University of Sunderland,University of Glasgow,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,2023-11,2025-12
NCT05429489,COMPLETED,Analgesia,PROCEDURE: Bilevel erector spinae plane block|PROCEDURE: Single level erector spinae plane block|DRUG: Intravenous morphine,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,6/27/2022,1/10/2024
NCT05447988,RECRUITING,Breast Tissue Accessory|Breast Cancer,DEVICE: Breast Tissue Expander,Establishment Labs,,FEMALE,"ADULT, OLDER_ADULT",NA,136,INDUSTRY,INTERVENTIONAL,12/14/2020,7/15/2026
NCT04214288,ACTIVE_NOT_RECRUITING,Advanced ER-Positive HER2-Negative Breast Cancer,DRUG: AZD9833|DRUG: Fulvestrant,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,240,INDUSTRY,INTERVENTIONAL,4/22/2020,3/29/2024
NCT06019988,NOT_YET_RECRUITING,Breast Cancer|Social Determinants of Health (SDOH),OTHER: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening,Abramson Cancer Center at Penn Medicine,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",NA,2500,OTHER,INTERVENTIONAL,1/1/2024,1/1/2025
NCT04680442,RECRUITING,Breast Cancer|Heart Failure,DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Trastuzumab emtansine,Population Health Research Institute,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,130,OTHER,INTERVENTIONAL,7/1/2021,12/1/2025
NCT05957042,RECRUITING,Breast Cancer|Contrast Enhanced Ultrasound,DRUG: Lumason,Milton S. Hershey Medical Center,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,9/1/2023,9/1/2031
NCT04213365,COMPLETED,Breast Cancer,OTHER: Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.,Centre Francois Baclesse,"National Cancer Institute, France|Ligue contre le cancer, France",FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/24/2020,2/11/2022
NCT05955521,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer|HER2-positive Breast Cancer,PROCEDURE: exosome and ctDNA evaluation,Samsung Medical Center,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,5/1/2021,7/1/2028
NCT05656131,RECRUITING,Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer,DRUG: Fluzoparib|DRUG: Fluzoparib+Camrelizumab,wang shusen,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,11/23/2022,12/31/2026
NCT06235931,RECRUITING,Breast Neoplasms,DRUG: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib,Second Affiliated Hospital of Soochow University,,FEMALE,OLDER_ADULT,NA,34,OTHER,INTERVENTIONAL,2/1/2024,12/1/2026
NCT04504331,TERMINATED,Breast Cancer|HER2-negative Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer,DRUG: Infigratinib|DRUG: Tamoxifen|DRUG: Omnipaque 350|DRUG: Iopamidol|DIAGNOSTIC_TEST: Computed tomography (CT),Jennifer Lee Caswell-Jin,"National Cancer Institute (NCI)|QED Therapeutics, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,4,OTHER,INTERVENTIONAL,10/13/2020,10/22/2021
NCT04717531,RECRUITING,Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/3/2021,5/31/2024
NCT06035731,NOT_YET_RECRUITING,"Cancer of Colon|Cancer, Lung|Cancer, Breast|Cancer Prostate|Cancer Pain|Anxiety Depression",OTHER: SOCIO-AESTHETICS care,Centre Hospitalier de Valence,,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,2024-03,2027-04
NCT06085742,RECRUITING,Breast Cancer,DRUG: Cyclophosphamide|DRUG: Methotrexate|DRUG: Capecitabine,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,11/22/2023,2034-09
NCT05309265,RECRUITING,Breast Cancer|Breast Neoplasm,OTHER: Multidisciplinary vocational rehabilitation intervention,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER_GOV,INTERVENTIONAL,5/9/2022,2024-05
NCT06084689,NOT_YET_RECRUITING,Adult Soft Tissue Sarcoma|Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Cancer|Biliary Tract Cancer,DRUG: Ezabenlimab + BI907828,Institut BergoniÃ©,Boehringer Ingelheim,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,1/1/2024,1/1/2027
NCT04491942,ACTIVE_NOT_RECRUITING,Advanced Bile Duct Carcinoma|Advanced Breast Carcinoma|Advanced Cervical Carcinoma|Advanced Endometrial Carcinoma|Advanced Esophageal Carcinoma|Advanced Gastric Carcinoma|Advanced Head and Neck Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Penile Carcinoma|Advanced Pleural Malignant Mesothelioma|Advanced Urothelial Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Stage III Cervical Cancer AJCC v8|Stage III Distal Bile Duct Cancer AJCC v8|Stage III Intrahepatic Bile Duct Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Penile Cancer AJCC v8|Stage III Pleural Malignant Mesothelioma AJCC v8|Stage IV Cervical Cancer AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Intrahepatic Bile Duct Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Pleural Malignant Mesothelioma AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Urothelial Carcinoma,DRUG: Cisplatin|DRUG: Elimusertib|DRUG: Gemcitabine Hydrochloride,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,74,NIH,INTERVENTIONAL,8/25/2021,12/31/2024
NCT04329065,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,BIOLOGICAL: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|DRUG: Paclitaxel|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Pertuzumab,University of Washington,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE2,16,OTHER,INTERVENTIONAL,4/20/2022,6/30/2027
NCT04471142,UNKNOWN,Seroma,DEVICE: neuromuscular bandage,"Instituto Nacional de Cancer, Brazil",,FEMALE,"ADULT, OLDER_ADULT",NA,270,OTHER_GOV,INTERVENTIONAL,11/8/2021,3/30/2023
NCT06195865,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: DIEP-flap|PROCEDURE: Implant,Vastra Gotaland Region,GÃ¶teborg University,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER_GOV,INTERVENTIONAL,1/1/2024,12/31/2032
NCT04303221,RECRUITING,Breast Cancer|Balance; Distorted,OTHER: Exercise,Elaine Caldeira de Oliveira Guirro,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,3/1/2020,3/1/2024
NCT05914831,RECRUITING,Breast Cancer Female,RADIATION: Ultra-fractionated WBI|RADIATION: Ultra-fractionated PBI,Oncology Institute of Vojvodina,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,INTERVENTIONAL,6/1/2023,5/31/2033
NCT05465031,NOT_YET_RECRUITING,"Breast Cancer|Neoplasm, Breast|Breast Diseases|Antihypertensive Agents|Sacubitril/Valsartan|Angiotensin II Type 1 Receptor Blockers|Angiotensin Receptor Antagonists|Molecular Mechanisms of Pharmacological Action|Heart Failure|Cardiac Toxicity|Cancer, Therapy-Related|Cancer Therapy-Related Cardiac Dysfunction|Cardiotoxicity",DRUG: Sacubitril-valsartan,Silesian Centre for Heart Diseases,"Medical Research Agency, Poland",FEMALE,"ADULT, OLDER_ADULT",PHASE4,600,OTHER,INTERVENTIONAL,2023-02,2028-02
NCT06155331,RECRUITING,Breast Cancer Stage 2 and 3,DRUG: Fenofibrate|OTHER: Placebo|DRUG: Doxorubicin|DRUG: Cyclophosphamide,Tanta University,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,44,OTHER,INTERVENTIONAL,2023-12,2025-12
NCT04886531,RECRUITING,Breast Cancer|HER2-positive Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer,DRUG: Neratinib|DRUG: Letrozole (L) or Anastrozole (A)|DRUG: Trastuzumab,Ruth O'Regan,"Puma Biotechnology, Inc.|University of Rochester",ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,7/21/2022,2024-02
NCT04573231,RECRUITING,Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer,DRUG: 18F-DCFPyL,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,5/24/2021,2025-11
NCT04591431,ACTIVE_NOT_RECRUITING,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,DRUG: Erlotinib|DRUG: Trastuzumab|DRUG: Trastuzumab emtansine|DRUG: Pertuzumab|DRUG: Lapatinib|DRUG: Everolimus|DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Alectinib|DRUG: Brigatinib|DRUG: Palbociclib|DRUG: Ponatinib|DRUG: Vismogedib|DRUG: Itacitinib|DRUG: Ipatasertib|DRUG: Entrectinib|DRUG: Atezolizumab|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Pemigatinib|DRUG: Oncology Drugs|DRUG: Pralsetinib|DRUG: Selpercatinib|DRUG: Talazoparib|DRUG: Tepotinib|DRUG: Alpelisib,Fondazione per la Medicina Personalizzata,,ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,INTERVENTIONAL,10/7/2020,2025-06
NCT05546021,ENROLLING_BY_INVITATION,Anesthesia; Adverse Effect|Breast Cancer,PROCEDURE: NOL monitor,University of Southern Denmark,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/1/2022,2025-03
NCT04621721,RECRUITING,"Breast Cancer Female|Chemotherapy-induced Peripheral Neuropathy|Gait Disorders, Neurologic|Balance; Distorted|Muscle Weakness",BEHAVIORAL: Gait/balance & resistive exercise,University of South Florida,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,312,OTHER,INTERVENTIONAL,8/14/2020,9/30/2024
NCT04282031,RECRUITING,Advanced Solid Tumor|HR+/HER2- Breast Cancer,DRUG: BPI-1178|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: BPI-1178,"Beta Pharma (Suzhou) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,224,INDUSTRY,INTERVENTIONAL,6/15/2020,3/15/2024
NCT05888831,RECRUITING,Advanced Solid Tumors,DRUG: BMS-986449|DRUG: Nivolumab,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,INTERVENTIONAL,6/6/2023,7/1/2027
NCT05711030,RECRUITING,"Breast Neoplasms|Breast Neoplasm Female|Cancer, Breast|Breast Cancer",PROCEDURE: Thoracic paravertebral block multiple (3) injections|PROCEDURE: Thoracic paravertebral block single injection,Ciusss de L'Est de l'ÃŽle de MontrÃ©al,,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,11/4/2022,12/1/2023
NCT05262621,COMPLETED,Cancer,OTHER: progressive muscle relaxation|OTHER: Listening to relaxing music once/day,The Nethersole School of Nursing,,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,3/8/2022,8/10/2022
NCT05860621,RECRUITING,Breast Cancer Female|Hormone-receptor-positive Breast Cancer,BEHAVIORAL: Brief Physical Activity Counselling|BEHAVIORAL: Structured Exercise Program,Grupo LusÃ³fona,FundaÃ§Ã£o para a CiÃªncia e a Tecnologia|Faculdade de Motricidade Humana,FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,INTERVENTIONAL,1/5/2022,2025-02
NCT04692831,RECRUITING,HER-2 Positive Malignant Carcinoma of Breast|HER-2 Protein Overexpression|HER2-positive Metastatic Breast Cancer,COMBINATION_PRODUCT: 89Zr-ss-pertuzumab PET/CT,Memorial Sloan Kettering Cancer Center,National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,11/30/2020,11/30/2024
NCT05051631,RECRUITING,Breast Cancer,OTHER: Intervention plus 12 months maintenance|OTHER: Intervention plus 10 months maintenance|OTHER: Intervention plus 8 months maintenance|OTHER: Intervention plus 6 months maintenance|OTHER: Intervention plus 4 months maintenance,Vanderbilt University Medical Center,,FEMALE,ADULT,NA,500,OTHER,INTERVENTIONAL,3/9/2022,2024-08
NCT04150042,RECRUITING,Pancreatic Adenocarcinoma Metastatic|BRCA1 Mutation|BRCA2 Mutation|Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Ductal Adenocarcinoma|Breast Cancer Metastatic|Breast Cancer Stage IV|Pancreatic Cancer Stage IV|HER2-negative Breast Cancer|HER2 Negative Breast Carcinoma|Adenocarcinoma of the Breast|PALB2 Gene Mutation,DRUG: Melphalan|DRUG: BCNU|DRUG: Vitamin B12B|DRUG: Vitamin C|DRUG: Ethanol|DEVICE: Autologous Hematopoietic Stem Cells,"General Oncology, Inc.","Myriad Genetics, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,INTERVENTIONAL,1/13/2021,2025-12
NCT05716542,RECRUITING,Breast Cancer|Cancer of the Breast,OTHER: Physical Activity Intervention,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,5/11/2023,11/30/2024
NCT04983121,RECRUITING,Breast Neoplasms,DRUG: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788),Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,8/1/2021,8/15/2027
NCT03981731,COMPLETED,Breast Cancer|Gynecologic Cancer,OTHER: Cardiac coherence,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,53,OTHER,INTERVENTIONAL,2/14/2020,1/14/2022
NCT05406531,RECRUITING,Breast Cancer Female|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,BEHAVIORAL: Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|BEHAVIORAL: Positive Psychology - online|BEHAVIORAL: Autogenic Training - online,Masaryk University,Masaryk Memorial Cancer Institute,FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,INTERVENTIONAL,6/6/2022,2025-06
NCT03954431,NOT_YET_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Dedicated breast CT(BCT),University of Arizona,National Institutes of Health (NIH)|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,2024-01,2027-12
NCT05033925,UNKNOWN,Breast Cancer Stage IV,DIETARY_SUPPLEMENT: FADA (active fraction of Ficus septica leaf) 800 mg/day|DIETARY_SUPPLEMENT: FADA (active fraction of Ficus septica leaf) 2000 mg/day|OTHER: Placebo capsule,Gadjah Mada University,"Ahmad Dahlan University|Dr. Kariadi General Hospital|PT Konimex|LPDP, Kementerian Keuangan, Indonesia",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,324,OTHER,INTERVENTIONAL,9/7/2021,12/30/2023
NCT04719455,UNKNOWN,Breast Cancer|Breast Neoplasms,BEHAVIORAL: Adherence Improving self-Management Strategy|OTHER: Regular care,Radboud University Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,12/13/2020,12/31/2022
NCT06229392,NOT_YET_RECRUITING,Breast Cancer|Breast Cancer Triple Negative,BIOLOGICAL: Fluzone Quadrivalent,Rush University Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,2/1/2024,12/31/2025
NCT04732455,COMPLETED,Peripheral Neuropathy|Chemotherapy-induced Peripheral Neuropathy|Breast Cancer,DRUG: Lidocaine in Saline|DRUG: Duloxetine 30 MG|DRUG: Normal saline,Gamal Mohamed Taha Abouelmagd,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/15/2021,7/5/2022
NCT05498155,RECRUITING,Breast Cancer,DRUG: Neoadjuvant Olaparib monotherapy group|COMBINATION_PRODUCT: Neoadjuvant combination therapy with olaparib plus durvalumab,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,INTERVENTIONAL,11/7/2022,12/7/2026
NCT05871125,ENROLLING_BY_INVITATION,Breast Cancer,BEHAVIORAL: Reimbursement,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/1/2023,4/1/2026
NCT05453825,RECRUITING,Colorectal Cancer|Triple Negative Breast Cancer|Gastric Cancer|Ovarian Cancer,BIOLOGICAL: navicixizumab+paclitaxel|BIOLOGICAL: navicixizumab+irinotecan|BIOLOGICAL: navicixizumab monotherapy,"OncXerna Theraputics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,180,INDUSTRY,INTERVENTIONAL,8/5/2022,12/15/2024
NCT04781725,UNKNOWN,Breast Cancer,DRUG: INT230-6|OTHER: Saline injection,Ottawa Hospital Research Institute,"Intensity Therapeutics, Inc.|Ontario Institute for Cancer Research",FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,3/25/2021,3/1/2023
NCT04303325,RECRUITING,Depression,DRUG: Esketamine|DRUG: Saline Solution,"China Medical University, China",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,36,OTHER,INTERVENTIONAL,10/8/2021,12/30/2023
NCT05241925,NOT_YET_RECRUITING,Breast Cancer Female|Exercise Addiction,"OTHER: Rehabilitation, exercise",University of Nove de Julho,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,5/20/2023,12/30/2025
NCT05843292,NOT_YET_RECRUITING,Triple-negative Breast Cancer,DRUG: Taxane and Carboplatin|DRUG: Short-term Sintilimab|PROCEDURE: Surgery,Shanghai Jiao Tong University School of Medicine,"Innovent Biologics, Inc.|CSPC Ouyi Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE4,48,OTHER,INTERVENTIONAL,7/1/2023,12/31/2034
NCT05013255,RECRUITING,Breast Cancer|Muscle Fatigue,DRUG: Pioglitazone 15mg|DRUG: Pioglitazone 30 mg,West Virginia University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,12/23/2021,2023-04
NCT06046755,NOT_YET_RECRUITING,"Breast Cancer|Obesity|Weight Change, Body|Epigenetic Disorder",OTHER: Very low calorie ketogenic diet (VLCKD)|BEHAVIORAL: Group educational intervention program (IGOBE),Hospital Clinico Universitario de Santiago,Hospital Arquitecto Marcide,FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,10/15/2023,12/21/2025
NCT04818125,COMPLETED,Breast Cancer,"OTHER: Patients with breast cancer (stage I, II III or IV)",Institut Claudius Regaud,,FEMALE,"ADULT, OLDER_ADULT",NA,61,OTHER,INTERVENTIONAL,3/31/2021,7/29/2022
NCT04761055,ACTIVE_NOT_RECRUITING,Breast Screening,OTHER: Clinical Breast exam (CBE)|DEVICE: iBreastExam device|DIAGNOSTIC_TEST: mammogram,Memorial Sloan Kettering Cancer Center,UE LifeSciences Inc.|Earlier.org,FEMALE,"ADULT, OLDER_ADULT",NA,310,OTHER,INTERVENTIONAL,1/29/2021,2025-01
NCT04116125,NOT_YET_RECRUITING,Breast Neoplasm Female|Lymphatic Metastasis,PROCEDURE: Radiotherapy,Kyungpook National University Chilgok Hospital,Korean Breast Cancer Study Group,FEMALE,"ADULT, OLDER_ADULT",NA,1380,OTHER,INTERVENTIONAL,7/1/2020,6/30/2025
NCT05165225,ACTIVE_NOT_RECRUITING,Breast Cancer|HER2-low-expressing Breast Cancer|Hormone Receptor-positive Breast Cancer|Neoadjuvant Therapy,DRUG: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,7/13/2021,3/31/2028
NCT06016725,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Stage I Colorectal Cancer AJCC v8|Stage I Prostate Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Prostate Cancer AJCC v8,OTHER: Exercise Intervention|OTHER: Informational Intervention|OTHER: Nutritional Assessment|OTHER: Physical Performance Testing|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,National Institute on Aging (NIA),ALL,OLDER_ADULT,NA,70,OTHER,INTERVENTIONAL,8/28/2023,5/15/2025
NCT05629065,ENROLLING_BY_INVITATION,Breast Cancer|Gastrointestinal Cancer|Gynecologic Cancer|Thoracic Cancer|Genitourinary Cancer,OTHER: Clinician Nudge Email|OTHER: Patient Nudge Letter and Share questionaire,Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,INTERVENTIONAL,11/28/2022,12/31/2025
NCT05305365,RECRUITING,Brain Metastases|Breast Cancer,DRUG: QBS72S,Melanie Hayden Gephart,"Quadriga Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,8/16/2022,2026-08
NCT04595565,RECRUITING,HER2-negative Breast Cancer|Triple Negative Breast Cancer,DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Sacituzumab govitecan,German Breast Group,Gilead Sciences|Austrian Breast & Colorectal Cancer Study Group|Spanish Breast Cancer Research Group (GEICAM)|ETOP IBCSG Partners Foundation|Cancer Trials Ireland|UNICANCER,ALL,"ADULT, OLDER_ADULT",PHASE3,1332,OTHER,INTERVENTIONAL,10/28/2020,3/30/2029
NCT05954442,RECRUITING,Triple Negative Breast Cancer|Metastatic Breast Cancer|Mutation,DRUG: Everolimus|DRUG: Investigator's Choice of Chemotherapy,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,203,OTHER,INTERVENTIONAL,9/13/2023,2026-08
NCT04503265,RECRUITING,Advanced Malignant Neoplasm|Breast Cancer|Ovarian Cancer|Homologous Recombination Deficiency|Prostate Cancer|Pancreatic Cancer,DRUG: AMXI-5001:Dose Escalation Phase I|DRUG: AMXI-5001:Dose Expansion Phase II,"AtlasMedx, Incorporated",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,122,INDUSTRY,INTERVENTIONAL,8/12/2020,2025-01
NCT04843865,RECRUITING,Breast Cancer|Musculoskeletal Pain,DIETARY_SUPPLEMENT: Chinese Herbs,Universiti Tunku Abdul Rahman,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,4/22/2022,2024-04
NCT05876065,RECRUITING,Advanced Breast Cancer,DRUG: XC|DRUG: TPC,Wenjin Yin,,FEMALE,"ADULT, OLDER_ADULT",NA,86,OTHER,INTERVENTIONAL,6/1/2023,2027-02
NCT05896865,RECRUITING,Breast Cancer Stage III,RADIATION: Whole breast / chest wall & regional lymph node irradiation|RADIATION: Internal mammary or supraclavicular lymph node boost,Samsung Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,3/16/2023,3/16/2030
NCT05704842,RECRUITING,Breast Cancer,BEHAVIORAL: Exercise,"Virtua Health, Inc.","Carevive Systems, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,12/22/2022,6/1/2026
NCT04273542,RECRUITING,Breast Cancer Female|BRCA1 Mutation|BRCA2 Mutation,OTHER: liquid biopsy,Centre Jean Perrin,International Cancer Research Group|Institut Max Planck d'optique quantique,FEMALE,"ADULT, OLDER_ADULT",NA,1100,OTHER,INTERVENTIONAL,5/31/2021,2029-05
NCT05901142,RECRUITING,Exercise|Breast Neoplasm Female,"BEHAVIORAL: Exercise-based multi-phasic, multi-modal intervention",University Hospitals of Derby and Burton NHS Foundation Trust,University of Wolverhampton|University of Hull|Sheffield Teaching Hospitals NHS Foundation Trust|University of Bath|Aston University|Staffordshire University,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,6/16/2023,2024-06
NCT04923542,RECRUITING,Brain Metastases|HR+ Metastatic Breast Cancer,RADIATION: Stereotactic Radiosurgery (SRS)|DRUG: Abemaciclib|DRUG: Endocrine therapy,H. Lee Moffitt Cancer Center and Research Institute,Eli Lilly and Company,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,31,OTHER,INTERVENTIONAL,11/30/2021,12/31/2024
NCT05457842,TERMINATED,Sentinel Lymph Node Biopsy|Breast Cancer|Melanoma,DRUG: pudexacianinium chloride,Astellas Pharma Inc,,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,INTERVENTIONAL,8/10/2022,9/20/2022
NCT04892342,RECRUITING,"Neoplasms, Breast|Neoplasms, Lung|Neoplasms,Colorectal|Neoplasms, Bladder|Neoplasm of Stomach|Neoplasms,Ovarian",DRUG: ESG401,"Shanghai Escugen Biotechnology Co., Ltd",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,177,INDUSTRY,INTERVENTIONAL,9/14/2021,2025-04
NCT05004142,UNKNOWN,Breast Neoplasms,DRUG: FCN-437c+Fulvestrant|DRUG: FCN-437c+Letrozole+Goserelin,"Ahon Pharmaceutical Co., Ltd.",Hebei Medical University Fourth Hospital|The First Hospital of Jilin University|Affiliated Hospital of Hebei University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,6/30/2020,6/30/2023
NCT04941365,WITHDRAWN,Metastatic Melanoma|Metastatic Breast Cancer|Advanced Renal Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer Stage III|Healthy,DIAGNOSTIC_TEST: single arm,Institut du Cancer de Montpellier - Val d'Aurelle,Fondazione IRCCS ISTITUTO NAZIONALE TUMORI,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,7/7/2022,2024-03
NCT05041842,RECRUITING,Metastatic Breast Cancer With a Isolated Brain Progression,DRUG: Tucatinib|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Hormone therapy|DRUG: Pertuzumab/ Trastuzumab,UNICANCER,Seagen Inc.|ARCAGY/ GINECO GROUP,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,12/17/2021,3/30/2026
NCT03685331,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Advanced Breast Cancer|BRCA2 Mutation|BRCA1 Mutation,DRUG: Palbociclib|DRUG: Olaparib|DRUG: Fulvestrant,Abramson Cancer Center at Penn Medicine,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,54,OTHER,INTERVENTIONAL,10/15/2020,2024-04
NCT04993430,RECRUITING,"ER-Positive, HER2-Negative Breast Cancer",DRUG: HRS8807|DRUG: HRS8807|DEVICE: HRS8807ã€SHR6390|DRUG: HRS8807ã€SHR6390,"Shanghai Hengrui Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,INTERVENTIONAL,10/26/2021,12/31/2024
NCT04877821,RECRUITING,Triple Negative Breast Cancer,DRUG: Sintilimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,INTERVENTIONAL,9/15/2021,12/31/2025
NCT04836221,COMPLETED,"Cancer, Breast|Diabetes Mellitus|Hypertension|Cancer Prostate",BEHAVIORAL: Support,Medstar Health Research Institute,"Pfizer|American Cancer Society, Inc.",ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,INTERVENTIONAL,5/5/2021,6/10/2023
NCT05869721,RECRUITING,Upper Limb Functions|Sleep Quality|Upper Limb Muscle Strength|Shoulder Mobility|Heart Rate Variability|Mood|Health-related Quality of Life,OTHER: Yoga,The Hong Kong Polytechnic University,,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,5/4/2023,7/30/2024
NCT05921331,NOT_YET_RECRUITING,Breast Cancer,DEVICE: The RJBC-APP|OTHER: Routine post-surgical follow-up,Shanghai Jiao Tong University School of Medicine,,FEMALE,"ADULT, OLDER_ADULT",NA,490,OTHER,INTERVENTIONAL,8/1/2023,8/1/2026
NCT05444231,RECRUITING,Breast Cancer Female,BEHAVIORAL: Brain Training A|BEHAVIORAL: Brain Training B|BEHAVIORAL: Brain Training C,The University of Texas at Dallas,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,6/1/2022,6/1/2025
NCT05595330,COMPLETED,Breast Cancer Lymphedema,BEHAVIORAL: Lymphedema prevention protocols,First Affiliated Hospital Xi'an Jiaotong University,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,3/1/2020,12/8/2020
NCT06146231,RECRUITING,Mammaplasty|Breast Cancer|Poland Syndrome,DEVICE: Motiva FloraÂ® Tissue Expander,Establishment Labs,NAMSA,FEMALE,"ADULT, OLDER_ADULT",NA,66,INDUSTRY,INTERVENTIONAL,8/18/2023,2027-04
NCT05299021,COMPLETED,Mammary Cancer|Serratus Anterior Plane Block|Postoperative Pain,PROCEDURE: Double-point SAPB|PROCEDURE: Single-point SAPB,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,12/1/2021,12/8/2023
NCT04712721,RECRUITING,Glioblastoma Multiforme|Brain Neoplasms|Gastroesophageal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma,DRUG: 68Ga-FF58,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,80,INDUSTRY,INTERVENTIONAL,10/14/2021,7/23/2024
NCT05027321,RECRUITING,Breast Neoplasm Female,BEHAVIORAL: Preparation in Self-Hypnosis by anchoring|BEHAVIORAL: Conversational Hypnosis|BEHAVIORAL: Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis,"Hospital St. Joseph, Marseille, France",,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,10/11/2022,2024-07
NCT05336721,RECRUITING,Triple-negative Breast Cancer,DRUG: Chiauranib|DRUG: capecitabine,"Chipscreen Biosciences, Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,38,INDUSTRY,INTERVENTIONAL,11/5/2021,8/9/2024
NCT04665921,ACTIVE_NOT_RECRUITING,"Carcinoma, Non-Small Cell Lung|HER2 Negative Breast Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Endometrial Neoplasms|Esophageal Neoplasms|Gastroesophageal Junction Carcinoma|Stomach Neoplasms|Colorectal Neoplasms|Exocrine Pancreatic Adenocarcinoma|Appendiceal Adenocarcinoma|Pseudomyxoma Peritonei",DRUG: SGN-STNV,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,111,INDUSTRY,INTERVENTIONAL,1/18/2021,3/31/2026
NCT05351021,COMPLETED,Peripheral Neuropathy|Breast Cancer,DRUG: Metformin|DRUG: Placebo,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,76,OTHER,INTERVENTIONAL,4/12/2022,10/30/2022
NCT04606030,RECRUITING,Lymphedema|Edema,DEVICE: BioBridgeÂ® Collagen Matrix|PROCEDURE: Vascularized Lymph Node Transfer (VLNT),Fibralign Corporation,University of Chicago,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,INTERVENTIONAL,10/26/2020,2/15/2024
NCT04760431,NOT_YET_RECRUITING,HER2-positive Breast Cancer|Brain Metastases,DRUG: Trastuzumab|DRUG: Taxanes|DRUG: Pertuzumab|DRUG: Tyrosine kinase inhibitor,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Peking University International Hospital|Sun Yat-sen University|Zhejiang University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,10/1/2021,9/30/2025
NCT05238831,WITHDRAWN,Advanced Breast Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Prostate Carcinoma|Advanced Sarcoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,DRUG: Alectinib|DRUG: Alpelisib|DRUG: Anastrozole|BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cobimetinib|DRUG: Entrectinib|DRUG: Eribulin|DRUG: Fulvestrant|BIOLOGICAL: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|DRUG: Irinotecan|DRUG: Letrozole|DRUG: Nab-paclitaxel|DRUG: Niraparib|DRUG: Olaparib|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Vemurafenib|DRUG: Vinorelbine|DRUG: Vismodegib,OHSU Knight Cancer Institute,"Genentech, Inc.|Oregon Health and Science University",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,1/30/2023,5/31/2026
NCT05283330,RECRUITING,Cervical Cancer|Prostate Cancer Metastatic|Breast Cancer|Colon Cancer|NSCLC|Cutaneous Melanoma,DRUG: Â²Â¹Â²Pb-DOTAM-GRPR1,Orano Med LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,12/22/2022,2025-01
NCT04569747,RECRUITING,HER2-positive Breast Cancer|Invasive Carcinoma of the Breast|Breast Cancer|Node Negative Breast Cancer|Micrometastasis Breast Cancer|Hormone Receptor Positive Breast Cancer,COMBINATION_PRODUCT: Pertuzumab+TRASTUZUMAB|DRUG: ADJUVANT ENDOCRINE THERAPY,Dana-Farber Cancer Institute,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,375,OTHER,INTERVENTIONAL,1/11/2021,9/1/2030
NCT05353387,NOT_YET_RECRUITING,Menopause|Cervix Cancer|Breast Cancer,OTHER: Motivational Interviewing,Istanbul Saglik Bilimleri University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,4/30/2022,10/30/2022
NCT05315687,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Carcinoma in the Liver|Prognostic Stage IV Breast Cancer AJCC v8,DEVICE: Y-90 SIR-Spheres|PROCEDURE: Yttrium-90 Microsphere Radioembolization|OTHER: Systemic Therapy,Emory University,National Cancer Institute (NCI)|Sirtex Medical,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,8/17/2022,7/31/2025
NCT04225585,RECRUITING,Coping Skills Training for Persistent Post-Surgical Pain|General Health Education,BEHAVIORAL: CST-PSP|BEHAVIORAL: General health education,Duke University,University of Pittsburgh Medical Center,ALL,"ADULT, OLDER_ADULT",NA,307,OTHER,INTERVENTIONAL,6/8/2021,4/30/2025
NCT04520386,UNKNOWN,Breast Cancer|Pancreatic Cancer|Lung Cancer,DRUG: OMT-111,MetiMedi Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,78,INDUSTRY,INTERVENTIONAL,2020-10,2022-10
NCT04721886,RECRUITING,Breast Carcinoma,PROCEDURE: Ultrasonsgraphy|DRUG: Perflutren Lipid Microcpheres|PROCEDURE: Contrast - Enhanced Ultrasound,Thomas Jefferson University,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,25,OTHER,INTERVENTIONAL,11/24/2020,1/1/2025
NCT04121286,RECRUITING,Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors,DRUG: JAB-3312,"Jacobio Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,6/10/2020,2023-12
NCT04448886,RECRUITING,Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer,DRUG: Pembrolizumab|DRUG: Sacituzumab Govitecan,"Ana C Garrido-Castro, MD",Merck Sharp & Dohme LLC|Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,INTERVENTIONAL,9/23/2020,6/1/2027
NCT05241119,RECRUITING,Breast Cancer,PROCEDURE: SLNB|PROCEDURE: pALND|PROCEDURE: ALND,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/1/2021,10/31/2028
NCT04537286,RECRUITING,Breast Cancer,DRUG: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1),Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,8/25/2020,10/15/2023
NCT05782686,RECRUITING,"Margin, Tumor-Free|Breast Cancer|Surgery",PROCEDURE: Margin shaving,Hospital Universitari de Bellvitge,,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,INTERVENTIONAL,10/7/2020,10/16/2025
NCT05339685,RECRUITING,Breast Cancer,DRUG: BL-M02D1,"Sichuan Baili Pharmaceutical Co., Ltd.","SystImmune Inc.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,INTERVENTIONAL,5/20/2022,2024-05
NCT04619485,ACTIVE_NOT_RECRUITING,Breast Cancer|Genitourinary Syndrome of Menopause,DEVICE: CO2 LASER|DEVICE: CO2 SHAM LASER,Hospital Clinic of Barcelona,,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,10/30/2020,8/30/2022
NCT05629585,RECRUITING,Breast Cancer,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Capecitabine|DRUG: Pembrolizumab,AstraZeneca,Daiichi Sankyo|SWOG Clinical Trials Partnerships,ALL,"ADULT, OLDER_ADULT",PHASE3,1075,INDUSTRY,INTERVENTIONAL,11/28/2022,3/27/2030
NCT05821686,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Human Interleukin-2 (IL-2) (Proleukin),Gregory Knapp,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,1/2/2024,2025-04
NCT06104085,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: 99mTc-MY6349 SPECT/CT scan,Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/13/2023,12/31/2026
NCT05682885,RECRUITING,Breast Cancer Related Lymphedema|Lymphedema Arm,PROCEDURE: Lymphatic Bypass Supermicrosurgery,Dharmais National Cancer Center Hospital,,ALL,"ADULT, OLDER_ADULT",NA,140,OTHER_GOV,INTERVENTIONAL,10/6/2022,2024-07
NCT06246786,NOT_YET_RECRUITING,Triple Negative Breast Cancer|DNA Damage Repair Deficiency,DRUG: Cyclosporin A,Virginia G. Kaklamani,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,OTHER,INTERVENTIONAL,2024-03,2027-03
NCT04507789,UNKNOWN,Breast Cancer|Exercise Therapy|Radiotherapy|Upper Extremity Problem,OTHER: exercise intervention|OTHER: routine radiotherapy protokol,Hacettepe University,Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,10/10/2020,4/10/2021
NCT04544189,RECRUITING,Breast Neoplasms,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,INTERVENTIONAL,1/20/2021,6/24/2028
NCT05634889,RECRUITING,Breast Cancer,RADIATION: De-escalation,Region Skane,Exact Sciences Corporation,ALL,"ADULT, OLDER_ADULT",NA,1350,OTHER,INTERVENTIONAL,3/17/2023,12/31/2033
NCT05044988,UNKNOWN,HR+/HER2- Advanced and/or Metastatic Breast Cancer,DRUG: HS-10342,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INDUSTRY,INTERVENTIONAL,9/30/2021,12/31/2023
NCT06245889,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Olaparib|DRUG: Capecitabine,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,2024-02,2030-06
NCT05673200,RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Decitabine and Cedazuridine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,24,NIH,INTERVENTIONAL,9/25/2023,2/23/2027
NCT04894955,RECRUITING,Breast Cancer,DEVICE: MARIA,"Micrima, Ltd.",,FEMALE,"ADULT, OLDER_ADULT",NA,400,INDUSTRY,INTERVENTIONAL,1/27/2022,3/31/2023
NCT04487912,WITHDRAWN,Breast Cancer|Sentinel Lymph Node,DRUG: Tilmanocept|DRUG: Nanocolloid,"University Hospital, Ghent",Norgine,FEMALE,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,INTERVENTIONAL,11/24/2020,5/1/2021
NCT05841355,RECRUITING,Breast Cancer Screening,OTHER: Educate|OTHER: Empower,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,3/14/2023,8/31/2027
NCT06049355,NOT_YET_RECRUITING,Breast Carcinoma|Prostate Carcinoma,OTHER: Exercise Intervention|PROCEDURE: Biospecimen Collection|OTHER: Educational Intervention,OHSU Knight Cancer Institute,Oregon Health and Science University|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,INTERVENTIONAL,1/1/2024,9/1/2028
NCT05364255,COMPLETED,"ER-positive, HER2-negative Breast Cancer","DRUG: [14C]AZD9833 Oral Solution, 75 mg",AstraZeneca,Quotient Sciences,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,5/10/2022,6/20/2022
NCT05323955,RECRUITING,Brain Metastases|Human Epidermal Growth Factor 2 Positive Carcinoma of Breast|Advanced Breast Cancer,DRUG: Trastuzumab|DRUG: Trastuzumab Emtansine (T-DM1)|DRUG: Pertuzumab|DRUG: Tucatinib,"Carey Anders, M.D.",Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,3/23/2023,2025-04
NCT05704855,COMPLETED,Breast Cancer,BEHAVIORAL: Combined Exercise + Behavioural Counselling|BEHAVIORAL: Active Control,University of Toronto,,FEMALE,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,2/1/2023,9/30/2023
NCT05837767,RECRUITING,Invasive Ductal Breast Carcinoma|Invasive Ductal Breast Carcinoma Stage IV|Lobular Breast Carcinoma|Lobular Breast Carcinoma Stage IV|Non Small Cell Lung Cancer|NSCLC|Gastrointestinal Cancer|Gastrointestinal Squamous Cell Cancer|Gastrointestinal Adenocarcinoma|Pancreatic Cancer|Bladder Cancer|Renal Cell Carcinoma|Melanoma|Sarcoma|Metastatic Solid Tumor,RADIATION: Stereotactic body radiotherapy|RADIATION: Lattice Radiation Therapy,Memorial Sloan Kettering Cancer Center,Varian Medical Systems,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,7/24/2023,7/24/2026
NCT04331067,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Nivolumab|BIOLOGICAL: Cabiralizumab|PROCEDURE: Tumor biopsy|PROCEDURE: Bone marrow|PROCEDURE: Blood draw,Washington University School of Medicine,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,15,OTHER,INTERVENTIONAL,11/19/2020,5/31/2026
NCT05144867,RECRUITING,"Breast Cancer|Brain Metastases, Adult|Stereotactic Radiosurgery|Whole Brain Radiotherapy",RADIATION: Stereotactic Radiosurgery,Postgraduate Institute of Medical Education and Research,,ALL,"ADULT, OLDER_ADULT",PHASE3,98,OTHER_GOV,INTERVENTIONAL,8/31/2021,3/31/2024
NCT05823467,RECRUITING,Breast Cancer,DRUG: TMP-SMX DS|DEVICE: ciNPT dressing,University of Alberta,,FEMALE,"ADULT, OLDER_ADULT",NA,105,OTHER,INTERVENTIONAL,6/26/2023,12/31/2025
NCT06229067,NOT_YET_RECRUITING,Breast Cancer|Triple Negative Breast Cancer,DRUG: Adebrelimab|DRUG: Vinorelbine|DRUG: Cyclophosphamide (tablet)|DRUG: Capecitabine,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,182,OTHER,INTERVENTIONAL,1/19/2024,1/19/2027
NCT05911867,RECRUITING,Mobility Limitation|Muscle Relaxation|Kinematics|Postural; Defect|Breast Cancer,OTHER: combination of mobilization with movement and muscle energy techniques|OTHER: muscle energy techniques Interventions:|OTHER: mobilization with movement,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,6/1/2023,9/30/2023
NCT05137067,COMPLETED,Breast Cancer|Lung Cancer|Prostate Cancer,"DIETARY_SUPPLEMENT: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|DRUG: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|DRUG: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).",Optimal Health Research,,ALL,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,1/20/2021,5/25/2023
NCT05040867,UNKNOWN,Breast Cancer|Cardiotoxicity|Autonomic Imbalance,OTHER: Physical exercise program,GO fit Lab- Ingesport,"MarquÃ©s de Valdecilla University Hospital|Center for Sport Studies, Rey Juan Carlos University",FEMALE,"ADULT, OLDER_ADULT",NA,90,NETWORK,INTERVENTIONAL,9/13/2021,9/20/2022
NCT05023967,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Extended Release Metformin Hydrochloride|OTHER: Monitoring|OTHER: Nutritional Assessment|OTHER: Short-Term Fasting,M.D. Anderson Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,4/4/2023,11/20/2025
NCT06061666,RECRUITING,Breast Cancer|Insomnia,OTHER: Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days),Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,6/1/2023,6/30/2024
NCT04478266,TERMINATED,Breast Cancer,DRUG: Amcenestrant-matching placebo|DRUG: SAR439859|DRUG: Palbociclib|DRUG: Letrozole|DRUG: Goserelin|DRUG: Letrozole-matching placebo,Sanofi,,ALL,"ADULT, OLDER_ADULT",PHASE3,1068,INDUSTRY,INTERVENTIONAL,10/14/2020,5/26/2023
NCT04933266,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: Subpectoral plexus block (low dose)|PROCEDURE: Subpectoral plexus block (High dose),Chinese University of Hong Kong,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,12/1/2023,12/31/2025
NCT05704166,RECRUITING,Acute Lung Injury|Prevention,DRUG: Pirfenidone/Placebo,Fujian Medical University Union Hospital,"Beijing Continent Pharmaceutical Co, Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,214,OTHER,INTERVENTIONAL,3/16/2023,5/31/2024
NCT05693766,RECRUITING,Invasive Mammary Carcinoma|Metastatic Breast Cancer,DRUG: Capecitabine|OTHER: Endocrine-therapy|OTHER: MammoPrint Â® and BluePrint assays,Sonya Reid,Agendia|Susan G. Komen Breast Cancer Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,INTERVENTIONAL,9/11/2023,8/31/2037
NCT05579366,RECRUITING,Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Endometrial Cancer|Non-small Cell Lung Cancer|Mesothelioma|Triple Negative Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor-positive Breast Cancer,DRUG: PRO1184,ProfoundBio US Co.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,134,INDUSTRY,INTERVENTIONAL,12/7/2022,2025-09
NCT05460819,NOT_YET_RECRUITING,Hot Flashes|Breast Cancer|Acupuncture,OTHER: Acupuncture treatment|OTHER: Sham Acupuncture treatment,Nanjing University of Traditional Chinese Medicine,Health Science Center of Xi'an Jiaotong University,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,8/1/2022,7/31/2027
NCT04965766,RECRUITING,Metastatic Breast Cancer,DRUG: U3-1402,"Gustave Roussy, Cancer Campus, Grand Paris",Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,170,OTHER,INTERVENTIONAL,5/11/2021,6/11/2026
NCT05676866,NOT_YET_RECRUITING,Node-positive Breast Cancer,PROCEDURE: Targeted axillary lymph node dissection,Assiut University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,30,OTHER,INTERVENTIONAL,12/1/2023,8/1/2025
NCT05217966,RECRUITING,Breast Cancer,RADIATION: Radiation: Single Pre-Operative Radiation Therapy,Maisonneuve-Rosemont Hospital,McGill University Health Centre/Research Institute of the McGill University Health Centre,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,10/8/2021,12/31/2030
NCT04253366,COMPLETED,Breast Cancer,DEVICE: Clinical investigation device class IIa not marked CE,Umbria Bioengineering Technologies,,FEMALE,"ADULT, OLDER_ADULT",NA,353,INDUSTRY,INTERVENTIONAL,9/16/2020,8/20/2021
NCT04517266,RECRUITING,Breast Cancer,RADIATION: omit of IMI group|RADIATION: IMI group,Ruijin Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,214,OTHER,INTERVENTIONAL,3/1/2021,10/30/2030
NCT05867966,NOT_YET_RECRUITING,Cancer|Breast Cancer|Digestive Cancer,BEHAVIORAL: psychoeduc/self-care/self-hypnosis group,University of Liege,CHU of LiÃ¨ge|Fonds pour la Recherche Scientifique (FRS-FNRS),ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,7/1/2023,12/31/2026
NCT05255666,WITHDRAWN,Triple Negative Breast Cancer|Brain Metastases,DRUG: Pembrolizumab|DRUG: Liposomal Irinotecan,Washington University School of Medicine,Merck Sharp & Dohme LLC|Ipsen,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,7/31/2023,1/31/2030
NCT05560685,RECRUITING,Breast Cancer,OTHER: Outcomes4Me|OTHER: Semi-structured interview,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Eastern Cooperative Oncology Group,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,10/3/2022,10/3/2024
NCT06068985,NOT_YET_RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: PHESGO,Latin American Cooperative Oncology Group,Roche Pharma AG|OncoclÃ­nicas,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,2024-02,2031-07
NCT06217185,RECRUITING,HER2-positive Breast Cancer|Advanced Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Taxanes|DRUG: Capecitabine,Hebei Medical University Fourth Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,1/2/2024,6/30/2027
NCT05122585,COMPLETED,Breast Cancer,PROCEDURE: MagSeed and MagTrace in breast cancer patiÃ«nts,Zuyderland Medisch Centrum,"Sysmex America, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,8/1/2021,2/9/2022
NCT05388500,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Paclitaxel + Trastuzumab|DRUG: Trastuzumab,Institut de cancÃ©rologie Strasbourg Europe,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,800,OTHER,INTERVENTIONAL,12/15/2022,12/15/2030
NCT05262400,RECRUITING,Breast Cancer|Solid Tumors,DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,240,INDUSTRY,INTERVENTIONAL,3/14/2022,9/13/2026
NCT05806385,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DEVICE: Cryoablation|COMBINATION_PRODUCT: Cryoablation combined with PD1 Inhibitor,Texas Tech University Health Sciences Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,OTHER,INTERVENTIONAL,2024-01,2027-06
NCT05663112,COMPLETED,Sentinel Lymph Node|Breast Cancer,PROCEDURE: Sentinel lymph node biopsy|PROCEDURE: Breast massage|PROCEDURE: Blue dye injection,Celal Bayar University,,ALL,"ADULT, OLDER_ADULT",NA,77,OTHER,INTERVENTIONAL,12/6/2021,7/6/2023
NCT06064812,RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer Stage I|ER+ Breast Cancer,DRUG: FWD1802|DRUG: palbocilib,"Forward Pharmaceuticals Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,99,INDUSTRY,INTERVENTIONAL,9/12/2023,2026-02
NCT04629612,UNKNOWN,Breast Neoplasms|Pain|Analgesia|Regional Anesthesia,PROCEDURE: Regional anesthesia,"Taipei Veterans General Hospital, Taiwan",,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER_GOV,INTERVENTIONAL,12/1/2020,11/30/2021
NCT04537312,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Ductal Breast Carcinoma In Situ|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prophylactic Mastectomy,PROCEDURE: Robot-assisted Nipple Sparing Mastectomy|OTHER: Survey Administration|DEVICE: RNSM,William Carson,,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,INTERVENTIONAL,11/17/2020,12/31/2023
NCT06116812,RECRUITING,Breast Cancer|Laughter Therapy|Mindfulness Therapy|Life Quality|Anxiety and Depression|Spiritual Well-being,OTHER: the laughter therapy group|OTHER: the mindfulness therapy group,Kafkas University,,FEMALE,ADULT,NA,105,OTHER,INTERVENTIONAL,1/1/2024,4/1/2024
NCT02562612,WITHDRAWN,Breast Cancer,DRUG: SM-88,"Tyme, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,2022-10,2023-10
NCT05374512,RECRUITING,Breast Cancer,DRUG: Dato-DXd|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Eribulin mesylate,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,INTERVENTIONAL,5/16/2022,12/3/2025
NCT05429866,RECRUITING,"Breast Cancer|Melanoma|Non Small Cell Lung Cancer|Non-melanoma Skin Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Mesothelioma, Malignant|Bladder Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|MSI-H Colorectal Cancer","DRUG: Checkpoint Blockade, Immune",Jules Bordet Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,441,OTHER,INTERVENTIONAL,9/1/2022,12/1/2024
NCT04274933,TERMINATED,Breast Cancer|Cancer,DRUG: Venetoclax|DRUG: Capecitabine,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE1,4,INDUSTRY,INTERVENTIONAL,5/21/2020,10/8/2020
NCT04190433,WITHDRAWN,Breast Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Sarcoma,DRUG: Carvedilol|DRUG: Lisinopril|DRUG: Pravastatin|DRUG: Spironolactone,Mayo Clinic,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,9/1/2020,4/18/2023
NCT04714983,RECRUITING,Liver Metastases|Liver Metastasis Colon Cancer|Colorectal Cancer|Breast Cancer|Gastric Cancer|Periampullary Cancer|Melanoma|Renal Cell Cancer|Sarcoma|Squamous Cell Carcinoma|Gastrointestinal Stromal Tumors,BIOLOGICAL: DNX-2440,"DNAtrix, Inc.",H. Lee Moffitt Cancer Center and Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,2/15/2021,12/31/2023
NCT04354233,RECRUITING,Metastatic Breast Cancer,DEVICE: Physical activity intervention with connected devices,Centre Leon Berard,"Fondation ARC|Janssen, LP",FEMALE,"ADULT, OLDER_ADULT",NA,244,OTHER,INTERVENTIONAL,6/24/2020,2025-06
NCT04247633,RECRUITING,Breast Cancer,DRUG: Palbociclib,Samsung Medical Center,Korean Cancer Study Group,ALL,"ADULT, OLDER_ADULT",PHASE2,578,OTHER,INTERVENTIONAL,2/11/2020,2025-02
NCT05949333,NOT_YET_RECRUITING,Breast Neoplasms,DRUG: Eflapegrastim,Eunseong Medical Foundation Good GANG-AN HOSPITAL,Hanmi Pharmaceutical Company Limited,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,2023-08,2025-01
NCT04518085,COMPLETED,"Pain, Postoperative|Fatigue|Breast Cancer",BEHAVIORAL: Medical hypnosis|BEHAVIORAL: Internet-based Acceptance and Commitment Therapy (iACT)|BEHAVIORAL: Mindfulness session|BEHAVIORAL: Treatment as Usual (TAU),University of Oslo,Oslo University Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,203,OTHER,INTERVENTIONAL,10/1/2020,11/1/2023
NCT04397185,RECRUITING,Breast Cancer Female,DEVICE: Breast Cancer Locator (BCL) guided partial mastectomy|DEVICE: Wire Localized (WL) partial mastectomy,"CairnSurgical, Inc.",,FEMALE,"ADULT, OLDER_ADULT",NA,448,INDUSTRY,INTERVENTIONAL,12/23/2020,2024-09
NCT04941885,RECRUITING,Breast Cancer,DRUG: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,INTERVENTIONAL,6/25/2021,7/1/2025
NCT05113485,RECRUITING,Breast Cancer,BEHAVIORAL: Diabetes Prevention Program-based lifestyle change intervention (DPP)|BEHAVIORAL: Highly Microbiota-Accessible Foods (HMAFs) intervention,"University of California, Los Angeles",,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,4/1/2022,2023-06
NCT05269186,RECRUITING,Breast Cancer|Pelvic Cancer,DEVICE: Virtual reality software,Centre Hospitalier Departemental Vendee,,ALL,"ADULT, OLDER_ADULT",NA,256,OTHER,INTERVENTIONAL,10/5/2022,8/1/2024
NCT05394285,NOT_YET_RECRUITING,Breast Cancer,DRUG: Hetrombopag|DRUG: rh-TPO,Henan Cancer Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER_GOV,INTERVENTIONAL,6/28/2022,6/28/2024
NCT05251766,UNKNOWN,Breast Cancer|Chemotherapy Effect,DRUG: Nab paclitaxel|DRUG: Docetaxel,Xuli Meng,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,4/20/2022,6/30/2023
NCT04582955,UNKNOWN,Triple-negative Breast Cancer,DRUG: Chidamide in combination with chemotherapy,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,10/30/2020,2022-12
NCT05573555,RECRUITING,Breast Cancer,DRUG: ARV-471|DRUG: Ribociclib,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,35,INDUSTRY,INTERVENTIONAL,3/1/2023,10/6/2027
NCT05837455,NOT_YET_RECRUITING,Breast Cancer|Cancer of the Breast,DEVICE: VENTANA MIB-1 Ki67 assay|DEVICE: Oncotype DXÂ® Recurrence Score|DEVICE: PAM50-based Prosigna breast cancer gene signature assay|DRUG: Anastrozole|DRUG: Combination anthracycline and/or taxane based treatment,Washington University School of Medicine,Swim Across America|The Foundation for Barnes-Jewish Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE2,81,OTHER,INTERVENTIONAL,2/28/2024,8/31/2027
NCT05998655,RECRUITING,Breast Cancer Female,OTHER: tele nursing,Ataturk University,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,9/1/2023,2024-05
NCT04817566,RECRUITING,Breast Cancer|Cognitive Impairment,DEVICE: Anodal tDCS|DEVICE: Sham tDCS|BEHAVIORAL: Intensive cognitive training,University Medicine Greifswald,University of Greifswald,FEMALE,ADULT,NA,52,OTHER,INTERVENTIONAL,11/2/2021,2024-08
NCT03832855,RECRUITING,Advanced Cancer,BIOLOGICAL: pING-hHER3FL,Herbert Lyerly,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,7/13/2020,3/1/2025
NCT05309655,RECRUITING,Breast Cancer|Triple Negative Breast Cancer|Cardiovascular Complications,DRUG: Adenosine Stress Cardiac Magnetic Resonance Imaging|DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: Computed Tomography Angiogram|OTHER: Laboratory Testing|BEHAVIORAL: Quality of Life Survey,Wake Forest University Health Sciences,National Cancer Institute (NCI),FEMALE,ADULT,EARLY_PHASE1,90,OTHER,INTERVENTIONAL,9/2/2022,2027-12
NCT06230055,RECRUITING,Her-2 Negative Breast Cancer With Leptomeningeal Metastasis,DEVICE: Ommaya reservoir|DRUG: Systematic chemotherapy,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE4,48,OTHER,INTERVENTIONAL,3/1/2024,1/1/2027
NCT05546255,RECRUITING,Triple Negative Breast Cancer,DRUG: Eribulin Mesylate|DRUG: Lobaplatin,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,6/1/2020,12/31/2023
NCT05816655,RECRUITING,Metastatic Breast Cancer,DRUG: Fulvestrant plus AI plus ribociclib|DRUG: AI plus ribociclib,Korea University Guro Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,202,OTHER,INTERVENTIONAL,5/31/2023,6/30/2029
NCT04584255,RECRUITING,Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Breast Cancer|HER2-negative Breast Cancer|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|Deleterious PALB2 Gene Mutation,DRUG: Niraparib|DRUG: Dostarlimab,Dana-Farber Cancer Institute,Translational Breast Cancer Research Consortium|Johns Hopkins University|GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE2,62,OTHER,INTERVENTIONAL,12/18/2020,7/17/2029
NCT06076616,RECRUITING,Breast Cancer|Lifestyle|Rehabilitation|Prehabilitation|Surgery,BEHAVIORAL: Prehabilitation and rehabilitation,Franciscus Gasthuis,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,12/1/2022,1/1/2024
NCT05252416,RECRUITING,Advanced Solid Tumors|HR+ Breast Cancer|CCNE1 Amplification|HER2-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Carcinosarcoma,DRUG: BLU-222|DRUG: Carboplatin|DRUG: Ribociclib|DRUG: Fulvestrant,Blueprint Medicines Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,366,INDUSTRY,INTERVENTIONAL,4/7/2022,9/30/2026
NCT05680116,COMPLETED,Breast Cancer,"DEVICE: MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|OTHER: Home based exercise",Acibadem University,,FEMALE,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,2/1/2023,6/15/2023
NCT04504916,COMPLETED,Triple-negative Breast Cancer|Non-squamous Non-small-cell Lung Cancer|NSCLC|Estrogen-receptor-positive Breast Cancer|Progesterone-receptor-positive Breast Cancer|Estrogen-receptor-negative Breast Cancer|ER-negative Breast Cancer|Progesterone-receptor Negative Breast Cancer|PR-negative Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|PR-positive Breast Cancer|Platinum-resistant Ovarian Cancer|Gastric Cancer|Pancreatic Cancer,DRUG: Zilovertamab vedotin,"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INDUSTRY,INTERVENTIONAL,10/7/2020,6/12/2023
NCT05232916,RECRUITING,Breast Cancer,BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100,"Greenwich LifeSciences, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,598,INDUSTRY,INTERVENTIONAL,8/11/2022,2026-12
NCT04826016,WITHDRAWN,Advanced Breast Cancer,DRUG: POL6326|DRUG: Eribulin|DRUG: Nab paclitaxel,MedSIR,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,3/16/2022,3/16/2022
NCT06113016,NOT_YET_RECRUITING,Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Early Stage Breast Carcinoma,PROCEDURE: Biospecimen Collection|OTHER: Educational Intervention|OTHER: Exercise Intervention|DRUG: Fisetin|OTHER: Physical Performance Testing|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Jonsson Comprehensive Cancer Center,National Institutes of Health (NIH)|National Cancer Institute (NCI),FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,164,OTHER,INTERVENTIONAL,9/30/2024,10/31/2027
NCT06046716,COMPLETED,Sexual Functioning,BEHAVIORAL: Mindful compassion based on behavioural change taxonomy experimental group,London Metropolitan University,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,9/1/2022,9/13/2023
NCT05528263,RECRUITING,Acupuncture|Early-stage Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,DEVICE: Acupuncture|OTHER: Nature scenery with a relaxation exercise,Dana-Farber Cancer Institute,The Comprehensive and Integrative Medicine Institute of South Korea,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,9/8/2022,2/28/2025
NCT06174363,RECRUITING,Breast Cancer,DRUG: Maxigesic|DRUG: 0.9% saline solution,Yonsei University,,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,4/3/2023,2/26/2025
NCT05244993,NOT_YET_RECRUITING,Breast Neoplasm Female,DRUG: AK105|DRUG: Anlotinib hydrochloride|DRUG: Albumin Paclitaxel,Liaoning Tumor Hospital & Institute,Huludao central hospital|Anshan Tumor Hospital|Chaoyang Central Hospital|Fukuang General Hospital of Liaoning health industry group,FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,INTERVENTIONAL,2022-07,2024-03
NCT05738993,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: BCD-178|DRUG: Perjeta,Biocad,,MALE,ADULT,PHASE1,100,INDUSTRY,INTERVENTIONAL,8/8/2022,1/31/2024
NCT06135493,RECRUITING,Peripheral Neuropathy Due to Chemotherapy,DRUG: Losartan,Future University in Egypt,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,84,OTHER,INTERVENTIONAL,12/12/2023,6/30/2024
NCT04293393,ACTIVE_NOT_RECRUITING,Early Breast Cancer,DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Taxane|DRUG: Letrozole|DRUG: Abemaciclib|DRUG: LHRH Analogue,Spanish Breast Cancer Research Group,Eli Lilly and Company,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,10/2/2020,2/28/2033
NCT04601116,RECRUITING,Breast Cancer Female|Estrogen Receptor Positive Tumor,DRUG: Atorvastatin 80 Mg Oral Tablet|DRUG: Placebo oral tablet,Aarhus University Hospital,"Rigshospitalet, Denmark|Hospital of Southern Jutland|University of Copenhagen|Bornholms Hospital|Naestved Hospital|Vejle Hospital|Odense University Hospital|Nordsjaellands Hospital|Aalborg University Hospital|Herning Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE3,3360,OTHER,INTERVENTIONAL,1/4/2021,1/1/2035
NCT05619016,RECRUITING,Esophageal Neoplasms|Gastric Neoplasms Malignant|Breast Cancer|HER2-positive Gastric Cancer,DIAGNOSTIC_TEST: [68Ga]Ga-ABY-025 PET|DIAGNOSTIC_TEST: Biopsy and analysis of HER2 expression,Karolinska University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,INTERVENTIONAL,11/23/2022,12/31/2025
NCT05656716,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Nutritional intervention|BEHAVIORAL: Physical exercise intervention,Universidad de Granada,University Hospital Virgen de las Nieves,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,2023-01,2023-09
NCT04378816,UNKNOWN,Shared Decision Making|Self-Efficacy for Decision Making,OTHER: Shared decision making support tool,Taipei Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,INTERVENTIONAL,5/5/2020,5/5/2021
NCT04554316,COMPLETED,Scar|Breast Neoplasms|Breast Diseases|Surgical Wound,DEVICE: Steri-strip,Albert Einstein Healthcare Network,,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,11/1/2020,7/15/2023
NCT05749016,RECRUITING,Locally Advanced Breast Cancer|Chemotherapy Effect,DRUG: inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/1/2021,12/1/2023
NCT05294016,RECRUITING,Breast Cancer|Medical Device,DEVICE: BRA CONNECT device,Hopital Nord Franche-Comte,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,4/13/2022,11/28/2024
NCT05576545,COMPLETED,Breast Cancer|Breast Neoplasm|Breast Malignant Tumor|Resilience|Self-efficacy,DEVICE: The Breast Cancer Self-Care App,Kaohsiung Medical University Chung-Ho Memorial Hospital,,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,INTERVENTIONAL,9/18/2020,8/15/2022
NCT04327063,COMPLETED,Malignant Neoplasm of Breast,DRUG: Saline|DRUG: Ropivacaine,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,182,OTHER,INTERVENTIONAL,8/4/2020,1/28/2022
NCT05156463,WITHDRAWN,Breast Cancer|Colon Cancer,COMBINATION_PRODUCT: PAI Tool and Exercise Coaching,Milton S. Hershey Medical Center,National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,4/12/2022,4/12/2022
NCT03981263,RECRUITING,Breast Cancer,DEVICE: MEAVANTI prothesis|DEVICE: Standard prothesis,"University Hospital, Toulouse",,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,1/28/2021,2024-05
NCT04879563,RECRUITING,Breast Cancer|Prostate Cancer|Quality of Life|Survivorship|Toxicity,OTHER: ASCAPE-based follow-up strategy,Region Ã–rebro County,"UBITECH|ATOS|Siemens Corporation, Corporate Technology|Intrasoft|University of Patras|FORTH - Foundation for Research and Technology Hellas|Sphynx Technology Solutions AG|Faculty of Sciences, University of Novi Sad, Serbia|DFKI - German Research Center for Artificial Intelligence|CareAcross|National and Kapodistrian University of Athens, Greece|Fundacio Clinic Barcelona|Arthur's Legal|Fundacion iSYS",ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,INTERVENTIONAL,2/1/2021,12/31/2023
NCT04914663,RECRUITING,Breast Cancer,BEHAVIORAL: Exercise training,University of Florida,"National Heart, Lung, and Blood Institute (NHLBI)",FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,2023-11,5/31/2024
NCT05400993,RECRUITING,Breast Cancer,COMBINATION_PRODUCT: Chidamide,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,INTERVENTIONAL,5/23/2022,5/23/2024
NCT04736108,NOT_YET_RECRUITING,Prostate Cancer,DRUG: Abiraterone acetate|DRUG: Prednisolone|DRUG: Goserelin,West China Hospital,,MALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,2021-05,2024-12
NCT05183126,RECRUITING,Breast Cancer,DRUG: Paclitaxel|DRUG: Paclitaxel,University of Michigan Rogel Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,22,OTHER,INTERVENTIONAL,3/28/2022,2024-05
NCT05239663,RECRUITING,Chemotherapy-Related Cognitive Impairment|Breast Cancer,DRUG: Ganglioside-Monosialic Acid|DRUG: 250ml normal saline (NS),Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,306,OTHER,INTERVENTIONAL,2/8/2022,2/8/2024
NCT04189263,TERMINATED,Breast Cancer,OTHER: Carbohydrate restricted dietary intervention|DRUG: standard of care aromatase inhibitors,Farin Amersi,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,6,OTHER,INTERVENTIONAL,2/4/2020,3/30/2023
NCT04574063,ACTIVE_NOT_RECRUITING,Breast Cancer|Lifestyle Risk Reduction,BEHAVIORAL: Lifestyle intervention to reduce breast cancer risk,Royal Marsden NHS Foundation Trust,"National Institute for Health Research, United Kingdom",FEMALE,ADULT,NA,240,OTHER,INTERVENTIONAL,9/16/2020,2023-12
NCT04862663,RECRUITING,Locally Advanced (Inoperable) or Metastatic Breast Cancer,DRUG: Capivasertib|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,895,INDUSTRY,INTERVENTIONAL,5/10/2021,8/14/2029
NCT05765916,RECRUITING,Fear of Cancer Recurrence|Breast Cancer,BEHAVIORAL: Online mindfulness and acceptance intervention,National University of Singapore,,FEMALE,"ADULT, OLDER_ADULT",NA,244,OTHER,INTERVENTIONAL,9/30/2022,12/30/2023
NCT04330716,COMPLETED,Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Metastatic Prostate Cancer,BEHAVIORAL: Standard Genetic Counseling|BEHAVIORAL: Educational Video,Dana-Farber Cancer Institute,Ambry Genetics,ALL,"ADULT, OLDER_ADULT",NA,269,OTHER,INTERVENTIONAL,12/1/2020,12/31/2023
NCT04647916,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Prognostic Stage IV Breast Cancer AJCC v8,BIOLOGICAL: Sacituzumab Govitecan,SWOG Cancer Research Network,National Cancer Institute (NCI)|Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,44,NETWORK,INTERVENTIONAL,6/8/2021,2026-12
NCT04389216,RECRUITING,Breast Cancer Female,DEVICE: Cool-tip electrode for Radiofrequency Ablation,Hospital Universitari de Bellvitge,,FEMALE,OLDER_ADULT,NA,30,OTHER,INTERVENTIONAL,5/1/2020,12/15/2024
NCT05512416,NOT_YET_RECRUITING,Breast Cancer,DRUG: dalpiciclib plus letrozole,The Affiliated Hospital of Qingdao University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,2022-08,2024-05
NCT05637216,RECRUITING,Radiation Induced Fibrosis,DRUG: Losartan 25 milligram capsule|DRUG: Placebo,Shaw Cancer Center,Steadman Philippon Research Institute,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,8/17/2023,8/17/2027
NCT05439005,RECRUITING,Breast Cancer,DRUG: Dexmedetomidine,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,158,OTHER,INTERVENTIONAL,12/7/2022,3/15/2026
NCT05608252,RECRUITING,Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer,DRUG: VS-6766|DRUG: Abemaciclib|DRUG: Fulvestrant,Adrienne G. Waks,"Verastem, Inc.|Eli Lilly and Company",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,63,OTHER,INTERVENTIONAL,2/23/2023,12/31/2028
NCT04651452,RECRUITING,Breast Cancer,BEHAVIORAL: Value Affirmation|BEHAVIORAL: Reflective Journaling,Carnegie Mellon University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,2/1/2021,12/31/2025
NCT04803305,COMPLETED,Non-small Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Prostate Cancer|Breast Cancer|Ovarian Cancer|Loss of Appetite|Fatigue|Cachexia|Anorexia,DRUG: PF-06946860|DRUG: Placebo for PF-06946860,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,INTERVENTIONAL,5/11/2021,8/9/2022
NCT06028152,RECRUITING,Breast Cancer|Lung Cancer|Genito Urinary Cancer,"OTHER: End-of-life conversation game called ""Hello""",Milton S. Hershey Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,10/31/2023,2024-11
NCT04259905,COMPLETED,Breast Cancer|Physical Activity,BEHAVIORAL: Active video game teleconference support group|BEHAVIORAL: Standard support group + pedometer,"The University of Texas Medical Branch, Galveston",M.D. Anderson Cancer Center|National Institute on Aging (NIA),FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,5/11/2020,3/29/2022
NCT04985552,UNKNOWN,Breast Cancer,PROCEDURE: DIEP Breast Reconstruction|DEVICE: ciNPT|OTHER: Conventional Tape Dressings,McMaster University,,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,2021-10,2022-10
NCT04711252,ACTIVE_NOT_RECRUITING,ER-Positive HER2-Negative Breast Cancer,DRUG: AZD9833|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: AZD9833 placebo|DRUG: Palbociclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1370,INDUSTRY,INTERVENTIONAL,1/28/2021,2/1/2029
NCT06006806,RECRUITING,Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Stage I,RADIATION: Pencil Beam Scanning Proton Therapy,Thompson Cancer Survival Center,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,7/7/2023,7/7/2027
NCT04198727,RECRUITING,Breast Neoplasm Malignant Female,OTHER: DPD activity assessment|DRUG: Capecitabine,Centre Antoine Lacassagne,Cerbaliance,FEMALE,"ADULT, OLDER_ADULT",NA,155,OTHER,INTERVENTIONAL,7/20/2020,2026-04
NCT04335006,TERMINATED,Breast Cancer|Triple Negative Breast Cancer,DRUG: Carelizumab|DRUG: Nab-paclitaxel|DRUG: Apatinib,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,80,INDUSTRY,INTERVENTIONAL,7/14/2020,4/14/2023
NCT04469127,NOT_YET_RECRUITING,Breast Cancer Stage IV,DRUG: Lutetium-177-DOTAGA-PEG-IAC,"Advanced Imaging Projects, LLC","All India Institute of Medical Sciences, New Delhi|University of Witwatersrand, South Africa|Postgraduate Institute of Medical and Research|US Department of Veterans Affairs",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,INTERVENTIONAL,1/30/2023,8/30/2024
NCT05178927,COMPLETED,Breast Cancer,DEVICE: HoloLens v2,University of Florida,Florida Breast Cancer Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,8/2/2022,9/30/2023
NCT05349227,RECRUITING,Ovarian Cancer|Breast Cancer|Lung Cancer|Gastric Cancer|Survivorship,BEHAVIORAL: Digital Health Coaching Program|DEVICE: Fitbit,Pack Health,"National Institute of Nursing Research (NINR)|Daiichi Sankyo|GlaxoSmithKline|Dana-Farber Cancer Institute|University of Nebraska|Ohio State University Comprehensive Cancer Center|Gilead Sciences|The University of Texas Health Science Center, Houston|M.D. Anderson Cancer Center",ALL,"ADULT, OLDER_ADULT",NA,660,INDUSTRY,INTERVENTIONAL,6/23/2022,2025-12
NCT04432727,COMPLETED,Breast Cancer Lymphedema,DEVICE: Flexitouch Plus with Cellular Connectivity (FT-CC),Tactile Medical,,FEMALE,"ADULT, OLDER_ADULT",NA,29,INDUSTRY,INTERVENTIONAL,8/13/2020,11/19/2021
NCT04821609,UNKNOWN,Breast Cancer|Physical Activity|Lymphedema of Upper Arm,BEHAVIORAL: Resistance Training,Pontificia Universidad Catolica de Chile,"Universidad de Granada|National Fund for Research and Development in Health, Chile|Hospital Dr Sotero del Rio",FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,12/1/2021,2023-06
NCT04429893,RECRUITING,Cancer Breast|Chronic Pain Syndrome,DRUG: magnesium sulphate|DRUG: bupivicaine,Alexandria University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,80,OTHER,INTERVENTIONAL,1/1/2022,2022-09
NCT04892693,RECRUITING,Advanced Breast Cancer,DRUG: Talazoparib Oral Capsule,Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,5/25/2021,5/10/2025
NCT05221593,COMPLETED,Neutropenia,DRUG: Lithium Carbonate,Al-Azhar University,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,50,OTHER,INTERVENTIONAL,8/1/2020,6/1/2022
NCT06214793,NOT_YET_RECRUITING,Breast Cancer|Metastatic Breast Cancer,DRUG: Taletrectinib,"Megan Kruse, MD",AnHeart Therapeutics Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,INTERVENTIONAL,2024-04,1/1/2030
NCT06258993,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Behavioral: Core Exercise Promotion Intervention,Dartmouth-Hitchcock Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,85,OTHER,INTERVENTIONAL,2/15/2024,4/1/2026
NCT04498793,UNKNOWN,HER2-negative Breast Cancer,BIOLOGICAL: Tislelizumab|DRUG: Nab paclitaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DEVICE: Cyclophosphamide,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","First Affiliated Hospital Xi'an Jiaotong University|Wuhan Union Hospital, China|Beijing Huanxing Cancer Hospital",ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,2020-09,2022-12
NCT04427293,RECRUITING,Triple Negative Breast Cancer,DRUG: Lenvatinib|DRUG: Pembrolizumab,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,7/9/2020,2026-07
NCT05431504,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: Dalpiciclib in combination with endocrine therapy by Physicians choice,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,INTERVENTIONAL,2022-06,2027-12
NCT05032404,COMPLETED,Breast Cancer Female,DEVICE: BNT103,Blue Note Therapeutics,Healthcare Innovation Technology Lab,FEMALE,ADULT,NA,15,INDUSTRY,INTERVENTIONAL,9/1/2021,12/31/2021
NCT05440227,RECRUITING,Cancer-related Fatigue,DRUG: PG2 Lyo. Injection 500mg|DRUG: Placebo 0.9% normal saline,PhytoHealth Corporation,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,INDUSTRY,INTERVENTIONAL,6/15/2022,2022-12
NCT05350527,RECRUITING,Breast Cancer,OTHER: Consultation of a Web Platform,"University Hospital, Montpellier",EDOP Society,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,6/22/2022,4/1/2025
NCT05501704,RECRUITING,Male Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Receptor Negative Breast Carcinoma,DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Degarelix|DRUG: Abemaciclib,Jose Pablo Leone,Eli Lilly and Company|Translational Breast Cancer Research Consortium (TBCRC),MALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,10/11/2023,4/1/2036
NCT04824027,RECRUITING,Breast Cancer,PROCEDURE: Harmonic motion imaging,Columbia University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,6/14/2021,2024-01
NCT05288127,RECRUITING,HRD 100 Gene Expression High|Triple Negative Breast Cancer,DRUG: Talazoparib,University of Malaya,Cancer Research Malaysia|Pfizer|Pantai Hospital Kuala Lumpur|Hospital Sultan Ismail,FEMALE,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,3/8/2022,2025-11
NCT05548127,RECRUITING,Breast Cancer,DRUG: ARV-471|DRUG: Abemaciclib,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,INTERVENTIONAL,2/23/2023,12/3/2025
NCT05730608,RECRUITING,Breast Cancer Female|Breast Cancer Recurrent,OTHER: 18F-FDG PET/CT,Vestre Viken Hospital Trust,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,2/16/2023,12/31/2032
NCT05362760,RECRUITING,Hormone Receptor-positive Metastatic Breast Cancer|HER2-negative Metastatic Breast Cancer,DRUG: Abemaciclib + Aromatase Inhibitor|DRUG: Abemaciclib + Fulvestrant,Prof. Wolfgang Janni,Eli Lilly and Company,FEMALE,"ADULT, OLDER_ADULT",PHASE4,300,OTHER,INTERVENTIONAL,4/27/2022,2029-04
NCT04876560,COMPLETED,Breast Cancer|Obesity|Cardiovascular Disease Other,OTHER: Application of CDSS to provide nutritional care in breast cancer patients from home|OTHER: General lifestyle advice to breast cancer patients by phone,"Iaso Maternity Hospital, Athens, Greece",Harokopio University,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,3/11/2020,4/15/2021
NCT05969860,RECRUITING,Advanced Malignant Solid Neoplasm|Advanced Anal Carcinoma|Advanced Biliary Tract Carcinoma|Advanced Bladder Carcinoma|Advanced Breast Carcinoma|Advanced Carcinoid Tumor|Advanced Cervical Carcinoma|Advanced Colorectal Carcinoma|Advanced Gastric Carcinoma|Advanced Glioblastoma|Advanced Head and Neck Carcinoma|Advanced HER2 Positive Breast Carcinoma|Advanced Lung Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Germ Cell Tumor|Advanced Neuroendocrine Carcinoma|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Prostate Small Cell Neuroendocrine Carcinoma|Advanced Prostate Carcinoma,PROCEDURE: Clinical Encounter|OTHER: Home Health Encounter|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,8/23/2023,1/1/2025
NCT05509829,RECRUITING,Breast Cancer|Seroma|Wound Complication,DEVICE: Negative pressure wound therapy,Zuyderland Medisch Centrum,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,5/1/2023,12/1/2023
NCT04526561,RECRUITING,Breast Cancer,PROCEDURE: Latissimus dorsi flap|PROCEDURE: Thoracodorsal artery perforator flap to breast|PROCEDURE: Deep inferior epigastric perforator flap,Vastra Gotaland Region,,FEMALE,"ADULT, OLDER_ADULT",NA,550,OTHER_GOV,INTERVENTIONAL,8/1/2020,12/31/2025
NCT05914753,NOT_YET_RECRUITING,Breast Cancer|Chemotherapy Effect,"DRUG: Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|DRUG: Epirubicin, Cyclophosphamide, Docetaxel",Zhejiang Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,7/1/2023,6/1/2025
NCT05806060,RECRUITING,Triple-Negative Breast Cancer,"DRUG: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|DRUG: nab-paclitaxel, with maintenance of capecitabine|DRUG: Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|DRUG: VEGFR and TPC",Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,192,OTHER,INTERVENTIONAL,4/25/2023,2/28/2026
NCT05627960,RECRUITING,Triple Negative Breast Cancer|Hormone-Resistant Breast Cancer|Non Small Cell Lung Cancer|Mesothelioma,DRUG: AG-01 Compound,A&G Pharmaceutical Inc.,University of Maryland Greenebaum Cancer Center,ALL,"ADULT, OLDER_ADULT",PHASE1,77,INDUSTRY,INTERVENTIONAL,2/14/2022,2026-11
NCT05408260,RECRUITING,Malignant Breast Neoplasm,PROCEDURE: Ultrasonography|PROCEDURE: Automated Breast Ultrasound,Thomas Jefferson University,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,11/18/2022,2024-12
NCT05496829,RECRUITING,Breast Cancer,BEHAVIORAL: Multicomponent Adherence Intervention|OTHER: Usual Care,Columbia University,National Institute on Minority Health and Health Disparities (NIMHD),ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,3/2/2023,3/31/2027
NCT04656353,RECRUITING,Breast Cancer,BEHAVIORAL: Intervention Arm|BEHAVIORAL: Control Group,"University Health Network, Toronto",,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,10/1/2020,12/31/2023
NCT05322460,NOT_YET_RECRUITING,Long-term Effects of Cancer Treatment|Long-term Effects Secondary to Cancer Therapy in Adults,OTHER: CUMACA-M Program,Cristina GarcÃ­a-Vivar,Instituto de Salud Carlos III,FEMALE,"ADULT, OLDER_ADULT",NA,182,OTHER,INTERVENTIONAL,2023-01,2024-06
NCT05020860,RECRUITING,Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab|DRUG: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf,Baylor Breast Care Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,185,OTHER,INTERVENTIONAL,4/18/2023,2029-11
NCT04742153,RECRUITING,Advanced or Metastatic Breast Cancer,DRUG: MRG002,Shanghai Miracogen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,INTERVENTIONAL,5/13/2021,2023-02
NCT05269160,RECRUITING,Radiation Dermatitis|Breast Cancer|Head and Neck Cancer,DRUG: Dermaprazole 1%|DRUG: Dermaprazole 2%,Michelle S Ludwig,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,57,OTHER,INTERVENTIONAL,4/24/2023,2027-01
NCT04590560,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,FEMALE,ADULT,NA,60000,OTHER,INTERVENTIONAL,2/6/2020,2026-02
NCT05371860,WITHDRAWN,Breast Cancer|HER2-positive Breast Cancer,OTHER: Omit breast radiation,Armando Giuliano,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2023-07,2028-10
NCT06022029,RECRUITING,"Triple Negative Breast Cancer|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle Cell Lymphoma|Bladder Cancer|Uveal Melanoma, Recurrent|Cervix Cancer|Carcinoma in Situ|Head and Neck Squamous Cell Carcinoma|Skin Cancer|Metastatic Cancer|Tumor, Solid|Tumor Recurrence",DRUG: ONM-501|DRUG: Cemiplimab,"OncoNano Medicine, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,168,INDUSTRY,INTERVENTIONAL,10/13/2023,8/29/2026
NCT05326360,COMPLETED,Postoperative Nausea and Vomiting|Breast Cancer Female,DRUG: Ramosetron Hydrochloride,Pusan National University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE4,144,OTHER,INTERVENTIONAL,12/17/2020,10/31/2021
NCT05692960,RECRUITING,"Sexual Dysfunction, Physiological|Body Image|Libido; Loss, Aversion",OTHER: Hypnotic Relaxation Intervention (HRI)|DEVICE: Vulvovaginal Atrophy (VVA),"The University of Tennessee, Knoxville",Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,11/22/2022,9/30/2024
NCT03238053,NOT_YET_RECRUITING,"Laser-Induced Scar|Breast Cancer|Endometrial Cancer|Menopause|Vaginal Atrophy|Bladder, Overactive",PROCEDURE: Vaginal laser treatment|DEVICE: sham|DEVICE: laser system,Herning Hospital,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,10/1/2022,12/31/2026
NCT04579029,RECRUITING,Breast Cancer|Lymphedema,PROCEDURE: Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging,Royal Marsden NHS Foundation Trust,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,10/13/2021,2024-04
NCT05203029,COMPLETED,Breast Cancer Survivors,OTHER: Online exercise,Isfahan University of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",NA,198,OTHER,INTERVENTIONAL,1/5/2022,7/29/2022
NCT05726929,RECRUITING,Breast Cancer|Neuropathic Pain,OTHER: Osteopathic treatment|OTHER: Capsaicin QUTENZA Patch (TAU),Institut Toulousain d'OstÃ©opathie,Institut Claudius Regaud,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,1/11/2023,12/8/2024
NCT04672460,COMPLETED,Advanced Solid Tumors|Solid Tumors|Ovarian Cancer|Breast Cancer|Prostate Cancer|NSCLC|Pancreatic Cancer|Colorectal Cancer,DRUG: TALZENNA capsule|DRUG: Talazoparib soft gel capsule|DRUG: Talazoparib soft gel capsule,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1,73,INDUSTRY,INTERVENTIONAL,12/21/2020,7/22/2022
NCT04142060,TERMINATED,Breast Cancer,DRUG: Enzalutamide,SOLTI Breast Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,INTERVENTIONAL,6/1/2020,10/10/2022
NCT04616729,RECRUITING,Breast Cancer Female,DRUG: Triptorelin 3.75 MG Injection|PROCEDURE: Transvaginal oocyte retrieval|DRUG: Triptorelin Injection,Universitair Ziekenhuis Brussel,Universitaire Ziekenhuizen KU Leuven,FEMALE,ADULT,PHASE1|PHASE2,30,OTHER,INTERVENTIONAL,11/1/2022,12/31/2025
NCT05673629,RECRUITING,Breast Cancer,DRUG: Utidelone Injection in combination with AC|DRUG: Docetaxel Injection in combination with AC,"Beijing Biostar Pharmaceuticals Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,552,INDUSTRY,INTERVENTIONAL,5/30/2023,12/31/2025
NCT06106529,NOT_YET_RECRUITING,Breast Cancer|Hot Flash Due to Medication,DRUG: Oxybutynin|DRUG: Venlafaxine,Reinier de Graaf Groep,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,260,OTHER,INTERVENTIONAL,1/8/2024,1/1/2029
NCT05665660,RECRUITING,Breast Cancer,BEHAVIORAL: CARE|BEHAVIORAL: CARE + COACH,Johns Hopkins Bloomberg School of Public Health,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,6/6/2023,2025-12
NCT05020561,UNKNOWN,Survivorship|Breast Cancer,BEHAVIORAL: Group life-coaching|BEHAVIORAL: Individual life-coaching,McGill University Health Centre/Research Institute of the McGill University Health Centre,Quebec Breast Cancer Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,9/15/2021,9/1/2023
NCT06166953,NOT_YET_RECRUITING,Breast Cancer,OTHER: digital technology-supported education,Baskent University,,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,12/11/2023,12/30/2025
NCT04685460,UNKNOWN,Breast Neoplasms|Radiotherapy Side Effect,OTHER: customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images,Jiangxi Provincial Cancer Hospital,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,3/1/2020,4/20/2021
NCT05629429,RECRUITING,Metastatic Breast Cancer,DRUG: Olaparib|DRUG: Chemotherapy drug,National Taiwan University Hospital,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,300,OTHER,INTERVENTIONAL,2/7/2023,12/31/2025
NCT05615753,RECRUITING,Breast Cancer,BEHAVIORAL: Acupuncture,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,62,OTHER,INTERVENTIONAL,1/12/2023,5/31/2025
NCT06125353,COMPLETED,Breast Cancer,DIETARY_SUPPLEMENT: Melatonin,Harokopio University,,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,1/1/2022,5/31/2022
NCT05176860,COMPLETED,Lung Cancer|Liver Cancer|Breast Cancer|Other Cancer,DEVICE: CBCT Imaging,"Varian, a Siemens Healthineers Company",,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,INTERVENTIONAL,12/20/2022,7/30/2023
NCT05079360,WITHDRAWN,Metastatic Breast Cancer,"DRUG: Sabizabulin|DRUG: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator",Veru Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,3/15/2023,5/26/2024
NCT05375461,RECRUITING,"HR-positive,HER2-negative in Advanced Breast Cancer",DRUG: TQB3616 capsules|DRUG: TQB3616-matching placebo|DRUG: Fluvestrin injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,287,INDUSTRY,INTERVENTIONAL,3/18/2022,2023-12
NCT05880160,RECRUITING,"Cardiotoxicity|HER2-positive Breast Cancer|Heart Failure|Cancer, Therapy-Related",OTHER: Phased withdrawal of heart failure medications,"University College, London",British Heart Foundation|Barts & The London NHS Trust|University College London Hospitals,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,7/14/2023,2025-09
NCT05399160,COMPLETED,Quality of Life,BEHAVIORAL: Nurse-led Supportive Care,Izmir Bakircay University,,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,1/3/2022,6/10/2022
NCT05209529,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer|BRCA1 Mutation|BRCA2 Mutation,DRUG: olaparib|DRUG: Durvalumab,European Organisation for Research and Treatment of Cancer - EORTC,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,152,NETWORK,INTERVENTIONAL,9/1/2022,2/18/2030
NCT06075953,RECRUITING,Ductal Carcinoma in Situ,DRUG: Tamoxifen|DRUG: Exemestane|DRUG: Letrozole|DRUG: Anastrazole|DRUG: Testosterone + Anastrazole|DRUG: Elacestrant|DRUG: Z-endoxifen,QuantumLeap Healthcare Collaborative,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,INTERVENTIONAL,1/30/2024,2033-11
NCT05731453,RECRUITING,Breast Cancer,GENETIC: Polygenetic risk score,Vestre Viken Hospital Trust,Oslo University Hospital,FEMALE,ADULT,NA,80,OTHER,INTERVENTIONAL,2023-02,11/11/2035
NCT04326660,COMPLETED,"Cancer, Breast|Obesity, Abdominal",OTHER: SCOPE-Chinese Women,"University of California, San Francisco",Central South University,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,7/20/2020,12/30/2021
NCT05161260,ACTIVE_NOT_RECRUITING,Breast Cancer,BEHAVIORAL: Yoga Breathing|BEHAVIORAL: Attention Control,Sundar Balasubramanian,PranaScience Institute LLC|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,INTERVENTIONAL,11/17/2021,6/30/2023
NCT05345860,RECRUITING,Early-stage Breast Cancer,OTHER: The MRD strategy for high risk or MRD+ TNBC patients|OTHER: The MRD strategy for high risk or MRD+ HER2+ patients|OTHER: The MRD strategy for high risk or MRD+ ER+ patients|OTHER: The MRD strategy for low risk and MRD- TNBC patients|OTHER: The MRD strategy for low risk and MRD- HER2+ patients|OTHER: The MRD strategy for low risk and MRD- ER+ patients,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Huanxing Cancer Hospital|Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center",FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,3/24/2022,3/24/2027
NCT04895761,ACTIVE_NOT_RECRUITING,Breast Cancer,BIOLOGICAL: DPX-Survivac|DRUG: Letrozole 2.5mg|DRUG: Cyclophosphamide 50mg|RADIATION: XRT 10Gy x2,Providence Health & Services,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,INTERVENTIONAL,9/10/2021,9/1/2026
NCT05076760,RECRUITING,Solid Tumor|Advanced Cancer|Metastatic Cancer|Non Small Cell Lung Cancer|Cutaneous Squamous Cell Carcinoma|Merkel Cell Carcinoma|Melanoma|Pancreatic Cancer|Triple Negative Breast Cancer|Head and Neck Cancer,BIOLOGICAL: MEM-288 Intratumoral Injection|BIOLOGICAL: Nivolumab,"Memgen, Inc.",Duke Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE1,61,INDUSTRY,INTERVENTIONAL,2/23/2022,2026-11
NCT06180460,RECRUITING,Brain Tumor|Brain Metastases|Brain Cancer|Metastatic Lung Cancer|Metastatic Breast Cancer|Metastatic Melanoma|Metastatic Colon Cancer|Metastatic Kidney Cancer,BEHAVIORAL: CALM|BEHAVIORAL: Treatment as usual,Virginia Commonwealth University,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,11/10/2023,7/31/2025
NCT04253561,RECRUITING,Metastatic Breast Cancer,DRUG: Ipatasertib|DRUG: Trastuzumab|DRUG: Pertuzumab,SOLTI Breast Cancer Research Group,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE1,15,OTHER,INTERVENTIONAL,2/25/2020,8/25/2025
NCT05761353,COMPLETED,Mastectomy; Lymphedema,DEVICE: Endermologie|DEVICE: Negative pressure therapy,Cairo University,,FEMALE,ADULT,NA,68,OTHER,INTERVENTIONAL,6/29/2022,10/30/2023
NCT05253053,RECRUITING,Advanced Solid Tumor|Cholangiocarcinoma|Biliary Tract Cancer|HER2-negative Breast Cancer|Triple Negative Breast Cancer|Small-cell Lung Cancer|Bladder Cancer|Prostate Cancer|Thyroid Cancer|Gastric Cancer|Gallbladder Cancer,DRUG: TT-00420|DRUG: Combination Product: Atezolizumab|DRUG: Combination Product: Nab-Paclitaxel,"TransThera Sciences (Nanjing), Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,114,INDUSTRY,INTERVENTIONAL,4/13/2022,2024-12
NCT04137653,RECRUITING,Breast Cancer,DRUG: nab-Paclitaxel+carboplatin|DRUG: Paclitaxel+carboplatin,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1498,OTHER,INTERVENTIONAL,7/19/2021,11/30/2026
NCT04178460,TERMINATED,Gastric Cancer|Triple Negative Breast Cancer|Biliary Tract Carcinoma|Endometrial Carcinoma,DRUG: Niraparib combined with MGD013,"Zai Lab (Shanghai) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,2/3/2020,3/2/2022
NCT05143229,RECRUITING,Breast Cancer,DRUG: Alpelisib|DRUG: Sacituzumab govitecan,University of Kansas Medical Center,Novartis Pharmaceuticals|Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,3/28/2022,2025-12
NCT04434560,TERMINATED,"Brain Metastases, Adult",DRUG: Nivolumab|DRUG: Ipilimumab,"Sarah Sammons, MD",Bristol-Myers Squibb|Duke University,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,INTERVENTIONAL,11/4/2020,6/17/2021
NCT04877860,RECRUITING,Breast Cancer,"OTHER: Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|OTHER: Multimodal rehabilitation program + traditional biomedical information|OTHER: Control group",Universidad de Granada,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,4/4/2022,2024-04
NCT05327153,RECRUITING,Breast Cancer Female,BEHAVIORAL: Acceptance and Commitment Therapy,Universiti Sains Malaysia,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,10/20/2022,11/20/2024
NCT05412953,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,OTHER: Questionnaire Administration|BEHAVIORAL: Tonation Breathing Technique,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,2/22/2022,3/15/2026
NCT05921253,RECRUITING,Breast Cancer|Lymphoma,DEVICE: PARASYM neuromodulation device|DEVICE: PARASYM neuromodulation device,University of Oklahoma,,ALL,"ADULT, OLDER_ADULT",NA,104,OTHER,INTERVENTIONAL,12/1/2023,2026-09
NCT05379153,NOT_YET_RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Vaginal Atrophy,DEVICE: Laser Therapy|DEVICE: Sham Intervention|OTHER: Questionnaire Administration|OTHER: Quality of Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,INTERVENTIONAL,2024-04,2027-05
NCT04666961,RECRUITING,Ductal Carcinoma in Situ|Extensive Disease|Mastectomy,DRUG: Tamoxifen 20 mg|DRUG: Anastrozole 1Mg Tab,Institut Cancerologie de l'Ouest,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,262,OTHER,INTERVENTIONAL,2/3/2021,8/1/2033
NCT05454553,RECRUITING,Breast Cancer,OTHER: myocardial perfusion SPECT,Institut de cancÃ©rologie Strasbourg Europe,,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,10/27/2022,10/27/2024
NCT06121453,RECRUITING,Breast Cancer,BEHAVIORAL: Multicomponent Adherence Intervention,Columbia University,National Institute on Minority Health and Health Disparities (NIMHD),ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,11/1/2023,12/10/2026
NCT05071560,COMPLETED,Breast Cancer,OTHER: Combined exercise training,Associacao de Investigacao de Cuidados de Suporte em Oncologia,Centro Hospitalar de Vila Nova de Gaia/Espinho|Universidad Europea de Madrid|University Institute of Maia,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,5/1/2021,9/30/2021
NCT05570253,RECRUITING,Breast Cancer|Metastatic Triple-Negative Breast Cancer,DRUG: Eribulin|DRUG: SDX-7320|OTHER: Placebo,Memorial Sloan Kettering Cancer Center,"SynDevRx, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,10/3/2022,2027-10
NCT05111561,RECRUITING,Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Triple-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm,DRUG: BET Bromodomain Inhibitor ZEN-3694|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,42,NIH,INTERVENTIONAL,8/2/2022,3/14/2024
NCT06143553,RECRUITING,Metastatic Breast Cancer (MBC),DRUG: Paclitaxel Polymeric Micelles for Injection|DRUG: Eribulin Mesilate injection|DRUG: Capecitabine Tablets|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Vinorelbine Tartrate Injection|DRUG: Paclitaxel (albumin-bound),"Shanghai Yizhong Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,168,INDUSTRY,INTERVENTIONAL,10/30/2023,2025-07
NCT04904653,RECRUITING,Hemopatch|Breast Cancer|Axillary Lymphadenectomy,DEVICE: Hemopatch|OTHER: Control group,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,AsociaciÃ³n De Cirujanos De Mama De Toledo,FEMALE,"ADULT, OLDER_ADULT",PHASE4,118,OTHER,INTERVENTIONAL,11/8/2021,2022-11
NCT04437160,RECRUITING,Triple Negative Breast Cancer,DRUG: Epirubicin or Pirarubicin|DRUG: Cyclophosphamide,Chinese Academy of Medical Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE2,286,OTHER,INTERVENTIONAL,2/1/2020,2027-12
NCT05978960,RECRUITING,Breast Cancer,OTHER: Nutrition and resistance training exercise intervention,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,5/20/2023,8/20/2024
NCT04708860,ACTIVE_NOT_RECRUITING,Breast Cancer|Metastatic Breast Cancer,BEHAVIORAL: Prolonged Nightly Fasting|BEHAVIORAL: Exercise,Dana-Farber Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,1/15/2021,7/31/2024
NCT04932460,UNKNOWN,Breast Neoplasms|Neoadjuvant Therapy|Sentinel Lymph Node Biopsy,PROCEDURE: CEUS|PROCEDURE: blue dye,"First Affiliated Hospital, Sun Yat-Sen University",The Seventh Affiliated Hospital of Sun Yat-sen University|Affiliated Hospital of Guangdong Medical University|First Affiliated Hospital of Shantou University Medical College,FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,6/15/2021,8/15/2023
NCT04858529,RECRUITING,Neoadjuvant Therapies for HER2+ Breast Cancer,DRUG: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|DRUG: investigator-selected taxane/trastuzumab/pertuzumab (THP),Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,774,OTHER,INTERVENTIONAL,4/30/2021,4/30/2025
NCT04787029,RECRUITING,Breast Cancer Lymphedema,DEVICE: Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735)),Samsung Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,3/12/2021,12/30/2025
NCT05744687,RECRUITING,Locally Advanced or Metastatic Breast Cancer,DRUG: SPH4336 Tablets 400mg|DRUG: SPH4336 Tablets Placebo,"Shanghai Pharmaceuticals Holding Co., Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,374,INDUSTRY,INTERVENTIONAL,4/24/2023,12/16/2024
NCT05868187,RECRUITING,Breast Neoplasm,"BEHAVIORAL: Exercise, Problem-Solving Session and Education",University of Cincinnati,University of Dayton,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,3/1/2023,4/30/2024
NCT06224387,RECRUITING,Solid Tumors|Pancreatic Cancer|Non-small Cell Lung Cancer|Triple-negative Breast Cancer,DRUG: CTS2190 capsules,"CytosinLab Therapeutics Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,224,INDUSTRY,INTERVENTIONAL,6/26/2023,10/31/2025
NCT04958785,ACTIVE_NOT_RECRUITING,Triple-Negative Breast Cancer,DRUG: Magrolimab|DRUG: Nab-Paclitaxel|DRUG: Paclitaxel|DRUG: Sacituzumab Govitecan-hziy,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE2,90,INDUSTRY,INTERVENTIONAL,12/14/2021,2025-01
NCT05088785,RECRUITING,Breast Cancer,DRUG: FES,"Amsterdam UMC, location VUmc",,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,10/11/2021,2023-10
NCT03779685,UNKNOWN,Breast Cancer Female,PROCEDURE: General anesthesia|PROCEDURE: Regional anesthesia,Azienda Ospedaliera San Gerardo di Monza,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,3/1/2021,3/1/2022
NCT05040685,RECRUITING,Lymph Node Cancer Metastatic,PROCEDURE: Axillary mapping reverse,Hospital Universitari de Bellvitge,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,6/1/2021,12/1/2023
NCT05455385,COMPLETED,Breast Cancer,OTHER: standard 12-week rehabilitation program|OTHER: extra session hydrotherapy|OTHER: extra session ground exercises,Universitaire Ziekenhuizen KU Leuven,,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,6/5/2021,1/31/2022
NCT05816187,NOT_YET_RECRUITING,Breast Cancer|Colon Cancer,BEHAVIORAL: Education program on healthy habits|BEHAVIORAL: Habitual,Universidad Complutense de Madrid,Hospital Universitario Infanta Leonor,ALL,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,2023-06,2025-09
NCT06052085,RECRUITING,Breast Cancer,OTHER: Pain Neuroscience Education|OTHER: Biomedical Pain Education|OTHER: Standard Physiotherapy Program,Hacettepe University,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,2/15/2023,2/15/2025
NCT04580485,ACTIVE_NOT_RECRUITING,Ovarian Cancer|Bladder Cancer|Non Small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Cancer|Castration Resistant Prostate Cancer|Colorectal Cancer|Gastric/ Gastroesophageal Junction|Hepatocellular Carcinoma|Pancreatic Ductal Adenocarcinoma|Squamous Carcinoma of the Anal Canal,DRUG: INCB106385|DRUG: INCMGA00012,Incyte Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,INTERVENTIONAL,2/3/2021,1/30/2024
NCT06210438,NOT_YET_RECRUITING,TNBC|Brain Metastasis,DRUG: SHR-A1921 + Bevacizumab,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,INTERVENTIONAL,2/1/2024,6/30/2026
NCT04693338,COMPLETED,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Supportive Care,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,INTERVENTIONAL,8/20/2020,5/17/2023
NCT05832138,NOT_YET_RECRUITING,Survivorship|Cancer|Heart Diseases|Secondary Cancer|Colorectal Cancer|Breast Cancer,BEHAVIORAL: ONLOOP program,The Hospital for Sick Children,Women's College Hospital|Ottawa Hospital Research Institute,ALL,"ADULT, OLDER_ADULT",NA,900,OTHER,INTERVENTIONAL,2024-01,2027-06
NCT06226688,NOT_YET_RECRUITING,Breast Cancer Female,PROCEDURE: Biofeedback device and other group control group|PROCEDURE: Control group,Cairo University,,FEMALE,ADULT,NA,54,OTHER,INTERVENTIONAL,2/4/2024,4/4/2024
NCT05806138,RECRUITING,Breast Cancer|Cardiac Dysfunction,DRUG: Vericiguat|OTHER: Optimal medical therapy,Memorial Sloan Kettering Cancer Center,Merck Sharp & Dohme LLC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,7/17/2023,7/17/2028
NCT05045638,COMPLETED,Healthy Participants,DRUG: Rosuvastatin|DRUG: Sotorasib,Amgen,,ALL,ADULT,PHASE1,13,INDUSTRY,INTERVENTIONAL,8/20/2021,10/10/2021
NCT05526872,ACTIVE_NOT_RECRUITING,Breast Carcinoma,OTHER: Best Practice|BEHAVIORAL: Health Education|OTHER: Interview|OTHER: Planned Notification|OTHER: Survey Administration,Emory University,National Cancer Institute (NCI)|National Institutes of Health (NIH),FEMALE,"ADULT, OLDER_ADULT",NA,140,OTHER,INTERVENTIONAL,9/5/2022,3/31/2025
NCT05187338,RECRUITING,Lung Cancer|Liver Cancer|Colorectal Cancer|Pancreas Cancer|Ovary Cancer|Head and Neck Cancer|Breast Cancer|Gastric Cancer|Cervical Cancer|Esophageal Cancer|Sarcoma,DRUG: ipilimumab +pembrolizumab +durvalumab,Second Affiliated Hospital of Guangzhou Medical University,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,INTERVENTIONAL,11/1/2021,10/30/2025
NCT04224272,ACTIVE_NOT_RECRUITING,HER2+/HR+ Breast Cancer,DRUG: ZW25 (Zanidatamab)|DRUG: Palbociclib|DRUG: Fulvestrant,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,51,INDUSTRY,INTERVENTIONAL,6/10/2020,10/26/2025
NCT05658172,RECRUITING,Breast Cancer,"DIAGNOSTIC_TEST: Determination of tumormarkers (CA27.29, CEA, CA125)|DIAGNOSTIC_TEST: Determination of CTC levels|DIAGNOSTIC_TEST: Determination of ctDNA levels|OTHER: Biobanking of blood samples",Prof. Wolfgang Janni,German Federal Ministry of Education and Research,ALL,"ADULT, OLDER_ADULT",NA,3500,OTHER,INTERVENTIONAL,12/7/2022,2035-12
NCT05303038,RECRUITING,Metastatic Breast Cancer in the Liver,COMBINATION_PRODUCT: Cryoablation Combined with Tirelizumab and Bevacizumab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,5/1/2022,4/1/2024
NCT04746638,COMPLETED,Prostate Cancer|Breast Cancer Female,DIAGNOSTIC_TEST: whole body study and SPECT with 99mTc-RM26,Tomsk National Research Medical Center of the Russian Academy of Sciences,Uppsala University,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,INTERVENTIONAL,2/1/2021,6/1/2023
NCT05491694,NOT_YET_RECRUITING,Breast Cancer|TNBC - Triple-Negative Breast Cancer,DRUG: Toripalimab|DRUG: Epirubicin|PROCEDURE: High Intensity Focused Ultrasoun|DRUG: Cyclophosphamide|DRUG: Carboplatin|DRUG: Nab-paclitaxel,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,9/1/2022,12/30/2024
NCT05014295,RECRUITING,Breast Cancer|Prostate Cancer,OTHER: Accessing personal medical records online via online portals,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,4/30/2024,2025-06
NCT06253195,NOT_YET_RECRUITING,Advanced Solid Tumor|Metastatic Solid Tumor|Hormone-receptor-positive Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer,DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE1,78,INDUSTRY,INTERVENTIONAL,4/11/2024,10/26/2026
NCT06177795,ENROLLING_BY_INVITATION,Breast Cancer,BEHAVIORAL: Post-visit patient text messaging|BEHAVIORAL: Default pended order|BEHAVIORAL: High risk bidirectional post-visit text messaging,Abramson Cancer Center at Penn Medicine,National Institute on Aging (NIA)|Case Western Reserve University,FEMALE,"ADULT, OLDER_ADULT",NA,21416,OTHER,INTERVENTIONAL,12/18/2023,12/18/2024
NCT06214195,RECRUITING,Cardiotoxicity Induced by Drug Therapy for Breast Cancer,"DRUG: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)",Zhejiang Cancer Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,276,OTHER,INTERVENTIONAL,1/20/2024,12/1/2030
NCT05257395,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: XZP-3287+ Letrozole/Anastrozole|DRUG: Placebo + Letrozole/Anastrozole,"Xuanzhu Biopharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,372,INDUSTRY,INTERVENTIONAL,2022-02,2025-12
NCT05872295,RECRUITING,Breast Cancer|Gastric Cancer|Gastroesophageal-junction Cancer,DRUG: IKS014,Iksuda Therapeutics Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE1,165,INDUSTRY,INTERVENTIONAL,9/14/2023,2027-09
NCT05735795,RECRUITING,Breast Cancer,OTHER: Carbon Black Tattoo,Gaziosmanpasa Research and Education Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER_GOV,INTERVENTIONAL,2/7/2023,3/1/2024
NCT05933395,RECRUITING,Advanced Breast Cancer,DRUG: Fulvestrant|DRUG: Neratinib|DRUG: Alpelisib|DRUG: Everolimus|DRUG: Abemaciclib,Dartmouth-Hitchcock Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,135,OTHER,INTERVENTIONAL,10/10/2023,2031-10
NCT05760612,RECRUITING,Early-stage Breast Cancer|HER2-positive Breast Cancer|Adjuvant Treatment After Trastuzumab|RCB Classification 1-2|Neratini,DRUG: Trastuzumab and nelatinib|DRUG: Trastuzumab and Parstuzumab,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,INTERVENTIONAL,2/16/2023,11/1/2028
NCT05253066,NOT_YET_RECRUITING,Breast Neoplasms,DRUG: Chidamide combined with exemestane (+/- goserelin)|DRUG: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician),Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,130,OTHER,INTERVENTIONAL,2/25/2022,1/31/2025
NCT04378751,RECRUITING,High Risk for Breast Cancer,BEHAVIORAL: Decision aid video|BEHAVIORAL: Genetic counseling informational brochure,University of Illinois at Chicago,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,6/6/2023,12/31/2024
NCT04685551,WITHDRAWN,Cancer|Breast Cancer|Colon Cancer|Caregiver Burnout|Lung Cancer,"BEHAVIORAL: Change in knowledge, motivation, skills, and resources",Charles Drew University of Medicine and Science,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,7/1/2021,12/31/2024
NCT05555251,RECRUITING,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Gastric Adenocarcinoma,DRUG: BI-1607|DRUG: BI-1607|DRUG: Trastuzumab,BioInvent International AB,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,116,INDUSTRY,INTERVENTIONAL,7/28/2022,2026-12
NCT05919212,RECRUITING,Metastatic Breast Cancer,DIAGNOSTIC_TEST: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,2/1/2023,2/1/2026
NCT03940248,WITHDRAWN,Breast Cancer,RADIATION: Proton Accelerated Partial Breast Irradiation,University of Cincinnati,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,7/1/2020,7/8/2021
NCT04759248,RECRUITING,Breast Cancer,DRUG: Atezolizumab + Trastuzumab + Vinorelbine,SOLTI Breast Cancer Research Group,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,3/15/2021,2/24/2025
NCT05732051,RECRUITING,Breast Cancer|Metastatic Breast Cancer|Cancer Therapy-Related Cardiac Dysfunction|Cardiotoxicity|Heart Failure,DIETARY_SUPPLEMENT: Nicotinamide Riboside|DIETARY_SUPPLEMENT: Placebo,"University Hospital, Akershus","ChromaDex, Inc.|Norwegian Cancer Society|Norwegian Breast Cancer Association|Helse Sor-Ost",FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,3/16/2023,9/30/2035
NCT05180851,UNKNOWN,Head and Neck Cancer|Melanoma|Breast Cancer|Bladder Cancer|Ovarian Carcinoma|Cervical Carcinoma|Lung Cancer,DRUG: Recombinant L-IFN adenovirus injection,Shanghai Fengxian District Central Hospital,"Shanghai Yuansong Biotechnology Co., LTD",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,28,OTHER,INTERVENTIONAL,11/30/2021,12/31/2023
NCT04842812,RECRUITING,"Liver Cancer|Lung Cancer|Breast Cancer|Colo-rectal Cancer|Brain Tumor|Solid Tumor, Adult|PD1|CTLA4","BIOLOGICAL: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3",Second Affiliated Hospital of Guangzhou Medical University,Guangdong Zhaotai InVivo Biomedicine Co. Ltd.,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,INTERVENTIONAL,1/1/2021,1/1/2035
NCT05409248,RECRUITING,Breast Cancer|Cognitive Decline,OTHER: Personalized cognitive stimulation|OTHER: Sham cognitive stimulation,Universidad Antonio de Nebrija,Hospital de la Ribera,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,6/3/2022,2023-12
NCT05632848,RECRUITING,Triple Negative Breast Cancer,DRUG: Chidamide combined with Zimberelimab,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,47,OTHER,INTERVENTIONAL,6/15/2022,12/31/2025
NCT04936451,TERMINATED,Breast Cancer,DEVICE: TENS (transcutaneous electrical nerve stimulation)|DEVICE: TENS (transcutaneous electrical nerve stimulation) ECOMODYN,Institut Cancerologie de l'Ouest,,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,1/5/2022,4/14/2023
NCT04650451,SUSPENDED,"HER-2 Gene Amplification|HER2-positive Gastric Cancer|HER2-positive Breast Cancer|HER-2 Protein Overexpression|Solid Tumor, Adult",BIOLOGICAL: chimeric antigen receptor (CAR) T cell therapy,Bellicum Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,INTERVENTIONAL,12/7/2020,1/2/2027
NCT05277051,RECRUITING,Neoplasms,DRUG: GSK4381562|DRUG: Dostarlimab|DRUG: GSK4428859A,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE1,162,INDUSTRY,INTERVENTIONAL,3/22/2022,10/14/2026
NCT05161312,UNKNOWN,"Cancer, Breast|Quality of Life|Distress, Emotional",BEHAVIORAL: iACT-BC: Oncovox,Babes-Bolyai University,,FEMALE,"ADULT, OLDER_ADULT",NA,140,OTHER,INTERVENTIONAL,11/15/2021,2022-05
NCT04673448,RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|BRCA-Associated Malignant Neoplasm|BRCA-Associated Ovarian Carcinoma|Metastatic BRCA-Associated Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Primary Peritoneal Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Unresectable Breast Carcinoma|Unresectable Fallopian Tube Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Ovarian Carcinoma|Unresectable Pancreatic Carcinoma|Unresectable Primary Peritoneal Carcinoma,BIOLOGICAL: Dostarlimab|DRUG: Niraparib,University of Washington,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,10/18/2021,3/30/2026
NCT04509648,RECRUITING,Breast Cancer,RADIATION: External Beam radiotherapy using IMRT technique,Ruijin Hospital,,ALL,"ADULT, OLDER_ADULT",NA,197,OTHER,INTERVENTIONAL,12/1/2020,12/30/2026
NCT05228951,RECRUITING,Breast Cancer,"DRUG: Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole",Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,2/10/2022,12/31/2027
NCT05976412,RECRUITING,Breast Cancer,RADIATION: Regional lymph node radiotherapy|RADIATION: chest/whole breast irradiation,Ruijin Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,1355,OTHER,INTERVENTIONAL,7/28/2023,5/31/2031
NCT05638048,COMPLETED,Lung Cancer|Stomach Cancer|Breast Cancer|Liver Cancer|Colon Cancer|Rectal Cancer,BEHAVIORAL: Precision grip training|BEHAVIORAL: Use maximum strength grip training|BEHAVIORAL: Health education on routine grip strength training,Junyan Zhao,,ALL,ADULT,NA,270,OTHER,INTERVENTIONAL,7/10/2022,1/10/2023
NCT05677048,RECRUITING,Gynecologic Cancer|Ovary Cancer|Pancreatic Cancer|Breast Cancer|Lynch Syndrome|Hereditary Breast and Ovarian Cancer Syndrome|Colon Cancer|Endometrial Cancer|Uterus Cancer,BEHAVIORAL: Free genetic testing and counseling group|BEHAVIORAL: IGNITE-TX Group|BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,4/14/2023,10/31/2027
NCT04116151,COMPLETED,DERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH BREAST CANCER,"COMBINATION_PRODUCT: Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|COMBINATION_PRODUCT: Usual treatment",Hospital Universitario Reina Sofia de Cordoba,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,78,OTHER_GOV,INTERVENTIONAL,7/19/2022,7/30/2023
NCT05098951,UNKNOWN,"Breast Cancer|Stiffness of Hand, Not Elsewhere Classified",DEVICE: Acupuncture,Affiliated Hospital of Qinghai University,,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,10/20/2021,6/1/2023
NCT06072612,RECRUITING,Breast Cancer|Metastatic Breast Cancer|Breast Neoplasm|Breast Cancer Metastatic|End Stage Cancer,BIOLOGICAL: SV-BR-1-GM|DRUG: Cyclophosphamide|DRUG: Interferon infiltration of the inoculation site|DRUG: Retifanlimab|DRUG: Treatment of Physician's Choice,BriaCell Therapeutics Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE3,404,INDUSTRY,INTERVENTIONAL,10/20/2023,2025-12
NCT05104866,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Dato-DXd|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Eribulin|DRUG: Vinorelbine,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,732,INDUSTRY,INTERVENTIONAL,10/18/2021,8/15/2025
NCT04837248,RECRUITING,Breast Cancer,OTHER: Active Comparator: Group 1. Conventional treatment|OTHER: Experimental: Group 2. Experimental treatment.,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,8/2/2021,5/1/2024
NCT05245812,RECRUITING,Breast Cancer|High Risk of Breast Cancer,DEVICE: da Vinci SP Surgical System,"Deborah Farr, MD",,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,3/8/2022,2024-02
NCT05075512,RECRUITING,Breast Neoplasm Female,"DRUG: anlotinib, fulvestrant",Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,9/1/2021,8/31/2026
NCT04136912,RECRUITING,Breast Cancer|Thyroid Cancer,DRUG: Definity|DEVICE: Acoustic Angiography,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,INTERVENTIONAL,5/26/2022,2024-10
NCT04443348,RECRUITING,"Triple Negative Breast Cancer|Hormone Receptor Positive (HR+), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)",RADIATION: Radiation Therapy Boost|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Capecitabine,"Laura M. Spring, MD",Merck Sharp & Dohme LLC|Breast Cancer Research Foundation|Translational Breast Cancer Research Consortium,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,12/16/2020,2024-12
NCT05054751,UNKNOWN,Locally Advanced or Metastatic Breast Cancer,DRUG: GB491+ Fulvestrant|DRUG: Placebo+Fulvestrant,"Genor Biopharma Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,270,INDUSTRY,INTERVENTIONAL,9/10/2021,1/31/2024
NCT04584112,COMPLETED,Triple-Negative Breast Cancer,DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Nab-paclitaxel|DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Granulocyte colony-stimulating factor (G-CSF)|DRUG: Granulocyte-macrophage colony-stimulating factor (GM-CSF),Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE1,83,INDUSTRY,INTERVENTIONAL,9/28/2020,3/8/2023
NCT05656612,COMPLETED,Breast Cancer|Educational Problems|Bypass Complication,"OTHER: Written, Oral and Visual Education|OTHER: Written, Oral and Visual Education|OTHER: Written, Oral and Visual Education",Saglik Bilimleri Universitesi,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,8/1/2020,10/30/2020
NCT04165512,UNKNOWN,Lymphedema of Upper Limb|Breast Cancer Related Lymphedema,COMBINATION_PRODUCT: bupivacaine and triamcinolone,Marmara University,,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,INTERVENTIONAL,1/7/2020,2020-04
NCT04256512,COMPLETED,Breast Carcinoma,DEVICE: Medical Device Usage and Evaluation|OTHER: Questionnaire Administration,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,3/10/2020,1/18/2023
NCT05798312,COMPLETED,"Breast Cancer|Knowledge, Attitudes, Practice|Patient Empowerment|Patient Satisfaction",OTHER: Customizable support material|OTHER: Non-customizable support material,Medicos e Investigadores en la Lucha contra el Cancer de Mama,Roche Pharma AG,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,125,OTHER,INTERVENTIONAL,5/21/2021,3/13/2022
NCT04644848,UNKNOWN,Breast Neoplasm,DIAGNOSTIC_TEST: Ultrasonographical tattooing of suspicious axillary lymph nodes.|PROCEDURE: Sentinel lymph node biopsy|DIAGNOSTIC_TEST: Histopathological examination of the axillary nodes|PROCEDURE: Further axillary management,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,12/15/2020,2022-04
NCT04754412,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,"OTHER: Behavioral, Psychological or Informational Intervention|OTHER: Behavioral, Psychological or Informational Intervention|OTHER: Best Practice|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration",M.D. Anderson Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,7/23/2021,4/1/2026
NCT05872412,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,INTERVENTIONAL,6/1/2023,4/30/2024
NCT06065748,RECRUITING,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",DRUG: Giredestrant|DRUG: Fulvestrant|DRUG: Abemaciclib|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: LHRH Agonist|DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx),Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1050,INDUSTRY,INTERVENTIONAL,12/11/2023,12/30/2028
NCT05025748,COMPLETED,Stage II Breast Cancer|Stage III Breast Cancer|Stage IV Breast Cancer|Stage II Colorectal Cancer|Stage III Colorectal Cancer|Stage IV Colorectal Cancer|Stage II Lung Cancer|Stage III Lung Cancer|Stage IV Lung Cancer|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer|Stage II Ovarian Cancer|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Stage II Cervical Cancer|Stage III Cervical Cancer|Stage II Bladder Cancer|Stage III Bladder Cancer|Stage IV Bladder Cancer|Stage II Kidney Cancer|Stage III Kidney Cancer|Stage IV Kidney Cancer,BEHAVIORAL: Behavioral Intervention,Barbara Ann Karmanos Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,81,OTHER,INTERVENTIONAL,8/25/2021,8/31/2022
NCT05963412,COMPLETED,Breast Cancer,OTHER: Meaning Centered Coping Program,Dokuz Eylul University,,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,10/30/2021,12/30/2022
NCT05978648,RECRUITING,Breast Neoplasms,DRUG: Trilaciclib|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab,wang shusen,,ALL,"ADULT, OLDER_ADULT",PHASE2,116,OTHER,INTERVENTIONAL,9/20/2023,12/31/2027
NCT04841148,RECRUITING,Breast Cancer,DRUG: HCQ|DRUG: Avelumab|DRUG: Palbociclib,Abramson Cancer Center at Penn Medicine,Johns Hopkins University|Translational Breast Cancer Research Consortium|Pfizer|Breast Cancer Research Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,96,OTHER,INTERVENTIONAL,6/1/2021,2028-05
NCT05470348,RECRUITING,Breast Cancer|Solid Tumor,DRUG: BL-B01D1,"Sichuan Baili Pharmaceutical Co., Ltd.","SystImmune Inc.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,8/11/2022,2024-08
NCT05483712,RECRUITING,Breast Cancer,DEVICE: Brass Mesh Bolus,Nova Scotia Cancer Centre,Hannah Dahn,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/18/2023,11/21/2023
NCT06043466,RECRUITING,Colorectal Cancer|Esophagus Cancer|Gastric Cancer|Pancreas Cancer|Non-small Cell Lung Cancer|Breast Cancer|Bile Duct Cancer,BIOLOGICAL: CEA-targeted CAR-T cells,"Chongqing Precision Biotech Co., Ltd",Zhejiang University,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,8/11/2023,12/31/2027
NCT04929548,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pyrotinib Maleate Tablets,Wuhan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,1/5/2022,9/20/2027
NCT06165419,RECRUITING,Metastatic Cancer|Metastatic Lung Cancer|Metastatic Breast Cancer|Metastatic Tumor|Metastatic Tumor of Bone|Metastatic Tumor to the Spine|Spine Metastases|Metastasis,RADIATION: SBRT to the spine,Stony Brook University,The University of Texas Health Science Center at San Antonio,ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,INTERVENTIONAL,12/14/2023,5/31/2026
NCT04094519,COMPLETED,Prostate Cancer,DRUG: enzalutamide|DRUG: enzalutamide Placebo|DRUG: digoxin|DRUG: rosuvastatin,"Astellas Pharma Global Development, Inc.",Pfizer,MALE,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,1/27/2020,12/27/2020
NCT04514419,UNKNOWN,Breast Cancer,DRUG: HS627|DRUG: Pertuzumab,"BioRay Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,INTERVENTIONAL,6/30/2020,11/20/2021
NCT05743686,RECRUITING,Breast Neoplasms|Chemotherapeutic Toxicity,DEVICE: Application,Julie Lemieux,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,1/16/2023,12/31/2023
NCT04714619,TERMINATED,Advanced Breast Cancer,DRUG: CB-103,MedSIR,Cellestia Biotech AG,FEMALE,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,INTERVENTIONAL,5/6/2021,4/26/2022
NCT06053086,NOT_YET_RECRUITING,Breast Cancer,RADIATION: Treatment ETHOS radiotherapy|RADIATION: Conventional IMRT,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,2023-10,2028-10
NCT05967286,WITHDRAWN,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic HER2-Negative Breast Carcinoma|Unresectable HER2-Negative Breast Carcinoma,DRUG: Alpelisib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|PROCEDURE: Positron Emission Tomography,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,0,NIH,INTERVENTIONAL,10/23/2023,4/30/2025
NCT05134519,NOT_YET_RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC),Xijing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,11/26/2021,9/30/2025
NCT04985266,RECRUITING,ER+ Breast Cancer|HER2-negative Breast Cancer,DRUG: Palbociclib 125Mg Tab|DRUG: Fulvestrant injection|DRUG: Tamoxifen|DRUG: Letrozole|DRUG: Exemestane|DRUG: Anastrozole,Royal Marsden NHS Foundation Trust,"Pfizer|AstraZeneca|Institute of Cancer Research, United Kingdom|UNICANCER|Gustave Roussy, Cancer Campus, Grand Paris|Invitae Corporation",ALL,"ADULT, OLDER_ADULT",PHASE2,1100,OTHER,INTERVENTIONAL,3/30/2022,9/1/2030
NCT04521686,ACTIVE_NOT_RECRUITING,Cholangiocarcinoma|Chondrosarcoma|Glioma|Any Solid Tumor,DRUG: LY3410738|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab,Eli Lilly and Company,"Loxo Oncology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,200,INDUSTRY,INTERVENTIONAL,10/16/2020,2024-05
NCT06123286,NOT_YET_RECRUITING,Breast Cancer|Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)|Joint Pain,DIETARY_SUPPLEMENT: Tart Cherry|DIETARY_SUPPLEMENT: Omega 3 FA (Fish Oil),Philip Chang,The Cherry Marketing Institute,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,INTERVENTIONAL,2024-03,2026-01
NCT04622319,ACTIVE_NOT_RECRUITING,HER2-Positive Primary Breast Cancer|Residual Invasive Breast Cancer,DRUG: DS-8201a|DRUG: T-DM1,Daiichi Sankyo,AstraZeneca|NSABP Foundation Inc|German Breast Group|Spanish Breast Cancer Research Group (SOLTI),ALL,"ADULT, OLDER_ADULT",PHASE3,1600,INDUSTRY,INTERVENTIONAL,12/4/2020,12/31/2030
NCT05325866,RECRUITING,Solid Tumors,DRUG: Bemarituzumab,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,303,INDUSTRY,INTERVENTIONAL,9/23/2022,7/27/2026
NCT05900986,RECRUITING,Breast Cancer|DCIS|Invasive Duct Carcinoma of Breast,DRUG: LS301-IT 0.025 mg/kg|DRUG: LS301-IT 0.05 mg/kg|DRUG: LS301-IT 0.075 mg/kg|DRUG: LS301-IT 0.1 mg/kg,Integro Theranostics,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,INTERVENTIONAL,7/14/2023,2024-06
NCT05289466,RECRUITING,IORT-Intra-Operative Radiation Therapy,RADIATION: Intraoperative Radiotherapy|PROCEDURE: Oncoplastic partial mastectomy,Saint John's Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,12/16/2021,2026-02
NCT04906200,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Best Practice|OTHER: Internet-Based Intervention|OTHER: Survey Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),FEMALE,"CHILD, ADULT",NA,360,OTHER,INTERVENTIONAL,6/28/2021,8/31/2025
NCT04750122,RECRUITING,HER2-positive Early Breast Cancer,DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning,Peking University People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,46,OTHER,INTERVENTIONAL,3/28/2021,12/31/2026
NCT05393947,RECRUITING,Breast Cancer,OTHER: patient education,Saglik Bilimleri Universitesi,,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,7/1/2022,4/1/2023
NCT05523947,RECRUITING,HER2-Positive Solid Tumor,DRUG: YH32367,Yuhan Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,110,INDUSTRY,INTERVENTIONAL,8/26/2022,10/6/2026
NCT04334785,RECRUITING,Breast Cancer,DEVICE: cryo-ablation,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",NA,186,OTHER,INTERVENTIONAL,5/1/2020,5/1/2025
NCT03611985,WITHDRAWN,Breast Cancer,DRUG: Epidiferphane|DRUG: Taxane Chemotherapy,University of Florida,Prana Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,2020-03,2023-03
NCT04390685,UNKNOWN,Lymphedema,DRUG: Tacrolimus ointment,Odense University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,INTERVENTIONAL,2/26/2020,2022-09
NCT04261387,COMPLETED,Radiation Dermatitis,DRUG: LUT014 Gel|DRUG: Placebo for LUT014 Gel,Lutris Pharma Ltd.,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,28,INDUSTRY,INTERVENTIONAL,1/30/2021,7/15/2022
NCT04694885,RECRUITING,Breast Cancer Female|Chemotherapy Effect,BEHAVIORAL: Structured Hypnotherapy,Christian Schwegler,,FEMALE,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,7/31/2021,12/30/2024
NCT05223322,RECRUITING,Breast Cancer,BEHAVIORAL: Taking Charge during Treatment (TCT) Intervention,Medical College of Wisconsin,University of Illinois at Chicago,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,3/1/2022,7/1/2026
NCT06129747,RECRUITING,"Breast Cancer|Tumor, Breast",RADIATION: Radiation Therapy,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,INTERVENTIONAL,11/30/2023,8/9/2029
NCT06016387,RECRUITING,HER2-positive Breast Cancer|LMD,DRUG: Tucatinib 150 MG|DRUG: Trastuzumab|DRUG: Capecitabine|RADIATION: Brain & Spinal Radiation,Sunnybrook Health Sciences Centre,Seagen Inc.|Biocon Biologics,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/25/2023,10/5/2028
NCT04872985,RECRUITING,Breast Cancer|Hormone-receptor Positive Breast Cancer,DRUG: Pyrotinib|DRUG: Epirubicin|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Nab paclitaxel|DRUG: Placebo,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"Jiangsu HengRui Medicine Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,INTERVENTIONAL,4/20/2021,12/31/2028
NCT06254066,NOT_YET_RECRUITING,Female Breast Cancer Patients|Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer|HRD Positive Advanced Breast Cancer,DRUG: Adebrelimab plus Fluzoparib,Zhejiang Cancer Hospital,"Jiangsu Hengrui Pharmaceutical Co., Ltd.",FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,4/16/2024,12/31/2028
NCT05896566,RECRUITING,Breast Cancer,DRUG: Giredestrant|DRUG: Triptorelin|DRUG: Anastrozole,ETOP IBCSG Partners Foundation,Hoffmann-La Roche,FEMALE,"ADULT, OLDER_ADULT",PHASE2,220,NETWORK,INTERVENTIONAL,1/23/2024,6/1/2026
NCT05710666,RECRUITING,HER2-positive Breast Cancer,DRUG: trastuzumab deruxtecan (T-DXd) (IV),Cancer Trials Ireland,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,NETWORK,INTERVENTIONAL,10/26/2023,3/30/2028
NCT05402722,UNKNOWN,TNBC - Triple-Negative Breast Cancer,DRUG: Eribulin|DRUG: anti-PD-1 antibody,Beijing 302 Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,1/1/2022,6/30/2023
NCT05775822,COMPLETED,Breast Cancer,DIAGNOSTIC_TEST: CT scan and blood sample collection,Centro Cardiologico Monzino,Istituto Europeo di Oncologia,FEMALE,ADULT,NA,92,OTHER,INTERVENTIONAL,3/24/2022,1/31/2024
NCT06090747,RECRUITING,Breast Neoplasm,BEHAVIORAL: Hybrid lifestyle educational multidisciplinary intervention.|BEHAVIORAL: Hybrid lifestyle personalized multidisciplinary intervention.,Instituto Nacional de Cancerologia de Mexico,Anahuac University|Tecnologico de Monterrey|Instituto Nacional de Rehabilitacion|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,FEMALE,ADULT,NA,146,OTHER,INTERVENTIONAL,3/9/2023,12/31/2028
NCT05001347,COMPLETED,Ovarian Cancer|Head and Neck Cancer|Non Small Cell Lung Cancer|Gastrointestinal Cancer|Triple Negative Breast Cancer|Ovarian Carcinoma,DRUG: TJ004309,I-Mab Biopharma US Limited,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,INDUSTRY,INTERVENTIONAL,11/2/2021,2/8/2023
NCT05591547,RECRUITING,Breast Cancer,RADIATION: IMRT/VMAT-Based Accelerated Partial Breast Irradiation,Sanford Health,University of North Dakota,FEMALE,"ADULT, OLDER_ADULT",NA,91,OTHER,INTERVENTIONAL,3/1/2022,3/31/2027
NCT05853848,RECRUITING,Breast Cancer,BEHAVIORAL: Postcard|BEHAVIORAL: Letter|BEHAVIORAL: Auto-dialer|BEHAVIORAL: Live call,Geisinger Clinic,,FEMALE,"ADULT, OLDER_ADULT",NA,17650,OTHER,INTERVENTIONAL,5/10/2023,2024-06
NCT06133348,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Promoting Resilience in Stress Management Intervention,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/22/2024,2025-12
NCT05471648,COMPLETED,Breast Cancer,DRUG: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|DRUG: Perjeta (EU origin) 420 mg in 14 mL Injection|DRUG: Perjeta (US origin) 420 mg in 14 mL Injection,"EirGenix, Inc.",Sacura GmbH,MALE,ADULT,PHASE1,135,INDUSTRY,INTERVENTIONAL,5/16/2022,1/24/2023
NCT05166148,COMPLETED,Breast Cancer,OTHER: Session (a)|OTHER: Session (b)|OTHER: Session (c),Institut de cancÃ©rologie Strasbourg Europe,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,11/22/2021,4/28/2022
NCT05755048,RECRUITING,Breast Cancer,"BIOLOGICAL: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|BIOLOGICAL: Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)",Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE3,314,INDUSTRY,INTERVENTIONAL,3/28/2023,1/31/2026
NCT05774951,RECRUITING,"Breast Cancer, Early Breast Cancer",DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,4300,INDUSTRY,INTERVENTIONAL,3/31/2023,5/29/2036
NCT04478851,RECRUITING,Cancer|Head and Neck Cancer|Colon Cancer|Breast Cancer|Prostate Cancer|Cancer Caregivers,BEHAVIORAL: Group Exercise Classes,University of Calgary,"University of Alberta|Dalhousie University|Alberta Health services|University Health Network, Toronto|Memorial University of Newfoundland|University of British Columbia|University of Prince Edward Island",ALL,"ADULT, OLDER_ADULT",NA,1500,OTHER,INTERVENTIONAL,9/2/2020,12/31/2027
NCT06005025,RECRUITING,Breast Cancer|Nurse|Education|Counselling|Follow-up,OTHER: Reminder message,Tarsus University,Mersin University,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,4/1/2023,3/1/2024
NCT05444725,COMPLETED,Breast Cancer Female|Mammography Screening|Decision Making|Information Seeking Behavior,OTHER: Stage of Decision Making|OTHER: Choice framing|OTHER: Opportunity Framing,University of Aarhus,,FEMALE,ADULT,NA,3000,OTHER,INTERVENTIONAL,6/22/2022,9/5/2022
NCT06011525,RECRUITING,Chemotherapy-induced Alopecia,OTHER: standard cold cap|OTHER: scalp-cooling technique,Centre Francois Baclesse,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,8/3/2023,9/3/2026
NCT05086692,RECRUITING,"Advanced Solid Tumor|Unresectable Solid Tumor|Clear Cell Renal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer Squamous|Non-Small Cell Lung Cancer Non-squamous|Colorectal Cancer (MSI-H)|Gastric Cancer|Cervical Cancer|Basal Cell Carcinoma|Bladder Cancer|Merkel Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|Cutaneous Squamous Cell Carcinoma|Pleural Mesothelioma|Esophageal Cancer|Hepatocellular Carcinoma|Endometrial Carcinoma|Solid Tumor|Solid Tumor, Adult|MSI-H Solid Malignant Tumor|Cancer With A High Tumor Mutational Burden|Epithelial Ovarian Carcinoma|Primary Peritoneal Cancer|Gastroesophageal Junction (GEJ) Cancer|Acral Melanoma|Mucosal Melanoma|Cutaneous Melanoma|DMMR Solid Malignant Tumor|Fallopian Tube Cancer",DRUG: MDNA11|DRUG: Pembrolizumab,"Medicenna Therapeutics, Inc.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,INTERVENTIONAL,8/27/2021,12/30/2026
NCT05089292,COMPLETED,Screening Mammogram,BEHAVIORAL: Narrative breast health education,Icahn School of Medicine at Mount Sinai,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,99,OTHER,INTERVENTIONAL,7/1/2021,12/13/2022
NCT04294225,COMPLETED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,DRUG: Anastrozole|DRUG: Letrozole,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,161,OTHER,INTERVENTIONAL,4/28/2020,12/12/2022
NCT05746325,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Leptomeninges,OTHER: Digital Photography|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|DEVICE: Medical Device Usage and Evaluation,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,4/7/2023,3/1/2027
NCT04540692,RECRUITING,Breast Cancer,DRUG: Docetaxel or Paclitaxel|DRUG: Cyclophosphamide + Doxorrubicin,Latin American Cooperative Oncology Group,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,494,OTHER,INTERVENTIONAL,1/12/2021,8/23/2029
NCT05824325,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: SHR-A1811|DRUG: TROP2 ADC,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,56,OTHER,INTERVENTIONAL,3/14/2023,10/10/2026
NCT04494425,ACTIVE_NOT_RECRUITING,Advanced or Metastatic Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel,AstraZeneca,"Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo",ALL,"ADULT, OLDER_ADULT",PHASE3,866,INDUSTRY,INTERVENTIONAL,7/24/2020,6/19/2026
NCT05030792,COMPLETED,Breast Cancer Survivorship|Cancer-related Cognitive Impairment,OTHER: Attention-restorative therapy (ART)-based virtual reality (VR),University of Michigan Rogel Cancer Center,NRG Oncology,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,10/26/2021,5/16/2022
NCT05721248,RECRUITING,Breast Cancer|Metastatic Breast Cancer|HER2-positive Breast Cancer,OTHER: Cessation of anti-HER2 treatment,Dana-Farber Cancer Institute,National Cancer Institute (NCI)|Gateway for Cancer Research|Susan G. Komen Breast Cancer Foundation|Translational Breast Cancer Research Consortium|Johns Hopkins University,ALL,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,INTERVENTIONAL,4/19/2023,2036-02
NCT05325151,RECRUITING,Breast Carcinoma,OTHER: Educational Intervention|OTHER: Genetic Counseling|OTHER: Survey Administration,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),FEMALE,ADULT,NA,1000,OTHER,INTERVENTIONAL,6/13/2022,10/31/2025
NCT05113251,RECRUITING,Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer,DRUG: Trastuzumab Deruxtecan|DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: cyclophosphamide,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,INTERVENTIONAL,10/25/2021,4/30/2027
NCT05192525,UNKNOWN,Breast Cancer|Chemotherapeutic Toxicity,DEVICE: mChemotherapy,The Hong Kong Polytechnic University,Ruijin Hospital,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,6/7/2022,2/28/2023
NCT05412225,RECRUITING,Breast Cancer|Invasive Breast Cancer,DIAGNOSTIC_TEST: Pre-neoadjuvant radiotherapy (NART) biopsy|RADIATION: Neoadjuvant radiotherapy|PROCEDURE: Unilateral total mastectomy with axillary lymph node dissection,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,6/6/2022,6/6/2025
NCT06092892,NOT_YET_RECRUITING,"Breast Cancer|Axillary Nodal Disease|Female Breast Cancer|Axilla; Breast|Mastectomy; Lymphedema|Tumor, Breast",PROCEDURE: Breast Surgery (BCS or mastectomy) with TAD/SNB|RADIATION: Adjuvant Radiation Therapy,Alice Chung,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,INTERVENTIONAL,2/28/2024,2031-01
NCT05703555,NOT_YET_RECRUITING,Metastatic Lung Cancer|Metastatic Breast Cancer|Metastatic Gastric Cancer,DRUG: Tusamitamab ravtansine,Erasmus Medical Center,Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,2023-02,2025-05
NCT05760755,ENROLLING_BY_INVITATION,Breast Cancer Female,BEHAVIORAL: Stick Together,"Rigshospitalet, Denmark","Danish Committee for Health Education|TrygFonden, Denmark|Sygekassernes Helsefond|Danish Cancer Society|University Hospital, Gentofte, Copenhagen",FEMALE,ADULT,NA,50,OTHER,INTERVENTIONAL,2/1/2023,5/31/2024
NCT04273555,RECRUITING,HER2-positive Breast Cancer,DRUG: [18F]-FDG,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,3/1/2025,6/30/2028
NCT04535492,WITHDRAWN,Colorectal Cancer|Lung Cancer|Breast Cancer,BEHAVIORAL: Decision Making Support Tool,Medical University of South Carolina,National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,1/4/2022,6/30/2022
NCT05928325,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,OTHER: Comprehensive Geriatric Assessment|BEHAVIORAL: Health Education|OTHER: Medical Device Usage and Evaluation|OTHER: Supportive Care,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,OLDER_ADULT,NA,30,OTHER,INTERVENTIONAL,6/17/2021,12/31/2024
NCT04690855,TERMINATED,Breast Cancer|Triple Negative Breast Cancer,DRUG: Talazoparib|DRUG: Atezolizumab|RADIATION: Radiation,"Mylin A. Torres, MD","Genentech, Inc.|Pfizer|Emory University",ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,INTERVENTIONAL,10/4/2021,12/20/2022
NCT04626986,UNKNOWN,Breast Tumor|Microwave Ablation|Breast Conserving Surgery,PROCEDURE: microwave ablation|PROCEDURE: breast conserving surgery,Chinese PLA General Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,9/18/2020,5/30/2023
NCT05063786,RECRUITING,Advanced Breast Cancer,BIOLOGICAL: Trastuzumab|DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Vinorelbine|DRUG: Capecitabine|DRUG: Eribulin,Spanish Breast Cancer Research Group,ETOP IBCSG Partners Foundation|Breast International Group|Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,INTERVENTIONAL,9/14/2021,2026-09
NCT04188119,NOT_YET_RECRUITING,Breast Cancer,DRUG: Avelumab|DRUG: Aspirin|DRUG: Lansoprazole,The Christie NHS Foundation Trust,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,INTERVENTIONAL,12/1/2023,5/31/2025
NCT05455619,RECRUITING,HR+/HER2-negative Breast Cancer|Metastatic Breast Cancer,DRUG: Evexomostat,"SynDevRx, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,52,INDUSTRY,INTERVENTIONAL,8/26/2022,2026-09
NCT05838066,NOT_YET_RECRUITING,First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer,DRUG: KN026|DRUG: HB1801|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel,Shanghai JMT-Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,880,INDUSTRY,INTERVENTIONAL,2023-07,2027-12
NCT04234386,RECRUITING,Breast Cancer,RADIATION: GammaPod Radiation,"University of Maryland, Baltimore",,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,9/15/2021,2028-12
NCT05512286,NOT_YET_RECRUITING,Breast Cancer,RADIATION: Preoperative radiotherapy|RADIATION: Postmastectomy radiotherapy,Fudan University,Huashan Hospital|Hunan Cancer Hospital|Cancer Hospital of Guangxi Medical University|Yunnan Cancer Hospital|Zhejiang Cancer Hospital|Henan Cancer Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,9/1/2022,10/1/2027
NCT05382286,RECRUITING,Triple Negative Breast Cancer|PD-L1 Positive,DRUG: Sacituzumab Govitecan-hziy|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,Gilead Sciences,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,440,INDUSTRY,INTERVENTIONAL,7/25/2022,2027-02
NCT04262219,COMPLETED,Breast Cancer,BEHAVIORAL: iShare,Fox Chase Cancer Center,National Cancer Institute (NCI),ALL,"CHILD, ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,2/7/2020,10/12/2020
NCT04418219,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Refractory Breast Carcinoma,DRUG: Cyclophosphamide|BIOLOGICAL: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Recombinant Interferon Alpha 2b-like Protein|OTHER: Questionnaire Administration|OTHER: Quality of Life Assessment,Thomas Jefferson University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,INTERVENTIONAL,12/21/2020,1/1/2024
NCT05093387,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Carboplatin|BIOLOGICAL: Pembrolizumab|GENETIC: Transferrin Receptor-Targeted Liposomal p53 cDNA,Northwestern University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,11/10/2022,11/10/2022
NCT06024187,RECRUITING,Breast Neoplasms,PROCEDURE: Cold dissection|PROCEDURE: Electrocautery Dissection,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,INTERVENTIONAL,5/1/2022,5/31/2024
NCT04641247,ACTIVE_NOT_RECRUITING,Ovarian Neoplasms|Breast Neoplasms,DRUG: Niraparib,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,INTERVENTIONAL,4/16/2021,11/13/2025
NCT04852887,RECRUITING,Stage I Breast Cancer,"OTHER: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|DRUG: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)",NRG Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,1670,OTHER,INTERVENTIONAL,6/7/2021,2041-07
NCT05064085,ACTIVE_NOT_RECRUITING,Hormone Receptor-positive Breast Cancer,DRUG: Cemiplimab|DRUG: Capecitabine,H. Lee Moffitt Cancer Center and Research Institute,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1,13,OTHER,INTERVENTIONAL,10/12/2021,12/9/2025
NCT04298086,ACTIVE_NOT_RECRUITING,Breast Cancer|Primary Hormone Receptor Positive Breast Cancer,OTHER: Exercise Treatment|OTHER: Plant-Based Diet|OTHER: Physical activity|OTHER: Nutrition counseling|OTHER: Replication Exercise Test,Memorial Sloan Kettering Cancer Center,"American Cancer Society, Inc.|McGill University|University of Kansas Medical Center",FEMALE,"ADULT, OLDER_ADULT",PHASE2,43,OTHER,INTERVENTIONAL,3/4/2020,2025-03
NCT04957186,COMPLETED,Breast Cancer,OTHER: Collection of postoperative information|OTHER: Analysis of postoperative information collected from patients,Centre Hospitalier Universitaire de NÄ«mes,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,4/1/2021,6/30/2022
NCT05384119,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: TTI-101|DRUG: Palbociclib|DRUG: Aromatase inhibitor (AI)|DRUG: fulvestrant|DRUG: ribociclib,"Tvardi Therapeutics, Incorporated",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,INTERVENTIONAL,1/9/2023,6/28/2024
NCT05689619,RECRUITING,"Brain Metastases, Adult|Non Small Cell Lung Cancer|Breast Cancer",DIETARY_SUPPLEMENT: Silibinin|OTHER: Placebo,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,9/1/2023,9/1/2027
NCT05142787,RECRUITING,Breast Cancer,DEVICE: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics,Endomagnetics Ltd.,,ALL,"ADULT, OLDER_ADULT",NA,224,INDUSTRY,INTERVENTIONAL,3/2/2023,6/30/2025
NCT04862585,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Cimetidine|DRUG: Dexamethasone|DRUG: Diphenhydramine|DRUG: Famotidine|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|DRUG: Ranitidine,Ohio State University Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,INTERVENTIONAL,10/7/2021,12/31/2024
NCT05841186,NOT_YET_RECRUITING,Pegfilgrastim|Bone Pain|Chemotherapy|Breast Cancer|Patient-reported Outcomes,OTHER: Timing of pegfilgrastim administration,Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,84,OTHER,INTERVENTIONAL,5/1/2023,5/31/2025
NCT04232319,WITHDRAWN,Breast Cancer|Sleep Hygiene,BEHAVIORAL: Sleep Hygiene Training,University of Toledo Health Science Campus,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,1/15/2020,2020-07
NCT04973319,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,450,OTHER,INTERVENTIONAL,8/1/2021,8/1/2027
NCT04777786,TERMINATED,"Neoplasms, Breast",OTHER: Physical Therapy,University of South Carolina,Prisma Health-Midlands,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,4/1/2021,3/31/2023
NCT05426486,RECRUITING,HER2-positive Breast Cancer,DRUG: ARX788|DRUG: Pyrotinib maleate|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin,Caigang Liu,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,150,OTHER,INTERVENTIONAL,5/23/2022,12/30/2026
NCT04135586,RECRUITING,Physical Exercise,OTHER: Exercise training|OTHER: Control,Universidad Europea de Madrid,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,1/1/2020,12/1/2024
NCT05574686,RECRUITING,Hypertension|Breast Cancer,BEHAVIORAL: Telehealth Blood Pressure Monitoring and Food Insecurity,University of Mississippi Medical Center,"Cheryl Clark, MD, ScD|Saurabh Chandra, MD|Richard Summers, MD",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2/1/2023,5/31/2023
NCT05386719,RECRUITING,Breast Cancer|Early-stage Breast Cancer,OTHER: Prescreening|OTHER: Screening and Enrollment|BEHAVIORAL: Baseline|BEHAVIORAL: Interpret BMI|OTHER: Interpret HbA1c|OTHER: Interpret lipid panel and assess other risk factors|BEHAVIORAL: Assess 10 year risk of cardiovascular event|BEHAVIORAL: Recommendations|BEHAVIORAL: Follow-Up,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,ALL,"ADULT, OLDER_ADULT",NA,450,OTHER,INTERVENTIONAL,6/3/2022,6/1/2027
NCT04669119,UNKNOWN,"Breast Cancer Female|Pain, Postoperative",DIETARY_SUPPLEMENT: Bromelain/Boswellia Serrata Casperome|DIETARY_SUPPLEMENT: Centella Asiatica/Vitamins|DIETARY_SUPPLEMENT: Placebo,University of Bari Aldo Moro,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,120,OTHER,INTERVENTIONAL,12/31/2020,1/31/2022
NCT06164119,NOT_YET_RECRUITING,Breast Cancer,OTHER: manual treatment with osteopathic techniques and nutritional treatment|OTHER: manual treatment with osteopathic techniques|OTHER: nutritional treatment,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,2023-12,2025-12
NCT04972019,RECRUITING,"Cognitive Impairment, Mild",DEVICE: Telerehabilitation Experimental Group|OTHER: Telerehabilitation Sham Control Group,Bright Cloud International Corp,"National Cancer Institute (NCI)|Rutgers, The State University of New Jersey",FEMALE,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,INTERVENTIONAL,2/9/2022,9/30/2022
NCT04639986,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Sacituzumab Govitecan-hziy|DRUG: Eribulin Mesylate Injection|DRUG: Capecitabine Oral Product|DRUG: Gemcitabine Injection|DRUG: Vinorelbine injection,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,331,INDUSTRY,INTERVENTIONAL,11/23/2020,2024-03
NCT04586686,RECRUITING,Breast Cancer Female,PROCEDURE: Ovarian biopsy via laparoscopy|PROCEDURE: Transvaginal oocyte retrieval,Universitair Ziekenhuis Brussel,Hopital Antoine Beclere,FEMALE,ADULT,NA,41,OTHER,INTERVENTIONAL,11/1/2022,12/31/2024
NCT03713255,RECRUITING,Breast Cancer|Acute Pain|Anesthesia,PROCEDURE: PVB group|PROCEDURE: MTP block group|PROCEDURE: Control Group,Ottawa Hospital Research Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,1/1/2020,12/31/2023
NCT04541225,TERMINATED,"Glioma|Glioma, Malignant|Glioma, Mixed|Glial Cell Tumors|Breast Cancer|Breast Carcinoma|Cancer of Breast|Cancer of the Breast|Breast Tumor|Malignant Tumor of Breast|Advanced Breast Cancer|Advanced Breast Carcinoma|Metastatic Breast Cancer|Metastatic Breast Carcinoma|Prostate Cancer|Prostatic Cancer|Cancer of Prostate|Cancer of the Prostate|Prostate Neoplasm|Castrate Resistant Prostate Cancer|Castration-resistant Prostate Cancer|Castration Resistant Prostatic Neoplasms|Glioblastoma|Recurrent Glioblastoma",DRUG: NUV-422,Nuvation Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,74,INDUSTRY,INTERVENTIONAL,12/8/2020,8/31/2022
NCT06192225,RECRUITING,Anxiety,BEHAVIORAL: pre-trained guided slow paced breathing (~6 breaths per minute),The Netherlands Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,11/29/2023,11/2/2025
NCT04705025,TERMINATED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Lung Non-Small Cell Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8,BEHAVIORAL: Cognitive Behavior Therapy|OTHER: Interview|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Jonsson Comprehensive Cancer Center,Blue Note Therapeutics,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,4/8/2021,3/30/2023
NCT04909125,RECRUITING,Breast Cancer|Post Mastectomy,RADIATION: Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy,Royal North Shore Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,INTERVENTIONAL,6/1/2021,12/31/2027
NCT06033092,NOT_YET_RECRUITING,BRCA Mutation|PALB2 Gene Mutation|Ductal Carcinoma in Situ|Lobular Carcinoma in Situ,DRUG: Tamoxifen 10 Mg Tablet|OTHER: Intermittent caloric restriction|BEHAVIORAL: Step counter Device,European Institute of Oncology,Ente Ospedaliero Ospedali Galliera|Istituto Oncologico Veneto IRCCS|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,9/1/2023,7/31/2026
NCT04915755,ACTIVE_NOT_RECRUITING,"Neoplasms, Breast",DRUG: Niraparib|DRUG: Placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,40,INDUSTRY,INTERVENTIONAL,6/28/2021,8/28/2029
NCT05114525,COMPLETED,Breast Cancer,BEHAVIORAL: Survey questionnaire,Stanford University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,1/20/2021,10/12/2021
NCT05810025,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: RealRisks,Columbia University,National Institute on Minority Health and Health Disparities (NIMHD),FEMALE,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,2023-05,2024-07
NCT05670925,RECRUITING,Triple-Negative Breast Cancer,DRUG: Camrelizumab plus Famitinib with/without nab-Palitaxel,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,3/1/2023,9/1/2023
NCT06019325,RECRUITING,"Breast Cancer|Postoperative Pain, Acute|Postoperative Pain, Chronic|Neuropathic Pain",PROCEDURE: RIB,MuÄŸla SÄ±tkÄ± KoÃ§man University,,FEMALE,"ADULT, OLDER_ADULT",NA,254,OTHER,INTERVENTIONAL,9/7/2023,2025-01
NCT04764292,ACTIVE_NOT_RECRUITING,Breast Cancer,DEVICE: Contrast-enhanced mammography|DRUG: Iodinated Contrast Media (ICM),Wendie Berg,PA Breast Cancer Coalition,FEMALE,"ADULT, OLDER_ADULT",PHASE4,600,OTHER,INTERVENTIONAL,2/15/2021,1/31/2024
NCT06255392,NOT_YET_RECRUITING,Breast Cancer,DRUG: Fluzoparib|DRUG: Apatinib Mesylate|DRUG: Capecitabine tablets|DRUG: Vinorelbine Tartrate Oral|DRUG: Eribulin mesylate injection|DRUG: Gemcitabine Hydrochloride|DRUG: Paclitaxel-albumin,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,INTERVENTIONAL,2024-02,2031-03
NCT05802225,RECRUITING,Breast Cancer,DRUG: BCD-178|DRUG: Perjeta,Biocad,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,374,INDUSTRY,INTERVENTIONAL,1/30/2023,1/31/2026
NCT04638712,COMPLETED,Breast Cancer,"OTHER: Microbiopsy sample|OTHER: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level",Institut de cancÃ©rologie Strasbourg Europe,"UR 3072 - Mitochondries, Stress oxydant, Protection musculaire",FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,9/16/2020,5/20/2021
NCT05414812,RECRUITING,Breast Cancer|Fertility|Contraception|Menopausal Symptoms,BEHAVIORAL: Multi-component oncofertility care intervention,"University of California, San Diego",Cancer Resource Center of the Desert|El Centro Regional Medical Center|Pioneers Memorial Healthcare District,FEMALE,ADULT,NA,135,OTHER,INTERVENTIONAL,10/15/2021,4/30/2024
NCT06256055,RECRUITING,Malignant Mesothelioma|Colorectal Cancer|Bile Duct Cancer|Rectal Cancer|Ovary Cancer|Pancreatic Cancer|Breast Cancer Female,BIOLOGICAL: UCMYM802 Injection,UTC Therapeutics Inc.,Peking University Cancer Hospital & Institute,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,1/1/2024,2025-04
NCT04330625,TERMINATED,Hyperglycemia Drug Induced,BIOLOGICAL: REMD-477,Duke University,,ALL,"ADULT, OLDER_ADULT",PHASE1,1,OTHER,INTERVENTIONAL,11/13/2020,5/5/2021
NCT04899492,RECRUITING,Breast Cancer|Gynecologic Cancer|Digestive Cancer|Melanoma,BEHAVIORAL: Motivational Interviewing (MI)|BEHAVIORAL: Cognitive Behavioural Therapy (CBT)|BEHAVIORAL: Hypnotherapy|DRUG: Nicotine Replacement Therapy (NRT),Institut Cancerologie de l'Ouest,"National Cancer Institute, France",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,9/29/2021,2023-09
NCT04363892,UNKNOWN,Breast Cancer,OTHER: Optical and infrared imaging,Nova Scotia Health Authority,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,7/1/2020,2022-12
NCT05989022,RECRUITING,Breast Cancer Diagnosis,DIAGNOSTIC_TEST: Injection of contrast enhancing agent Gadovist for MRI investigation|DIAGNOSTIC_TEST: Injection of contrast enhancing agent Imeron for B-CT investigation,AB-CT - Advanced Breast-CT GmbH,CRO Dr. med. Kottmann GmbH,FEMALE,"ADULT, OLDER_ADULT",NA,428,INDUSTRY,INTERVENTIONAL,11/24/2023,2024-12
NCT04292847,SUSPENDED,Breast Cancer,OTHER: Referrals Recommendations,UNC Lineberger Comprehensive Cancer Center,Breast Cancer Research Foundation,FEMALE,OLDER_ADULT,NA,100,OTHER,INTERVENTIONAL,3/12/2020,6/15/2026
NCT05985187,ACTIVE_NOT_RECRUITING,HER2-positive Breast Cancer,DRUG: TQB2440 injection + Trastuzumab + Docetaxel|DRUG: Perjeta + Trastuzumab + Docetaxel,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,412,INDUSTRY,INTERVENTIONAL,10/20/2020,2023-12
NCT03730922,RECRUITING,Breast Neoplasm Female|Complication of Radiation Therapy|Breast Implant; Complications,PROCEDURE: Delayed-immediate reconstruction|PROCEDURE: Delayed reconstruction,Danish Breast Cancer Cooperative Group,,FEMALE,"ADULT, OLDER_ADULT",NA,590,OTHER,INTERVENTIONAL,1/1/2020,2035-11
NCT06002022,NOT_YET_RECRUITING,Breast Cancer|Quality of Life|Physical Activity|Sleep Quality|Stress|Pain,DEVICE: REBECCA system (smartwatch + mobile app use),FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,INTERVENTIONAL,9/1/2023,12/31/2025
NCT05185947,RECRUITING,Gynecologic Cancer|Gynecologic Neoplasms|Peritoneal Carcinomatosis|Peritoneal Neoplasms|Ovarian Cancer|Ovarian Neoplasms|Colorectal Cancer|Colorectal Neoplasms|Appendiceal Cancer|Appendiceal Neoplasms,DRUG: Paclitaxel|DRUG: Nilotinib,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,INTERVENTIONAL,10/13/2022,12/30/2031
NCT04570722,COMPLETED,Breast Cancer|Melanoma|Thoracic Cancer|Lymphedema of Upper Arm,OTHER: Ipsilateral peripheral IV insertion,Duke University,,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,INTERVENTIONAL,9/20/2021,1/9/2023
NCT04461847,UNKNOWN,Endoscopic Subcutaneous Mastectomy,PROCEDURE: subcutaneous mastectomy|PROCEDURE: endoscopic subcutaneous mastectomy,Beijing Friendship Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,287,OTHER,INTERVENTIONAL,12/1/2020,12/31/2022
NCT06158347,RECRUITING,Breast Cancer|Radiation Dermatitis,DEVICE: hyperbaric oxygen chamber,Ilsan Cha hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,11/6/2023,12/31/2024
NCT05635487,RECRUITING,HER2-positive Breast Cancer,DRUG: SHR-A1811|DRUG: Pyrotinib,Shengjing Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,INTERVENTIONAL,3/16/2023,2/28/2029
NCT05558722,RECRUITING,Breast Cancer Stage II,DRUG: Anlotinib,Xijing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/30/2022,7/30/2025
NCT04249622,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Best Practice|OTHER: Questionnaire Administration|DRUG: Rifaximin,Mayo Clinic,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,9/18/2020,12/1/2024
NCT06223022,RECRUITING,Breast Cancer|Colorectal Cancer|Prostate Cancer,BEHAVIORAL: Proactive nurse-led telephone follow-up,UmeÃ¥ University,,ALL,"ADULT, OLDER_ADULT",NA,512,OTHER,INTERVENTIONAL,1/20/2024,2025-12
NCT05371847,RECRUITING,Breast Cancer,OTHER: assessment for upper limb dysfunction|OTHER: retest assessment,KU Leuven,Universitaire Ziekenhuizen KU Leuven|Vrije Universiteit Brussel,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,4/26/2022,2025-02
NCT04265547,UNKNOWN,Breast Cancer Risk,BEHAVIORAL: Breast Cancer Risk Reduction Household Intervention,Columbia University,"National Institute of Environmental Health Sciences (NIEHS)|National Cancer Institute (NCI)|University of Wisconsin, Madison",FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,1/25/2020,1/25/2021
NCT05377047,RECRUITING,Breast Cancer Stage IV|Oligometastatic Disease,RADIATION: SABR,Vastra Gotaland Region,"Sahlgrenska University Hospital, Sweden|Azienda Ospedaliero-Universitaria Careggi|Region Ã–rebro County|Skane University Hospital|Uppsala University Hospital|Karolinska University Hospital|University Hospital, UmeÃ¥|Sundsvall Hospital|Karlstad Central Hospital|GÃ¤vle Hospital|Centrallasarettet VÃ¤sterÃ¥s|Oslo University Hospital|St. Olavs Hospital|Haukeland University Hospital|University of Stavanger|University Hospital of North Norway",ALL,"ADULT, OLDER_ADULT",NA,345,OTHER_GOV,INTERVENTIONAL,9/19/2022,12/31/2027
NCT06152822,RECRUITING,Breast Cancer With Brain Metastases,DRUG: pyrotinib+capecitabine+bevacizumab,Tongji Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/30/2023,11/30/2025
NCT04634747,NOT_YET_RECRUITING,Metastatic Triple-Negative Breast Carcinoma,DRUG: PVX-410,"OncoPep, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,53,INDUSTRY,INTERVENTIONAL,4/30/2022,4/1/2025
NCT04035447,ACTIVE_NOT_RECRUITING,Cancer|Young Adult|Pain|Psychological Distress|Fatigue|Breast Cancer|Melanoma|Hematologic Cancer|Germ Cell Tumor|Endocrine Cancer,BEHAVIORAL: Behavioral Symptom Management for Young Adult Cancer Survivors,Duke University,National Cancer Institute (NCI),ALL,ADULT,NA,120,OTHER,INTERVENTIONAL,1/22/2020,5/30/2024
NCT04606147,COMPLETED,Breast Cancer|Postoperative Pain,PROCEDURE: Serratus Anterior Plane Block|PROCEDURE: Erector spinae plane block,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/10/2020,5/20/2020
NCT05890287,RECRUITING,HR Positive HER2 Negative Advanced Breast Cancer,DRUG: Chidamide,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,5/16/2023,10/1/2026
NCT04102722,UNKNOWN,Breast Cancer Screening,DEVICE: MUST device,"Transonic Imaging, Inc.",,FEMALE,"ADULT, OLDER_ADULT",NA,1333,INDUSTRY,INTERVENTIONAL,1/14/2020,2021-11
NCT04158947,RECRUITING,HER2-positive Breast Cancer|Brain Metastases,DRUG: Afatinib|DRUG: T-DM1,xuexin he,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,INTERVENTIONAL,5/10/2020,3/31/2024
NCT04348747,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,BIOLOGICAL: Anti-HER2/HER3 Dendritic Cell Vaccine|BIOLOGICAL: Pembrolizumab,Roswell Park Cancer Institute,United States Department of Defense,FEMALE,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,INTERVENTIONAL,12/19/2022,12/15/2026
NCT05078047,RECRUITING,Lung Cancer Metastatic|Renal Cell Carcinoma|Head and Neck Cancer|Bladder Cancer|Triple Negative Breast Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|Melanoma,DRUG: Reduced dose intensity of IO,UNICANCER,,ALL,"ADULT, OLDER_ADULT",PHASE3,646,OTHER,INTERVENTIONAL,3/8/2022,3/7/2025
NCT04171700,TERMINATED,Solid Tumor,DRUG: Rucaparib,pharmaand GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE2,83,INDUSTRY,INTERVENTIONAL,1/16/2020,7/15/2022
NCT04205786,SUSPENDED,HR-positive Breast Cancer,DIETARY_SUPPLEMENT: Vitamin B12|OTHER: Blood collection|OTHER: Brief Pain Inventory - Short Form survey|OTHER: FACT-ES Trial Outcome Index (Version 4)|OTHER: Questionnaire to Assess Adherence to Aromatase Inhibitors|OTHER: Demographics Questionnaire,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,8/12/2021,6/1/2025
NCT05756166,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Celecoxib|PROCEDURE: Computed Tomography|BIOLOGICAL: Interferon Alpha-2|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Rintatolimod,Roswell Park Cancer Institute,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,OTHER,INTERVENTIONAL,2/28/2024,12/30/2025
NCT04736186,UNKNOWN,Breast Cancer,DRUG: Loperamide|DRUG: Loperamide and golden bifid|DRUG: Loperamide and montmorillonite powder,Tianjin Medical University Cancer Institute and Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,470,OTHER,INTERVENTIONAL,5/16/2020,4/30/2023
NCT04852419,COMPLETED,Breast Neoplasms,DRUG: ZN-c5,Zentera Therapeutics HK Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,5/31/2021,6/23/2022
NCT04397419,COMPLETED,Breast Cancer,DIETARY_SUPPLEMENT: Red Bull Energy Drink|OTHER: Still water,Plastic Surgery Group AG by Prof. Jian Farhadi,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,5/11/2020,1/1/2023
NCT04665986,UNKNOWN,Breast Cancer,DRUG: Navelbine|DRUG: Docetaxel,Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,INTERVENTIONAL,3/1/2021,2/28/2023
NCT04726319,ACTIVE_NOT_RECRUITING,"Cancer, Breast|Cancer, Ovarian|Cancer, Colorectal|Cancer, Prostate|Melanoma|Coronary Artery Disease|Diabetes Mellitus, Type 2",OTHER: FHAMe Intervention,University of Toronto,,ALL,"ADULT, OLDER_ADULT",NA,627,OTHER,INTERVENTIONAL,9/20/2021,2024-12
NCT04147819,COMPLETED,Cancers With HER2 Expression,DRUG: BAY2701439|DRUG: BAY2701439,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,INTERVENTIONAL,7/2/2020,9/26/2023
NCT05037019,WITHDRAWN,Breast Cancer,PROCEDURE: Radiation therapy,Lawson Health Research Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2020-05,2022-11
NCT04673019,COMPLETED,Metastatic Breast Cancer,BEHAVIORAL: Nurse AMIE (Addressing Metastatic Individuals Every day),Milton S. Hershey Medical Center,Penn State University|American Institute for Cancer Research,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,2/2/2021,2/28/2022
NCT05113966,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer,DRUG: Trilaciclib|DRUG: Sacituzumab Govitecan-hziy,"G1 Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,INTERVENTIONAL,11/22/2021,2024-07
NCT04262466,RECRUITING,Select Advanced Solid Tumors,DRUG: IMC-F106C|DRUG: IMC-F106C and atezolizumab and pembrolizumab|DRUG: IMC-F106C and chemotherapy|DRUG: IMC-F106C and tebentafusp,Immunocore Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,170,INDUSTRY,INTERVENTIONAL,2/25/2020,2026-02
NCT05485766,RECRUITING,Triple Negative Breast Neoplasms|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|BRCA Mutation|BRCA-Associated Breast Carcinoma,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Olaparib|PROCEDURE: Definitive Surgery,Okayama University,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,INTERVENTIONAL,2/29/2024,9/30/2027
NCT05882019,NOT_YET_RECRUITING,Breast Cancer,DEVICE: Breast Exam with Bexa,"Sure, Inc.",MaineHealth,FEMALE,"ADULT, OLDER_ADULT",NA,700,INDUSTRY,INTERVENTIONAL,2023-05,2023-12
NCT05774886,WITHDRAWN,Triple Negative Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer|Early Stage Triple-Negative Breast Carcinoma|Breast Neoplasms|Breast Carcinoma,COMBINATION_PRODUCT: Implantable Microdevice (IMD),Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,2023-05,9/1/2028
NCT04038619,RECRUITING,Colitis|Diarrhea|Malignant Genitourinary System Neoplasm|Melanoma|Lung Cancer|Ovarian Cancer|Uterine Cancer|Breast Cancer|Cervical Cancer,PROCEDURE: Fecal Microbiota Transplantation|DRUG: Loperamide,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,INTERVENTIONAL,2/1/2021,4/30/2025
NCT04926766,RECRUITING,Breast Cancer,RADIATION: External Beam radiotherapy using IMRT technique,Ruijin Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,217,OTHER,INTERVENTIONAL,1/23/2021,12/10/2026
NCT06107686,RECRUITING,NSCLC|Breast Cancer|HNSCC|Locally Advanced or Metastatic Solid Tumors,DRUG: YL202 should be intravenously infused,"MediLink Therapeutics (Suzhou) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INDUSTRY,INTERVENTIONAL,12/15/2023,2028-11
NCT06152419,RECRUITING,"Cancer, Breast|Cancer, Lung|Cancer Prostate|Cancer Head Neck|Cancer, Gastrointestinal",DEVICE: Questionnaire,"University Hospital, Ghent",Stichting tegen Kanker,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,10/17/2023,12/31/2024
NCT05700019,COMPLETED,Breast Cancer|Cancer,BEHAVIORAL: Pinkwashed Advertisements|BEHAVIORAL: Control - Standard Advertisements,"University of North Carolina, Chapel Hill",,ALL,"ADULT, OLDER_ADULT",NA,602,OTHER,INTERVENTIONAL,1/11/2023,1/19/2023
NCT05938686,RECRUITING,Breast Cancer|Quality of Life,OTHER: Home_Based Digital Mindful Dance Program,National Yang Ming University,,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,INTERVENTIONAL,7/1/2023,12/30/2024
NCT05698186,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Thero2-01S22|DRUG: Placebo|DRUG: Thero2-01S22|DRUG: Placebo,Institut de cancÃ©rologie Strasbourg Europe,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,320,OTHER,INTERVENTIONAL,5/15/2023,5/15/2027
NCT06001086,RECRUITING,Breast Cancer,"DRUG: Disitamb Vedotin ,pyrotinib",The First Affiliated Hospital with Nanjing Medical University,First Affiliated Hospital of Wenzhou Medical University,ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,INTERVENTIONAL,11/1/2023,12/31/2026
NCT04480619,NOT_YET_RECRUITING,Diagnosis and Clinical Management of Angiogenic Breast Cancer,DIAGNOSTIC_TEST: Ga-68-PEG-Î‘vÎ²3-IAC PET/CT,"Advanced Imaging Projects, LLC","All India Institute of Medical Sciences, New Delhi|Post Graduate Institute of Medical Education and Research|University of Witwatersrand, South Africa|US Department of Veterans Affairs",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,INTERVENTIONAL,8/30/2022,8/30/2024
NCT04639219,ACTIVE_NOT_RECRUITING,"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",DRUG: Trastuzumab deruxtecan,AstraZeneca,"Daiichi Sankyo Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,102,INDUSTRY,INTERVENTIONAL,12/30/2020,7/14/2026
NCT06115486,RECRUITING,Breast Cancer|Breast Carcinoma in Situ|Breast Cancer Female,OTHER: Control Arm ACSM Guidelines|OTHER: Experimental Arm 6-12-25 repetitions per set,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,1/9/2024,2027-01
NCT05501886,RECRUITING,Breast Cancer,DRUG: Gedatolisib|DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Alpelisib,Celcuity Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,701,INDUSTRY,INTERVENTIONAL,9/30/2022,9/30/2026
NCT05424666,RECRUITING,"Cancer, Breast",PROCEDURE: Harvesting method and Fat graft preparation method,Assiut University,,FEMALE,ADULT,NA,20,OTHER,INTERVENTIONAL,12/19/2022,9/1/2024
NCT04522648,RECRUITING,Breast Cancer,OTHER: Prospective surveillance,"Rigshospitalet, Denmark",Aarhus University Hospital|Odense University Hospital|Zealand University Hospital|Herlev Hospital,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,1/4/2021,2026-12
NCT04586751,COMPLETED,"Pain Syndrome|Pain, Postoperative|Chronic Pain|Breast Cancer|Breast Soft Tissue Neoplasm|Breast Neoplasms|Breast Cancer Female|Breast Pain|Anesthesia",OTHER: Pecs block|OTHER: no Pecs block,Aretaieion University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,8/1/2020,3/31/2022
NCT05504148,RECRUITING,Breast Cancer,DRUG: crocin|DRUG: Placebo,Qilu Hospital of Shandong University,,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,3/29/2021,9/25/2023
NCT05417451,RECRUITING,Breast Cancer,OTHER: Acupuncture,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,11/1/2021,5/31/2025
NCT04101851,RECRUITING,Breast Cancer Female|Breast Cancer,PROCEDURE: omission of SLNB,"Toralf Reimer, MD PhD","European Breast Cancer Reseach Association of Surgical Trialists|University Medicine Rostock, Rostock, Germany (sponsor)|Else KrÃ¶ner-Fresenius-Stiftung (funding)|German Society of Senology (funding)",FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,1/13/2021,2028-01
NCT05274451,RECRUITING,"Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Non-small Cell Lung Cancer|Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Advanced Breast Cancer|Advanced Lung Carcinoma|NSCLC|NSCLC, Recurrent|NSCLC Stage IV|Relapsed Cancer|Relapse/Recurrence|Recurrent Breast Cancer|Recurrent NSCLC",BIOLOGICAL: LYL797,"Lyell Immunopharma, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,INTERVENTIONAL,3/29/2022,2026-09
NCT06137651,NOT_YET_RECRUITING,Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Leptomeninges,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|RADIATION: Radiation Therapy|PROCEDURE: Resection|DRUG: Trotabresib|DRUG: Vinorelbine,Northwestern University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,34,OTHER,INTERVENTIONAL,12/31/2023,12/31/2031
NCT05765851,RECRUITING,Advanced Solid Tumor|Breast Cancer,DRUG: DS-1103a|DRUG: T-DXd,Daiichi Sankyo,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE1,78,INDUSTRY,INTERVENTIONAL,5/30/2023,6/30/2026
NCT06198751,NOT_YET_RECRUITING,Breast Cancer,DRUG: 6.0 mg/kg of TQB2102 for injection|DRUG: 7.5 mg/kg of TQB2102 for injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,104,INDUSTRY,INTERVENTIONAL,2024-02,2026-02
NCT05263648,WITHDRAWN,Breast Cancer|Head and Neck Cancer,OTHER: Virtual Reality Session,University of Oklahoma,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2023-09,2025-09
NCT05047848,UNKNOWN,Advanced Breast Cancer,DRUG: Chidamide|DRUG: Fulvestrant,Liaoning Tumor Hospital & Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,INTERVENTIONAL,8/18/2021,9/18/2023
NCT06162351,NOT_YET_RECRUITING,Breast|Cancer,DRUG: PLX038,Institut Curie,ProLynx LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,INTERVENTIONAL,2/13/2024,2/15/2026
NCT05097248,NOT_YET_RECRUITING,Breast Cancer,DRUG: Camrelizumab|DRUG: Liposomal Doxorubicin|DRUG: Losartan,"Wuhan Union Hospital, China","Jiangsu HengRui Medicine Co., Ltd.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,INTERVENTIONAL,2021-10,2024-10
NCT04975451,NOT_YET_RECRUITING,Breast Cancer,DRUG: Anlotinib,Anqin Zhang,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,10/1/2021,5/1/2024
NCT04616248,RECRUITING,"Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Unresectable Breast Carcinoma|Metastatic Melanoma|Unresectable Melanoma|Cutaneous Squamous Cell Carcinoma|Merkel Cell Carcinoma|Soft Tissue Sarcoma|Bone Sarcoma|Sarcoma,Soft Tissue|Sarcoma of Bone",BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140|DRUG: Poly ICLC|RADIATION: Radiation Therapy|BIOLOGICAL: Recombinant Flt3 Ligand,University of Southern California,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,INTERVENTIONAL,1/9/2023,1/9/2026
NCT05041751,WITHDRAWN,Breast Carcinoma,PROCEDURE: Acupuncture Point Injection|PROCEDURE: Massage Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,3/23/2022,3/23/2022
NCT04571437,UNKNOWN,Breast Cancer|Estrogen Receptor-positive Breast Cancer|Metastatic Breast Cancer,DRUG: Capecitabine|DRUG: Letrozole 2.5mg,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,204,OTHER,INTERVENTIONAL,3/1/2020,4/30/2022
NCT05207514,NOT_YET_RECRUITING,Breast Cancer,DRUG: Nanoxel M|DRUG: Taxotere|DRUG: Doxorubicin|DRUG: Cyclophosphamide,Samyang Biopharmaceuticals Corporation,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,320,INDUSTRY,INTERVENTIONAL,2/1/2022,2024-12
NCT04993014,RECRUITING,Breast Neoplasms|HER2-positive Breast Cancer|Circulating Tumor Cell,DRUG: Pertuzumab|DRUG: Trastuzumab|OTHER: Circulating tumor cells,AC Camargo Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,3/1/2021,4/30/2028
NCT06260033,NOT_YET_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor-Positive Breast Carcinoma|Metastatic Breast Carcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: F-18 16 Alpha-Fluoroestradiol|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|RADIATION: Stereotactic Body Radiation Therapy,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,18,OTHER,INTERVENTIONAL,6/11/2024,12/11/2025
NCT06087237,RECRUITING,Post-Surgical Complication|Breast Cancer Surgery,DRUG: Pentoxifylline|DRUG: Placebo,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,10/30/2023,6/30/2024
NCT05786014,RECRUITING,Breast Cancer|Cardiotoxicity|Cardiovascular Diseases,BEHAVIORAL: High Intensity Interval Exercise|BEHAVIORAL: Moderate Intensity Walking,University of Virginia,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,4/1/2023,3/15/2025
NCT05216900,RECRUITING,Breast Cancer,RADIATION: Neoadjuvant radiotherapy,UMC Utrecht,"Alexander Monro Hospital, Bilthoven|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,4/1/2023,3/1/2024
NCT05556200,RECRUITING,Breast Cancer|Triple-Negative Breast Cancer,DRUG: Anti-PD-1 monoclonal antibody|DRUG: VEGFR2 Tyrosine Kinase Inhibitor,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,INTERVENTIONAL,12/1/2022,9/1/2025
NCT04076033,COMPLETED,Breast Cancer,OTHER: functional compressive bandage,Elaine Caldeira de Oliveira Guirro,,FEMALE,"ADULT, OLDER_ADULT",NA,23,OTHER,INTERVENTIONAL,1/1/2020,12/30/2021
NCT05181033,RECRUITING,Breast Cancer,DRUG: Lenvatinib + Letrozole|DRUG: Fulvestrant,"National University Hospital, Singapore","Eisai Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,12/27/2021,2025-08
NCT05169437,ACTIVE_NOT_RECRUITING,"Solid Tumor|Breast Tumor|Colon Tumor, Malignant|Lung Tumor|Urologic Cancer|Pancreatic Cancer|Melanoma|Metastatic Cancer|Locally Advanced Solid Tumor|Esophageal Cancer|Endometrial Cancer|Head and Neck Cancer",DRUG: Niraparib,Tempus AI,GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE2,22,INDUSTRY,INTERVENTIONAL,3/15/2022,1/1/2025
NCT04541537,COMPLETED,Breast Cancer|Surgery,DIAGNOSTIC_TEST: SorbstarÂ®|DIAGNOSTIC_TEST: Dog Detection,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,1/25/2021,12/20/2021
NCT06022900,COMPLETED,Breast Cancer,BEHAVIORAL: Online training group|BEHAVIORAL: Face-to-face training group,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,3/9/2023,5/26/2023
NCT05762900,RECRUITING,Breast Cancer|Radiotherapy Side Effect,RADIATION: Ultra-fractionated radiation therapy,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,INTERVENTIONAL,10/25/2022,10/25/2030
NCT05528133,RECRUITING,Triple Negative Breast Cancer,RADIATION: Genomically Guided Radiation Therapy|RADIATION: Genomically Guided Radiation Therapy,H. Lee Moffitt Cancer Center and Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,INTERVENTIONAL,11/4/2022,11/1/2026
NCT05723237,ACTIVE_NOT_RECRUITING,Women's Health: Neoplasm of Breast,OTHER: Breast Cancer Education,Istanbul AydÄ±n University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/15/2023,12/30/2023
NCT05827614,RECRUITING,Non-small Cell Lung Cancer|Non-Small Cell Lung Adenocarcinoma|Non-Small Cell Squamous Lung Cancer|Head and Neck Squamous Cell Carcinoma|Esophageal Cancer|Gastric Cancer|Breast Cancer|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Liposarcoma,DRUG: BBI-355,Boundless Bio,,ALL,"ADULT, OLDER_ADULT",PHASE1,47,INDUSTRY,INTERVENTIONAL,3/24/2023,1/31/2026
NCT06234137,RECRUITING,Breast Neoplasm Female,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Inetetamab|DRUG: Pyrotinib,Wang Ouchen,,FEMALE,"ADULT, OLDER_ADULT",NA,154,OTHER,INTERVENTIONAL,11/27/2021,8/1/2031
NCT05052437,COMPLETED,Advanced and Metastatic Breast Cancer,DRUG: Utidelone Injection; capecitabine|DRUG: Utidelone,"Beijing Biostar Pharmaceuticals Co., Ltd.",Chengdu Biostar Pharmaceuticals,FEMALE,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,INTERVENTIONAL,10/15/2020,2/19/2021
NCT06056414,NOT_YET_RECRUITING,Breast Neoplasm,OTHER: Energy Resonance by Cutaneous Stimulation,Centre Henri Becquerel,,ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,10/2/2023,10/9/2023
NCT05191914,UNKNOWN,Breast Cancer,DRUG: Chidamide+ Fulvestrant,Liaoning Tumor Hospital & Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,2/7/2022,12/30/2022
NCT05021900,COMPLETED,Locally Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: Tenalisib|DRUG: Tenalisib,Rhizen Pharmaceuticals SA,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,INTERVENTIONAL,10/13/2021,3/31/2023
NCT06186700,NOT_YET_RECRUITING,Breast Cancer Female,DRUG: Pentoxifylline|DRUG: Placebo,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,12/25/2023,4/5/2024
NCT04398914,ACTIVE_NOT_RECRUITING,Breast Cancer Invasive,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab-paclitaxel|DRUG: EC chemotherapy|DRUG: Physician's choice|DRUG: T-DM1|PROCEDURE: Surgery,Shanghai Jiao Tong University School of Medicine,"Jiangsu HengRui Medicine Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,216,OTHER,INTERVENTIONAL,5/30/2020,12/30/2027
NCT05361837,RECRUITING,Analgesia,PROCEDURE: Single level serratus anterior plane block|PROCEDURE: Single level serratus anterior plane block with dexmedetomidine|PROCEDURE: Bilevel serratus anterior plane block|PROCEDURE: Bilevel serratus anterior plane block with dexmedetomidine,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,172,OTHER,INTERVENTIONAL,5/10/2022,4/25/2024
NCT05286437,RECRUITING,Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer,DRUG: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole,"National Cancer Centre, Singapore",MSD Pharma (Singapore) Pte Ltd,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,2/15/2023,12/31/2026
NCT04627714,UNKNOWN,Breast Neoplasms,OTHER: Adapted Physical Activity,"Central Hospital, Nancy, France",,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,11/10/2021,2022-11
NCT05984914,RECRUITING,"Stress|Breast Cancer|Telomere Length, Mean Leukocyte",BEHAVIORAL: PSAI|BEHAVIORAL: One day seminar,Maria Charalampopoulou,Hippocration General Hospital|Saint Savvas Anticancer Hospital|Hellenic Anticancer Institute,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/4/2021,2024-01
NCT06220214,NOT_YET_RECRUITING,"Breast Cancer|Locally Advanced Breast Cancer|Neoadjuvant Chemotherapy|HER2-positive Breast Cancer|Triple Negative Breast Cancer|TNBC, Triple Negative Breast Cancer",DIAGNOSTIC_TEST: CEDM|DIAGNOSTIC_TEST: CDBT,Alison Stopeck,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2024-01,2026-08
NCT06212414,RECRUITING,Breast Cancer Female,BEHAVIORAL: Mind Programme|BEHAVIORAL: Support Group,University of Coimbra,FundaÃ§Ã£o para a CiÃªncia e a Tecnologia,FEMALE,"ADULT, OLDER_ADULT",NA,153,OTHER,INTERVENTIONAL,10/1/2023,2025-12
NCT04824014,RECRUITING,ER+ Breast Cancer,DIAGNOSTIC_TEST: 4FMFES-PET,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Canadian Cancer Society (CCS)|UniversitÃ© de Sherbrooke,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,INTERVENTIONAL,11/1/2020,12/31/2025
NCT04385433,TERMINATED,Breast Cancer,DRUG: EXPERIMENTAL ARM|OTHER: CONTROL GROUP|RADIATION: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions),Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,15,OTHER,INTERVENTIONAL,12/4/2020,4/27/2023
NCT06206837,NOT_YET_RECRUITING,Breast Cancer,DRUG: vepdegestrant|DRUG: PF-07220060,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,INTERVENTIONAL,2/29/2024,11/17/2026
NCT05981014,RECRUITING,Breast Neoplasms,PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|DRUG: Nab-paclitaxel,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,196,OTHER,INTERVENTIONAL,8/1/2023,5/31/2035
NCT06161233,RECRUITING,Renal Cell Carcinoma Metastatic|Breast Cancer|Head and Neck Cancer|Thyroid Cancer|Ovary Cancer|Lung Cancer|Stomach Cancer,DEVICE: CAPABLE cohort,Istituti Clinici Scientifici Maugeri SpA,University of Pavia|Policlinico di Bari Ospedale Giovanni Paolo XXIII|Biomeris srl|The Netherlands Cancer Institute NKI|University of Haifa|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|IBM Research|Bitsens JSC|PoznaÅ„ University of Technology|Deontics LTD|Associazione Italiana Malati di Cancro AIMAC|Universidad Politecnica de Madrid,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,5/16/2023,1/31/2024
NCT04480437,COMPLETED,Breast Cancer,DEVICE: mp-BUS data collection,Swiss Federal Institute of Technology,Kantonsspital Baden,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/15/2020,12/13/2021
NCT05283837,NOT_YET_RECRUITING,Metastatic Breast Cancer,BIOLOGICAL: Pertuzumab (ZRC-3277)|BIOLOGICAL: Pertuzumab (PerjetaÂ®),Zydus Lifesciences Limited,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,268,INDUSTRY,INTERVENTIONAL,9/17/2022,12/31/2024
NCT04741737,RECRUITING,Mastectomy,PROCEDURE: reSLNB arm,Gangnam Severance Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,532,OTHER,INTERVENTIONAL,3/1/2020,1/31/2029
NCT05301114,RECRUITING,Social Determinants of Health|Breast Cancer|Prostate Cancer|Health Equity|Disparities,BEHAVIORAL: Community Health Worker support,Medstar Health Research Institute,George Washington University|Howard University|Georgetown University,ALL,"ADULT, OLDER_ADULT",NA,1116,OTHER,INTERVENTIONAL,5/5/2022,9/30/2026
NCT04541433,ACTIVE_NOT_RECRUITING,ER+ HER2- Advanced Breast Cancer,DRUG: AZD9833,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,INTERVENTIONAL,9/29/2020,12/31/2025
NCT06137833,NOT_YET_RECRUITING,Fatigue|Breast Cancer,DIETARY_SUPPLEMENT: APPOPRTALÂ®|OTHER: Placebo,Pharmanutra S.p.a.,Latis S.r.l.,FEMALE,"ADULT, OLDER_ADULT",NA,92,INDUSTRY,INTERVENTIONAL,11/27/2023,12/27/2024
NCT05588414,RECRUITING,Breast Cancer,PROCEDURE: Standardization of the sentinel node detection procedure,Centre Hospitalier Annecy Genevois,,ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,12/5/2022,7/15/2024
NCT05851014,RECRUITING,Breast Cancer,DRUG: GB491 combined with Letrozole|DRUG: Placebo combined with Letrozole,"Genor Biopharma Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,1/14/2022,1/30/2027
NCT05240937,NOT_YET_RECRUITING,Breast Cancer|Self Compassion,BEHAVIORAL: mindfulness-based self-compassion will be applied,University of Beykent,,FEMALE,ADULT,NA,70,OTHER,INTERVENTIONAL,5/15/2022,11/15/2022
NCT05266937,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer|Triple Negative Breast Cancer|PD-L1 Gene Mutation,"COMBINATION_PRODUCT: Atezolizumab,Paclitaxel, Carboplatin",Consorzio Oncotech,,ALL,"ADULT, OLDER_ADULT",PHASE2,49,OTHER,INTERVENTIONAL,7/3/2020,7/3/2024
NCT05429814,COMPLETED,Breast Cancer|Peripheral Neuropathies|Chemotherapy Effect,OTHER: Menthol Application,Necmettin Erbakan University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,7/1/2022,4/1/2023
NCT04538833,WITHDRAWN,Early Breast Cancer,DRUG: monosialic gangliosides|OTHER: Placebo,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,INTERVENTIONAL,9/9/2020,8/22/2022
NCT04243837,TERMINATED,Breast Cancer Related Lymphoedema|Lymphoedema,DRUG: LYT-100 MAD|OTHER: Matching Placebo for MAD|DRUG: LYT-100 Food Effect|DRUG: LYT-100 BCRL|DRUG: Placebo BCRL|DRUG: Placebo Food Effect,PureTech,Novotech (Australia) Pty Limited,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,INDUSTRY,INTERVENTIONAL,3/1/2020,9/9/2022
NCT03846583,WITHDRAWN,Breast Cancer,DRUG: Tucatinib|DRUG: Abemaciclib|DRUG: Trastuzumab|DRUG: Aromatase Inhibitor,Dana-Farber Cancer Institute,Eli Lilly and Company,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,6/28/2020,9/22/2020
NCT05930483,NOT_YET_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,BEHAVIORAL: Behavioral Dietary Intervention|BEHAVIORAL: Behavioral Intervention|PROCEDURE: Biospecimen Collection|OTHER: Dietary Intervention|OTHER: Educational Intervention|OTHER: Exercise Intervention|OTHER: Health Promotion and Education|OTHER: Internet-Based Intervention|OTHER: Interview|BEHAVIORAL: Lifestyle Counseling|OTHER: Medical Device Usage and Evaluation|OTHER: Medical Device Usage and Evaluation|OTHER: Nutritional Intervention|OTHER: Questionnaire Administration|BEHAVIORAL: Telephone-Based Intervention,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,620,OTHER,INTERVENTIONAL,2/11/2024,6/1/2027
NCT05239143,RECRUITING,Breast Cancer|Ovarian Cancer|Non Small Cell Lung Cancer|Colorectal Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Nasopharyngeal Cancer|Head and Neck Squamous Cell Carcinoma|Gastric Cancer,BIOLOGICAL: P-MUC1C-ALLO1 CAR-T cells|DRUG: Rimiducid,"Poseida Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,INTERVENTIONAL,2/15/2022,2039-04
NCT04632407,UNKNOWN,Cardiotoxicity,"DIETARY_SUPPLEMENT: Flax ""milk""|DIETARY_SUPPLEMENT: Oat fibre ""milk""",St. Boniface Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,10/21/2020,12/31/2022
NCT05483283,RECRUITING,Breast Cancer,OTHER: Empowerment and Navigation|OTHER: SOC,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,1/18/2023,2027-09
NCT04596683,UNKNOWN,Breast Cancer|Mastectomy; Lymphedema|Same Day Surgery|Nipple-sparing Mastectomy|Skin-sparing Mastectomy,PROCEDURE: Same-day NSM or SSM,Georgetown University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/4/2020,2/4/2022
NCT04948983,UNKNOWN,Breast Cancer|Mammary Cancer|Breast Tumor|Mammary Tumor,OTHER: Decision aid (DA) for breast cancer screening|OTHER: Standarised information for breast cancer screening,Pontificia Universidad Catolica de Chile,ComisiÃ³n Nacional de InvestigaciÃ³n CientÃ­fica y TecnolÃ³gica,FEMALE,"ADULT, OLDER_ADULT",NA,3269,OTHER,INTERVENTIONAL,7/1/2021,10/31/2022
NCT05359783,ACTIVE_NOT_RECRUITING,Breast Cancer|Sentinel Lymph Node,DRUG: Superparamagnetic Iron Oxide,Vastra Gotaland Region,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER_GOV,INTERVENTIONAL,11/1/2021,4/30/2024
NCT04297007,COMPLETED,Breast Cancer|Breast Neoplasms|Breast Diseases|Breast Fibroadenoma,OTHER: PECS block|OTHER: Rhomboid intercostal block,Medipol University,,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,3/23/2020,2/20/2021
NCT05346107,RECRUITING,Breast Cancer|HER2-positive Breast Cancer,"DRUG: pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage",Xijing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,1/1/2020,12/31/2023
NCT04563507,RECRUITING,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,Weill Medical College of Cornell University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,INTERVENTIONAL,11/12/2020,10/31/2025
NCT05454943,ACTIVE_NOT_RECRUITING,Metabolic Disturbance,BEHAVIORAL: Standardized TRE Protocol|BEHAVIORAL: Personalized TRE Protocol|BEHAVIORAL: External Support for TRE|BEHAVIORAL: Peer Support for TRE,University of Toronto,,FEMALE,"ADULT, OLDER_ADULT",NA,178,OTHER,INTERVENTIONAL,7/7/2022,12/6/2023
NCT04697043,UNKNOWN,Breast Cancer Stage IV,PROCEDURE: Systemic therapy followed by surgery if the disease is not progressive,Tehran University of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",NA,212,OTHER,INTERVENTIONAL,11/20/2020,12/20/2021
NCT04158843,RECRUITING,Breast Cancer|Oligometastasis,PROCEDURE: Radical resection|RADIATION: Radical radiotherapy|OTHER: Palliative treatment,xuexin he,,FEMALE,"ADULT, OLDER_ADULT",NA,183,OTHER,INTERVENTIONAL,5/9/2020,12/31/2026
NCT04862143,TERMINATED,Advanced Breast Cancer,DRUG: Alpelisib|DRUG: fulvestrant,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,INTERVENTIONAL,3/8/2022,9/19/2022
NCT04824807,COMPLETED,Lymphedema|Exercise,OTHER: Yoga|OTHER: Clinical Pilates|OTHER: An educational booklet,Eastern Mediterranean University,,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,10/29/2021,2/14/2023
NCT04343807,RECRUITING,"Breast Neoplasm Female|Pain, Postoperative|Pain|Analgesia|Anaesthesia|Breast Cancer",PROCEDURE: PECS Block|OTHER: Control Group,Aga Khan University,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,1/1/2022,8/30/2024
NCT05441943,RECRUITING,"Breast Cancer Lymphedema|Secondary Lymphedema|Iatrogenic Lymphedema|Lymphedema|Lymphedema of Upper Limb|Lymphedema Arm|Lymphedema, Breast Cancer|Breast Neoplasm|Neoplasms|Breast Cancer|Breast Diseases|Lymphatic Diseases|Skin Diseases|Postoperative Complications|Pathologic Processes|Anastomose|Surgery|Surgical; Lymphedema, Postmastectomy|Postmastectomy Lymphedema|Postmastectomy Lymphedema Syndrome Left Upper Limb|Postmastectomy Lymphedema Syndrome Right Upper Limb|Postmastectomy Lymphedema Syndrome",PROCEDURE: Lymphovenous anastomosis,Odense University Hospital,Danish Cancer Society,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,INTERVENTIONAL,5/11/2022,1/31/2024
NCT05198843,TERMINATED,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Inflammatory Carcinoma,DRUG: Dasatinib|DIETARY_SUPPLEMENT: Icosapent Ethyl,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,NIH,INTERVENTIONAL,11/8/2022,12/20/2023
NCT04547907,RECRUITING,"Breast Cancer,Her2 Positive",DRUG: Albumin binding paclitaxel+ trastuzumab+ patuzumab|DRUG: Docetaxel+ carboplatin+ trastuzumab + patuzumab,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,686,OTHER_GOV,INTERVENTIONAL,9/18/2020,12/31/2023
NCT06079983,NOT_YET_RECRUITING,Breast Cancer,DRUG: JSKN003|DRUG: Capecitabine tablets|DRUG: Gemcitabine hydrochloride for injection|DRUG: Vinorelbine tartrate injection|DRUG: Paclitaxel for injection (albumin-bound type)|DRUG: Docetaxel injection|DRUG: Eribulin mesylate injection,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,12/1/2023,3/1/2029
NCT05574907,ACTIVE_NOT_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: 68Ga-FAPI PET/CT scan,Peking Union Medical College Hospital,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,5/1/2021,2/1/2024
NCT04579107,RECRUITING,Breast Cancer,COMBINATION_PRODUCT: Contrast Enhanced Mammography,Karolinska Institutet,Stockholm South General Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,420,OTHER,INTERVENTIONAL,10/1/2021,5/31/2024
NCT04815083,RECRUITING,Breast Neoplasm Female|Breast Cancer,DRUG: Aminolevulinic Acid Hydrochloride|DEVICE: Eagle V1.2 Imaging System|DRUG: Placebo,"SBI ALApharma Canada, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,370,INDUSTRY,INTERVENTIONAL,4/27/2021,2026-06
NCT06040983,NOT_YET_RECRUITING,Breast Cancer|Radiation Dermatitis,DEVICE: FR-101 Chest Dressing,China Medical University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/18/2023,12/31/2024
NCT05666583,COMPLETED,Breast Cancer,OTHER: Art therapy,Cumhuriyet University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,9/1/2021,10/7/2022
NCT06139107,NOT_YET_RECRUITING,Breast Cancer,DRUG: Abemaciclib|DRUG: Letrozole,"Mridula George, MD",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,15,OTHER,INTERVENTIONAL,12/21/2023,9/30/2032
NCT05491083,RECRUITING,Advanced Solid Tumor|Triple Negative Breast Cancer,DRUG: Pembrolizumab & ADG106 (Phase Ib)|DRUG: Pembrolizumab & ADG106 (Phase II),"National University Hospital, Singapore",Adagene Inc|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,51,OTHER,INTERVENTIONAL,6/12/2023,12/31/2026
NCT05297643,RECRUITING,"Lymphedema, Breast Cancer",DEVICE: Ekstracorporeal Shock Wave Therapy (ESWT)|OTHER: complex decongestive therapy,Kirsehir Ahi Evran Universitesi,,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,7/1/2022,1/15/2024
NCT05780307,RECRUITING,Advanced Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Breast Cancer|Squamous Cell Cancer of Head and Neck|Colorectal Cancer,DRUG: IMM2520,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,Shandong Cancer Hospital and Institute,ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,INTERVENTIONAL,3/23/2023,10/26/2025
NCT04144907,RECRUITING,Colorectal Cancer|Breast Cancer,DIETARY_SUPPLEMENT: Phenylalanine intake,University of Alberta,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,4/26/2021,12/31/2025
NCT05132790,ACTIVE_NOT_RECRUITING,Breast Cancer,"DRUG: SHR-1316 at a dose 20mg/kg q3w|DRUG: SHR6390 at a dose of 150mg orally, daily|RADIATION: SBRT",Shengjing Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,9/25/2023,12/31/2028
NCT05146297,RECRUITING,Breast Cancer|Liver Cancer|Prostate Cancer,BEHAVIORAL: Clinical trial match-list|BEHAVIORAL: Match-list intervention,Icahn School of Medicine at Mount Sinai,,ALL,"ADULT, OLDER_ADULT",NA,1200,OTHER,INTERVENTIONAL,12/24/2022,2025-04
NCT05932667,TERMINATED,Advanced or Metastatic Breast Cancer,DRUG: Milademetan|BEHAVIORAL: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL),Institut Curie,Rain Oncology Inc,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,INTERVENTIONAL,10/12/2023,11/30/2023
NCT05280067,RECRUITING,Metastatic Breast Cancer in the Spine,DEVICE: ZetaFuseâ„¢ Bone Graft,"Zetagen Therapeutics, Inc",,FEMALE,"ADULT, OLDER_ADULT",NA,10,INDUSTRY,INTERVENTIONAL,9/1/2022,2024-09
NCT05474690,RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|DRUG: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab),Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,456,OTHER_GOV,INTERVENTIONAL,5/11/2022,9/30/2024
NCT05887297,RECRUITING,"Insomnia|Breast Cancer|Adherence, Medication|Quality of Life|Survivorship",BEHAVIORAL: Cognitive behavioural therapy for insomnia,University of Strathclyde,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,3/23/2023,12/23/2023
NCT05082597,RECRUITING,Axillary Web Syndrome|Breast Cancer|Lymphedema|Extracorporeal Shock Wave Therapy,DEVICE: Low energy ESWT,Taichung Veterans General Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,10/13/2021,8/31/2024
NCT04541290,COMPLETED,Breast Cancer Lymphedema,DRUG: Protopic 0.1 % Topical Ointment,Odense University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,9/22/2020,1/6/2022
NCT05432856,NOT_YET_RECRUITING,Cardiovascular Diseases|Cardiovascular Morbidity|Metabolic Disease,"BEHAVIORAL: Time restricted eating, nutrition education, and sedentary time reduction strategies",University of Alberta,Canadian Institutes of Health Research (CIHR),FEMALE,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,2/5/2024,2027-06
NCT06032390,NOT_YET_RECRUITING,Breast Cancer,OTHER: AI assisted mammography screening interpretation|OTHER: Standard mammography screening interpretation,Cancer Registry of Norway,Helse Vest|Helse Midt-Norge|Helse Nord|Norwegian Cancer Society,FEMALE,"ADULT, OLDER_ADULT",NA,150000,OTHER_GOV,INTERVENTIONAL,2024-01,2033-06
NCT04570956,RECRUITING,Breast Atypical Hyperplasia|Breast Lobular Carcinoma in Situ|Breast Atypical Lobular Hyperplasia,DRUG: Tamoxifen|DRUG: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|DRUG: Placebo,Amy C. Degnim,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,104,OTHER,INTERVENTIONAL,7/26/2021,12/31/2026
NCT04895397,UNKNOWN,Breast Cancer,DEVICE: ultrasound guided Nerve Block procedure,Sohag University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,5/20/2021,8/20/2023
NCT05027490,COMPLETED,"Breast Cancer|Gynecologic Cancer|Bronchial Cancer|Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy",OTHER: CANUT support|OTHER: Anthropometric measures|OTHER: Prehension strength measurement|BEHAVIORAL: QVA Questionnaire|BEHAVIORAL: QLQ C30 Questionnaire|BEHAVIORAL: Scratch & Snif Test|BEHAVIORAL: Taste Strip Test|BEHAVIORAL: 24 H feed back questionnaire|BEHAVIORAL: Condiment questionnaire|BEHAVIORAL: Tobacco questionnaire|OTHER: Nutrition interview,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",NA,209,OTHER,INTERVENTIONAL,1/27/2022,9/21/2023
NCT05398497,NOT_YET_RECRUITING,Breast Cancer|Breast Neoplasms,DEVICE: Cryoablation,Hospital do Coracao,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/15/2022,7/15/2024
NCT04688697,UNKNOWN,Breast Carcinoma|Breast Reconstruction,PROCEDURE: prepectoral implant-based reconstruction|PROCEDURE: subpectoral implant-based reconstruction,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,1/1/2021,11/30/2022
NCT04774497,UNKNOWN,Breast Cancer,OTHER: Oxygen inhalation treatment group|OTHER: Control group,Jiuda Zhao,,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,3/1/2021,12/31/2022
NCT06203197,NOT_YET_RECRUITING,Breast Cancer,OTHER: Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBÄ°S),Sanko University,University of Gaziantep,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/15/2024,10/30/2024
NCT05772390,RECRUITING,Breast Cancer|Recurrent,RADIATION: Partial breast re-irradiation,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,INTERVENTIONAL,3/31/2023,2032-03
NCT04822597,COMPLETED,Breast Cancer|Sentinel Lymph Node|Breast Neoplasms|Breast Cancer Female,DRUG: Lidocaine patch|DEVICE: Buzzy(R)|OTHER: Ice pack,"University of Wisconsin, Madison",National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE3,167,OTHER,INTERVENTIONAL,4/23/2021,5/9/2022
NCT04687956,RECRUITING,Lymphedema|Mastectomy|Breast Cancer,PROCEDURE: LYMPHA|PROCEDURE: control,Gangnam Severance Hospital,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,2/1/2021,12/31/2027
NCT05509790,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DRUG: LY3484356,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INDUSTRY,INTERVENTIONAL,10/9/2022,4/1/2025
NCT05203497,COMPLETED,Breast Cancer Female,DRUG: SPECT,Tomsk National Research Medical Center of the Russian Academy of Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,12/22/2021,3/1/2023
NCT06156397,NOT_YET_RECRUITING,Breast Cancer,OTHER: Standard Physiotherapy Exercise Group|OTHER: Telerehabilitation Based Supervised Exercise Group|OTHER: Mobile Application Supported Exercise Group,Medipol University,,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,11/30/2023,2/15/2024
NCT05693597,RECRUITING,Radiation Dermatitis,DRUG: Imtenan Oil|DRUG: Baraka Capsules,German University in Cairo,Ain Shams University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,INTERVENTIONAL,1/24/2023,2024-04
NCT06171607,RECRUITING,Breast Carcinoma,PROCEDURE: Contrast-Enhanced Ultrasound|DRUG: Perflutren Lipid Microspheres|DRUG: Sulfur Hexafluoride Lipid Microspheres,University of Southern California,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,INTERVENTIONAL,11/5/2020,11/5/2025
NCT05295043,NOT_YET_RECRUITING,Advanced HR+ HER2 Negative Breast Carcinoma,DRUG: (CDK)4/6 inhibitor,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,12/10/2022,1/1/2024
NCT05145907,ACTIVE_NOT_RECRUITING,Triple-negative Breast Cancer|Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: TJ107 +Pembrolizumab,I-Mab Biopharma Co. Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,133,INDUSTRY,INTERVENTIONAL,12/22/2021,12/31/2024
NCT06027983,NOT_YET_RECRUITING,HER2+ Advanced Breast Cancer|Other Solid Tumors,DRUG: Chimeric receptor T-cells + Trastuzumab|DRUG: Fludarabine and Cyclophosphosphamide,"National University Hospital, Singapore",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,OTHER,INTERVENTIONAL,11/1/2023,12/31/2027
NCT05704283,RECRUITING,Breast Carcinoma,DEVICE: Ultrasound Imaging,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,60,OTHER,INTERVENTIONAL,2/14/2023,4/1/2025
NCT04440943,COMPLETED,Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|MSI-H Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Other Solid Tumors,DRUG: CDX-527,Celldex Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INDUSTRY,INTERVENTIONAL,8/4/2020,4/6/2023
NCT05291507,RECRUITING,Breast Cancer,DEVICE: Muse MRgFUS System,University of Utah,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,34,OTHER,INTERVENTIONAL,8/2/2022,8/1/2027
NCT05036083,ACTIVE_NOT_RECRUITING,Breast Carcinoma|Invasive Breast Carcinoma,PROCEDURE: Contrast-Enhanced Mammography|PROCEDURE: Digital Tomosynthesis Mammography|OTHER: Electronic Health Record Review|DRUG: Iodinated Contrast Agent,M.D. Anderson Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,89,OTHER,INTERVENTIONAL,3/19/2021,12/31/2024
NCT04603183,ACTIVE_NOT_RECRUITING,Breast Cancer Metastatic,DRUG: Abemaciclib|DRUG: Paclitaxel|DRUG: Letrozole|DRUG: Fulvestrant,MedSIR,Eli Lilly and Company,ALL,"ADULT, OLDER_ADULT",PHASE2,162,OTHER,INTERVENTIONAL,6/2/2021,2024-05
NCT05035407,RECRUITING,"Kita-kyushu Lung Cancer Antigen 1, Human",DRUG: IL-2 (Aldesleukin)|DRUG: Cyclophosphamide|BIOLOGICAL: KK-LC-1 TCR|DRUG: Fludarabine,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,100,NIH,INTERVENTIONAL,3/8/2022,4/5/2026
NCT04824183,COMPLETED,"Breast Cancer|Mastectomy|Pain, Postoperative",OTHER: Music intervention,Chinese University of Hong Kong,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,6/5/2021,3/27/2022
NCT05131607,ACTIVE_NOT_RECRUITING,Breast Cancer Female,PROCEDURE: Supine MRI,Dartmouth-Hitchcock Medical Center,"CairnSurgical, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,3/17/2022,3/31/2024
NCT03544983,ENROLLING_BY_INVITATION,BRCA1 Mutation|BRCA2 Mutation,BEHAVIORAL: Web + Streamlined Telephone Genetic Counseling,Georgetown University,George Washington University,ALL,"ADULT, OLDER_ADULT",NA,426,OTHER,INTERVENTIONAL,5/1/2020,6/30/2025
NCT03929783,COMPLETED,Breast Neoplasms,PROCEDURE: Contrast Enhanced Digital Mammography,Thomas Jefferson University,,FEMALE,"ADULT, OLDER_ADULT",NA,107,OTHER,INTERVENTIONAL,6/23/2020,1/27/2023
NCT06120283,RECRUITING,Advanced Solid Tumor|Advanced Breast Cancer|Metastatic Breast Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Non-small Cell Lung Cancer,DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE1,79,INDUSTRY,INTERVENTIONAL,12/1/2023,2026-05
NCT05095207,RECRUITING,Breast Cancer|Metastasis,DRUG: Abemaciclib|DRUG: Bicalutamide,Icahn School of Medicine at Mount Sinai,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,INTERVENTIONAL,9/29/2021,2024-09
NCT04307407,COMPLETED,Breast Cancer,BEHAVIORAL: Aerobic Exercise,Norwegian School of Sport Sciences,Oslo University Hospital|Memorial Sloan Kettering Cancer Center|University of Oslo,FEMALE,"ADULT, OLDER_ADULT",NA,210,OTHER,INTERVENTIONAL,9/8/2020,3/2/2023
NCT05941507,RECRUITING,Advanced Solid Tumors,DRUG: LCB84|DRUG: Anti-PD-1 monoclonal antibody,"LegoChem Biosciences, Inc","AntibodyChem Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,INTERVENTIONAL,10/5/2023,2027-05
NCT05285943,RECRUITING,Radiodermatitis; Acute,DRUG: Olive oil cream|DRUG: Betamethasone Valerate Cream|OTHER: Base Cream,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,132,OTHER,INTERVENTIONAL,11/4/2021,2023-06
NCT06263543,NOT_YET_RECRUITING,Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Hormone-receptor-positive Breast Cancer|Human Epidermal Growth Factor 2 Low Breast Cancer,DRUG: Sacituzumab govitecan,"Reshma L. Mahtani, D.O.",Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,INTERVENTIONAL,2024-04,2026-10
NCT05401643,RECRUITING,Breast Cancer|Breast Neoplasms|Quality of Life|Survivorship,OTHER: Xemio mobile application,Fundacion Clinic per a la Recerca BiomÃ©dica,Fundacion iSYS,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,12/1/2020,6/30/2023
NCT05983107,RECRUITING,HR+/HER2- Advanced Breast Cancer|Targeted Therapy,DRUG: Everolimus|DRUG: Chidamide|DRUG: Endocrine therapy|DRUG: Ovarian function suppression(OFS),"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,INTERVENTIONAL,7/20/2023,7/15/2027
NCT05504707,RECRUITING,Triple Negative Breast Cancer|HER2-negative Breast Cancer,BIOLOGICAL: HER2 - primed Dendritic cells|BIOLOGICAL: HER3 - primed Dendritic cells,H. Lee Moffitt Cancer Center and Research Institute,The Shulas' Foundation,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,8/26/2022,2025-04
NCT05331807,RECRUITING,Breast Cancer Female,DIETARY_SUPPLEMENT: Omega-3 FA|DIETARY_SUPPLEMENT: Vitamin D|COMBINATION_PRODUCT: Combined Omega-3 and Vitamin D Supplementation,Universiti Sains Malaysia,,FEMALE,ADULT,EARLY_PHASE1,88,OTHER,INTERVENTIONAL,4/20/2022,12/30/2022
NCT05830097,RECRUITING,"Cancer, Breast|Cancer, Lung|Cancer of Pancreas|Cancer of Esophagus|Cancer Colorectal",DRUG: CBP-1019,"Coherent Biopharma (Hefei) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,260,INDUSTRY,INTERVENTIONAL,3/14/2023,9/30/2025
NCT05963997,RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer,DRUG: Samuraciclib|DRUG: Elacestrant Dihydrochloride,Carrick Therapeutics Limited,Berlin-Chemie AG Menarini Group,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,INTERVENTIONAL,10/9/2023,6/16/2025
NCT04290897,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,DRUG: Anhydrous Enol-oxaloacetate|OTHER: Questionnaire Administration,Jonsson Comprehensive Cancer Center,"Breast Cancer Research Foundation|MetVital, Inc.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,INTERVENTIONAL,9/29/2021,11/1/2025
NCT04249167,WITHDRAWN,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Atezolizumab|PROCEDURE: Cryosurgery|DRUG: Nab-paclitaxel,Mayo Clinic,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,1/23/2020,11/17/2021
NCT04936243,COMPLETED,Breast Cancer|Prostate Cancer|Patient Engagement|Patient Preference|Patient Satisfaction,BEHAVIORAL: FOLLOW UP VISIT-TELEMEDICINE|BEHAVIORAL: FOLLOW UP VISIT-FACE TO FACE,Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,8/1/2021,11/1/2022
NCT04571307,UNKNOWN,Breast Disease|Phyllodes Breast Tumor,PROCEDURE: cryotherapy,KK Women's and Children's Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER_GOV,INTERVENTIONAL,9/15/2021,10/15/2022
NCT05860907,NOT_YET_RECRUITING,Breast Cancer Stage IV,DRUG: Huaier Granule,Fudan University,LinkDoc Technology (Beijing) Co. Ltd.|Huazhong University of Science and Technology,ALL,"ADULT, OLDER_ADULT",PHASE4,384,OTHER,INTERVENTIONAL,2023-10,2027-10
NCT05865990,RECRUITING,"Metastatic Breast Cancer|Advanced Non-Small Cell Squamous Lung Cancer|Solid Tumor, Adult",DRUG: Patritumab deruxtecan,MedSIR,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,11/24/2023,2026-10
NCT04858997,UNKNOWN,Breast Neoplasms,DRUG: Palbociclib|DRUG: AI,Zhejiang Cancer Hospital,Pfizer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,INTERVENTIONAL,4/22/2021,6/30/2023
NCT05072197,RECRUITING,Breast Neoplasms,DEVICE: Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy,Cheng-Hsin General Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,5/16/2021,12/31/2023
NCT04254107,TERMINATED,Non-small Cell Lung Cancer|Gastric Carcinoma|Gastroesophageal Junction Carcinoma|Classical Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Bladder Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Cervical Cancer,DRUG: SEA-TGT|DRUG: sasanlimab|DRUG: brentuximab vedotin,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,132,INDUSTRY,INTERVENTIONAL,5/29/2020,12/1/2023
NCT05636943,RECRUITING,Metastatic Breast Cancer,BEHAVIORAL: Adapted Intimacy Enhancement|BEHAVIORAL: Intimacy Facts and Resources,Fox Chase Cancer Center,"American Cancer Society, Inc.",ALL,"ADULT, OLDER_ADULT",NA,112,OTHER,INTERVENTIONAL,1/1/2021,8/31/2024
NCT05954143,RECRUITING,Metastatic Breast Cancer|HER2-positive Breast Cancer,DRUG: BDC-1001|DRUG: Pertuzumab,"Bolt Biotherapeutics, Inc.",Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,INTERVENTIONAL,11/30/2023,2025-03
NCT05360407,COMPLETED,Breast Cancer,OTHER: Using mobile information application about before and after surgery,Suleyman Demirel University,,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,INTERVENTIONAL,4/1/2021,8/30/2021
NCT04869943,TERMINATED,Metastatic Breast Cancer,DRUG: Enobosarm|DRUG: Exemestane,Veru Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,52,INDUSTRY,INTERVENTIONAL,10/12/2021,1/9/2024
NCT04348643,RECRUITING,Solid Tumor|Lung Cancer|Colorectal Cancer|Liver Cancer|Pancreatic Cancer|Gastric Cancer|Breast Cancer,BIOLOGICAL: CEA CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,INTERVENTIONAL,2/20/2020,4/30/2024
NCT04251507,COMPLETED,Breast Neoplasm Female,DEVICE: Oculus Go Virtual Reality Goggles,Prisma Health-Upstate,Clemson University,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/13/2021,1/7/2022
NCT04819243,NOT_YET_RECRUITING,Premenopausal HR+/HER2- Metastatic Breast Cancer,"DRUG: Pabociclib, Endocrine, Talazoparib, Atezolizumab|DRUG: Pabociclib, Endocrine, Talazoparib,",Samsung Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,178,OTHER,INTERVENTIONAL,9/1/2021,12/31/2027
NCT05167643,RECRUITING,Advanced HR+ HER2 Negative Breast Carcinoma,DRUG: Enituzumab injection+Abesili tablets+Anastrozole tablets,Tianjin Medical University Cancer Institute and Hospital,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/23/2022,8/23/2024
NCT04829643,RECRUITING,Breast Cancer|Sentinel Lymph Node|Early-stage Breast Cancer,DIAGNOSTIC_TEST: PET/MRI,IRCCS San Raffaele,IBFM- Consiglio Nazionale delle Ricerche,ALL,"ADULT, OLDER_ADULT",NA,247,OTHER,INTERVENTIONAL,7/3/2020,2/14/2025
NCT05470543,COMPLETED,Nurse-led Supportive Care,BEHAVIORAL: Nurse-led supportive care,Izmir Bakircay University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,4/18/2022,1/13/2023
NCT06193707,NOT_YET_RECRUITING,Ultrasonography|Breast Neoplasm Female|Breast Carcinoma|Health Education,OTHER: the Remote Intervention|OTHER: the Traditional Intervention,Qianfoshan Hospital,,FEMALE,ADULT,NA,1250,OTHER,INTERVENTIONAL,2024-01,2027-12
NCT05058183,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: ctDNA,Royal Marsden NHS Foundation Trust,"Massachusetts General Hospital|Natera, Inc.",ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,6/5/2023,12/5/2028
NCT05918133,RECRUITING,TNBC,DRUG: PM8002|DRUG: nab-paclitaxel,Biotheus Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,INTERVENTIONAL,7/1/2022,10/30/2026
NCT04824833,COMPLETED,Hemodynamic Instability|Opioid Use|Block|Breast Cancer,PROCEDURE: Serratus anterior plane block,Zonguldak Bulent Ecevit University,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,3/1/2021,9/30/2021
NCT05969314,ACTIVE_NOT_RECRUITING,Breast Cancer|Oral Cancer,DRUG: Cannabis capsules,Tata Memorial Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER_GOV,INTERVENTIONAL,6/8/2022,12/31/2023
NCT06048367,RECRUITING,Advanced Solid Tumor|Lung Cancer|Pancreas Cancer|Breast Cancer|Thyroid Cancer|Colorectal Cancer|Cervical Cancer|Ovarian Cancer|Vulva Cancer,DRUG: CNSI-Fe(II) 30 mg|DRUG: CNSI-Fe(II) 60 mg|DRUG: CNSI-Fe(II) 90 mg,Sichuan Enray Pharmaceutical Sciences Company,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,10/14/2022,2/29/2024
NCT05038137,ACTIVE_NOT_RECRUITING,Pre-diabetes|Breast Cancer|Time Restricted Feeding,BEHAVIORAL: Time restricted feeding|BEHAVIORAL: Control,Medical University of South Carolina,,FEMALE,"ADULT, OLDER_ADULT",NA,29,OTHER,INTERVENTIONAL,5/4/2022,5/1/2024
NCT03936933,RECRUITING,Breast Cancer,DRUG: Goserelin acetate 3.6 mg Injection|DRUG: ZOLADEXÂ® 3.6mg Injection,Eurofarma Laboratorios S.A.,,FEMALE,ADULT,PHASE3,68,INDUSTRY,INTERVENTIONAL,10/30/2020,1/30/2025
NCT05313737,NOT_YET_RECRUITING,Breast Cancer,OTHER: Automated message|OTHER: Opt-out scheduling,VA Puget Sound Health Care System,,FEMALE,"ADULT, OLDER_ADULT",NA,871,FED,INTERVENTIONAL,4/18/2022,8/31/2022
NCT04454437,ACTIVE_NOT_RECRUITING,Metastatic Triple-negative Breast Cancer,DRUG: Sacituzumab Govitecan-hziy,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,INTERVENTIONAL,10/23/2020,2024-12
NCT06000033,NOT_YET_RECRUITING,Breast Cancer,DRUG: Disitamab Vedotin+Anlotinib,Qilu Hospital of Shandong University,,ALL,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,8/10/2023,12/31/2025
NCT04553133,RECRUITING,Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer,DRUG: PF-07104091 monotherapy dose escalation|DRUG: PF-07104091 + palbociclib + fulvestrant|DRUG: PF-07104091 + palbociclib + letrozole|DRUG: PF-07104091 monotherapy dose expansion (ovarian)|DRUG: PF-07104091 monotherapy dose expansion (SCLC)|DRUG: PF-07104091 + Fulvestrant (post CDK4/6)|DRUG: PF-0704091 + Fulvestrant (post CDK4/6),Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,320,INDUSTRY,INTERVENTIONAL,9/16/2020,1/7/2026
NCT05601037,RECRUITING,"Lymphedema, Breast Cancer",PROCEDURE: Axilla dissection + Lymphovenous anastomosis,"University Hospital, Ghent",,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,6/30/2021,12/27/2025
NCT04315233,RECRUITING,Metastatic Breast Cancer|Recurrent Ovarian Carcinoma,DRUG: Ribociclib|DRUG: Belinostat,University of Utah,Novartis|Acrotech Biopharma,ALL,"ADULT, OLDER_ADULT",PHASE1,34,OTHER,INTERVENTIONAL,5/3/2021,2026-08
NCT05490433,RECRUITING,Breast Cancer Patients in Stage 0-3A in Preoperative Evaluation,PROCEDURE: robot assisted nipple sparing mastectomy(RNSM)|PROCEDURE: Conventional nipple sparing mastectomy(CNSM),Yonsei University,,FEMALE,"ADULT, OLDER_ADULT",NA,790,OTHER,INTERVENTIONAL,10/26/2022,2030-06
NCT04493333,RECRUITING,Vaginal Atrophy|Postmenopausal Symptoms|Breast Cancer Female|Long-term Survivors,DRUG: Vaginal Dehydroepiandrosterone|COMBINATION_PRODUCT: Vaginal Polycarbophil Moisturizer,University of Arkansas,"AMAG Pharmaceuticals, Inc.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/7/2021,2025-06
NCT04850937,COMPLETED,Depression,DRUG: Esketamine|DRUG: normal saline,Yangzhou University,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,2/10/2021,5/10/2022
NCT05871437,RECRUITING,Early-stage Breast Cancer,DRUG: Huaier granule,Fudan University,LinkDoc Technology (Beijing) Co. Ltd.|Huazhong University of Science and Technology,ALL,"ADULT, OLDER_ADULT",PHASE4,379,OTHER,INTERVENTIONAL,5/8/2023,2025-08
NCT04251533,ACTIVE_NOT_RECRUITING,Triple Negative Breast Neoplasms,DRUG: alpelisib|DRUG: placebo|DRUG: nab-paclitaxel,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,137,INDUSTRY,INTERVENTIONAL,6/8/2020,9/2/2024
NCT05955833,RECRUITING,Breast Cancer|Metastatic Breast Cancer|HER2-positive Breast Cancer|Gastric Cancer|Metastatic Gastric Cancer|HER2-positive Gastric Cancer,DIAGNOSTIC_TEST: 89Zr-DFO*-trastuzumab PET scan,"Amsterdam UMC, location VUmc",AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,INTERVENTIONAL,6/26/2023,4/30/2024
NCT05403333,NOT_YET_RECRUITING,Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer,DRUG: utidelone,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,INTERVENTIONAL,6/10/2022,3/9/2025
NCT05070247,RECRUITING,"Pancreatic Cancer|Hepatocellular Cancer|Mesothelioma|Breast Cancer|Gastric Cancer|Esophageal Cancer|Nasopharyngeal Cancer|Kidney Cancer|Squamous Cell Cancer of Head and Neck (SCCHN)|Non-small Cell Lung Cancer (NSCLC), Non-squamous",DRUG: TAK-500|DRUG: Pembrolizumab,Takeda,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,313,INDUSTRY,INTERVENTIONAL,4/14/2022,8/11/2026
NCT04780347,UNKNOWN,Breast Cancer,DRUG: Albumin-bound paclitaxel plus capecitabine|DRUG: capecitabine,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,INTERVENTIONAL,12/15/2020,2/25/2023
NCT05181722,RECRUITING,Breast Cancer,OTHER: Patient navigator support,Johns Hopkins University,Association of University Radiologists (AUR) - GERRAF,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,7/18/2022,2024-06
NCT05350722,RECRUITING,Breast Cancer,RADIATION: Single dose ablative radiotherapy,"Amsterdam UMC, location VUmc",Dutch Cancer Society,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,8/24/2022,2035-03
NCT04674722,RECRUITING,Breast Cancer|Radiotoxicity,DRUG: Injection of 99mTc-NM-02|DRUG: Injection of 188Re-NM-02,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",NanoMab Technology (UK) Limited,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,40,OTHER,INTERVENTIONAL,8/24/2020,9/30/2024
NCT05825547,RECRUITING,Breast Cancer,PROCEDURE: Cryotherapy treatment,Centre Hospitalier Universitaire de NÄ«mes,,FEMALE,"ADULT, OLDER_ADULT",NA,5,OTHER,INTERVENTIONAL,2/16/2022,2023-12
NCT05872347,RECRUITING,Breast Cancer Brain Metastases,DRUG: SPH4336 Tablets,"Shanghai Pharmaceuticals Holding Co., Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,INDUSTRY,INTERVENTIONAL,9/19/2023,12/31/2025
NCT05238922,RECRUITING,Solid Tumors,DRUG: INCB0123667,Incyte Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1,340,INDUSTRY,INTERVENTIONAL,7/5/2022,7/30/2026
NCT06028022,RECRUITING,Estrogen Receptor-Positive Breast Carcinoma,DIETARY_SUPPLEMENT: Mushroom|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,10/18/2023,2025-10
NCT06056843,RECRUITING,Breast Cancer|Carcinoma in Situ,OTHER: Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.,International Agency for Research on Cancer,"Malabar Cancer Care Society Kannur, India|Bhabha Atomic Research Centre (BARC), India",FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,5/9/2022,5/31/2024
NCT05365243,WITHDRAWN,Alopecia|Chemotherapy-induced Alopecia|Hair Loss|Breast Cancer|Gynecologic Cancer,DEVICE: AMMA Portalbe Scalp Cooling System,Cooler Heads Care Inc.,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER_GOV,INTERVENTIONAL,8/15/2022,9/30/2023
NCT05415943,COMPLETED,Breast Cancer,DEVICE: Diagnostic microprobe (inPROBE) medical device,SDS Optic S.A.,,FEMALE,"ADULT, OLDER_ADULT",NA,18,INDUSTRY,INTERVENTIONAL,8/24/2022,3/2/2023
NCT05970107,NOT_YET_RECRUITING,Node-positive Breast Cancer,PROCEDURE: Axillary Lymph Node Dissection|PROCEDURE: Axillary Reverse Mapping|PROCEDURE: Lymphaticovenous Bypass,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,4/1/2024,9/1/2028
NCT05327543,RECRUITING,Breast Neoplasms|Cancer,BEHAVIORAL: Iyengar Yoga|BEHAVIORAL: Meditative Yoga,"Charite University, Berlin, Germany",,FEMALE,"ADULT, OLDER_ADULT",NA,138,OTHER,INTERVENTIONAL,5/9/2022,2024-12
NCT05505643,NOT_YET_RECRUITING,Breast Cancer|Breast Neoplasm,DEVICE: Endocare SlimLine Cryoprobe|PROCEDURE: Lumpectomy,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital|Varian Medical Systems,FEMALE,"ADULT, OLDER_ADULT",NA,256,OTHER,INTERVENTIONAL,2/28/2024,8/31/2031
NCT04576143,RECRUITING,HER2-negative Breast Cancer|Neoadjuvant Chemotherapy,DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Docetaxel|DRUG: Paclitaxel,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Women's Hospital School Of Medicine Zhejiang University|Changxing People's Hospital|Zhejiang Provincial People's Hospital|Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry|Huizhou Municipal Central Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,260,OTHER,INTERVENTIONAL,9/20/2020,9/20/2027
NCT05726643,NOT_YET_RECRUITING,Breast Cancer|Fatigue|Quality of Life,OTHER: resistive training|OTHER: kinesiotaping,Cairo University,,ALL,ADULT,NA,40,OTHER,INTERVENTIONAL,2/20/2023,6/20/2023
NCT04549207,RECRUITING,Breast Cancer|Castration-resistant Prostate Cancer,DRUG: Bone modifying agent,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,INTERVENTIONAL,10/9/2020,2025-11
NCT06072807,RECRUITING,Breast Cancer|Brain Metastases,DIAGNOSTIC_TEST: Brain Imaging with 18F-FES,Weill Medical College of Cornell University,GE Healthcare,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,12/27/2023,2026-12
NCT05812807,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma,BIOLOGICAL: Pembrolizumab|OTHER: Patient Observation|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,1295,OTHER,INTERVENTIONAL,5/10/2023,5/31/2033
NCT04282967,COMPLETED,Prostate Cancer|Breast Cancer Female,BEHAVIORAL: Exercise,Celina Shirazipour,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,INTERVENTIONAL,7/7/2020,3/30/2023
NCT02807597,RECRUITING,Breast Cancer|Cancer of the Breast,DRUG: LS301|DEVICE: Cancer Vision Goggles and standard fluorescence imaging systems|PROCEDURE: Surgery,Samuel Achilefu,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,97,OTHER,INTERVENTIONAL,2/18/2020,1/31/2024
NCT04173897,COMPLETED,Metastatic Breast Cancer,OTHER: LIBERATE website,University of Leeds,Breast Cancer Now,FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,6/6/2020,3/31/2021
NCT04752267,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Glioma|Malignant Brain Neoplasm|Metastatic Breast Carcinoma|Metastatic Colon Carcinoma|Metastatic Kidney Carcinoma|Metastatic Lung Carcinoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8,PROCEDURE: Computed Tomography|DRUG: 18F-FMAU|PROCEDURE: Multiparametric Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,University of Southern California,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,2/15/2021,2/15/2025
NCT06239467,NOT_YET_RECRUITING,Advanced Cancer|Breast Cancer,DRUG: OKI-219|DRUG: Fulvestrant|DRUG: Trastuzumab,"OnKure, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,INTERVENTIONAL,1/22/2024,8/1/2027
NCT04147767,UNKNOWN,Hypercholesterolemia|Breast Cancer|Obesity,DIETARY_SUPPLEMENT: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|DIETARY_SUPPLEMENT: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd),University of Leeds,The Leeds Teaching Hospitals NHS Trust|University of Oslo,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,2/10/2020,12/31/2021
NCT04921137,RECRUITING,Breast Cancer,OTHER: No endocrine therapy|OTHER: Endocrine therapy,Ottawa Hospital Research Institute,,ALL,OLDER_ADULT,PHASE4,100,OTHER,INTERVENTIONAL,8/19/2021,2024-09
NCT05781633,RECRUITING,"Mammary Neoplasms, Human",DRUG: eutidrone etoposide bevacizumab,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,43,OTHER,INTERVENTIONAL,7/20/2022,7/20/2025
NCT06018337,RECRUITING,Metastatic Breast Cancer,DRUG: DB-1303/BNT323|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,DualityBio Inc.,BioNTech SE,ALL,"ADULT, OLDER_ADULT",PHASE3,532,INDUSTRY,INTERVENTIONAL,1/18/2024,2028-05
NCT05780814,RECRUITING,Breast Cancer|Insomnia|Weight Gain,BEHAVIORAL: Cognitive-Behavioral Therapy for Insomnia (CBT-I)|BEHAVIORAL: Sleep Education Control (EDU),Johns Hopkins University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,2/1/2024,12/31/2028
NCT05205200,RECRUITING,Breast Cancer|Metastatic Cancer,DRUG: SHR-1316|DRUG: SHR6390|DRUG: Nab paclitaxel|DRUG: SERD|DRUG: AI,Fudan University,Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Liaoning Tumor Hospital & Institute|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,338,OTHER,INTERVENTIONAL,6/6/2022,8/1/2026
NCT06165900,RECRUITING,Stereotactic Radiotherapy|Immunotherapy|Breast Cancer,DRUG: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|DRUG: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,136,OTHER,INTERVENTIONAL,9/26/2023,12/15/2028
NCT05510700,RECRUITING,Breast Neoplasms|Insomnia,DEVICE: Acupuncture|DEVICE: Sham acupuncture,Shanghai University of Traditional Chinese Medicine,Longhua Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,INTERVENTIONAL,10/20/2022,2025-06
NCT04565600,COMPLETED,Pain Syndrome,DRUG: Etoricoxib,Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,144,OTHER,INTERVENTIONAL,3/1/2020,6/28/2021
NCT04917900,RECRUITING,Breast Cancer,DRUG: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab,West China Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,216,OTHER,INTERVENTIONAL,12/1/2020,12/31/2023
NCT05996107,RECRUITING,Breast Cancer,DRUG: Ribociclib|RADIATION: Postoperative Radiation Therapy,University of Michigan Rogel Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,2024-03,3/1/2030
NCT05949983,NOT_YET_RECRUITING,Breast Neoplasm,OTHER: APA Program|OTHER: Recommendations for physical activity,"University Hospital, Toulouse",,FEMALE,"ADULT, OLDER_ADULT",NA,866,OTHER,INTERVENTIONAL,1/1/2024,1/1/2026
NCT05072314,RECRUITING,Breast Cancer|Breast Cancer Female|Breast Conserving Surgery|Mastectomy,DRUG: lidocaine 2% and 10%|DRUG: Placebo,Monash University,Royal Perth Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE4,4300,OTHER,INTERVENTIONAL,7/27/2022,2028-07
NCT05314114,RECRUITING,Breast Cancer Female,PROCEDURE: No axillary surgery,Peking University,,FEMALE,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,7/3/2020,2028-09
NCT05251714,RECRUITING,Advanced Solid Tumor|Breast Cancer,DRUG: CFI-402257|DRUG: Fulvestrant,"Treadwell Therapeutics, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,INTERVENTIONAL,5/27/2022,2025-08
NCT04770714,UNKNOWN,Breast Cancer,DIAGNOSTIC_TEST: Breast MRI|DIAGNOSTIC_TEST: Contrast Enhanced Mammography,University of Arizona,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,1/19/2021,2023-01
NCT04524000,ACTIVE_NOT_RECRUITING,Advanced Breast Cancer,DRUG: Alpelisib|DRUG: Fulvestrant,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,INTERVENTIONAL,11/20/2020,1/31/2025
NCT06015100,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Inetetamab plus pyrotiniband and capecitabine,Yan Xue,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2/20/2021,8/31/2023
NCT05016310,ACTIVE_NOT_RECRUITING,Breast,DIETARY_SUPPLEMENT: High Dose Vitamin D|DIETARY_SUPPLEMENT: Standard of Care Vitamin D,Wake Forest University Health Sciences,Atrium Health Levine Cancer Institute,FEMALE,ADULT,NA,7,OTHER,INTERVENTIONAL,9/16/2021,2024-12
NCT05008510,WITHDRAWN,Metastatic Triple Negative Breast Cancer,DRUG: Sabizabulin|DRUG: Sacituzumab Govitecan-hziy|DRUG: Sabizabulin/Sacituzumab govitecan-hziy Combo,Veru Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,12/30/2021,6/30/2023
NCT04636710,RECRUITING,Breast Cancer|Inflammatory Breast Cancer|Sentinel Lymph Node,PROCEDURE: Lymphoscintigraphy,Dana-Farber Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,6/2/2021,12/1/2027
NCT04924010,COMPLETED,Breast Cancer|Chronic Pain|Chronic Postsurgical Pain|Quality of Life,BEHAVIORAL: Cognitive Behavioural Therapy (CBT)|BEHAVIORAL: Education and Mindfulness,Mater Misericordiae University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,5/31/2021,3/2/2023
NCT05291910,NOT_YET_RECRUITING,Breast Cancer,DRUG: Inetetamab|DRUG: Toripalimab|DRUG: Albumin-Bound Paclitaxel,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,70,OTHER,INTERVENTIONAL,3/12/2022,12/31/2025
NCT04319510,RECRUITING,Breast Cancer|Complementary Therapies,PROCEDURE: Craniosacral therapy|PROCEDURE: Craniosacral self-help group training|PROCEDURE: Treatment as usal / wait list,UniversitÃ¤t Duisburg-Essen,,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,9/18/2023,2025-12
NCT05438810,RECRUITING,Advanced Breast Cancer|Female Breast Cancer,"DRUG: FCN-437c,Fulvestrant,Goserelin acetate|DRUG: Placebo,Fulvestrant,Goserelin acetate","Ahon Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,312,OTHER,INTERVENTIONAL,1/18/2022,5/18/2024
NCT05081492,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,BIOLOGICAL: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody,City of Hope Medical Center,National Cancer Institute (NCI)|Imugene Limited,ALL,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,INTERVENTIONAL,10/18/2021,9/22/2024
NCT04738292,TERMINATED,ER-positive Breast Cancer|HER2-negative Breast Cancer|Metastatic Cancer,DRUG: Onapristone|DRUG: Fulvestrant,"University of Wisconsin, Madison",Context Therapeutics Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,INTERVENTIONAL,10/5/2021,5/15/2023
NCT04517292,UNKNOWN,Breast Cancer,"DRUG: Eribulin,cisplatin|DRUG: Gemcitabine,cisplatin",Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,INTERVENTIONAL,10/8/2020,10/31/2022
NCT05874492,NOT_YET_RECRUITING,Fibrosis|Breast Cancer,OTHER: Thermal cure with a primary dermatological indication,Association Francaise pour la Recherche Thermale,Floralis,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,INTERVENTIONAL,2023-09,2026-04
NCT05518292,RECRUITING,Breast Cancer,OTHER: rhomboid intercostal block|OTHER: serratus anterior plane block,Mansoura University,,FEMALE,ADULT,PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,9/1/2022,12/30/2022
NCT05505812,NOT_YET_RECRUITING,Breast Cancer,BIOLOGICAL: HS-IT101,The Affiliated Hospital of Qingdao University,"Qingdao Sino-Cell Biomedicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,10/8/2022,3/31/2027
NCT04930692,NOT_YET_RECRUITING,Breast Neoplasms|Sentinel Lymph Node,DIAGNOSTIC_TEST: Contrast-enhanced CT lymphography with the periareolar injection of iopamidol,"Saint Petersburg State University, Russia",,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,10/1/2022,8/1/2023
NCT06157892,RECRUITING,Breast Neoplasms|Gastroesophageal Junction Adenocarcinoma|HER2 Low Breast Neoplasms|HER2 Positive Breast Neoplasms|Stomach Neoplasms|Triple Negative Breast Neoplasms,DRUG: disitamab vedotin|DRUG: tucatinib,Seagen Inc.,"RemeGen Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,198,INDUSTRY,INTERVENTIONAL,2/29/2024,1/31/2030
NCT04387630,UNKNOWN,Breast Cancer,DRUG: Metformin|DRUG: Placebo oral tablet,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,120,OTHER,INTERVENTIONAL,6/5/2020,5/1/2023
NCT04556292,UNKNOWN,Breast Cancer Metastatic|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation,DRUG: SC10914,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,78,INDUSTRY,INTERVENTIONAL,8/12/2020,8/30/2022
NCT04450732,RECRUITING,HER2-positive Breast Cancer|HER2-positive Biliary Tract Cancer|HER2-Positive Salivary Gland Carcinomas|HER2-Positive Advanced Solid Tumor,DRUG: GQ1001,"GeneQuantum Healthcare (Suzhou) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,96,INDUSTRY,INTERVENTIONAL,7/7/2020,5/1/2024
NCT05547932,COMPLETED,Breast Cancer|Postoperative Pain|Respiratory Function Impaired,PROCEDURE: RIB+SAP blocks,MuÄŸla SÄ±tkÄ± KoÃ§man University,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,9/21/2022,4/14/2023
NCT04408118,COMPLETED,Metastatic Breast Cancer|Advanced Breast Cancer|Triple Negative Breast Cancer,DRUG: Atezolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab,MedSIR,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,10/5/2020,12/7/2023
NCT06195618,NOT_YET_RECRUITING,Breast Cancer Female,BIOLOGICAL: Peptide pulsed autologous Dendritic cell,Universidad Nacional de Colombia,FundaciÃ³n Salud de los Andes,FEMALE,"ADULT, OLDER_ADULT",PHASE1,8,OTHER,INTERVENTIONAL,7/1/2024,6/1/2026
NCT04740918,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Trastuzumab Emtansine|DRUG: Atezolizumab|OTHER: Placebo,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,96,INDUSTRY,INTERVENTIONAL,6/7/2021,4/30/2024
NCT03492918,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: Pembrolizumab,Yonsei University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,2022-04,2023-05
NCT05447702,RECRUITING,Triple Negative Breast Cancer,DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Nab-paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,West China Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,INTERVENTIONAL,11/1/2022,12/31/2026
NCT05000502,ACTIVE_NOT_RECRUITING,Female Breast Cancer,BEHAVIORAL: Home-based exercise intervention,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",NA,49,OTHER,INTERVENTIONAL,9/1/2021,1/31/2024
NCT05361018,RECRUITING,"Breast Neoplasm, Exercise",OTHER: Whole Body Vibration exercise - WBV,Karolinska Institutet,,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,10/17/2022,4/25/2024
NCT05410002,ACTIVE_NOT_RECRUITING,Cancer Breast|Cancer Prostate,DIETARY_SUPPLEMENT: Dietary Supplement: N-111|OTHER: Placebo,Optimal Health Research,,ALL,"ADULT, OLDER_ADULT",PHASE1,160,OTHER,INTERVENTIONAL,10/12/2022,6/14/2024
NCT04499118,UNKNOWN,HER2-negative Breast Cancer,DRUG: AT regimen|DRUG: TP regimen,Sichuan Provincial People's Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,2020-08,2021-08
NCT06248918,ENROLLING_BY_INVITATION,Breast Cancer Female|Survivorship|Health Behavior,BEHAVIORAL: WATSOCPAP,Istanbul Medipol University Hospital,The Scientific and Technological Research Council of Turkey,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,3/1/2024,10/1/2024
NCT05177432,RECRUITING,Breast Cancer,DEVICE: QPOP,"National University Hospital, Singapore",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,26,OTHER,INTERVENTIONAL,12/6/2021,12/31/2025
NCT04733118,RECRUITING,Early Breast Cancer,DRUG: Trastuzumab and Pertuzumab (FDC SC) and T-DM1,MedSIR,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE2,393,OTHER,INTERVENTIONAL,8/5/2021,2028-03
NCT04016818,NOT_YET_RECRUITING,Breast Cancer,DRUG: 18F-FDG|DEVICE: Breast-dedicated PET camera,Stanford University,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,2024-05,2024-12
NCT05125432,UNKNOWN,Breast Cancer,DEVICE: Acupuncture group,Affiliated Hospital of Qinghai University,,FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,INTERVENTIONAL,11/25/2021,11/30/2023
NCT05216718,UNKNOWN,Thyroid Nodule,PROCEDURE: Mini-flap|PROCEDURE: Conventional flap,Inje University,,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,1/24/2022,12/1/2023
NCT05753618,RECRUITING,Early-stage Breast Cancer,DRUG: Granulocyte Colony-Stimulating Factor (G-CSF)|DRUG: Omission of Granulocyte Colony-Stimulating Factor (G-CSF),Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,INTERVENTIONAL,4/17/2023,2025-10
NCT06048718,NOT_YET_RECRUITING,Breast Cancer|Metastatic Breast Cancer,DRUG: Trastuzumab-Deruxtecan (T-DXd),MedSIR,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,INTERVENTIONAL,2024-04,2026-07
NCT06202118,NOT_YET_RECRUITING,Breast Cancer|Recurrent Breast Cancer|Breast Carcinoma,DEVICE: Diffusing Alpha Radiation Emitters Therapy (DaRT),Alpha Tau Medical LTD.,,ALL,OLDER_ADULT,NA,10,INDUSTRY,INTERVENTIONAL,2024-02,2026-06
NCT04307329,ACTIVE_NOT_RECRUITING,Breast Cancer,BIOLOGICAL: Monalizumab|BIOLOGICAL: Trastuzumab,The Netherlands Cancer Institute,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,38,OTHER,INTERVENTIONAL,3/23/2021,5/1/2030
NCT05344729,COMPLETED,Recurrent/Metastatic Breast Cancer,DRUG: TQB3616 Capsule,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,INTERVENTIONAL,7/6/2021,8/30/2021
NCT05512260,RECRUITING,"Neoplasm, Colorectal|Neoplasm, Breast|Neoplasm, Ovarian",DEVICE: Individual decision aid (iDA),Karolinska Institutet,Jonkoping University|MalmÃ¶ University|UmeÃ¥ University|Leiden University|Dalarna University|Karolinska University Hospital,ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,3/1/2023,12/31/2024
NCT05720260,RECRUITING,Premenopausal Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer,DRUG: Goserelin|DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Durvalumab,National Taiwan University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,INTERVENTIONAL,1/17/2023,12/31/2025
NCT06259929,NOT_YET_RECRUITING,Breast Cancer,DRUG: Abemaciclib 150 MG + Giredestrant 30 MG,Fondazione Oncotech,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,51,OTHER,INTERVENTIONAL,4/1/2024,4/1/2027
NCT04300829,UNKNOWN,Breast Adenocarcinoma|Radiation Dermatitis|Radiation Toxicity,DRUG: cicaderma + simple hygiene rules|OTHER: Simple hygiene rules and a maximum of one topical treatment,Centre Leon Berard,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,248,OTHER,INTERVENTIONAL,6/6/2020,10/9/2022
NCT04720729,RECRUITING,HER2-negative Metastatic Breast Cancer,BIOLOGICAL: Chemotherapy monitoring by circulating tumor DNA analysis,Institut Curie,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,214,OTHER,INTERVENTIONAL,3/23/2021,2025-06
NCT05303129,ACTIVE_NOT_RECRUITING,Breast Cancer|Metastatic Breast Cancer,BIOLOGICAL: Blood sampling,Centre Francois Baclesse,,FEMALE,"ADULT, OLDER_ADULT",NA,165,OTHER,INTERVENTIONAL,5/27/2022,2025-06
NCT04403529,RECRUITING,Triple Negative Breast Cancer,DRUG: Traditional Chinese Medicine Formulation|DRUG: Placebo Formulation,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,INTERVENTIONAL,5/25/2020,5/31/2024
NCT05741164,NOT_YET_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Refractory Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Pembrolizumab|DRUG: Propranolol|OTHER: Questionnaire Administration,Roswell Park Cancer Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,2/15/2024,12/15/2027
NCT04659564,COMPLETED,Breast Cancer Related Lymphedema|Lymphedema of Upper Arm|Lymphedema|Quality of Life,DEVICE: User of Dayspring device,"Koya Medical, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,INTERVENTIONAL,8/5/2020,5/28/2021
NCT05293964,RECRUITING,Breast Cancer,DRUG: SIM0270|DRUG: Palbociclib|DRUG: everolimus,"Jiangsu Simcere Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,210,INDUSTRY,INTERVENTIONAL,5/18/2022,9/8/2025
NCT04879264,UNKNOWN,Breast Cancer Female,DIAGNOSTIC_TEST: self-rating scale for severity of sleep disorders|DIAGNOSTIC_TEST: self-rating scale for distress caused by sleep disorders,University Hospital Schleswig-Holstein,Zealand University Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,6/1/2021,6/30/2022
NCT06150664,NOT_YET_RECRUITING,Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Hodgkin Lymphoma|Head and Neck Squamous Cell Carcinoma|Malignant Melanoma,DRUG: CTX-8371,Compass Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INDUSTRY,INTERVENTIONAL,2024-01,2026-04
NCT06003764,RECRUITING,"Dermatitis, Radiation Induced",OTHER: Pulsed electromagnetic field|OTHER: traditional skin care,Ahram Canadian University,,FEMALE,ADULT,NA,50,OTHER,INTERVENTIONAL,11/1/2023,3/30/2024
NCT05694364,RECRUITING,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Triple Negative Breast Cancer Malignancies,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: PRGN-3007,H. Lee Moffitt Cancer Center and Research Institute,"Precigen, Inc",ALL,"ADULT, OLDER_ADULT",PHASE1,88,OTHER,INTERVENTIONAL,1/25/2023,2026-01
NCT05862064,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer,"DRUG: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|DRUG: epirubicin,cyclophosphamide,paclitaxel",Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,606,OTHER,INTERVENTIONAL,7/1/2023,7/1/2028
NCT04968964,RECRUITING,Breast Cancer|Cancer of the Breast,DEVICE: DiviTumÂ® TKa assay|OTHER: Study Care Plans,Washington University School of Medicine,Biovica,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,3/7/2022,3/31/2027
NCT05227664,RECRUITING,Metastatic Triple-negative Breast Cancer|Locally Advanced Triple-negative Breast Cancer,DRUG: AK117|DRUG: AK112|DRUG: Nab paclitaxel|DRUG: paclitaxel,Akeso,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,INTERVENTIONAL,3/23/2022,10/30/2023
NCT05252988,RECRUITING,Early-stage Breast Cancer|HER2 Positive Breast Cancer|Hormone Receptor Positive,DRUG: Neratinib|DRUG: Loperamide|DRUG: Colesevelam,Spanish Breast Cancer Research Group,"Puma Biotechnology, Inc.|Pierre Fabre Laboratories",ALL,"ADULT, OLDER_ADULT",PHASE2,315,OTHER,INTERVENTIONAL,8/31/2022,2030-01
NCT05616988,RECRUITING,Psychological,OTHER: psychological-clinical intervention with three days of expressive writing by Pennebaker,University of Roma La Sapienza,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,10/26/2022,1/30/2024
NCT06172088,NOT_YET_RECRUITING,Breast Cancer Patients Treated With Aromatase Inhibitors,OTHER: Fasting,University Hospital Tuebingen,"Robert Bosch Hospital Stuttgart|Charite University, Berlin, Germany",FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,12/15/2023,9/30/2025
NCT06123988,NOT_YET_RECRUITING,HER2-positive Breast Cancer|Advanced Breast Cancer,BEHAVIORAL: Prolonged Overnight Fasting|BEHAVIORAL: Moderate-Intensity Exercise|BEHAVIORAL: General Health Education Sessions,University of Miami,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,260,OTHER,INTERVENTIONAL,3/31/2024,3/31/2029
NCT04145388,ACTIVE_NOT_RECRUITING,Lynch Syndrome|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Family Characteristics|Genetic Predisposition,OTHER: online cancer risk assessment|OTHER: Usual care,Kaiser Permanente,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",NA,18623,OTHER,INTERVENTIONAL,7/1/2020,8/31/2025
NCT05749588,RECRUITING,Triple-negative Breast Cancer,DRUG: A1: SHR-A1811|DRUG: A2: SHR-A1811 with Camrelizumab|DRUG: B1: TROP2 ADC|DRUG: B2: TROP2 ADC with Camrelizumab|DRUG: C1: SHR-A1811|DRUG: C2: SHR-A1811 with BP102|DRUG: D1: TROP2 ADC|DRUG: D2: TROP2 ADC with BP102|DRUG: E1: SHR-A1811|DRUG: F1: TROP2 ADC|DRUG: G1: SHR-A1811|DRUG: H1: TROP2 ADC,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,3/30/2023,2026-06
NCT04348188,UNKNOWN,Breast Cancer|Colon Cancer,BEHAVIORAL: Education program on healthy habits,Universidad Complutense de Madrid,Hospital Universitario Infanta Leonor,ALL,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,2020-06,2021-11
NCT05984888,RECRUITING,Breast Cancer,BEHAVIORAL: MIND Diet Intervention Group|BEHAVIORAL: General Health Curriculum (GHC) Group,Ohio State University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,8/1/2023,2025-06
NCT06055088,RECRUITING,Breast Cancer|Neuropathy,OTHER: Hand and foot exercise,Amasya University,,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,INTERVENTIONAL,6/1/2023,3/29/2024
NCT04692818,RECRUITING,Breast Tumor,DIAGNOSTIC_TEST: GE Logiq E10 clinical ultrasound scanner|DIAGNOSTIC_TEST: Verasonics research scanner,Mayo Clinic,United States Department of Defense,FEMALE,"ADULT, OLDER_ADULT",NA,125,OTHER,INTERVENTIONAL,11/19/2021,12/31/2025
NCT05614518,COMPLETED,Bone Metastases,DRUG: Sodium Fluoride F-18 Injection|DRUG: Technetium[99mTc] Methylenediphosphonate Injection,"HTA Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,280,INDUSTRY,INTERVENTIONAL,3/29/2021,6/2/2022
NCT04481802,UNKNOWN,Breast Cancer|Radiation Dermatitis,DEVICE: RadiaAce gel|DEVICE: Biafine,AceTech,,FEMALE,"ADULT, OLDER_ADULT",NA,120,INDUSTRY,INTERVENTIONAL,7/14/2021,2022-10
NCT05683418,RECRUITING,Colorectal Cancer|Gastric Cancer|HER2-negative Breast Cancer|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Cervical Cancer|Ovarian Cancer|Endometrial Cancer,DRUG: TOS-358,Totus Medicines,,ALL,"ADULT, OLDER_ADULT",PHASE1,241,INDUSTRY,INTERVENTIONAL,2/15/2023,2025-12
NCT04437602,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Contrast Enhanced Mammography (CEM),Region Halland,,FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,INTERVENTIONAL,11/2/2020,12/31/2023
NCT05296577,RECRUITING,Breast Cancer,DRUG: anlotinib and vinorelbine|DRUG: Vinorelbine injection,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,134,OTHER_GOV,INTERVENTIONAL,3/22/2022,12/1/2024
NCT06106477,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Intermittent Fasting,Medical College of Wisconsin,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/15/2024,7/15/2027
NCT04671329,COMPLETED,Breast Cancer,DEVICE: Affirm Contrast Biopsy procedure,"Hologic, Inc.",,FEMALE,"ADULT, OLDER_ADULT",NA,67,INDUSTRY,INTERVENTIONAL,3/5/2021,8/18/2022
NCT04660929,RECRUITING,"HER2-positive|Adenocarcinoma|Bile Duct Cancer|Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Breast Neoplasm|Carcinoma, Ductal|Carcinoma, Hepatocellular|Cancer|Lung Cancer, Non-Small-Cell|Carcinoma, Ovarian Epithelial|Carcinoma, Small Cell|Carcinoma, Squamous|Carcinoma, Transitional Cell|Colorectal Cancer|Esophagogastric Junction Neoplasms|Inflammatory Breast Cancer|Stomach Neoplasms|Malignant Neoplasms|Ovarian Neoplasms|Pancreatic Cancer|HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|Prostate Cancer|Head and Neck Cancer|Endometrial Cancer|Lung Cancer, Small Cell",BIOLOGICAL: CT-0508|BIOLOGICAL: Pembrolizumab,Carisma Therapeutics Inc,,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,2/2/2021,2024-12
NCT04350229,COMPLETED,Breast Cancer,DRUG: Drug omission|OTHER: Control group,Instituto do Cancer do Estado de SÃ£o Paulo,,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,INTERVENTIONAL,3/27/2020,6/20/2022
NCT05704829,NOT_YET_RECRUITING,HER2-positive Early Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Standard-of-Care,West German Study Group,AstraZeneca,FEMALE,"ADULT, OLDER_ADULT",PHASE2,402,OTHER,INTERVENTIONAL,2023-12,2028-06
NCT06210529,RECRUITING,Breast Cancer,DEVICE: a high-intensity focused ultrasound tumor treatment system (Super Knife),Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,10/1/2022,12/31/2024
NCT05501158,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Tamoxifen,Nalagenetics Pte Ltd,SJH Initiatives|Indonesia University|MRCCC Siloam Hospitals Semanggi,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,150,INDUSTRY,INTERVENTIONAL,1/1/2021,6/30/2024
NCT05163223,RECRUITING,Breast Cancer,BIOLOGICAL: AST-301(pNGVL3-hICD)|DRUG: rhuGM-CSF|DRUG: Placebo|DRUG: Pembrolizumab|DRUG: Capecitabine,Aston Sci. Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,146,INDUSTRY,INTERVENTIONAL,2/28/2022,2025-12
NCT05321823,RECRUITING,Breast Cancer,DEVICE: iBreast device|OTHER: Clinical Breast Examination|DIAGNOSTIC_TEST: Breast ultrasound|DIAGNOSTIC_TEST: Mammography,Obafemi Awolowo University,Pfizer,FEMALE,"ADULT, OLDER_ADULT",NA,4100,OTHER,INTERVENTIONAL,12/8/2021,10/31/2023
NCT04348123,RECRUITING,Breast Cancer,OTHER: Survey|BEHAVIORAL: Education Session,Case Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,3/15/2022,2024-04
NCT05878678,RECRUITING,Breast Cancer,DEVICE: Fixed positions of arm down and arm up,Shanghai Proton and Heavy Ion Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,5/15/2023,7/30/2024
NCT05911958,RECRUITING,HER2 Low Breast Carcinoma,DRUG: SHR-A1811 for injection,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,66,OTHER_GOV,INTERVENTIONAL,7/5/2023,5/31/2029
NCT05743023,ACTIVE_NOT_RECRUITING,Breast Cancer Survivors,BEHAVIORAL: Ayurvedic lifestyle protocol,"Robert Schneider, MD",,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,9/1/2022,6/1/2023
NCT04741802,COMPLETED,Feasibility and Acceptability of the TOPS Program,BEHAVIORAL: TOPS,Duke University,National Institutes of Health (NIH),FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,6/11/2021,8/30/2022
NCT04260802,RECRUITING,Cancer|Neoplasms|Metastatic Cancer|Triple Negative Breast Cancer|Gastric Cancer|Cervical Cancer|Ovarian Cancer|Hepatocellular Carcinoma|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Urothelial Neoplasm|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Locally Advanced Solid Tumor|Locally Advanced Malignant Neoplasm|Squamous Cell Carcinoma|Sarcoma|Merkel Cell Carcinoma|Bladder Cancer,DRUG: OC-001|DRUG: OC-001 in Combination,"Ocellaris Pharma, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,80,INDUSTRY,INTERVENTIONAL,10/6/2020,9/30/2026
NCT05216302,RECRUITING,Breast Cancer,BEHAVIORAL: Group-based Nordic Walking Exercise Program,Raquel Sebio,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,11/1/2021,11/1/2023
NCT04424758,UNKNOWN,Breast Cancer,OTHER: Video information about mammography screening|OTHER: Video information about smart energy systems,University of Copenhagen,,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,6/16/2020,7/30/2020
NCT06044623,NOT_YET_RECRUITING,Metastatic Breast Cancer|Advanced Breast Cancer|Quality of Life|Toxicity|Older Patients,DRUG: CDK 4/6 inhibitors|DRUG: Endocrine therapy,Region Ã–rebro County,"University of Patras|University of Florence|Azienda USL Toscana Centro|Helsinki University Central Hospital|Institute for Medical Technology Assessment - the Netherlands|Security Labs Consulting Limited|Circular Economy Foundation|Universidad Nacional de EducaciÃ³n a Distancia|Hellenic Cooperative Oncology Group|University Hospital, Akershus|Uppsala County Council, Sweden|Hospital Clinic of Barcelona|Phaze Clinical Research & Pharma Consulting|BrÃ¶stcancerfÃ¶rbundet|Eunomia Ltd|University of Applied Sciences and Arts Northwestern Switzerland|CareAcross Ltd|Ã–rebro University, Sweden",ALL,OLDER_ADULT,PHASE3,495,OTHER,INTERVENTIONAL,2023-11,2031-04
NCT05663723,NOT_YET_RECRUITING,Peripheral Nervous System Diseases AND Breast Neoplasms,"DEVICE: Intervention group with the IV and V LED board|DEVICE: Intervention group with the IV, V and Violet LED board|DEVICE: Control group with LED board without emitting light",Erica Alves Nogueira Fabro,COSMEDICAL,FEMALE,"ADULT, OLDER_ADULT",NA,186,OTHER_GOV,INTERVENTIONAL,1/10/2023,12/30/2024
NCT05640778,RECRUITING,Luminal B/HER2-negative Breast Cancer,DRUG: Dalpiciclib combined with aromatase inhibitors,"Second Affiliated Hospital, School of Medicine, Zhejiang University","GeneCast Biotechnology Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,10/1/2022,10/31/2025
NCT05254678,RECRUITING,Breast Cancer|Upper Extremity Dysfunction,BEHAVIORAL: general exercise,University of Alberta,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/20/2023,6/30/2024
NCT05390723,COMPLETED,Communication|Breast Cancer|Quality of Life,BEHAVIORAL: Communciation intervention,Leiden University,Dutch Cancer Society|The Netherlands Cancer Institute,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,6/5/2022,9/1/2023
NCT05022823,ACTIVE_NOT_RECRUITING,Breast Cancer Related Lymphedema,"DEVICE: Compression sleeve, worn during exercise|DEVICE: Adjustable Compression (AC) garment, worn during exercise|DEVICE: Compression sleeve, daytime wear|BEHAVIORAL: Decongestive Progressive Resistance Exercise program|BEHAVIORAL: Home exercise program",AHS Cancer Control Alberta,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,6/29/2022,5/31/2024
NCT02802423,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: BLEX 404 Oral Liquid,"BioLite, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,INTERVENTIONAL,3/1/2024,8/28/2025
NCT04501523,RECRUITING,Triple-negative Breast Cancer,DRUG: Tislelizumab|DRUG: capecitabine,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,460,OTHER,INTERVENTIONAL,8/3/2020,2032-08
NCT05142202,ACTIVE_NOT_RECRUITING,Breast Cancer,RADIATION: Breast Irradiation after Breast-Conserving Surgery,The Greater Poland Cancer Centre,,FEMALE,"ADULT, OLDER_ADULT",NA,147,OTHER,INTERVENTIONAL,10/1/2021,12/31/2025
NCT05684458,NOT_YET_RECRUITING,Breast Cancer|Symptoms and Signs|Quality of Life,PROCEDURE: Reiki,Ankara Medipol University,,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,2/1/2023,8/31/2023
NCT05328258,RECRUITING,Breast Cancer Female|Acute Leukemia|Lymphoma|Osteosarcoma|Soft Tissue Sarcoma|Ewing Sarcoma,DRUG: Triptorelin Embonate|DRUG: Sodium Chloride solution 0.9%,Kenny Rodriguez-Wallberg,,FEMALE,"CHILD, ADULT",PHASE3,500,OTHER,INTERVENTIONAL,3/31/2023,1/31/2032
NCT04604158,UNKNOWN,Cancer|Cancer Metastatic|Neoplasms|Breast Cancer|Lung Cancer|Glioblastoma|Prostate Cancer|Gynecologic Cancer|Colorectal Cancer|Sarcoma|Kidney Cancer|Bladder Cancer|Lymphoma|Leukemia|Head and Neck Cancer|Pancreas Cancer|Multiple Myeloma|Anxiety|Social Isolation|Stress|Loneliness|Melanoma|Uterine Cancer,BEHAVIORAL: Elly Mobile Phone Application,Gillian Gresham,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,12/2/2020,7/8/2022
NCT04225858,NOT_YET_RECRUITING,Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer|Sentinel Lymph Node,PROCEDURE: Omission of sentinel lymph node biopsy,The Netherlands Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,340,OTHER,INTERVENTIONAL,2020-01,2027-07
NCT06008158,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Estrogen Receptor-Positive Breast Carcinoma|HER2-Negative Breast Carcinoma,RADIATION: Accelerated Partial Breast Irradiation,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,9/29/2023,11/17/2025
NCT06115902,RECRUITING,Breast Cancer,DRUG: TQB2102 for injection,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,INTERVENTIONAL,11/17/2023,2026-12
NCT05018702,RECRUITING,"HER2-positive, Metastatic Breast Cancer",DRUG: ARX788,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,INTERVENTIONAL,7/14/2021,6/30/2023
NCT05219578,TERMINATED,Non Small Cell Lung Cancer|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Urothelial Carcinoma|TNBC - Triple-Negative Breast Cancer,DRUG: RTX-224,Rubius Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,7,INDUSTRY,INTERVENTIONAL,1/12/2022,11/30/2022
NCT05455658,RECRUITING,Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,BIOLOGICAL: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|BIOLOGICAL: Sargramostim,University of Washington,"National Cancer Institute (NCI)|University of Wisconsin, Madison",ALL,"ADULT, OLDER_ADULT",PHASE2,33,OTHER,INTERVENTIONAL,11/17/2022,4/30/2024
NCT05654623,RECRUITING,Advanced Breast Cancer,DRUG: ARV-471|DRUG: Fulvestrant,Pfizer,"Arvinas Estrogen Receptor, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,INTERVENTIONAL,3/3/2023,5/15/2028
NCT03560102,TERMINATED,"Breast Cancer, Invasive Ductal",DEVICE: Philips SonalleveÂ® MR-HIFU Breast Therapy System,Kantonsspital Winterthur KSW,,FEMALE,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,1/13/2020,2/5/2020
NCT05458102,TERMINATED,Human Immunodeficiency Virus Type 1 (HIV-1) Infection,DRUG: Vesatolimod|DRUG: Cobicistat|DRUG: Voriconazole|DRUG: Rifabutin,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,INTERVENTIONAL,8/19/2022,10/13/2023
NCT03936478,SUSPENDED,Breast Cancer|DCIS|LCIS,RADIATION: MRIdian Radiation Treatment Unit,"University of Wisconsin, Madison",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,5/16/2022,2031-01
NCT06257758,RECRUITING,Advanced or Metastatic Solid Tumors|Breast Cancer|Recurrent Ovarian Cancer|Prostate Cancer,DRUG: VIO-01,Valerio Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,165,INDUSTRY,INTERVENTIONAL,1/10/2024,12/28/2028
NCT06112158,NOT_YET_RECRUITING,University Students|Breast Self-examination|Health Education,BEHAVIORAL: Education Intervention,Esra Ã–ZER,Ankara Medipol University,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,11/30/2023,6/30/2024
NCT06136923,RECRUITING,Multiple Sclerosis|Lung Cancer|Breast Cancer,DEVICE: CT-100-D-004-A|DEVICE: CT-100-D-004-B,"Click Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,180,INDUSTRY,INTERVENTIONAL,10/19/2023,12/23/2023
NCT05823623,RECRUITING,Breast Cancer,DRUG: Inetetamab|DRUG: Pyrotinib|DRUG: Oral Vinorelbine Tartrate,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,2/13/2022,2025-12
NCT05260723,COMPLETED,Sedentary Behavior|Sedentary Time|Breast Cancer,BEHAVIORAL: Behavioral: Sit Less,"University of California, San Diego",,FEMALE,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,3/29/2022,5/7/2023
NCT04300478,COMPLETED,Overweight|Breast Cancer|Obesity,BEHAVIORAL: REx Condition First|BEHAVIORAL: Sedentary Control Condition First,"University of Colorado, Denver",Colorado Clinical & Translational Sciences Institute|National Cancer Institute (NCI)|National Center for Advancing Translational Sciences (NCATS),FEMALE,ADULT,NA,21,OTHER,INTERVENTIONAL,2/7/2020,2/5/2022
NCT05159778,COMPLETED,Malignant Neoplasm of Breast,BIOLOGICAL: Imprime PGG|BIOLOGICAL: Pembrolizumab,"HiberCell, Inc.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,INTERVENTIONAL,11/9/2021,4/12/2023
NCT05603078,RECRUITING,Breast Neoplasms,RADIATION: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5),"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"CHILD, ADULT",NA,102,OTHER,INTERVENTIONAL,6/21/2022,2028-07
NCT04895358,RECRUITING,Breast Neoplasms,BIOLOGICAL: pembrolizumab|DRUG: paclitaxel|DRUG: nab-paclitaxel|DRUG: liposomal doxorubicin|DRUG: capecitabine|DRUG: normal saline|DRUG: dextrose,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,800,INDUSTRY,INTERVENTIONAL,6/18/2021,7/21/2028
NCT05931302,RECRUITING,Lobular Breast Carcinoma,DIAGNOSTIC_TEST: 68Ga-FAPI-46 PET scan,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Institut Curie|Centre Antoine Lacassagne,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,11/16/2023,2026-04
NCT05057078,COMPLETED,Breast Cancer|Nursing Caries,BEHAVIORAL: mindfulness-based stress reduction program,Ankara University,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,9/29/2021,6/30/2022
NCT06217458,NOT_YET_RECRUITING,DCIS|Breast Carcinoma in Situ|Calcification,DIAGNOSTIC_TEST: Contrast Enhanced Mammography,Clinical Hospital Center Rijeka,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,3/1/2024,1/1/2027
NCT05674578,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,BEHAVIORAL: Patient Navigation|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,11/14/2022,12/31/2023
NCT04134884,RECRUITING,Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor,DRUG: Talazoparib|DRUG: ASTX727,Kathy Miller,"Pfizer|Astex Pharmaceuticals, Inc.|Van Andel Institute Stand Up to Cancer Team",ALL,"ADULT, OLDER_ADULT",PHASE1,38,OTHER,INTERVENTIONAL,4/1/2020,7/1/2025
NCT05286684,RECRUITING,Breast Cancer,"PROCEDURE: Consultation|PROCEDURE: Cerebral and medullary MRI, lumbar puncture, CSF sampling|BIOLOGICAL: biological test",Centre Oscar Lambret,,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,1/4/2023,2026-12
NCT05755984,NOT_YET_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: 3D printed model,M.D. Anderson Cancer Center,University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,4/30/2024,2/28/2028
NCT05333328,RECRUITING,Breast Cancer|Estrogen Receptor Positive Tumor|HER2-negative Breast Cancer|Premenopausal Breast Cancer|Node-positive Breast Cancer,DRUG: Ovarian function suppression with endocrine treatments,Gangnam Severance Hospital,Seoul National University,FEMALE,ADULT,PHASE4,418,OTHER,INTERVENTIONAL,2/6/2023,2033-01
NCT03873428,RECRUITING,FES TEP in Detection of Estrogen Receptors,OTHER: FES PET,Centre Georges Francois Leclerc,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,10/18/2021,10/18/2025
NCT04281641,RECRUITING,HER2-positive Breast Cancer,DIAGNOSTIC_TEST: TCHP,Fudan University,,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,4/21/2020,4/30/2030
NCT04305834,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Abemaciclib|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,OLDER_ADULT,PHASE2,43,OTHER,INTERVENTIONAL,3/25/2020,8/21/2024
NCT05368428,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Early Stage Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Transcutaneous Electrical Nerve Stimulation,Emory University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,10/19/2022,3/31/2025
NCT04841928,COMPLETED,"Pain, Chronic|Breast Cancer",BEHAVIORAL: Mindful attention|BEHAVIORAL: Decentering|BEHAVIORAL: Value-based action,University of Aarhus,Danish Council for Independent Research,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,3/1/2021,8/1/2021
NCT04241341,ACTIVE_NOT_RECRUITING,Breast Cancer Lymphedema,PROCEDURE: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|PROCEDURE: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|OTHER: quality-of-life questionnaires|OTHER: measured by arm volume,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,INTERVENTIONAL,1/22/2020,2026-01
NCT05800834,RECRUITING,"Wounds and Injuries|Cancer Pain|Cancer, Breast|Cancer Head Neck",DRUG: Morphine Sulfate|DRUG: Lidocaine Hcl 2% Jelly,"Instituto Nacional de Cancer, Brazil",,ALL,"ADULT, OLDER_ADULT",PHASE2,106,OTHER_GOV,INTERVENTIONAL,9/12/2023,2024-04
NCT05068141,UNKNOWN,Triple Negative Breast Cancer,DRUG: SG001|DRUG: Nab-paclitaxel,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,79,INDUSTRY,INTERVENTIONAL,10/1/2021,10/1/2023
NCT04360941,RECRUITING,Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Recurrent Breast Cancer|Metastatic Breast Cancer|ER+ Breast Cancer|HER2-positive Breast Cancer,DRUG: Palbociclib|DRUG: Avelumab,Royal Marsden NHS Foundation Trust,Pfizer|Breast Cancer Now,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,INTERVENTIONAL,8/11/2020,12/31/2025
NCT05063136,RECRUITING,Breast Cancer,DRUG: Capecitabine+endocrine therapy|DRUG: Placebo+endocrine therapy,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1979,OTHER_GOV,INTERVENTIONAL,9/28/2021,2028-09
NCT04493034,RECRUITING,Breast Cancer,BEHAVIORAL: Art Therapy|BEHAVIORAL: Music Therapy,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,4/21/2021,6/1/2024
NCT05297734,RECRUITING,End of Life|Cancer,OTHER: Receive technology-based supportive cancer care|BEHAVIORAL: Receive redesigned team-based supportive cancer care,Stanford University,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",NA,2996,OTHER,INTERVENTIONAL,6/24/2022,10/15/2026
NCT05710328,RECRUITING,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Invasive Breast Carcinoma,DRUG: Chemotherapy|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography|PROCEDURE: Surgical Procedure,ECOG-ACRIN Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",PHASE2,235,NETWORK,INTERVENTIONAL,5/10/2023,3/31/2025
NCT05905341,WITHDRAWN,Breast Cancer|Ovarian Cancer|Liposarcoma|Non-small Cell Lung Cancer (NSCLC)|Endometrial|Solid Tumors,DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,1/15/2024,4/13/2028
NCT06153836,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8,PROCEDURE: Neurotization Procedure|OTHER: Questionnaire Administration|PROCEDURE: Subcutaneous Mastectomy,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,INTERVENTIONAL,12/5/2023,11/10/2025
NCT04568941,UNKNOWN,Breast Cancer|Sentinel Lymph Node,BEHAVIORAL: Vacuum-Assisted Biopsy|BEHAVIORAL: Core Needle Biopsy|BEHAVIORAL: Intraoperative Excisional Biopsy,Shandong Cancer Hospital and Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,11/1/2020,6/1/2021
NCT05966441,NOT_YET_RECRUITING,Chemotherapy-induced Peripheral Neuropathy,DIETARY_SUPPLEMENT: Curcumin|DRUG: Paclitaxel,Ain Shams University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,8/30/2023,3/10/2024
NCT05278741,RECRUITING,Breast Cancer,PROCEDURE: Surgery for unilateral breast reconstruction,Centre Georges Francois Leclerc,,FEMALE,"ADULT, OLDER_ADULT",NA,32,OTHER,INTERVENTIONAL,11/25/2022,5/25/2025
NCT05225428,RECRUITING,Genetic Testing|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Colorectal Cancer|Renal Cancer|Melanoma|Sarcoma,BEHAVIORAL: Video Education|BEHAVIORAL: Genetic Counseling,Dana-Farber Cancer Institute,National Cancer Institute (NCI)|National Human Genome Research Institute (NHGRI),ALL,"ADULT, OLDER_ADULT",NA,1020,OTHER,INTERVENTIONAL,8/4/2022,9/1/2026
NCT05785741,RECRUITING,Advanced Solid Tumor,DRUG: DB-1310,DualityBio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,287,INDUSTRY,INTERVENTIONAL,4/10/2023,8/31/2026
NCT05645536,ENROLLING_BY_INVITATION,Breast Cancer,DRUG: TOL2506|DRUG: Tamoxifen|DRUG: Letrozole tablets|DRUG: Anastrozole Tablets|DRUG: Exemestane Tablets,Tolmar Inc.,,ALL,ADULT,PHASE3,250,INDUSTRY,INTERVENTIONAL,12/28/2022,2028-06
NCT05458284,RECRUITING,Breast Cancer|Taxane-Induced Peripheral Neuropathy,PROCEDURE: Real Acupuncture|OTHER: Sham Acupuncture,Memorial Sloan Kettering Cancer Center,Gateway for Cancer Research,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,7/11/2022,2025-07
NCT04791384,RECRUITING,Breast Cancer,DRUG: Abemaciclib|DRUG: Elacestrant,"Criterium, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,INTERVENTIONAL,4/21/2022,2025-01
NCT05536128,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: Olaparib|DRUG: Fulvestrant,Seoul National University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,INTERVENTIONAL,12/31/2022,12/31/2025
NCT04722341,RECRUITING,Colorectal Cancer|Breast Cancer,BEHAVIORAL: Time-Restricted Eating (TRE)|BEHAVIORAL: Control,Cedars-Sinai Medical Center,National Cancer Institute (NCI)|University of Alabama at Birmingham,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,1/1/2022,12/31/2026
NCT04230941,COMPLETED,Cancer-related Problem/Condition|Cognitive Impairment,BEHAVIORAL: MAAT-G,University of Rochester,National Institute on Aging (NIA),ALL,OLDER_ADULT,NA,4,OTHER,INTERVENTIONAL,6/12/2020,2/1/2022
NCT05112536,COMPLETED,Triple Negative Breast Cancer|Breast Cancer,DRUG: Trilaciclib|DRUG: Cylophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Carboplatin (Investigator discretion)|BIOLOGICAL: Pembrolizumab (Investigator discretion),"G1 Therapeutics, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,INTERVENTIONAL,11/19/2021,3/13/2023
NCT05918328,ACTIVE_NOT_RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: Albumin paclitaxel+trastuzumab+pyrrolitinib|DRUG: Docetaxel+Carboplatin+trastuzumab+Parstuzumab,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,610,OTHER_GOV,INTERVENTIONAL,5/3/2023,5/3/2026
NCT05131841,UNKNOWN,Metastatic Breast Cancer,DRUG: Cipterbin Combined With Vinorelbine,Zhejiang Cancer Hospital,Proswell Medical Corporation,FEMALE,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,INTERVENTIONAL,1/4/2021,12/30/2022
NCT06130241,NOT_YET_RECRUITING,Sentinel Lymph Node,PROCEDURE: sentinle lymphnode biopsy,Assiut University,,FEMALE,ADULT,NA,30,OTHER,INTERVENTIONAL,11/30/2023,4/1/2025
NCT04102436,NOT_YET_RECRUITING,Endocrine/Neuroendocrine|Non-Small Cell Lung Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancers|Ovarian Cancer,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Aldesleukin|BIOLOGICAL: Sleeping Beauty Transposed PBL,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,210,NIH,INTERVENTIONAL,2/20/2024,12/31/2029
NCT05873036,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Aerobic Training|DIAGNOSTIC_TEST: Progressive Resistance Training,Superior University,,FEMALE,"ADULT, OLDER_ADULT",NA,74,OTHER,INTERVENTIONAL,4/1/2023,8/31/2023
NCT04614194,RECRUITING,Breast Cancer,DRUG: Letrozole|DRUG: Abemaciclib,University of Texas Southwestern Medical Center,Eli Lilly and Company|Cancer Prevention Research Institute of Texas,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,4/15/2021,4/15/2025
NCT05190094,RECRUITING,"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer",DRUG: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole),"International Cancer Research Group, United Arab Emirates","King Saud University Medical City, Riyadh, Saudi Arabia|Max-Planck-Institut fÃ¼r Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-UniversitÃ¤t MÃ¼nchen (LMU), Garching, Germany|King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,12/20/2022,2026-06
NCT04261218,COMPLETED,Breast Cancer,DRUG: tomivosertib|DRUG: paclitaxel,Translational Research in Oncology,Effector Therapeutics|Stand Up To Cancer,ALL,"ADULT, OLDER_ADULT",PHASE1,19,OTHER,INTERVENTIONAL,8/25/2020,7/4/2022
NCT05172518,NOT_YET_RECRUITING,Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer,DRUG: Taxane plus Intermittent Capecitabine|DRUG: Utidelone plus Intermittent Capecitabine|DRUG: Taxane plus Metronomic Capecitabine|DRUG: Utidelone plus Metronomic Capecitabine,Sun Yat-sen University,Chengdu Biostar Pharmaceuticals,FEMALE,"ADULT, OLDER_ADULT",PHASE3,512,OTHER,INTERVENTIONAL,3/1/2022,3/1/2030
NCT04262518,UNKNOWN,Breast Cancer|Invasive Breast Cancer|Metastatic Breast Cancer|Breast Carcinoma|Metastatic Breast Carcinoma,DEVICE: Outcomes4Me Mobile App,Outcomes4Me,Massachusetts General Hospital,ALL,"ADULT, OLDER_ADULT",NA,125,INDUSTRY,INTERVENTIONAL,6/1/2020,2020-10
NCT04694794,COMPLETED,Chemotherapeutic Toxicity|Chemotherapeutic Agent Toxicity|Chemotherapy Effect,OTHER: Educational Brochure,Milton S. Hershey Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,3/24/2021,8/21/2023
NCT04550494,RECRUITING,Advanced Pancreatic Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|HER2-Positive Breast Carcinoma|Locally Advanced Breast Carcinoma|Locally Advanced Gastric Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Ovarian Carcinoma|Locally Advanced Pancreatic Carcinoma|Locally Advanced Prostate Carcinoma|Metastatic Breast Carcinoma|Metastatic Gastric Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Prostate Carcinoma|Platinum-Sensitive Ovarian Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Talazoparib,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,36,NIH,INTERVENTIONAL,4/26/2021,12/1/2024
NCT05325632,RECRUITING,HER2-positive Breast Cancer,BIOLOGICAL: HER-2 pulsed DC1|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Paclitaxel|PROCEDURE: Resection surgery,H. Lee Moffitt Cancer Center and Research Institute,ImmunoRestoration,ALL,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,INTERVENTIONAL,10/28/2021,1/31/2025
NCT04752332,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DRUG: Abemaciclib|DRUG: Standard Adjuvant ET|DRUG: Placebo,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,2450,INDUSTRY,INTERVENTIONAL,5/10/2021,2/9/2024
NCT05174832,RECRUITING,Triple Negative Breast Cancer,DRUG: Cisplatin|DRUG: Nab-paclitaxel|DRUG: Pembrolizumab|DRUG: Olaparib,Fudan University,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,136,OTHER,INTERVENTIONAL,9/7/2022,3/1/2025
NCT06027632,NOT_YET_RECRUITING,Breast Cancer|Cognitive Dysfunction,OTHER: Cognitive exercises with supervision|OTHER: Cognitive exercises without supervision,Centre Francois Baclesse,UNICANCER,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,2023-09,2029-03
NCT04832594,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: AI selection for supplemental breast MRI,Karolinska University Hospital,"KTH Royal Institute of Technology|Region Stockholm|BrÃ¶stcancerfÃ¶rbundet, Sweden",FEMALE,"ADULT, OLDER_ADULT",NA,2500,OTHER,INTERVENTIONAL,4/1/2021,7/1/2025
NCT06110832,COMPLETED,Breast Cancer,BEHAVIORAL: Mindfulness-based Meditation and Yoga program,Kutahya Health Sciences University,KoÃ§ University,FEMALE,ADULT,NA,41,OTHER,INTERVENTIONAL,5/11/2023,12/31/2023
NCT05800132,NOT_YET_RECRUITING,Breast Cancer,DEVICE: MammoScreen,Therapixel,,FEMALE,"ADULT, OLDER_ADULT",NA,5000,INDUSTRY,INTERVENTIONAL,2023-05,2027-05
NCT05638594,RECRUITING,Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Dalpiciclib|DRUG: Letrozole|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Gonadotropin-releasing hormone agonist,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,236,OTHER,INTERVENTIONAL,12/20/2022,12/10/2027
NCT04669132,COMPLETED,Nausea Post Chemotherapy,DRUG: Olanzapine|DRUG: Netupitant|DRUG: Palonesetron,Instituto Brasileiro de Controle do Cancer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,12/17/2020,1/17/2022
NCT03730818,COMPLETED,Breast Cancer,OTHER: Water-based Exercise Group|OTHER: Land-based Exercise Group,Universitat Pompeu Fabra,Hospital del Mar|Centre Esportiu Claror MarÃ­tim,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,9/1/2020,4/30/2023
NCT05593094,RECRUITING,Advanced Solid Tumors|HER2-positive Breast Cancer,DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c,Suzhou Zanrong Pharma Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,210,INDUSTRY,INTERVENTIONAL,10/15/2020,10/30/2024
NCT06105632,NOT_YET_RECRUITING,Advanced or Metastatic Breast Cancer,DRUG: PF-07220060|DRUG: Fulvestrant|DRUG: Everolimus|DRUG: Exemestane,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,INTERVENTIONAL,12/15/2023,11/13/2028
NCT06131632,NOT_YET_RECRUITING,Inflammatory Breast Cancer,PROCEDURE: Breast conserving surgery|PROCEDURE: Radical modified mastectomy,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,3/1/2024,1/1/2028
NCT04961632,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Tamoxifen|DRUG: Tamoxifen,"National Cancer Centre, Singapore","National Medical Research Council (NMRC), Singapore",ALL,"ADULT, OLDER_ADULT",PHASE1,75,OTHER,INTERVENTIONAL,12/23/2020,2025-11
NCT04352777,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Hormone Receptor Positive Tumor,DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Aromatase Inhibitors,Duke University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,18,OTHER,INTERVENTIONAL,9/14/2020,12/30/2024
NCT06023277,NOT_YET_RECRUITING,Metastatic Breast Cancer,BIOLOGICAL: ConvitVax,Jacinto Convit World Organization Inc.,FundaciÃ³n Jacinto Convit|Instituto Oncologico Luis Razetti,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,INTERVENTIONAL,4/1/2024,3/31/2027
NCT05836077,RECRUITING,Posttraumatic Growth|Psychological Resilience|Breast Cancer Patients,OTHER: Education with pecha kucha method,Istanbul Sabahattin Zaim University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,4/10/2023,6/30/2023
NCT05673694,RECRUITING,Breast Cancer,DRUG: EG017,"Changchun GeneScience Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,INTERVENTIONAL,3/8/2023,1/2/2026
NCT04458532,RECRUITING,Early Stage Breast Cancer,OTHER: Aerobic Training|OTHER: Aerobic Training|OTHER: Aerobic Training|OTHER: Aerobic Training,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,152,OTHER,INTERVENTIONAL,10/8/2020,2025-07
NCT05285332,NOT_YET_RECRUITING,Breast Neoplasms|Treatment|Metastatic Breast Cancer|Survival,PROCEDURE: surgical treatment 1|PROCEDURE: surgical treatment 2|DRUG: Systemic therapy,Changhai Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,362,OTHER,INTERVENTIONAL,8/1/2022,5/1/2031
NCT04433494,RECRUITING,Breast Cancer|Solid Tumor,"DRUG: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg","TYK Medicines, Inc",,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,12/7/2020,2023-12
NCT05429294,RECRUITING,HER2-positive Breast Cancer,DRUG: Pyrotinib,First Affiliated Hospital Xi'an Jiaotong University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,209,OTHER,INTERVENTIONAL,6/1/2022,10/30/2024
NCT05910294,RECRUITING,Improve Sexual Health|Improve Vulvovaginal Health,OTHER: questionnaires|OTHER: moisturizers|OTHER: moisturizers,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,6/1/2023,2027-06
NCT05747794,RECRUITING,Breast Carcinoma,BIOLOGICAL: eftilagimod alpha|DRUG: Paclitaxel|OTHER: placebo,Immutep S.A.S.,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,849,INDUSTRY,INTERVENTIONAL,5/22/2023,7/31/2027
NCT04818632,COMPLETED,"ER+, HER2-, Metastatic Breast Cancer",DRUG: AZD9833|DRUG: AZD9833|DRUG: AZD9833 with palbociclib|DRUG: AZD9833 with everolimus,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,28,INDUSTRY,INTERVENTIONAL,11/12/2021,9/7/2023
NCT06260332,RECRUITING,Breast Cancer,BEHAVIORAL: Supportive Care (Fitbit),New Mexico Cancer Care Alliance,University of New Mexico,FEMALE,ADULT,NA,25,OTHER,INTERVENTIONAL,10/20/2023,12/31/2024
NCT04593277,RECRUITING,Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Malignant Neoplasm|Leukemia|Lymphoma|Malignant Solid Neoplasm|Sarcoma|Stage I Colorectal Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Thyroid Gland Carcinoma,OTHER: Internet Mobile Technology|OTHER: Internet-Based Intervention|OTHER: Questionnaire Administration|PROCEDURE: Supportive Care|OTHER: Informational Intervention,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,700,OTHER,INTERVENTIONAL,10/23/2022,12/31/2025
NCT04837677,COMPLETED,Sarcoma|Melanoma|Lung Cancer|Breast Cancer|Esophageal Cancer|Cervical Cancer|Head and Neck Cancer,DRUG: PRT1419,Prelude Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,INTERVENTIONAL,8/11/2021,2/6/2023
NCT04419077,COMPLETED,Anxiety|Chemotherapy Effect|Breast Cancer|Head Cancer Neck,BEHAVIORAL: Virtual reality exposure,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,6/7/2020,6/16/2022
NCT06042894,RECRUITING,Breast Cancer,DRUG: BL-B01D1|DRUG: SI-B003,"Sichuan Baili Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,INDUSTRY,INTERVENTIONAL,12/12/2023,2025-12
NCT05655494,NOT_YET_RECRUITING,Cancer,BEHAVIORAL: Stand-alone Research Portal|BEHAVIORAL: Portal with Virtual Community Health Educator (vCHE),University of Florida,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,INTERVENTIONAL,12/20/2023,8/31/2027
NCT04424732,RECRUITING,Breast Neoplasm Malignant Female,RADIATION: Stereotactic Body Radiotherapy,King Hussein Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,6/1/2020,6/1/2026
NCT04328194,UNKNOWN,Breast Cancer,DIAGNOSTIC_TEST: Serum Autotaxin|RADIATION: chest x-ray|DIAGNOSTIC_TEST: Breast ultrasound or mammography|DIAGNOSTIC_TEST: Histopathological examination of breast mass specimens|RADIATION: Magnetic Resonance Imaging ( MRI) and Bone scan|DIAGNOSTIC_TEST: Peripheral haemogram|DIAGNOSTIC_TEST: Renal and liver functions|DIAGNOSTIC_TEST: Prothrombin time and concentration|DIAGNOSTIC_TEST: Cancer Antigen 15-3 (CA15-3).|OTHER: Full medical history|OTHER: Full clinical examination,Assiut University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,5/1/2021,11/1/2022
NCT04966377,COMPLETED,Breast Cancer,BEHAVIORAL: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS),Ondokuz MayÄ±s University,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,6/1/2021,2/1/2022
NCT05092477,COMPLETED,Diabetes|Breast Cancer,BEHAVIORAL: Integrated Intervention for Breast Cancer Survivors with Diabetes|BEHAVIORAL: Attention Control,Icahn School of Medicine at Mount Sinai,Northwestern University Feinberg School of Medicine|Feinstein Institute for Medical Research|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,INTERVENTIONAL,1/27/2022,7/24/2023
NCT04913532,RECRUITING,Breast Cancer|Surgery|Adjuvant Radiotherapy,RADIATION: Hypofractionation with simultaneous integrated boost,Capital Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,6/22/2021,7/31/2025
NCT04641377,UNKNOWN,Breast Cancer Female,OTHER: Multicomponent exercise intervention plus health education|OTHER: Health Education,Federal University of Pelotas,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,2021-02,2023-03
NCT04438577,UNKNOWN,Breast Cancer,DRUG: Lidocaine mucilage-ICG,Shantou Central Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,8/20/2020,2024-01
NCT05923177,RECRUITING,Primary Breast Cancer,DRUG: SPECT,Tomsk National Research Medical Center of the Russian Academy of Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,INTERVENTIONAL,9/1/2023,9/1/2024
NCT05909332,RECRUITING,Breast Cancer|Triple Negative Breast Cancer,DRUG: Antivascular therapy|DRUG: Chemotherapy,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,548,OTHER,INTERVENTIONAL,6/20/2023,5/30/2031
NCT05557877,RECRUITING,Benign Breast Neoplasm|Breast Carcinoma|Breast Fibrocystic Change,PROCEDURE: Biospecimen Collection|DRUG: Low-Dose Aspirin|OTHER: Questionnaire Administration|PROCEDURE: Ultrasound-Guided Biopsy,Mayo Clinic,National Cancer Institute (NCI),FEMALE,ADULT,PHASE2,100,OTHER,INTERVENTIONAL,2/14/2023,1/30/2027
NCT06112977,ENROLLING_BY_INVITATION,Breast Cancer|Risk Reduction,PROCEDURE: Prepectoral implant-based immediate breast reconstruction,University of Oxford,"National Institute for Health Research, United Kingdom",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,11/1/2023,2/1/2025
NCT06058377,RECRUITING,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|OTHER: Genetic Testing|PROCEDURE: Mammography|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment,National Cancer Institute (NCI),,FEMALE,"ADULT, OLDER_ADULT",PHASE3,3680,NIH,INTERVENTIONAL,11/27/2023,5/31/2026
NCT05989477,RECRUITING,Patient Engagement|Patient Activation|Patient Reported Outcome Measures,OTHER: At-home Breast Oncology care Delivered with E-health solutions - ABODE,"University Health Network, Toronto",,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,6/22/2023,6/22/2026
NCT05417594,RECRUITING,Advanced Solid Malignancies,DRUG: AZD9574|DRUG: Temozolomide|DRUG: [11C]AZ1419 3391|DRUG: Datopotamab Deruxtecan (Dato-DXd)|DRUG: Trastuzumab Deruxtecan (T-DXd),AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,490,INDUSTRY,INTERVENTIONAL,6/24/2022,1/12/2026
NCT04088877,COMPLETED,Breast Cancer|Body Image,BEHAVIORAL: Exercise|BEHAVIORAL: Art Sculpting Class,University of Alberta,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,1/1/2020,8/31/2020
NCT04753177,UNKNOWN,The Neoadjuvant Therapy,"DRUG: Ribocyclib, fulvestrant, triptorelin|DRUG: Doxorubicin, cyclophosphamide, paclitaxel","Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary",,FEMALE,ADULT,PHASE2|PHASE3,120,OTHER,INTERVENTIONAL,1/28/2021,1/28/2024
NCT05576077,RECRUITING,Breast Cancer|Colorectal Cancer|Uveal Melanoma|Cutaneous Melanoma|Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: TBio-4101|DRUG: Pembrolizumab,"Turnstone Biologics, Corp.",,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,1/17/2023,6/30/2025
NCT04721977,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Tucatinib|BIOLOGICAL: Trastuzumab|DRUG: Capecitabine,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,INTERVENTIONAL,4/8/2021,12/6/2028
NCT04133077,RECRUITING,Breast Cancer Female,BIOLOGICAL: blood samples collection,Centre Jean Perrin,,FEMALE,"ADULT, OLDER_ADULT",NA,85,OTHER,INTERVENTIONAL,11/19/2021,5/31/2026
NCT05505357,RECRUITING,Breast Cancer Invasive,PROCEDURE: Breast surgery omission,Seoul National University Hospital,"Ministry of Health & Welfare, Korea",FEMALE,"ADULT, OLDER_ADULT",NA,533,OTHER,INTERVENTIONAL,9/22/2022,2031-03
NCT05414357,RECRUITING,Breast Cancer|Sleep|Quality of Life,DIAGNOSTIC_TEST: Functional Magnetic Resonance Imaging at rest and in activation with attentional task,Centre Francois Baclesse,UMR_S 1077 Inserm-EPHE-Normandie UniversitÃ©,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,3/20/2023,2027-09
NCT05622240,RECRUITING,Breast Cancer,DRUG: 99mTc-MIRC213,Peking Union Medical College Hospital,,FEMALE,"CHILD, ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,INTERVENTIONAL,9/7/2022,12/31/2023
NCT04999540,NOT_YET_RECRUITING,Breast Cancer,DRUG: Tucidinostat|DRUG: Fulvestrant,Guangdong Women and Children Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,INTERVENTIONAL,11/1/2021,12/30/2024
NCT04137640,NOT_YET_RECRUITING,Breast Cancer,DRUG: palbociclib combined with letrozole|DRUG: epirubicin combined with cyclophosphamide and sequential docetaxel,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,152,OTHER,INTERVENTIONAL,7/19/2021,5/31/2026
NCT05663801,NOT_YET_RECRUITING,Cancer|Breast,DRUG: Use of Bupivacaine in pectoral nerve block in mastectomy|DRUG: use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|DRUG: Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy,Beni-Suef University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,INTERVENTIONAL,2023-02,10/1/2023
NCT05960201,RECRUITING,"Carcinoma, Lobular",DRUG: [18F]fluoroestradiol (FES),Asan Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,8/10/2023,12/31/2024
NCT05554380,RECRUITING,Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Ipatasertib|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,33,NIH,INTERVENTIONAL,9/22/2023,8/31/2025
NCT04630080,ACTIVE_NOT_RECRUITING,Breast Cancer,DEVICE: Scalp cooling,Chinese University of Hong Kong,,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,INTERVENTIONAL,1/8/2021,12/31/2025
NCT03903224,UNKNOWN,Breast Cancer|Acute Postoperative Pain,PROCEDURE: Combined Modified Pectoralis and Transversus Plane Blocks|PROCEDURE: Erector Spinae block,Assiut University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,2/8/2021,12/1/2022
NCT05544240,RECRUITING,Metastatic Cancer|Metastatic Breast Cancer|Metastatic Lung Cancer|Solid Tumor|Cancer,DRUG: SV-101,Williams Cancer Foundation,"Syncromune, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,2/1/2023,12/31/2023
NCT05968157,RECRUITING,Breast Cancer,PROCEDURE: Breast MRI,"University of Massachusetts, Worcester",,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,12/15/2023,1/1/2025
NCT04080934,RECRUITING,"Lymphedema|Seroma|Pain, Postoperative|Pain, Chest",BEHAVIORAL: Swimming,Ottawa Hospital Research Institute,University of Ottawa|Bruyere Research Institute,ALL,"ADULT, OLDER_ADULT",NA,128,OTHER,INTERVENTIONAL,1/1/2023,12/31/2025
NCT05552001,RECRUITING,Triple Negative Breast Cancer|Metastatic Breast Cancer,DRUG: Sacituzumab govitecan,UNICANCER,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE3,96,OTHER,INTERVENTIONAL,10/5/2023,5/1/2026
NCT05460780,RECRUITING,Breast Cancer Female|Breast Cancer Prevent|Breast Reconstruction,DEVICE: MATTISSE TEC,Quanta Medical,Lattice Medical,FEMALE,"ADULT, OLDER_ADULT",NA,50,INDUSTRY,INTERVENTIONAL,7/1/2022,12/31/2028
NCT05562440,COMPLETED,Breast Cancer,OTHER: Focus Group Discussion,Nalagenetics Pte Ltd,SJH Initiatives|MRCCC Siloam Hospitals Semanggi,FEMALE,"ADULT, OLDER_ADULT",NA,10,INDUSTRY,INTERVENTIONAL,11/8/2022,2/12/2023
NCT05449340,RECRUITING,Breast Cancer,DEVICE: BEAUTIFY application,Centre Hospitalier Universitaire de NÄ«mes,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,7/25/2022,2024-07
NCT06074757,COMPLETED,Metastatic Breast Cancer,DRUG: Fulvestrant injection,"Kashiv BioSciences, LLC",,FEMALE,ADULT,PHASE1,48,INDUSTRY,INTERVENTIONAL,3/1/2023,10/1/2023
NCT04144140,COMPLETED,Lymphoma|Advanced Solid Tumors,DRUG: E7766,Eisai Inc.,H3 Biomedicine Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,2/24/2020,7/26/2022
NCT04817540,RECRUITING,"HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study",DRUG: Herzuma,Gangnam Severance Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,INTERVENTIONAL,9/1/2021,3/30/2027
NCT06026657,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Naxitamab|BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells,Margaret Gatti-Mays,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,42,OTHER,INTERVENTIONAL,3/1/2024,12/31/2024
NCT05189535,COMPLETED,Breast Cancer Female|Peripheral Neuropathy,DRUG: Pentoxifylline|DRUG: Paclitaxel|DRUG: Placebo,Ain Shams University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,66,OTHER,INTERVENTIONAL,10/3/2021,9/28/2023
NCT04426435,COMPLETED,Breast Cancer,DRUG: honey based (HB) syrup,Shiraz University of Medical Sciences,Shahid Beheshti University of Medical Sciences,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/15/2020,10/5/2020
NCT04469296,RECRUITING,Breast Cancer|Surgery,DIETARY_SUPPLEMENT: iso-caloric ketogenic diet|DIETARY_SUPPLEMENT: protein restricted diet,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,INTERVENTIONAL,5/18/2021,2025-03
NCT04906395,RECRUITING,Breast Cancer,DRUG: TOL2506|DRUG: Tamoxifen|DRUG: Letrozole Tablets|DRUG: Anastrozole Tablets|DRUG: Exemestane Tablets,Tolmar Inc.,,ALL,ADULT,PHASE3,250,INDUSTRY,INTERVENTIONAL,7/1/2021,4/30/2025
NCT04440995,COMPLETED,Breast Neoplasm,PROCEDURE: pectoral nerve block,Yonsei University,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,7/8/2020,10/10/2021
NCT05424835,RECRUITING,"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",DRUG: SHR-A1811|DRUG: Pyrotinib in combination with Capecitabine.,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,269,INDUSTRY,INTERVENTIONAL,7/29/2022,12/31/2024
NCT04839835,UNKNOWN,Breast Cancer|Anxiety,"OTHER: waiting room enriched with music, paintings and artificial plants",Namik Kemal University,,FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,INTERVENTIONAL,11/1/2020,3/3/2022
NCT05177796,WITHDRAWN,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Panitumumab|BIOLOGICAL: Pembrolizumab,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,3/11/2022,7/26/2023
NCT04936295,RECRUITING,Breast Cancer,DRUG: Fulvestrant plus Anlotinib,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,INTERVENTIONAL,6/16/2021,6/1/2025
NCT05301595,WITHDRAWN,Breast Cancer,PROCEDURE: TAP block|PROCEDURE: QL Block,Ottawa Hospital Research Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2022-04,2023-03
NCT05901935,NOT_YET_RECRUITING,HER2-positive Advanced Breast Cancer,DRUG: DP303c|DRUG: Trastuzumab|DRUG: Vinorelbine Tartrate|DRUG: Capecitabine tablets,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,420,INDUSTRY,INTERVENTIONAL,2023-07,2028-07
NCT04267796,RECRUITING,Breast Carcinoma,OTHER: Aerobic Exercise|OTHER: Dietary Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Resistance Training,M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Foundation for Women's Cancers,FEMALE,"ADULT, OLDER_ADULT",NA,62,OTHER,INTERVENTIONAL,11/22/2021,4/30/2025
NCT04331535,RECRUITING,Coronary Artery Disease|Atrial Fibrillation|Type 2 Diabetes|Colorectal Cancer|Breast Cancer|Prostate Cancer,DIAGNOSTIC_TEST: Polygenic risk score (PRS),"Boston VA Research Institute, Inc.",VA Boston Healthcare System,ALL,"ADULT, OLDER_ADULT",NA,1076,OTHER,INTERVENTIONAL,7/17/2020,9/30/2025
NCT04551495,RECRUITING,Invasive Lobular Breast Carcinoma|ER+ Breast Cancer|HER2-negative Breast Cancer,DRUG: Entrectinib|DRUG: Letrozole|DRUG: Goserelin,Jules Bordet Institute,Hoffmann-La Roche,FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,INTERVENTIONAL,1/14/2021,2024-07
NCT04789096,RECRUITING,Breast Cancer|HER2-positive Breast Cancer,DRUG: Tucatinib|DRUG: Pembrolizumab|DRUG: Trastuzumab|DRUG: Capecitabine,"Breast Cancer Trials, Australia and New Zealand",,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,3/7/2023,2025-09
NCT04400695,RECRUITING,Breast Cancer,DRUG: RC48-ADC|DRUG: Paclitaxel Injection|DRUG: Docetaxel Injection|DRUG: Vinorelbine Tartrate Injection|DRUG: Capecitabine Tablets,"RemeGen Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,366,INDUSTRY,INTERVENTIONAL,9/29/2020,12/30/2024
NCT05700396,RECRUITING,Breast Cancer|Breast Neoplasms|Breast Carcinoma|Breast Cancer Female,BEHAVIORAL: Breast Cancer Survivor Education Program,Massachusetts General Hospital,"American Cancer Society, Inc.|Pfizer",FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,2/28/2023,12/31/2023
NCT06091696,NOT_YET_RECRUITING,Post-operative Breast Cancer,OTHER: inspiratory muscle training,University of Hail,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,12/1/2023,9/1/2024
NCT04712396,COMPLETED,"Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)",DRUG: Capivasertib|DRUG: Itraconazole,AstraZeneca,Parexel,ALL,ADULT,PHASE1,11,INDUSTRY,INTERVENTIONAL,2/1/2021,3/25/2021
NCT05594095,RECRUITING,Breast Neoplasm|Breast Cancer|Hormone Receptor Positive Tumor|HER2-negative Breast Cancer|Advanced Breast Cancer,DRUG: PIK3CA inhibitor|DRUG: AKT inhibitor|DRUG: Carrelizumab|DRUG: Famitinib|DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: SHR-A1811|DRUG: TROP2 ADC|DRUG: Everolimus|DRUG: Aromatase Inhibitors or Fulvestrant|DRUG: Goserelin|DRUG: TPC|DRUG: RTK Inhibitor,Fudan University,Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,INTERVENTIONAL,12/30/2022,12/1/2026
NCT05161195,RECRUITING,Metastatic Breast Cancer,DRUG: Ribociclib|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Goserelin|DRUG: Tamoxifen|DRUG: Fulvestrant,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,137,INDUSTRY,INTERVENTIONAL,7/7/2022,9/3/2029
NCT04862195,TERMINATED,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,DEVICE: Attuneâ„¢|DEVICE: Cerenaâ„¢,Blue Note Therapeutics,,ALL,"ADULT, OLDER_ADULT",NA,31,INDUSTRY,INTERVENTIONAL,5/15/2021,9/1/2022
NCT06214598,NOT_YET_RECRUITING,Breast Cancer,DIETARY_SUPPLEMENT: Supplement|DIETARY_SUPPLEMENT: AI diet|DIETARY_SUPPLEMENT: Placebo,University of Belgrade,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,3/1/2024,11/30/2026
NCT05790096,NOT_YET_RECRUITING,Breast Cancer,BIOLOGICAL: Granulokine|BIOLOGICAL: Filgrastine,Blau Farmaceutica S.A.,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,INTERVENTIONAL,2023-05,2024-12
NCT05036096,RECRUITING,Breast Cancer,DEVICE: CBBCT Imaging|DEVICE: Digital Mammography,Koning Corporation,,FEMALE,"ADULT, OLDER_ADULT",NA,1024,INDUSTRY,INTERVENTIONAL,10/30/2021,12/30/2024
NCT03983395,TERMINATED,Breast Cancer,"BIOLOGICAL: ISB 1302 250 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|BIOLOGICAL: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|BIOLOGICAL: ISB 1302 escalating doses,1200 ng/kg D15,22|BIOLOGICAL: ISB 1302 at the MTD and/or RP2D dose",Ichnos Sciences SA,Glenmark Pharmaceuticals S.A.,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,INDUSTRY,INTERVENTIONAL,4/8/2020,7/24/2020
NCT05154396,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Neratinib,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,1/1/2022,12/31/2024
NCT04430595,UNKNOWN,Breast Cancer,BIOLOGICAL: 4SCAR T cells,Shenzhen Geno-Immune Medical Institute,The Seventh Affiliated Hospital of Sun Yat-sen University,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,INTERVENTIONAL,6/1/2020,12/31/2023
NCT05150535,RECRUITING,Breast Carcinoma,RADIATION: Hypofractionation Radiotherapy.|RADIATION: Ultra-hypofractionation radiotherapy,Sohag University,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,10/1/2021,10/1/2023
NCT05101096,RECRUITING,Advanced Solid Tumor|Metastatic Triple-Negative Breast Cancer|HR+/HER2- Metastatic Breast Cancer|Metastatic Urothelial Cancer,DRUG: Sacituzumab Govitecan-hziy,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,143,INDUSTRY,INTERVENTIONAL,10/20/2021,2026-05
NCT04751435,RECRUITING,Educational Materials for Genetic Testing|Breast Cancer|Ovarian Cancer|Prostate Cancer|Pancreatic Cancer,OTHER: Cognitive interview,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,625,OTHER,INTERVENTIONAL,11/16/2021,8/31/2026
NCT05168696,COMPLETED,Breast Cancer Female|Anxiety|Fatigue,OTHER: Virtual Reality Glasses,Necmettin Erbakan University,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,4/4/2022,11/30/2022
NCT05982496,NOT_YET_RECRUITING,Breast Cancer Female|Lobular Breast Carcinoma|PET/MRI|Axillary Lymphadenopathy|Luminal A Breast Cancer,DRUG: FES|PROCEDURE: PET/MRI A|PROCEDURE: PET/MRI B|PROCEDURE: PET/MRI C|PROCEDURE: PET/MRI D|GENETIC: Translational analysis,UniversitÃ  Vita-Salute San Raffaele,Associazione Italiana per la Ricerca sul Cancro|IRCCS San Raffaele,FEMALE,"ADULT, OLDER_ADULT",NA,221,OTHER,INTERVENTIONAL,10/15/2023,11/1/2028
NCT04136496,RECRUITING,Breast Cancer|Axillary Lymphadenitis,DEVICE: Black-Eye Ink,The Ottawa Hospital,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,1/2/2020,2023-08
NCT04531696,RECRUITING,Breast Cancer|Hereditary Diseases,PROCEDURE: Blood draw|PROCEDURE: Post-mortem tissue collection,Universitaire Ziekenhuizen KU Leuven,KU Leuven|Universiteit Antwerpen,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/30/2020,2035-09
NCT05058196,ACTIVE_NOT_RECRUITING,Breast Cancer,RADIATION: Whole breast radiotherapy|RADIATION: Intra Operative Radiotherapy,UNICANCER,,FEMALE,OLDER_ADULT,NA,104,OTHER,INTERVENTIONAL,10/1/2021,2025-09
NCT05076695,RECRUITING,Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer,DRUG: Palbociclib|DRUG: trastuzumab|DRUG: pyrotinib|DRUG: fulvestrant,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,INTERVENTIONAL,10/15/2021,10/15/2024
NCT04963595,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: Pyrotinib|DRUG: Vinorelbine|DRUG: Inetetamab,Zhiyong Yu,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,8/1/2021,7/31/2024
NCT05377996,RECRUITING,Triple Negative Breast Cancer|Breast Cancer|Endometrial Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer,DRUG: XMT-1660,Mersana Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,166,INDUSTRY,INTERVENTIONAL,8/15/2022,2026-01
NCT05233696,WITHDRAWN,Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Unresectable Breast Carcinoma|Metastatic Breast Cancer|PD-L1 Gene Mutation,DRUG: Nab-paclitaxel|DRUG: Paclitaxel|RADIATION: Radiation Therapy|DRUG: Pembrolizumab,"University of Colorado, Denver",Cancer League of Colorado,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,1/4/2022,12/1/2022
NCT04535895,WITHDRAWN,Breast Cancer|Radiotherapy Side Effect,RADIATION: Simultaneous integrated boost,Medical University of Graz,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,4/16/2020,8/31/2025
NCT04586335,RECRUITING,Ovarian Cancer|Breast Cancer|Solid Tumor|Prostate Cancer|Endometrial Cancer,DRUG: CYH33,"Haihe Biopharma Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,350,INDUSTRY,INTERVENTIONAL,9/28/2020,1/28/2024
NCT05770596,RECRUITING,Vitamin C|Post-mastectomy Pain Syndrome,DRUG: vitamin C group|OTHER: placebo group,Tanta University,,FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,INTERVENTIONAL,4/1/2023,12/1/2024
NCT04457596,RECRUITING,Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Synchronous Bilateral Breast Carcinoma,BIOLOGICAL: Trastuzumab Emtansine|DRUG: Placebo Administration|DRUG: Tucatinib|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI)|Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE3,1031,OTHER,INTERVENTIONAL,1/6/2021,2035-05
NCT05025735,UNKNOWN,Metastatic Breast Cancer|HER2-negative Breast Cancer,DRUG: Dapagliflozin 10Mg Tab,Saint Luke's Health System,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,8/25/2021,2023-07
NCT05388435,ACTIVE_NOT_RECRUITING,Advanced Solid Tumor,DRUG: SKL27969,"SK Life Science, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,96,INDUSTRY,INTERVENTIONAL,9/12/2022,2024-09
NCT05406635,RECRUITING,Cardiotoxicity|HER2-positive Breast Cancer,DIAGNOSTIC_TEST: Biomarkers: Troponins and natriuretic peptides,Odense University Hospital,Aarhus University Hospital|Aalborg University Hospital|University of Copenhagen,FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,10/1/2021,9/1/2025
NCT05107674,RECRUITING,"Ovarian Cancer, Epithelial|Gastric Cancer|GastroEsophageal Junction (GEJ) Cancer|Head and Neck Squamous Cell Carcinoma|Metastatic or Unresectable Melanoma|Non-small Cell Lung Cancer (NSCLC)|Metastatic Castration-resistant Prostate Cancer (mCRPC)|Malignant Pleural Mesothelioma (MPM)|Triple Negative Breast Cancer (TNBC)|Metastatic Urothelial Carcinoma|Cervical Cancer|Diffuse Large B Cell Lymphoma (DLBCL)|Richter Transformation|Microsatellite Stable Colorectal Carcinoma",DRUG: NX-1607|DRUG: Paclitaxel,"Nurix Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,345,INDUSTRY,INTERVENTIONAL,9/29/2021,2/28/2026
NCT02201381,WITHDRAWN,Cancer|Overall Survival,DRUG: Metabolic treatment,Health Clinics Limited,,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,INTERVENTIONAL,5/23/2022,9/23/2027
NCT06140576,NOT_YET_RECRUITING,Breast Neoplasms,DRUG: Sindilimab|DRUG: Nab-paclitaxel|DRUG: Lenvatinib,Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,58,OTHER,INTERVENTIONAL,11/30/2023,12/31/2026
NCT05931874,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Core Intervention|BEHAVIORAL: E-Coach|BEHAVIORAL: Buddy|BEHAVIORAL: General Mindfulness Training|BEHAVIORAL: MVPA-Specific Mindfulness Training,Northwestern University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,304,OTHER,INTERVENTIONAL,1/8/2024,8/31/2026
NCT03613181,NOT_YET_RECRUITING,Leptomeningeal Carcinomatosis|Leptomeningeal Metastases|Brain Metastases|HER2-negative Breast Cancer,DRUG: ANG1005|DRUG: Physician's Best Choice,Angiochem Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,INTERVENTIONAL,2023-12,2024-12
NCT05799976,NOT_YET_RECRUITING,"Pneumonia, Pneumococcal|Diabetes Mellitus|Breast Cancer|Colorectal Cancer",BEHAVIORAL: Text message nudge,Ascension South East Michigan,,ALL,"ADULT, OLDER_ADULT",NA,30000,OTHER,INTERVENTIONAL,2023-09,2024-02
NCT05885776,RECRUITING,Breast Cancer,DRUG: Pyrrolidineã€trastuzumabã€AI,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,INTERVENTIONAL,9/13/2022,9/30/2025
NCT04245176,ACTIVE_NOT_RECRUITING,Breast Cancer|Invasive Breast Cancer|in Situ Breast Cancer|Genetic Testing,BEHAVIORAL: Standard Genetic Counseling|BEHAVIORAL: Quantitative Genetic Counseling,Dana-Farber Cancer Institute,"Myriad Genetics, Inc.",ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,1/31/2020,12/1/2024
NCT06023576,RECRUITING,Breast Cancer|Cardiotoxicity,OTHER: antihypertensive medications|DIAGNOSTIC_TEST: Blood pressure measurement|DIAGNOSTIC_TEST: Echocardiogram|OTHER: Symptom-limited cardiopulmonary exercise test|OTHER: Quality of Life Measures|DIAGNOSTIC_TEST: Biomarkers,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,INTERVENTIONAL,8/18/2023,8/18/2027
NCT04506476,RECRUITING,Breast Cancer,"DEVICE: Fitness tracker based activity training for Arm A and B. Booklet ""physical training, exercise and cancer"" and an introduction about physical activity during cancer therapy for Arm A, B, C",University Hospital Tuebingen,,FEMALE,"ADULT, OLDER_ADULT",NA,201,OTHER,INTERVENTIONAL,8/1/2020,8/1/2025
NCT04650581,RECRUITING,Breast Cancer,DRUG: Ipatasertib|DRUG: Fulvestrant|OTHER: Placebo,Canadian Cancer Trials Group,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE3,250,NETWORK,INTERVENTIONAL,1/27/2021,12/31/2026
NCT06132776,RECRUITING,Chemotherapy-induced Peripheral Neuropathy,DEVICE: HiToP 191 PNP|DEVICE: Placebo device,Vienna Hospital Association,,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER_GOV,INTERVENTIONAL,11/3/2023,12/31/2024
NCT05494281,RECRUITING,"Breast Neoplasms|Pain, Postoperative|Pain, Chronic|Post-Mastectomy Chronic Pain Syndrome",PROCEDURE: Serratus Anterior Plane Block with local anesthetic|PROCEDURE: Serratus Anterior Plane Block with saline solution,Moroccan Society of Surgery,,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,8/1/2022,7/31/2023
NCT04389281,RECRUITING,Advanced Solid Tumor Cancer,COMBINATION_PRODUCT: X-PACT,"Immunolight, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,12/8/2021,2025-08
NCT05338281,WITHDRAWN,Breast Cancer|Surgical Site Infection|Wound Dehiscence,DEVICE: Negative Pressure Wound Therapy,"Western University, Canada",Lawson Health Research Institute,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2023-09,2025-10
NCT05585476,NOT_YET_RECRUITING,Female Urogenital Diseases|Breast Cancer Female,DEVICE: C02 microablative laser|COMBINATION_PRODUCT: Regenerative topical treatment,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,"Lumenis Be Ltd.|Mucosa Innovations, S.L.",FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,INTERVENTIONAL,2022-12,2026-01
NCT06084481,RECRUITING,Hepatocellular Carcinoma|Pancreatic Ductal Adenocarcinoma|Biliary Tract Cancers|Esophageal Squamous Cell Carcinoma|Triple Negative Breast Cancer|Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer|Head and Neck Squamous-Cell Carcinoma,DRUG: ABBV-400,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,INTERVENTIONAL,11/9/2023,7/20/2026
NCT05755581,NOT_YET_RECRUITING,Female Breast Cancer,DRUG: Hormonal Antineoplastics|DRUG: Chemotherapy drug,Sohag University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,INTERVENTIONAL,4/1/2023,8/1/2025
NCT05100498,COMPLETED,Breast Neoplasm Female|Fertility Preservation,DEVICE: Web-based oncofertility support tool,Mackay Medical College,"Taipei Veterans General Hospital, Taiwan",ALL,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,1/1/2020,8/5/2021
NCT05940298,RECRUITING,Prostate Cancer|Breast Cancer,DRUG: Intravenous injection of [99mTc]Tc-DB8,Tomsk National Research Medical Center of the Russian Academy of Sciences,Uppsala University,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,INTERVENTIONAL,7/3/2023,2/1/2024
NCT04120298,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,BEHAVIORAL: Supervised exercise,UMC Utrecht,"German Cancer Research Center|Australian Catholic University|Karolinska Institutet|The Netherlands Cancer Institute|Medical University of Gdansk|FundaciÃ³n Onkologikoa Fundazioa|Europa Donna|German Sport University, Cologne|University Hospital Heidelberg|Nurogames GmbH, Cologne",ALL,"ADULT, OLDER_ADULT",NA,357,OTHER,INTERVENTIONAL,1/8/2020,7/1/2027
NCT03804944,RECRUITING,Breast Cancer,RADIATION: Focal Radiation therapy|DRUG: Pembrolizumab (200mg IV for 30 minutes|BIOLOGICAL: CDX-301,Weill Medical College of Cornell University,United States Department of Defense|Merck Sharp & Dohme LLC|Celldex Therapeutics,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,3/17/2020,2027-12
NCT04278144,RECRUITING,HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Colorectal Cancer|HER2-positive Gastroesophageal Cancer|HER2-positive Endometrial Cancer,DRUG: BDC-1001|DRUG: Nivolumab,"Bolt Biotherapeutics, Inc.",Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,390,INDUSTRY,INTERVENTIONAL,2/24/2020,10/31/2026
NCT04282044,RECRUITING,"Solid Tumor, Adult|Triple Negative Breast Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Osteosarcoma|Epithelial Ovarian Cancer|Gastric Cancer|Non-small Cell Lung Cancer|Malignant Melanoma",BIOLOGICAL: CRX100 suspension for infusion|COMBINATION_PRODUCT: Fludarabine|COMBINATION_PRODUCT: Cyclophosphamide,BioEclipse Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,1/8/2021,2026-10
NCT03619044,TERMINATED,HER2-positive Breast Cancer,OTHER: 2 FES-PET Imaging will be performed:,Institut Claudius Regaud,,FEMALE,"ADULT, OLDER_ADULT",NA,4,OTHER,INTERVENTIONAL,8/28/2020,7/9/2021
NCT05594498,RECRUITING,Breast Cancer|Radiation Dermatitis,DEVICE: StrataXRT,Sunnybrook Health Sciences Centre,,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/13/2022,6/30/2023
NCT04149444,WITHDRAWN,Metastatic Triple Negative Breast Cancer,DRUG: Trifluridine/Tipiracil,AHS Cancer Control Alberta,Tom Baker Cancer Centre,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2020-02,6/9/2020
NCT04390698,COMPLETED,Opioid Free Anesthesia,PROCEDURE: paravertebral block|DRUG: opioid free anesthesia|PROCEDURE: sham block|PROCEDURE: opioid general anesthesia,Peking University People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,7/1/2020,3/15/2022
NCT04907344,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Camrelizumab|DRUG: Nab-Paclitaxel|DRUG: Carboplatin,Tianjin Medical University Cancer Institute and Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,420,OTHER,INTERVENTIONAL,6/15/2021,6/30/2025
NCT04220476,WITHDRAWN,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,Weill Medical College of Cornell University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,3/4/2020,12/31/2028
NCT05898399,RECRUITING,Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: ART6043|DRUG: Olaparib|DRUG: Talazoparib|DRUG: Olaparib|DRUG: Talazoparib,Artios Pharma Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,250,INDUSTRY,INTERVENTIONAL,6/30/2023,12/14/2026
NCT05018676,RECRUITING,Breast Cancer With Low Expression of HER2,DRUG: ARX788,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,10/20/2021,6/30/2023
NCT05973864,NOT_YET_RECRUITING,Triple Negative Breast Neoplasms,DRUG: Pembrolizumab injection|DRUG: Capecitabine tablets|RADIATION: Local radiotherapy,UNICANCER,,ALL,"ADULT, OLDER_ADULT",PHASE3,418,OTHER,INTERVENTIONAL,2024-01,2029-01
NCT04913064,RECRUITING,Breast Carcinoma,OTHER: Questionnaire Administration|DRUG: White Button Mushroom Extract,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,7/27/2021,7/12/2024
NCT04275661,UNKNOWN,Analgesia|Breast Cancer,PROCEDURE: Ultrasound (US) bi-level erector spinae block|DRUG: levobupivacaine|DRUG: Ketamine|DRUG: Magnesium Sulfate,Assiut University,,FEMALE,ADULT,PHASE2,60,OTHER,INTERVENTIONAL,8/1/2020,2022-04
NCT05673746,RECRUITING,Peripheral Neuropathy,"PROCEDURE: Acupuncture|DRUG: treatment of physician choice, according to the standard of care",IRCCS Azienda Ospedaliero-Universitaria di Bologna,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,9/1/2020,2023-12
NCT05759546,RECRUITING,Breast Cancer Metastatic,DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI,Fudan University,Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Liaoning Tumor Hospital & Institute|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,2/1/2023,6/1/2027
NCT04556773,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Capivasertib|DRUG: Anastrozole|DRUG: Fulvestrant|DRUG: Capecitabine,AstraZeneca,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited",ALL,"ADULT, OLDER_ADULT",PHASE1,139,INDUSTRY,INTERVENTIONAL,12/17/2020,11/28/2025
NCT05092373,RECRUITING,Advanced Breast Carcinoma|Advanced Endometrial Carcinoma|Advanced Fallopian Tube Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Malignant Abdominal Neoplasm|Advanced Malignant Female Reproductive System Neoplasm|Advanced Malignant Thoracic Neoplasm|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Renal Cell Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Malignant Abdominal Neoplasm|Malignant Solid Neoplasm|Metastatic Breast Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Malignant Abdominal Neoplasm|Metastatic Malignant Female Reproductive System Neoplasm|Metastatic Malignant Thoracic Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Renal Cell Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8,BIOLOGICAL: Atezolizumab|DRUG: Cabozantinib S-malate|DRUG: Nab-paclitaxel|PROCEDURE: Tumor Treating Fields Therapy,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,INTERVENTIONAL,4/29/2022,9/1/2026
NCT06183164,RECRUITING,Breast Cancer Patients Receiving Chemotherapy,OTHER: Mindfulness: Awareness-Based Stress Reduction Program,Firat University,,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,12/29/2023,8/29/2024
NCT06144164,RECRUITING,Lymphedema|Lymphedema Arm|Lymphedema of Upper Arm|Breast Cancer|Breast Carcinoma|Female Breast Cancer,PROCEDURE: Immediate Lymphatic Reconstruction|DIAGNOSTIC_TEST: Volumetric arm measurements|OTHER: Lymphatic massage|OTHER: Range of motion exercises|OTHER: Compression garment use,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,285,OTHER,INTERVENTIONAL,11/16/2023,3/16/2030
NCT04450264,COMPLETED,Breast Cancer,BEHAVIORAL: African Immigrant Breast Cancer Education Program,Icahn School of Medicine at Mount Sinai,National Institute on Minority Health and Health Disparities (NIMHD),ALL,"ADULT, OLDER_ADULT",NA,155,OTHER,INTERVENTIONAL,2/5/2020,6/29/2023
NCT05904964,RECRUITING,HR Positive/HER2 Low Expression Metastatic Breast Cancer,DRUG: Disitamab vedotin|OTHER: Endocrine therapy,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,288,OTHER,INTERVENTIONAL,7/1/2023,3/1/2030
NCT05297773,RECRUITING,Breast Cancer,BEHAVIORAL: Aerobic Training Group|BEHAVIORAL: Resistance Training Group|OTHER: Control group,Fundacao Champalimaud,University of Lisbon,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,INTERVENTIONAL,12/16/2022,4/30/2024
NCT04373564,RECRUITING,Motor Function|Cognitive Function|Contrast Media,PROCEDURE: Motor Tests|PROCEDURE: Cognitive Tests|PROCEDURE: Unenhanced-MRI of the brain|PROCEDURE: Gadolinium Measurements|DRUG: Gadoxetate disodium|DRUG: Gadobenate dimeglumine|DRUG: Gadodiamide|DRUG: Gadoterate meglumine|DRUG: Gadobutrol|DRUG: Gadoteridol,Guerbet,Bayer AG (Sponsor)|Bracco (Sponsor)|GEHC (Sponsor),ALL,ADULT,PHASE4,2076,INDUSTRY,INTERVENTIONAL,3/24/2021,12/31/2028
NCT05378464,RECRUITING,HER2-positive Breast Cancer,BIOLOGICAL: Dendritic Cell (DC1) Vaccine|DRUG: Trastuzumab|DRUG: Pepinemab|BIOLOGICAL: T-Cell therapy,H. Lee Moffitt Cancer Center and Research Institute,Vaccinex Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,28,OTHER,INTERVENTIONAL,5/31/2022,2026-05
NCT05826964,RECRUITING,Breast Cancer|ER-positive Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer,DRUG: AI+CDK4/6i|DRUG: SERD+CDK4/6i|DRUG: mTOR inhibitor + AI|DRUG: mTOR inhibitor + SERD|DRUG: mTOR inhibitor + Selective estrogen receptor modulator|DRUG: PI3K inhibitor + SERD|DRUG: PI3K inhibitor + AI|DRUG: Chemotherapy|DRUG: Oral SERD,University of Miami,,ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,INTERVENTIONAL,6/12/2023,7/31/2029
NCT04588246,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Digestive System Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Brain Neoplasm|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Memantine|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Stereotactic Radiosurgery|RADIATION: Whole-Brain Radiotherapy,NRG Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,350,OTHER,INTERVENTIONAL,12/15/2020,1/31/2030
NCT05796973,RECRUITING,Prostate Cancer|Breast Cancer|Kidney Cancer|Ovarian Cancer|Metastatic Breast Cancer|Metastatic Kidney Cancer|Metastatic Renal Cell Carcinoma|Metastatic Renal Cancer|Metastatic Prostate Cancer|Metastatic Prostate Adenocarcinoma|Metastatic Ovarian Cancer|Metastatic Ovary Cancer,BEHAVIORAL: Guided physical exercise|DRUG: Atorvastatin|OTHER: Independent exercise,Tampere University Hospital,Tampere University|Aalto University|University of Helsinki|University of Turku,ALL,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,INTERVENTIONAL,3/31/2023,12/31/2027
NCT04215146,ACTIVE_NOT_RECRUITING,Breast Cancer Metastatic,DRUG: Paclitaxel|BIOLOGICAL: Pelareorep|DRUG: Avelumab,Oncolytics Biotech,"PrECOG, LLC.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,INDUSTRY,INTERVENTIONAL,6/10/2020,2024-07
NCT05732064,RECRUITING,Breast Cancer|Perioperative Period|Dexmedetomidine|Esketamine|Sleep Quality,DRUG: Dexmedetomidine|DRUG: Esketamine|DRUG: Normal saline,Peking University First Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,180,OTHER,INTERVENTIONAL,5/22/2023,2024-07
NCT04849364,RECRUITING,Breast Cancer|Triple Negative Breast Cancer,DRUG: Capecitabine|DRUG: Talazoparib|DRUG: Pembrolizumab|DRUG: Inavolisib,"Bryan Schneider, MD","Genentech, Inc.|Pfizer|Foundation Medicine|Indiana University|Vera Bradley Foundation for Breast Cancer Research",ALL,"ADULT, OLDER_ADULT",PHASE2,197,OTHER,INTERVENTIONAL,8/24/2021,1/31/2034
NCT05222464,COMPLETED,Breast Cancer,OTHER: Standard of care treatments,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,56,OTHER,INTERVENTIONAL,2/25/2022,9/22/2022
NCT04383210,ACTIVE_NOT_RECRUITING,Locally Advanced Solid Tumor|Metastatic Solid Tumor|Pancreatic Cancer|Lung Cancer|Head and Neck Cancer|Breast Cancer|Kidney Cancer|Colorectal Cancer|Bladder Cancer|Ovarian Cancer|Sarcoma|Gallbladder Cancer|Bile Duct Cancer|Esophageal Cancer|Uterine Cancer|Cholangiocarcinoma|Prostate Cancer,DRUG: Seribantumab,Elevation Oncology,,ALL,"ADULT, OLDER_ADULT",PHASE2,75,INDUSTRY,INTERVENTIONAL,9/29/2020,2025-03
NCT04767464,COMPLETED,Breast Cancer|Breast Neoplasm,OTHER: Compass Course,Mary Radomski,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,3/1/2021,11/7/2023
NCT05464173,RECRUITING,Breast Cancer,DRUG: Chidamide|DRUG: Abemaciclib|DRUG: endocrinotherapyï¼ˆdoctor's choiceï¼‰,"Biyun Wang, MD",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,OTHER,INTERVENTIONAL,7/1/2022,5/1/2025
NCT05035173,ACTIVE_NOT_RECRUITING,Survivorship|Breast Cancer|Cervical Cancer|Endometrial Cancer,OTHER: Survivorship Clinic Assessments|OTHER: Survivorship Clinic Nurse Resource|OTHER: Survivorship Clinic Dietitian Resource,University College Cork,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Irish Cancer Society|Breakthrough Cancer Research|Cancer Research@UCC|Cancer Trials Cork|Clinical Research Facilites - Cork (CRF-C)|Cork University Hospital|Enhancing Cancer Awareness and Survivorship Programmes (ECASP),FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,3/13/2021,2024-04
NCT06224673,NOT_YET_RECRUITING,HER2 Low Breast Carcinoma|Triple Negative Breast Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive Breast Carcinoma,DRUG: ARX788|PROCEDURE: Computed Tomography (CT)|PROCEDURE: Biospecimen Collection,"Laura Huppert, MD, BA","Ambrx, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,3/1/2024,7/31/2028
NCT06046664,ACTIVE_NOT_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: ONCOTYPE DX DCIS test,Royal Marsden NHS Foundation Trust,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,7/7/2020,12/31/2023
NCT05382364,ACTIVE_NOT_RECRUITING,Metastatic HER2+ Advanced Breast Cancer|Breast Neoplasms|Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)|Colorectal Cancer,DRUG: Tucatinib,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INDUSTRY,INTERVENTIONAL,6/29/2022,12/29/2025
NCT03651973,RECRUITING,Breast Cancer|Surgery,OTHER: Standard follow-up|OTHER: Learning workshops,Center Eugene Marquis,,FEMALE,"ADULT, OLDER_ADULT",NA,144,OTHER,INTERVENTIONAL,1/13/2020,8/31/2025
NCT06020573,RECRUITING,Breast Cancer|Resection Margin,DEVICE: Clip-on electrode with fiber optics,Erbe Elektromedizin GmbH,,FEMALE,"ADULT, OLDER_ADULT",NA,24,INDUSTRY,INTERVENTIONAL,9/26/2023,4/30/2024
NCT04568161,RECRUITING,Cardiotoxicity|Cardiovascular Disease|Neurovascular Disorder|Endothelial Disfunction|Breast Cancer,PROCEDURE: Physical Characteristics|PROCEDURE: Muscular Sympathetic Nervous Activity|DIAGNOSTIC_TEST: Cardiac Function|DIAGNOSTIC_TEST: Heart rate|DIAGNOSTIC_TEST: Blood pressure|DIAGNOSTIC_TEST: Blood Assessments|DIAGNOSTIC_TEST: Muscle blood flow|DIAGNOSTIC_TEST: Endothelium-dependent vascular function|DIAGNOSTIC_TEST: Vascular intima-media thickness|DIAGNOSTIC_TEST: Physical Capacity|DRUG: Anthracycline & Cyclophosphamide treatment scheme,University of Sao Paulo General Hospital,Universidade Federal Fluminense|Hospital Israelita Albert Einstein,FEMALE,ADULT,NA,15,OTHER,INTERVENTIONAL,8/3/2020,3/3/2024
NCT05296746,RECRUITING,Breast Cancer Stage II,DRUG: Ribociclib (neoadjuvant)|DRUG: Chemotherapy (adjuvant)|DRUG: Ribociclib (adjuvant),SOLTI Breast Cancer Research Group,Novartis|UNICANCER,ALL,"ADULT, OLDER_ADULT",PHASE2,1100,OTHER,INTERVENTIONAL,5/3/2022,7/1/2030
NCT05162846,RECRUITING,Breast Cancer|Colorectal Cancer|Ovarian Cancer|Prostate Cancer|Pancreatic Cancer|Endometrial Cancer|History of Cancer,OTHER: Publicly available genetic testing resources|BEHAVIORAL: Virtual genetics navigator|BEHAVIORAL: Motivational interviewing (MI),University of Michigan Rogel Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,759,OTHER,INTERVENTIONAL,4/21/2022,2026-05
NCT04629846,UNKNOWN,Breast Cancer,DRUG: Trastuzumab|DRUG: QL1209|DRUG: Pertuzumab|DRUG: Docetaxel|PROCEDURE: surgery,"Qilu Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,544,INDUSTRY,INTERVENTIONAL,2020-11,2022-12
NCT06144346,RECRUITING,Breast Cancer|Metastatic Cancer|Metastatic Breast Cancer,RADIATION: Stereotactic Ablative Radiation Therapy|PROCEDURE: Locoregional treatment|OTHER: Standard of Care,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,9/20/2023,9/20/2028
NCT04353973,RECRUITING,Cancer,OTHER: Pre-Test Intervention|OTHER: Standard of Care|OTHER: Post-Test Intervention,Abramson Cancer Center at Penn Medicine,AstraZeneca|Fox Chase Cancer Center|Basser Center for BRCA|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",NA,560,OTHER,INTERVENTIONAL,8/17/2020,12/31/2024
NCT05708664,COMPLETED,Breast Cancer,PROCEDURE: precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,8/1/2021,1/1/2023
NCT05300464,RECRUITING,Breast Cancer,DEVICE: Clinical investigation medical device class IIa marked CE,Umbria Bioengineering Technologies,,FEMALE,"ADULT, OLDER_ADULT",NA,600,INDUSTRY,INTERVENTIONAL,1/7/2023,5/31/2024
NCT05559164,RECRUITING,Cardiac Toxicity|Early-stage Breast Cancer,DRUG: Lipitor 40mg Tablet,"Rutgers, The State University of New Jersey",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,9/19/2022,3/1/2027
NCT04646564,RECRUITING,Breast Cancer Metastatic,DRUG: standard of care|RADIATION: radiotherapy + standard of care,Chinese Academy of Medical Sciences,"Liaoning Tumor Hospital & Institute|Wuhan University|China-Japan Union Hospital, Jilin University|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University|West China Hospital|Shanxi Province Cancer Hospital|Peking Union Medical College Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE3,170,OTHER,INTERVENTIONAL,4/6/2021,4/30/2026
NCT05755646,RECRUITING,Hand-Foot Syndrome|Breast Cancer,OTHER: Ice Plant Intensive Cream plus Standard Care|OTHER: Standard Care,University Hospital Tuebingen,Robert Bosch Gesellschaft fÃ¼r Medizinische Forschung mbH,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,3/10/2023,2/28/2024
NCT04669873,RECRUITING,Malignant Neoplasm of Breast,RADIATION: Active Comparator: Standard|RADIATION: Experimental 1: Hypofractionated radiotherapy|RADIATION: Experimental 2: Accelerated Partial Breast Irradiation,Instituto Brasileiro de Controle do Cancer,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,3/4/2021,12/31/2026
NCT05409664,ACTIVE_NOT_RECRUITING,Breast Cancer|Physical Inactivity,BEHAVIORAL: Physical activity adoption|BEHAVIORAL: Self monitoring,University of South Carolina,"University of Colorado, Denver|Brown University|InquisitHealth, Inc.",FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,11/10/2022,1/31/2025
NCT06176261,NOT_YET_RECRUITING,Breast Cancer|Breast Cancer Female|Metastatic Triple-Negative Breast Carcinoma|ER Positive Breast Cancer|HER2-negative Breast Cancer|HER2 Negative Breast Carcinoma|ER-negative Breast Cancer,DRUG: Datopotamab Deruxtecan,"Sarah Sammons, MD",Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,INTERVENTIONAL,2024-05,1/1/2029
NCT05550415,RECRUITING,Triple Negative Breast Cancer|Chemotherapy Effect|Simvastatin Adverse Reaction,DRUG: Simvastatin 40mg|DRUG: Placebo,Indonesia University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,INTERVENTIONAL,8/19/2022,2025-02
NCT04585750,RECRUITING,Advanced Solid Tumor|Advanced Malignant Neoplasm|Metastatic Cancer|Metastatic Solid Tumor|Lung Cancer|Ovarian Cancer|Endometrial Cancer|Prostate Cancer|Colorectal Cancer|Breast Cancer|Other Cancer|Locally Advanced|Head and Neck Cancer,DRUG: PC14586|DRUG: pembrolizumab,"PMV Pharmaceuticals, Inc",Merck Sharp & Dohme LLC,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,230,INDUSTRY,INTERVENTIONAL,10/29/2020,7/14/2026
NCT06184750,NOT_YET_RECRUITING,Breast Carcinoma|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ|Estrogen Receptor-Positive Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|OTHER: Questionnaire Administration|DRUG: Tamoxifen,National Cancer Institute (NCI),,FEMALE,ADULT,PHASE2,200,NIH,INTERVENTIONAL,6/10/2024,7/30/2027
NCT04998682,RECRUITING,Breast Cancer,PROCEDURE: Axillary Dissection,University of Miami,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,3/1/2022,2025-03
NCT04905082,ACTIVE_NOT_RECRUITING,Breast Carcinoma|Colorectal Carcinoma|Lung Carcinoma|Malignant Solid Neoplasm|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma,OTHER: Best Practice|OTHER: Educational Intervention|OTHER: Educational Intervention|PROCEDURE: Genomic Profile|OTHER: Survey Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,465,OTHER,INTERVENTIONAL,12/30/2021,6/30/2024
NCT04858516,NOT_YET_RECRUITING,"Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer",DRUG: palbociclib and exemestane plus trastuzumab and pyrotinib,Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,57,OTHER,INTERVENTIONAL,4/30/2021,4/30/2025
NCT04243616,RECRUITING,Invasive Breast Cancer,DRUG: Cemiplimab|DRUG: Paclitaxel|DRUG: Carboplatin (not mandatory)|DRUG: Doxorubicin|DRUG: Cyclophosphamide,Medical College of Wisconsin,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,3/5/2020,1/1/2026
NCT04768868,RECRUITING,Advanced Solid Tumors,DRUG: IMP7068,"Impact Therapeutics, Inc.",Covance,ALL,"ADULT, OLDER_ADULT",PHASE1,350,INDUSTRY,INTERVENTIONAL,2/25/2021,8/30/2023
NCT06184867,RECRUITING,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Breast Cancer|Pancreas Cancer|Colorectal Cancer|Endometrial Cancer|Prostate Cancer,DIAGNOSTIC_TEST: Relational Agent|OTHER: Clinical Letter,"Rutgers, The State University of New Jersey",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,56,OTHER,INTERVENTIONAL,10/26/2023,1/31/2025
NCT05146843,NOT_YET_RECRUITING,Breast Neoplasms,DRUG: Mitoquinone|OTHER: Placebo,D'Or Institute for Research and Education,InCor Heart Institute|Instituto do Cancer do Estado de SÃ£o Paulo,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,INTERVENTIONAL,6/2/2022,12/2/2023
NCT04464967,WITHDRAWN,Advanced Solid Tumor|Metastatic Cancer|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|Esophageal Cancer|Ovarian Cancer|Endometrium Cancer|Bladder Cancer|Pancreatic Cancer|Colorectal Cancer|Non Small Cell Lung Cancer|EGF-R Positive Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Cervical Cancer|Sarcoma,BIOLOGICAL: SNK01|DRUG: Trastuzumab|DRUG: Cetuximab,"NKGen Biotech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,2021-03,2023-02
NCT04141943,UNKNOWN,Breast Cancer,OTHER: Virtual reality,Yonsei University,,FEMALE,ADULT,NA,196,OTHER,INTERVENTIONAL,3/13/2020,2021-10
NCT04391543,NOT_YET_RECRUITING,Breast Cancer,OTHER: Experimental session,Le Mans Universite,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,1/15/2021,6/15/2024
NCT04826367,COMPLETED,Breast Cancer,OTHER: Telerehabilitation-based relaxation exercise group (EG),Hacettepe University,,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,1/20/2021,12/1/2022
NCT05525767,RECRUITING,Solid Tumor,DRUG: Bevacizumab,Hebei Medical University Fourth Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,INTERVENTIONAL,3/31/2022,12/31/2025
NCT05664867,WITHDRAWN,Hereditary Cancer Syndrome,OTHER: Mainstream Genetic Testing Model|OTHER: Enhanced Standard of Care Model,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,2023-08,2027-12
NCT04276597,WITHDRAWN,Pulmonary Neuroendocrine Neoplasm|Pheochromocytoma|Paraganglioma|Thymus Carcinoid|Unknown Primary Tumors|Neuroendocrine Tumors|Neuroendocrine Skin Carcinoma|Neuroendocrine Breast Tumor|Neuroendocrine Carcinoma Metastatic|Neuroendocrine Neoplasm of Ovary,DRUG: 177Lu-DOTATOC,Excel Diagnostics and Nuclear Oncology Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,3/4/2020,7/15/2021
NCT05736367,NOT_YET_RECRUITING,Breast Cancer,DRUG: U-13C-glucose,"Rutgers, The State University of New Jersey",Ludwig Institute for Cancer Research,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,INTERVENTIONAL,4/15/2024,6/30/2028
NCT05259267,UNKNOWN,Breast Cancer,BEHAVIORAL: Online Group Therapy for PTG|BEHAVIORAL: Online Support Group,Dokuz Eylul University,The Scientific and Technological Research Council of Turkey,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,1/15/2022,2022-10
NCT03606967,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Personalized Synthetic Long Peptide Vaccine|DRUG: Poly ICLC|BIOLOGICAL: Tremelimumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,INTERVENTIONAL,4/13/2021,12/31/2024
NCT04219267,COMPLETED,Breast Cancer,BEHAVIORAL: character strengths-based intervention|BEHAVIORAL: early memories,Chinese University of Hong Kong,,FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,INTERVENTIONAL,5/4/2020,12/20/2020
NCT05420467,RECRUITING,Breast Cancer,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Nab paclitaxel|DRUG: Cyclophosphamide,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,2413,OTHER,INTERVENTIONAL,7/10/2022,12/20/2027
NCT04024267,RECRUITING,Fatigue|Breast Cancer,OTHER: Eurythmy therapy|OTHER: CoordiFit,University of Bern,Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,INTERVENTIONAL,3/10/2020,11/30/2024
NCT06088056,NOT_YET_RECRUITING,Breast Cancer|Brain Metastases|Radiotherapy,DRUG: Combination use of SRT with T-DXd,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,17,OTHER,INTERVENTIONAL,2023-11,2026-07
NCT05780567,RECRUITING,Breast Cancer,"DRUG: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|DRUG: Placebo capsules, Letrozole, Anastrozole, Tamoxifen","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1946,INDUSTRY,INTERVENTIONAL,3/30/2023,2027-01
NCT04740697,RECRUITING,Breast Cancer,OTHER: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.,Institut Claudius Regaud,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,2/12/2021,2024-02
NCT05180656,COMPLETED,Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III,BEHAVIORAL: Yoga Intervention,University of Toronto,,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,12/13/2021,7/27/2022
NCT04158856,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab,xuexin he,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/1/2020,5/31/2030
NCT04190056,TERMINATED,Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,BIOLOGICAL: Pembrolizumab|DRUG: Tamoxifen|DRUG: Vorinostat,"University of California, San Francisco",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,INTERVENTIONAL,3/11/2021,6/15/2023
NCT04418856,RECRUITING,Breast Cancer|Circadian Rhythms|Fatigue|Sleep Disturbance|Cognitive Impairment|Inflammatory Response|Depression,DEVICE: Light Glasses (Experimental)|DEVICE: Light Glasses (Comparison),Reykjavik University,The Icelandic Research Fund,FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,6/8/2020,2024-07
NCT06008483,RECRUITING,Bone Cancer|Bone Tumor|Solid Tumor|Metastatic Cancer to the Bone|Metastatic Tumor to the Bone,DRUG: 153-Sm-DOTMP (Samarium-153-DOTMP),"QSAM Therapeutics, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,17,INDUSTRY,INTERVENTIONAL,4/5/2022,11/1/2024
NCT04655183,WITHDRAWN,Advanced Solid Tumor|Breast Cancer,DRUG: Niraparib|DRUG: M4344|DRUG: Niraparib|DRUG: M4344|DRUG: Niraparib|DRUG: Niraparib,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,12/1/2020,9/1/2023
NCT04562233,TERMINATED,Breast Cancer|Resistance Training,"BEHAVIORAL: Online-delivered physical activity intervention.|BEHAVIORAL: Printed, individualized resistance-based physical activity program.","Rutgers, The State University of New Jersey",,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,12/1/2020,8/24/2023
NCT05233800,RECRUITING,Breast Cancer Survivor|Insomnia,BEHAVIORAL: Faster Asleep Smart Speaker Program|BEHAVIORAL: Faster Asleep Website,Medstar Health Research Institute,Media Rez,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,4/5/2022,2024-03
NCT05538000,NOT_YET_RECRUITING,Breast Cancer,OTHER: Face to face and telephonic interviews,Institut de CancÃ©rologie de Lorraine,,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,2024-09,2027-09
NCT04252300,COMPLETED,Drug Interactions,DRUG: Rosuvastatin|DRUG: Rosuvastatin + BAY1817080,Bayer,,ALL,ADULT,PHASE1,14,INDUSTRY,INTERVENTIONAL,3/2/2020,12/7/2020
NCT04314700,TERMINATED,Breast Cancer Female,DEVICE: OCT- based investigational imaging device,Perimeter Medical Imaging,,FEMALE,"ADULT, OLDER_ADULT",NA,58,INDUSTRY,INTERVENTIONAL,2/11/2020,12/7/2021
NCT05837533,RECRUITING,Breast Cancer Stage IV|Breast Cancer Metastatic|Communication,OTHER: Communication model,Medicos e Investigadores en la Lucha contra el Cancer de Mama,,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,5/17/2023,2025-06
NCT04148937,COMPLETED,Advanced Cancer,DRUG: LY3475070|DRUG: Pembrolizumab,Eli Lilly and Company,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,52,INDUSTRY,INTERVENTIONAL,1/16/2020,6/20/2022
NCT04883814,ACTIVE_NOT_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: 18F-fluoroestradiol PET/CT,Hoag Memorial Hospital Presbyterian,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,124,OTHER,INTERVENTIONAL,1/15/2021,12/15/2023
NCT06135714,RECRUITING,Breast Cancer|Oligometastasis|Metastatic Breast Cancer,DRUG: Systemic therapy for 12 weeks after primary registration|PROCEDURE: Radiation therapy (SBRT/conventional RT)|PROCEDURE: Surgery|DRUG: Same systemic therapy after secondary registration,Tokyo Medical and Dental University,,ALL,"ADULT, OLDER_ADULT",PHASE3,340,OTHER,INTERVENTIONAL,11/8/2023,10/31/2032
NCT05967533,RECRUITING,Advanced Colorectal Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Renal Cell Carcinoma|Advanced Triple-Negative Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,DRUG: Fermented Wheat Germ Extract,"University of California, Davis",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,INTERVENTIONAL,6/2/2023,2025-12
NCT05305937,NOT_YET_RECRUITING,Malignant Tumor of Breast|Benign Breast Lumps|High-Risk Breast Cancer,DEVICE: MRI scan,Meir Medical Center,Tel Aviv University,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,2022-05,5/31/2025
NCT05633914,RECRUITING,HR+/HER2- Breast Cancer,DRUG: Tucidinostat|DRUG: nab-paclitaxel,Hunan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,2/7/2023,12/1/2025
NCT06059300,ENROLLING_BY_INVITATION,Breast Cancer Screening,DIAGNOSTIC_TEST: Digital Breast Tomosynthesis,Radboud University Medical Center,Erasmus Medical Center|UMC Utrecht|LRCB Dutch Expert Centre for Screening|Dutch Breast Cancer Association|University of Sydney|Hologic B.V.|Volpara Health Technologies Ltd|Lunit Inc.|Screenpoint Medical BV|Sectra Benelux|iCAD|Dutch Foundation of Population Screening,FEMALE,"ADULT, OLDER_ADULT",NA,18200,OTHER,INTERVENTIONAL,7/17/2023,7/1/2028
NCT04379414,RECRUITING,"Breast Cancer|Symptom, Behavioral",BEHAVIORAL: YES portal,Dana-Farber Cancer Institute,Breast Cancer Research Foundation,FEMALE,ADULT,NA,400,OTHER,INTERVENTIONAL,9/16/2020,3/1/2028
NCT04461600,TERMINATED,Triple Negative Breast Cancer,DRUG: AL101,"Ayala Pharmaceuticals, Inc,",,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INDUSTRY,INTERVENTIONAL,8/14/2020,10/11/2022
NCT04233385,RECRUITING,"Breast Cancer|Mastectomy; Lymphedema|Pain, Shoulder|Mobility Limitation",OTHER: Myofascial Massage|OTHER: Light Touch,MetroHealth Medical Center,,FEMALE,"ADULT, OLDER_ADULT",NA,202,OTHER,INTERVENTIONAL,2/4/2020,4/30/2025
NCT04681287,ACTIVE_NOT_RECRUITING,HER2 Positive Metastatic Breast Cancer,DRUG: inetetamab and PD-1 inhibitor combined with chemotherapy.,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER_GOV,INTERVENTIONAL,4/23/2021,12/30/2024
NCT05045287,RECRUITING,Breast Carcinoma,RADIATION: hypofractionated radiotherapy,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,4/8/2021,4/30/2025
NCT04562987,COMPLETED,Breast Neoplasms|Breast Cancer Female,BEHAVIORAL: Physical Activity|BEHAVIORAL: Attentional Control,University of Nebraska,National Institute of General Medical Sciences (NIGMS)|Wake Forest University,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,1/15/2021,7/7/2022
NCT04647487,COMPLETED,Breast Cancer,DRUG: LY3484356,Eli Lilly and Company,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,86,INDUSTRY,INTERVENTIONAL,4/21/2021,11/11/2022
NCT04546347,COMPLETED,Healthy Volunteers,"RADIATION: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|DRUG: AZD9833 film-coated tablet A Dose 1|DRUG: AZD9833 Oral Solution|DRUG: AZD9833 film-coated tablet B Dose 1|DRUG: AZD9833 film-coated tablet A Dose 2|DRUG: AZD9833 film-coated tablet B Dose 2",AstraZeneca,Quotient Sciences,FEMALE,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,INTERVENTIONAL,9/17/2020,1/7/2021
NCT05258747,COMPLETED,Ovarian Cancer|Breast Cancer,"DRUG: Olaparib tablets, 150 mg|DRUG: LynparzaÂ® (olaparib) tablets 150 mg",Sandoz,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,INTERVENTIONAL,4/7/2022,10/20/2022
NCT05625087,RECRUITING,Breast Cancer Stage IV,DRUG: Alpelisib|DRUG: Ribociclib,UNICANCER,Novartis|Breast Cancer Research Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,162,OTHER,INTERVENTIONAL,10/19/2023,2030-06
NCT03832985,ACTIVE_NOT_RECRUITING,Hereditary Breast and Ovarian Cancer Syndrome|Lynch Syndrome|Familial Hypercholesterolemia,GENETIC: Receive an adult-onset result|GENETIC: Receive a pediatric-onset result|GENETIC: Control - No Result,Geisinger Clinic,National Human Genome Research Institute (NHGRI),ALL,"CHILD, ADULT, OLDER_ADULT",EARLY_PHASE1,427,OTHER,INTERVENTIONAL,11/25/2020,6/30/2024
NCT05198622,UNKNOWN,Breast Cancer|Chronic Pain|Intercostobrachial Nerve Injury,PROCEDURE: Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|PROCEDURE: Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection,Shaukat Khanum Memorial Cancer Hospital & Research Centre,,FEMALE,"ADULT, OLDER_ADULT",NA,182,OTHER,INTERVENTIONAL,1/30/2022,10/1/2022
NCT04197687,RECRUITING,Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,BIOLOGICAL: Multi-epitope HER2 Peptide Vaccine TPIV100|BIOLOGICAL: Pertuzumab|OTHER: Placebo Administration|BIOLOGICAL: Sargramostim|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine,Academic and Community Cancer Research United,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,480,OTHER,INTERVENTIONAL,2/20/2020,1/15/2025
NCT05553522,RECRUITING,Brain Metastases|HER2-positive Breast Cancer,"COMBINATION_PRODUCT: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine",Baptist Health South Florida,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,INTERVENTIONAL,9/18/2023,11/1/2025
NCT04149522,TERMINATED,"Breast Cancer|Radiotherapy; Adverse Effect, Dermatitis or Eczema|Radiotherapy Side Effect|Radiation Burn|Radiation Dermatitis|Radiotherapy; Complications",DEVICE: Mepitel FilmÂ®,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,1/15/2020,11/6/2023
NCT05760222,RECRUITING,Breast Cancer,OTHER: Acupuncture,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,11/25/2021,12/25/2024
NCT05651087,NOT_YET_RECRUITING,Hormone Receptor-positive Breast Cancer,DRUG: LACUDY,Gun Oh Chong,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,12/20/2022,2/28/2023
NCT05675085,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DIAGNOSTIC_TEST: Personalized screening protocol,Istituto Oncologico Veneto IRCCS,Regione del Veneto (Italy),FEMALE,ADULT,NA,10269,OTHER,INTERVENTIONAL,1/20/2020,1/31/2026
NCT06020222,RECRUITING,Chemotherapy-induced Peripheral Neuropathy,DEVICE: cryotherapy|OTHER: education,Kaohsiung Medical University Chung-Ho Memorial Hospital,Taiwan Nurses Association,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,INTERVENTIONAL,5/1/2023,12/31/2024
NCT05430347,NOT_YET_RECRUITING,Breast Cancer,COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHPy|COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHP,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,4/15/2023,9/30/2025
NCT06015087,RECRUITING,"Fasting, Diet, Chemotherapy, Toxicity",OTHER: fasting diet,University of Thessaly,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,7/1/2022,2024-07
NCT04551885,TERMINATED,"Solid Tumor, Adult",DRUG: FT516|DRUG: Avelumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2,Fate Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,INTERVENTIONAL,9/7/2020,8/11/2023
NCT04669587,RECRUITING,Estrogen Receptor-Positive|HER2-Negative|Locally Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: ZB716|DRUG: Palbociclib,EnhancedBio USA Inc.,Zenopharm,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,OTHER,INTERVENTIONAL,7/26/2021,1/31/2024
NCT05573022,RECRUITING,"Cancer, Breast|Cancer Colorectal",OTHER: Pre-consultation electronic patient decision aid|OTHER: In-consultation paper-based patient decision aid,Vejle Hospital,The Ottawa Hospital Research Institute,ALL,"ADULT, OLDER_ADULT",NA,274,OTHER,INTERVENTIONAL,11/15/2022,2024-12
NCT06125522,RECRUITING,Breast Cancer,DRUG: vepdegestrant|DRUG: Samuraciclib,Pfizer,"Arvinas Estrogen Receptor, Inc.|Carrick Therapeutics Limited",ALL,"ADULT, OLDER_ADULT",PHASE2,67,INDUSTRY,INTERVENTIONAL,1/10/2024,2/2/2027
NCT05806047,NOT_YET_RECRUITING,Hormone Receptor-positive Advanced Breast Cancer,DRUG: chidamide combined with fulvestrant,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,INTERVENTIONAL,5/1/2023,11/1/2024
NCT05989347,NOT_YET_RECRUITING,Breast Cancer|Hyperinsulinism|HER2-negative Breast Cancer,DRUG: Dapagliflozin 10mg,Yale University,AstraZeneca,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,2024-04,2025-12
NCT04416087,RECRUITING,"Cancer, Breast",OTHER: Exercise,Turku University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER_GOV,INTERVENTIONAL,9/7/2020,12/31/2024
NCT05042687,RECRUITING,Breast Cancer,DRUG: Tc99m sestamibi,M.D. Anderson Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,12/13/2021,12/31/2024
NCT05677022,NOT_YET_RECRUITING,Breast Cancer,OTHER: Adapted motor activity,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/1/2023,6/1/2026
NCT05441722,RECRUITING,Breast Cancer|Chemotherapy-induced Peripheral Neuropathy,BEHAVIORAL: Exercise prehabilitation,Northumbria University,Gateshead Health NHS Foundation Trust|Newcastle-upon-Tyne Hospitals NHS Trust|Northumbria Healthcare NHS Foundation Trust,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,5/26/2022,1/1/2024
NCT06172322,NOT_YET_RECRUITING,HR Positive/HER-2 Negative Breast Cancer,DRUG: NTQ1062 with Fulvestrant,Nanjing Chia-tai Tianqing Pharmaceutical,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,INTERVENTIONAL,12/20/2023,2025-07
NCT04576247,TERMINATED,Breast Cancer Female|Overweight and Obesity,BEHAVIORAL: Combined aerobic and resistance exercise,"University of Colorado, Denver",Colorado Clinical & Translational Sciences Institute|National Cancer Institute (NCI),FEMALE,ADULT,NA,3,OTHER,INTERVENTIONAL,6/5/2020,9/20/2021
NCT05787587,RECRUITING,Advanced or Metastatic Solid Tumors|Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer,DRUG: IDE-161,IDEAYA Biosciences,,ALL,"ADULT, OLDER_ADULT",PHASE1,68,INDUSTRY,INTERVENTIONAL,4/5/2023,2025-09
NCT05252546,COMPLETED,HER2-positive Recurrent / Metastatic Breast Cancer,DRUG: pyrotinib tablet|DRUG: Montmorillonite Power|DRUG: Loperamide,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,ADULT,PHASE1,36,INDUSTRY,INTERVENTIONAL,3/8/2022,8/2/2022
NCT05708573,COMPLETED,Healthy Participants,DRUG: Rosuvastatin|DRUG: ALXN2040,"Alexion Pharmaceuticals, Inc.",,ALL,ADULT,PHASE1,20,INDUSTRY,INTERVENTIONAL,2/1/2023,4/5/2023
NCT05460273,ACTIVE_NOT_RECRUITING,"Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Cancer",DRUG: Datopotamab Deruxtecan (Dato-DXd),AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,119,INDUSTRY,INTERVENTIONAL,7/11/2022,6/23/2024
NCT05911373,RECRUITING,"Analgesia|Cancer, Breast",OTHER: group serratus plan block|OTHER: group serratus and parasternal plan block,Ataturk University,,ALL,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,6/21/2023,1/15/2024
NCT05754346,COMPLETED,"Lymphedema, Breast Cancer|Lymphedema of Upper Limb",OTHER: Complete Decongestive Therapy|OTHER: Upper extremity exercises combined with diaphragmatic breathing exercises,Izmir Bakircay University,Bezmialem Vakif University|Istanbul Kent University,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,3/20/2023,12/1/2023
NCT05641246,COMPLETED,Hand and Foot Syndrome,DRUG: (CARBAMIDEÂ®)|DRUG: (VOLTARENÂ®) Emulgel 1%,German University in Cairo,Cairo University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,INTERVENTIONAL,12/8/2022,12/8/2023
NCT04606446,RECRUITING,Locally Advanced or Metastatic ER+ HER2- Breast Cancer|Locally Advanced or Metastatic Castration-resistant Prostate Cancer|Locally Advanced or Metastatic Non-small Cell Lung Cancer,DRUG: PF-07248144|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib|DRUG: PF-07220060,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1,186,INDUSTRY,INTERVENTIONAL,11/16/2020,11/8/2026
NCT04315246,WITHDRAWN,"Leptomeningeal Metastasis|Solid Tumor, Adult",BIOLOGICAL: radiolabeled DPTA-omburtamab,Y-mAbs Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,INTERVENTIONAL,8/31/2022,12/31/2024
NCT04965246,RECRUITING,Inflammation|Cognitive Impairment|Anxiety|Alcohol Drinking,BEHAVIORAL: Physical Activity|OTHER: Usual Care,Milton S. Hershey Medical Center,,FEMALE,OLDER_ADULT,NA,56,OTHER,INTERVENTIONAL,11/22/2021,2024-11
NCT04508764,RECRUITING,Hereditary Breast and Ovarian Cancer|Lynch Syndrome,OTHER: Families Accelerating Cascade Testing Toolkit,Washington University School of Medicine,The Foundation for Barnes-Jewish Hospital,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,4/9/2021,10/31/2024
NCT06107673,RECRUITING,Breast Cancer,DRUG: Dalpiciclib|DRUG: Aromatase inhibitor|DRUG: Docetaxel injection|DRUG: Epirubicin Hydrochloride Injection|DRUG: Cyclophosphamide injection,Hebei Medical University Fourth Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,144,OTHER,INTERVENTIONAL,9/30/2023,12/1/2025
NCT05391373,COMPLETED,Laughter Therapy,BEHAVIORAL: Laughter therapy,Izmir Bakircay University,,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,INTERVENTIONAL,2/17/2022,6/12/2022
NCT05020964,UNKNOWN,Advanced Breast Cancer,DRUG: Trastuzumab and Pyrotinib,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,INTERVENTIONAL,8/20/2021,9/1/2023
NCT05484973,NOT_YET_RECRUITING,Alopecia|Chemotherapy-induced Alopecia|Hair Loss|Breast Cancer,DEVICE: AMMA Portalbe Scalp Cooling System,Cooler Heads Care Inc.,,FEMALE,"ADULT, OLDER_ADULT",NA,99,OTHER_GOV,INTERVENTIONAL,10/1/2023,3/1/2025
NCT04398446,ACTIVE_NOT_RECRUITING,Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Breast Cancer|Ovarian Cancer|Uterine Cancer|Pancreatic Cancer,DRUG: Hemp-based CBD|OTHER: Placebo oral tablet,Main Line Health,"Ananda Hemp, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,INTERVENTIONAL,5/27/2020,4/1/2023
NCT05456373,RECRUITING,Breast Cancer,DEVICE: ClearEdge device,LS BioPath,,FEMALE,"ADULT, OLDER_ADULT",NA,288,INDUSTRY,INTERVENTIONAL,10/10/2022,12/31/2024
NCT04489173,RECRUITING,Breast Neoplasm|Chemotherapy Effect,DRUG: trifluridine/tipiracil,Borstkanker Onderzoek Groep,Erasmus Medical Center|UMC Utrecht|Servier|BOOG Study Center,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,NETWORK,INTERVENTIONAL,9/25/2020,2024-07
NCT05412446,COMPLETED,Breast Cancer|Female,DRUG: ADAPT6-SPECT,Tomsk National Research Medical Center of the Russian Academy of Sciences,Uppsala University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,5/1/2022,12/31/2022
NCT04342546,RECRUITING,Breast Cancer|Capsular Contracture Associated With Breast Implant,DEVICE: NovaGray RILA BreastÂ® test,Institut du Cancer de Montpellier - Val d'Aurelle,,MALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,12/11/2020,2027-06
NCT04389073,UNKNOWN,Metastatic Breast Cancer,DRUG: Vinorelbine 40mg|BIOLOGICAL: Toripalimab 240mg|BIOLOGICAL: Bevacizumab 5 mg/kg|DRUG: Cyclophosphamide 50 mg|DRUG: Capecitabine 500Mg Oral Tablet|DRUG: Cisplatin,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Beijing Huanxing Cancer Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE2,138,OTHER,INTERVENTIONAL,4/1/2020,12/31/2023
NCT05334810,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: DP303c,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,191,INDUSTRY,INTERVENTIONAL,5/1/2022,12/31/2023
NCT03928210,COMPLETED,Breast Cancer|Circulating Tumor Cells (CTCs),DRUG: Digoxin,"University Hospital, Basel, Switzerland",ETH Zurich - The Aceto Lab,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,58,OTHER,INTERVENTIONAL,7/8/2020,12/1/2023
NCT05892146,RECRUITING,Chemotherapeutic Toxicity|Cardiotoxicity|Heart Failure|Breast Cancer|Lymphoma,DRUG: Prevention therapy|DRUG: Rescue therapy,National Cheng-Kung University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,5/5/2021,12/31/2025
NCT05588973,NOT_YET_RECRUITING,Head and Neck Cancer|Breast Cancer,OTHER: MEDISKIN cream|OTHER: Panthenol cream,Angelos Kassianos,"German Oncology Center, Cyprus|RSL Revolutionary Labs Ltd",ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,2022-12,2023-06
NCT04750473,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Lobular Carcinoma|Metastatic Breast Lobular Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,PROCEDURE: Computed Tomography|DRUG: Fluciclovine F18|DRUG: Gallium Ga 68 Gozetotide|PROCEDURE: Positron Emission Tomography,Emory University,National Cancer Institute (NCI)|National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",PHASE1,22,OTHER,INTERVENTIONAL,7/16/2021,12/31/2024
NCT05856773,NOT_YET_RECRUITING,Breast Cancer,RADIATION: Proton Therapy,Proton Collaborative Group,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,276,NETWORK,INTERVENTIONAL,2024-02,2041-02
NCT05576389,ENROLLING_BY_INVITATION,Germline BRCA-mutated HER2-negative Breast Cancer,DRUG: Camrelizumab+Fluzoparib,Peking University People's Hospital,"Jiangsu Hengrui Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,94,OTHER,INTERVENTIONAL,10/1/2022,12/31/2026
NCT06194565,RECRUITING,Breast Cancer,DRUG: 99mTc-ABH2,Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,3/20/2023,1/30/2024
NCT05712889,RECRUITING,Neoplasms,DRUG: VIP236,"Vincerx Pharma, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,1/24/2023,2024-12
NCT04736589,NOT_YET_RECRUITING,Breast Cancer,DRUG: Inetetamab|DRUG: Rapamycin|DRUG: Pyrotinib|DRUG: Chemotherapy,Peking Union Medical College,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,270,OTHER,INTERVENTIONAL,2/2/2021,2/2/2027
NCT04296942,TERMINATED,Breast Cancer|Triple Negative Breast Cancer|HER2+ Breast Cancer|Hormone Receptor Negative Breast Cancer|Metastatic Breast Cancer,BIOLOGICAL: Brachyury-TRICOM|DRUG: Entinostat|BIOLOGICAL: M7824|BIOLOGICAL: Ado-trastuzumab emtansine,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,1,NIH,INTERVENTIONAL,5/4/2021,10/22/2021
NCT04538742,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Tucatinib,AstraZeneca,"Daiichi Sankyo Company, Limited",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,245,INDUSTRY,INTERVENTIONAL,12/28/2020,7/2/2025
NCT04672265,ACTIVE_NOT_RECRUITING,Cancer Screening,OTHER: Mother tongue and Norwegian,Oslo University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,11355,OTHER,INTERVENTIONAL,4/15/2021,12/31/2030
NCT04190342,COMPLETED,Breast Neoplasm Female|Symptom Cluster|Tai ji,OTHER: control group|BEHAVIORAL: tai chi group,Charles Darwin University,The Affiliated Hospital Of Southwest Medical University|The Affiliated Hospital of Putian University,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,5/4/2020,4/6/2021
NCT05080842,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: AC682,Accutar Biotechnology Inc,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,11/12/2021,2/29/2024
NCT05860465,RECRUITING,Locally Advanced or Metastatic Breast Cancer,DRUG: SPH4336 Tablets|DRUG: SPH4336 Tablets Placebo,"Shanghai Pharmaceuticals Holding Co., Ltd",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,254,INDUSTRY,INTERVENTIONAL,9/8/2023,8/30/2025
NCT04737265,ACTIVE_NOT_RECRUITING,Cardiotoxicity|Toxicity Due to Chemotherapy|Breast Cancer|Lymphoma|Cardiomyopathies|Heart Failure,OTHER: Biomarker Guided Intervention,Abramson Cancer Center at Penn Medicine,"National Heart, Lung, and Blood Institute (NHLBI)",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,101,OTHER,INTERVENTIONAL,3/18/2021,2025-05
NCT06171789,RECRUITING,Endometrial Cancer|Ovarian Cancer|Triple Negative Breast Cancer|GastroEsophageal Cancer|Non-small Cell Lung Cancer|Urothelial Carcinoma,DRUG: PRO1107,ProfoundBio US Co.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,214,INDUSTRY,INTERVENTIONAL,1/29/2024,2027-02
NCT04789889,ACTIVE_NOT_RECRUITING,Quality of Life,RADIATION: intraoperative radiotherapy|RADIATION: postoperative radiotherapy,Xiangyun Zong,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,3/1/2021,2/28/2025
NCT05401942,NOT_YET_RECRUITING,Breast Cancer Female,OTHER: Tele-monitoring through mobile application,Ain Shams University,,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,2022-06,2024-05
NCT05753865,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: SYHX2011|DRUG: Paclitaxel for injection (albumin-bound),"CSPC Ouyi Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,454,INDUSTRY,INTERVENTIONAL,5/1/2023,9/1/2024
NCT04947189,RECRUITING,Triple Negative Breast Cancer,DRUG: Seviteronel-D (Seivteronel in combination with dexamethasone)|DRUG: Docetaxel,"St Vincent's Hospital, Sydney",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER,INTERVENTIONAL,11/1/2022,2024-12
NCT05515289,RECRUITING,Breast Cancer,DRUG: SHR6390,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,12/18/2022,9/28/2023
NCT04395989,ACTIVE_NOT_RECRUITING,TNBC - Triple-Negative Breast Cancer,"DRUG: A1: Pyrotinib with nab-paclitaxel|DRUG: A2: nab-paclitaxel|DRUG: B1: everolimus with nab-paclitaxel|DRUG: B2: nab-paclitaxel|DRUG: C1: PD-1 with nab-paclitaxel and famitinib|DRUG: C2: nab-paclitaxel|DRUG: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|DRUG: D2: nab-paclitaxel, with maintenance of capecitabine|DRUG: E1: everolimus with nab-paclitaxel|DRUG: E2: nab-paclitaxel",Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,139,OTHER,INTERVENTIONAL,7/28/2020,12/31/2024
NCT05959889,RECRUITING,Breast Cancer|Doxorubicin Induced Cardiotoxicity,OTHER: Placebo|DRUG: Montelukast,Damanhour University,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,3/1/2023,5/1/2024
NCT05292742,RECRUITING,Breast Cancer|Adjuvant Therapy,DRUG: Pyrotinib+Trastuzumab+Capecitabine|DRUG: Trastuzumab+Pertuzumab/Trastuzumab,Fujian Medical University Union Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,206,OTHER,INTERVENTIONAL,7/2/2021,12/31/2027
NCT05960188,RECRUITING,Breast Cancer Screening,BEHAVIORAL: AI Opinion,Brigham and Women's Hospital,,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,3/1/2023,9/1/2028
NCT04095689,SUSPENDED,Triple Negative Breast Cancer|Anthracycline-refractory TNBC,DRUG: Docetaxel|DRUG: Pembrolizumab|DRUG: IL-12 gene therapy,The Methodist Hospital Research Institute,Merck Sharp & Dohme LLC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,3/17/2021,2024-08
NCT05086731,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Localized Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma|Metastatic Breast Cancer,OTHER: Best Practice|OTHER: Informational Intervention|OTHER: Medical Device Usage and Evaluation|OTHER: Quality-of-Life Assessment|OTHER: Survey Administration,Emory University,NRG Oncology|National Cancer Institute (NCI)|National Institutes of Health (NIH),FEMALE,"ADULT, OLDER_ADULT",NA,33,OTHER,INTERVENTIONAL,10/22/2021,12/31/2024
NCT04150731,COMPLETED,Breast Cancer,RADIATION: 16Î±-18F-fluor-17Î²-estradiol,University of Aarhus,"GCP-unit at Aarhus University Hospital, Aarhus, Denmark|REDCap",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,OTHER,INTERVENTIONAL,10/23/2020,6/28/2023
NCT05206331,RECRUITING,Breast Cancer,DEVICE: contrast enhanced mammography|DRUG: Iodinated Contrast Media (ICM),Margarita Louise Zuley,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE4,1855,OTHER,INTERVENTIONAL,2/1/2022,2026-11
NCT05672342,NOT_YET_RECRUITING,Breast Carcinoma|Chemotherapy-Induced Peripheral Neuropathy|Colon Carcinoma,DRUG: Cannabidiol|DRUG: Delta-8-Tetrahydrocannabinol|DRUG: Placebo Administration|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,120,OTHER,INTERVENTIONAL,3/6/2024,10/31/2024
NCT05896189,RECRUITING,Breast Cancer|Cognitive Impairments,BEHAVIORAL: Arm 1: Computerized Cognitive Training-Global Stimulation Games|BEHAVIORAL: Arm 2: Computerized Cognitive Training-Neuroplasticity Games,NRG Oncology,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,386,OTHER,INTERVENTIONAL,2/2/2024,11/30/2027
NCT05073172,NOT_YET_RECRUITING,Breast Carcinoma|Head and Neck Carcinoma|Radiation-Induced Dermatitis,DRUG: Calendula Ointment|OTHER: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|OTHER: Polyethylene Glycol Hydrogel|DRUG: Silicone-based Film Forming Topical Gel|DRUG: Silver Sulfadiazine|DRUG: Topical Hydrocortisone,OHSU Knight Cancer Institute,Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,1/1/2024,7/1/2025
NCT05587972,RECRUITING,Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Multiple Myeloma,OTHER: survey,"Carevive Systems, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,INTERVENTIONAL,10/6/2022,12/6/2023
NCT05041972,WITHDRAWN,HER2 Mutation-Related Tumors|HER2 Amplified Solid Tumors,DRUG: ARX788,"Ambrx, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,11/5/2021,4/20/2022
NCT04781062,ACTIVE_NOT_RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Blood and urine molecular analysis (Timing 0)|DIAGNOSTIC_TEST: Blood and urine molecular analysis (Timing 1),Ospedale Policlinico San Martino,Associazione Italiana per la Ricerca sul Cancro|Universita degli Studi di Genova|Sidra Medicine|Dana-Farber Cancer Institute,FEMALE,"ADULT, OLDER_ADULT",NA,367,OTHER,INTERVENTIONAL,1/19/2021,2024-12
NCT04158362,RECRUITING,Cancer Metastatic,DRUG: Paclitaxel injection|DRUG: Capecitabine tablets|DRUG: Letrozole 2.5mg|DRUG: Anastrozole 1mg|DRUG: Fulvestrant Prefilled Syringe|DRUG: Abemaciclib,UNICANCER,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,INTERVENTIONAL,6/11/2020,2028-06
NCT05346510,RECRUITING,Breast Cancer,PROCEDURE: ALND Group,Shengjing Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,INTERVENTIONAL,3/1/2022,8/31/2027
NCT05582538,RECRUITING,Triple Negative Breast Cancer Metastatic,DRUG: Ceralasertib|DRUG: Durvalumab|DRUG: Nab-paclitaxel,IFOM ETS - The AIRC Institute of Molecular Oncology,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,INTERVENTIONAL,12/15/2022,2025-11
NCT04902872,ACTIVE_NOT_RECRUITING,"Solid Tumor, Adult|Epithelial Ovarian Cancer|Small Cell Lung Carcinoma|Breast Cancer|Colorectal Cancer|Pancreas Cancer|Appendix Cancer|Non-small Cell Lung Cancer|Gastric Cancer|Esophagus Cancer|Urothelial Carcinoma|Sarcoma",DRUG: CBX-12,Cybrexa Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,130,INDUSTRY,INTERVENTIONAL,5/3/2021,2024-09
NCT05861362,COMPLETED,Breast Cancer,RADIATION: Curative radiotherapy|BEHAVIORAL: 5:2 intermittent fasting,MVZ Leopoldina GmbH,,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,6/1/2022,11/17/2022
NCT04873362,RECRUITING,Breast Cancer,DRUG: Atezolizumab|DRUG: Trastuzumab Emtansine|DRUG: Placebo|DRUG: Trastuzumab,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1700,INDUSTRY,INTERVENTIONAL,5/4/2021,6/29/2035
NCT06060938,RECRUITING,Breast Cancer,OTHER: Risk stratified arm|OTHER: Control arm,Herlev and Gentofte Hospital,Danish Cancer Society|University of Cambridge|University of Aarhus|The Novo Nordic Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,962,OTHER,INTERVENTIONAL,9/28/2023,12/31/2034
NCT06169072,RECRUITING,Breast Cancer|Sentinel Lymph Node,DRUG: Superparamagnetic Iron Oxide|DEVICE: Technetium99,Vastra Gotaland Region,,ALL,"ADULT, OLDER_ADULT",PHASE2,220,OTHER_GOV,INTERVENTIONAL,1/1/2023,7/1/2027
NCT04874038,RECRUITING,"Post-mastectomy Pain Syndrome|Breast Cancer|Pain, Postoperative|Pain, Chronic",DRUG: Lidocaine 20mg/ml|DRUG: Placebo,"University Health Network, Toronto",Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",PHASE3,1150,OTHER,INTERVENTIONAL,9/22/2021,12/1/2024
NCT05534438,RECRUITING,Oligometastatic Breast Carcinoma|Breast Cancer|Metastatic Breast Cancer|Metastatic Breast Carcinoma|ER+ Breast Cancer|HER2+ Breast Cancer,RADIATION: Stereotactic body radiotherapy,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,9/6/2022,9/6/2025
NCT05717972,RECRUITING,"Distress, Emotional|Sleep",OTHER: Kombucha,National Yang Ming University,,ALL,ADULT,NA,60,OTHER,INTERVENTIONAL,12/12/2022,12/12/2025
NCT04236310,UNKNOWN,Breast Cancer|HER2-positive Breast Cancer|ER-positive Breast Cancer,DRUG: SHR6390|DRUG: Anastrozole|DRUG: Pyrotinib|DRUG: Trastuzumab,Ruijin Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,INTERVENTIONAL,1/15/2020,12/31/2022
NCT04328610,UNKNOWN,"Lymphedema, Breast Cancer",PROCEDURE: LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique,Pusan National University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,INTERVENTIONAL,3/5/2020,2/28/2022
NCT06061172,RECRUITING,"Asthma|Breast Neoplasms|Coronary Disease|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Pulmonary Disease, Chronic Obstructive|Comorbidities and Coexisting Conditions",OTHER: gp-multitool.de,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,ALL,OLDER_ADULT,NA,120,OTHER,INTERVENTIONAL,10/2/2023,5/31/2024
NCT05680662,NOT_YET_RECRUITING,Breast Cancer Female|Triple Negative Breast Cancer,"COMBINATION_PRODUCT: quercetin, EGCG, metformin , zinc","Ministry of Health, Saudi Arabia",,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,200,OTHER_GOV,INTERVENTIONAL,1/1/2023,1/31/2024
NCT06259162,RECRUITING,Triple Negative Breast Cancer|Immune Checkpoint Inhibitor,PROCEDURE: LAG-3 expression / immune checkpoint protein expression,Samsung Medical Center,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,128,OTHER,INTERVENTIONAL,11/18/2022,12/31/2027
NCT05464810,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Invasive Breast Carcinoma,DRUG: Letrozole|DRUG: Simvastatin,Emory University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,40,OTHER,INTERVENTIONAL,9/2/2022,4/15/2025
NCT05698238,NOT_YET_RECRUITING,"Clear Cell Renal Cell Carcinoma Metastatic|TNBC - Triple-Negative Breast Cancer|Head and Neck Cancer|Non-small-cell Lung Carcinoma|Mesothelioma, Malignant",DRUG: CA9hu-1,"Mabpro, a.s.",,ALL,"ADULT, OLDER_ADULT",PHASE1,50,INDUSTRY,INTERVENTIONAL,2024-01,2027-01
NCT05099562,UNKNOWN,Breast Cancer,DEVICE: Acupuncture,Affiliated Hospital of Qinghai University,,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,INTERVENTIONAL,12/1/2021,12/1/2023
NCT06001762,RECRUITING,Breast Cancer|Early-stage Breast Cancer|High Risk Breast Carcinoma,DRUG: Abemaciclib|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: LHRH Agonist,Dana-Farber Cancer Institute,Eli Lilly and Company,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,INTERVENTIONAL,2024-02,1/1/2027
NCT05932862,RECRUITING,Advanced Solid Tumor,DRUG: XL309 (ISM3091),Exelixis,,ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,INTERVENTIONAL,8/17/2023,12/9/2025
NCT03811262,WITHDRAWN,"Breast Cancer|Anesthesia, Local",PROCEDURE: ESP BLOCK|PROCEDURE: PECS BLOCK,University of Padova,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,1/1/2022,2023-01
NCT05259410,RECRUITING,Breast Cancer Female,BEHAVIORAL: TRE|BEHAVIORAL: MedTRE,University of Illinois at Chicago,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,8/1/2022,3/1/2026
NCT06045572,NOT_YET_RECRUITING,Breast Cancer Female,DEVICE: VTM examination and breast biopsy,"Galzu Institute of Research, Teaching, Science and Applied Technology",Hospital Santa Casa de Misericordia de Campos|Hospital Escola Alvaro Alvim|Universidade Estadual do Norte Fluminense (UENF),FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,10/1/2023,5/1/2024
NCT04606472,RECRUITING,Solid Tumor,DRUG: SI-B003,"Sichuan Baili Pharmaceutical Co., Ltd.",SystImmune Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,159,INDUSTRY,INTERVENTIONAL,11/10/2020,2024-05
NCT05304962,RECRUITING,Breast Cancer,DRUG: RGT-419B|DRUG: RGT-419B in combination with hormonal therapy,Regor Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,INTERVENTIONAL,3/4/2022,8/28/2024
NCT05039931,WITHDRAWN,Breast Cancer|Solid Tumor,DRUG: GNC-035,"Sichuan Baili Pharmaceutical Co., Ltd.",SystImmune Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,INTERVENTIONAL,9/15/2021,2023-06
NCT04787042,RECRUITING,Cancer|Solid Tumor|Melanoma|Renal Cell Carcinoma|Triple-negative Breast Cancer|Non Small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Carcinoma|MSI-High,BIOLOGICAL: ST-067|BIOLOGICAL: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|BIOLOGICAL: pembrolizumab,"Simcha IL-18, Inc.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,316,INDUSTRY,INTERVENTIONAL,8/6/2021,1/30/2025
NCT05770531,RECRUITING,Metastatic HER2-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Sacituzumab Govitecan,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,10/2/2023,10/1/2028
NCT05049031,COMPLETED,Breast Cancer,OTHER: Questionnaire,"University Hospital, Toulouse",,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,10/6/2021,2/1/2022
NCT06026631,NOT_YET_RECRUITING,Breast Cancer|Lipid Cell; Tumor|Nutrition Related Cancer|Body Weight,PROCEDURE: Lipidomic analysis for breast cancer patients,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,FEMALE,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,9/30/2023,8/10/2024
NCT04561362,RECRUITING,"Advanced Solid Tumor|Urinary Bladder Neoplasm|Triple Negative Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Ovarian Neoplasm",DRUG: BT8009|DRUG: Pembrolizumab,BicycleTx Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,329,INDUSTRY,INTERVENTIONAL,7/17/2020,2025-12
NCT04259762,RECRUITING,"Cancer, Breast|Cancer, Colon|Cancer, Cervix","BEHAVIORAL: Breast, Colorectal, and Cervical Cancer Screening Interventions",New Mexico Cancer Care Alliance,National Institute of General Medical Sciences (NIGMS),ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,6/1/2021,12/31/2024
NCT05646862,RECRUITING,Breast Cancer,DRUG: Inavolisib|DRUG: Fulvestrant|DRUG: Alpelisib,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,6/7/2023,3/30/2029
NCT04500262,RECRUITING,Breast Cancer,DEVICE: Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|DEVICE: Core needle biopsy (CNB),NeoDynamics AB,,FEMALE,"ADULT, OLDER_ADULT",NA,479,INDUSTRY,INTERVENTIONAL,7/13/2020,3/31/2025
NCT06252662,NOT_YET_RECRUITING,Breast Cancer,DRUG: Dexmedetomidine|DRUG: Liposomal bupivacaine,"United States Naval Medical Center, Portsmouth",,ALL,"ADULT, OLDER_ADULT",PHASE4,200,FED,INTERVENTIONAL,2024-04,2025-07
NCT04706962,RECRUITING,Solid Tumor|TNBC - Triple-Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Epithelial Ovarian Cancer|Endometrial Cancer|Cutaneous Melanoma|Thyroid Cancer|Small-cell Lung Cancer|Prostate Cancer|SORT1+ Cancers,DRUG: TH1902,Theratechnologies,PPD|Altasciences Company Inc.|Windtree Therapeutics|Syneos Health|Innovaderm Research Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,INTERVENTIONAL,3/4/2021,2024-12
NCT04063410,WITHDRAWN,Mammoplasty Patient,PROCEDURE: Angiography|PROCEDURE: MRI-Based Angiogram|OTHER: Quality-of-Life Assessment,University of Cincinnati,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,1/1/2023,12/31/2024
NCT05390710,COMPLETED,Solid Tumor|TNBC - Triple-Negative Breast Cancer,COMBINATION_PRODUCT: LAE005 + Afuresertib + Nab-Paclitaxel,Laekna Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INDUSTRY,INTERVENTIONAL,6/12/2021,12/11/2023
NCT04534010,RECRUITING,Breast Cancer,DEVICE: NACgraft,Stanford University,,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,4/28/2021,4/15/2024
NCT06057610,NOT_YET_RECRUITING,HER2-PositiveRecurrent or Metastatic Breast Cancer,DRUG: SHR-A1811 Injection|DRUG: SHR-A1811 Injection ï¼› Pertuzumab Injection|DRUG: Trastuzumab Injectionï¼›Pertuzumab Injection ï¼› Docetaxel Injection,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,864,INDUSTRY,INTERVENTIONAL,2023-10,2032-10
NCT05148910,UNKNOWN,Breast Cancer|Contraception,DEVICE: Silver and copper IUD (TCu380Ag)|DEVICE: Copper IUD (TCu380A),University of Sao Paulo General Hospital,Edson Santos Ferreira-Filho|Nilson Roberto de Melo|Isabel Cristina Esposito Sorpreso|JosÃ© Maria Soares JÃºnior|JosÃ© Roberto Filassi|KÃ¡tia CÃ¢ndido Carvalho|Walter da Silva Pinheiro,FEMALE,ADULT,NA,90,OTHER,INTERVENTIONAL,8/6/2020,12/31/2022
NCT05224310,COMPLETED,Mastectomy|Breast Cancer,"PROCEDURE: PECS block, SAP block",Suez Canal University,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,4/1/2022,7/30/2022
NCT04927910,UNKNOWN,Breast Neoplasms|Cancer Survivor,OTHER: Ture self-acupressure|OTHER: Sham self-acupressure|OTHER: Usual care,The Hong Kong Polytechnic University,The Huazhong University of Science and Technology Union Shenzhen Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,INTERVENTIONAL,6/5/2021,3/29/2022
NCT05792410,NOT_YET_RECRUITING,HER2 Low Advanced or Metastatic Breast Cancer,DRUG: SHR-A1811 & Dalpiciclib Isethionate Tablets|DRUG: SHR-A1811 & Fulvestrant|DRUG: SHR-A1811 & Bevacizumab injection,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,INTERVENTIONAL,2023-04,2/27/2025
NCT05862610,NOT_YET_RECRUITING,Breast Neoplasm,DRUG: Trilaciclib plus chemotherapy|DRUG: Chemotherapy,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,INTERVENTIONAL,7/30/2023,6/30/2027
NCT05447910,RECRUITING,Breast Adenocarcinoma|Invasive Breast Carcinoma|Resectable Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Letrozole,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,7/21/2022,6/15/2025
NCT04973930,RECRUITING,Major Depressive Disorder|Breast Cancer|Venlafaxine,BEHAVIORAL: Interpersonal Psychotherapy|DRUG: Venlafaxine HCl ER,New York State Psychiatric Institute,Columbia University,ALL,"ADULT, OLDER_ADULT",PHASE3,20,OTHER,INTERVENTIONAL,3/1/2022,12/31/2024
NCT04460430,TERMINATED,Breast Cancer,DRUG: Neratinib + endocrine therapy,SOLTI Breast Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,7/23/2020,11/29/2021
NCT04699630,RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer,DRUG: U3-1402,"SCRI Development Innovations, LLC",Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,121,OTHER,INTERVENTIONAL,5/3/2021,2025-11
NCT04619030,UNKNOWN,Sarcoma|Breast Cancer|Cleft Lip and Palate|Surgical Flap,OTHER: Augmented Reality|OTHER: Traditional leaflet,NHS Greater Glasgow and Clyde,The Glasgow School of Art,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,11/30/2020,3/30/2022
NCT05367830,NOT_YET_RECRUITING,Breast Cancer Female,BEHAVIORAL: the Bone@BC app,"Rigshospitalet, Denmark",,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,12/1/2022,10/30/2024
NCT05067530,NOT_YET_RECRUITING,Triple Negative Breast Neoplasms,DRUG: Palbociclib|DRUG: Paclitaxel|DRUG: Carboplatin,Medical University of Gdansk,,ALL,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,INTERVENTIONAL,1/1/2022,12/6/2026
NCT04351230,WITHDRAWN,Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Abemaciclib|BIOLOGICAL: Trastuzumab Emtansine,Academic and Community Cancer Research United,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,11/11/2020,2/16/2022
NCT04722692,RECRUITING,DCIS|Breast Cancer|Breast Neoplasms|Sentinel Lymph Node,DIAGNOSTIC_TEST: Delayed SLND|DIAGNOSTIC_TEST: Late SLND,Uppsala University,"VÃ¤stmanlands Hospital, VÃ¤sterÃ¥s, Sweden|Sahlgrenska University Hospital, Sweden|University Hospital, Linkoeping|Skane University Hospital|Blekinge County Council Hospital|VÃ¤xjÃ¶ Hospital, VÃ¤xjÃ¶, Sweden|The University of Hong Kong-Shenzhen Hospital|Norrlands University Hospital|Dalarna County Hospital, Falun, Sweden|Baylor College of Medicine",FEMALE,"ADULT, OLDER_ADULT",PHASE3,500,OTHER,INTERVENTIONAL,3/1/2020,12/30/2027
NCT04481230,COMPLETED,"Osteoarthritis, Knee|Breast Cancer",DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg,Centre Jean Perrin,,ALL,ADULT,EARLY_PHASE1,6,OTHER,INTERVENTIONAL,11/12/2020,9/19/2022
NCT05939830,RECRUITING,Axillary Lymph Node Dissection|Pathological Complete Response|Neoadjuvant Systemic Therapy|Breast Cancer|Axillary Lymph,PROCEDURE: Stained region Lymph Node Biopsy (SrLNB)|RADIATION: Regional lymph node radiotherapy (RNI) including the axilla,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,92,OTHER,INTERVENTIONAL,9/11/2023,2026-07
NCT05861830,RECRUITING,Advanced Breast Cancer,DRUG: The combination of Dalpiciclib with physician-selected endocrine therapy|DRUG: Chemotherapy selected by the physician,Peking Union Medical College Hospital,"Jiangsu HengRui Medicine Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,INTERVENTIONAL,5/15/2023,6/30/2026
NCT04334330,RECRUITING,Breast Cancer|Brain Metastases,"DRUG: Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant",Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,INTERVENTIONAL,12/4/2020,12/31/2024
NCT05365230,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: On-demand personalized follow-up care|OTHER: Guideline-based follow-up care (standard of care),Ottawa Hospital Research Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,264,OTHER,INTERVENTIONAL,8/19/2022,2026-07
NCT04303988,UNKNOWN,Breast Cancer,DRUG: Pyrotinib|DRUG: Temozolomide Injection|DRUG: SHR-1316|DRUG: Bevacizumab|DRUG: Cisplatin/Carboplatin,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,INTERVENTIONAL,3/30/2020,1/30/2022
NCT05757388,RECRUITING,Post Operative Pain,DRUG: Parecoxib + paracetamol|DRUG: Normal saline,Khon Kaen University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,3/28/2023,5/10/2023
NCT04660188,COMPLETED,Survivorship|Breast Cancer,OTHER: Multidisciplinary collaborative care arm,"National Cancer Centre, Singapore",National University of Singapore|SingHealth Polyclinics,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,3/1/2021,7/20/2022
NCT05830461,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: Online psychological care program to reduce psychological distress in women who attend a breast clinic|BEHAVIORAL: Psychological care program to reduce psychological distress in women who attend a breast clinic,University of Guadalajara,Instituto Mexicano del Seguro Social|Tecnologico de Monterrey|Universidad Internacional del Ecuador|University of Twente,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/19/2023,2024-08
NCT06178861,ACTIVE_NOT_RECRUITING,Breast Cancer|Radiation Therapy,DEVICE: Group wearing a radiotherapy bra,Yonsei University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,38,OTHER,INTERVENTIONAL,12/1/2022,10/20/2024
NCT06257264,NOT_YET_RECRUITING,Breast Cancer|Small Cell Lung Cancer|Ovarian Cancer|Gastric Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Advanced Solid Tumor|Endometrial Cancer|Prostate Cancer,DRUG: BG-68501|DRUG: Fulvestrant,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE1,108,INDUSTRY,INTERVENTIONAL,2/19/2024,10/12/2026
NCT05319873,RECRUITING,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Fulvestrant|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|DRUG: Ribociclib|BIOLOGICAL: Trastuzumab|DRUG: Tucatinib,Jonsson Comprehensive Cancer Center,Seagen Inc.|Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,OTHER,INTERVENTIONAL,4/7/2022,4/1/2025
NCT05296564,RECRUITING,"Sarcoma, Synovial|Sarcoma,Soft Tissue|Melanoma Stage IV|Triple Negative Breast Cancer|Metastatic Cancer|Non Small Cell Lung Cancer|Bladder Urothelial Carcinoma|Neuroblastoma, Metastatic|Ovary Cancer",DRUG: CYCLOPHOSPHAMIDE and FLUDARABIN|DRUG: Cyclophosphamide|BIOLOGICAL: HBI 0201-ESO TCRT|DRUG: Aldesleukin,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,3,OTHER,INTERVENTIONAL,4/1/2022,12/30/2027
NCT04983238,COMPLETED,Metastatic Breast Cancer,DRUG: BYON5667 & SYD985|DRUG: Placebo & SYD985,Byondis B.V.,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,INTERVENTIONAL,1/10/2022,6/26/2023
NCT05194072,RECRUITING,"Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms|Triple Negative Breast Neoplasms|HER2 Negative Breast Neoplasms|Hormone Receptor Positive Breast Neoplasms|Endometrial Neoplasms|Carcinoma, Non-Small-Cell Lung|Cholangiocarcinoma|Gallbladder Carcinoma|Adenoid Cystic Carcinoma",DRUG: SGN-B7H4V,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,430,INDUSTRY,INTERVENTIONAL,1/12/2022,1/31/2027
NCT05069038,RECRUITING,Breast Cancer,DRUG: Palbociclib 125mg,University of Nebraska,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,3/2/2022,9/1/2031
NCT04734262,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Sitravatinib|DRUG: Tislelizumab|DRUG: Nab-paclitaxel,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,INTERVENTIONAL,4/1/2021,6/30/2024
NCT05529862,RECRUITING,Advanced or Metastatic Breast Cancer (BC),GENETIC: Pre-treatment biopsy|GENETIC: Post treatment biopsy|GENETIC: Pre treatment blood sampling|GENETIC: Post treatment blood sampling,Institut Paoli-Calmettes,Novartis Pharmaceuticals,FEMALE,"ADULT, OLDER_ADULT",NA,241,OTHER,INTERVENTIONAL,6/20/2023,10/1/2027
NCT04808362,ACTIVE_NOT_RECRUITING,Advanced Solid Tumors|NSCLC|Triple-negative Breast Cancer|CRC,BIOLOGICAL: OMO-103,Peptomyc S.L.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,22,INDUSTRY,INTERVENTIONAL,4/28/2021,2024-12
NCT05208762,RECRUITING,"Carcinoma, Non-Small-Cell Lung|Squamous Cell Carcinoma of the Head and Neck|Esophageal Squamous Cell Carcinoma|Ovarian Neoplasms|Melanoma|Triple Negative Breast Neoplasms|Gastric Cancer",DRUG: SGN-PDL1V|DRUG: pembrolizumab,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,322,INDUSTRY,INTERVENTIONAL,10/25/2022,12/31/2026
NCT05828238,RECRUITING,Breast Cancer Stage II|Breast Cancer Stage III|Solid Tumor,DRUG: [18F]SF-DEVD-2|DRUG: [18F]-FDG,Affiliated Hospital of Jiangnan University,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,2023-01,2024-01
NCT06185972,NOT_YET_RECRUITING,Breast Cancer,DRUG: Definity|DEVICE: Sonalleve Focused Ultrasound Device,Sunnybrook Health Sciences Centre,Terry Fox Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,2/1/2024,2/1/2029
NCT04216472,ACTIVE_NOT_RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Refractory Breast Carcinoma|Triple-Negative Breast Carcinoma,DRUG: Alpelisib|DRUG: Nab-paclitaxel,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,INTERVENTIONAL,2/5/2020,12/31/2025
NCT04118062,ACTIVE_NOT_RECRUITING,Metastatic Uveal Melanoma|Triple Negative Breast Cancer|Luminal B Breast Cancer|Pediatric Cancer,BEHAVIORAL: Questionnaires|BEHAVIORAL: Semi-structured individual interviews|OTHER: Focus Group|OTHER: DELPHI Consensus Method,Institut Curie,,ALL,"ADULT, OLDER_ADULT",NA,190,OTHER,INTERVENTIONAL,2/2/2021,5/26/2024
NCT04024462,ACTIVE_NOT_RECRUITING,HER2-positive Early Breast Cancer,DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Pertuzumab and Trastuzumab FDC SC|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|PROCEDURE: Surgery|RADIATION: Post-Operative Radiotherapy|DRUG: Hormone Therapy,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,200,INDUSTRY,INTERVENTIONAL,2/5/2020,11/11/2025
NCT05592938,RECRUITING,Breast Cancer|Breast Cancer Recurrent,RADIATION: rPBI,"University Health Network, Toronto","Sunnybrook Health Sciences Centre|Royal Victoria Regional Health Centre|AC Camargo Cancer Center|King Hussein Cancer Center|Tata Memorial Hospital|NYU Langone Health|Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)|Peter MacCallum Cancer Centre, Australia",ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,6/27/2023,6/27/2027
NCT06148038,NOT_YET_RECRUITING,Breast Cancer,DRUG: CBD Oral|OTHER: Control,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,INTERVENTIONAL,1/31/2024,9/30/2026
NCT06185738,NOT_YET_RECRUITING,Breast Cancer|Head and Neck Cancer|Sarcoma,OTHER: WCM app,University of Illinois at Chicago,Northwestern University|Northeastern Illinois University,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2024-01,2026-01
NCT05649072,RECRUITING,Ovarian Cancer|Breast Cancer|Colorectal Cancer,BEHAVIORAL: Genetic Testing and Counseling|BEHAVIORAL: Screening Form,M.D. Anderson Cancer Center,Community Outreach and Engagement Fund for Underserved Texans,FEMALE,"ADULT, OLDER_ADULT",NA,1000,OTHER,INTERVENTIONAL,11/18/2022,2/2/2027
NCT06052488,RECRUITING,Breast Cancer,BEHAVIORAL: Strength After Breast Cancer,MGH Institute of Health Professions,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/2/2024,2025-03
NCT05490472,RECRUITING,"Solid Tumors|ER+ Breast Cancer|Triple Negative Breast Cancer, TNBC|ARID1A Gene Mutation|Small Cell Lung Cancer, SCLC",DRUG: JAB-2485 (Aurora A inhibitor)|DRUG: JAB-2485 (Aurora A inhibitor),"Jacobio Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,102,INDUSTRY,INTERVENTIONAL,12/20/2022,2026-08
NCT05816538,NOT_YET_RECRUITING,Paravertebral Block|Pectoralis and Serratus Plane Nerve Blocks|Breast Cancer|Immunologic Suppression|Levobupivacaine,PROCEDURE: Paravertebral nerve block (PVB)|PROCEDURE: Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|DEVICE: Regional anesthetic technique with ultrasound guidance|DEVICE: Regional anesthetic technique with peripheral nerve stimulation.|DRUG: Levobupivacaine 0.5%|PROCEDURE: General anesthesia,University of Rijeka,,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,2023-04,2025-12
NCT05568472,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Hormone Receptor-Positive Breast Carcinoma,OTHER: Best Practice|PROCEDURE: Biospecimen Collection|PROCEDURE: Endocrine Drug Therapy|BEHAVIORAL: Health Education|OTHER: Questionnaire Administration|OTHER: Symptom Specific Assessment Tool,SWOG Cancer Research Network,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,540,NETWORK,INTERVENTIONAL,3/29/2023,5/1/2028
NCT05021172,COMPLETED,Breast Carcinoma|Colorectal Carcinoma,OTHER: Best Practice|OTHER: Informational Intervention|OTHER: Questionnaire Administration|OTHER: Survey Administration,"University of California, San Francisco",Mount Zion Health Fund,ALL,OLDER_ADULT,NA,75,OTHER,INTERVENTIONAL,8/24/2021,6/30/2022
NCT04539938,ACTIVE_NOT_RECRUITING,HER2 Positive Breast Cancer,DRUG: tucatinib|DRUG: trastuzumab deruxtecan,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INDUSTRY,INTERVENTIONAL,12/1/2020,10/31/2025
NCT05381038,NOT_YET_RECRUITING,Solid Tumor|Gastrointestinal Cancer|Breast Cancer,DEVICE: QPOP|DEVICE: CURATE.AI|DRUG: Azacitidine + docetaxel|DRUG: Azacitidine + paclitaxel|DRUG: Azacitidine + irinotecan,"National University Hospital, Singapore",The N.1 Institute for Health (N.1)|Cancer Science Institute of Singapore,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,INTERVENTIONAL,2022-06,4/4/2027
NCT04770272,ACTIVE_NOT_RECRUITING,Triple-negative Breast Cancer,DRUG: Atezolizumab 840 MG in 14 ML Injection|DRUG: Atezolizumab 1200 MG in 20 ML Injection|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|PROCEDURE: Biopsy Arm A|PROCEDURE: Biopsy Arm B|PROCEDURE: Surgery,Palleos Healthcare GmbH,"Roche Pharma AG|Phaon Scientific GmbH|University Hospital, Essen|University Hospital Erlangen",ALL,"ADULT, OLDER_ADULT",PHASE2,416,INDUSTRY,INTERVENTIONAL,3/1/2021,8/31/2024
NCT06010862,RECRUITING,Gastric Cancer|Colon Cancer|Pancreas Cancer|Esophagus Cancer|Cholangiocarcinoma|Lung Cancer|Breast Cancer,BIOLOGICAL: CEA CAR-T cells|BIOLOGICAL: CEA CAR-T cells,"Chongqing Precision Biotech Co., Ltd",The First Affiliated Hospital of Nanchang University,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,9/30/2023,9/30/2026
NCT04265872,RECRUITING,Breast Cancer,DRUG: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,Baylor Research Institute,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,10/15/2020,12/1/2024
NCT06133088,RECRUITING,Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed,DRUG: dalpiciclib; fluvestrant; compound gossypol acetate tablets,Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,INTERVENTIONAL,8/1/2023,8/31/2025
NCT05623488,RECRUITING,Breast Cancer,DRUG: huCART-meso cells|DEVICE: Mesothelin Expression Testing,University of Pennsylvania,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,2/6/2023,2038-02
NCT05107388,NOT_YET_RECRUITING,Breast Cancer|Diabetes,DEVICE: FreeStyle Libre Pro,Centre Hospitalier Universitaire de Besancon,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2021-12,2024-03
NCT06222788,NOT_YET_RECRUITING,Breast Cancer,DEVICE: Convertible Plasma Jet,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),"Ozmosis Research Inc.|MinistÃ¨re de l'Ã‰conomie, de l'Innovation et de l'Ã‰nergie, QuÃ©bec, Canada|Quebec Breast Cancer Foundation",FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,2024-03,2025-07
NCT05802342,NOT_YET_RECRUITING,To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients,DRUG: Monosialotetrahexose ganglioside sodium injection,"Qilu Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,150,INDUSTRY,INTERVENTIONAL,4/20/2023,12/31/2025
NCT06016738,RECRUITING,Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|HER2 Negative Breast Carcinoma,DRUG: OP-1250|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,"Olema Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,INTERVENTIONAL,11/16/2023,9/30/2027
NCT05845138,RECRUITING,Breast Cancer,DRUG: SHR-A1811 for injection ; capecitabine,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,116,INDUSTRY,INTERVENTIONAL,7/25/2023,12/31/2025
NCT06227338,NOT_YET_RECRUITING,Breast Cancer,DRUG: Indocyanine green,Jules Bordet Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,INTERVENTIONAL,2/1/2024,1/1/2026
NCT04332588,RECRUITING,HER2-positive Breast Cancer,DRUG: [18F]FMISO PET/MRI imaging,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,INTERVENTIONAL,2024-12,2027-08
NCT05448638,COMPLETED,Breast Cancer,PROCEDURE: the combination of transversus thoracic muscle plane and pectoral nerves blocks|PROCEDURE: the pectoral nerves block only,Zhejiang Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,116,OTHER,INTERVENTIONAL,7/12/2022,8/5/2023
NCT05538572,ACTIVE_NOT_RECRUITING,Breast Cancer|Glioblastoma|Head and Neck Squamous Cell Carcinoma|Malignant Mesothelioma|Non-small Cell Lung Cancers|Sarcoma|Endometrial Cancer,DRUG: PRT3645,Prelude Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,22,INDUSTRY,INTERVENTIONAL,12/27/2022,2024-12
NCT05741372,RECRUITING,Liver Cirrhosis,DRUG: Rosuvastatin|DRUG: Digoxin|DRUG: Metformin hydrochlorid|DRUG: Furosemide,Boehringer Ingelheim,,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,INTERVENTIONAL,4/25/2023,1/27/2025
NCT04277338,COMPLETED,Primary Breast Cancer,DRUG: SPECT,Tomsk National Research Medical Center of the Russian Academy of Sciences,"Institute of Bioorganic Chemistry, Russian Academy of Sciences|Uppsala University",FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,2/10/2020,10/4/2021
NCT05759572,RECRUITING,Breast Cancer Metastatic,DRUG: Apatinib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI,Fudan University,Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Liaoning Tumor Hospital & Institute|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University,FEMALE,"ADULT, OLDER_ADULT",PHASE2,145,OTHER,INTERVENTIONAL,2/1/2023,6/1/2027
NCT05834764,RECRUITING,HER2-positive Breast Cancer,DRUG: Pyrotinib,The First Affiliated Hospital with Nanjing Medical University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,188,OTHER,INTERVENTIONAL,4/8/2023,12/31/2028
NCT04965064,RECRUITING,Breast Cancer,DRUG: Capecitabine and Neratinib.,University of Rochester,,ALL,"ADULT, OLDER_ADULT",PHASE2,22,OTHER,INTERVENTIONAL,9/23/2022,9/1/2025
NCT05275361,COMPLETED,Breast Cancer,BEHAVIORAL: Social Contact Reminder,Washington University School of Medicine,American Society of Clinical Oncology,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,3/18/2022,6/30/2022
NCT04928261,RECRUITING,Breast Cancer,DRUG: Trastuzumab,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,INTERVENTIONAL,12/13/2021,2025-09
NCT04235946,UNKNOWN,Cancer Related Fatigue|Breast Cancer,OTHER: accompanied and adapted water polo program,Institut Paoli-Calmettes,Laboratoire Management Sport Cancer EA 4670,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,3/15/2021,12/31/2021
NCT05556473,RECRUITING,Intracranial Glioma|Metastatic Brain Tumor|Breast Cancer|Neuroendocrine Tumors|Rectal Cancer,DRUG: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan,Barbara Ann Karmanos Cancer Institute,Washington University School of Medicine,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,9/29/2022,12/31/2024
NCT06182046,NOT_YET_RECRUITING,Breast Cancer Related Lymphedema,PROCEDURE: Complete decongestive treatment program|PROCEDURE: Balance exercises,Oya Topuz,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/1/2024,7/1/2025
NCT04533373,RECRUITING,Breast Cancer|Breast Reconstruction|Sensory Restoration,PROCEDURE: DIEP Flap Neurotization,Johns Hopkins University,Axogen Corporation,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,12/1/2020,12/31/2025
NCT04120246,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Refractory Breast Carcinoma,DRUG: Alpha-tocopheryloxyacetic Acid|BIOLOGICAL: Trastuzumab,Veana Therapeutics,University of Washington,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,4/8/2020,2/1/2025
NCT04594473,RECRUITING,Breast Cancer,BEHAVIORAL: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program,University of Utah,,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,3/24/2021,1/1/2024
NCT04827446,COMPLETED,Breast Cancer|Prostate Cancer|Hematologic Malignancy|Survivorship|Fatigue,"OTHER: Wearable Sensor|OTHER: Blue-blocking glasses|OTHER: Clear glasses|OTHER: Full SYNC app|OTHER: ""Dummy"" SYNC app",University of Michigan Rogel Cancer Center,"Arcascope, Inc|National Cancer Institute (NCI)",ALL,"ADULT, OLDER_ADULT",NA,139,OTHER,INTERVENTIONAL,7/15/2021,3/9/2023
NCT05340673,RECRUITING,Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma,DRUG: Agent Affecting Integumentary System|OTHER: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE1,200,OTHER,INTERVENTIONAL,6/21/2022,6/21/2024
NCT05101564,RECRUITING,Breast Cancer|HER2-negative Breast Cancer|ER Positive Breast Cancer,DRUG: Alpelisib|DRUG: Tamoxifen|DRUG: Zotatifin|DRUG: Fulvestrant,Stanford University,United States Department of Defense,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,INTERVENTIONAL,3/20/2023,2026-12
NCT04946864,RECRUITING,"Breast Cancer|Solid Tumor, Adult",DRUG: APG-2575|DRUG: Palbociclib,Ascentage Pharma Group Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,INTERVENTIONAL,8/13/2021,10/1/2024
NCT05901064,RECRUITING,Seroma,PROCEDURE: Axillary clearance,"University Hospital, Linkoeping",,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,1/21/2021,12/31/2025
NCT05512364,RECRUITING,ER-positive Breast Cancer|HER2-negative Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer,DRUG: Elacestrant|DRUG: Tamoxifen|DRUG: Letrozole 2.5mg|DRUG: Anastrozole 1mg|DRUG: Exemestane 25 MG,European Organisation for Research and Treatment of Cancer - EORTC,Breast International Group|Menarini Group,ALL,"ADULT, OLDER_ADULT",PHASE3,220,NETWORK,INTERVENTIONAL,12/15/2023,5/1/2030
NCT06103864,RECRUITING,Breast Cancer,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Pembrolizumab,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,625,INDUSTRY,INTERVENTIONAL,11/23/2023,4/23/2029
NCT04720664,TERMINATED,Breast Cancer|Metastatic Breast Cancer|Hormone Receptor Positive Breast Carcinoma,DRUG: SM-88,Georgetown University,"Tyme, Inc",ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,INTERVENTIONAL,9/22/2021,2/10/2023
NCT03982173,WITHDRAWN,Metastatic Colorectal Cancer|Triple Negative Breast Cancer|Prostate Adenocarcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma,DRUG: Tremelimumab|DRUG: Durvalumab,"Gustave Roussy, Cancer Campus, Grand Paris",,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2020-09,12/5/2024
NCT04438564,RECRUITING,Breast Cancer|Colorectal Cancer|Cancer of Ovary|Cancer of Endometrium,"OTHER: Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer",China Medical University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,5/18/2020,7/31/2023
NCT05128773,TERMINATED,Breast Cancer,DRUG: Amcenestrant|DRUG: Tamoxifen|DRUG: Amcenestrant-matching placebo|DRUG: Tamoxifen-matching placebo,Sanofi,"Breast International Group|Alliance Foundation Trials, LLC.|European Organisation for Research and Treatment of Cancer - EORTC",ALL,"ADULT, OLDER_ADULT",PHASE3,3,INDUSTRY,INTERVENTIONAL,2/17/2022,10/13/2022
NCT04521764,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Breast Adenocarcinoma|Recurrent Breast Carcinoma,BIOLOGICAL: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein,Mayo Clinic,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE1,33,OTHER,INTERVENTIONAL,9/23/2020,8/15/2024
NCT05416164,NOT_YET_RECRUITING,Breast Cancer,RADIATION: Omission of radiotherapy,The Netherlands Cancer Institute,Dutch Cancer Society|Borstkanker Onderzoek Groep,FEMALE,"ADULT, OLDER_ADULT",NA,595,OTHER,INTERVENTIONAL,2022-07,2037-05
NCT04702061,COMPLETED,"Breast Neoplasms|Pain, Postoperative",OTHER: Erector spina plane block before general anaesthesia|OTHER: Thoracic epidural block before general anaesthesia,Inonu University,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,1/11/2021,3/31/2021
NCT05520723,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer|Breast Cancer,DRUG: Sacituzumab govitecan|DRUG: Loperamide|DRUG: Granulocyte Colony-Stimulating Factor,MedSIR,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,2/7/2023,12/14/2025
NCT05821023,COMPLETED,Breast Cancer Screening,OTHER: messages,Johns Hopkins University,University of Minnesota|Beth Israel Deaconess Medical Center|National Institute on Aging (NIA),FEMALE,OLDER_ADULT,NA,4173,OTHER,INTERVENTIONAL,5/12/2023,6/19/2023
NCT04509284,COMPLETED,"Breast Cancer|Surgery|Chemotherapy Effect|Radiotherapy Side Effect|Pain, Chronic",OTHER: Training|OTHER: Control,Aalborg University,Danish Cancer Society|Danish Cancer Survivor and Late Effects Group|Universidad de Granada,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,8/10/2020,9/23/2021
NCT04368702,SUSPENDED,Gastric Cancer|Invasive Breast Cancer|in Situ Breast Cancer|Mantle Cell Lymphoma|Larynx Cancer|Bladder Cancer,RADIATION: Viewray MRIdianÂ® Linac,Dana-Farber Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,5/1/2021,6/18/2024
NCT04916002,RECRUITING,Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Basal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer|Oropharynx Squamous Cell Carcinoma,DRUG: vidutolimod|DRUG: cemiplimab,Regeneron Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,225,INDUSTRY,INTERVENTIONAL,11/30/2021,7/29/2027
NCT04494958,COMPLETED,Triple Negative Breast Cancer,"DRUG: Combination, Palbociclib + Binimetinib",Fundacion Oncosur,"Pfizer|Apices Soluciones S.L.|Pierre Fabre IbÃ©rica, S.A.",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,NETWORK,INTERVENTIONAL,11/18/2020,12/14/2023
NCT04574323,COMPLETED,Breast Cancer|Body Weight Changes,RADIATION: Curative radiotherapy|OTHER: Paleolithic lifestyle intervention,MVZ Leopoldina GmbH,,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,3/19/2020,7/16/2020
NCT05090358,RECRUITING,Breast Cancer|Breast Cancer Stage IV|Metastatic Breast Cancer,DIETARY_SUPPLEMENT: Ketogenic Diet|DIETARY_SUPPLEMENT: Low Carbohydrate Diet|DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Canagliflozin,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,106,OTHER,INTERVENTIONAL,10/8/2021,10/8/2024
NCT05159323,UNKNOWN,Breast Carcinoma; Magnetic Resonance Imaging; Diffusion Spectrum Imaging,DIAGNOSTIC_TEST: Diffusion Spectrum Imaging,Xiang Zhang,,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,INTERVENTIONAL,8/20/2021,8/19/2022
NCT05429684,RECRUITING,HER2+ Breast Cancer,DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: T-DM1|DRUG: Everolimus|DRUG: CDK4/6 inhibitor|DRUG: AI|DRUG: Anti-PD-1 monoclonal antibody,First Affiliated Hospital Xi'an Jiaotong University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,120,OTHER,INTERVENTIONAL,1/1/2021,2/28/2024
NCT05255523,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: pyrotinib,Fujian Medical University Union Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,2/20/2022,12/20/2024
NCT05199584,ACTIVE_NOT_RECRUITING,Solid Tumors With PTCH1 Loss-of-function Mutations,DRUG: ENV-101 (taladegib),"Endeavor Biomedicines, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,44,INDUSTRY,INTERVENTIONAL,5/24/2022,2024-05
NCT04843358,NOT_YET_RECRUITING,Breast Cancer|Quality of Life|Expressive Writing|Psychological,BEHAVIORAL: Emotional Disclosure|BEHAVIORAL: Non-Emotional Writing,Sultan Qaboos University,,FEMALE,ADULT,NA,64,OTHER,INTERVENTIONAL,1/1/2022,12/30/2024
NCT04535323,ACTIVE_NOT_RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Adenocarcinoma|Genitourinary Syndrome of Menopause|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Therapeutic Autologous Platelet-rich Plasma,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,9/23/2020,12/31/2024
NCT05577923,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: Trastuzumab|DRUG: pyrotinib|DRUG: Dalpiciclib|DRUG: fulvestrant,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,INTERVENTIONAL,11/1/2022,3/1/2026
NCT04764084,UNKNOWN,HER2-negative Breast Cancer|Gastric Adenocarcinoma|Cholangiocarcinoma|Pancreatic Cancer,DRUG: Niraparib|DRUG: Anlotinib,Peking University Cancer Hospital & Institute,,ALL,"ADULT, OLDER_ADULT",PHASE1,52,OTHER,INTERVENTIONAL,4/1/2021,2/28/2023
NCT04796623,UNKNOWN,"HR-positive, HER2-negative Advanced Breast Cancer",DRUG: TQB3616 capsules|DRUG: Fulvestrant injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,INTERVENTIONAL,2/4/2021,1/31/2023
NCT06225284,NOT_YET_RECRUITING,Triple Negative Breast Cancer|Premenopausal Breast Cancer,DRUG: Goserelin Acetate 3.6mgã€Goserelin Acetate 10.8mgã€Leuprolide Acetate 3.75mgã€Leuprorelin Acetate 22.5mgã€Triptorelin pamoate 11.25mgã€Triptorelin pamoate 22.5mg,National Taiwan University Hospital,Ministry of Health and Welfare|Debiopharm International SA,FEMALE,ADULT,PHASE2,124,OTHER,INTERVENTIONAL,2/15/2024,2030-12
NCT04997941,RECRUITING,Premenopausal Breast Cancer|Hormone Receptor-positive Breast Cancer,DRUG: Tamoxifen Oral Product|DIAGNOSTIC_TEST: Assessment of Ki-67|PROCEDURE: Surgery,Seoul National University Hospital,,FEMALE,ADULT,PHASE2,238,OTHER,INTERVENTIONAL,10/21/2021,12/31/2028
NCT05889728,RECRUITING,Breast Cancer,DRUG: [68Ga]GA-NeoB,"St Vincent's Hospital, Sydney",Novartis,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,2/20/2023,2/23/2025
NCT05978128,RECRUITING,Breast Carcinoma|Lung Carcinoma,BEHAVIORAL: Health Education|OTHER: Health Promotion and Education|BEHAVIORAL: Patient Navigation|OTHER: Survey Administration,Jonsson Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,INTERVENTIONAL,7/28/2023,9/30/2029
NCT05586841,NOT_YET_RECRUITING,HR+/HER2- Advanced Breast Cancer,DRUG: Dalpiciclib|DRUG: Chidamide,Beijing 302 Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,INTERVENTIONAL,11/1/2022,11/30/2025
NCT05949541,RECRUITING,Breast Cancer|Advanced Breast Cancer,DRUG: Everolimus 10 mg|DRUG: CDK4/6 Inhibitor SHR6390|DRUG: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,265,OTHER,INTERVENTIONAL,7/26/2023,2028-01
NCT04294628,RECRUITING,Advanced Malignant Solid Neoplasm|HER2-Positive Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Trastuzumab Deruxtecan,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,63,NIH,INTERVENTIONAL,9/1/2020,12/31/2024
NCT06082141,RECRUITING,Acute Pain|Opioid Use,PROCEDURE: Transversus thoracis plane block combined with serratus anterior plane block|PROCEDURE: Serratus anterior plan block,Bezmialem Vakif University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,7/12/2023,2024-06
NCT05306041,RECRUITING,HER2-positive Breast Cancer,DRUG: Inavolisib|DRUG: PHESGO|DRUG: Endocrine therapy,German Breast Group,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE2,170,OTHER,INTERVENTIONAL,1/2/2023,2027-01
NCT05658341,RECRUITING,Quality of Life|Breast Cancer,BEHAVIORAL: ADA|BEHAVIORAL: Usual Care,Siel Bleu,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,11/6/2023,2025-11
NCT05989828,NOT_YET_RECRUITING,Triple Negative Breast Cancer,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Mammogram|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Ultrasound Imaging,University of Southern California,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,4/1/2024,4/1/2027
NCT04802941,RECRUITING,"Decision Support Systems, Clinical",DEVICE: Neoadjuvant Chemotherapy by CDSS (MedicBK)|DRUG: General practice,"Center of Personalized Medicine, Pirogova","Center for New Medical Technologies, Novosibirsk, Russia|I.M. Sechenov First Moscow State Medical University|Novosibirsk Oncology Center",ALL,"ADULT, OLDER_ADULT",NA,1200,OTHER,INTERVENTIONAL,3/12/2021,3/30/2024
NCT03820141,RECRUITING,Breast Cancer,DRUG: Durvalumab|DRUG: Trastuzumab|DRUG: Pertuzumab,The Methodist Hospital Research Institute,AstraZeneca,FEMALE,"ADULT, OLDER_ADULT",PHASE2,39,OTHER,INTERVENTIONAL,3/3/2020,2025-02
NCT05048641,NOT_YET_RECRUITING,Breast Cancer,OTHER: Whatsapp reminder,Chinese University of Hong Kong,,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,INTERVENTIONAL,6/1/2022,5/31/2024
NCT05969184,RECRUITING,Breast Neoplasm Female,"DRUG: CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)",Peking University Cancer Hospital & Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,94,OTHER,INTERVENTIONAL,12/25/2021,12/25/2024
NCT04797728,COMPLETED,Breast Cancer|Hormone Receptor Positive Breast Carcinoma,DRUG: Elacestrant,SOLTI Breast Cancer Research Group,"Radius Health, Inc.",FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,23,OTHER,INTERVENTIONAL,2/9/2021,2/25/2022
NCT04610528,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: U3 1402|DRUG: U3 1402,SOLTI Breast Cancer Research Group,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,80,OTHER,INTERVENTIONAL,12/22/2020,9/30/2023
NCT04454528,RECRUITING,Breast Cancer,RADIATION: Hypofractionated radiotherapy|DRUG: Pembrolizumab infusion|PROCEDURE: Blood and tissue sampling,Abramson Cancer Center at Penn Medicine,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,27,OTHER,INTERVENTIONAL,12/7/2020,2024-08
NCT05690828,RECRUITING,Breast Cancer,BEHAVIORAL: Cognitive remediation,Institut BergoniÃ©,University of Bordeaux|Association Oncogite,FEMALE,ADULT,NA,164,OTHER,INTERVENTIONAL,2/1/2023,12/1/2024
NCT05746728,NOT_YET_RECRUITING,Metastatic Triple-negative Breast Cancer,DRUG: Surufatinib|DRUG: Tislelizumab,Huihua Xiong,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,45,OTHER,INTERVENTIONAL,2023-04,2025-08
NCT05400941,NOT_YET_RECRUITING,"Cancer, Breast|Health Care Utilization",BEHAVIORAL: Practice Led Intervention,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,910,OTHER,INTERVENTIONAL,2023-12,2025-12
NCT04042701,RECRUITING,Breast Cancer|Non-small Cell Lung Carcinoma,DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Pembrolizumab,Daiichi Sankyo,AstraZeneca UK Limited|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,115,INDUSTRY,INTERVENTIONAL,2/10/2020,3/1/2024
NCT06125080,RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: Utidelone|DRUG: Tirelizumab|DRUG: Bevacizumab,Huihua Xiong,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,INTERVENTIONAL,10/30/2023,10/30/2026
NCT04487236,RECRUITING,Advanced Solid Tumors|HER2-positive Breast Cancer,DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle,Suzhou Zanrong Pharma Limited,,ALL,"ADULT, OLDER_ADULT",PHASE1,84,INDUSTRY,INTERVENTIONAL,10/15/2020,6/30/2024
NCT05461534,NOT_YET_RECRUITING,Breast Cancer|Sexual Dysfunction,BEHAVIORAL: mindfulness yoga,The First Affiliated Hospital of Zhengzhou University,,FEMALE,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,8/1/2022,8/1/2024
NCT05560334,RECRUITING,Breast Cancer,DRUG: Pemigatinib Pill,Tianjin Medical University Cancer Institute and Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,9/8/2022,9/8/2025
NCT05212701,WITHDRAWN,Fatigue|Locally Advanced or Metastatic Breast Cancer,DRUG: Reparixin|DRUG: Placebo,DompÃ© Farmaceutici S.p.A,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,4/19/2022,2024-07
NCT05130580,ACTIVE_NOT_RECRUITING,Breast Carcinoma,OTHER: Enhanced Consultation|OTHER: Standard of Care Consultation|PROCEDURE: Conventional Imaging|OTHER: Educational Intervention|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,National Institutes of Health (NIH)|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,10/13/2020,2/2/2027
NCT05928780,NOT_YET_RECRUITING,TNBC - Triple-Negative Breast Cancer,DRUG: A1:SG with SHR3680|DRUG: A2:SG|DRUG: B1:SG with SHR1210|DRUG: B2:SG|DRUG: C1:SG with SHR3162|DRUG: C2:SG|DRUG: D1:SG with VEGFRI|DRUG: D2:SG,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,125,OTHER,INTERVENTIONAL,7/1/2023,9/1/2025
NCT05735080,RECRUITING,Breast Cancer|Breast Cancer Metastatic|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Ovarian Cancer|CCNE1 Amplification|Solid Tumor|Advanced Cancer|Metastatic Cancer,DRUG: INX-315,Incyclix Bio,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,81,INDUSTRY,INTERVENTIONAL,3/28/2023,2026-06
NCT06008301,NOT_YET_RECRUITING,Breast Cancer Female,OTHER: State-Trait Anxiety Inventory (STAI),Boston Medical Center,Breast Cancer Alliance,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2024-03,2026-03
NCT05022602,COMPLETED,Breast Cancer Stage,DEVICE: Imagio,Seno Medical Instruments Inc.,American College of Radiology,ALL,"ADULT, OLDER_ADULT",NA,38,INDUSTRY,INTERVENTIONAL,8/19/2021,2/17/2022
NCT03946202,RECRUITING,Breast Cancer,DRUG: Hydrogen Peroxide,"Institute of Cancer Research, United Kingdom","Kortuc, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,184,OTHER,INTERVENTIONAL,6/16/2020,12/31/2026
NCT05831878,RECRUITING,Advanced Breast Cancer,DRUG: Disitamab vedotin,RenJi Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,5/4/2023,2026-08
NCT05376878,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain,OTHER: Copper Cu 64-DOTA-Trastuzumab|PROCEDURE: Magnetic Resonance Imaging|DEVICE: Positron Emission Tomography|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Deruxtecan,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,INTERVENTIONAL,12/21/2022,2/25/2026
NCT05494502,RECRUITING,"Breast Neoplasms|Mastectomy|Nerve Block|Dexmedetomidine|Pain, Postoperative|Chronic Pain|Prognosis",PROCEDURE: Erector spinae plane block|PROCEDURE: Control group,Peking University First Hospital,Peking University Cancer Hospital & Institute,ALL,"ADULT, OLDER_ADULT",NA,1206,OTHER,INTERVENTIONAL,5/23/2023,2027-07
NCT05887102,RECRUITING,Breast Neoplasms|Breast Cancer,BEHAVIORAL: PACHA Program,CHU de Quebec-Universite Laval,Canadian Institutes of Health Research (CIHR)|Quebec Breast Cancer Foundation,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,6/7/2023,2024-12
NCT04555902,COMPLETED,Breast Cancer,BEHAVIORAL: Postcard|BEHAVIORAL: Small Gift|BEHAVIORAL: Loss Frame and Fear Appeals,Geisinger Clinic,,FEMALE,ADULT,NA,1342,OTHER,INTERVENTIONAL,10/2/2020,10/5/2021
NCT05982678,NOT_YET_RECRUITING,HER2-positive Breast Cancer,DRUG: Trastuzumab deruxtecan,The Netherlands Cancer Institute,Daiichi Sankyo|AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,INTERVENTIONAL,10/1/2023,10/1/2034
NCT05760378,RECRUITING,Triple-Negative Breast Cancer,DRUG: Famitinib|DRUG: Camrelizumab|DRUG: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,223,OTHER,INTERVENTIONAL,3/17/2023,1/1/2027
NCT05146778,RECRUITING,"Breast Cancer|Mastectomy|Pain, Chronic|Pain, Post Operative",PROCEDURE: Opioid-free anesthesia|PROCEDURE: Conventional opioid-based anesthesia,Gangnam Severance Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,230,OTHER,INTERVENTIONAL,12/16/2021,10/31/2025
NCT04726878,COMPLETED,"Breast Cancer|Pain, Acute|Anesthesia, Local",PROCEDURE: Erector spinae plane block|PROCEDURE: Sham block|PROCEDURE: General anesthesia|PROCEDURE: Patient-controlled analgesia|DRUG: Oxycodone|DRUG: paracetamol,Medical University of Lublin,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,INTERVENTIONAL,2/1/2021,8/17/2021
NCT04208178,ACTIVE_NOT_RECRUITING,Advanced HER2+Breast Cancer,DRUG: Alpelisib|DRUG: Alpelisib matching Placebo|DRUG: Trastuzumab|DRUG: Pertuzumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,20,INDUSTRY,INTERVENTIONAL,7/16/2020,4/2/2024
NCT05234502,NOT_YET_RECRUITING,Breast Cancer Female,"OTHER: Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|OTHER: Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)",Necmettin Erbakan University,,FEMALE,ADULT,NA,56,OTHER,INTERVENTIONAL,1/30/2022,1/30/2025
NCT05085678,COMPLETED,Breast Cancer|Quality of Life|Self Efficacy,DEVICE: Co'moon (online website to support women with AET),Universitaire Ziekenhuizen KU Leuven,KU Leuven,FEMALE,"ADULT, OLDER_ADULT",NA,77,OTHER,INTERVENTIONAL,12/1/2020,12/31/2022
NCT05266378,RECRUITING,Breast Cancer,PROCEDURE: PECs block|OTHER: Not receiving PECs Block,Gangnam Severance Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,INTERVENTIONAL,2/23/2022,3/24/2025
NCT05334732,RECRUITING,Breast Cancer,BEHAVIORAL: SIS TALK Back Intervention,Virginia Commonwealth University,Georgetown University,FEMALE,"ADULT, OLDER_ADULT",NA,460,OTHER,INTERVENTIONAL,3/1/2021,1/31/2025
NCT05329532,RECRUITING,Triple Negative Breast Cancer|Renal Cell Cancer|High Grade Ovarian Serous Adenocarcinoma|Squamous Cell Carcinoma of the Head and Neck,BIOLOGICAL: Modi-1/Modi-1v|BIOLOGICAL: Pembrolizumab|DEVICE: MicronJet600â„¢ microneedle device (NanoPass),Scancell Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,144,INDUSTRY,INTERVENTIONAL,4/7/2022,6/30/2026
NCT01801878,WITHDRAWN,Breast Neoplasms|Skin Abnormalities,BIOLOGICAL: Adipose SVF cell|BIOLOGICAL: Normal saline,Seoul National University Hospital,,FEMALE,ADULT,NA,0,OTHER,INTERVENTIONAL,12/1/2020,12/30/2021
NCT05192278,UNKNOWN,Breast Cancer,OTHER: erector spinae block,Mansoura University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,12/12/2021,9/1/2022
NCT04722978,RECRUITING,Triple Negative Breast Cancer,DRUG: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|DRUG: Gemcitabine combined with carboplatin plus placebo,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,228,OTHER,INTERVENTIONAL,4/20/2021,2025-02
NCT05882578,ACTIVE_NOT_RECRUITING,Breast Cancer|Exercise Oncology|Cancer Survivors|Fitness Capacity,OTHER: Oncological physical exercise intervention|OTHER: Active Physical Activities intervention,Tigers Running Club,,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,1/12/2023,7/31/2023
NCT05663294,RECRUITING,Breast Cancer,RADIATION: external beams radiotherapy|RADIATION: brachytherapy,Istituto Clinico Humanitas,Mediolanum Cardio Research,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,1/9/2023,2029-12
NCT05866432,RECRUITING,Breast Cancer Stage IV,DRUG: Datopotamab deruxtecan,Medical University of Vienna,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,7/1/2023,5/23/2026
NCT05871918,RECRUITING,HER-2 Positive Breast Cancer,DRUG: TCbHP VS ddEC-THP,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,832,OTHER,INTERVENTIONAL,10/8/2022,12/31/2023
NCT05396118,ENROLLING_BY_INVITATION,Breast Cancer|Neuroendocrine Tumors|Neuroendocrine Carcinoma|Neuroendocrine Carcinoma Metastatic,DRUG: 18F-FDG|DRUG: Injection of hyperpolarized [1-13C]Pyruvate|PROCEDURE: PET/MR/MRS/MRSI scanning,"Rigshospitalet, Denmark",,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,INTERVENTIONAL,5/18/2022,2024-12
NCT06239194,NOT_YET_RECRUITING,Biliary Tract Cancer|Breast Cancer|Cervical Cancer|Colon Cancer|Endometrial Cancer|Esophageal Cancer|Gastric Cancer|GastroEsophageal Cancer|Head and Neck Cancer|Hepatocellular Cancer|Non-small Cell Lung Cancer|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Renal Cancer|Thyroid Cancer,DRUG: MDX2001,"ModeX Therapeutics, An OPKO Health Company",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,INTERVENTIONAL,2024-05,2029-02
NCT04446494,RECRUITING,Breast Cancer Related Lymphedema,PROCEDURE: Identification and preservation of arm lymphatics (DEPART),Wuhan University,,FEMALE,"ADULT, OLDER_ADULT",NA,1200,OTHER,INTERVENTIONAL,6/20/2020,9/30/2025
NCT05654532,RECRUITING,Breast Cancer,DRUG: AC699,Accutar Biotechnology Inc,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,INTERVENTIONAL,12/29/2022,12/31/2024
NCT04772118,COMPLETED,Lung Cancer|Breast Cancer|Gynecologic Cancer,OTHER: Carevive PROmptâ„¢,"Carevive Systems, Inc.",,ALL,"ADULT, OLDER_ADULT",NA,51,INDUSTRY,INTERVENTIONAL,2/16/2021,11/1/2021
NCT05187832,RECRUITING,Advanced or Metastatic Breast Cancer,DRUG: AND019 PO QD,Kind Pharmaceuticals LLC,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,61,INDUSTRY,INTERVENTIONAL,10/5/2022,2025-05
NCT05411432,NOT_YET_RECRUITING,HER2-positive Breast Cancer and Gastric Cancer,DRUG: 68Ga labeled HER2 Affibody,Xijing Hospital,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,56,OTHER,INTERVENTIONAL,6/1/2022,12/1/2023
NCT04389632,RECRUITING,"Carcinoma, Non-Small Cell Lung|Squamous Cell Carcinoma of Head and Neck|HER2 Negative Breast Neoplasms|Esophageal Squamous Cell Carcinoma|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Ovarian Neoplasms|Cutaneous Squamous Cell Cancer|Exocrine Pancreatic Adenocarcinoma|Urinary Bladder Neoplasms|Uterine Cervical Neoplasms|Stomach Neoplasms",DRUG: sigvotatug vedotin|DRUG: pembrolizumab|DRUG: cisplatin|DRUG: carboplatin,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,1006,INDUSTRY,INTERVENTIONAL,6/8/2020,10/31/2024
NCT06103318,NOT_YET_RECRUITING,Breast Cancer|Cognitive Dysfunction,BEHAVIORAL: ICOgnition,Institut CatalÃ  d'Oncologia,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge|Carlos III Health Institute,FEMALE,"ADULT, OLDER_ADULT",NA,176,OTHER,INTERVENTIONAL,12/14/2023,9/7/2025
NCT04861077,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: [18F]FMISO-PET with contrast-enhanced MRI,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,INTERVENTIONAL,6/1/2025,8/2/2027
NCT04425018,RECRUITING,Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer,DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Margetuximab|DRUG: Trastuzumab,Dana-Farber Cancer Institute,MacroGenics|Translational Breast Cancer Research Consortium,ALL,"ADULT, OLDER_ADULT",PHASE2,171,OTHER,INTERVENTIONAL,7/13/2020,7/1/2027
NCT04727632,RECRUITING,Estrogen Receptor Positive Breast Cancer,DRUG: [18F]Fluoroestradiol (FES) PET/CT,University of Utah,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,INTERVENTIONAL,3/31/2021,4/30/2025
NCT05978232,NOT_YET_RECRUITING,Breast Cancer|Prostate Cancer,BEHAVIORAL: NAVAH,Case Comprehensive Cancer Center,Susan G. Komen Breast Cancer Foundation|Gilead Sciences|University Hospitals Cleveland Medical Center,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,6/1/2024,7/11/2028
NCT06098118,NOT_YET_RECRUITING,Breast Cancer Screening,BEHAVIORAL: MyMammogram decision aid,Dartmouth-Hitchcock Medical Center,,FEMALE,ADULT,NA,100,OTHER,INTERVENTIONAL,2024-01,2024-07
NCT05123118,COMPLETED,"Smoking, Cigarette|Breastfeeding",BEHAVIORAL: Integrated intervention of smoking cessation and breastfeeding|BEHAVIORAL: Attention placebo control,Xiaozhong Wen,National Center for Advancing Translational Sciences (NCATS),FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/1/2021,10/30/2023
NCT05159518,COMPLETED,Sarcoma|Castrate Resistant Prostate Cancer|Hormone Receptor Positive HER2 Negative Breast Cancer|Non-small Cell Lung Cancer|Solid Tumors With Known MYC Amplification,DRUG: PRT2527,Prelude Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,2/14/2022,12/6/2023
NCT04891718,WITHDRAWN,Solid Tumour,BIOLOGICAL: MVC-101|BIOLOGICAL: Nivolumab|COMBINATION_PRODUCT: MVC-101 + Nivolumab,Presage Biosciences,Takeda,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,INDUSTRY,INTERVENTIONAL,9/15/2021,6/5/2022
NCT05073432,COMPLETED,Breast Cancer,OTHER: Experimental,University of Rochester,,ALL,OLDER_ADULT,PHASE1,10,OTHER,INTERVENTIONAL,7/28/2021,3/15/2023
NCT04722718,UNKNOWN,Breast Cancer,DRUG: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,Jiuda Zhao,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,INTERVENTIONAL,2/1/2021,1/31/2023
NCT05311618,RECRUITING,Pancreatic Cancer|Breast Cancer|Gastric Cancer|Non Small Cell Lung Cancer|Cervical Cancer|Endocervical Cancer|Squamous Cell Carcinoma of Head and Neck|Bladder Urothelial Cancer|Colorectal Cancer|Esophageal Cancer|Ovarian Cancer|Renal Cell Carcinoma|Prostate Cancer|Melanoma|Mesothelioma|Cholangiocarcinoma,DRUG: NGM438|DRUG: Pembrolizumab,"NGM Biopharmaceuticals, Inc",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,71,INDUSTRY,INTERVENTIONAL,5/11/2022,2024-06
NCT04298918,TERMINATED,Breast Cancer,DRUG: Placebo|DRUG: Venetoclax|DRUG: Trastuzumab emtansine,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,INDUSTRY,INTERVENTIONAL,9/23/2020,2/4/2021
NCT06183736,NOT_YET_RECRUITING,Advanced Solid Tumors,DRUG: CVL237 tablets,"Convalife (Shanghai) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,98,INDUSTRY,INTERVENTIONAL,12/20/2023,6/30/2027
NCT05975736,RECRUITING,Mammography|Breast Cancer|Radiology,BEHAVIORAL: Search only for masses|BEHAVIORAL: Search only for calcifications|BEHAVIORAL: Search for both together|BEHAVIORAL: Search for one after the other,Brigham and Women's Hospital,,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,9/1/2022,9/1/2028
NCT04268134,ACTIVE_NOT_RECRUITING,Breast Cancer,DIETARY_SUPPLEMENT: Omega-3 fatty acid supplement,University of Michigan Rogel Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,77,OTHER,INTERVENTIONAL,7/28/2020,12/30/2023
NCT06201234,NOT_YET_RECRUITING,Hormone Receptor Positive HER-2 Negative Breast Cancer|Advanced or Metastatic Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|PALB2 Gene Mutation,DRUG: Niraparib + Elacestrant|DRUG: Niraparib,German Breast Group,"Stemline Therapeutics, Inc.|GlaxoSmithKline",ALL,"ADULT, OLDER_ADULT",PHASE2,176,OTHER,INTERVENTIONAL,3/31/2024,3/31/2028
NCT05969041,RECRUITING,"Epithelial Tumors, Malignant",DRUG: MT-302 (A),Myeloid Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,8/2/2023,8/31/2028
NCT06057636,RECRUITING,Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Neoplasms|Triple Negative Breast Neoplasms|Neoplasm Metastasis,BEHAVIORAL: Self-Administered Hypnosis|BEHAVIORAL: Self-Administered White Noise Hypnosis,"The University of Tennessee, Knoxville",Baylor University,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/8/2023,7/31/2024
NCT06058936,RECRUITING,Breast Cancer Female,OTHER: exercises using virtual reality technology,University of Hail,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,9/15/2023,7/30/2024
NCT04270136,COMPLETED,Breast Cancer|Mastectomy|Ambulatory Care,PROCEDURE: total mastectomy,"Centre Hospitalier Universitaire, Amiens",Centre Hospitalier de Beauvais|Centre Hospitalier de Saint-Quentin,FEMALE,"ADULT, OLDER_ADULT",NA,1,OTHER,INTERVENTIONAL,1/1/2021,9/12/2023
NCT05977036,NOT_YET_RECRUITING,Metastatic Breast Cancer|Unresectable Breast Cancer,DEVICE: DiviTumÂ® TKa assay|DRUG: CDK4/6 + Endocrine therapy,Washington University School of Medicine,Biovica,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,INTERVENTIONAL,2/28/2024,2/28/2034
NCT04424641,TERMINATED,Locally Advanced or Metastatic Solid Tumor(s)|Prostate Cancer|Esophageal Cancer|Triple Negative Breast Cancer (TNBC)|Squamous Cell Carcinoma of Head and Neck (SCCHN)|Non-small Cell Lung Cancer (NSCLC)|Bladder Cancer|Uterine Cancer,BIOLOGICAL: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,Genmab,AbbVie,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,INTERVENTIONAL,7/15/2020,10/29/2021
NCT04558034,TERMINATED,Cryotherapy Effect|Peripheral Neuropathy|Nail Toxicity,OTHER: cryotherapy,Parkview Health,,FEMALE,"ADULT, OLDER_ADULT",NA,14,OTHER,INTERVENTIONAL,8/4/2020,2/3/2021
NCT04107636,RECRUITING,Breast Cancer,PROCEDURE: Vacuum assisted biopsy|PROCEDURE: conventional lumpectomy,Radboud University Medical Center,Canisius-Wilhelmina Hospital|The Netherlands Cancer Institute|St. Antonius Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,INTERVENTIONAL,8/2/2021,2023-12
NCT05585034,RECRUITING,"Head and Neck Squamous Cell Carcinoma|Melanoma Excluding Uveal Melanoma|Non-small Cell Lung Cancer, Squamous or Non-squamous|Urothelial Carcinoma|Renal Cell Carcinoma, Clear Cell|Castration-resistant Prostate Cancer|Ovarian Cancer, Epithelial|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer",BIOLOGICAL: XmAbÂ®808|BIOLOGICAL: KeytrudaÂ® (pembrolizumab),"Xencor, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,INTERVENTIONAL,12/14/2022,2027-12
NCT04995328,COMPLETED,Radiation Dermatitis,OTHER: Radiation Care Gel,China Medical University Hospital,,ALL,"ADULT, OLDER_ADULT",NA,23,OTHER,INTERVENTIONAL,8/3/2021,10/7/2022
NCT05901428,RECRUITING,Hormone Receptor Positive HER-2 Negative Breast Cancer,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1736,OTHER,INTERVENTIONAL,6/1/2023,2028-06
NCT04767828,UNKNOWN,TTP,DRUG: PYRROTINI|RADIATION: Brain radiation therapy,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,43,OTHER,INTERVENTIONAL,5/1/2020,2022-06
NCT05091528,TERMINATED,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer,DRUG: SBT6050|DRUG: trastuzumab deruxtecan|DRUG: tucatinib|DRUG: trastuzumab|DRUG: capecitabine|DRUG: trastuzumab deruxtecan,Silverback Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2,INDUSTRY,INTERVENTIONAL,2/8/2022,7/7/2022
NCT04177628,COMPLETED,"Shared Decision Making|Breast Neoplasms|Radiotherapy, Adjuvant",BEHAVIORAL: Shared decision making supported by an in-consultation patient decision aid,Vejle Hospital,Danish Breast Cancer Cooperative Group|University of Southern Denmark|Danish Comprehensive Cancer Center,FEMALE,"ADULT, OLDER_ADULT",NA,678,OTHER,INTERVENTIONAL,3/4/2020,7/31/2023
NCT05243641,RECRUITING,Metastatic Breast Cancer|Breast Cancer,DRUG: Neratinib|DRUG: Capmatinib,M.D. Anderson Cancer Center,"Celcuity Inc|Novartis|Puma Biotechnology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,56,OTHER,INTERVENTIONAL,8/18/2022,12/31/2028
NCT05848141,NOT_YET_RECRUITING,Breast Cancer Survivors,BEHAVIORAL: Exercise training,University of Florida,,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,2023-11,2024-05
NCT04514484,ACTIVE_NOT_RECRUITING,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Triple-Negative Breast Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,18,NIH,INTERVENTIONAL,11/22/2021,11/2/2025
NCT04927884,TERMINATED,Advanced Triple Negative Breast Cancer,BIOLOGICAL: N-803|BIOLOGICAL: PD-L1 t-haNK|DRUG: Sacituzumab Govitecan-Hziy|DRUG: Cyclophosphamide,"ImmunityBio, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,3,INDUSTRY,INTERVENTIONAL,9/27/2021,1/4/2023
NCT06105684,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: Capecitabine Pill,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,2024-04,2028-12
NCT04890028,RECRUITING,Brain Metastases|MRI,RADIATION: F-DOPA PET/CT,Institut Cancerologie de l'Ouest,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,12/3/2021,2024-02
NCT05754528,RECRUITING,Breast Cancer,DRUG: Standard of care administration of Endocrine therapy|DRUG: Dose-frequency escalation administration of Endocrine therapy,Ottawa Hospital Research Institute,,ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,INTERVENTIONAL,7/28/2023,2029-07
NCT05870241,COMPLETED,Post Mastectomy Lymphedema,OTHER: Ga-As Laser|OTHER: Microcurrent Electrical Stimulation|OTHER: traditional therapy,Cairo University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,5/25/2023,9/30/2023
NCT04073823,TERMINATED,Breast Cancer Related Lymphedema,DEVICE: Flexitouch Plus|DEVICE: Flexitouch Plus FT with software modification,Tactile Medical,,FEMALE,"ADULT, OLDER_ADULT",NA,2,INDUSTRY,INTERVENTIONAL,1/23/2020,2/8/2020
NCT06096623,RECRUITING,Cancer|Breast Cancer|Colorectal Cancer,BEHAVIORAL: Weekly Survey,UNC Lineberger Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,11/6/2023,2026-05
NCT05966584,RECRUITING,Breast Cancer,DRUG: Benralizumab|DRUG: fulvestrant or AIs) and PI3K inhibition (alpelisib),Memorial Sloan Kettering Cancer Center,AstraZeneca|Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,7/6/2023,2026-07
NCT05605184,RECRUITING,Health Care Survey,OTHER: Survey,Technical University of Munich,,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,9/1/2022,2023-08
NCT05338723,RECRUITING,Chemotherapy-induced Cardiotoxicity|Breast Cancer,DRUG: Rosuvastatin 20mg,Tanta University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,INTERVENTIONAL,9/15/2020,9/15/2023
NCT05451784,RECRUITING,Metastatic Triple-Negative Breast Carcinoma,DRUG: PD1+ TILs (NUMARZU-001) product infusion,Fundacio Clinic Barcelona,SOLTI Breast Cancer Research Group,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,INTERVENTIONAL,7/20/2022,9/30/2027
NCT04108858,TERMINATED,Anatomic Stage IV Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Metastatic Breast Carcinoma,DRUG: Copanlisib|BIOLOGICAL: Pertuzumab|BIOLOGICAL: Trastuzumab,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2,NIH,INTERVENTIONAL,5/20/2021,4/29/2022
NCT06065423,COMPLETED,Breast Cancer Related Lymphedema|Telerehabilitation,"OTHER: Manuel Lymphatic Drainage(MLD), Exercises",Marmara University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,9/1/2021,6/1/2023
NCT05129332,RECRUITING,Dyspareunia,OTHER: Vaginal Moisturizer|DEVICE: Vaginal Dilator,Columbia University,,FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,INTERVENTIONAL,8/3/2022,2/29/2024
NCT05472532,RECRUITING,Cancer Metastatic|Prostate Cancer|Breast Cancer|Lung Cancer|Ovarian Cancer|Gastric Cancer,PROCEDURE: Patient sampling.,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",NA,132,OTHER,INTERVENTIONAL,2/14/2023,12/14/2024
NCT04159818,RECRUITING,Metastatic Breast Cancer,DRUG: Nivolumab|DRUG: Cisplatin|DRUG: Low dose doxorubicin,The Netherlands Cancer Institute,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,INTERVENTIONAL,2/21/2020,12/15/2026
NCT05963984,RECRUITING,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer,DRUG: Samuraciclib|DRUG: Fulvestrant,Carrick Therapeutics Limited,Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,INTERVENTIONAL,12/14/2023,6/16/2025
NCT04925284,RECRUITING,Non Small Cell Lung Cancer|Cervical Cancer|SCCHN|Pancreatic Cancer|Esophageal SCC|Metastatic Castration-resistant Prostate Cancer|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Epithelial Ovarian Cancer|Endometrial Cancer|Tissue Factor-Expressing Solid Tumors,DRUG: XB002|DRUG: Nivolumab|DRUG: Bevacizumab,Exelixis,,ALL,"ADULT, OLDER_ADULT",PHASE1,573,INDUSTRY,INTERVENTIONAL,6/7/2021,10/7/2024
NCT04592484,COMPLETED,Advanced Solid Tumor,BIOLOGICAL: CDK-002,Codiak BioSciences,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,27,INDUSTRY,INTERVENTIONAL,9/15/2020,12/23/2022
NCT05791084,NOT_YET_RECRUITING,"Health Literacy|Distress, Emotional|Preparedness|Mobile Application",OTHER: mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.,Jonkoping University,,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,INTERVENTIONAL,9/1/2023,3/30/2029
NCT06222684,NOT_YET_RECRUITING,Breast Cancer|Pain|Anxiety,OTHER: Music therapy,Saglik Bilimleri Universitesi,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,1/20/2024,5/30/2024
NCT05232084,COMPLETED,Breast Cancer|Breast Neoplasms|Breast Diseases,DRUG: Bupivacaine + Fentanyl,Medipol University,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,1/27/2022,5/25/2023
NCT04890184,UNKNOWN,Breast Cancer,DIETARY_SUPPLEMENT: grape juice|OTHER: control,National Nutrition and Food Technology Institute,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,5/8/2021,7/15/2021
NCT04364672,RECRUITING,Breast Cancer,DRUG: 18F-labeled DPA-714 PET scan,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,6/1/2025,7/1/2026
NCT05067972,TERMINATED,Ovarian Neoplasms|Endometrial Neoplasms|Breast Neoplasms,DRUG: PF-07260437|DIAGNOSTIC_TEST: B7-H4 IHC,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,10/7/2021,10/17/2023
NCT05726162,RECRUITING,Sleep Quality,DEVICE: biofeedback-based music program|OTHER: Control,Seoul National University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,8/21/2023,1/30/2024
NCT06075810,RECRUITING,Breast Cancer|Breast Neoplasm|Breast Cancer Stage IV,DRUG: MBQ-167,MBQ Pharma,Congressionally Directed Medical Research Programs,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,11/9/2023,10/31/2024
NCT04550910,UNKNOWN,Radiotherapy Side Effect|Locoregional Recurrence,RADIATION: Hypofractionation Schedules for Breast Cancer patients after mastecomy,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",NA,166,OTHER,INTERVENTIONAL,1/1/2020,2/1/2022
NCT04950010,TERMINATED,Breast Cancer|Breast Neoplasm Female,BEHAVIORAL: High-Intensity Interval Training|BEHAVIORAL: Moderate-Intensity Exercise,University of Nebraska,National Institute of General Medical Sciences (NIGMS),FEMALE,"ADULT, OLDER_ADULT",NA,7,OTHER,INTERVENTIONAL,3/28/2022,7/15/2022
NCT05939310,NOT_YET_RECRUITING,Breast Cancer|Breast Cancer Invasive,PROCEDURE: Fluorescence guided detection of tumor positive margins.,University Medical Center Groningen,Martini Ziekenhuis,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,70,OTHER,INTERVENTIONAL,12/1/2023,7/1/2024
NCT04630210,WITHDRAWN,Breast Cancer,DRUG: Letrozole|DRUG: Atezolizumab,Universitaire Ziekenhuizen KU Leuven,KU Leuven,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,2021-02,1/31/2025
NCT05766410,RECRUITING,Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Therapy,DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib|DRUG: Letrozole,National Taiwan University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,9/16/2022,9/30/2026
NCT05769010,RECRUITING,Metastatic Breast Cancer,DRUG: SHR-A1811|DRUG: Pyrotinib|DRUG: Bevacizumab,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,INTERVENTIONAL,3/31/2023,4/30/2026
NCT05094310,RECRUITING,Breast Cancer,DEVICE: Acupuncture,Affiliated Hospital of Qinghai University,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,4/1/2022,10/31/2023
NCT04214210,RECRUITING,Hereditary Cancer|Breast Cancer|Ovarian Cancer,OTHER: Adapted Family Gene Toolkit|OTHER: Targeted intervention,University of Basel,"Yonsei University|University Hospital, Basel, Switzerland|Hopital du Jura, Delemont, Switzerland|Department of Computer Science Yonsei University, Seoul, Korea|National Cancer Center, Korea|Chungnam National University|Ente Ospedaliero Cantonale, Ticino, Switzerland|Swiss National Science Foundation|Insel Gruppe AG, University Hospital Bern|University Hospital, Geneva",ALL,"ADULT, OLDER_ADULT",NA,228,OTHER,INTERVENTIONAL,4/15/2022,12/31/2024
NCT05720910,NOT_YET_RECRUITING,Breast Cancer|Comorbidities and Coexisting Conditions|Lung Cancer|Colorectal Cancer|Prostate Cancer,OTHER: GERONTE,Institut BergoniÃ©,EUCLID Clinical Trial Platform|University of Bordeaux,ALL,OLDER_ADULT,NA,720,OTHER,INTERVENTIONAL,2023-04,2026-01
NCT05181462,RECRUITING,Triple Negative Breast Cancer,DRUG: Carboplatin|DRUG: Gemcitabine|DRUG: Nadunolimab,Cantargia AB,Spanish Breast Cancer Research Group,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,116,INDUSTRY,INTERVENTIONAL,1/11/2022,2026-08
NCT05230810,RECRUITING,HER2-positive Metastatic Breast Cancer,DRUG: Alpelisib|DRUG: Tucatinib|DRUG: Fulvestrant,"Criterium, Inc.",Novartis|Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,INTERVENTIONAL,8/25/2022,6/30/2025
NCT05583110,RECRUITING,HER2-positive Metastatic Breast Cancer|Locally Advanced HER2 Positive Breast Carcinoma,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Vinorelbine,Spanish Breast Cancer Research Group,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,49,OTHER,INTERVENTIONAL,3/8/2023,2026-08
NCT05082610,RECRUITING,"Cancer|Tumor, Solid|Nonsmall Cell Lung Cancer|Triple Negative Breast Cancer|Malignant Neoplasm|Metastatic Cancer|Advanced Solid Tumor",DRUG: HMBD-002|DRUG: Pembrolizumab,Hummingbird Bioscience,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,240,INDUSTRY,INTERVENTIONAL,1/1/2022,2025-01
NCT05098210,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Hormone Receptor-Positive Breast Carcinoma|Locally Advanced Cutaneous Melanoma|Metastatic Acral Lentiginous Melanoma|Metastatic Conjunctival Melanoma|Metastatic Cutaneous Melanoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Mucosal Melanoma|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Acral Lentiginous Melanoma|Recurrent Cutaneous Melanoma|Recurrent Mucosal Melanoma|Refractory HER2-Negative Breast Carcinoma|Unresectable Acral Lentiginous Melanoma|Unresectable Cutaneous Melanoma|Unresectable Mucosal Melanoma,BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Nivolumab|DRUG: Poly ICLC,Fred Hutchinson Cancer Center,Amazon.com Services LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,6/9/2022,11/1/2025
NCT05258461,UNKNOWN,Breast Cancer,OTHER: use of a smartphone app for adverse event management|OTHER: conventional adverse event management,Peking Union Medical College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,3/7/2022,12/7/2022
NCT04584853,RECRUITING,Breast Cancer Female,"DRUG: Abemaciclib|DRUG: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)","Institute of Cancer Research, United Kingdom",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,2032,OTHER,INTERVENTIONAL,12/23/2020,3/31/2032
NCT05600153,NOT_YET_RECRUITING,Breast Neoplasm Female|Breast Reconstruction|Wound Complication,PROCEDURE: implant exchange operation,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Affiliated Hangzhou First People's Hospital, Zhejiang University",FEMALE,"ADULT, OLDER_ADULT",NA,136,OTHER,INTERVENTIONAL,2022-12,2024-12
NCT04261153,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: Cognitive stimulation,Centre Francois Baclesse,Centre Henri Becquerel,FEMALE,OLDER_ADULT,NA,55,OTHER,INTERVENTIONAL,6/5/2020,2023-12
NCT04332653,RECRUITING,Any Advanced Solid Tumors|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|Ovarian Cancer,DRUG: NT-I7|DRUG: Pembrolizumab,NeoImmuneTech,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,238,INDUSTRY,INTERVENTIONAL,6/10/2020,6/20/2024
NCT05692661,RECRUITING,Triple Negative Breast Cancer|HER2-positive Breast Cancer,RADIATION: proton plus carbon ion radiotherapy,Shanghai Proton and Heavy Ion Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,1/10/2023,1/10/2026
NCT05714553,RECRUITING,Advanced Cancer|Advanced Solid Tumor|Neoplasm Malignant|Metastatic Cancer|Melanoma|Classical Hodgkin Lymphoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Urothelial Carcinoma|Head and Neck Squamous Cell Carcinoma|Subungual Squamous Cell Carcinoma|Oesophageal Carcinoma|MSI-H Colorectal Cancer|Gastric Cancer|Triple Negative Breast Cancer|Endometrial Carcinoma|Pleural Mesothelioma,DRUG: Fosifloxuridine Nafalbenamide|DRUG: Leucovorin|DRUG: Pembrolizumab|DRUG: Docetaxel,NuCana plc,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,91,OTHER,INTERVENTIONAL,3/8/2023,2025-01
NCT05503160,NOT_YET_RECRUITING,New Healthcare Approach,BEHAVIORAL: Intervention,Technical University of Munich,Federal Joint Committee,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,2022-11,2025-06
NCT04739761,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Trastuzumab Deruxtecan,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,506,INDUSTRY,INTERVENTIONAL,6/22/2021,2/8/2024
NCT05335473,RECRUITING,HR Positive HER2 Negative Advanced Breast Cancer,DRUG: Eribulin and Tucidinostat,Henan Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,87,OTHER_GOV,INTERVENTIONAL,5/13/2022,11/1/2025
NCT04704661,RECRUITING,Advanced Breast Carcinoma|Advanced Colon Carcinoma|Advanced Colorectal Carcinoma|Advanced Endometrial Carcinoma|Advanced Gastric Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Salivary Gland Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2-Positive Breast Carcinoma|Malignant Hepatobiliary Neoplasm|Metastatic Breast Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Major Salivary Gland Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm,DRUG: Ceralasertib|BIOLOGICAL: Trastuzumab Deruxtecan,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE1,15,NIH,INTERVENTIONAL,8/9/2021,3/31/2026
NCT05353361,RECRUITING,Breast Cancer,DRUG: SHR-A1811ï¼šPyrotinib|DRUG: SHR-A1811ï¼›Pertuzumab|DRUG: SHR-A1811ï¼›Adebrelimab|DRUG: SHR-A1811ï¼›Albumin paclitaxel,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,402,INDUSTRY,INTERVENTIONAL,5/23/2022,12/31/2025
NCT05625698,COMPLETED,Breast Cancer,DRUG: MagTrace only|COMBINATION_PRODUCT: MagTrace and Magseed,Vastra Gotaland Region,Uppsala University Hospital,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER_GOV,INTERVENTIONAL,10/1/2021,11/28/2023
NCT05427344,RECRUITING,Colon Cancer|Breast Cancer,OTHER: Water exercise group|OTHER: Land exercise group|OTHER: Control group,Tel Aviv University,Israel National Insurance Institute|Hadassah Medical Organization,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,4/1/2023,8/30/2027
NCT05692674,RECRUITING,Breast Cancer,RADIATION: adjuvant hypofractionated intensity-modulated proton radiotherapy,Shanghai Proton and Heavy Ion Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,67,OTHER,INTERVENTIONAL,1/10/2023,9/1/2028
NCT04808674,RECRUITING,Cognitive Remediation|Breast Cancer,BEHAVIORAL: Cognitive remediation program,Hospices Civils de Lyon,,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,12/17/2021,7/17/2025
NCT05827081,NOT_YET_RECRUITING,Early Breast Cancer,DRUG: Ribociclib|DRUG: Letrozole|DRUG: Ansastrozole|DRUG: Goserelin|DRUG: Leuprolide|DRUG: Exemestane,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,3100,INDUSTRY,INTERVENTIONAL,4/10/2024,9/20/2030
NCT05257876,COMPLETED,Chronic Pain|Breast Neoplasms|Cancer Survivors,OTHER: Breathing exercise,Charles Darwin University,The Affiliated Hospital Of Southwest Medical University,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,INTERVENTIONAL,1/1/2023,8/12/2023
NCT04736576,COMPLETED,Breast Cancer,DEVICE: Wearable device,Pfizer,Japan Breast Cancer Research Group (JBCRG),FEMALE,"ADULT, OLDER_ADULT",NA,99,INDUSTRY,INTERVENTIONAL,2/24/2021,3/24/2023
NCT05244434,WITHDRAWN,Advanced Breast Adenocarcinoma|Advanced HER2-Negative Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor-Positive Breast Carcinoma|Metastatic Breast Adenocarcinoma|Metastatic HER2-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,OTHER: Best Practice|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|OTHER: Laboratory Biomarker Analysis,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,7/3/2022,1/26/2023
NCT06219434,RECRUITING,Breast Carcinoma,BEHAVIORAL: Mindfulness Relaxation|PROCEDURE: Functional Magnetic Resonance Imaging|PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration,Thomas Jefferson University,,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,11/13/2023,2024-12
NCT05787834,RECRUITING,Breast Carcinoma,OTHER: Best Practice|OTHER: Medical Device Usage and Evaluation|PROCEDURE: Respiratory Muscle Training|OTHER: Survey Administration,Roswell Park Cancer Institute,,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,INTERVENTIONAL,10/16/2023,10/16/2029
NCT06207734,RECRUITING,Breast Cancer,DRUG: Continuation of CDK4/6 inhibitor Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor Palbociclib|DRUG: Continuation of CDK4/6 inhibitor -Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor -Palbociclib|DRUG: Continuation of CDK4/6 inhibitor Abemaciclib|DRUG: Discontinuation of CDK4/6 inhibitor Abemaciclib,Institut fÃ¼r Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,1/17/2024,7/10/2028
NCT04964934,RECRUITING,ER-Positive HER2-Negative Breast Cancer,DRUG: AZD9833|DRUG: AZD9833 Placebo|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: Letrozole|DRUG: Letrozole placebo|DRUG: Palbociclib|DRUG: Abemaciclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist|DRUG: Ribociclib,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,6/30/2021,11/26/2027
NCT05967884,NOT_YET_RECRUITING,Breast Cancer,"DRUG: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab",Ottawa Hospital Research Institute,Ontario Institute for Cancer Research,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,8/4/2023,8/1/2024
NCT04588298,COMPLETED,HER2-negative Breast Cancer,DRUG: AZD9833,AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,INTERVENTIONAL,11/2/2020,6/19/2023
NCT05655598,RECRUITING,Advanced Breast Cancer|Treatment-Refractory Solid Tumors|Retinoblastoma Deficiency|SCLC|Soft Tissue Sarcoma|Endometrial Cancer|Bladder Cancer,DRUG: Palbociclib Oral Product|DRUG: TAS-116|DRUG: TAS-116|DRUG: TAS-116,Brown University,,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,INTERVENTIONAL,9/12/2023,2025-08
NCT05056844,RECRUITING,Breast Carcinoma,PROCEDURE: Contrast Enhanced Digital Mammography|PROCEDURE: Digital Tomosynthesis Mammography|DRUG: Iodinated Contrast Agent|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,INTERVENTIONAL,4/15/2021,4/30/2024
NCT04436744,COMPLETED,Early Breast Cancer,DRUG: Giredestrant|DRUG: Anastrozole|DRUG: Palbociclib|PROCEDURE: Surgery,Hoffmann-La Roche,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,221,INDUSTRY,INTERVENTIONAL,9/4/2020,11/24/2021
NCT05864144,RECRUITING,"Solid Tumor, Adult|Advanced Solid Tumor|Head and Neck Cancer|Breast Cancer|Colon Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Prostate Cancer|Uterine Cancer|Cervix Cancer|Ovarian Cancer|Kidney Cancer|Bladder Cancer|Thyroid Cancer|Melanoma|Sarcoma|Advanced Cancer|Metastatic Cancer|Refractory Cancer|Non Small Cell Lung Cancer",DRUG: SNS-101 (anti-VISTA)|DRUG: Cemiplimab,"Sensei Biotherapeutics, Inc.",Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,169,INDUSTRY,INTERVENTIONAL,5/31/2023,2027-06
NCT05488444,WITHDRAWN,Breast Cancer,BEHAVIORAL: Navigator Phone Calls|BEHAVIORAL: Exit Interview,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,8/25/2022,10/17/2023
NCT04529044,NOT_YET_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma,DRUG: Lutetium Lu 177 Dotatate,OHSU Knight Cancer Institute,Novartis|Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,INTERVENTIONAL,9/1/2022,12/20/2023
NCT05164874,ENROLLING_BY_INVITATION,Breast Cancer,DEVICE: Mobile Mammography Unit,UniversitÃ© de Caen Normandie,"National Cancer Institute, France|Regional health agency, Normandy France|Pink ribbon (Ruban Rose, France)|Normandy regional cancer screening coordination center|Departmental councils",FEMALE,"ADULT, OLDER_ADULT",NA,91982,OTHER,INTERVENTIONAL,2/14/2022,2024-09
NCT05860374,RECRUITING,Sarcoma|Carcinoma|Breast Cancer|Pancreatic Cancer|Colorectal Cancer|Gastric Cancer|Liver Cancer|Lung Cancer|Gynecologic Cancer,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),Shanghai Yunying Medical Technology,The Affiliated Hospital of Xuzhou Medical University,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,INDUSTRY,INTERVENTIONAL,3/2/2023,3/2/2026
NCT04959474,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage 1 Breast Cancer AJCC v8|Anatomic Stage 1A Breast Cancer AJCC v8|Anatomic Stage 1B Breast Cancer AJCC v8|Anatomic Stage 2 Breast Cancer AJCC v8|Anatomic Stage 2A Breast Cancer AJCC v8|Anatomic Stage 2B Breast Cancer AJCC v8|Anatomic Stage 3 Breast Cancer AJCC v8|Anatomic Stage 3A Breast Cancer AJCC v8|Anatomic Stage 3B Breast Cancer AJCC v8|Anatomic Stage 3C Breast Cancer AJCC v8|Breast Ductal Carcinoma in Situ|Invasive Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage 1 Breast Cancer AJCC v8|Prognostic Stage 1A Breast Cancer AJCC v8|Prognostic Stage 1B Breast Cancer AJCC v8|Prognostic Stage 2 Breast Cancer AJCC v8|Prognostic Stage 2A Breast Cancer AJCC v8|Prognostic Stage 2B Breast Cancer AJCC v8|Prognostic Stage 3 Breast Cancer AJCC v8|Prognostic Stage 3A Breast Cancer AJCC v8|Prognostic Stage 3B Breast Cancer AJCC v8|Prognostic Stage 3C Breast Cancer AJCC v8|Triple Negative Breast Carcinoma,OTHER: Best Practice|RADIATION: Stereotactic Body Radiation Therapy|PROCEDURE: Sentinel Lymph Node Biopsy|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment|PROCEDURE: Resection|OTHER: Dietary Intervention,Thomas Jefferson University,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,INTERVENTIONAL,8/23/2021,1/1/2026
NCT06197581,RECRUITING,"Breast Cancer, Familial Male|Radiotherapy; Complications|Chemotherapeutic Toxicity|Immune Checkpoint Inhibitor|CDK4/6 Inhibitor|Trastuzumab|Pertuzumab|PARP Inhibitor",RADIATION: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients),"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER,INTERVENTIONAL,9/15/2023,9/15/2026
NCT04927481,RECRUITING,Breast Cancer,DRUG: Mitoxantrone Hydrochloride Liposome Injection,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,73,INDUSTRY,INTERVENTIONAL,6/11/2021,5/30/2024
NCT05841381,NOT_YET_RECRUITING,Breast Cancer,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Paclitaxel,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,876,OTHER,INTERVENTIONAL,5/6/2023,5/6/2033
NCT06100874,RECRUITING,Her 2 Positive Breast Cancer|Breast Cancer Female|Breast Cancer Metastatic,DRUG: Sacituzumab Govitecan|DRUG: Trastuzumab|DRUG: Trastuzumab and Hyaluronidase-oysk,Adrienne G. Waks,Gilead Sciences,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,2024-04,11/30/2027
NCT05574881,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Dalpiciclib|DRUG: Fulvestrant|DRUG: Pertuzumab|DRUG: Trastuzumab,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,OTHER,INTERVENTIONAL,9/1/2022,1/1/2024
NCT05530876,ACTIVE_NOT_RECRUITING,Breast Cancer,OTHER: Telerehabilitation with virtual game,University of Sao Paulo,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,3/2/2020,12/2/2022
NCT05390476,RECRUITING,Triple Negative Breast Cancer,DRUG: Capecitabine|DRUG: Tucidinostat,wang shusen,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,INTERVENTIONAL,8/1/2022,12/1/2024
NCT05227898,ACTIVE_NOT_RECRUITING,Cancer,DEVICE: Device: Attuneâ„¢|DEVICE: Device: Cerenaâ„¢,Blue Note Therapeutics,Curebase Inc.,ALL,"ADULT, OLDER_ADULT",NA,352,INDUSTRY,INTERVENTIONAL,3/10/2022,12/15/2022
NCT05507398,NOT_YET_RECRUITING,Breast Cancer Female,"DRUG: Placebo, metformin and atorvastatin",Tanta University,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,2022-10,2023-09
NCT05020574,RECRUITING,Breast Cancer|Breast Cancer Female|Genetic Predisposition to Disease,DRUG: Cephalexin,"University of California, San Francisco",The Plastic Surgery Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,INTERVENTIONAL,9/28/2021,12/31/2025
NCT06085274,RECRUITING,Breast Cancer,PROCEDURE: ICG guided sentinel lymph node biopsy,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,11/1/2023,4/30/2026
NCT04613674,UNKNOWN,Triple Negative Breast Cancer,DRUG: Camrelizumab Plus Chemotherapy|DRUG: placebo+chemotherapy,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,581,INDUSTRY,INTERVENTIONAL,12/9/2020,1/30/2024
NCT04265274,WITHDRAWN,Metastatic Breast Cancer,DRUG: Disulfiram|DRUG: Vinorelbin|DRUG: Cisplatin|DRUG: Copper,"National Cancer Institute, Slovakia",,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,INTERVENTIONAL,1/1/2020,1/1/2023
NCT04689581,COMPLETED,Postoperative Pain|Analgesia,OTHER: Ultrasound guided bi-level erector spinae plane block|OTHER: Ultrasound guided modified pectoral nerve block,Kocaeli University,,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,INTERVENTIONAL,1/1/2020,1/15/2021
NCT05989776,RECRUITING,Breast Cancer,BEHAVIORAL: Informational brochure for patients and brief training for oncologists,University Paul Sabatier of Toulouse,"National Cancer Institute, France|Institut Claudius Regaud|RÃ©seau Onco-Occitanie|RÃ©seau ONCOPL",FEMALE,ADULT,NA,750,OTHER,INTERVENTIONAL,6/1/2022,2026-12
NCT04949776,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: Mammograms,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,FEMALE,"ADULT, OLDER_ADULT",NA,27000,OTHER,INTERVENTIONAL,3/1/2022,2024-02
NCT05012176,ACTIVE_NOT_RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,BEHAVIORAL: Behavioral Intervention|BEHAVIORAL: Behavioral Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Ohio State University Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,11/1/2021,12/31/2024
NCT04293276,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,DRUG: Pyrotinib|DRUG: SHR6390,Henan Cancer Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,41,OTHER_GOV,INTERVENTIONAL,4/1/2020,2023-05
NCT04967976,RECRUITING,Breast Cancer|Radiation|Breast Reconstruction|Synthetic Mesh,PROCEDURE: TiLoop Bra mesh in expander-implant breast reconstrution|PROCEDURE: sub-pectoral expander-implant breast reconstruction,Tianjin Medical University Cancer Institute and Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,8/1/2021,8/1/2026
NCT04659499,NOT_YET_RECRUITING,Early Breast Cancer,DRUG: Nab-paclitaxel in combination with pyrotinib,Peking Union Medical College Hospital,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,261,OTHER,INTERVENTIONAL,2021-01,2025-06
NCT04667481,COMPLETED,Breast Cancer|Invasive Breast Carcinoma,OTHER: Aerobic Exercise Intervention|OTHER: Resistance Exercise Intervention|OTHER: Exercise Intervention: Digital copies and outline of sessions|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,University of Washington,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,INTERVENTIONAL,1/5/2022,11/10/2022
NCT05408676,COMPLETED,Mammary Cancer|PONV,DEVICE: electric stimulation therapy,Fudan University,,FEMALE,ADULT,NA,198,OTHER,INTERVENTIONAL,6/10/2022,5/2/2023
NCT04691999,WITHDRAWN,Breast Cancer,BEHAVIORAL: Intermittent Fasting,Duke University,,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,12/2/2021,2023-08
NCT05054374,COMPLETED,Breast Cancer|Breast Cancer Stage IV|HER2-negative Breast Cancer|Solid Carcinoma|MEK1 Gene Mutation|MEK2 Gene Mutation|Metastatic Breast Cancer,DRUG: Mirdametinib|DRUG: Fulvestrant,Memorial Sloan Kettering Cancer Center,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,OTHER,INTERVENTIONAL,9/14/2021,10/26/2023
NCT06207474,COMPLETED,Breast Neoplasms,OTHER: Video + Chatbot|OTHER: Video + Paper|OTHER: Paper + Chatbot|OTHER: Paper + Paper,Yonsei University,,FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER,INTERVENTIONAL,4/18/2022,4/18/2023
NCT05301881,RECRUITING,Breast Cancer Invasive|Metastatic Cancer|Oligoprogressive,PROCEDURE: Surgery|RADIATION: Radiotherapy|OTHER: Radiofrequent ablation,The Netherlands Cancer Institute,Maarten van de Weijden Foundation,ALL,"ADULT, OLDER_ADULT",PHASE2,118,OTHER,INTERVENTIONAL,4/17/2023,4/1/2040
NCT05452681,RECRUITING,Breast Cancer|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,OTHER: Educational Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Control Intervention,Ohio State University Comprehensive Cancer Center,,FEMALE,ADULT,NA,30,OTHER,INTERVENTIONAL,8/1/2022,9/30/2023
NCT04901299,WITHDRAWN,Stage IV (Metastatic) Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer|HER2-negative Breast Cancer|Invasive Breast Cancer,DRUG: NERATINIB|DRUG: FULVESTRANT,Massachusetts General Hospital,"Celcuity Inc|Puma Biotechnology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2023-07,7/1/2025
NCT04090398,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|OTHER: Electronic Health Record Review|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|RADIATION: Radium Ra 223 Dichloride|PROCEDURE: Single Photon Emission Computed Tomography,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,INTERVENTIONAL,8/4/2020,6/30/2024
NCT05858398,NOT_YET_RECRUITING,Breast Cancer,BIOLOGICAL: pharmacokinetics blood sample assessment,Centre Henri Becquerel,Erasmus Medical Center|Universitaire Ziekenhuizen KU Leuven,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,INTERVENTIONAL,5/30/2023,5/2/2026
NCT05910398,RECRUITING,Breast Cancer Invasive,DRUG: pyrotinib,RenJi Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,488,OTHER,INTERVENTIONAL,6/1/2023,2030-08
NCT04678544,COMPLETED,"Neoplasm, Breast",DEVICE: Scalp cooling system 2,Samsung Medical Center,Paxman,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,INTERVENTIONAL,12/23/2020,8/30/2022
NCT05007444,RECRUITING,"Breast Cancer|Quality of Life|Tumor, Breast",DRUG: P2Et (Caesalpinia spinosa extract)|DRUG: Placebo,Hospital Universitario San Ignacio,Pontificia Universidad Javeriana,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,INTERVENTIONAL,3/1/2022,6/30/2023
NCT04902144,COMPLETED,Breast Carcinoma|Colon Carcinoma|Malignant Solid Neoplasm|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma,OTHER: Electronic Health Record Review|OTHER: Questionnaire Administration|BEHAVIORAL: Behavioral Intervention,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,INTERVENTIONAL,8/3/2020,12/31/2021
NCT04215744,UNKNOWN,Breast Cancer,BEHAVIORAL: Ice water immersion,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,2020-02,2022-12
NCT05301998,ACTIVE_NOT_RECRUITING,Breast Cancer|Skin Elasticity,OTHER: Skin and thickness measurement/breast MRI,"University Hospital, Montpellier",,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,3/31/2022,12/1/2023
NCT05900544,NOT_YET_RECRUITING,Coronary Disease|Emphysema or COPD|Breast Density,OTHER: System implementation of patient-centered incidental findings report,University of Montana,,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,INTERVENTIONAL,2024-10,2029-03
NCT05821244,RECRUITING,Breast Cancer,BEHAVIORAL: Exercise Timing Groups,University of Utah,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,7/5/2023,12/31/2023
NCT04431674,COMPLETED,Breast Cancer,DRUG: Definity Suspension for Injection,Sunnybrook Health Sciences Centre,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,7/22/2020,6/21/2023
NCT06216574,NOT_YET_RECRUITING,Breast Cancer Female,OTHER: Internet-based Intervention,Wake Forest University Health Sciences,National Cancer Institute (NCI)|University of Virginia,FEMALE,"ADULT, OLDER_ADULT",NA,320,OTHER,INTERVENTIONAL,2024-02,2027-08
NCT05524584,RECRUITING,Breast Cancer|Metastatic Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer,DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Abemaciclib,"University of California, Irvine",,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,8/31/2022,12/31/2028
NCT04536584,ACTIVE_NOT_RECRUITING,Breast Cancer Female,OTHER: Personalized Coaching (Arm A)|OTHER: Standard supportive approach (Arm B),Centre Oscar Lambret,Stimulab,FEMALE,"ADULT, OLDER_ADULT",NA,1133,OTHER,INTERVENTIONAL,12/18/2020,2024-12
NCT06136884,RECRUITING,Triple Negative Breast Cancer|High Grade Serous Ovarian Cancer|Endometrial Cancer,DRUG: AO-252,A2A Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1,144,INDUSTRY,INTERVENTIONAL,11/2/2023,1/27/2027
NCT06078384,NOT_YET_RECRUITING,Triple-negative Breast Cancer,DRUG: Pembrolizumab 25 mg/ml|DRUG: Paclitaxel injection,UNICANCER,MSD France|Vall d'Hebron Institute of Oncology|SOLTI Breast Cancer Research Group,ALL,"ADULT, OLDER_ADULT",PHASE2,354,OTHER,INTERVENTIONAL,2/1/2024,12/1/2031
NCT06251544,NOT_YET_RECRUITING,"Breast Cancer|Tumor, Breast|Breast Tumor|Malignant Neoplasm of Breast|Mammary Cancer|Mammary Neoplasm|Mammary Neoplasms, Human|Neoplasm, Breast",GENETIC: HTR2 T Cells|GENETIC: HTR2 T Cells,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,INTERVENTIONAL,2024-03,2033-06
NCT05103644,RECRUITING,Breast Cancer,DRUG: Atorvastatin 80mg|OTHER: placebo,Beni-Suef University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,INTERVENTIONAL,10/30/2021,12/30/2024
NCT04464174,COMPLETED,Triple Negative Breast Cancer,DRUG: Ipatasertib|DRUG: Capecitabine|DRUG: Eribulin|DRUG: Carboplatin|DRUG: Gemcitabine,MedSIR,Hoffmann-La Roche,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,INTERVENTIONAL,10/8/2020,11/10/2023
NCT05144698,RECRUITING,Solid Tumor|Breast Cancer|Small Cell and Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Gastric Junction Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Cancer|Squamous Cell Carcinoma of Oral Cavity|Squamous Cell Carcinoma of Larynx|Squamous Cell Carcinoma of Nasopharynx|Squamous Cell Carcinoma of Other Specified Sites of Skin|Carcinoma of Unknown Primary|Bladder Cancer|Malignant Melanoma,BIOLOGICAL: RAPA-201 Rapamycin Resistant T Cells|DRUG: Chemotherapy Prior to RAPA-201 Therapy,Rapa Therapeutics LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,22,INDUSTRY,INTERVENTIONAL,8/1/2021,12/31/2024
NCT03159598,WITHDRAWN,Breast Cancer,DEVICE: Tissue Glu|DEVICE: Drain|OTHER: Questionnaires,Case Comprehensive Cancer Center,,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,INTERVENTIONAL,11/1/2020,9/1/2021
NCT04187898,RECRUITING,Neutropenia|Breast Cancer,BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|DRUG: Docetaxel|DRUG: Cyclophosphamide,"Spectrum Pharmaceuticals, Inc",,ALL,ADULT,PHASE1,90,INDUSTRY,INTERVENTIONAL,3/11/2020,6/30/2025
NCT06224244,RECRUITING,Breast Neoplasms|Breast Cancer,RADIATION: Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|RADIATION: Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost,Regina Elena Cancer Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,INTERVENTIONAL,2/1/2022,1/1/2025
NCT05359874,WITHDRAWN,Breast Cancer,DRUG: Bevacizumab-IRDye800CW,Technical University of Munich,,MALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,INTERVENTIONAL,2021-06,2023-03
NCT04664829,RECRUITING,Metastatic Triple-Negative Breast Carcinoma,DRUG: Bexarotene|DRUG: Capecitabine,"National Cancer Centre, Singapore","National Medical Research Council (NMRC), Singapore",FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,INTERVENTIONAL,10/1/2020,9/30/2025
NCT05078398,RECRUITING,Breast Cancer|Breast Surgery|Opioid Use,BEHAVIORAL: POINT Protocol|BEHAVIORAL: Usual care,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,6/1/2022,1/1/2024
NCT04134598,RECRUITING,Breast Cancer,"RADIATION: Breast irradiation (RT)|DRUG: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen",Azienda Ospedaliero-Universitaria Careggi,University of Florence,FEMALE,OLDER_ADULT,PHASE3,926,OTHER,INTERVENTIONAL,2/8/2021,2/8/2030
NCT05337657,UNKNOWN,Advanced Breast Cancer,DRUG: GB491+Letrozole,"Genor Biopharma Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,INTERVENTIONAL,6/2/2021,2/1/2024
NCT05108298,RECRUITING,"Breast Cancer, NOS|CNS Primary Tumor, NOS|Cervical Cancer, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS|Melanoma|Bone Cancer, NOS",OTHER: Questionnaires,Eastern Cooperative Oncology Group,,ALL,ADULT,NA,400,NETWORK,INTERVENTIONAL,11/10/2021,11/1/2024
NCT04445844,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Triple-negative Breast Cancer,BIOLOGICAL: Pelareorep|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Retifanlimab,"Mridula George, MD",Incyte Corporation|Oncolytics Biotech|National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,7/13/2020,9/30/2024
NCT06144944,RECRUITING,Breast Cancer Invasive|Hormone-receptor-positive Breast Cancer|HER2 Low Breast Carcinoma|Early-stage Breast Cancer,"DRUG: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|DRUG: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"Jiangsu HengRui Medicine Co., Ltd.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,160,OTHER,INTERVENTIONAL,1/17/2024,12/31/2031
NCT05215574,RECRUITING,Pancreatic Cancer|Breast Cancer|Gastric Cancer|Non-small Cell Lung Cancer|Cervical Cancer|Endocervical Cancer|Squamous Cell Carcinoma of Head and Neck|Bladder Urothelial Cancer|Colorectal Carcinoma|Esophageal Cancer|Ovarian Cancer|Renal Cell Carcinoma|Prostate Cancer|Melanoma|Mesothelioma|Cholangiocarcinoma,DRUG: NGM831|DRUG: NGM831 plus pembrolizumab (KEYTRUDAÂ®)|DRUG: NGM831 and NGM438 plus pembrolizumab (KEYTRUDAÂ®),"NGM Biopharmaceuticals, Inc",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,130,INDUSTRY,INTERVENTIONAL,3/31/2022,2026-03
NCT05458674,RECRUITING,Breast Cancer,DRUG: Tucatinib|DRUG: Eribulin|DRUG: Trastuzumab,"Criterium, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,INTERVENTIONAL,11/17/2022,5/26/2025
NCT03959774,UNKNOWN,Breast Cancer|Colorectal Cancer|Lung Cancer,DEVICE: IPC NET,Institut Paoli-Calmettes,,ALL,OLDER_ADULT,NA,119,OTHER,INTERVENTIONAL,12/30/2020,12/30/2023
NCT04732598,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Paclitaxel + bevacizumab therapy|DRUG: Paclitaxel + bevacizumab + atezolizumab,Japanese Foundation for Cancer Research,Chugai Pharmaceutical,ALL,"ADULT, OLDER_ADULT",PHASE3,280,OTHER,INTERVENTIONAL,1/21/2021,9/30/2025
NCT05708144,COMPLETED,Breast Cancer,DIAGNOSTIC_TEST: ICG-SG incubation solution,Xiang'an Hospital of Xiamen University,,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,2/17/2023,10/30/2023
NCT06081244,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Sacituzumab govitecan|DRUG: Pembrolizumab,West German Study Group,Gilead Sciences|Merck Sharp & Dohme LLC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,348,OTHER,INTERVENTIONAL,2023-12,2029-09
NCT05218044,RECRUITING,Ductal Carcinoma in Situ,PROCEDURE: Cryoablation,Glendale Adventist Medical Center d/b/a Adventist Health Glendale,Helen Rey Breast Cancer Research Foundation|California Oncology Research Institute|Doterra Healing Hands Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,11/1/2021,11/1/2026
NCT05318274,RECRUITING,Ductal Breast Carcinoma in Situ|Invasive Breast Cancer|Early-stage Breast Cancer|Stage 0 Breast Cancer|Stage I Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer,RADIATION: Hypofractionated radiotherapy,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,INTERVENTIONAL,4/26/2021,6/30/2026
NCT05837598,RECRUITING,Cancer|Severe Major Depression|Schizophrenia|Bipolar Disorder|Lung Cancer|Breast Cancer|Head and Neck Cancer|Gastrointestinal Cancer|Genitourinary Cancer,BEHAVIORAL: Virtual Cancer and Mental Health Tumor Board,Massachusetts General Hospital,Trefler Foundation,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,5/31/2023,5/31/2024
NCT05376644,COMPLETED,Breast Cancer Female,DRUG: 99mTc-ADAPT6|DRUG: 99mTc-DARPinG3,Tomsk National Research Medical Center of the Russian Academy of Sciences,Uppsala University,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,INTERVENTIONAL,5/1/2022,1/21/2023
NCT05807074,RECRUITING,Breast Cancer,DRUG: Tranexamic Acid|OTHER: Saline,"University of California, San Francisco",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,150,OTHER,INTERVENTIONAL,4/20/2023,9/30/2024
NCT04213898,UNKNOWN,Triple-negative Breast Cancer,DRUG: SHR-1210+Albumin-bound paclitaxel + epirubicin,Henan Cancer Hospital,,FEMALE,ADULT,PHASE1|PHASE2,39,OTHER_GOV,INTERVENTIONAL,2020-01,2023-01
NCT04009044,RECRUITING,Cancer Survivor|Ductal Breast Carcinoma In Situ|Invasive Breast Carcinoma,DRUG: Afimoxifene|PROCEDURE: Core Biopsy|OTHER: Questionnaire Administration,Northwestern University,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",PHASE2,156,OTHER,INTERVENTIONAL,2/17/2020,6/25/2024
NCT05444101,RECRUITING,"Pain, Chronic|Breast Cancer",BEHAVIORAL: Mindful attention|BEHAVIORAL: Decentering|BEHAVIORAL: Values and committed action,University of Aarhus,Danish Council for Independent Research,FEMALE,"ADULT, OLDER_ADULT",NA,185,OTHER,INTERVENTIONAL,9/1/2022,10/1/2024
NCT04502680,NOT_YET_RECRUITING,Triple Negative Breast Cancer,DRUG: Eribulin Mesylate,The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,2021-06,2024-06
NCT05537740,RECRUITING,Advanced Solid Tumors,DRUG: BAY3375968|DRUG: Pembrolizumab,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,270,INDUSTRY,INTERVENTIONAL,10/11/2022,5/4/2027
NCT05601440,RECRUITING,Breast Cancer,DRUG: RP-6306|DRUG: Gemcitabine|OTHER: Observation|DRUG: Niraparib|DRUG: Fulvestrant,Canadian Cancer Trials Group,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,484,NETWORK,INTERVENTIONAL,6/13/2023,2028-06
NCT04762901,WITHDRAWN,Breast Cancer,DRUG: Niraparib|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Pegfilgrastim|DRUG: Carboplatin,Wake Forest University Health Sciences,"Tesaro, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,4/1/2021,2026-01
NCT05789901,NOT_YET_RECRUITING,HIV Infections|Breast Cancer|Pediatric Emergency Medicine,OTHER: MARVIN|OTHER: MARVIN-Pharma|OTHER: MARVINA|OTHER: MARVIN-CHAMP,McGill University Health Centre/Research Institute of the McGill University Health Centre,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),ALL,"CHILD, ADULT, OLDER_ADULT",NA,400,OTHER,INTERVENTIONAL,1/1/2024,12/31/2034
NCT04806724,RECRUITING,Breast Cancer|Gynecologic Cancer,BEHAVIORAL: Opening the Conversation|BEHAVIORAL: Side by Side,Oregon State University,"American Cancer Society, Inc.",ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,9/1/2021,12/31/2024
NCT06102824,RECRUITING,HER2-negative Breast Cancer|Advanced Breast Cancer,DRUG: Organoid-guided treatment|DRUG: Taxane|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine|DRUG: Eribulin|DRUG: Anthracycline|DRUG: Carboplatin|DRUG: Utidelone|DRUG: Trastuzumab deruxtecan|DRUG: Sacituzumab govitecan,Guangdong Provincial People's Hospital,"First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Shantou Central Hospital",ALL,"ADULT, OLDER_ADULT",PHASE2,252,OTHER,INTERVENTIONAL,1/20/2024,6/30/2028
NCT04796324,RECRUITING,Metastatic Breast Cancer,DRUG: Ixabepilone Injection,Allarity Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,INTERVENTIONAL,3/1/2021,11/1/2025
NCT06212440,RECRUITING,Sentinel Lymph Node Biopsy|Neoadjuvant Therapy|Breast Neoplasm,DIAGNOSTIC_TEST: Identification rate of sentinel lymph node for each dual method,"National Cancer Center, Korea",,FEMALE,"ADULT, OLDER_ADULT",NA,348,OTHER_GOV,INTERVENTIONAL,5/4/2021,6/30/2026
NCT04434040,ACTIVE_NOT_RECRUITING,Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA,DRUG: Atezolizumab|DRUG: Sacituzumab govitecan,Dana-Farber Cancer Institute,"Genentech, Inc.|Stand Up To Cancer",ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,7/2/2020,12/30/2027
NCT06251401,RECRUITING,Breast Cancer|Cardiovascular Diseases,BEHAVIORAL: In-person supervised cardiac rehabilitation|BEHAVIORAL: Virtual cardiac rehabilitation,Women's College Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,3/21/2023,2024-12
NCT05306340,RECRUITING,"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",DRUG: Giredestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Tamoxifen|DRUG: Everolimus|DRUG: LHRH Agonist|DRUG: Dexamethasone Mouth Rinse,"Genentech, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,320,INDUSTRY,INTERVENTIONAL,8/3/2022,3/31/2026
NCT05904340,NOT_YET_RECRUITING,Breast Neoplasms|Chemotherapy-induced Peripheral Neuropathy,DEVICE: Transcutaneous Electrical Nerve Stimulation,National Taipei University of Nursing and Health Sciences,Changhua Christian Hospital,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,INTERVENTIONAL,7/1/2023,4/22/2024
NCT04579380,ACTIVE_NOT_RECRUITING,"Uterine Neoplasms|Uterine Cervical Neoplasms|Biliary Tract Neoplasms|Urologic Neoplasms|Carcinoma, Non-Small-Cell Lung|HER2 Mutations Breast Neoplasms",DRUG: tucatinib|DRUG: trastuzumab|DRUG: fulvestrant,Seagen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,217,INDUSTRY,INTERVENTIONAL,1/11/2021,5/31/2025
NCT05386524,RECRUITING,Breast Cancer,DRUG: sintilimab|DRUG: bevacizumab biosimilar|DRUG: pegylated liposomal doxorubicin,Fudan University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,INTERVENTIONAL,6/15/2022,3/15/2025
NCT05567601,NOT_YET_RECRUITING,Ovarian Cancer|AIDS-related Kaposi Sarcoma|Multiple Myeloma|Metastatic Breast Cancer,DRUG: DOXIL/CAELYX,Baxter Healthcare Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,11/30/2023,4/1/2024
NCT05337280,COMPLETED,Breast Cancer,DEVICE: Imagio OA/US,Seno Medical Instruments Inc.,American College of Radiology,ALL,"ADULT, OLDER_ADULT",NA,20,INDUSTRY,INTERVENTIONAL,3/30/2021,1/4/2023
NCT05524480,NOT_YET_RECRUITING,Cancer Prevention,BEHAVIORAL: Salud en Mis Manos - Dissemination and Implementation Assistance|BEHAVIORAL: Salud en Mis Manos- Usual Implementation Practice,"The University of Texas Health Science Center, Houston",Centers for Disease Control and Prevention,FEMALE,"ADULT, OLDER_ADULT",NA,2000,OTHER,INTERVENTIONAL,2/2/2024,9/30/2024
NCT04991480,ACTIVE_NOT_RECRUITING,Advanced Cancer|Metastatic Cancer|Breast Cancer,DRUG: ART4215|DRUG: Talazoparib|DRUG: Niraparib,Artios Pharma Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,390,INDUSTRY,INTERVENTIONAL,9/13/2021,2026-01
NCT05983380,RECRUITING,Breast Cancer Lymphedema,OTHER: Hand Mobility and Grip Strengthening Exercises|OTHER: Usual Care,Texas Woman's University,Presbyterian Healthcare Services,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,10/1/2023,4/30/2024
NCT05632601,RECRUITING,Cardiovascular Diseases,DIAGNOSTIC_TEST: PET scan,Ottawa Heart Institute Research Corporation,,FEMALE,ADULT,NA,210,OTHER,INTERVENTIONAL,4/26/2023,5/24/2024
NCT05496101,RECRUITING,Breast Cancer Female,PROCEDURE: Intraoperative CLI + FAR LightPath imaging,King's College London,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,11/21/2022,12/31/2024
NCT05795101,RECRUITING,Invasive Breast Cancer|Inflammatory Breast Cancer Stage III|HER2-positive Breast Cancer|HER2 Low Breast Adenocarcinoma|Breast Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab,"Filipa Lynce, MD",AstraZeneca|Daiichi Sankyo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,5/4/2023,12/1/2032
NCT04340180,ACTIVE_NOT_RECRUITING,Breast Benign Tumor|Breast Malignant Tumor,DRUG: Standard of Care (SOC) gadolinium Breast MRI|DRUG: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.,University of Alabama at Birmingham,Bracco Corporate,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,7/14/2021,3/31/2024
NCT05812924,RECRUITING,Breast Cancer|Genitourinary Syndrome of Menopause,BIOLOGICAL: Platelet-rich plasma (PRP),University of Miami,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,9/26/2023,9/30/2026
NCT04758780,RECRUITING,Triple Negative Breast Cancer,DRUG: 89Zr-TLX250 PET/CT,Institut Cancerologie de l'Ouest,Telix Pharmaceutical|SIRIC ILIAD,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,INTERVENTIONAL,9/21/2021,2024-06
NCT03930680,RECRUITING,Healthy,DRUG: Dexrazoxane,University of Arkansas,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,INTERVENTIONAL,9/14/2021,10/31/2025
NCT05681728,RECRUITING,Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,INTERVENTIONAL,2/1/2022,6/1/2024
NCT04305236,TERMINATED,Breast Neoplasm|Hormone Receptor Positive Breast Carcinoma,DRUG: Abemaciclib|DRUG: Fulvestrant,"University of California, Irvine",Eli Lilly and Company,FEMALE,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,INTERVENTIONAL,7/23/2020,2/16/2022
NCT05468034,RECRUITING,Breast Cancer|Indolent Metastatic Breast Cancer,BEHAVIORAL: Exercise Intervention,Indiana University,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,4/26/2023,2027-12
NCT04711824,RECRUITING,"Breast Cancer|Brain Metastases, Adult",DRUG: Olaparib|RADIATION: Stereotactic Radiosurgery|DRUG: Durvalumab|DRUG: Physicians Choice systemic chemotherapy,Colette Shen,"AstraZeneca|University of North Carolina, Chapel Hill",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,INTERVENTIONAL,3/9/2022,2026-09
NCT04751201,COMPLETED,Breast Cancer|Prostate Cancer,BEHAVIORAL: Mindfulness open and circular program,Institut de CancÃ©rologie de Lorraine,,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,9/1/2021,7/13/2022
NCT05463601,RECRUITING,Metastatic Breast Cancer,"DRUG: Mecapegfilgrastim|DRUG: dalpiciclib|DRUG: exemestane, fulvestrant, letrozole, tamoxifen",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"Jiangsu HengRui Medicine Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,INTERVENTIONAL,8/1/2022,12/1/2024
NCT05130801,RECRUITING,Breast Cancer,DIAGNOSTIC_TEST: pHLIPÂ® ICG NIRF imaging,Memorial Sloan Kettering Cancer Center,Stryker Instruments|pHLIP Inc.,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,55,OTHER,INTERVENTIONAL,11/19/2021,2026-11
NCT04889924,RECRUITING,Breast Cancer|Chemotherapy|Sentinel Lymph Node|Axillary Lymph Nodes Dissection|Radiotherapy Side Effect,RADIATION: Axillary Radiotherapy|PROCEDURE: Lymphadenectomy,Hospital Universitari de Bellvitge,,ALL,"ADULT, OLDER_ADULT",NA,1660,OTHER,INTERVENTIONAL,6/1/2021,12/31/2026
NCT05316324,RECRUITING,Breast Cancer,PROCEDURE: Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|PROCEDURE: Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM),Memorial Sloan Kettering Cancer Center,The Plastic Surgery Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,352,OTHER,INTERVENTIONAL,3/23/2022,2024-03
NCT05941299,RECRUITING,"Mastectomy, Segmental|Breast Neoplasm Malignant Female",DEVICE: REGENERA breast implant implantation,Tensive SRL,,FEMALE,"ADULT, OLDER_ADULT",NA,92,INDUSTRY,INTERVENTIONAL,9/29/2023,12/30/2029
NCT06149611,NOT_YET_RECRUITING,Breast Cancer,DRUG: [14C] TQB3616,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,MALE,ADULT,PHASE1,8,INDUSTRY,INTERVENTIONAL,2024-01,2024-12
NCT05253170,NOT_YET_RECRUITING,Breast Cancer|Radiotherapy; Complications,RADIATION: Hypofractionation|RADIATION: Conventional Fractionation,Seoul National University Bundang Hospital,Seoul National University Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE3,622,OTHER,INTERVENTIONAL,4/1/2022,12/31/2032
NCT05955170,RECRUITING,HER2-positive Breast Cancer,DRUG: Tucatinib in Combination of Oral VP16 and trastuzumab,Institut Curie,Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,INTERVENTIONAL,12/19/2023,12/19/2027
NCT04191499,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Inavolisib|DRUG: Placebo|DRUG: Palbociclib|DRUG: Fulvestrant,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,325,INDUSTRY,INTERVENTIONAL,1/29/2020,9/30/2030
NCT05721976,RECRUITING,"Cancer, Breast|Cancer, Uterus|Cancer, Ovary|Obesity|Activity, Motor|Diet, Healthy","BEHAVIORAL: With Love, Grandma (""Con CariÃ±o, Abuelita"")",University of Miami Sylvester Comprehensive Cancer Center,The V Foundation for Cancer Research,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/22/2023,5/31/2024
NCT05958199,RECRUITING,Metastatic Malignant Neoplasm,DRUG: NPX267,"NextPoint Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,131,INDUSTRY,INTERVENTIONAL,7/21/2023,2026-01
NCT05382299,RECRUITING,Triple Negative Breast Cancer|PD-L1 Negative,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,INTERVENTIONAL,7/20/2022,2027-05
NCT05383170,ACTIVE_NOT_RECRUITING,Advanced Head and Neck Squamous Cell Carcinoma|Advanced Breast Cancer|Advanced Melanoma,DRUG: CyPep-1|DRUG: Pembrolizumab 25 MG/ML [KEYTRUDAÂ®],Cytovation AS,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,90,INDUSTRY,INTERVENTIONAL,3/21/2023,2025-02
NCT06121570,RECRUITING,Breast Neoplasms,PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|DRUG: Nab-paclitaxel,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,INTERVENTIONAL,11/1/2023,8/31/2031
NCT05810870,RECRUITING,Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: MEN1611|DRUG: Eribulin,MedSIR,Menarini Group,ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,INTERVENTIONAL,5/24/2023,2027-07
NCT05569811,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Patritumab deruxtecan|DRUG: Chemotherapy|DRUG: Letrozole,SOLTI Breast Cancer Research Group,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,INTERVENTIONAL,11/25/2022,7/31/2030
NCT05761470,RECRUITING,Her-2 Negative Breast Cancer|HRR Gene Mutation,DRUG: Camrelizumab|DRUG: Fluzoparib|DRUG: Nab-paclitaxel,Ying Lin,,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,INTERVENTIONAL,5/6/2022,12/31/2028
NCT05065411,SUSPENDED,Metastatic Breast Cancer,"DRUG: Enobosarm & Abemaciclib Combo|DRUG: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant",Veru Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,186,INDUSTRY,INTERVENTIONAL,4/11/2022,12/31/2025
NCT05840211,RECRUITING,Locally Advanced or Unresectable Metastatic Breast Cancer|Stage IV Breast Cancer,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Capecitabine,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,654,INDUSTRY,INTERVENTIONAL,5/8/2023,2028-12
NCT05877599,RECRUITING,Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Colorectal Carcinoma|Pancreatic Adenocarcinoma|Breast Cancer|Other Solid Tumors,"BIOLOGICAL: Autologous, engineered T Cells targeting TP53 R175H","Neogene Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,INTERVENTIONAL,7/27/2023,2039-08
NCT04802876,RECRUITING,MSI-H Colorectal Cancer|Melanoma|Anal Carcinoma|Mesothelioma|Triple Negative Breast Cancer|Lung Adenocarcinoma|Cholangiocarcinoma|Cervical Carcinoma|Kidney Clear Cell Carcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma|Uterine Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Sarcoma|Lung Squamous Cell Carcinoma|Urothelial Carcinoma|Thyroid Carcinoma|Hepatocellular Carcinoma|Uveal Melanoma|HER2-positive Breast Cancer|Pancreatic Adenocarcinoma|Squamous Esophageal Carcinoma|Epithelial Ovarian Cancer|Uterine Carcinosarcoma|Small Cell Lung Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Colorectal Adenocarcinoma|Prostate Adenocarcinoma|Carcinoma of Unknown Primary|Other Histology,DRUG: Spartalizumab|DRUG: Tislelizumab,SOLTI Breast Cancer Research Group,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE2,184,OTHER,INTERVENTIONAL,4/12/2021,3/31/2027
NCT04924699,RECRUITING,Advanced Breast Cancer|Metastatic Breast Cancer,DRUG: MRG002|DRUG: Trastuzumab Emtansine for Injection,Shanghai Miracogen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,350,INDUSTRY,INTERVENTIONAL,6/30/2021,2023-10
NCT05042999,COMPLETED,Breast Neoplasm Female,DEVICE: Oculus Go Virtual Reality Goggles,Prisma Health-Upstate,Clemson University,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,9/15/2021,1/7/2022
NCT05029999,RECRUITING,Metastatic Triple Negative Breast Cancer,DRUG: PLD Chemotherapy|DRUG: CDX-1140|DRUG: CDX-301,University of Texas Southwestern Medical Center,Celldex Therapeutics|Gateway for Cancer Research,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,INTERVENTIONAL,4/20/2022,4/20/2025
NCT05038735,RECRUITING,Breast Cancer,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Alpelisib-matching placebo,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,234,INDUSTRY,INTERVENTIONAL,11/29/2021,9/23/2026
NCT05708235,NOT_YET_RECRUITING,Breast Cancer,DRUG: Giredestrant|DRUG: Abemaciclib|DRUG: Inavolisib,MedSIR,,ALL,"ADULT, OLDER_ADULT",PHASE2,1260,OTHER,INTERVENTIONAL,3/1/2024,12/30/2028
NCT04920669,COMPLETED,Postoperative Pain,PROCEDURE: erector spinae block with bupivacaine|PROCEDURE: erector spinae block with bupivacaine + dexmedetomidine,Mohamed Elsayed Hassan,,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,7/1/2021,9/30/2021
NCT04874935,COMPLETED,Breast Cancer,DRUG: Lansoprazole|DRUG: Placebo,Tanta University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,66,OTHER,INTERVENTIONAL,6/10/2021,11/5/2022
NCT04166799,ACTIVE_NOT_RECRUITING,Breast Cancer|Radiation Dermatitis,DEVICE: Mepitel Film,Sunnybrook Health Sciences Centre,,ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,INTERVENTIONAL,1/30/2020,2024-12
NCT05861635,RECRUITING,Breast Cancer|Neoadjuvant Therapy,DRUG: Disitamab Vedotin combined with Tislelizumab,"Wuhan Union Hospital, China",,ALL,"ADULT, OLDER_ADULT",PHASE4,42,OTHER,INTERVENTIONAL,2/1/2023,2/1/2026
NCT04257396,RECRUITING,Adjuvant Radiotherapy for Breast Cancer,DEVICE: Carbon-Fibre Adjustable Reuseable Accessory (CARA),British Columbia Cancer Agency,Canadian Cancer Society (CCS),ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,6/11/2020,12/31/2024
NCT05189496,RECRUITING,Radiation Pneumonitis,BEHAVIORAL: hyperbaric oxygen therapy,Guangdong Provincial People's Hospital,"First Affiliated Hospital, Sun Yat-Sen University",ALL,"ADULT, OLDER_ADULT",NA,380,OTHER,INTERVENTIONAL,3/1/2022,12/31/2024
NCT05132296,RECRUITING,Breast Carcinoma,BEHAVIORAL: Behavioral Intervention|OTHER: Best Practice|DEVICE: FitBit|BEHAVIORAL: Nutrition Education|OTHER: Physical Activity|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,5/21/2021,2/2/2027
NCT05298696,COMPLETED,Peripheral Neuropathy|Breast Cancer,DRUG: Cilostazol|DRUG: Placebo,Mansoura University,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,71,OTHER,INTERVENTIONAL,3/28/2022,12/30/2022
NCT04739696,ACTIVE_NOT_RECRUITING,"Breast Cancer|Lung Cancer|Colon Cancer|Solid Tumor, Adult",BEHAVIORAL: PEPRR|BEHAVIORAL: Pep-Pal,"University of Colorado, Denver",National Cancer Institute (NCI),ALL,ADULT,NA,510,OTHER,INTERVENTIONAL,2/5/2021,9/30/2024
NCT05713435,RECRUITING,Genitourinary Syndrome of Menopause,DEVICE: intravaginal laser,Universitaire Ziekenhuizen KU Leuven,,FEMALE,"ADULT, OLDER_ADULT",NA,162,OTHER,INTERVENTIONAL,12/27/2022,2025-12
NCT05873296,RECRUITING,Breast Cancer Female,BEHAVIORAL: Health Education,Federal University of Maranhao,,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,INTERVENTIONAL,7/1/2023,12/30/2023
NCT04861896,COMPLETED,"Cancer, Breast|Cancer-related Problem/Condition|Quality of Life|Hormone Dependent Neoplasms|Adherence, Medication","BEHAVIORAL: ""My Guide"" (psychoeducation & self-management program)",Northwestern University,,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,INTERVENTIONAL,4/1/2021,11/7/2023
NCT04961996,ACTIVE_NOT_RECRUITING,Early Breast Cancer,DRUG: Giredestrant|DRUG: Endocrine Therapy of Physician's Choice|DRUG: LHRH Agonist|DRUG: Abemaciclib,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,4200,INDUSTRY,INTERVENTIONAL,8/27/2021,11/21/2033
NCT04509596,ACTIVE_NOT_RECRUITING,Breast Cancer Metastatic,"DRUG: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C",Dizal Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INDUSTRY,INTERVENTIONAL,9/21/2020,2024-05
NCT04969835,RECRUITING,Pancreatic Cancer|Colorectal Cancer|Non-small Cell Lung Cancer|Head and Neck Cancer|Cancer of Unknown Primary Site|Ovarian Cancer|Breast Cancer|Soft Tissue Sarcoma|Bladder Cancer|Oesophageal Cancer|Prostate Cancer|Biliary Tract Cancer,DRUG: AVA6000,Avacta Life Sciences Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,INTERVENTIONAL,7/16/2021,6/30/2023
NCT06243796,ACTIVE_NOT_RECRUITING,Breast-cancer,PROCEDURE: Flap fixation technique,Nakhon Phanom Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER_GOV,INTERVENTIONAL,12/1/2023,6/30/2024
NCT05631795,RECRUITING,Advanced Breast Cancer,DRUG: Alpelisib|DRUG: Fulvestrant,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,100,INDUSTRY,INTERVENTIONAL,8/9/2022,11/15/2024
NCT05058495,COMPLETED,Breast Cancer Related Lymphedema,OTHER: Mobile Lymphedema Self-Care Support Program|OTHER: standart lymphedema education,Dokuz Eylul University,,FEMALE,ADULT,NA,98,OTHER,INTERVENTIONAL,9/1/2021,12/1/2021
NCT05809895,WITHDRAWN,Triple Negative Breast Cancer,DRUG: Ociperlimab|DRUG: Tislelizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Placebo|DRUG: Pembrolizumab|DRUG: Gemcitabine,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,INTERVENTIONAL,9/15/2023,7/18/2029
NCT05491395,RECRUITING,Breast Cancer,RADIATION: Hypofractionation,Barretos Cancer Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,INTERVENTIONAL,6/27/2022,5/1/2029
NCT05634395,RECRUITING,Breast Cancer,DEVICE: Activity tracker,Institut Curie,,FEMALE,OLDER_ADULT,NA,200,OTHER,INTERVENTIONAL,2/17/2023,11/13/2024
NCT05716295,RECRUITING,Advanced or Metastatic Solid Tumors,"DRUG: MDK-703|DRUG: Checkpoint Inhibitor, Immune","Medikine, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,150,INDUSTRY,INTERVENTIONAL,2/8/2023,2025-09
NCT05900895,NOT_YET_RECRUITING,Metastatic Breast Cancer,DRUG: Olaparib|DRUG: 17b-estradiol,Mary D Chamberlin,Dartmouth-Hitchcock Medical Center,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,INTERVENTIONAL,2024-02,2028-12
NCT04371913,RECRUITING,Breast Cancer,RADIATION: 600cGY x 5 fractions,Weill Medical College of Cornell University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,6/30/2020,12/31/2027
NCT04443413,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,RADIATION: Proton Beam Radiation Therapy|OTHER: Questionnaire Administration|RADIATION: X-ray Therapy,Mayo Clinic,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,146,OTHER,INTERVENTIONAL,6/15/2020,6/1/2024
NCT04365569,RECRUITING,Breast Cancer,BEHAVIORAL: Nutrition and physical activity counseling program,Case Comprehensive Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,1/6/2021,6/1/2024
NCT06042569,RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma,DRUG: Cyclophosphamide|DRUG: Docetaxel|OTHER: Medical Chart Review|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,OLDER_ADULT,PHASE2,174,OTHER,INTERVENTIONAL,4/28/2024,3/20/2027
NCT05913713,NOT_YET_RECRUITING,Breast Cancer,BEHAVIORAL: 12-week Intervention Period|BEHAVIORAL: 12-week Observation Period,University of Florida,National Institute on Aging (NIA),FEMALE,"ADULT, OLDER_ADULT",NA,158,OTHER,INTERVENTIONAL,2023-11,5/25/2025
NCT04316169,WITHDRAWN,Solid Tumor|Advanced Breast Cancer,DRUG: Abemaciclib|DRUG: Hydroxychloroquine 200 mg|DRUG: Faslodex|DRUG: Anastrazole|DRUG: Letrozole|DRUG: Hydroxychloroquine 400 mg|DRUG: Hydroxychloroquine 600 mg,Medical College of Wisconsin,,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,INTERVENTIONAL,10/21/2021,2028-01
NCT06215469,NOT_YET_RECRUITING,Breast Cancer|Early-stage Breast Cancer|Hair Loss|Alopecia|Chemotherapy-induced Alopecia,DEVICE: Amma Portable Scalp Cooling System (PSCS)|OTHER: Questionnaires,"University of California, San Francisco",Cooler Heads Care Inc.,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,2/1/2024,7/31/2025
NCT05618613,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Elacestrant|DRUG: Onapristone,Context Therapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,67,INDUSTRY,INTERVENTIONAL,12/2/2022,4/30/2026
NCT04222413,RECRUITING,Advanced Solid Tumors|Metastatic Pancreatic Cancer|Pediatric Solid Tumor|Advanced Breast Cancer|Malignant Peripheral Nerve Sheath Tumor|Colorectal Neoplasms,DRUG: Metarrestin,National Cancer Institute (NCI),,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,98,NIH,INTERVENTIONAL,10/27/2020,12/31/2024
NCT05373069,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: Mechanical ischemic preconditioning of diep-type flap,Assistance Publique - HÃ´pitaux de Paris,INSERM Bichat hospital,FEMALE,"ADULT, OLDER_ADULT",NA,35,OTHER,INTERVENTIONAL,2022-05,2024-05
NCT05275569,RECRUITING,Cancer,PROCEDURE: True acupuncture + standard antiemetic treatment|PROCEDURE: Sham acupuncture + standard antiemetic treatment,Affiliated Hospital of Qinghai University,,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,INTERVENTIONAL,3/15/2022,12/31/2024
NCT06059469,RECRUITING,TNBC - Triple-Negative Breast Cancer,DIAGNOSTIC_TEST: Ga-PSMA PET/CT,Jules Bordet Institute,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,5/30/2022,2024-09
NCT04258813,RECRUITING,"Blood Pressure|Hypertension|Cancer|Cancer, Breast|Cancer of Prostate|Cancer Colorectal|Cancer, Endometrial|Cancer of Head and Neck|Non Small Cell Lung Cancer|CVD - Cardiovascular Disease|Diabetes Mellitus|Hypercholesterolemia|Diabetes|Cancer of Esophagus|Cancer of Liver|Cancer, Renal Cell|Cancer of Pancreas|Cancer Ovaries",BEHAVIORAL: iGuide Intervention (Self-guided)|BEHAVIORAL: iGuide 2 Intervention (Tailored/Targeted)|BEHAVIORAL: Control,Duke University,,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,INTERVENTIONAL,6/14/2021,3/31/2024
NCT04851613,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: Afuresertib,Laekna LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,2/18/2022,12/30/2024
NCT06099769,RECRUITING,Metastatic Breast Cancer,DRUG: Enzalutamide|DRUG: Mifepristone|DRUG: TPC,Memorial Sloan Kettering Cancer Center,"Astellas Pharma US, Inc.|Breast Cancer Research Foundation|Corcept Therapeutics",ALL,"ADULT, OLDER_ADULT",PHASE2,201,OTHER,INTERVENTIONAL,10/18/2023,2027-10
NCT05920369,RECRUITING,Axillary Web Syndrome,OTHER: low-energy extracorporeal shockwave and a tailored exercise program|OTHER: low-energy extracorporeal shockwave|OTHER: tailored exercise program,Cairo University,,FEMALE,"ADULT, OLDER_ADULT",NA,93,OTHER,INTERVENTIONAL,4/15/2023,9/1/2023
NCT05261269,COMPLETED,HER2-negative Metastatic Breast Cancer,DRUG: DAN-222|DRUG: Niraparib,"Dantari, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,INTERVENTIONAL,2/2/2022,10/11/2023
NCT05837169,ACTIVE_NOT_RECRUITING,Anxiety|Breast Cancer|Survivorship,OTHER: Mindfulness-based stress reduction,Medicos e Investigadores en la Lucha contra el Cancer de Mama,,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,INTERVENTIONAL,9/23/2021,2024-01
NCT06236269,NOT_YET_RECRUITING,Breast Cancer Stage IV,DRUG: Sacituzumab Govitecan,SOLTI Breast Cancer Research Group,,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,2/20/2024,2/20/2027
NCT05501769,ACTIVE_NOT_RECRUITING,Breast Cancer,DRUG: ARV-471 in combination with Everolimus,"Arvinas Estrogen Receptor, Inc.",Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,INTERVENTIONAL,9/8/2022,11/30/2024
NCT05302336,RECRUITING,Breast Cancer|Chemotherapeutic Toxicity,DRUG: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,FEMALE,"ADULT, OLDER_ADULT",PHASE4,402,OTHER,INTERVENTIONAL,5/1/2022,12/30/2024
NCT03988036,COMPLETED,Breast Cancer,DRUG: Pembrolizumab|DRUG: Trastuzumab Biosimilar ABP 980|DRUG: Pertuzumab,West German Study Group,"Merck Sharp & Dohme LLC|NanoString Technologies, Inc.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,INTERVENTIONAL,8/18/2020,5/31/2022
NCT05403736,ACTIVE_NOT_RECRUITING,Cancer,OTHER: Cardiac Aggressive Risk MitigAtion Plan,Cedars-Sinai Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,10/7/2022,8/31/2024
NCT06071234,NOT_YET_RECRUITING,Breast Cancer,PROCEDURE: 3D printed technology,Guangdong Provincial People's Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,INTERVENTIONAL,10/8/2023,12/30/2025
NCT04805736,COMPLETED,Breast Cancer,PROCEDURE: Microwave Ablation|DRUG: Camrelizumab|PROCEDURE: Breast Surgery,The First Affiliated Hospital with Nanjing Medical University,"Jiangsu HengRui Medicine Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,INTERVENTIONAL,3/25/2021,4/30/2023
NCT05395936,RECRUITING,Breast Cancer|Mastectomy,OTHER: Myocardial Probe Temperature Screen|OTHER: Data Collection,Wake Forest University Health Sciences,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,INTERVENTIONAL,9/29/2022,2024-02
NCT05621434,NOT_YET_RECRUITING,HER2-positive Recurrent/Metastatic Breast Cancer,"DRUG: Inetetamab, pyrotinib, chemotherapy",Fujian Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,INTERVENTIONAL,12/10/2022,12/10/2025
NCT05347134,ACTIVE_NOT_RECRUITING,Triple Negative Breast Cancer,DRUG: SKB264,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,254,INDUSTRY,INTERVENTIONAL,6/10/2022,12/31/2024
NCT05748834,RECRUITING,Breast Cancer,DRUG: Tucatinib|DRUG: Doxil,"SCRI Development Innovations, LLC",Seagen Inc.,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,7/24/2023,2026-07
NCT05128734,NOT_YET_RECRUITING,Breast Cancer Triple Negative,DRUG: Temozolomide|DRUG: Olaparib,AHS Cancer Control Alberta,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,7/1/2024,7/1/2028
NCT05388734,RECRUITING,Breast Cancer|Non-metastatic|Newly Diagnosed|Feasibility Study,OTHER: alternative medicine education consultation,"University Hospital, Grenoble",University Grenoble Alps|Laboratoire TIMC-IMAG,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,9/28/2022,2024-08
NCT06125834,RECRUITING,Advanced Breast Cancer|Objective Response Rate|Trastuzumab Emtansine,DRUG: Trastuzumab Emtansine (T-DM1),The First Affiliated Hospital with Nanjing Medical University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,INTERVENTIONAL,6/1/2023,5/31/2026
NCT04019834,COMPLETED,"Breast Cancer|Mastectomy|Anesthesia, Local|Narcotic Use",DRUG: regional nerve block with local anesthesia of bupivacaine with steroid|OTHER: Placebo regional nerveblock with normal saline,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,21,OTHER,INTERVENTIONAL,7/6/2020,11/25/2021
NCT05620134,RECRUITING,"Cancer|Tumor, Solid|Advanced Solid Tumor|Metastatic Cancer|Melanoma|Colorectal Cancer|Breast Cancer",DRUG: JK08,Salubris Biotherapeutics Inc,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,149,INDUSTRY,INTERVENTIONAL,10/17/2022,2/20/2026
NCT06176534,NOT_YET_RECRUITING,Advanced Breast Cancer|Treatment|HR Low/HER2 Negative,DRUG: Experimental: chemotheyapy|DRUG: Active Comparator: endocrine therapy,Henan Cancer Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2,240,OTHER_GOV,INTERVENTIONAL,12/20/2023,12/20/2026
NCT05565534,RECRUITING,Breast Cancer|PreDiabetes|Type 2 Diabetes,BEHAVIORAL: Nurse-practitioner led intervention,Weill Medical College of Cornell University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,INTERVENTIONAL,2/28/2023,2026-12
NCT04248998,ACTIVE_NOT_RECRUITING,Triple-negative Breast Cancer,DIETARY_SUPPLEMENT: Fasting-mimicking diet|DRUG: Metformin|DRUG: Preoperative chemotherapy,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",IFOM ETS - The AIRC Institute of Molecular Oncology|European Institute of Oncology|University of Milan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,5/5/2020,5/1/2024
NCT04522557,COMPLETED,Breast Neoplasms,DRUG: IFNÎ±-2a,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,21,OTHER,INTERVENTIONAL,8/6/2020,7/14/2021
NCT05296798,RECRUITING,Locally Advanced or Metastatic Breast Cancer,DRUG: Phesgo|DRUG: Giredestrant|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: LHRH Agonist|DRUG: Optional Endocrine Therapy of Investigator's Choice,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,812,INDUSTRY,INTERVENTIONAL,7/4/2022,9/30/2032
NCT06223698,NOT_YET_RECRUITING,Breast Cancer,DRUG: Letrozole|DRUG: Anastrozole|DRUG: Exemestane|DRUG: Tamoxifen,Region Ã–rebro County,"Mid-Sweden Regional Cancer Centre|Akademiska University Hospital, Uppsala, Sweden",FEMALE,"ADULT, OLDER_ADULT",PHASE3,3832,OTHER,INTERVENTIONAL,5/2/2024,5/2/2035
NCT05753657,RECRUITING,Metastatic Breast Cancer|Hyperinsulinism|Hyperglycemia Drug Induced,DRUG: Pioglitazone,Rambam Health Care Campus,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,INTERVENTIONAL,12/25/2022,12/31/2027
NCT04523857,RECRUITING,Breast Cancer,DRUG: Abemaciclib|DRUG: Hydroxychloroquine,Abramson Cancer Center at Penn Medicine,,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,INTERVENTIONAL,11/1/2021,2028-12
NCT05192798,RECRUITING,Triple-negative Breast Cancer,DRUG: Albumin-Bound Paclitaxel|DRUG: Apatinib Mesylate|DRUG: Bevacizumab,First Affiliated Hospital Bengbu Medical College,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,128,OTHER,INTERVENTIONAL,1/14/2022,6/1/2024
NCT05088057,RECRUITING,Triple Negative Breast Cancer (TNBC),DRUG: Camrelizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel,Aiping Shi,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,9/20/2021,11/1/2024
NCT04432857,ACTIVE_NOT_RECRUITING,"Triple-negative Breast Cancer|NSCLC, Squamous or Non-Squamous|Urothelial Carcinoma of the Bladder|Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Cervical Cancer",DRUG: AN0025|DRUG: Pembrolizumab,"Adlai Nortye Biopharma Co., Ltd.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INDUSTRY,INTERVENTIONAL,8/20/2020,11/28/2025
NCT04656457,UNKNOWN,Breast Cancer,DEVICE: Treadmill|OTHER: resisted exercises,Cairo University,,FEMALE,ADULT,NA,60,OTHER,INTERVENTIONAL,12/12/2020,4/1/2021
NCT06150898,NOT_YET_RECRUITING,Early-stage Breast Cancer|Estrogen-receptor-positive Breast Cancer,PROCEDURE: Prospective data and sample collection|DRUG: Ketorolac 10 Mg Oral Tablet|DRUG: Pregabalin 75mg,Jules Bordet Institute,KU Leuven|University of Milan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,112,OTHER,INTERVENTIONAL,2/20/2024,2026-12
NCT05444998,NOT_YET_RECRUITING,Breast Cancer,"DRUG: Intuzumab, pyrrolidone, nab-paclitaxel",Xijing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,11/1/2022,12/31/2023
NCT04298398,UNKNOWN,Cancer,BEHAVIORAL: Mindfulness Based-Cognitive Therapy (MBCT)|BEHAVIORAL: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|OTHER: Treatment as usual (no intervention),"Instituto Portugues de Oncologia, Francisco Gentil, Porto","Polytechnic Institute of Porto|VTT Technical Research Centre, Finland|University of Oulu|Linnaeus University|European Commission",ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,9/1/2021,2021-09
NCT05439499,RECRUITING,Advanced Breast Cancer|Female Breast Cancer,"DRUG: FCN-437c, Letrozole or anastrozole, Goserelin acetate|DRUG: Placebo, Letrozole or anastrozole, Goserelin acetate","Ahon Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,434,OTHER,INTERVENTIONAL,3/2/2022,3/2/2025
NCT06098599,COMPLETED,Advanced Breast Cancer,DRUG: Doxorubicin hydrochloride liposome injection,Luye Pharma Group Ltd.,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,INTERVENTIONAL,5/17/2022,2/9/2023
NCT04152499,RECRUITING,Epithelial Ovarian Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Urothelial Carcinoma|Non-Small Cell Lung Cancer|Small-Cell Lung Cancer|Endometrial Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer,DRUG: SKB264,Klus Pharma Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,430,INDUSTRY,INTERVENTIONAL,2/28/2020,2025-12
NCT06025799,COMPLETED,Breast Cancer Female,BEHAVIORAL: Mindfulness-based stress reduction intervention,Alexandria University,,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,8/24/2023,12/6/2023
NCT04560699,ACTIVE_NOT_RECRUITING,Musculoskeletal Pain,OTHER: Physiotherapeutic treatment and medical care|OTHER: medical care,Frederiksberg University Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,111,OTHER,INTERVENTIONAL,10/14/2020,3/30/2024
NCT04954599,RECRUITING,"Unspecified Adult Solid Tumor, Protocol Specific",DRUG: CP-506|DRUG: Carboplatin|DRUG: Immune checkpoint inhibitor,Maastricht University,Erasmus Medical Center|Jules Bordet Institute|Academisch Ziekenhuis Maastricht,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,126,OTHER,INTERVENTIONAL,4/25/2023,2026-05
NCT05452499,COMPLETED,"Breast Neoplasms|Pain, Chronic|Kinesiophobia|Breast Cancer",OTHER: Pain neuroscience education and therapeutic exercise,Universidad AutÃ³noma de YucatÃ¡n,,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,INTERVENTIONAL,9/5/2022,1/9/2023
NCT06145399,RECRUITING,Breast Cancer|Breast Carcinoma|Metastatic Breast Cancer|Metastatic Breast Carcinoma|Female Breast Cancer,DIAGNOSTIC_TEST: 18F-FDG PET/CT|DIAGNOSTIC_TEST: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|DRUG: 18F-FDHT,Memorial Sloan Kettering Cancer Center,,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,10/24/2023,10/24/2026
NCT05366699,SUSPENDED,"Lymphedema, Breast Cancer|Lymphedema",PROCEDURE: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|PROCEDURE: Axillary lymphadenetomy alone,Stanford University,,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,9/10/2021,6/1/2030
NCT05070299,COMPLETED,Breast Cancer|Gynecologic Cancer,BEHAVIORAL: Psychosexual Educational Partner Program (PEPP),University of Michigan Rogel Cancer Center,The Breast Cancer Research Foundation,FEMALE,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,3/15/2022,8/29/2022
NCT05511844,RECRUITING,HER2-positive Breast Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|HER2 Gene Mutation,DRUG: ORM-5029,"Orum Therapeutics USA, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1,87,INDUSTRY,INTERVENTIONAL,10/3/2022,2025-10
NCT06039644,NOT_YET_RECRUITING,Breast Cancer,DIETARY_SUPPLEMENT: Probiotic|OTHER: Placebo,GenMont Biotech Incorporation,Mackay Memorial Hospital,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,INTERVENTIONAL,4/1/2024,4/1/2026
NCT06161181,RECRUITING,Metastatic Breast Cancer,DEVICE: Decision Support System,European Institute of Oncology,Pfizer,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,5/3/2023,12/30/2023
NCT05941598,NOT_YET_RECRUITING,Chemotherapy-Related Cognitive Impairment,DEVICE: Electroacupuncture|DEVICE: Sham acupuncture,Beijing University of Chinese Medicine,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,INTERVENTIONAL,8/1/2023,12/30/2024
NCT06142344,RECRUITING,Liver Metastases|Breast Cancer,DEVICE: Quiremspheresâ„¢,The Netherlands Cancer Institute,Universitaire Ziekenhuizen KU Leuven,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,10/19/2023,1/19/2026
NCT05242874,RECRUITING,Chemotherapy-induced Nausea and Vomiting,"DRUG: Fosaprepitant , Tropisetron and Olanzapine|DRUG: Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine",Henan Cancer Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,403,OTHER_GOV,INTERVENTIONAL,1/1/2022,6/1/2024
NCT05771974,RECRUITING,Chemotherapy-induced Peripheral Neuropathy,DEVICE: Compression therapy using surgical gloves,Young-Joon Kang,,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,INTERVENTIONAL,6/13/2023,2026-02
NCT05269381,RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Merkel Cell Carcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Cervical Carcinoma|Locally Advanced Endometrial Carcinoma|Locally Advanced Gastric Adenocarcinoma|Locally Advanced Gastroesophageal Junction Adenocarcinoma|Locally Advanced Head and Neck Squamous Cell Carcinoma|Locally Advanced Hepatocellular Carcinoma|Locally Advanced Lung Non-Small Cell Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Merkel Cell Carcinoma|Locally Advanced Renal Cell Carcinoma|Locally Advanced Skin Squamous Cell Carcinoma|Locally Advanced Triple-Negative Breast Carcinoma|Locally Advanced Unresectable Breast Carcinoma|Locally Advanced Unresectable Cervical Carcinoma|Locally Advanced Unresectable Gastric Adenocarcinoma|Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma|Locally Advanced Unresectable Renal Cell Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Cervical Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IV Merkel Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Skin Squamous Cell Carcinoma|Stage III Cervical Cancer AJCC v8|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Cervical Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Cervical Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Cervical Cancer AJCC v8|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Cervical Carcinoma|Unresectable Endometrial Carcinoma|Unresectable Gastric Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Renal Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma|Unresectable Triple-Negative Breast Carcinoma|Unresectable Urothelial Carcinoma,DRUG: Cyclophosphamide|BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Sargramostim,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,INTERVENTIONAL,3/31/2022,2/24/2026
NCT05525481,RECRUITING,ER+ Breast Cancer,DRUG: Tamoxifen,Erasmus Medical Center,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,11/1/2022,2/28/2024
NCT04997798,RECRUITING,Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer,DRUG: Trastuzumab Pyrotinib Exemestane Dalpiciclib,First Affiliated Hospital of Zhejiang University,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,9/1/2022,2024-12
NCT05727098,COMPLETED,Breast Cancer,DRUG: Bupivacaine Hydrochloride|DRUG: Bupivacaine Hydrochloride and dexmedetomedine|DRUG: Bupivacaine Hydrochloride and ketamine,"National Cancer Institute, Egypt",,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,75,OTHER,INTERVENTIONAL,1/1/2023,4/30/2023
NCT04934098,RECRUITING,"Breast Cancer Related Lymphedema|Lymphedema, Secondary|Lymphedema of Upper Arm|Breast Neoplasms",DEVICE: Adjustable Compression Wrap|DEVICE: Compression Bandage,"Instituto Nacional de Cancer, Brazil",,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,INTERVENTIONAL,7/1/2021,12/31/2023
NCT06062498,NOT_YET_RECRUITING,Estrogen-receptor-positive Breast Cancer|HER2/Neu-Negative Breast Cancer|Advanced Breast Cancerv|Metastatic Breast Cancer,"DRUG: elacestrant, palbociclib, abemaciclib, ribociclib",Northwestern University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,174,OTHER,INTERVENTIONAL,9/30/2023,7/1/2025
NCT05273944,UNKNOWN,Breast Cancer|Ovarian Cancer,DRUG: Doxorubicin Hydrochloride Liposome Injection,"Shenzhen Kangzhe Pharmaceutical Co., Ltd.",Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Hunan Cancer Hospital|The Second Affiliated Hospital of Chongqing Medical University|First Affiliated Hospital of Jinan University|Zhejiang Provincial People's Hospital|Yuncheng Central Hospital|Shantou Central Hospital|Yuebei People's Hospital|Cancer Hospital of Guizhou Province|Guangzhou Panyu Central Hospital|Dongguan People's Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,INTERVENTIONAL,7/28/2021,4/30/2022
NCT05940844,NOT_YET_RECRUITING,Metastatic Cancer|Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer|Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Urothelial Carcinoma,DRUG: OB-002,Orion Biotechnology Polska Sp. z o.o.,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,INTERVENTIONAL,2024-01,2025-08
NCT04261244,NOT_YET_RECRUITING,Breast Cancer,RADIATION: preoperative radiotherapy|RADIATION: postoperative radiotherapy,"Heinrich-Heine University, Duesseldorf",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1826,OTHER,INTERVENTIONAL,7/1/2020,12/31/2030
NCT03554044,ACTIVE_NOT_RECRUITING,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma,DRUG: Anastrozole|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Paclitaxel|BIOLOGICAL: Talimogene Laherparepvec|DRUG: Tamoxifen|DRUG: Nab paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,"University of California, San Francisco",Amgen,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,INTERVENTIONAL,2/5/2020,4/30/2025
NCT04419181,SUSPENDED,HER2-positive Breast Cancer,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Trastuzumab emtansine,University of Rochester,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,INTERVENTIONAL,8/11/2024,6/1/2026
NCT04420598,COMPLETED,Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis,DRUG: Trastuzumab deruxtecan,MedSIR,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,INTERVENTIONAL,5/25/2020,4/4/2023
NCT04482244,ACTIVE_NOT_RECRUITING,Advanced Breast Cancer|Anxiety|CBD,DRUG: Cannabidiol|OTHER: Placebo,Dana-Farber Cancer Institute,Hans and Mavis Lopater Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,INTERVENTIONAL,1/19/2022,7/18/2024
NCT05333874,ACTIVE_NOT_RECRUITING,"Breast Cancer, Early-Onset",DRUG: Neoadjuvant chemotherapy administered before surgical extraction of a tumor|OTHER: Observational,"Rutgers, The State University of New Jersey",,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,34,OTHER,INTERVENTIONAL,4/6/2022,11/28/2027
NCT05180474,RECRUITING,"Breast Cancer, Breast Neoplasms|Endometrial Cancer, Endometrial Neoplasm|Ovarian Cancer, Ovarian Neoplasms|Squamous Non Small Cell Lung Cancer (NSCLC-SCC)",BIOLOGICAL: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.,Genmab,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,500,INDUSTRY,INTERVENTIONAL,12/13/2021,8/12/2025
NCT05133674,ACTIVE_NOT_RECRUITING,Breast Cancer|Breast Carcinoma|Breast Tumors|Cancer of Breast|Malignant Neoplasm of Breast,DRUG: Tamoxifen 20 mg,Karolinska University Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,4/4/2022,3/1/2023
NCT04541381,RECRUITING,Gastrointestinal Cancer|Head and Neck Cancer|Dihydropyrimidine Dehydrogenase Deficiency|UGT1A1 Gene Mutation|Breast Cancer,OTHER: Availability of clinical decision support based on pharmacogenomic results.,University of Chicago,,ALL,"ADULT, OLDER_ADULT",NA,860,OTHER,INTERVENTIONAL,2/7/2022,3/31/2028
NCT05115799,RECRUITING,Breast Cancer|Mastectomy; Lymphedema|Thrombi|Thrombosis|Shoulder Syndrome|Movement Disorders,"OTHER: Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|OTHER: Kinesiotherapy, Physiotherapy, Health Education",University of Malaga,,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,12/1/2021,12/4/2023
NCT06006299,RECRUITING,Breast Cancer|Insomnia,DEVICE: transauricular Vagus Nerve Stimulation,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,INTERVENTIONAL,9/26/2023,12/31/2024
NCT04824599,COMPLETED,Breast Neoplasm,PROCEDURE: PECS II|PROCEDURE: Local anesthetic infiltration|PROCEDURE: Subcutaneus local anesthetic infiltration|DRUG: Ropivacaine|DEVICE: bk medical Flex Focus 500 Ultrasound Machine,Karlstad Central Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,2/19/2021,5/1/2022
NCT04842799,COMPLETED,Breast Neoplasm Female,OTHER: Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|OTHER: Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform,"Institute of Cancer Research, United Kingdom",University of Sussex|University of Manchester|Cancer Research UK,FEMALE,"ADULT, OLDER_ADULT",NA,1140,OTHER,INTERVENTIONAL,7/5/2021,1/16/2023
NCT05595499,RECRUITING,Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Fisetin|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI)|National Institute on Aging (NIA),FEMALE,OLDER_ADULT,PHASE2,88,OTHER,INTERVENTIONAL,3/27/2023,5/15/2025
NCT05430399,RECRUITING,Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer,DRUG: utidelone|DRUG: docetaxel,Sun Yat-sen University,"Beijing Biostar Pharmaceuticals Co., Ltd.|Hunan Cancer Hospital",FEMALE,"ADULT, OLDER_ADULT",PHASE3,349,OTHER,INTERVENTIONAL,6/21/2022,6/1/2027
NCT04754399,COMPLETED,Arthralgia|Breast Cancer,DRUG: Cannabidiol (CBD),University of Michigan Rogel Cancer Center,American Society of Clinical Oncology,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,INTERVENTIONAL,4/16/2021,10/10/2023
NCT04441099,TERMINATED,Advanced Solid Tumor|Advanced Cancer|Triple Negative Breast Cancer,DRUG: NBE-002,NBE-Therapeutics AG,Cmed Clinical Services,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,INDUSTRY,INTERVENTIONAL,6/19/2020,8/14/2023
NCT04631835,RECRUITING,Breast Cancer,DRUG: HS-10352,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,INTERVENTIONAL,9/8/2020,8/31/2023
NCT05069935,TERMINATED,"Solid Tumor, Adult",DRUG: FT538|DRUG: Cyclophosphamide|DRUG: Fludarabine|COMBINATION_PRODUCT: Monoclonal antibody - Dose Escalation|COMBINATION_PRODUCT: Monoclonal antibody - Dose Expansion,Fate Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,INTERVENTIONAL,10/15/2021,8/11/2023
NCT05609435,RECRUITING,Breast Cancer,OTHER: REASSURE,"University of Wisconsin, Madison",National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,INTERVENTIONAL,11/16/2022,2025-11
NCT04728035,NOT_YET_RECRUITING,Advanced Breast Cancer,DRUG: Irinotecan Liposome Injection,"CSPC Ouyi Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,136,INDUSTRY,INTERVENTIONAL,2021-04,2024-04
NCT05240235,RECRUITING,Breast Cancer and Rehabilitation,"OTHER: Education, compression and exercise therapy|OTHER: Education, compression and exercise therapy manual lymph drainage",Acibadem University,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,11/21/2023,7/15/2024
NCT05003635,RECRUITING,Breast Cancer Female,DEVICE: EVEBRA device,Maastricht University Medical Center,ZonMw: The Netherlands Organisation for Health Research and Development,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,INTERVENTIONAL,7/12/2021,2026-10
NCT05277935,RECRUITING,Breast Neoplasm Female|Quality of Life,DEVICE: Use of the WeCancer app combined with the smartwatch.,BeneficÃªncia Portuguesa de SÃ£o Paulo,,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,INTERVENTIONAL,4/22/2022,5/31/2024
NCT04289935,RECRUITING,Breast Cancer,PROCEDURE: Vacuum assisted biopsy (VAB),"Klinik Hirslanden, Zurich",,ALL,"ADULT, OLDER_ADULT",NA,420,OTHER,INTERVENTIONAL,8/17/2020,2025-06
NCT04542135,RECRUITING,Breast Cancer,DRUG: Sulindac Pill|DRUG: Placebo,Alison Stopeck,Medical University of South Carolina|Cedars-Sinai Medical Center,FEMALE,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,INTERVENTIONAL,11/20/2020,2/28/2025
NCT06193369,NOT_YET_RECRUITING,Lymphoma|Breast Cancer|Testicular Cancer|Sarcoma,BEHAVIORAL: Digital Peer Navigation,"University Health Network, Toronto",Canadian Cancer Society (CCS)|Young Adult Cancer Canada,ALL,ADULT,NA,80,OTHER,INTERVENTIONAL,2024-05,2025-12
NCT04990895,RECRUITING,Colorectal Cancer|Breast Cancer,OTHER: Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires,AHS Cancer Control Alberta,Tom Baker Cancer Centre,ALL,"ADULT, OLDER_ADULT",PHASE3,128,OTHER,INTERVENTIONAL,3/30/2022,10/1/2024
NCT04457895,RECRUITING,Breast Cancer,BEHAVIORAL: educational yoga program|OTHER: no intervention,Institut du Cancer de Montpellier - Val d'Aurelle,,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,INTERVENTIONAL,2/11/2021,2025-08
NCT04572295,ACTIVE_NOT_RECRUITING,Breast Neoplasms,DRUG: E7090|DRUG: Fulvestrant|DRUG: Exemestane,"Eisai Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE1,72,INDUSTRY,INTERVENTIONAL,10/9/2020,12/31/2024
NCT06199895,RECRUITING,Pancreatic Adenocarcinoma|Cholangiocarcinoma|Lung Cancer|Stomach Cancer|Esophageal Carcinoma|Breast Cancer,DRUG: Paclitaxel Polymeric Micelles for Injection,Liu Huang,,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,INTERVENTIONAL,11/28/2023,2025-11
NCT06120595,RECRUITING,Cancer Related Fatigue,BEHAVIORAL: REBECCA-assisted intervention,Helse Stavanger HF,,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER_GOV,INTERVENTIONAL,11/1/2022,5/1/2025
NCT04391296,NOT_YET_RECRUITING,Breast Cancer,"PROCEDURE: Arm I (Prepectoral), Arm II (Subpectoral)",Gangnam Severance Hospital,,FEMALE,"ADULT, OLDER_ADULT",NA,114,OTHER,INTERVENTIONAL,6/1/2020,6/30/2025
NCT04707196,COMPLETED,Breast Neoplasms|Neoplasm Metastasis,DRUG: Abemaciclib|DRUG: Nonsteroidal Aromatase Inhibitor (NSAI)|DRUG: Fulvestrant,Eli Lilly and Company,,FEMALE,"ADULT, OLDER_ADULT",PHASE4,200,INDUSTRY,INTERVENTIONAL,2/22/2021,1/9/2023
NCT04305496,ACTIVE_NOT_RECRUITING,Locally Advanced (Inoperable) or Metastatic Breast Cancer,DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Placebo,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,818,INDUSTRY,INTERVENTIONAL,4/16/2020,6/7/2024
NCT05383196,RECRUITING,Breast Cancer|Invasive Breast Cancer|Unresectable Breast Carcinoma|Locally Advanced Breast Cancer|Metastatic Breast Cancer|Inflammatory Breast Cancer|Triple Negative Breast Cancer (TNBC)|Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma,DRUG: Onvansertib|DRUG: Paclitaxel,"Antonio Giordano, MD",Cardiff Oncology,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,INTERVENTIONAL,9/30/2022,2/15/2029
NCT03542695,ACTIVE_NOT_RECRUITING,Breast Carcinoma|Calcification,PROCEDURE: Computed Tomography|DRUG: Copper Cu-64-DOTA-alendronate|OTHER: Pharmacokinetic Study|PROCEDURE: Positron Emission Tomography,City of Hope Medical Center,National Cancer Institute (NCI),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,1,OTHER,INTERVENTIONAL,11/3/2021,2/20/2025
NCT05219695,RECRUITING,Fibroadenoma|Breast Cancer Stage I,PROCEDURE: Harmonic motion imaging guided focused ultrasound (HMIgFUS),Columbia University,,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,INTERVENTIONAL,1/19/2022,2025-05
NCT05690295,RECRUITING,Breast Cancer Survivors|Postmenopause|Resistance Training,OTHER: Prolonged resistance-type exercise training,Universidad de La Frontera,,FEMALE,ADULT,NA,52,OTHER,INTERVENTIONAL,3/22/2023,2024-08
NCT06061835,RECRUITING,Breast Cancer|Postsurgical Acquired Absence of Organ,OTHER: Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|OTHER: CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.,I.M. Sechenov First Moscow State Medical University,,FEMALE,"ADULT, OLDER_ADULT",NA,135,OTHER,INTERVENTIONAL,5/6/2023,7/30/2024
NCT03295695,WITHDRAWN,"Breast Cancer|Breast Cancer, Female|Breast Cancer, Male|Breast Neoplasms",DIAGNOSTIC_TEST: Fluoro-D-glucose-positron Emission Tomography|BIOLOGICAL: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)|DIAGNOSTIC_TEST: Echocardiogram,H. Lee Moffitt Cancer Center and Research Institute,,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,INTERVENTIONAL,2020-12,2022-12
NCT06247995,NOT_YET_RECRUITING,Breast Cancer,DRUG: [68Ga]Ga-NeoB|DRUG: [177Lu]Lu-NeoB|DRUG: Capecitabine,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,58,INDUSTRY,INTERVENTIONAL,5/16/2024,9/9/2031
NCT03990896,RECRUITING,Breast Cancer,DRUG: Talazoparib,Massachusetts General Hospital,Pfizer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,INTERVENTIONAL,11/18/2021,7/31/2024
NCT05259696,RECRUITING,Oncology|Melanoma|Ovarian Cancer|NSCLC|Non Small Cell Lung Cancer|Colorectal Cancer|Pancreatic Cancer|Cancer|CRC|Colon Cancer|Breast Cancer|Gastric Cancer|EGJ|Esophagogastric Junction Cancer|Head and Neck Cancer|Urothelial Cancer|Bladder Cancer,BIOLOGICAL: E-602|BIOLOGICAL: Cemiplimab,"Palleon Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,273,INDUSTRY,INTERVENTIONAL,2/11/2022,2025-06
NCT05587296,ACTIVE_NOT_RECRUITING,"Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer|Hot Flashes",DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,405,INDUSTRY,INTERVENTIONAL,10/14/2022,12/4/2026
NCT04867096,RECRUITING,Breast Cancer,OTHER: Physical activity,Centre Hospitalier Universitaire de Besancon,,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,INTERVENTIONAL,4/8/2021,2023-08
NCT05722795,NOT_YET_RECRUITING,Breast Cancer|Triple Negative Breast Cancer,DRUG: Imatinib 400 MG Oral Tablet,Vastra Gotaland Region,"Sahlgrenska University Hospital, Sweden|Lund University",ALL,"ADULT, OLDER_ADULT",NA,40,OTHER_GOV,INTERVENTIONAL,2/6/2023,12/31/2024
